identification	O
of	O
apc2	O
,	O
a	O
homologue	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
tumour	I-Disease
suppressor	O
.	O
	
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
apc	I-Disease
)	I-Disease
tumour	I-Disease
-	O
suppressor	O
protein	O
controls	O
the	O
wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
gsk	O
-	O
3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O
	
in	O
colon	B-Disease
carcinoma	I-Disease
cells	O
,	O
loss	O
of	O
apc	O
leads	O
to	O
the	O
accumulation	O
of	O
betacatenin	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
tcf	O
-	O
4	O
transcription	O
factor	O
(	O
reviewed	O
in	O
[	O
1	O
]	O
[	O
2	O
]	O
)	O
.	O
	
like	O
apc	O
,	O
apc2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin	O
-	O
tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
apc	O
-	O
/	O
-	O
colon	B-Disease
carcinoma	I-Disease
cells	O
.	O
	
apc	O
and	O
apc2	O
may	O
therefore	O
have	O
comparable	O
functions	O
in	O
development	O
and	O
cancer	B-Disease
.	O
	
a	O
common	O
msh2	O
mutation	O
in	O
english	O
and	O
north	O
american	O
hnpcc	B-Disease
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
the	O
frequency	O
,	O
origin	O
,	O
and	O
phenotypic	O
expression	O
of	O
a	O
germline	O
msh2	O
gene	O
mutation	O
previously	O
identified	O
in	O
seven	O
kindreds	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
cancer	I-Disease
syndrome	I-Disease
(	O
hnpcc	B-Disease
)	O
was	O
investigated	O
.	O
	
although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	B-Disease
cancer	I-Disease
families	O
analysed	O
from	O
eastern	O
england	O
,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
english	O
hnpcc	B-Disease
kindreds	O
analysed	O
.	O
	
in	O
contrast	O
,	O
the	O
msh2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	O
colorectal	B-Disease
families	O
from	O
newfoundland	O
.	O
	
to	O
investigate	O
the	O
origin	O
of	O
this	O
mutation	O
in	O
colorectal	B-Disease
cancer	I-Disease
families	O
from	O
england	O
(	O
n	O
=	O
4	O
)	O
,	O
newfoundland	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
the	O
united	O
states	O
(	O
n	O
=	O
3	O
)	O
,	O
haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
linked	O
to	O
msh2	O
was	O
performed	O
.	O
	
these	O
findings	O
suggested	O
a	O
founder	O
effect	O
within	O
newfoundland	O
similar	O
to	O
that	O
reported	O
by	O
others	O
for	O
two	O
mlh1	O
mutations	O
in	O
finnish	O
hnpcc	B-Disease
families	O
.	O
	
we	O
calculated	O
age	O
related	O
risks	O
of	O
all	O
,	O
colorectal	B-Disease
,	I-Disease
endometrial	I-Disease
,	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
nt943	O
+	O
3	O
a	O
-	O
-	O
>	O
t	O
msh2	O
mutation	O
carriers	O
(	O
n	O
=	O
76	O
)	O
for	O
all	O
patients	O
and	O
for	O
men	O
and	O
women	O
separately	O
.	O
	
for	O
both	O
sexes	O
combined	O
,	O
the	O
penetrances	O
at	O
age	O
60	O
years	O
for	O
all	O
cancers	B-Disease
and	O
for	O
colorectal	B-Disease
cancer	I-Disease
were	O
0	O
.	O
	
the	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
	
1	O
)	O
in	O
males	O
than	O
females	O
(	O
0	O
.	O
	
63	O
v	O
0	O
.	O
	
30	O
and	O
0	O
.	O
	
84	O
v	O
0	O
.	O
	
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O
	
for	O
females	O
there	O
was	O
a	O
high	O
risk	O
of	O
endometrial	B-Disease
cancer	I-Disease
(	O
0	O
.	O
	
5	O
at	O
age	O
60	O
years	O
)	O
and	O
premenopausal	B-Disease
ovarian	I-Disease
cancer	I-Disease
(	O
0	O
.	O
	
2	O
at	O
50	O
years	O
)	O
.	O
	
these	O
intersex	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
risks	O
have	O
implications	O
for	O
screening	O
programmes	O
and	O
for	O
attempts	O
to	O
identify	O
colorectal	B-Disease
cancer	I-Disease
susceptibility	O
modifiers	O
.	O
	
age	O
of	O
onset	O
in	O
huntington	B-Disease
disease	I-Disease
:	O
sex	O
specific	O
influence	O
of	O
apolipoprotein	O
e	O
genotype	O
and	O
normal	O
cag	O
repeat	O
length	O
.	O
	
age	O
of	O
onset	O
(	O
ao	O
)	O
of	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
cag	O
repeat	O
in	O
the	O
hd	B-Disease
gene	O
.	O
	
apolipoprotein	O
e	O
(	O
apoe	O
)	O
genotype	O
,	O
in	O
turn	O
,	O
is	O
known	O
to	O
influence	O
ao	O
in	O
alzheimer	B-Disease
disease	I-Disease
,	O
rendering	O
the	O
apoe	O
gene	O
a	O
likely	O
candidate	O
to	O
affect	O
ao	O
in	O
other	O
neurological	B-Disease
diseases	I-Disease
too	O
.	O
	
we	O
therefore	O
determined	O
apoe	O
genotype	O
and	O
normal	O
cag	O
repeat	O
length	O
in	O
the	O
hd	B-Disease
gene	O
for	O
138	O
hd	B-Disease
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
cag	O
repeat	O
length	O
.	O
	
in	O
addition	O
to	O
highlighting	O
the	O
effect	O
of	O
the	O
normal	O
repeat	O
length	O
upon	O
ao	O
in	O
maternally	O
inherited	O
hd	B-Disease
and	O
in	O
male	O
patients	O
,	O
we	O
show	O
that	O
the	O
apoe	O
epsilon2epsilon3	O
genotype	O
is	O
associated	O
with	O
significantly	O
earlier	O
ao	O
in	O
males	O
than	O
in	O
females	O
.	O
	
our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B-Disease
in	O
hd	B-Disease
may	O
allow	O
interacting	O
genes	O
to	O
exert	O
gender	O
specific	O
effects	O
upon	O
ao	O
.	O
	
familial	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
associated	O
with	O
recurrent	O
bacteremic	B-Disease
infections	I-Disease
due	I-Disease
to	I-Disease
neisseria	I-Disease
.	O
	
the	O
serum	O
of	O
a	O
29	O
-	O
year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	B-Disease
gonococcal	I-Disease
infection	I-Disease
and	O
a	O
history	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
was	O
found	O
to	O
lack	O
serum	O
hemolytic	O
complement	O
activity	O
.	O
	
the	O
absence	B-Disease
of	I-Disease
functional	I-Disease
c7	I-Disease
activity	O
could	O
not	O
be	O
accounted	O
for	O
on	O
the	O
basis	O
of	O
an	O
inhibitor	O
.	O
	
complete	B-Disease
absence	I-Disease
of	I-Disease
c7	I-Disease
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	O
syndrome	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight	O
-	O
year	O
-	O
old	O
son	O
.	O
	
hla	O
histocompatibility	O
typing	O
of	O
the	O
family	O
members	O
did	O
not	O
demonstrate	O
evidence	O
for	O
genetic	O
linkage	O
of	O
c7	B-Disease
deficiency	I-Disease
with	O
the	O
major	O
histocompatibility	O
loci	O
.	O
	
this	O
report	O
represents	O
the	O
first	O
cases	O
of	O
c7	B-Disease
deficiency	I-Disease
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	B-Disease
neisseria	I-Disease
infections	I-Disease
.	O
	
increased	O
incidence	O
of	O
cancer	B-Disease
in	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
.	O
	
objective	O
previous	O
reports	O
have	O
suggested	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
among	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
(	O
chh	B-Disease
)	O
.	O
	
this	O
study	O
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	O
among	O
patients	O
with	O
chh	B-Disease
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O
	
study	O
design	O
one	O
hundred	O
twenty	O
-	O
two	O
patients	O
with	O
chh	B-Disease
were	O
identified	O
through	O
2	O
countrywide	O
epidemiologic	O
surveys	O
in	O
1974	O
and	O
in	O
1986	O
.	O
	
this	O
cohort	O
underwent	O
follow	O
-	O
up	O
for	O
cancer	B-Disease
incidence	O
through	O
the	O
finnish	O
cancer	O
registry	O
to	O
the	O
end	O
of	O
1995	O
.	O
	
results	O
a	O
statistically	O
significant	O
excess	O
risk	O
of	O
cancer	B-Disease
was	O
seen	O
among	O
the	O
patients	O
with	O
chh	B-Disease
(	O
standardized	O
incidence	O
ratio	O
6	O
.	O
	
3	O
to	O
16	O
)	O
,	O
which	O
was	O
mainly	O
attributable	O
to	O
non	B-Disease
-	I-Disease
hodgkins	I-Disease
lymphoma	I-Disease
(	O
standardized	O
incidence	O
ratio	O
90	O
,	O
95	O
%	O
confidence	O
interval	O
18	O
to	O
264	O
)	O
.	O
	
in	O
addition	O
,	O
a	O
significant	O
excess	O
risk	O
of	O
basal	B-Disease
cell	I-Disease
carcinoma	I-Disease
was	O
seen	O
(	O
standardized	O
incidence	O
ratio	O
35	O
,	O
95	O
%	O
confidence	O
interval	O
7	O
.	O
	
the	O
cancer	B-Disease
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B-Disease
incidence	O
in	O
the	O
finnish	O
population	O
.	O
	
conclusions	O
this	O
study	O
confirms	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
,	O
especially	O
non	B-Disease
-	I-Disease
hodgkins	I-Disease
lymphoma	I-Disease
,	O
probably	O
attributable	O
to	O
defective	O
immunity	O
,	O
among	O
patients	O
with	O
chh	B-Disease
.	O
	
genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
.	O
	
dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
(	I-Disease
dpd	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
characterised	O
by	O
thymine	O
-	O
uraciluria	O
in	O
homozygous	O
deficient	O
patients	O
and	O
has	O
been	O
associated	O
with	O
a	O
variable	O
clinical	O
phenotype	O
.	O
	
in	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
dpd	B-Disease
deficiency	I-Disease
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	B-Disease
of	I-Disease
dpd	I-Disease
.	O
	
analysis	O
of	O
the	O
prevalence	O
of	O
the	O
various	O
mutations	O
among	O
dpd	B-Disease
patients	O
has	O
shown	O
that	O
the	O
g	O
-	O
-	O
>	O
a	O
point	O
mutation	O
in	O
the	O
invariant	O
splice	O
donor	O
site	O
is	O
by	O
far	O
the	O
most	O
common	O
(	O
52	O
%	O
)	O
,	O
whereas	O
the	O
other	O
six	O
mutations	O
are	O
less	O
frequently	O
observed	O
.	O
	
a	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed	O
,	O
with	O
convulsive	B-Disease
disorders	I-Disease
,	O
motor	B-Disease
retardation	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
being	O
the	O
most	O
abundant	O
manifestations	O
.	O
	
an	O
altered	O
beta	O
-	O
alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	B-Disease
abnormalities	I-Disease
encountered	O
in	O
patients	O
with	O
dpd	B-Disease
deficiency	I-Disease
.	O
	
fibroblast	O
growth	O
factor	O
homologous	O
factor	O
2	O
(	O
fhf2	O
)	O
:	O
gene	O
structure	O
,	O
expression	O
and	O
mapping	O
to	O
the	O
borjeson	B-Disease
-	I-Disease
forssman	I-Disease
-	I-Disease
lehmann	I-Disease
syndrome	I-Disease
region	O
in	O
xq26	O
delineated	O
by	O
a	O
duplication	O
breakpoint	O
in	O
a	O
bfls	B-Disease
-	O
like	O
patient	O
.	O
	
borjeson	B-Disease
-	I-Disease
forssman	I-Disease
-	I-Disease
lehmann	I-Disease
syndrome	I-Disease
(	O
bfls	B-Disease
)	O
is	O
a	O
syndromal	O
x	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
,	O
which	O
maps	O
by	O
linkage	O
to	O
the	O
q26	O
region	O
of	O
the	O
human	O
x	O
chromosome	O
.	O
	
we	O
have	O
identified	O
a	O
male	O
patient	O
with	O
bfls	B-Disease
-	O
like	O
features	O
and	O
a	O
duplication	O
,	O
46	O
,	O
y	O
,	O
dup	O
(	O
x	O
)	O
(	O
q26q28	O
)	O
,	O
inherited	O
from	O
his	O
phenotypically	O
normal	O
mother	O
.	O
	
the	O
fhf2	O
gene	O
localisation	O
and	O
tissue	O
-	O
specific	O
expression	O
pattern	O
suggest	O
it	O
to	O
be	O
a	O
candidate	O
gene	O
for	O
familial	O
cases	O
of	O
the	O
bfls	B-Disease
syndrome	I-Disease
and	O
other	O
syndromal	O
and	O
non	O
-	O
specific	O
forms	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
mapping	O
to	O
the	O
region	O
.	O
	
germline	O
e	O
-	O
cadherin	O
gene	O
(	O
cdh1	O
)	O
mutations	O
predispose	O
to	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
and	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
inherited	O
mutations	O
in	O
the	O
e	O
-	O
cadherin	O
gene	O
(	O
cdh1	O
)	O
were	O
described	O
recently	O
in	O
three	O
maori	O
kindreds	O
with	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
.	O
	
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	B-Disease
cancer	I-Disease
susceptibility	O
in	O
non	O
-	O
maori	O
populations	O
is	O
due	O
to	O
germline	O
cdh1	O
mutations	O
.	O
	
therefore	O
,	O
we	O
screened	O
eight	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
kindreds	O
of	O
british	O
and	O
irish	O
origin	O
for	O
germline	O
cdh1	O
mutations	O
,	O
by	O
sscp	O
analysis	O
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences	O
.	O
	
each	O
family	O
contained	O
(	O
i	O
)	O
two	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years	O
;	O
or	O
(	O
ii	O
)	O
three	O
or	O
more	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
.	O
	
in	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non	O
-	O
penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancer	I-Disease
;	O
thus	O
,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
,	O
a	O
cdh1	O
mutation	O
carrier	O
developed	O
colorectal	B-Disease
cancer	I-Disease
at	O
age	O
30	O
years	O
.	O
	
we	O
have	O
confirmed	O
that	O
germline	O
mutations	O
in	O
the	O
cdh1	O
gene	O
cause	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
in	O
non	O
-	O
maori	O
populations	O
.	O
	
however	O
,	O
only	O
a	O
minority	O
of	O
familial	O
gastric	B-Disease
cancers	I-Disease
can	O
be	O
accounted	O
for	O
by	O
cdh1	O
mutations	O
.	O
	
loss	O
of	O
e	O
-	O
cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	B-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
cdh1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
thus	O
,	O
cdh1	O
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancers	I-Disease
.	O
	
a	O
zinc	O
finger	O
truncation	O
of	O
murine	O
wt1	O
results	O
in	O
the	O
characteristic	O
urogenital	B-Disease
abnormalities	I-Disease
of	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
.	O
	
the	O
wilms	B-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
,	O
wt1	O
,	O
plays	O
a	O
key	O
role	O
in	O
urogenital	O
development	O
,	O
and	O
wt1	B-Disease
dysfunction	I-Disease
is	O
implicated	O
in	O
both	O
neoplastic	B-Disease
(	O
wilms	B-Disease
tumor	I-Disease
,	O
mesothelioma	B-Disease
,	O
leukemias	B-Disease
,	O
and	O
breast	B-Disease
cancer	I-Disease
)	O
and	O
nonneoplastic	B-Disease
(	O
glomerulosclerosis	B-Disease
)	O
disease	O
.	O
	
the	O
analysis	O
of	O
diseases	O
linked	O
specifically	O
with	O
wt1	O
mutations	O
,	O
such	O
as	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
(	O
dds	B-Disease
)	O
,	O
can	O
provide	O
valuable	O
insight	O
concerning	O
the	O
role	O
of	O
wt1	O
in	O
development	O
and	O
disease	O
.	O
	
dds	B-Disease
is	O
a	O
rare	O
childhood	O
disease	O
characterized	O
by	O
a	O
nephropathy	B-Disease
involving	O
mesangial	B-Disease
sclerosis	I-Disease
,	O
xy	O
pseudohermaphroditism	B-Disease
,	O
and	O
/	O
or	O
wilms	B-Disease
tumor	I-Disease
(	O
wt	B-Disease
)	O
.	O
	
dds	B-Disease
patients	O
are	O
constitutionally	O
heterozygous	O
for	O
exonic	O
point	O
mutations	O
in	O
wt1	O
,	O
which	O
include	O
mutations	O
predicted	O
to	O
truncate	O
the	O
protein	O
within	O
the	O
c	O
-	O
terminal	O
zinc	O
finger	O
(	O
zf	O
)	O
region	O
.	O
	
we	O
report	O
that	O
heterozygosity	O
for	O
a	O
targeted	O
murine	O
wt1	O
allele	O
,	O
wt1	O
(	O
tmt396	O
)	O
,	O
which	O
truncates	O
zf3	O
at	O
codon	O
396	O
,	O
induces	O
mesangial	B-Disease
sclerosis	I-Disease
characteristic	O
of	O
dds	B-Disease
in	O
adult	O
heterozygous	O
and	O
chimeric	O
mice	O
.	O
	
male	B-Disease
genital	I-Disease
defects	I-Disease
also	O
were	O
evident	O
and	O
there	O
was	O
a	O
single	O
case	O
of	O
wilms	B-Disease
tumor	I-Disease
in	O
which	O
the	O
transcript	O
of	O
the	O
nontargeted	O
allele	O
showed	O
an	O
exon	O
9	O
skipping	O
event	O
,	O
implying	O
a	O
causal	O
link	O
between	O
wt1	B-Disease
dysfunction	I-Disease
and	O
wilms	B-Disease
tumorigenesis	I-Disease
in	O
mice	O
.	O
	
however	O
,	O
the	O
mutant	O
wt1	O
(	O
tmt396	O
)	O
protein	O
accounted	O
for	O
only	O
5	O
%	O
of	O
wt1	O
in	O
both	O
heterozygous	O
embryonic	O
stem	O
cells	O
and	O
the	O
wt	B-Disease
.	O
	
mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
dmt1	O
.	O
	
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
hh	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption	O
.	O
	
we	O
recently	O
reported	O
that	O
hfe	O
,	O
the	O
protein	O
defective	O
in	O
hh	B-Disease
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	O
(	O
tfr	O
)	O
in	O
duodenal	O
crypt	O
cells	O
and	O
proposed	O
that	O
mutations	O
in	O
hfe	O
attenuate	O
the	O
uptake	O
of	O
transferrin	O
-	O
bound	O
iron	O
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells	O
,	O
leading	O
to	O
up	O
-	O
regulation	O
of	O
transporters	O
for	O
dietary	O
iron	O
.	O
	
the	O
positive	O
control	O
for	O
dmt1	O
up	O
-	O
regulation	O
was	O
a	O
murine	O
model	O
of	O
dietary	B-Disease
iron	I-Disease
deficiency	I-Disease
that	O
demonstrated	O
greatly	O
increased	O
levels	O
of	O
duodenal	O
dmt1	O
(	O
ire	O
)	O
mrna	O
.	O
	
neurophysiologic	O
follow	O
-	O
up	O
of	O
long	O
-	O
term	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
.	O
	
objective	O
to	O
monitor	O
the	O
effects	O
of	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
by	O
means	O
of	O
somatosensory	O
evoked	O
potentials	O
(	O
seps	O
)	O
and	O
motor	O
evoked	O
potentials	O
(	O
meps	O
)	O
.	O
	
background	O
seps	O
and	O
meps	O
have	O
proved	O
useful	O
in	O
revealing	O
signs	O
of	O
progressively	O
severe	O
,	O
central	O
dying	B-Disease
-	I-Disease
back	I-Disease
axonopathy	I-Disease
in	O
early	O
stages	O
of	O
adult	O
-	O
onset	O
ald	B-Disease
.	O
	
methods	O
eight	O
patients	O
with	O
adult	O
-	O
onset	O
ald	B-Disease
underwent	O
clinical	O
examination	O
,	O
brain	O
and	O
spine	O
mri	O
,	O
and	O
sep	O
and	O
mep	O
studies	O
before	O
and	O
after	O
3	O
years	O
of	O
lorenzos	O
oil	O
dietary	O
therapy	O
.	O
	
three	O
of	O
these	O
patients	O
had	O
pure	O
spinal	B-Disease
sep	I-Disease
abnormalities	I-Disease
and	O
in	O
the	O
remaining	O
two	O
patients	O
seps	O
showed	O
signs	O
of	O
involvement	O
of	O
both	O
the	O
spinal	O
and	O
cerebral	O
somatosensory	O
tracts	O
.	O
	
after	O
treatment	O
,	O
the	O
three	O
patients	O
with	O
pure	O
spinal	B-Disease
abnormalities	I-Disease
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
,	O
whereas	O
the	O
two	O
patients	O
with	O
a	O
more	O
advanced	O
stage	O
of	O
disease	O
(	O
exhibited	O
by	O
seps	O
)	O
showed	O
substantially	O
unchanged	O
clinical	O
and	O
neurophysiologic	O
features	O
.	O
	
conclusions	O
lorenzos	O
oil	O
therapy	O
had	O
no	O
effect	O
on	O
patients	O
with	O
evidence	O
of	O
inflammatory	B-Disease
brain	I-Disease
lesions	I-Disease
.	O
	
gch1	O
mutation	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
.	O
	
the	O
authors	O
report	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
gch1	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
and	O
no	O
obvious	O
family	O
history	O
of	O
dystonia	B-Disease
.	O
	
these	O
findings	O
demonstrate	O
that	O
gch1	O
mutations	O
must	O
be	O
considered	O
even	O
in	O
patients	O
with	O
dystonic	B-Disease
symptoms	O
not	O
typical	O
of	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
.	O
	
germline	O
mutations	O
of	O
the	O
apc	B-Disease
gene	O
in	O
korean	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
.	O
	
we	O
extensively	O
analyzed	O
genomic	O
dna	O
and	O
messenger	O
rna	O
(	O
mrna	O
)	O
from	O
62	O
unrelated	O
korean	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
for	O
identification	O
of	O
germline	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
mutations	O
.	O
	
nineteen	O
of	O
the	O
detected	O
mutations	O
were	O
presumed	O
to	O
be	O
novel	O
,	O
thus	O
emphasizing	O
the	O
heterogeneity	O
of	O
the	O
mutational	O
spectrum	O
in	O
korean	O
fap	B-Disease
patients	O
.	O
	
using	O
this	O
combined	O
approach	O
,	O
we	O
identified	O
germline	O
apc	B-Disease
gene	O
mutations	O
in	O
29	O
of	O
the	O
48	O
fap	B-Disease
patients	O
(	O
60	O
%	O
)	O
,	O
including	O
6	O
patients	O
in	O
whom	O
sscp	O
analysis	O
failed	O
to	O
distinguish	O
the	O
mutant	O
allele	O
.	O
	
our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
ptt	O
was	O
superior	O
to	O
that	O
with	O
sscp	O
,	O
and	O
suggest	O
that	O
ptt	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
apc	B-Disease
gene	O
in	O
fap	B-Disease
patients	O
.	O
	
molecular	O
epidemiology	O
of	O
c9	B-Disease
deficiency	I-Disease
heterozygotes	O
with	O
an	O
arg95stop	O
mutation	O
of	O
the	O
c9	O
gene	O
in	O
japan	O
.	O
	
deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
c9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	I-Disease
in	O
japan	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries	O
.	O
	
genetic	O
analyses	O
of	O
japanese	O
c9	B-Disease
deficiency	I-Disease
have	O
shown	O
that	O
a	O
c	O
-	O
to	O
-	O
t	O
transition	O
leading	O
to	O
tga	O
stop	O
codon	O
for	O
arg95	O
in	O
exon	O
4	O
of	O
the	O
c9	O
gene	O
(	O
arg95stop	O
)	O
is	O
common	O
in	O
japanese	O
c9	B-Disease
deficiency	I-Disease
.	O
	
an	O
estimated	O
frequency	O
(	O
0	O
.	O
	
12	O
%	O
)	O
of	O
complete	O
c9	B-Disease
deficiency	I-Disease
due	O
to	O
homozygous	O
arg95stop	O
mutation	O
was	O
consistent	O
with	O
frequencies	O
determined	O
by	O
serological	O
studies	O
the	O
hereditary	B-Disease
hemochromatosis	I-Disease
protein	O
,	O
hfe	O
,	O
specifically	O
regulates	O
transferrin	O
-	O
mediated	O
iron	O
uptake	O
in	O
hela	O
cells	O
.	O
	
hfe	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
feder	O
,	O
j	O
.	O
	
these	O
results	O
also	O
have	O
implications	O
for	O
the	O
understanding	O
of	O
cellular	O
iron	O
homeostasis	O
in	O
organs	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
heart	O
,	O
and	O
spleen	O
that	O
are	O
iron	O
loaded	O
in	O
hereditary	B-Disease
hemochromatotic	I-Disease
individuals	O
lacking	O
functional	O
hfe	O
.	O
	
mutation	O
and	O
haplotype	O
studies	O
of	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
ashkenazi	O
jewish	O
population	O
.	O
	
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	O
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O
	
the	O
fmf	B-Disease
gene	O
(	O
mefv	O
)	O
was	O
cloned	O
recently	O
,	O
and	O
four	O
missense	O
mutations	O
were	O
identified	O
.	O
	
consistent	O
with	O
another	O
recent	O
report	O
,	O
the	O
e148q	O
mutation	O
was	O
observed	O
in	O
patients	O
of	O
several	O
ethnicities	O
and	O
on	O
multiple	O
microsatellite	O
haplotypes	O
,	O
but	O
haplotype	O
data	O
indicate	O
an	O
ancestral	O
relationships	O
between	O
non	O
-	O
jewish	O
italian	O
and	O
ashkenazi	O
jewish	O
patients	O
with	O
fmf	B-Disease
and	O
other	O
affected	O
populations	O
.	O
	
nevertheless	O
,	O
e148q	O
helps	O
account	O
for	O
recessive	O
inheritance	O
in	O
an	O
ashkenazi	O
family	O
previously	O
reported	O
as	O
an	O
unusual	O
case	O
of	O
dominantly	O
inherited	O
fmf	B-Disease
.	O
	
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
with	O
defective	O
fas	O
:	O
genotype	O
influences	O
penetrance	O
.	O
	
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
alps	B-Disease
)	O
is	O
a	O
disorder	B-Disease
of	I-Disease
lymphocyte	I-Disease
homeostasis	I-Disease
and	I-Disease
immunological	I-Disease
tolerance	I-Disease
.	O
	
of	O
17	O
unique	O
apt1	O
mutations	O
in	O
unrelated	O
alps	B-Disease
probands	O
,	O
12	O
(	O
71	O
%	O
)	O
occurred	O
in	O
exons	O
7	O
-	O
9	O
,	O
which	O
encode	O
the	O
intracellular	O
portion	O
of	O
fas	O
.	O
	
two	O
missense	O
fas	O
variants	O
,	O
not	O
restricted	O
to	O
patients	O
with	O
alps	B-Disease
,	O
were	O
identified	O
.	O
	
among	O
the	O
alps	B-Disease
-	O
associated	O
fas	O
mutants	O
,	O
dominant	O
inhibition	O
of	O
apoptosis	O
was	O
much	O
more	O
pronounced	O
in	O
mutants	O
affecting	O
the	O
intracellular	O
,	O
versus	O
extracellular	O
,	O
portion	O
of	O
the	O
fas	O
receptor	O
.	O
	
mutations	O
causing	O
disruption	O
of	O
the	O
intracellular	O
fas	O
death	O
domain	O
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
alps	B-Disease
phenotype	O
features	O
in	O
mutation	O
-	O
bearing	O
relatives	O
.	O
	
significant	O
alps	B-Disease
-	O
related	O
morbidity	O
occurred	O
in	O
44	O
%	O
of	O
relatives	O
with	O
intracellular	O
mutations	O
,	O
versus	O
0	O
%	O
of	O
relatives	O
with	O
extracellular	O
mutations	O
.	O
	
thus	O
,	O
the	O
location	O
of	O
mutations	O
within	O
apt1	O
strongly	O
influences	O
the	O
development	O
and	O
the	O
severity	O
of	O
alps	B-Disease
.	O
	
multicentric	O
origin	O
of	O
hemochromatosis	B-Disease
gene	O
(	O
hfe	O
)	O
mutations	O
.	O
	
genetic	B-Disease
hemochromatosis	I-Disease
(	O
gh	B-Disease
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
european	O
ancestry	O
.	O
	
in	O
northwestern	O
europe	O
,	O
>	O
80	O
%	O
of	O
gh	B-Disease
patients	O
are	O
homozygous	O
for	O
one	O
mutation	O
,	O
the	O
substitution	O
of	O
tyrosine	O
for	O
cysteine	O
at	O
position	O
282	O
(	O
c282y	O
)	O
in	O
the	O
unprocessed	O
protein	O
.	O
	
in	O
a	O
proportion	O
of	O
gh	B-Disease
patients	O
,	O
two	O
mutations	O
are	O
present	O
,	O
c282y	O
and	O
h63d	O
.	O
	
these	O
selection	O
pressures	O
could	O
be	O
due	O
to	O
infectious	B-Disease
diseases	I-Disease
,	O
environmental	O
conditions	O
,	O
or	O
other	O
genetic	B-Disease
disorders	I-Disease
such	O
as	O
anemia	B-Disease
.	O
	
we	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(	O
dbs	O
)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
scandinavia	O
for	O
mutations	O
in	O
hfe	O
,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	B-Disease
.	O
	
identification	O
of	O
the	O
mutation	O
in	O
the	O
alkaptonuria	B-Disease
mouse	O
model	O
.	O
	
alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
,	O
an	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
hgd	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O
	
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
associated	O
with	O
enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
is	O
caused	O
by	O
pds	B-Disease
mutations	O
.	O
	
enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
(	O
eva	B-Disease
)	O
,	O
known	O
as	O
the	O
most	O
common	O
form	O
of	O
inner	B-Disease
ear	I-Disease
abnormality	I-Disease
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	O
interest	O
because	O
this	O
anomaly	O
is	O
inherited	O
in	O
a	O
recessive	O
manner	O
.	O
	
the	O
locus	O
for	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
eva	B-Disease
has	O
been	O
mapped	O
to	O
the	O
same	O
chromosomal	O
region	O
,	O
7q31	O
,	O
as	O
the	O
pendred	B-Disease
syndrome	I-Disease
locus	O
.	O
	
in	O
the	O
present	O
study	O
,	O
seven	O
mutations	O
in	O
the	O
pds	B-Disease
gene	O
(	O
pds	O
)	O
,	O
the	O
gene	O
responsible	O
for	O
pendred	B-Disease
syndrome	I-Disease
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
eva	B-Disease
.	O
	
the	O
present	O
results	O
provide	O
evidence	O
that	O
mutations	O
in	O
pds	O
cause	O
both	O
syndromic	B-Disease
and	I-Disease
non	I-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
.	O
	
mutational	O
analysis	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
29	O
unrelated	O
japanese	O
patients	O
with	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
.	O
	
background	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ald	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disease	I-Disease
characterized	O
by	O
progressive	O
neurologic	B-Disease
dysfunction	I-Disease
,	O
occasionally	O
associated	O
with	O
adrenal	B-Disease
insufficiency	I-Disease
.	O
	
the	O
classic	O
form	O
of	O
ald	B-Disease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B-Disease
cerebral	I-Disease
ald	I-Disease
)	O
,	O
with	O
rapid	O
neurologic	B-Disease
deterioration	I-Disease
leading	O
to	O
a	O
vegetative	O
state	O
.	O
	
adult	O
-	O
onset	O
cerebral	B-Disease
ald	I-Disease
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	B-Disease
dysfunction	I-Disease
.	O
	
milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B-Disease
and	O
addison	B-Disease
disease	I-Disease
only	O
also	O
have	O
been	O
recognized	O
.	O
	
objectives	O
to	O
conduct	O
mutational	O
analyses	O
in	O
29	O
japanese	O
patients	O
with	O
ald	B-Disease
from	O
29	O
unrelated	O
families	O
,	O
to	O
obtain	O
knowledge	O
of	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
,	O
and	O
to	O
study	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
japanese	O
patients	O
.	O
	
methods	O
the	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B-Disease
cerebral	I-Disease
ald	I-Disease
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ald	I-Disease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
.	O
	
we	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
japanese	O
patients	O
with	O
ald	B-Disease
by	O
genomic	O
southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
rna	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts	O
,	O
lymphoblastoid	O
cells	O
,	O
or	O
peripheral	O
blood	O
leukocytes	O
.	O
	
results	O
three	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ald	I-Disease
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O
	
the	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations	O
,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ald	B-Disease
gene	O
.	O
	
conclusions	O
there	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ald	B-Disease
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ald	B-Disease
.	O
	
a	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta	O
-	O
catenin	O
.	O
	
one	O
of	O
the	O
target	O
genes	O
for	O
beta	O
-	O
catenin	O
/	O
tcf	O
encodes	O
c	O
-	O
myc	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
wnt	O
pathway	O
can	O
lead	O
to	O
cancer	B-Disease
,	O
particularly	O
in	O
the	O
colon	O
.	O
	
most	O
colon	B-Disease
cancers	I-Disease
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta	O
-	O
catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	B-Disease
and	I-Disease
some	I-Disease
other	I-Disease
cancers	I-Disease
harbour	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O
	
recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-Disease
tumours	I-Disease
resembling	O
pilomatricomas	B-Disease
.	O
	
given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B-Disease
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O
	
here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
.	O
	
we	O
found	O
nuclear	O
lef	O
-	O
1	O
in	O
the	O
dividing	O
tumour	B-Disease
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	B-Disease
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O
	
at	O
least	O
75	O
%	O
of	O
these	O
tumours	B-Disease
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O
	
this	O
percentage	O
of	O
ctnnb1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	B-Disease
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta	O
-	O
catenin	O
/	O
lef	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
	
the	O
pendred	B-Disease
syndrome	I-Disease
gene	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O
	
pendred	B-Disease
syndrome	I-Disease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-Disease
deafness	I-Disease
and	O
characterized	O
by	O
congenital	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
and	O
goitre	B-Disease
.	O
	
this	O
disorder	O
was	O
mapped	O
to	O
chromosome	O
7	O
and	O
the	O
gene	O
causing	O
pendred	B-Disease
syndrome	I-Disease
(	O
pds	B-Disease
)	O
was	O
subsequently	O
identified	O
by	O
positional	O
cloning	O
.	O
	
pendrin	O
is	O
closely	O
related	O
to	O
a	O
family	O
of	O
sulfate	O
transport	O
proteins	O
that	O
includes	O
the	O
rat	O
sulfate	O
-	O
anion	O
transporter	O
(	O
encoded	O
by	O
sat	O
-	O
1	O
;	O
29	O
%	O
amino	O
acid	O
sequence	O
identity	O
)	O
,	O
the	O
human	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
transporter	O
(	O
encoded	O
by	O
dtd	O
;	O
32	O
%	O
)	O
and	O
the	O
human	O
sulfate	O
transporter	O
downregulated	O
in	O
adenoma	B-Disease
(	O
encoded	O
by	O
dra	O
;	O
45	O
%	O
)	O
.	O
	
our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
pendred	B-Disease
syndrome	I-Disease
.	O
	
hfe	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	B-Disease
probands	O
:	O
evidence	O
for	O
s65c	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O
	
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
hh	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
of	O
iron	O
metabolism	O
.	O
	
the	O
hfe	O
candidate	O
gene	O
encoding	O
an	O
hla	O
class	O
i	O
-	O
like	O
protein	O
involved	O
in	O
hh	B-Disease
was	O
identified	O
in	O
1996	O
.	O
	
two	O
missense	O
mutations	O
have	O
been	O
described	O
c282y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
hh	B-Disease
chromosomes	O
,	O
and	O
h63d	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
c282y	O
hh	B-Disease
chromosomes	O
.	O
	
the	O
results	O
confirm	O
that	O
the	O
c282y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	B-Disease
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
h63d	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
hh	B-Disease
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
c282y	O
mutation	O
.	O
	
8	O
%	O
of	O
hh	B-Disease
chromosomes	O
that	O
were	O
neither	O
c282y	O
nor	O
h63d	O
.	O
	
this	O
enrichment	O
of	O
s65c	O
among	O
hh	B-Disease
chromosomes	O
suggests	O
that	O
the	O
s65c	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O
	
germline	O
brca1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O
	
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
more	O
accurate	O
frequency	O
estimates	O
of	O
breast	B-Disease
cancer	I-Disease
susceptibility	O
gene	O
1	O
(	O
brca1	O
)	O
germline	O
alterations	O
in	O
the	O
ovarian	B-Disease
cancer	I-Disease
population	O
.	O
	
to	O
achieve	O
this	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
brca1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O
	
this	O
is	O
the	O
first	O
population	O
-	O
based	O
ovarian	B-Disease
cancer	I-Disease
study	O
reporting	O
brca1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region	O
.	O
	
one	O
hundred	O
and	O
seven	O
ovarian	B-Disease
cancer	I-Disease
cases	O
were	O
analyzed	O
for	O
brca1	O
alterations	O
using	O
the	O
rnase	O
mismatch	O
cleavage	O
assay	O
followed	O
by	O
direct	O
sequencing	O
.	O
	
both	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	B-Disease
.	O
	
the	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
caucasian	O
cancer	B-Disease
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele	O
-	O
specific	O
amplification	O
.	O
	
the	O
rare	O
form	O
of	O
the	O
q356r	O
polymorphism	O
was	O
significantly	O
(	O
p	O
=	O
0	O
.	O
	
3	O
)	O
associated	O
with	O
a	O
family	O
history	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
suggesting	O
that	O
this	O
polymorphism	O
may	O
influence	O
ovarian	B-Disease
cancer	I-Disease
risk	O
.	O
	
in	O
summary	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
some	O
uncharacterized	O
variants	O
and	O
rare	O
forms	O
of	O
polymorphisms	O
in	O
determining	O
ovarian	B-Disease
cancer	I-Disease
risk	O
,	O
and	O
highlight	O
the	O
necessity	O
to	O
screen	O
for	O
missense	O
alterations	O
as	O
well	O
as	O
truncating	O
mutations	O
in	O
this	O
population	O
.	O
	
adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-Disease
protein	I-Disease
deficiency	I-Disease
(	O
x	B-Disease
-	I-Disease
ald	I-Disease
)	O
:	O
implications	O
for	O
therapy	O
.	O
	
inherited	B-Disease
defects	I-Disease
in	O
the	O
peroxisomal	O
atp	O
-	O
binding	O
cassette	O
(	O
abc	O
)	O
transporter	O
adrenoleukodystrophy	B-Disease
protein	O
(	O
aldp	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B-Disease
disorder	I-Disease
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
x	B-Disease
-	I-Disease
ald	I-Disease
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O
	
by	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cdnas	O
encoding	O
aldp	O
and	O
its	O
closest	O
relative	O
aldrp	O
,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta	O
-	O
oxidation	O
in	O
fibroblasts	O
of	O
x	B-Disease
-	I-Disease
ald	I-Disease
patients	O
.	O
	
these	O
results	O
suggest	O
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	O
in	O
x	B-Disease
-	I-Disease
ald	I-Disease
could	O
be	O
possible	O
by	O
drug	O
-	O
induced	O
overexpression	O
or	O
ectopic	O
expression	O
of	O
aldrp	O
.	O
	
germline	O
mutations	O
of	O
the	O
brca1	O
tumor	B-Disease
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
however	O
,	O
a	O
defective	O
g2	O
-	O
m	O
checkpoint	O
in	O
these	O
cells	O
is	O
accompanied	O
by	O
extensive	O
chromosomal	B-Disease
abnormalities	I-Disease
.	O
	
mutant	O
fibroblasts	O
contain	O
multiple	O
,	O
functional	O
centrosomes	O
,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation	O
,	O
abnormal	O
nuclear	O
division	O
,	O
and	O
aneuploidy	B-Disease
.	O
	
defective	O
cd95	O
/	O
apo	O
-	O
1	O
/	O
fas	O
signal	O
complex	O
formation	O
in	O
the	O
human	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
,	I-Disease
type	I-Disease
ia	I-Disease
.	O
	
heterozygous	O
mutations	O
in	O
the	O
cd95	O
(	O
apo	O
-	O
1	O
/	O
fas	O
)	O
receptor	O
occur	O
in	O
most	O
individuals	O
with	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
alps	B-Disease
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism	O
.	O
	
we	O
show	O
that	O
local	O
or	O
global	O
alterations	O
in	O
the	O
structure	O
of	O
the	O
cytoplasmic	O
death	O
domain	O
from	O
nine	O
independent	O
alps	B-Disease
cd95	O
death	O
-	O
domain	O
mutations	O
result	O
in	O
a	O
failure	O
to	O
bind	O
the	O
fadd	O
/	O
mort1	O
signaling	O
protein	O
.	O
	
despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele	O
,	O
lymphocytes	O
from	O
alps	B-Disease
patients	O
showed	O
markedly	O
decreased	O
fadd	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
cd95	O
crosslinking	O
.	O
	
these	O
data	O
suggest	O
that	O
intracytoplasmic	O
cd95	O
mutations	O
in	O
alps	B-Disease
impair	O
apoptosis	O
chiefly	O
by	O
disrupting	O
death	O
-	O
domain	O
interactions	O
with	O
the	O
signaling	O
protein	O
fadd	O
/	O
mort1	O
.	O
	
analysis	O
of	O
alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
ccc	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
hgo	O
)	O
.	O
	
we	O
recently	O
showed	O
that	O
alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
is	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
hgo	O
)	O
.	O
	
herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
hgo	O
in	O
seven	O
new	O
aku	B-Disease
pedigrees	O
.	O
	
these	O
analyses	O
identified	O
two	O
novel	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
inv4	O
+	O
31a	O
-	O
-	O
>	O
g	O
and	O
inv11	O
+	O
18a	O
-	O
-	O
>	O
g	O
)	O
and	O
six	O
novel	O
aku	B-Disease
mutations	O
(	O
inv1	O
-	O
1g	O
-	O
-	O
>	O
a	O
,	O
w60g	O
,	O
y62c	O
,	O
a122d	O
,	O
p230t	O
,	O
and	O
d291e	O
)	O
,	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	O
found	O
in	O
aku	B-Disease
.	O
	
fabry	B-Disease
disease	I-Disease
:	O
identification	O
of	O
novel	O
alpha	O
-	O
galactosidase	O
a	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches	O
.	O
	
fabry	B-Disease
disease	I-Disease
(	O
fd	B-Disease
)	O
(	O
angiokeratoma	B-Disease
corporis	I-Disease
diffusum	I-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
inborn	I-Disease
error	I-Disease
of	I-Disease
glycosphingolipid	I-Disease
metabolism	I-Disease
caused	O
by	O
defects	O
in	O
the	O
lysosomal	O
alpha	O
-	O
galactosidase	O
a	O
gene	O
(	O
gla	O
)	O
.	O
	
clinically	O
,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	B-Disease
,	O
severe	B-Disease
acroparesthesia	I-Disease
,	O
renal	B-Disease
failure	I-Disease
,	O
and	O
vasculopathy	B-Disease
of	I-Disease
the	I-Disease
heart	I-Disease
and	I-Disease
brain	I-Disease
.	O
	
while	O
demonstration	O
of	O
alpha	B-Disease
-	I-Disease
galactosidase	I-Disease
deficiency	I-Disease
in	O
leukocytes	O
is	O
diagnostic	O
in	O
affected	O
males	O
,	O
enzymatic	O
detection	O
of	O
female	O
carriers	O
is	O
often	O
inconclusive	O
,	O
due	O
to	O
random	O
x	O
-	O
chromosomal	O
inactivation	O
,	O
underlining	O
the	O
need	O
of	O
molecular	O
investigations	O
for	O
accurate	O
genetic	O
counseling	O
.	O
	
by	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence	O
-	O
based	O
detection	O
systems	O
,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha	B-Disease
-	I-Disease
gal	I-Disease
a	I-Disease
deficiency	I-Disease
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
fd	B-Disease
.	O
	
prenatal	O
diagnosis	O
by	O
fish	O
in	O
a	O
family	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
caused	O
by	O
duplication	O
of	O
plp	O
gene	O
.	O
	
a	O
diagnosis	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
mim	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	O
boy	O
.	O
	
the	O
proband	O
was	O
found	O
to	O
carry	O
the	O
duplication	O
,	O
thus	O
confirming	O
the	O
diagnosis	O
of	O
pelizaeus	B-Disease
merzbacher	I-Disease
disease	I-Disease
,	O
but	O
neither	O
the	O
aunt	O
nor	O
the	O
fetus	O
carried	O
a	O
duplication	O
.	O
	
dominant	O
negative	O
effect	O
of	O
the	O
apc1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O
	
inactivation	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O
	
patients	O
with	O
familial	B-Disease
apc	I-Disease
(	O
fap	B-Disease
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
apc	B-Disease
gene	O
and	O
develop	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	O
subsequent	O
carcinomas	B-Disease
early	O
in	O
life	O
.	O
	
the	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
apc	B-Disease
mutation	O
(	O
genotype	O
-	O
phenotype	O
correlation	O
)	O
.	O
	
together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
apc	B-Disease
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
apc	B-Disease
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
apc	B-Disease
mutants	O
.	O
	
loss	O
of	O
apc	B-Disease
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta	O
-	O
catenin	O
-	O
/	O
tcf	O
-	O
mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells	O
.	O
	
here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
apc	B-Disease
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B-Disease
.	O
	
wild	O
-	O
type	O
apc	B-Disease
activity	O
in	O
beta	O
-	O
catenin	O
-	O
/	O
tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
apc	B-Disease
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O
	
in	O
contrast	O
,	O
mutant	O
apc	B-Disease
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B-Disease
polyposis	I-Disease
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	O
-	O
type	O
apc	B-Disease
activity	O
.	O
	
these	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
fap	B-Disease
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B-Disease
tumor	I-Disease
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
	
germ	O
-	O
line	O
mutations	O
in	O
the	O
brca1	O
tumor	O
-	O
suppressor	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
combined	B-Disease
genetic	I-Disease
deficiency	I-Disease
of	I-Disease
c6	I-Disease
and	I-Disease
c7	I-Disease
in	O
man	O
.	O
	
by	O
routine	O
screening	O
of	O
sera	O
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub	B-Disease
-	I-Disease
total	I-Disease
deficiency	I-Disease
of	I-Disease
c6	I-Disease
and	I-Disease
c7	I-Disease
.	O
	
no	O
clinical	O
disease	O
was	O
associated	O
with	O
this	O
deficiency	O
which	O
was	O
transmitted	O
through	O
the	O
subjects	O
family	O
as	O
a	O
single	O
genetic	O
characteristic	O
,	O
the	O
c6	B-Disease
deficiency	I-Disease
being	O
associated	O
with	O
a	O
silent	O
allele	O
at	O
the	O
structural	O
locus	O
.	O
	
changes	O
at	O
p183	O
of	O
emerin	O
weaken	O
its	O
protein	O
-	O
protein	O
interactions	O
resulting	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
edmd	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
muscular	I-Disease
dystrophy	I-Disease
characterized	O
by	O
early	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
,	I-Disease
achilles	I-Disease
tendons	I-Disease
and	I-Disease
spine	I-Disease
,	O
slowly	O
progressive	O
muscle	B-Disease
wasting	I-Disease
and	O
weakness	B-Disease
,	O
and	O
cardiomyopathy	B-Disease
associated	O
with	O
cardiac	B-Disease
conduction	I-Disease
defects	I-Disease
.	O
	
mutations	O
spanning	O
the	O
emerin	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
edmd	B-Disease
.	O
	
we	O
present	O
here	O
the	O
effect	O
,	O
on	O
emerin	O
protein	O
expression	O
,	O
of	O
two	O
missense	O
mutations	O
identified	O
in	O
unrelated	O
edmd	B-Disease
patients	O
.	O
	
in	O
comparison	O
with	O
the	O
usual	O
edmd	B-Disease
phenotype	O
,	O
patients	O
with	O
p183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms	O
,	O
elbow	B-Disease
contractures	I-Disease
,	O
ankle	B-Disease
contractures	I-Disease
,	O
upper	B-Disease
limb	I-Disease
weakness	I-Disease
and	O
lower	B-Disease
limb	I-Disease
weakness	I-Disease
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	B-Disease
involvement	I-Disease
.	O
	
this	O
is	O
the	O
first	O
report	O
of	O
protein	O
studies	O
on	O
patients	O
with	O
missense	O
mutations	O
resulting	O
in	O
the	O
clinical	O
features	O
of	O
edmd	B-Disease
.	O
	
microdeletions	O
at	O
chromosome	O
bands	O
1q32	O
-	O
q41	O
as	O
a	O
cause	O
of	O
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
.	O
	
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
(	O
vws	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
comprising	O
cleft	B-Disease
lip	I-Disease
and	O
/	O
or	O
cleft	B-Disease
palate	I-Disease
and	O
lip	B-Disease
pits	I-Disease
.	O
	
along	O
with	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
and	O
lip	B-Disease
pits	I-Disease
,	O
affected	O
relatives	O
exhibit	O
developmental	B-Disease
delays	I-Disease
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted	O
.	O
	
to	O
further	O
localize	O
the	O
vws	B-Disease
gene	O
we	O
searched	O
for	O
other	O
deletions	O
that	O
cause	O
vws	B-Disease
.	O
	
in	O
this	O
family	O
,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
vws	B-Disease
.	O
	
no	O
deletions	O
were	O
detected	O
in	O
seven	O
cases	O
of	O
popliteal	B-Disease
pterygia	I-Disease
syndrome	I-Disease
,	O
76	O
cases	O
of	O
mixed	O
syndromic	B-Disease
forms	I-Disease
of	I-Disease
cleft	I-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
,	O
and	O
178	O
cases	O
of	O
nonsyndromic	B-Disease
cleft	I-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
.	O
	
splicing	O
defects	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
,	O
atm	O
:	O
underlying	O
mutations	O
and	O
consequences	O
.	O
	
mutations	O
resulting	O
in	O
defective	O
splicing	O
constitute	O
a	O
significant	O
proportion	O
(	O
30	O
/	O
62	O
[	O
48	O
%	O
]	O
)	O
of	O
a	O
new	O
series	O
of	O
mutations	O
in	O
the	O
atm	O
gene	O
in	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
at	B-Disease
)	O
that	O
were	O
detected	O
by	O
the	O
protein	O
-	O
truncation	O
assay	O
followed	O
by	O
sequence	O
analysis	O
of	O
genomic	O
dna	O
.	O
	
no	O
atm	O
protein	O
was	O
detected	O
by	O
western	O
blotting	O
in	O
any	O
at	B-Disease
cell	O
line	O
in	O
which	O
splicing	O
mutations	O
were	O
identified	O
.	O
	
alpha	O
-	O
cardiac	O
actin	O
is	O
a	O
novel	O
disease	O
gene	O
in	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
.	O
	
we	O
identified	O
the	O
alpha	O
-	O
cardiac	O
actin	O
gene	O
(	O
actc	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
(	O
fhc	B-Disease
)	O
.	O
	
linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
fhc	B-Disease
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied	O
,	O
with	O
lod	O
scores	O
varying	O
between	O
-	O
2	O
.	O
	
mutation	O
analysis	O
of	O
actc	O
revealed	O
an	O
ala295ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
(	O
idc	B-Disease
)	O
.	O
	
overgrowth	B-Disease
of	I-Disease
oral	I-Disease
mucosa	I-Disease
and	I-Disease
facial	I-Disease
skin	I-Disease
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B-Disease
.	O
	
aspartylglucosaminuria	B-Disease
(	O
agu	B-Disease
)	O
is	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
aspartylglucosaminidase	I-Disease
(	O
aga	O
)	O
.	O
	
the	O
main	O
symptom	O
is	O
progressive	O
mental	B-Disease
retardation	I-Disease
.	O
	
we	O
were	O
able	O
to	O
examine	O
66	O
finnish	O
agu	B-Disease
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O
	
biopsy	O
specimens	O
of	O
16	O
oral	O
lesions	O
,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth	O
,	O
plus	O
two	O
facial	B-Disease
lesions	I-Disease
were	O
studied	O
histologically	O
.	O
	
skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B-Disease
of	I-Disease
the	I-Disease
facial	I-Disease
skin	I-Disease
already	O
common	O
in	O
childhood	O
.	O
	
of	O
44	O
patients	O
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B-Disease
angiofibromas	I-Disease
,	O
tumours	B-Disease
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	B-Disease
sclerosis	I-Disease
.	O
	
oedemic	B-Disease
buccal	I-Disease
mucosa	I-Disease
(	O
leucoedema	B-Disease
)	O
and	O
gingival	B-Disease
overgrowths	I-Disease
were	O
more	O
frequent	O
in	O
agu	B-Disease
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
	
1	O
)	O
.	O
	
of	O
16	O
oral	B-Disease
mucosal	I-Disease
lesions	I-Disease
studied	O
histologically	O
,	O
15	O
represented	O
fibroepithelial	B-Disease
or	I-Disease
epithelial	I-Disease
hyperplasias	I-Disease
and	O
were	O
reactive	O
in	O
nature	O
.	O
	
immunohistochemically	O
,	O
expression	O
of	O
aga	O
in	O
agu	B-Disease
patients	O
mucosal	B-Disease
lesions	I-Disease
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O
	
thus	O
,	O
the	O
high	O
frequency	O
of	O
mucosal	B-Disease
overgrowth	I-Disease
in	O
agu	B-Disease
patients	O
does	O
not	O
appear	O
to	O
be	O
directly	O
associated	O
with	O
lysosomal	O
storage	O
or	O
with	O
alterations	O
in	O
the	O
level	O
of	O
aga	O
expression	O
.	O
	
characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
lowe	B-Disease
syndrome	I-Disease
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
ocrl1	O
gene	O
.	O
	
the	O
oculocerebrorenal	B-Disease
syndrome	I-Disease
of	I-Disease
lowe	I-Disease
(	O
ocrl	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
characterized	O
by	O
major	O
abnormalities	B-Disease
of	I-Disease
eyes	I-Disease
,	I-Disease
nervous	I-Disease
system	I-Disease
,	I-Disease
and	I-Disease
kidneys	I-Disease
.	O
	
we	O
have	O
examined	O
the	O
ocrl1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
ocrl	B-Disease
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in	O
-	O
frame	O
deletion	O
.	O
	
this	O
observation	O
has	O
direct	O
implications	O
for	O
genetic	O
counseling	O
of	O
lowe	B-Disease
syndrome	I-Disease
families	O
.	O
	
mefv	O
-	O
gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
:	O
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
m694v	O
homozygous	O
genotype	O
-	O
genetic	O
and	O
therapeutic	O
implications	O
.	O
	
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
is	O
a	O
recessively	B-Disease
inherited	I-Disease
disorder	I-Disease
that	O
is	O
common	O
in	O
patients	O
of	O
armenian	O
ancestry	O
.	O
	
to	O
date	O
,	O
its	O
diagnosis	O
,	O
which	O
can	O
be	O
made	O
only	O
retrospectively	O
,	O
is	O
one	O
of	O
exclusion	O
,	O
based	O
entirely	O
on	O
nonspecific	O
clinical	O
signs	O
that	O
result	O
from	O
serosal	B-Disease
inflammation	I-Disease
and	O
that	O
may	O
lead	O
to	O
unnecessary	O
surgery	O
.	O
	
renal	B-Disease
amyloidosis	I-Disease
,	O
prevented	O
by	O
colchicine	O
,	O
is	O
the	O
most	O
severe	O
complication	O
of	O
fmf	B-Disease
,	O
a	O
disorder	O
associated	O
with	O
mutations	O
in	O
the	O
mefv	O
gene	O
.	O
	
to	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
mefv	O
-	O
gene	O
analysis	O
,	O
we	O
investigated	O
90	O
armenian	O
fmf	B-Disease
patients	O
from	O
77	O
unrelated	O
families	O
that	O
were	O
not	O
selected	O
through	O
genetic	O
-	O
linkage	O
analysis	O
.	O
	
eight	O
mutations	O
,	O
one	O
of	O
which	O
(	O
r408q	O
)	O
is	O
new	O
,	O
were	O
found	O
to	O
account	O
for	O
93	O
%	O
of	O
the	O
163	O
independent	O
fmf	B-Disease
alleles	O
,	O
with	O
both	O
fmf	B-Disease
alleles	O
identified	O
in	O
89	O
%	O
of	O
the	O
patients	O
.	O
	
the	O
m694v	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	B-Disease
amyloidosis	I-Disease
and	O
arthritis	B-Disease
,	O
compared	O
with	O
other	O
genotypes	O
(	O
p	O
=	O
.	O
	
noninvasive	O
test	O
for	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
using	O
hair	O
root	O
analysis	O
.	O
	
identification	O
of	O
the	O
fmr1	O
gene	O
and	O
the	O
repeat	O
-	O
amplification	O
mechanism	O
causing	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
led	O
to	O
development	O
of	O
reliable	O
dna	O
-	O
based	O
diagnostic	O
methods	O
,	O
including	O
southern	O
blot	O
hybridization	O
and	O
pcr	O
.	O
	
using	O
an	O
immunocytochemical	O
technique	O
on	O
blood	O
smears	O
,	O
we	O
recently	O
developed	O
a	O
novel	O
test	O
for	O
identification	O
of	O
patients	O
with	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
.	O
	
here	O
we	O
describe	O
a	O
new	O
diagnostic	O
test	O
to	O
identify	O
male	O
patients	O
with	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
on	O
the	O
basis	O
of	O
lack	O
of	O
fmrp	O
in	O
their	O
hair	O
roots	O
.	O
	
expression	O
of	O
fmrp	O
in	O
hair	O
roots	O
was	O
studied	O
by	O
use	O
of	O
an	O
fmrp	O
-	O
specific	O
antibody	O
test	O
,	O
and	O
the	O
percentage	O
of	O
fmrp	O
-	O
expressing	O
hair	O
roots	O
in	O
controls	O
and	O
in	O
male	O
fragile	B-Disease
x	I-Disease
patients	O
was	O
determined	O
.	O
	
control	O
individuals	O
showed	O
clear	O
expression	O
of	O
fmrp	O
in	O
nearly	O
every	O
hair	O
root	O
,	O
whereas	O
male	O
fragile	B-Disease
x	I-Disease
patients	O
lacked	O
expression	O
of	O
fmrp	O
in	O
almost	O
all	O
their	O
hair	O
roots	O
.	O
	
mentally	B-Disease
retarded	I-Disease
female	O
patients	O
with	O
a	O
full	O
mutation	O
showed	O
fmrp	O
expression	O
in	O
only	O
some	O
of	O
their	O
hair	O
roots	O
(	O
<	O
55	O
%	O
)	O
,	O
and	O
no	O
overlap	O
with	O
normal	O
female	O
controls	O
was	O
observed	O
.	O
	
the	O
advantages	O
of	O
this	O
test	O
are	O
(	O
1	O
)	O
plucking	O
of	O
hair	O
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	B-Disease
retarded	I-Disease
patient	O
,	O
(	O
2	O
)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	O
center	O
,	O
and	O
(	O
3	O
)	O
the	O
result	O
of	O
the	O
test	O
is	O
available	O
within	O
5	O
h	O
of	O
plucking	O
.	O
	
in	O
addition	O
,	O
this	O
test	O
enabled	O
us	O
to	O
identify	O
two	O
fragile	B-Disease
x	I-Disease
patients	O
who	O
did	O
not	O
show	O
the	O
full	O
mutation	O
by	O
analysis	O
of	O
dna	O
isolated	O
from	O
blood	O
cells	O
.	O
	
in	O
swedish	O
families	O
with	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
,	O
linkage	O
to	O
the	O
hpc1	O
locus	O
on	O
chromosome	O
1q24	O
-	O
25	O
is	O
restricted	O
to	O
families	O
with	O
early	O
-	O
onset	O
prostate	B-Disease
cancer	I-Disease
.	O
	
prostate	B-Disease
cancer	I-Disease
clusters	O
in	O
some	O
families	O
,	O
and	O
an	O
estimated	O
5	O
%	O
-	O
10	O
%	O
of	O
all	O
cases	O
are	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
prostate	O
cancer	O
-	O
susceptibility	O
genes	O
.	O
	
we	O
previously	O
reported	O
evidence	O
of	O
linkage	O
to	O
the	O
1q24	O
-	O
25	O
region	O
(	O
hpc1	O
)	O
in	O
91	O
north	O
american	O
and	O
swedish	O
families	O
each	O
with	O
multiple	O
cases	O
of	O
prostate	B-Disease
cancer	I-Disease
(	O
smith	O
et	O
al	O
.	O
	
1996	O
)	O
.	O
	
in	O
the	O
present	O
report	O
we	O
analyze	O
40	O
(	O
12	O
original	O
and	O
28	O
newly	O
identified	O
)	O
swedish	O
families	O
with	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
(	O
hpc	B-Disease
)	O
that	O
,	O
on	O
the	O
basis	O
of	O
40	O
markers	O
spanning	O
a	O
25	O
-	O
cm	O
interval	O
within	O
1q24	O
-	O
25	O
,	O
have	O
evidence	O
of	O
linkage	O
.	O
	
these	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
of	O
linkage	O
to	O
hpc1	O
in	O
a	O
subset	O
of	O
families	O
with	O
prostate	B-Disease
cancer	I-Disease
,	O
particularly	O
those	O
with	O
an	O
early	O
age	O
at	O
diagnosis	O
.	O
	
molecular	O
basis	O
of	O
feline	O
beta	B-Disease
-	I-Disease
glucuronidase	I-Disease
deficiency	I-Disease
:	O
an	O
animal	O
model	O
of	O
mucopolysaccharidosis	B-Disease
vii	I-Disease
.	O
	
a	O
family	O
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	O
and	O
biochemical	O
abnormalities	O
consistent	O
with	O
mucopolysaccharidosis	B-Disease
vii	I-Disease
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
beta	B-Disease
-	I-Disease
glucuronidase	I-Disease
deficiency	I-Disease
.	O
	
carriers	O
identified	O
in	O
this	O
manner	O
produced	O
affected	O
kittens	O
in	O
prospective	O
breedings	O
,	O
and	O
a	O
feline	O
mps	B-Disease
vii	I-Disease
breeding	O
colony	O
has	O
been	O
established	O
.	O
	
a	O
common	O
molecular	O
basis	O
for	O
rearrangement	B-Disease
disorders	I-Disease
on	O
chromosome	O
22q11	O
.	O
	
the	O
chromosome	O
22q11	O
region	O
is	O
susceptible	O
to	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
and	O
malignant	B-Disease
tumors	I-Disease
.	O
	
three	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
,	O
cat	B-Disease
-	I-Disease
eye	I-Disease
syndrome	I-Disease
,	O
der	B-Disease
(	I-Disease
)	I-Disease
syndrome	I-Disease
and	O
velo	B-Disease
-	I-Disease
cardio	I-Disease
-	I-Disease
facial	I-Disease
syndrome	I-Disease
/	O
digeorge	B-Disease
syndrome	I-Disease
(	O
vcfs	B-Disease
/	O
dgs	B-Disease
)	O
are	O
associated	O
with	O
tetrasomy	O
,	O
trisomy	O
or	O
monosomy	O
,	O
respectively	O
,	O
for	O
part	O
of	O
chromosome	O
22q11	O
.	O
	
vcfs	B-Disease
/	O
dgs	B-Disease
is	O
the	O
most	O
common	O
syndrome	O
associated	O
with	O
22q11	O
rearrangements	O
.	O
	
in	O
order	O
to	O
determine	O
whether	O
there	O
are	O
particular	O
regions	O
on	O
22q11	O
that	O
are	O
prone	O
to	O
rearrangements	O
,	O
the	O
deletion	O
end	O
-	O
points	O
in	O
a	O
large	O
number	O
of	O
vcfs	B-Disease
/	O
dgs	B-Disease
patients	O
were	O
defined	O
by	O
haplotype	O
analysis	O
.	O
	
most	O
vcfs	B-Disease
/	O
dgs	B-Disease
patients	O
have	O
a	O
similar	O
3	O
mb	O
deletion	O
,	O
some	O
have	O
a	O
nested	O
distal	O
deletion	O
breakpoint	O
resulting	O
in	O
a	O
1	O
.	O
	
to	O
investigate	O
this	O
hypothesis	O
,	O
we	O
developed	O
hamster	O
-	O
human	O
somatic	O
hybrid	O
cell	O
lines	O
from	O
vcfs	B-Disease
/	O
dgs	B-Disease
patients	O
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	O
within	O
similar	O
low	O
copy	O
repeats	O
,	O
termed	O
lcr22s	O
.	O
	
to	O
support	O
this	O
idea	O
further	O
,	O
we	O
identified	O
a	O
family	O
that	O
carries	O
an	O
interstitial	O
duplication	O
of	O
the	O
same	O
3	O
mb	O
region	O
that	O
is	O
deleted	O
in	O
vcfs	B-Disease
/	O
dgs	B-Disease
patients	O
.	O
	
we	O
present	O
models	O
to	O
explain	O
how	O
the	O
lcr22s	O
can	O
mediate	O
different	O
homologous	O
recombination	O
events	O
,	O
thereby	O
generating	O
a	O
number	O
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
.	O
	
functional	O
consequences	O
of	O
mutations	O
in	O
the	O
early	O
growth	O
response	O
2	O
gene	O
(	O
egr2	O
)	O
correlate	O
with	O
severity	O
of	O
human	O
myelinopathies	B-Disease
.	O
	
this	O
idea	O
is	O
based	O
partly	O
on	O
the	O
phenotype	O
of	O
homozygous	O
krox20	O
(	O
egr2	O
)	O
knockout	O
mice	O
,	O
which	O
display	O
hypomyelination	B-Disease
of	I-Disease
the	I-Disease
pns	I-Disease
and	O
a	O
block	O
of	O
schwann	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O
	
mutations	O
in	O
the	O
human	O
egr2	O
gene	O
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	B-Disease
peripheral	I-Disease
neuropathies	I-Disease
charcot	B-Disease
-	I-Disease
marie	I-Disease
-	I-Disease
tooth	I-Disease
type	I-Disease
1	I-Disease
,	O
dejerine	B-Disease
-	I-Disease
sottas	I-Disease
syndrome	I-Disease
and	O
congenital	B-Disease
hypomyelinating	I-Disease
neuropathy	I-Disease
.	O
	
autosomal	B-Disease
recessive	I-Disease
familial	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
with	O
continued	O
secretion	O
of	O
mutant	O
weakly	O
active	O
vasopressin	O
.	O
	
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
post	O
-	O
natal	O
development	O
of	O
arginine	B-Disease
vasopressin	I-Disease
(	I-Disease
avp	I-Disease
)	I-Disease
deficiency	I-Disease
due	O
to	O
mutations	O
in	O
the	O
avp	O
gene	O
.	O
	
all	O
published	O
mutations	O
affect	O
the	O
signal	O
peptide	O
or	O
the	O
neurophysin	O
-	O
ii	O
carrier	O
protein	O
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone	O
,	O
leading	O
to	O
neuronal	B-Disease
damage	I-Disease
.	O
	
we	O
studied	O
an	O
unusual	O
palestinian	O
family	O
consisting	O
of	O
asymptomatic	O
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	O
with	O
neurohypophyseal	B-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
suggesting	O
autosomal	O
recessive	O
inheritance	O
.	O
	
the	O
youngest	O
child	O
(	O
2	O
years	O
old	O
)	O
was	O
only	O
mildly	O
affected	O
but	O
had	O
leu	O
-	O
avp	O
levels	O
similar	O
to	O
her	O
severely	O
affected	O
8	O
-	O
year	O
-	O
old	O
brother	O
,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	B-Disease
of	I-Disease
active	I-Disease
avp	I-Disease
in	O
very	O
young	O
children	O
.	O
	
.	O
	
a	O
somatic	O
mutation	O
in	O
the	O
x	O
linked	O
piga	O
gene	O
is	O
responsible	O
for	O
the	O
deficiency	B-Disease
of	I-Disease
glycosyl	I-Disease
phosphatidylinositol	I-Disease
(	I-Disease
gpi	I-Disease
)	I-Disease
-	I-Disease
anchored	I-Disease
proteins	I-Disease
on	O
blood	O
cells	O
from	O
patients	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
.	O
	
no	O
inherited	O
form	O
of	O
gpi	B-Disease
-	I-Disease
anchor	I-Disease
deficiency	I-Disease
has	O
been	O
described	O
.	O
	
because	O
conventional	O
piga	O
gene	O
knockout	O
is	O
associated	O
with	O
high	O
embryonic	B-Disease
lethality	I-Disease
in	O
chimeric	O
mice	O
,	O
we	O
used	O
the	O
cre	O
/	O
loxp	O
system	O
.	O
	
piga	O
(	O
-	O
)	O
cells	O
had	O
no	O
growth	O
advantage	O
,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
.	O
	
the	O
c282y	O
mutation	O
causing	O
hereditary	B-Disease
hemochromatosis	I-Disease
does	O
not	O
produce	O
a	O
nan	O
allele	O
.	O
	
targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	B-Disease
gene	O
(	O
hfe	O
)	O
locus	O
.	O
	
this	O
mutation	O
is	O
identical	O
to	O
the	O
disease	O
-	O
causing	O
mutation	O
in	O
patients	O
with	O
hereditary	B-Disease
hemochromatosis	I-Disease
.	O
	
genotype	O
-	O
phenotype	O
analysis	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
identification	O
of	O
a	O
missense	O
mutation	O
associated	O
with	O
a	O
milder	O
phenotype	O
.	O
	
direct	O
sequencing	O
of	O
the	O
emerin	O
gene	O
in	O
22	O
families	O
with	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
emd	B-Disease
)	O
revealed	O
mutations	O
in	O
21	O
(	O
95	O
%	O
)	O
,	O
confirming	O
that	O
emerin	O
mutations	O
can	O
be	O
identified	O
in	O
the	O
majority	O
of	O
families	O
with	O
x	B-Disease
-	I-Disease
linked	I-Disease
emd	I-Disease
.	O
	
age	O
at	O
onset	O
was	O
later	O
for	O
first	O
symptoms	O
and	O
for	O
development	O
of	O
ankle	B-Disease
contractures	I-Disease
and	O
muscle	B-Disease
weakness	I-Disease
.	O
	
severe	O
clinical	O
expression	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
edmd	B-Disease
)	O
is	O
a	O
relatively	O
rare	O
benign	B-Disease
neuromuscular	I-Disease
disorder	I-Disease
which	O
can	O
vary	O
remarkably	O
in	O
onset	O
,	O
course	O
and	O
severity	O
.	O
	
in	O
the	O
present	O
study	O
,	O
a	O
tctac	O
deletion	O
spanning	O
the	O
nucleotides	O
631	O
-	O
635	O
of	O
the	O
emerin	O
gene	O
caused	O
an	O
unusually	O
severe	O
disease	O
phenotype	O
including	O
loss	B-Disease
of	I-Disease
ambulation	I-Disease
and	O
severe	O
muscle	B-Disease
wasting	I-Disease
in	O
two	O
affected	O
brothers	O
.	O
	
the	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
common	O
mutations	O
in	O
brca1	O
and	O
brca2	O
do	O
not	O
contribute	O
to	O
early	O
prostate	B-Disease
cancer	I-Disease
in	O
jewish	O
men	O
.	O
	
background	O
families	O
with	O
a	O
high	O
incidence	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
and	O
subsequently	O
shown	O
to	O
have	O
terminating	O
mutations	O
in	O
brca1	O
or	O
brca2	O
,	O
appear	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
prostate	B-Disease
cancer	I-Disease
among	O
male	O
relatives	O
.	O
	
we	O
aimed	O
to	O
determine	O
whether	O
the	O
common	O
germline	O
mutations	O
of	O
brca1	O
or	O
brca2	O
in	O
ashkenazi	O
jewish	O
men	O
predisposed	O
them	O
to	O
prostate	B-Disease
cancer	I-Disease
.	O
	
methods	O
we	O
examined	O
genomic	O
dna	O
from	O
83	O
(	O
for	O
brca1	O
185delag	O
)	O
or	O
82	O
(	O
for	O
brca2	O
6174delt	O
)	O
ashkenazi	O
jewish	O
prostate	B-Disease
cancer	I-Disease
patients	O
,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	O
age	O
,	O
for	O
the	O
most	O
common	O
germline	O
mutation	O
in	O
each	O
gene	O
seen	O
in	O
the	O
ashkenazi	O
population	O
.	O
	
results	O
our	O
study	O
should	O
have	O
been	O
able	O
to	O
detect	O
a	O
4	O
-	O
5	O
-	O
fold	O
increase	O
in	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
due	O
to	O
mutation	O
of	O
brca1	O
or	O
brca2	O
.	O
	
conclusions	O
the	O
incidence	O
of	O
each	O
of	O
the	O
germline	O
mutations	O
in	O
these	O
prostate	B-Disease
cancer	I-Disease
patients	O
closely	O
matched	O
their	O
incidence	O
(	O
about	O
1	O
%	O
)	O
in	O
the	O
general	O
ashkenazi	O
jewish	O
population	O
.	O
	
this	O
suggests	O
that	O
unlike	O
cases	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
mutations	O
in	O
brca1	O
or	O
brca2	O
do	O
not	O
significantly	O
predispose	O
men	O
to	O
prostate	B-Disease
cancer	I-Disease
beta	O
-	O
catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
ctnnb1	O
gene	O
in	O
hepatoblastoma	B-Disease
.	O
	
hepatoblastoma	B-Disease
is	O
a	O
rare	O
malignant	B-Disease
tumor	I-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O
	
epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B-Disease
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O
	
in	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
apc	B-Disease
tumor	I-Disease
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	B-Disease
tumorigenesis	O
.	O
	
in	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta	O
-	O
catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B-Disease
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
,	O
we	O
observed	O
increased	O
beta	O
-	O
catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-Disease
.	O
	
sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
(	O
ctnnb1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	B-Disease
samples	O
.	O
	
our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta	O
-	O
catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-Disease
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
may	O
substitute	O
biallelic	O
apc	O
inactivation	O
in	O
this	O
tumor	B-Disease
type	O
.	O
	
decrease	O
in	O
gtp	O
cyclohydrolase	O
i	O
gene	O
expression	O
caused	O
by	O
inactivation	O
of	O
one	O
allele	O
in	O
hereditary	B-Disease
progressive	I-Disease
dystonia	I-Disease
with	O
marked	O
diurnal	O
fluctuation	O
.	O
	
hereditary	B-Disease
progressive	I-Disease
dystonia	I-Disease
with	O
marked	O
diurnal	O
fluctuation	O
(	O
hpd	B-Disease
;	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
,	O
drd	B-Disease
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
the	O
gtp	O
cyclohydrolase	O
i	O
(	O
gch1	O
)	O
gene	O
.	O
	
these	O
results	O
suggest	O
that	O
some	O
novel	O
mutations	O
should	O
exist	O
on	O
one	O
of	O
the	O
alleles	O
in	O
some	O
unknown	O
region	O
of	O
the	O
gch1	O
gene	O
,	O
and	O
may	O
decrease	O
the	O
gch1	O
mrna	O
causing	O
the	O
hpd	B-Disease
/	O
drd	B-Disease
symptoms	O
.	O
	
sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B-Disease
syndrome	I-Disease
thyrocytes	O
.	O
	
pendred	B-Disease
syndrome	I-Disease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-Disease
deafness	I-Disease
,	O
characterized	O
by	O
dyshormonogenic	B-Disease
goiter	I-Disease
associated	O
with	O
sensory	B-Disease
-	I-Disease
neural	I-Disease
deafness	I-Disease
.	O
	
the	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
pds	B-Disease
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B-Disease
goiter	I-Disease
and	O
sensory	B-Disease
-	I-Disease
neural	I-Disease
deafness	I-Disease
remains	O
an	O
enigma	O
.	O
	
we	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
pendred	B-Disease
syndrome	I-Disease
patients	O
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O
	
small	O
deletions	O
in	O
the	O
type	O
ii	O
collagen	O
triple	O
helix	O
produce	O
kniest	B-Disease
dysplasia	I-Disease
.	O
	
kniest	B-Disease
dysplasia	I-Disease
is	O
a	O
moderately	O
severe	O
type	B-Disease
ii	I-Disease
collagenopathy	I-Disease
,	O
characterized	O
by	O
short	O
trunk	O
and	O
limbs	O
,	O
kyphoscoliosis	B-Disease
,	O
midface	B-Disease
hypoplasia	I-Disease
,	O
severe	O
myopia	B-Disease
,	O
and	O
hearing	B-Disease
loss	I-Disease
.	O
	
mutations	O
in	O
the	O
gene	O
that	O
encodes	O
type	O
ii	O
collagen	O
(	O
col2a1	O
)	O
,	O
the	O
predominant	O
protein	O
of	O
cartilage	O
,	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
individuals	O
with	O
kniest	B-Disease
dysplasia	I-Disease
.	O
	
we	O
used	O
heteroduplex	O
analysis	O
to	O
identify	O
sequence	O
anomalies	O
in	O
five	O
individuals	O
with	O
kniest	B-Disease
dysplasia	I-Disease
.	O
	
sequencing	O
of	O
the	O
index	O
patients	O
genomic	O
dna	O
identified	O
four	O
new	O
dominant	O
mutations	O
in	O
col2a1	O
that	O
result	O
in	O
kniest	B-Disease
dysplasia	I-Disease
a	O
21	O
-	O
bp	O
deletion	O
in	O
exon	O
16	O
,	O
an	O
18	O
-	O
bp	O
deletion	O
in	O
exon	O
19	O
,	O
and	O
4	O
-	O
bp	O
deletions	O
in	O
the	O
splice	O
donor	O
sites	O
of	O
introns	O
14	O
and	O
20	O
.	O
	
these	O
data	O
suggest	O
that	O
kniest	B-Disease
dysplasia	I-Disease
results	O
from	O
shorter	O
type	O
ii	O
collagen	O
monomers	O
,	O
and	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
specific	O
col2a1	O
domain	O
,	O
which	O
may	O
span	O
from	O
exons	O
12	O
to	O
24	O
,	O
leads	O
to	O
the	O
kniest	B-Disease
dysplasia	I-Disease
phenotype	O
.	O
	
classical	B-Disease
galactosemia	I-Disease
and	O
mutations	O
at	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
galt	O
)	O
gene	O
.	O
	
classical	B-Disease
galactosemia	I-Disease
is	O
caused	O
by	O
a	O
deficiency	O
in	O
activity	O
of	O
the	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
galt	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
caused	O
by	O
mutations	O
at	O
the	O
galt	O
gene	O
.	O
	
the	O
considerable	O
genetic	O
heterogeneity	O
documented	O
to	O
date	O
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	O
heterogeneity	O
that	O
is	O
observed	O
in	O
galactosemia	B-Disease
.	O
	
mutations	O
of	O
the	O
vhl	B-Disease
gene	O
in	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
:	O
definition	O
of	O
a	O
risk	O
factor	O
for	O
vhl	B-Disease
patients	O
to	O
develop	O
an	O
rcc	B-Disease
.	O
	
to	O
investigate	O
the	O
nature	O
of	O
somatic	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	O
vhl	B-Disease
)	O
mutations	O
,	O
we	O
analyzed	O
173	O
primary	O
sporadic	O
human	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
for	O
mutations	O
of	O
the	O
vhl	B-Disease
tumor	I-Disease
suppressor	O
gene	O
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
pcr	O
)	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
sscp	O
)	O
of	O
dna	O
.	O
	
vhl	B-Disease
mutations	O
were	O
found	O
only	O
in	O
the	O
nonpapillary	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
rcc	B-Disease
)	O
subtype	O
,	O
as	O
previously	O
reported	O
.	O
	
to	O
compare	O
somatic	O
and	O
germline	O
mutations	O
,	O
we	O
used	O
the	O
vhl	B-Disease
database	O
,	O
which	O
includes	O
507	O
mutations	O
.	O
	
we	O
postulated	O
that	O
a	O
specific	O
pattern	O
of	O
vhl	B-Disease
mutations	O
is	O
associated	O
with	O
sporadic	B-Disease
rcc	I-Disease
.	O
	
we	O
then	O
analyzed	O
the	O
occurrence	O
of	O
rcc	B-Disease
in	O
vhl	B-Disease
families	O
,	O
based	O
on	O
the	O
nature	O
of	O
mutations	O
.	O
	
we	O
observed	O
rcc	B-Disease
in	O
at	O
least	O
one	O
member	O
of	O
the	O
vhl	B-Disease
families	O
in	O
77	O
%	O
of	O
cases	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
versus	O
55	O
%	O
in	O
cases	O
with	O
missense	O
mutations	O
(	O
p	O
<	O
0	O
.	O
	
thus	O
,	O
mutations	O
resulting	O
in	O
truncated	O
proteins	O
may	O
lead	O
to	O
a	O
higher	O
risk	O
of	O
rcc	B-Disease
in	O
vhl	B-Disease
patients	O
defective	O
ctla	O
-	O
4	O
cycling	O
pathway	O
in	O
chediak	B-Disease
-	I-Disease
higashi	I-Disease
syndrome	I-Disease
:	O
a	O
possible	O
mechanism	O
for	O
deregulation	O
of	O
t	O
lymphocyte	O
activation	O
.	O
	
chediak	B-Disease
-	I-Disease
higashi	I-Disease
syndrome	I-Disease
(	O
chs	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
trafficking	O
regulator	O
gene	O
,	O
lyst	O
.	O
	
it	O
results	O
in	O
defective	O
membrane	O
targeting	O
of	O
the	O
proteins	O
present	O
in	O
secretory	O
lysosomes	O
,	O
and	O
it	O
is	O
associated	O
with	O
a	O
variety	O
of	O
features	O
,	O
including	O
a	O
lymphoproliferative	B-Disease
syndrome	I-Disease
with	O
hemophagocytosis	B-Disease
.	O
	
the	O
murine	O
equivalent	O
of	O
chs	B-Disease
,	O
beige	O
mice	O
,	O
present	O
similar	O
characteristics	O
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	B-Disease
syndrome	I-Disease
.	O
	
we	O
show	O
herein	O
that	O
ctla	O
-	O
4	O
is	O
present	O
in	O
enlarged	O
,	O
abnormal	O
vesicles	O
in	O
chs	B-Disease
t	O
cells	O
and	O
is	O
not	O
properly	O
expressed	O
at	O
the	O
cell	O
surface	O
after	O
t	O
cell	O
activation	O
,	O
whereas	O
its	O
surface	O
expression	O
is	O
not	O
impaired	O
.	O
	
it	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	O
of	O
ctla	O
-	O
4	O
by	O
chs	B-Disease
t	O
cells	O
is	O
involved	O
in	O
the	O
generation	O
of	O
lymphoproliferative	B-Disease
disease	I-Disease
.	O
	
proteolipoprotein	O
gene	O
analysis	O
in	O
82	O
patients	O
with	O
sporadic	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
:	O
duplications	O
,	O
the	O
major	O
cause	O
of	O
the	O
disease	O
,	O
originate	O
more	O
frequently	O
in	O
male	O
germ	O
cells	O
,	O
but	O
point	O
mutations	O
do	O
not	O
.	O
	
the	O
clinical	O
european	O
network	O
on	O
brain	B-Disease
dysmyelinating	I-Disease
disease	I-Disease
.	O
	
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
developmental	I-Disease
defect	I-Disease
of	I-Disease
myelination	I-Disease
affecting	O
the	O
central	O
nervous	O
system	O
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(	O
plp	O
)	O
locus	O
.	O
	
investigating	O
82	O
strictly	O
selected	O
sporadic	O
cases	O
of	O
pmd	B-Disease
,	O
we	O
found	O
plp	O
mutations	O
in	O
77	O
%	O
;	O
complete	O
plp	O
-	O
gene	O
duplications	O
were	O
the	O
most	O
frequent	O
abnormality	O
(	O
62	O
%	O
)	O
,	O
whereas	O
point	O
mutations	O
in	O
coding	O
or	O
splice	O
-	O
site	O
regions	O
of	O
the	O
gene	O
were	O
involved	O
less	O
frequently	O
(	O
38	O
%	O
)	O
.	O
	
chromosome	O
breakage	O
in	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
and	I-Disease
angelman	I-Disease
syndromes	I-Disease
involves	O
recombination	O
between	O
large	O
,	O
transcribed	O
repeats	O
at	O
proximal	O
and	O
distal	O
breakpoints	O
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
and	O
angelman	B-Disease
syndrome	I-Disease
(	O
as	B-Disease
)	O
are	O
distinct	O
neurobehavioral	B-Disease
disorders	I-Disease
that	O
most	O
often	O
arise	O
from	O
a	O
4	O
-	O
mb	O
deletion	O
of	O
chromosome	O
15q11	O
-	O
q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis	O
,	O
respectively	O
.	O
	
one	O
of	O
five	O
pws	B-Disease
/	O
as	B-Disease
patients	O
analyzed	O
to	O
date	O
has	O
an	O
identifiable	O
,	O
rearranged	O
herc2	O
transcript	O
derived	O
from	O
the	O
deletion	O
event	O
.	O
	
linkage	O
analysis	O
in	O
a	O
large	O
brazilian	O
family	O
with	O
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	O
locus	O
for	O
cleft	B-Disease
palate	I-Disease
at	O
17p11	O
.	O
	
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
(	O
vws	B-Disease
)	O
,	O
which	O
has	O
been	O
mapped	O
to	O
1q32	O
-	O
41	O
,	O
is	O
characterized	O
by	O
pits	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
sinuses	I-Disease
of	I-Disease
the	I-Disease
lower	I-Disease
lip	I-Disease
,	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
(	O
cl	B-Disease
/	I-Disease
p	I-Disease
)	O
,	O
cleft	B-Disease
palate	I-Disease
(	O
cp	B-Disease
)	O
,	O
bifid	B-Disease
uvula	I-Disease
,	O
and	O
hypodontia	B-Disease
(	O
h	B-Disease
)	O
.	O
	
the	O
expression	O
of	O
vws	B-Disease
,	O
which	O
has	O
incomplete	O
penetrance	O
,	O
is	O
highly	O
variable	O
.	O
	
both	O
the	O
occurrence	O
of	O
cl	B-Disease
/	I-Disease
p	I-Disease
and	O
cp	B-Disease
within	O
the	O
same	O
genealogy	O
and	O
a	O
recurrence	O
risk	O
<	O
40	O
%	O
for	O
cp	B-Disease
among	O
descendants	O
with	O
vws	B-Disease
have	O
suggested	O
that	O
the	O
development	O
of	O
clefts	B-Disease
in	O
this	O
syndrome	O
is	O
influenced	O
by	O
modifying	O
genes	O
at	O
other	O
loci	O
.	O
	
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
conducted	O
linkage	O
analysis	O
in	O
a	O
large	O
brazilian	O
kindred	O
with	O
vws	B-Disease
,	O
considering	O
as	O
affected	O
the	O
individuals	O
with	O
cp	B-Disease
,	O
regardless	O
of	O
whether	O
it	O
is	O
associated	O
with	O
other	O
clinical	O
signs	O
of	O
vws	B-Disease
.	O
	
1	O
,	O
together	O
with	O
the	O
vws	B-Disease
gene	O
at	O
1p32	O
-	O
41	O
,	O
enhances	O
the	O
probability	O
of	O
cp	B-Disease
in	O
an	O
individual	O
carrying	O
the	O
two	O
at	O
-	O
risk	O
genes	O
.	O
	
if	O
this	O
hypothesis	O
is	O
confirmed	O
in	O
other	O
vws	B-Disease
pedigrees	O
,	O
it	O
will	O
represent	O
one	O
of	O
the	O
first	O
examples	O
of	O
a	O
gene	O
,	O
mapped	O
through	O
linkage	O
analysis	O
,	O
which	O
modifies	O
the	O
expression	O
of	O
a	O
major	O
gene	O
.	O
	
the	O
gene	O
for	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
,	O
atm	O
,	O
spans	O
about	O
150	O
kb	O
of	O
genomic	O
dna	O
.	O
	
using	O
dna	O
as	O
the	O
starting	O
material	O
,	O
we	O
screened	O
the	O
atm	O
gene	O
in	O
92	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
,	O
using	O
an	O
optimized	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
sscp	O
)	O
technique	O
that	O
detected	O
all	O
previously	O
known	O
mutations	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
pcr	O
)	O
segments	O
being	O
analyzed	O
.	O
	
a	O
novel	O
frameshift	O
mutation	O
in	O
the	O
mcleod	B-Disease
syndrome	I-Disease
gene	O
in	O
a	O
japanese	O
family	O
.	O
	
we	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
xk	O
gene	O
(	O
xk	O
)	O
in	O
a	O
japanese	O
patient	O
with	O
mcleod	B-Disease
syndrome	I-Disease
.	O
	
a	O
50	O
-	O
year	O
-	O
old	O
man	O
showed	O
progressive	O
muscular	B-Disease
atrophy	I-Disease
,	O
choreic	B-Disease
movement	I-Disease
,	O
elevated	O
level	O
of	O
serum	O
creatinine	O
kinase	O
,	O
and	O
acanthocytosis	B-Disease
.	O
	
we	O
conclude	O
this	O
single	O
-	O
base	O
deletion	O
causes	O
defective	O
kx	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
the	O
mcleod	B-Disease
phenotype	O
in	O
this	O
patient	O
.	O
	
.	O
	
brca1	O
encodes	O
a	O
tumor	B-Disease
suppressor	O
that	O
is	O
mutated	O
in	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
formation	O
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
brca1	O
,	O
hrad50	O
,	O
hmre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
hcc	O
/	O
1937	O
breast	B-Disease
cancer	I-Disease
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
brca1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	O
-	O
type	O
brca1	O
.	O
	
relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
in	O
females	O
with	O
phenylalanine	B-Disease
hydroxylase	I-Disease
deficiency	I-Disease
:	O
report	O
from	O
the	O
maternal	B-Disease
phenylketonuria	I-Disease
collaborative	O
study	O
.	O
	
objective	O
to	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
(	O
pku	B-Disease
)	O
.	O
	
methodology	O
pah	O
gene	O
mutations	O
were	O
examined	O
in	O
222	O
hyperphenylalaninemic	B-Disease
females	O
enrolled	O
in	O
the	O
maternal	B-Disease
pku	I-Disease
collaborative	O
study	O
(	O
mpkucs	O
)	O
.	O
	
based	O
on	O
previous	O
knowledge	O
about	O
mutation	O
-	O
phenotype	O
associations	O
,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(	O
severe	O
pku	B-Disease
,	O
moderate	O
pku	B-Disease
,	O
mild	O
pku	B-Disease
,	O
and	O
mild	B-Disease
hyperphenylalaninemia	I-Disease
[	O
mhp	B-Disease
]	O
)	O
.	O
	
the	O
iq	O
of	O
pah	B-Disease
-	I-Disease
deficient	I-Disease
mothers	O
with	O
a	O
severe	O
pku	B-Disease
mutation	O
in	O
combination	O
with	O
a	O
mhp	B-Disease
mutation	O
or	O
a	O
mild	O
pku	B-Disease
mutation	O
was	O
99	O
and	O
96	O
,	O
respectively	O
,	O
whereas	O
the	O
iq	O
of	O
pku	B-Disease
mothers	O
with	O
two	O
severe	O
pku	B-Disease
mutations	O
or	O
with	O
one	O
severe	O
and	O
one	O
moderate	O
pku	B-Disease
mutation	O
was	O
83	O
and	O
84	O
,	O
respectively	O
.	O
	
of	O
the	O
patients	O
with	O
pku	B-Disease
,	O
92	O
%	O
had	O
been	O
treated	O
during	O
childhood	O
.	O
	
females	O
with	O
moderate	O
or	O
mild	O
pku	B-Disease
who	O
were	O
treated	O
early	O
and	O
treated	O
for	O
>	O
6	O
years	O
showed	O
iq	O
scores	O
10	O
points	O
above	O
average	O
for	O
their	O
group	O
.	O
	
conclusions	O
the	O
reproductive	O
outcome	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances	O
.	O
	
both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
pku	B-Disease
.	O
	
the	O
significant	O
relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
observed	O
in	O
the	O
present	O
study	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
pku	B-Disease
who	O
plan	O
pregnancy	O
.	O
	
spinal	B-Disease
xanthomatosis	I-Disease
:	O
a	O
variant	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
.	O
	
we	O
describe	O
seven	O
dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive	O
,	O
mainly	O
spinal	B-Disease
cord	I-Disease
syndrome	I-Disease
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
.	O
	
mri	O
demonstrated	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	O
cord	O
.	O
	
we	O
conclude	O
that	O
spinal	B-Disease
xanthomatosis	I-Disease
is	O
a	O
clinical	O
and	O
radiological	O
separate	O
entity	O
of	O
ctx	B-Disease
that	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
chronic	B-Disease
myelopathy	I-Disease
.	O
	
a	O
transgene	O
insertion	O
creating	O
a	O
heritable	O
chromosome	O
deletion	O
mouse	O
model	O
of	O
prader	B-Disease
-	I-Disease
willi	I-Disease
and	I-Disease
angelman	I-Disease
syndromes	I-Disease
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
and	O
angelman	B-Disease
syndrome	I-Disease
(	O
as	B-Disease
)	O
result	O
from	O
the	O
loss	O
of	O
function	O
of	O
imprinted	O
genes	O
in	O
human	O
chromosome	O
15q11	O
-	O
q13	O
.	O
	
we	O
report	O
here	O
the	O
characterization	O
of	O
a	O
transgene	O
insertion	O
(	O
epstein	O
-	O
barr	O
virus	O
latent	O
membrane	O
protein	O
2a	O
,	O
lmp2a	O
)	O
into	O
mouse	O
chromosome	O
7c	O
,	O
which	O
has	O
resulted	O
in	O
mouse	O
models	O
for	O
pws	B-Disease
and	O
as	B-Disease
dependent	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O
	
epigenotype	O
(	O
allelic	O
expression	O
and	O
dna	O
methylation	O
)	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
analyses	O
indicate	O
that	O
the	O
transgene	O
-	O
induced	O
mutation	O
has	O
generated	O
a	O
complete	O
deletion	O
of	O
the	O
pws	B-Disease
/	O
as	B-Disease
-	O
homologous	O
region	O
but	O
has	O
not	O
deleted	O
flanking	O
loci	O
.	O
	
because	O
the	O
intact	O
chromosome	O
7	O
,	O
opposite	O
the	O
deleted	O
homolog	O
,	O
maintains	O
the	O
correct	O
imprint	O
in	O
somatic	O
cells	O
of	O
pws	B-Disease
and	O
as	B-Disease
mice	O
and	O
establishes	O
the	O
correct	O
imprint	O
in	O
male	O
and	O
female	O
germ	O
cells	O
of	O
as	B-Disease
mice	O
,	O
homologous	O
association	O
and	O
replication	O
asynchrony	O
are	O
not	O
part	O
of	O
the	O
imprinting	O
mechanism	O
.	O
	
this	O
heritable	O
-	O
deletion	O
mouse	O
model	O
will	O
be	O
particularly	O
useful	O
for	O
the	O
identification	O
of	O
the	O
etiological	O
genes	O
and	O
mechanisms	O
,	O
phenotypic	O
basis	O
,	O
and	O
investigation	O
of	O
therapeutic	O
approaches	O
for	O
pws	B-Disease
.	O
	
linkage	O
analysis	O
of	O
5	O
novel	O
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
kindreds	O
to	O
1q32	O
-	O
q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait	O
.	O
	
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
(	O
vws	B-Disease
,	O
mim	O
119300	O
)	O
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
clefting	I-Disease
condition	I-Disease
with	O
cardinal	O
features	O
of	O
mucous	B-Disease
cysts	I-Disease
(	O
lower	B-Disease
-	I-Disease
lip	I-Disease
pits	I-Disease
)	O
and	O
clefts	B-Disease
to	I-Disease
the	I-Disease
lip	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
palate	I-Disease
.	O
	
the	O
vws	B-Disease
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32	O
-	O
q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping	O
.	O
	
we	O
have	O
investigated	O
5	O
novel	O
vws	B-Disease
families	O
through	O
probands	O
attended	O
for	O
cleft	B-Disease
lip	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
palate	I-Disease
repair	O
at	O
the	O
department	O
of	O
maxillofacial	O
surgery	O
of	O
hopital	O
trousseau	O
,	O
paris	O
,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vws	B-Disease
region	O
in	O
1q32	O
-	O
q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees	O
.	O
	
our	O
results	O
support	O
linkage	O
of	O
vws	B-Disease
within	O
a	O
region	O
of	O
tightly	O
linked	O
markers	O
and	O
do	O
not	O
favour	O
locus	O
heterogeneity	O
of	O
the	O
disease	O
trait	O
.	O
	
nan	O
mutation	O
of	O
the	O
murine	O
atp7b	O
(	O
wilson	B-Disease
disease	I-Disease
)	O
gene	O
results	O
in	O
intracellular	B-Disease
copper	I-Disease
accumulation	I-Disease
and	O
late	B-Disease
-	I-Disease
onset	I-Disease
hepatic	I-Disease
nodular	I-Disease
transformation	I-Disease
.	O
	
mutations	O
in	O
the	O
atp7b	O
gene	O
lead	O
to	O
wilson	B-Disease
disease	I-Disease
,	O
a	O
copper	B-Disease
toxicity	I-Disease
disorder	I-Disease
characterized	O
by	O
dramatic	O
build	O
-	O
up	O
of	O
intracellular	O
hepatic	O
copper	O
with	O
subsequent	O
hepatic	B-Disease
and	I-Disease
neuro	I-Disease
-	I-Disease
logical	I-Disease
abnormalities	I-Disease
.	O
	
using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
atp7b	O
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(	O
nan	O
)	O
for	O
the	O
wilson	B-Disease
disease	I-Disease
gene	O
.	O
	
an	O
increase	O
in	O
copper	O
concentration	O
was	O
also	O
observed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo	O
-	O
zygous	O
mutants	O
,	O
although	O
milk	O
from	O
the	O
mutant	O
glands	O
was	O
copper	B-Disease
deficient	I-Disease
.	O
	
morphological	B-Disease
abnormalities	I-Disease
resembling	O
cirrhosis	B-Disease
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	O
mutants	O
older	O
than	O
7	O
months	O
of	O
age	O
.	O
	
progeny	O
of	O
the	O
homozygous	O
mutant	O
females	O
demonstrated	O
neurological	B-Disease
abnormalities	I-Disease
and	O
growth	B-Disease
retardation	I-Disease
characteristic	O
of	O
copper	B-Disease
deficiency	I-Disease
.	O
	
in	O
summary	O
,	O
inactivation	O
of	O
the	O
murine	O
atp7b	O
gene	O
produces	O
a	O
form	O
of	O
cirrhotic	B-Disease
liver	I-Disease
disease	I-Disease
that	O
resembles	O
wilson	B-Disease
disease	I-Disease
in	O
humans	O
and	O
the	O
toxic	O
milk	O
phenotype	O
in	O
the	O
mouse	O
.	O
	
french	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
patients	O
do	O
not	O
exhibit	O
gametic	O
segregation	O
distortion	O
:	O
a	O
sperm	O
typing	O
analysis	O
.	O
	
segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	B-Disease
repeat	I-Disease
disorders	I-Disease
.	O
	
on	O
the	O
basis	O
of	O
a	O
sperm	O
typing	O
study	O
performed	O
in	O
patients	O
of	O
japanese	O
descent	O
with	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
mjd	B-Disease
)	O
,	O
it	O
was	O
reported	O
that	O
disease	O
alleles	O
are	O
preferentially	O
transmitted	O
during	O
meiosis	O
.	O
	
we	O
performed	O
a	O
sperm	O
typing	O
study	O
of	O
five	O
mjd	B-Disease
patients	O
of	O
french	O
descent	O
and	O
analysis	O
of	O
the	O
pooled	O
data	O
shows	O
a	O
ratio	O
of	O
mutant	O
to	O
normal	O
alleles	O
of	O
379	O
436	O
(	O
46	O
.	O
	
however	O
,	O
analysis	O
of	O
the	O
variance	O
in	O
repeat	O
number	O
in	O
sperm	O
from	O
the	O
french	O
mjd	B-Disease
patients	O
overlapped	O
significantly	O
with	O
the	O
variance	O
in	O
repeat	O
number	O
observed	O
in	O
the	O
c	O
/	O
c	O
homozygous	O
japanese	O
patients	O
.	O
	
missense	O
mutation	O
in	O
the	O
alternative	O
splice	O
region	O
of	O
the	O
pax6	O
gene	O
in	O
eye	B-Disease
anomalies	I-Disease
.	O
	
the	O
pax6	O
gene	O
is	O
involved	O
in	O
ocular	O
morphogenesis	O
,	O
and	O
pax6	O
mutations	O
have	O
been	O
detected	O
in	O
various	O
types	O
of	O
ocular	B-Disease
anomalies	I-Disease
,	O
including	O
aniridia	B-Disease
,	O
peters	B-Disease
anomaly	I-Disease
,	O
corneal	B-Disease
dystrophy	I-Disease
,	O
congenital	B-Disease
cataract	I-Disease
,	O
and	O
foveal	B-Disease
hypoplasia	I-Disease
.	O
	
we	O
ascertained	O
a	O
novel	O
missense	O
mutation	O
in	O
four	O
pedigrees	O
with	O
peters	B-Disease
anomaly	I-Disease
,	O
congenital	B-Disease
cataract	I-Disease
,	O
axenfeldt	B-Disease
anomaly	I-Disease
,	O
and	O
/	O
or	O
foveal	B-Disease
hypoplasia	I-Disease
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
is	O
the	O
first	O
mutation	O
identified	O
in	O
the	O
splice	O
-	O
variant	O
region	O
.	O
	
penetrances	O
of	O
brca1	O
1675dela	O
and	O
1135insa	O
with	O
respect	O
to	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
for	O
genetic	O
counseling	O
and	O
predictive	O
testing	O
in	O
families	O
with	O
inherited	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	O
should	O
be	O
known	O
.	O
	
index	O
cases	O
for	O
the	O
present	O
study	O
were	O
found	O
two	O
different	O
ways	O
through	O
a	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancers	I-Disease
(	O
n	O
=	O
16	O
)	O
and	O
through	O
our	O
family	O
cancer	B-Disease
clinic	O
(	O
n	O
=	O
14	O
)	O
.	O
	
their	O
relatives	O
were	O
described	O
with	O
respect	O
to	O
absence	O
/	O
presence	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
the	O
overall	O
findings	O
were	O
that	O
disease	O
started	O
to	O
occur	O
at	O
age	O
30	O
years	O
and	O
that	O
by	O
age	O
50	O
years	O
48	O
%	O
of	O
the	O
mutation	O
-	O
carrying	O
women	O
had	O
experienced	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
more	O
ovarian	B-Disease
cancers	I-Disease
than	O
breast	B-Disease
cancers	I-Disease
were	O
recorded	O
.	O
	
both	O
penetrance	O
and	O
expression	O
(	O
breast	B-Disease
cancer	I-Disease
vs	O
.	O
	
ovarian	B-Disease
cancer	I-Disease
)	O
were	O
different	O
from	O
those	O
in	O
reports	O
of	O
the	O
ashkenazi	O
founder	O
mutations	O
.	O
	
the	O
dermatofibrosarcoma	B-Disease
protuberans	I-Disease
-	O
associated	O
collagen	O
type	O
ialpha1	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
pdgf	O
)	O
b	O
-	O
chain	O
fusion	O
gene	O
generates	O
a	O
transforming	O
protein	O
that	O
is	O
processed	O
to	O
functional	O
pdgf	O
-	O
bb	O
.	O
	
dermatofibrosarcoma	B-Disease
protuberans	I-Disease
(	O
dfsp	B-Disease
)	O
displays	O
chromosomal	O
rearrangements	O
involving	O
chromosome	O
17	O
and	O
22	O
,	O
which	O
fuse	O
the	O
collagen	O
type	O
ialpha1	O
(	O
colia1	O
)	O
gene	O
to	O
the	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
pdgf	O
)	O
b	O
-	O
chain	O
(	O
pdgfb	O
)	O
gene	O
.	O
	
finally	O
,	O
colia1	O
/	O
pdgfb	O
-	O
expressing	O
cells	O
generated	O
tumors	B-Disease
after	O
s	O
.	O
	
injection	O
into	O
nude	O
mice	O
,	O
and	O
tumor	B-Disease
growth	O
was	O
reduced	O
by	O
treatment	O
with	O
cgp57148b	O
.	O
	
we	O
conclude	O
that	O
the	O
colia1	O
/	O
pdgfb	O
fusion	O
associated	O
with	O
dfsp	B-Disease
contributes	O
to	O
tumor	B-Disease
development	O
through	O
ectopic	O
production	O
of	O
pdgf	O
-	O
bb	O
and	O
the	O
formation	O
of	O
an	O
autocrine	O
loop	O
.	O
	
our	O
findings	O
,	O
thus	O
,	O
suggest	O
that	O
pdgf	O
receptors	O
could	O
be	O
a	O
target	O
for	O
pharmacological	O
treatment	O
of	O
dfsp	B-Disease
and	O
giant	B-Disease
cell	I-Disease
fibroblastoma	I-Disease
,	O
e	O
.	O
	
,	O
through	O
the	O
use	O
of	O
pdgf	O
receptor	O
kinase	O
inhibitors	O
such	O
as	O
cgp57148b	O
.	O
	
identification	O
of	O
a	O
common	O
pex1	O
mutation	O
in	O
zellweger	B-Disease
syndrome	I-Disease
.	O
	
the	O
zellweger	B-Disease
spectrum	I-Disease
of	I-Disease
disease	I-Disease
,	O
encompassing	O
zellweger	B-Disease
syndrome	I-Disease
and	O
the	O
progressively	O
milder	O
phenotypes	O
of	O
neonatal	B-Disease
adrenoleukodystrophy	I-Disease
and	O
infantile	B-Disease
refsum	I-Disease
disease	I-Disease
,	O
is	O
due	O
to	O
a	O
failure	O
to	O
form	O
functional	O
peroxisomes	O
.	O
	
however	O
,	O
previous	O
studies	O
have	O
focused	O
on	O
mildly	O
affected	O
patients	O
and	O
there	O
is	O
still	O
no	O
report	O
of	O
two	O
mutant	O
pex1	O
alleles	O
in	O
any	O
zellweger	B-Disease
syndrome	I-Disease
patient	O
.	O
	
furthermore	O
,	O
mutations	O
in	O
the	O
pmp70	O
gene	O
have	O
also	O
been	O
identified	O
in	O
two	O
zellweger	B-Disease
syndrome	I-Disease
patients	O
from	O
cg1	O
,	O
raising	O
the	O
possibility	O
that	O
cg1	O
patients	O
may	O
represent	O
a	O
mixture	O
of	O
pex1	O
-	O
deficient	O
and	O
pmp70	O
-	O
deficient	O
individuals	O
.	O
	
to	O
address	O
the	O
molecular	O
basis	O
of	O
disease	O
in	O
zellweger	B-Disease
syndrome	I-Disease
patients	O
from	O
cg1	O
,	O
we	O
examined	O
all	O
24	O
pex1	O
exons	O
in	O
four	O
patients	O
,	O
including	O
both	O
patients	O
that	O
have	O
mutations	O
in	O
pmp70	O
.	O
	
subsequent	O
studies	O
demonstrated	O
that	O
this	O
mutation	O
is	O
present	O
in	O
one	O
-	O
half	O
of	O
all	O
cg1	O
patients	O
and	O
correlates	O
with	O
the	O
zellweger	B-Disease
syndrome	I-Disease
phenotype	O
.	O
	
as	O
this	O
mutation	O
leads	O
to	O
a	O
loss	O
of	O
protein	O
function	O
its	O
frequency	O
makes	O
it	O
the	O
most	O
common	O
cause	O
of	O
zellweger	B-Disease
syndrome	I-Disease
,	O
helping	O
to	O
explain	O
the	O
high	O
percentage	O
of	O
patients	O
that	O
belong	O
to	O
cg1	O
.	O
	
novel	O
mutations	O
in	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
gene	O
and	O
their	O
effects	O
on	O
transcriptional	O
,	O
translational	O
,	O
and	O
clinical	O
phenotypes	O
.	O
	
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
immunodeficiency	I-Disease
characterized	O
by	O
thrombocytopenia	B-Disease
,	O
eczema	B-Disease
,	O
and	O
recurrent	O
infections	O
,	O
and	O
caused	O
by	O
mutations	O
in	O
the	O
was	B-Disease
protein	O
(	O
wasp	O
)	O
gene	O
.	O
	
no	O
protein	O
was	O
detected	O
in	O
two	O
individuals	O
with	O
severe	O
was	B-Disease
.	O
	
reduced	O
levels	O
of	O
a	O
normal	O
-	O
size	O
wasp	O
with	O
a	O
missense	O
mutation	O
were	O
seen	O
in	O
two	O
individuals	O
with	O
xlt	B-Disease
.	O
	
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene	O
,	O
leading	O
to	O
the	O
absence	O
of	O
the	O
dystrophin	O
protein	O
in	O
striated	O
muscle	O
.	O
	
on	O
the	O
basis	O
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	O
codons	O
in	O
cultured	O
cells	O
,	O
we	O
tested	O
the	O
effect	O
of	O
gentamicin	O
on	O
cultured	O
muscle	O
cells	O
from	O
the	O
mdx	O
mouse	O
-	O
an	O
animal	O
model	O
for	O
dmd	B-Disease
that	O
possesses	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
dystrophin	O
gene	O
.	O
	
we	O
identified	O
a	O
treatment	O
regimen	O
that	O
resulted	O
in	O
the	O
presence	O
of	O
dystrophin	O
in	O
the	O
cell	O
membrane	O
in	O
all	O
striated	O
muscles	O
examined	O
and	O
that	O
provided	O
functional	O
protection	O
against	O
muscular	B-Disease
injury	I-Disease
.	O
	
furthermore	O
,	O
these	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	B-Disease
dystrophy	I-Disease
and	O
other	O
diseases	O
caused	O
by	O
premature	O
stop	O
codon	O
mutations	O
.	O
	
this	O
treatment	O
could	O
prove	O
effective	O
in	O
up	O
to	O
15	O
%	O
of	O
patients	O
with	O
dmd	B-Disease
.	O
	
loss	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
product	O
causes	O
oxidative	O
damage	O
in	O
target	O
organs	O
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
is	O
characterized	O
by	O
a	O
markedly	O
increased	O
sensitivity	O
to	O
ionizing	O
radiation	O
,	O
increased	O
incidence	O
of	O
cancer	B-Disease
,	O
and	O
neurodegeneration	B-Disease
,	O
especially	O
of	O
the	O
cerebellar	O
purkinje	O
cells	O
.	O
	
we	O
therefore	O
hypothesized	O
that	O
a	B-Disease
-	I-Disease
t	I-Disease
is	O
due	O
to	O
oxidative	O
damage	O
resulting	O
from	O
loss	O
of	O
function	O
of	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
gene	O
product	O
.	O
	
to	O
assess	O
this	O
hypothesis	O
,	O
we	O
employed	O
an	O
animal	O
model	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
,	O
the	O
mouse	O
with	O
a	O
disrupted	O
atm	O
gene	O
.	O
	
these	O
observations	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
phenotype	O
and	O
lay	O
a	O
rational	O
foundation	O
for	O
therapeutic	O
intervention	O
.	O
	
recessively	O
inherited	O
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
with	O
normal	O
stature	O
,	O
club	B-Disease
foot	I-Disease
,	O
and	O
double	B-Disease
layered	I-Disease
patella	I-Disease
caused	O
by	O
a	O
dtdst	O
mutation	O
.	O
	
we	O
have	O
observed	O
over	O
25	O
different	O
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulphate	O
transporter	O
gene	O
(	O
dtdst	O
)	O
in	O
association	O
with	O
the	O
recessive	B-Disease
disorders	I-Disease
achondrogenesis	B-Disease
1b	I-Disease
,	O
atelosteogenesis	B-Disease
2	I-Disease
,	O
and	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O
	
we	O
had	O
not	O
seen	O
a	O
case	O
of	O
homozygosity	O
for	O
c862t	O
(	O
r279w	O
)	O
until	O
we	O
analysed	O
dna	O
from	O
a	O
36	O
year	O
old	O
male	O
with	O
tall	O
-	O
normal	O
stature	O
(	O
180	O
cm	O
)	O
who	O
asked	O
for	O
genetic	O
counselling	O
for	O
suspected	O
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
.	O
	
he	O
was	O
treated	O
for	O
club	B-Disease
foot	I-Disease
and	O
hip	B-Disease
dysplasia	I-Disease
at	O
birth	O
.	O
	
skeletal	O
changes	O
consistent	O
with	O
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
,	O
with	O
the	O
peculiar	O
finding	O
of	O
a	O
double	B-Disease
layered	I-Disease
patella	I-Disease
,	O
were	O
recognised	O
during	O
childhood	O
.	O
	
cleft	B-Disease
palate	I-Disease
,	O
swelling	B-Disease
of	I-Disease
the	I-Disease
ear	I-Disease
pinna	I-Disease
,	O
and	O
hitch	B-Disease
hiker	I-Disease
thumb	I-Disease
were	O
absent	O
.	O
	
he	O
was	O
found	O
to	O
be	O
homozygous	O
,	O
and	O
both	O
healthy	O
parents	O
heterozygous	O
,	O
for	O
the	O
r279w	O
mutation	O
in	O
dtdst	O
,	O
and	O
his	O
fibroblasts	O
showed	O
a	O
sulphate	O
incorporation	O
defect	O
typical	O
of	O
dtdst	B-Disease
disorders	I-Disease
.	O
	
counselling	O
was	O
given	O
for	O
a	O
recessive	B-Disease
disorder	I-Disease
,	O
thereby	O
considerably	O
reducing	O
the	O
probability	O
of	O
affected	O
offspring	O
.	O
	
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
is	O
more	O
frequently	O
caused	O
by	O
dominant	O
mutations	O
in	O
the	O
comp	O
(	O
edm1	B-Disease
,	O
mckusick	O
132400	O
)	O
and	O
col9a2	O
genes	O
(	O
edm2	B-Disease
,	O
mckusick	O
600204	O
)	O
.	O
	
a	O
few	O
other	O
patients	O
and	O
families	O
with	O
features	O
similar	O
to	O
our	O
proband	O
have	O
been	O
described	O
previously	O
and	O
considered	O
to	O
have	O
autosomal	O
recessive	O
med	B-Disease
(	O
edm4	B-Disease
,	O
mckusick	O
226900	O
)	O
.	O
	
homozygosity	O
for	O
a	O
novel	O
dtdst	O
mutation	O
in	O
a	O
child	O
with	O
a	O
'	O
broad	O
bone	O
-	O
platyspondylic	O
'	O
variant	O
of	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O
	
atypical	O
or	O
variant	O
forms	O
of	O
well	O
-	O
known	O
chondrodysplasias	B-Disease
may	O
pose	O
diagnostic	O
problems	O
.	O
	
we	O
report	O
on	O
a	O
girl	O
with	O
clinical	O
features	O
suggesting	O
diastrophic	B-Disease
dysplasia	I-Disease
but	O
with	O
unusual	O
radiographic	O
features	O
including	O
severe	O
platyspondyly	B-Disease
,	O
wide	O
metaphyses	O
,	O
and	O
fibular	O
overgrowth	O
,	O
which	O
are	O
partially	O
reminiscent	O
of	O
metatropic	B-Disease
dysplasia	I-Disease
.	O
	
the	O
type	O
of	O
somatic	O
mutation	O
at	O
apc	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
is	O
determined	O
by	O
the	O
site	O
of	O
the	O
germline	O
mutation	O
:	O
a	O
new	O
facet	O
to	O
knudson	O
'	O
s	O
'	O
two	O
-	O
hit	O
'	O
hypothesis	O
.	O
	
apc	O
is	O
often	O
cited	O
as	O
a	O
prime	O
example	O
of	O
a	O
tumor	B-Disease
suppressor	O
gene	O
.	O
	
truncating	O
germline	O
and	O
somatic	O
mutations	O
(	O
or	O
,	O
infrequently	O
,	O
allelic	O
loss	O
)	O
occur	O
in	O
tumors	B-Disease
in	O
fap	B-Disease
(	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
)	O
.	O
	
most	O
sporadic	B-Disease
colorectal	I-Disease
cancers	I-Disease
also	O
have	O
two	O
apc	B-Disease
mutations	O
.	O
	
clues	O
from	O
attenuated	B-Disease
polyposis	I-Disease
,	O
missense	O
germline	O
variants	O
with	O
mild	O
disease	O
and	O
the	O
somatic	O
mutation	O
cluster	O
region	O
(	O
codons	O
1	O
,	O
250	O
-	O
1	O
,	O
450	O
)	O
indicate	O
,	O
however	O
,	O
that	O
apc	B-Disease
mutations	O
might	O
not	O
result	O
in	O
simple	O
loss	O
of	O
protein	O
function	O
.	O
	
we	O
have	O
found	O
that	O
fap	B-Disease
patients	O
with	O
germline	O
apc	B-Disease
mutations	O
within	O
a	O
small	O
region	O
(	O
codons	O
1	O
,	O
194	O
-	O
1	O
,	O
392	O
at	O
most	O
)	O
mainly	O
show	O
allelic	O
loss	O
in	O
their	O
colorectal	B-Disease
adenomas	I-Disease
,	O
in	O
contrast	O
to	O
other	O
fap	B-Disease
patients	O
,	O
whose	O
second	O
hits	O
tend	O
to	O
occur	O
by	O
truncating	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
	
our	O
results	O
indicate	O
that	O
different	O
apc	B-Disease
mutations	O
provide	O
cells	O
with	O
different	O
selective	O
advantages	O
,	O
with	O
mutations	O
close	O
to	O
codon	O
1	O
,	O
300	O
providing	O
the	O
greatest	O
advantage	O
.	O
	
a	O
different	O
germline	O
-	O
somatic	O
apc	B-Disease
mutation	O
association	O
exists	O
in	O
fap	B-Disease
desmoids	I-Disease
.	O
	
apc	O
is	O
not	O
,	O
therefore	O
,	O
a	O
classical	O
tumor	B-Disease
suppressor	O
.	O
	
our	O
findings	O
also	O
indicate	O
a	O
new	O
mechanism	O
for	O
disease	O
severity	O
if	O
a	O
broader	O
spectrum	O
of	O
mutations	O
is	O
selected	O
in	O
tumors	B-Disease
,	O
the	O
somatic	O
mutation	O
rate	O
is	O
effectively	O
higher	O
and	O
more	O
tumors	B-Disease
grow	O
.	O
	
mxi1	O
mutations	O
in	O
human	O
neurofibrosarcomas	B-Disease
.	O
	
mxi1	O
is	O
thought	O
to	O
negatively	O
regulate	O
myc	O
function	O
and	O
may	O
therefore	O
be	O
a	O
potential	O
tumor	B-Disease
suppressor	O
gene	O
.	O
	
little	O
effort	O
has	O
yet	O
been	O
made	O
to	O
find	O
alterations	O
involving	O
this	O
gene	O
in	O
human	O
solid	B-Disease
tumors	I-Disease
.	O
	
we	O
screened	O
31	O
human	O
gastric	B-Disease
cancers	I-Disease
,	O
7	O
esophageal	B-Disease
cancers	I-Disease
,	O
85	O
bone	B-Disease
and	I-Disease
soft	I-Disease
tissue	I-Disease
tumors	I-Disease
of	O
various	O
types	O
,	O
including	O
4	O
neurofibrosarcomas	B-Disease
.	O
	
we	O
also	O
examined	O
29	O
human	O
tumor	B-Disease
cell	O
lines	O
consisting	O
of	O
12	O
esophageal	B-Disease
cancers	I-Disease
,	O
7	O
glioma	B-Disease
/	O
glioblastomas	B-Disease
and	O
10	O
others	O
for	O
mxi1	O
mutations	O
in	O
exons	O
1	O
,	O
2	O
,	O
4	O
(	O
hlh	O
domain	O
)	O
,	O
5	O
and	O
6	O
.	O
	
we	O
discovered	O
a	O
missense	O
mutation	O
,	O
gca	O
to	O
gta	O
(	O
ala	O
54	O
val	O
)	O
,	O
in	O
exon	O
2	O
in	O
a	O
neurofibrosarcoma	B-Disease
patient	O
(	O
case	O
1	O
)	O
,	O
two	O
missense	O
mutations	O
,	O
aaa	O
to	O
caa	O
(	O
lys	O
118	O
gln	O
)	O
and	O
gaa	O
to	O
gga	O
(	O
glu	O
154	O
gly	O
)	O
in	O
exon	O
5	O
of	O
another	O
neurofibrosarcoma	B-Disease
patient	O
(	O
case	O
2	O
)	O
,	O
and	O
3	O
amino	O
acid	O
substitutions	O
,	O
gtg	O
to	O
gcg	O
(	O
val	O
179	O
ala	O
)	O
,	O
gtt	O
to	O
gct	O
(	O
val	O
181	O
ala	O
)	O
and	O
ttc	O
to	O
ctc	O
(	O
phe	O
186	O
leu	O
)	O
,	O
in	O
a	O
third	O
neurofibrosarcoma	B-Disease
patient	O
(	O
case	O
3	O
)	O
.	O
	
our	O
data	O
demonstrate	O
that	O
mutations	O
occur	O
in	O
the	O
mxi1	O
gene	O
in	O
neurofibrosarcoma	B-Disease
.	O
	
missense	O
mutations	O
in	O
the	O
functional	O
domain	O
of	O
mxi1	O
in	O
these	O
cases	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neurofibrosarcoma	B-Disease
.	O
	
a	O
population	O
-	O
based	O
study	O
of	O
the	O
clinical	O
expression	O
of	O
the	O
hemochromatosis	B-Disease
gene	O
.	O
	
background	O
and	O
methods	O
hereditary	B-Disease
hemochromatosis	I-Disease
is	O
associated	O
with	O
homozygosity	O
for	O
the	O
c282y	O
mutation	O
in	O
the	O
hemochromatosis	B-Disease
(	O
hfe	O
)	O
gene	O
on	O
chromosome	O
6	O
,	O
elevated	O
serum	O
transferrin	O
saturation	O
,	O
and	O
excess	B-Disease
iron	I-Disease
deposits	I-Disease
throughout	O
the	O
body	O
.	O
	
four	O
of	O
the	O
homozygous	O
subjects	O
had	O
previously	O
been	O
given	O
a	O
diagnosis	O
of	O
hemochromatosis	B-Disease
,	O
and	O
12	O
had	O
not	O
.	O
	
eleven	O
of	O
the	O
16	O
homozygous	O
subjects	O
underwent	O
liver	O
biopsy	O
;	O
3	O
had	O
hepatic	B-Disease
fibrosis	I-Disease
,	O
and	O
1	O
,	O
who	O
had	O
a	O
history	O
of	O
excessive	B-Disease
alcohol	I-Disease
consumption	I-Disease
,	O
had	O
cirrhosis	B-Disease
and	O
mild	O
microvesicular	B-Disease
steatosis	I-Disease
.	O
	
eight	O
of	O
the	O
16	O
homozygous	O
subjects	O
had	O
clinical	O
findings	O
that	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
,	O
such	O
as	O
hepatomegaly	B-Disease
,	O
skin	B-Disease
pigmentation	I-Disease
,	O
and	O
arthritis	B-Disease
.	O
	
however	O
,	O
only	O
half	O
of	O
those	O
who	O
were	O
homozygous	O
had	O
clinical	O
features	O
of	O
hemochromatosis	B-Disease
,	O
and	O
one	O
quarter	O
had	O
serum	O
ferritin	O
levels	O
that	O
remained	O
normal	O
over	O
a	O
four	O
-	O
year	O
period	O
.	O
	
the	O
clinical	O
use	O
of	O
molecular	O
analyses	O
in	O
recessive	B-Disease
disorders	I-Disease
relies	O
on	O
the	O
exact	O
characterization	O
of	O
both	O
mutant	O
alleles	O
in	O
the	O
affected	O
patient	O
.	O
	
we	O
present	O
a	O
child	O
in	O
whom	O
phenylketonuria	B-Disease
was	O
apparently	O
caused	O
by	O
homozygosity	O
for	O
the	O
mutation	O
e390g	O
in	O
exon	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
gene	O
.	O
	
early	O
onset	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
a	O
boy	O
with	O
emerin	O
gene	O
deletion	O
.	O
	
a	O
boy	O
developed	O
contractures	B-Disease
of	I-Disease
the	I-Disease
achilles	I-Disease
tendons	I-Disease
at	O
3	O
years	O
and	O
of	O
the	O
postcervical	O
muscles	O
at	O
7	O
years	O
,	O
although	O
neither	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
nor	O
cardiac	B-Disease
abnormality	I-Disease
were	O
recognized	O
by	O
the	O
age	O
of	O
9	O
years	O
.	O
	
these	O
results	O
confirmed	O
the	O
diagnosis	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
edmd	B-Disease
)	O
,	O
and	O
reinforce	O
the	O
necessity	O
of	O
molecular	O
genetic	O
diagnosis	O
of	O
the	O
membrane	O
protein	O
emerin	O
in	O
younger	O
patients	O
with	O
possible	O
edmd	B-Disease
before	O
appearance	O
of	O
the	O
typical	O
symptoms	O
,	O
to	O
avoid	O
sudden	B-Disease
cardiac	I-Disease
death	I-Disease
.	O
	
duchenne	B-Disease
/	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
:	O
correlation	O
of	O
phenotype	O
by	O
electroretinography	O
with	O
sites	O
of	O
dystrophin	O
mutations	O
.	O
	
the	O
dark	O
-	O
adapted	O
electroretinogram	O
(	O
erg	O
)	O
of	O
patients	O
with	O
duchenne	B-Disease
and	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
/	O
bmd	B-Disease
)	O
shows	O
a	O
marked	O
reduction	O
in	O
b	O
-	O
wave	O
amplitude	O
.	O
	
genotype	O
-	O
phenotype	O
studies	O
of	O
mouse	O
models	O
for	O
dmd	B-Disease
show	O
position	O
-	O
specific	O
effects	O
of	O
the	O
mutations	O
upon	O
the	O
phenotype	O
mice	O
with	O
5	O
defects	O
of	O
dystrophin	O
have	O
normal	O
ergs	O
,	O
those	O
with	O
defects	O
in	O
the	O
central	O
region	O
have	O
a	O
normal	O
b	O
-	O
wave	O
amplitude	O
associated	O
with	O
prolonged	O
implicit	O
times	O
for	O
both	O
the	O
b	O
-	O
wave	O
and	O
oscillatory	O
potentials	O
,	O
and	O
mice	O
with	O
3	O
defects	O
have	O
a	O
phenotype	O
similar	O
to	O
that	O
seen	O
in	O
dmd	B-Disease
/	O
bmd	B-Disease
patients	O
.	O
	
we	O
have	O
undertaken	O
a	O
systematic	O
evaluation	O
of	O
dmd	B-Disease
/	O
bmd	B-Disease
patients	O
through	O
clinical	O
examination	O
and	O
review	O
of	O
the	O
literature	O
in	O
order	O
to	O
determine	O
whether	O
the	O
position	O
-	O
specific	O
effects	O
of	O
mutations	O
noted	O
in	O
the	O
mouse	O
are	O
present	O
in	O
man	O
.	O
	
we	O
have	O
found	O
that	O
,	O
in	O
man	O
,	O
a	O
wider	O
variation	O
of	O
dmd	B-Disease
defects	I-Disease
correlate	O
with	O
reductions	O
in	O
the	O
b	O
-	O
wave	O
amplitude	O
.	O
	
our	O
results	O
suggest	O
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
erg	O
b	O
-	O
wave	O
phenotype	O
is	O
the	O
mutation	O
position	O
,	O
rather	O
than	O
muscle	B-Disease
disease	I-Disease
severity	O
.	O
	
cis	O
and	O
trans	O
effects	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
mutation	O
in	O
a	O
cell	O
culture	O
model	O
.	O
	
the	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
has	O
been	O
identified	O
as	O
a	O
ctg	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
3	O
-	O
utr	O
)	O
of	O
the	O
dm	B-Disease
protein	O
kinase	O
gene	O
(	O
dmpk	O
)	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
pathogenesis	O
remain	O
unknown	O
.	O
	
studies	O
using	O
dm	B-Disease
patient	O
materials	O
have	O
often	O
produced	O
confusing	O
results	O
.	O
	
therefore	O
,	O
to	O
study	O
the	O
effects	O
of	O
the	O
dm	B-Disease
mutation	O
in	O
a	O
controlled	O
environment	O
,	O
we	O
have	O
established	O
a	O
cell	O
culture	O
model	O
system	O
using	O
c2c12	O
mouse	O
myoblasts	O
.	O
	
by	O
expressing	O
chimeric	O
reporter	O
constructs	O
containing	O
a	O
reporter	O
gene	O
fused	O
to	O
a	O
human	O
dmpk	O
3	O
-	O
utr	O
,	O
we	O
identified	O
both	O
cis	O
and	O
trans	O
effects	O
that	O
are	O
mediated	O
by	O
the	O
dm	B-Disease
mutation	O
.	O
	
these	O
results	O
provide	O
evidence	O
that	O
the	O
dm	B-Disease
mutation	O
acts	O
in	O
cis	O
to	O
reduce	O
protein	O
production	O
(	O
consistent	O
with	O
dmpk	B-Disease
haploinsufficiency	I-Disease
)	O
and	O
in	O
trans	O
as	O
a	O
riboregulator	O
to	O
inhibit	O
myogenesis	O
.	O
	
coats	B-Disease
'	I-Disease
disease	I-Disease
of	O
the	O
retina	O
(	O
unilateral	B-Disease
retinal	I-Disease
telangiectasis	I-Disease
)	O
caused	O
by	O
somatic	O
mutation	O
in	O
the	O
ndp	O
gene	O
:	O
a	O
role	O
for	O
norrin	O
in	O
retinal	O
angiogenesis	O
.	O
	
coats	B-Disease
disease	I-Disease
is	O
characterized	O
by	O
abnormal	B-Disease
retinal	I-Disease
vascular	I-Disease
development	I-Disease
(	O
so	O
-	O
called	O
retinal	B-Disease
telangiectasis	I-Disease
)	O
which	O
results	O
in	O
massive	O
intraretinal	B-Disease
and	I-Disease
subretinal	I-Disease
lipid	I-Disease
accumulation	I-Disease
(	O
exudative	B-Disease
retinal	I-Disease
detachment	I-Disease
)	O
.	O
	
the	O
classical	O
form	O
of	O
coats	B-Disease
disease	I-Disease
is	O
almost	O
invariably	O
isolated	O
,	O
unilateral	O
and	O
seen	O
in	O
males	O
.	O
	
a	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
coats	B-Disease
disease	I-Disease
gave	O
birth	O
to	O
a	O
son	O
affected	O
by	O
norrie	B-Disease
disease	I-Disease
.	O
	
subsequently	O
analysis	O
of	O
the	O
retinas	O
of	O
nine	O
enucleated	O
eyes	O
from	O
males	O
with	O
coats	B-Disease
disease	I-Disease
demonstrated	O
in	O
one	O
a	O
somatic	O
mutation	O
in	O
the	O
ndp	O
gene	O
which	O
was	O
not	O
present	O
within	O
non	O
-	O
retinal	O
tissue	O
.	O
	
we	O
suggest	O
that	O
coats	B-Disease
telangiectasis	I-Disease
is	O
secondary	O
to	O
somatic	O
mutation	O
in	O
the	O
ndp	O
gene	O
which	O
results	O
in	O
a	O
deficiency	B-Disease
of	I-Disease
norrin	I-Disease
(	O
the	O
protein	O
product	O
of	O
the	O
ndp	O
gene	O
)	O
within	O
the	O
developing	O
retina	O
.	O
	
hereditary	O
tp53	O
codon	O
292	O
and	O
somatic	O
p16ink4a	O
codon	O
94	O
mutations	O
in	O
a	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
family	O
.	O
	
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
that	O
is	O
characterized	O
by	O
various	O
types	O
of	O
cancer	B-Disease
in	O
childhood	O
and	O
adult	O
cases	O
.	O
	
although	O
hereditary	O
tp53	O
mutation	O
is	O
very	O
rare	O
in	O
different	O
human	O
cancers	B-Disease
,	O
it	O
has	O
been	O
frequently	O
reported	O
in	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
.	O
	
on	O
the	O
other	O
hand	O
,	O
hereditary	O
mutations	O
of	O
tp57kip2	O
,	O
p15ink4b	O
,	O
and	O
p16ink4a	O
,	O
which	O
affect	O
the	O
cell	O
cycle	O
similar	O
to	O
tp53	O
,	O
were	O
observed	O
in	O
some	O
types	O
of	O
cancer	B-Disease
.	O
	
in	O
a	O
turkish	O
family	O
with	O
the	O
diagnosis	O
of	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
,	O
we	O
analyzed	O
the	O
mutation	O
pattern	O
of	O
tp53	O
,	O
p57kip2	O
,	O
p15ink4b	O
,	O
and	O
p16ink4a	O
in	O
the	O
peripheral	O
blood	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
homo	O
/	O
hemizygous	O
deletion	O
)	O
pattern	O
of	O
tp53	O
and	O
p15ink4b	O
/	O
p16ink4a	O
in	O
two	O
tumor	B-Disease
tissues	O
.	O
	
the	O
propositus	O
had	O
a	O
seminoma	B-Disease
,	O
his	O
daughter	O
a	O
medulloblastoma	B-Disease
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins	O
,	O
a	O
tp53	O
codon	O
292	O
missense	O
point	O
mutation	O
(	O
aaa	O
-	O
-	O
>	O
ata	O
;	O
lys	O
-	O
-	O
>	O
ile	O
)	O
in	O
the	O
peripheral	O
blood	O
cells	O
.	O
	
tumor	O
tissue	O
obtained	O
from	O
the	O
propositus	O
with	O
the	O
seminoma	B-Disease
revealed	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tp53	O
gene	O
.	O
	
in	O
the	O
analyses	O
of	O
tumor	B-Disease
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter	O
,	O
a	O
p16ink4a	O
codon	O
94	O
missense	O
point	O
mutation	O
(	O
gcg	O
-	O
-	O
>	O
gag	O
;	O
ala	O
-	O
-	O
>	O
glu	O
)	O
was	O
observed	O
with	O
the	O
hereditary	O
tp53	O
mutation	O
.	O
	
p16ink4a	O
codon	O
94	O
mutation	O
observed	O
in	O
our	O
family	O
is	O
a	O
novel	O
mutation	O
in	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
.	O
	
existence	O
of	O
the	O
p16ink4a	O
mutation	O
and	O
the	O
hereditary	O
tp53	O
mutation	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tp53	O
gene	O
(	O
seminoma	B-Disease
/	O
medulloblastoma	B-Disease
)	O
may	O
be	O
evidence	O
for	O
a	O
common	O
mechanism	O
involved	O
in	O
tumorogenesis	B-Disease
.	O
	
the	O
gene	O
alterations	O
in	O
tp53	O
and	O
p16ink4a	O
genes	O
may	O
be	O
used	O
as	O
tumor	B-Disease
markers	O
in	O
our	O
family	O
.	O
	
a	O
novel	O
mutation	O
in	O
the	O
sodium	O
/	O
iodide	O
symporter	O
gene	O
in	O
the	O
largest	O
family	O
with	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
.	O
	
we	O
previously	O
reported	O
nine	O
children	O
with	O
an	O
autosomally	O
recessive	O
form	O
of	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
an	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
a	O
large	O
hutterite	O
family	O
with	O
extensive	O
consanguinity	O
living	O
in	O
central	O
canada	O
.	O
	
since	O
the	O
original	O
report	O
,	O
we	O
have	O
diagnosed	O
congenital	B-Disease
hypothyroidism	I-Disease
by	O
newborn	O
tsh	O
screening	O
in	O
9	O
additional	O
children	O
from	O
the	O
family	O
.	O
	
expression	O
experiments	O
by	O
transfection	O
of	O
the	O
mutant	O
nis	O
complimentary	O
dna	O
into	O
cos	O
-	O
7	O
cells	O
showed	O
no	O
perchlorate	O
-	O
sensitive	O
iodide	O
uptake	O
,	O
confirming	O
that	O
the	O
mutation	O
is	O
the	O
direct	O
cause	O
of	O
the	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
these	O
patients	O
.	O
	
it	O
is	O
now	O
possible	O
to	O
use	O
gene	O
diagnostics	O
of	O
this	O
unique	O
nis	O
mutation	O
to	O
identify	O
patients	O
with	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
an	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
this	O
family	O
and	O
to	O
determine	O
the	O
carrier	O
state	O
of	O
potential	O
parents	O
for	O
genetic	O
counseling	O
and	O
arranging	O
rapid	O
and	O
early	O
diagnosis	O
of	O
their	O
infants	O
.	O
	
molecular	O
analysis	O
in	O
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
:	O
early	O
diagnosis	O
of	O
an	O
asymptomatic	O
carrier	O
.	O
	
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
fndi	B-Disease
)	O
is	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hormone	I-Disease
arginine	I-Disease
vasopressin	I-Disease
(	O
avp	O
)	O
and	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O
	
the	O
alteration	O
found	O
in	O
the	O
second	O
exon	O
of	O
the	O
gene	O
in	O
this	O
family	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
disease	O
,	O
as	O
all	O
individuals	O
harboring	O
the	O
mutation	O
had	O
been	O
previously	O
diagnosed	O
or	O
have	O
eventually	O
developed	O
fndi	B-Disease
.	O
	
identification	O
of	O
the	O
molecular	O
defect	O
underlying	O
fndi	B-Disease
in	O
affected	O
families	O
is	O
a	O
powerful	O
tool	O
for	O
early	O
asymptomatic	O
diagnosis	O
in	O
infants	O
.	O
	
deficit	O
of	O
in	O
vivo	O
mitochondrial	O
atp	O
production	O
in	O
patients	O
with	O
friedreich	B-Disease
ataxia	I-Disease
.	O
	
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
,	O
the	O
most	O
common	O
of	O
the	O
inherited	B-Disease
ataxias	I-Disease
,	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
degenerative	I-Disease
disorder	I-Disease
,	O
characterized	O
clinically	O
by	O
onset	O
before	O
the	O
age	O
of	O
25	O
of	O
progressive	B-Disease
gait	I-Disease
and	I-Disease
limb	I-Disease
ataxia	I-Disease
,	O
absence	B-Disease
of	I-Disease
deep	I-Disease
tendon	I-Disease
reflexes	I-Disease
,	O
extensor	B-Disease
plantar	I-Disease
responses	I-Disease
,	O
and	O
loss	B-Disease
of	I-Disease
position	I-Disease
and	I-Disease
vibration	I-Disease
sense	I-Disease
in	O
the	O
lower	O
limbs	O
.	O
	
frda	B-Disease
is	O
caused	O
by	O
a	O
gaa	O
triplet	O
expansion	O
in	O
the	O
first	O
intron	O
of	O
the	O
frda	B-Disease
gene	O
on	O
chromosome	O
9q13	O
in	O
97	O
%	O
of	O
patients	O
.	O
	
the	O
frda	B-Disease
gene	O
encodes	O
a	O
widely	O
expressed	O
210	O
-	O
aa	O
protein	O
,	O
frataxin	O
,	O
which	O
is	O
located	O
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
frda	B-Disease
patients	O
.	O
	
here	O
we	O
report	O
in	O
vivo	O
evidence	O
of	O
impaired	O
mitochondrial	O
respiration	O
in	O
skeletal	O
muscle	O
of	O
frda	B-Disease
patients	O
.	O
	
using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	O
rate	O
of	O
muscle	O
mitochondrial	O
atp	O
production	O
(	O
v	O
(	O
max	O
)	O
)	O
below	O
the	O
normal	O
range	O
in	O
all	O
12	O
frda	B-Disease
patients	O
and	O
a	O
strong	O
negative	O
correlation	O
between	O
mitochondrial	O
v	O
(	O
max	O
)	O
and	O
the	O
number	O
of	O
gaa	O
repeats	O
in	O
the	O
smaller	O
allele	O
.	O
	
our	O
results	O
show	O
that	O
frda	B-Disease
is	O
a	O
nuclear	O
-	O
encoded	O
mitochondrial	B-Disease
disorder	I-Disease
affecting	O
oxidative	O
phosphorylation	O
and	O
give	O
a	O
rationale	O
for	O
treatments	O
aimed	O
to	O
improve	O
mitochondrial	O
function	O
in	O
this	O
condition	O
.	O
	
identification	O
of	O
a	O
novel	O
r21x	O
mutation	O
in	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
arg1	O
)	O
in	O
four	O
portuguese	O
patients	O
with	O
argininemia	B-Disease
.	O
	
argininemia	B-Disease
is	O
a	O
rare	O
autossomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
cytosolic	I-Disease
liver	I-Disease
-	I-Disease
type	I-Disease
arginase	I-Disease
enzyme	I-Disease
(	O
l	O
-	O
arginine	O
urea	O
-	O
hydrolase	O
;	O
e	O
.	O
	
c	O
.	O
	
3	O
.	O
	
5	O
.	O
	
3	O
.	O
	
1	O
)	O
.	O
	
in	O
order	O
to	O
investigate	O
the	O
molecular	O
basis	O
for	O
argininemia	B-Disease
in	O
four	O
unrelated	O
portuguese	O
patients	O
(	O
two	O
from	O
northern	O
portugal	O
and	O
two	O
from	O
madeira	O
island	O
)	O
we	O
performed	O
a	O
dna	O
sequence	O
analysis	O
of	O
all	O
the	O
exons	O
and	O
exon	O
/	O
intron	O
boundaries	O
of	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
arg1	O
)	O
.	O
	
mutation	O
of	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
cyp27	O
)	O
results	O
in	O
truncation	O
of	O
mrna	O
expressed	O
in	O
leucocytes	O
in	O
a	O
japanese	O
family	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
.	O
	
objectives	O
a	O
japanese	O
family	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
was	O
investigated	O
for	O
a	O
sequence	O
alteration	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
cyp27	O
)	O
.	O
	
the	O
application	O
of	O
blood	O
leucocytes	O
can	O
be	O
a	O
simple	O
technique	O
on	O
analysing	O
a	O
constructive	O
abnormality	B-Disease
of	I-Disease
cyp27	I-Disease
mrna	O
.	O
	
clinical	O
and	O
molecular	O
genetic	O
analysis	O
of	O
19	O
wolfram	B-Disease
syndrome	I-Disease
kindreds	O
demonstrating	O
a	O
wide	O
spectrum	O
of	O
mutations	O
in	O
wfs1	O
.	O
	
wolfram	B-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disorder	I-Disease
characterized	O
by	O
juvenile	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
progressive	O
optic	B-Disease
atrophy	I-Disease
.	O
	
direct	O
dna	O
sequencing	O
was	O
done	O
to	O
screen	O
the	O
entire	O
coding	O
region	O
of	O
the	O
wfs1	O
gene	O
in	O
30	O
patients	O
from	O
19	O
british	O
kindreds	O
with	O
wolfram	B-Disease
syndrome	I-Disease
.	O
	
hence	O
,	O
molecular	O
screening	O
for	O
wolfram	B-Disease
syndrome	I-Disease
in	O
affected	O
families	O
and	O
for	O
wolfram	B-Disease
syndrome	I-Disease
-	O
carrier	O
status	O
in	O
subjects	O
with	O
psychiatric	B-Disease
disorders	I-Disease
or	O
diabetes	B-Disease
mellitus	I-Disease
will	O
require	O
complete	O
analysis	O
of	O
exon	O
8	O
and	O
upstream	O
exons	O
.	O
	
late	O
-	O
onset	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
:	O
a	O
subset	O
with	O
distinct	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O
.	O
	
to	O
determine	O
the	O
prevalence	O
and	O
characterize	O
demographic	O
,	O
clinical	O
,	O
and	O
genetic	O
features	O
of	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
of	O
late	O
onset	O
,	O
all	O
patients	O
experiencing	O
their	O
first	O
fmf	B-Disease
attack	O
at	O
age	O
40	O
years	O
or	O
more	O
were	O
identified	O
using	O
the	O
computerized	O
registry	O
of	O
our	O
fmf	B-Disease
clinic	O
,	O
and	O
then	O
thoroughly	O
interviewed	O
and	O
examined	O
.	O
	
the	O
control	O
group	O
consisted	O
of	O
40	O
consecutive	O
fmf	B-Disease
patients	O
,	O
who	O
arrived	O
at	O
the	O
fmf	B-Disease
clinic	O
for	O
their	O
regular	O
follow	O
-	O
up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	O
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination	O
.	O
	
mutational	O
analysis	O
in	O
the	O
fmf	B-Disease
gene	O
was	O
performed	O
using	O
a	O
commercial	O
kit	O
.	O
	
only	O
20	O
of	O
4000	O
(	O
0	O
.	O
	
5	O
%	O
)	O
patients	O
had	O
late	O
-	O
onset	O
fmf	B-Disease
.	O
	
none	O
had	O
chronic	O
or	O
prolonged	O
manifestations	O
of	O
fmf	B-Disease
,	O
for	O
example	O
,	O
amyloidosis	B-Disease
,	O
chronic	B-Disease
arthritis	I-Disease
,	O
or	O
protracted	O
myalgia	B-Disease
,	O
p	O
<	O
0	O
.	O
	
1	O
,	O
compared	O
to	O
our	O
regular	O
fmf	B-Disease
population	O
.	O
	
we	O
conclude	O
that	O
the	O
onset	O
of	O
fmf	B-Disease
in	O
a	O
late	O
age	O
defines	O
a	O
milder	O
form	O
of	O
disease	O
with	O
typical	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
is	O
associated	O
with	O
a	O
high	O
frequency	O
of	O
brca1	O
mutations	O
.	O
	
maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
14	I-Disease
in	O
a	O
boy	O
with	O
a	O
normal	O
karyotype	O
.	O
	
we	O
report	O
on	O
a	O
boy	O
with	O
a	O
maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
14	I-Disease
(	O
upd	B-Disease
(	O
14	O
)	O
)	O
.	O
	
at	O
7	O
years	O
of	O
age	O
he	O
was	O
referred	O
to	O
us	O
by	O
the	O
paediatrician	O
because	O
of	O
symptoms	O
of	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
he	O
showed	O
short	B-Disease
stature	I-Disease
,	O
obesity	B-Disease
,	O
mild	O
developmental	B-Disease
delay	I-Disease
,	O
cryptorchidism	B-Disease
,	O
and	O
some	O
mild	O
dysmorphic	B-Disease
features	I-Disease
.	O
	
the	O
history	O
further	O
indicated	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
at	O
the	O
end	O
of	O
the	O
pregnancy	O
.	O
	
after	O
birth	O
he	O
showed	O
hypotonia	B-Disease
with	O
poor	O
sucking	O
,	O
for	O
which	O
gavage	O
feeding	O
was	O
needed	O
.	O
	
after	O
1	O
year	O
he	O
became	O
obese	B-Disease
despite	O
a	O
normal	O
appetite	O
.	O
	
recurrent	O
middle	B-Disease
ear	I-Disease
infections	I-Disease
,	O
a	O
high	O
pain	O
threshold	O
,	O
and	O
a	O
great	O
skill	O
with	O
jigsaw	O
puzzles	O
were	O
reported	O
.	O
	
dna	O
analysis	O
for	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
showed	O
no	O
abnormalities	O
.	O
	
two	O
years	O
later	O
he	O
was	O
re	O
-	O
examined	O
because	O
we	O
thought	O
his	O
features	O
fitted	O
the	O
pws	B-Disease
-	O
like	O
phenotype	O
associated	O
with	O
maternal	O
upd	B-Disease
(	O
14	O
)	O
.	O
	
dna	O
analysis	O
showed	O
maternal	B-Disease
heterodisomy	I-Disease
for	O
chromosome	O
14	O
.	O
	
in	O
all	O
the	O
previously	O
described	O
11	O
cases	O
with	O
maternal	O
upd	B-Disease
(	O
14	O
)	O
,	O
a	O
robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
was	O
detected	O
cytogenetically	O
before	O
dna	O
analysis	O
.	O
	
this	O
is	O
the	O
first	O
report	O
of	O
diagnosis	O
of	O
maternal	O
upd	B-Disease
(	O
14	O
)	O
based	O
on	O
clinical	O
features	O
.	O
	
this	O
finding	O
underlines	O
the	O
importance	O
of	O
dna	O
analysis	O
for	O
maternal	O
upd	O
(	O
14	O
)	O
in	O
patients	O
with	O
a	O
similar	O
pws	B-Disease
-	O
like	O
phenotype	O
even	O
without	O
previous	O
identification	O
of	O
a	O
robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
.	O
	
clinical	O
and	O
genetic	O
study	O
of	O
friedreich	B-Disease
ataxia	I-Disease
in	O
an	O
australian	O
population	O
.	O
	
friedreich	B-Disease
ataxia	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
frda	B-Disease
gene	O
that	O
encodes	O
a	O
210	O
-	O
amino	O
acid	O
protein	O
called	O
frataxin	O
.	O
	
we	O
found	O
a	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
of	O
the	O
two	O
expanded	O
alleles	O
and	O
age	O
at	O
onset	O
,	O
age	O
into	O
wheelchair	O
,	O
scoliosis	B-Disease
,	O
impaired	O
vibration	O
sense	O
,	O
and	O
the	O
presence	O
of	O
foot	B-Disease
deformity	I-Disease
.	O
	
there	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
allele	O
and	O
cardiomyopathy	B-Disease
,	O
diabetes	B-Disease
mellitus	I-Disease
,	O
loss	B-Disease
of	I-Disease
proprioception	I-Disease
,	O
or	O
bladder	B-Disease
symptoms	I-Disease
.	O
	
the	O
larger	O
allele	O
size	O
correlated	O
with	O
bladder	B-Disease
symptoms	I-Disease
and	O
the	O
presence	O
of	O
foot	B-Disease
deformity	I-Disease
.	O
	
the	O
duration	O
of	O
disease	O
is	O
correlated	O
with	O
wheelchair	O
use	O
and	O
the	O
presence	O
of	O
diabetes	B-Disease
,	O
scoliosis	B-Disease
,	O
bladder	B-Disease
symptoms	I-Disease
and	O
impaired	B-Disease
proprioception	I-Disease
,	O
and	O
vibration	O
sense	O
but	O
no	O
other	O
complications	O
studied	O
.	O
	
novel	O
mutations	O
in	O
xlrs1	O
causing	O
retinoschisis	B-Disease
,	O
including	O
first	O
evidence	O
of	O
putative	O
leader	O
sequence	O
change	O
.	O
	
juvenile	B-Disease
retinoschisis	I-Disease
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
xlrs1	O
gene	O
.	O
	
we	O
screened	O
31	O
new	O
unrelated	O
patients	O
and	O
families	O
for	O
xlrs1	O
mutations	O
in	O
addition	O
to	O
previously	O
reported	O
mutations	O
for	O
60	O
of	O
our	O
families	O
(	O
retinoschisis	B-Disease
consortium	O
,	O
hum	O
mol	O
genet	O
1998	O
;	O
7	O
1185	O
-	O
1192	O
)	O
.	O
	
growth	O
hormone	O
treatment	O
increases	O
co	O
(	O
2	O
)	O
response	O
,	O
ventilation	O
and	O
central	O
inspiratory	O
drive	O
in	O
children	O
with	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
.	O
	
we	O
studied	O
whether	O
the	O
beneficial	O
effects	O
of	O
growth	O
hormone	O
(	O
gh	O
)	O
treatment	O
on	O
growth	O
and	O
body	O
composition	O
in	O
pws	B-Disease
are	O
accompanied	O
by	O
an	O
improvement	O
in	O
respiratory	O
function	O
.	O
	
conclusion	O
treatment	O
of	O
children	O
with	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	O
on	O
central	O
respiratory	O
structures	O
.	O
	
the	O
observed	O
increase	O
in	O
ventilation	O
and	O
inspiratory	O
drive	O
may	O
contribute	O
to	O
the	O
improved	O
activity	O
level	O
reported	O
by	O
parents	O
of	O
pws	B-Disease
children	O
during	O
growth	O
hormone	O
therapy	O
g130v	O
,	O
a	O
common	O
frda	B-Disease
point	O
mutation	O
,	O
appears	O
to	O
have	O
arisen	O
from	O
a	O
common	O
founder	O
.	O
	
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
is	O
the	O
most	O
common	O
inherited	B-Disease
ataxia	I-Disease
.	O
	
g130v	O
,	O
when	O
present	O
with	O
an	O
expanded	O
gaa	O
repeat	O
on	O
the	O
other	O
allele	O
,	O
is	O
associated	O
with	O
an	O
atypical	O
frda	B-Disease
phenotype	O
.	O
	
most	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
patients	O
have	O
expansion	O
of	O
a	O
(	O
cgg	O
)	O
(	O
n	O
)	O
sequence	O
with	O
>	O
200	O
repeats	O
(	O
full	O
mutation	O
)	O
in	O
the	O
fmr1	O
gene	O
responsible	O
for	O
this	O
condition	O
.	O
	
constitutional	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	O
vhl	B-Disease
)	O
gene	O
deletions	O
detected	O
in	O
vhl	B-Disease
families	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
	
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
disease	I-Disease
is	O
an	O
autosomal	B-Disease
dominantly	I-Disease
inherited	I-Disease
cancer	I-Disease
syndrome	I-Disease
predisposing	O
to	O
a	O
variety	O
of	O
tumor	B-Disease
types	O
that	O
include	O
retinal	O
hemangioblastomas	B-Disease
,	O
hemangioblastomas	B-Disease
of	O
the	O
central	O
nervous	O
system	O
,	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
,	O
pancreatic	B-Disease
cysts	I-Disease
and	I-Disease
tumors	I-Disease
,	O
pheochromocytomas	B-Disease
,	O
endolymphatic	B-Disease
sac	I-Disease
tumors	I-Disease
,	O
and	O
epididymal	B-Disease
cystadenomas	I-Disease
[	O
w	O
.	O
	
the	O
vhl	B-Disease
gene	O
was	O
localized	O
to	O
chromosome	O
3p25	O
-	O
26	O
and	O
cloned	O
[	O
f	O
.	O
	
latif	O
et	O
al	O
.	O
	
,	O
science	O
(	O
washington	O
dc	O
)	O
,	O
260	O
1317	O
-	O
1320	O
,	O
1993	O
]	O
.	O
	
germline	O
mutations	O
in	O
the	O
vhl	B-Disease
gene	O
have	O
been	O
detected	O
in	O
the	O
majority	O
of	O
vhl	B-Disease
kindreds	O
.	O
	
the	O
reported	O
frequency	O
of	O
detection	O
of	O
vhl	B-Disease
germline	O
mutations	O
has	O
varied	O
from	O
39	O
to	O
80	O
%	O
(	O
j	O
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
use	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
fish	O
)	O
as	O
a	O
method	O
to	O
detect	O
and	O
characterize	O
vhl	B-Disease
germline	O
deletions	O
.	O
	
we	O
reexamined	O
a	O
group	O
of	O
vhl	B-Disease
patients	O
shown	O
previously	O
by	O
single	O
-	O
strand	O
conformation	O
and	O
sequencing	O
analysis	O
not	O
to	O
harbor	O
point	O
mutations	O
in	O
the	O
vhl	B-Disease
locus	O
.	O
	
we	O
found	O
constitutional	O
deletions	O
in	O
29	O
of	O
30	O
vhl	B-Disease
patients	O
in	O
this	O
group	O
using	O
cosmid	O
and	O
p1	O
probes	O
that	O
cover	O
the	O
vhl	B-Disease
locus	O
.	O
	
we	O
then	O
tested	O
six	O
phenotypically	O
normal	O
offspring	O
from	O
four	O
of	O
these	O
vhl	B-Disease
families	O
two	O
were	O
found	O
to	O
carry	O
the	O
deletion	O
and	O
the	O
other	O
four	O
were	O
deletion	O
-	O
free	O
.	O
	
in	O
addition	O
,	O
germline	O
mosaicism	O
of	O
the	O
vhl	B-Disease
gene	O
was	O
identified	O
in	O
one	O
family	O
.	O
	
in	O
sum	O
,	O
fish	O
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	O
vhl	B-Disease
germline	O
deletions	O
and	O
practically	O
useful	O
in	O
cases	O
where	O
other	O
methods	O
of	O
screening	O
have	O
failed	O
to	O
detect	O
a	O
vhl	B-Disease
gene	I-Disease
abnormality	I-Disease
spectrum	O
of	O
hsnf5	O
/	O
ini1	O
somatic	O
mutations	O
in	O
human	O
cancer	B-Disease
and	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
	
the	O
hsnf5	O
/	O
ini1	O
gene	O
which	O
encodes	O
a	O
member	O
of	O
the	O
swi	O
/	O
snf	O
chromatin	O
atp	O
-	O
dependent	O
remodeling	O
complex	O
,	O
is	O
a	O
new	O
tumor	B-Disease
suppressor	O
gene	O
localized	O
on	O
chromosome	O
22q11	O
.	O
	
2	O
and	O
recently	O
shown	O
to	O
be	O
mutated	O
in	O
malignant	B-Disease
rhabdoid	I-Disease
tumors	I-Disease
.	O
	
we	O
have	O
searched	O
for	O
hsnf5	O
/	O
ini1	O
mutations	O
in	O
229	O
tumors	B-Disease
of	O
various	O
origins	O
using	O
a	O
screening	O
method	O
based	O
on	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O
	
mutations	O
were	O
retrieved	O
in	O
most	O
rhabdoid	B-Disease
tumors	I-Disease
,	O
whatever	O
their	O
sites	O
of	O
occurrence	O
,	O
indicating	O
the	O
common	O
pathogenetic	O
origin	O
of	O
these	O
tumors	B-Disease
.	O
	
recurrent	O
hsnf5	O
/	O
ini1	O
alterations	O
were	O
also	O
observed	O
in	O
choroid	B-Disease
plexus	I-Disease
carcinomas	I-Disease
and	O
in	O
a	O
subset	O
of	O
central	O
primitive	O
neuroectodermal	B-Disease
tumors	I-Disease
(	O
cpnets	O
)	O
and	O
medulloblastomas	B-Disease
.	O
	
in	O
contrast	O
,	O
hsnf5	O
/	O
ini1	O
point	O
mutations	O
were	O
not	O
detected	O
in	O
breast	B-Disease
cancers	I-Disease
,	O
wilms	B-Disease
tumors	I-Disease
,	O
gliomas	B-Disease
,	O
ependymomas	B-Disease
,	O
sarcomas	B-Disease
and	O
other	O
tumor	B-Disease
types	O
,	O
even	O
though	O
most	O
analyzed	O
cases	O
harbored	O
loss	O
of	O
heterozygosity	O
at	O
22q11	O
.	O
	
these	O
results	O
suggest	O
that	O
rhabdoid	B-Disease
tumors	I-Disease
,	O
choroid	B-Disease
plexus	I-Disease
carcinomas	I-Disease
and	O
a	O
subset	O
of	O
medulloblastomas	B-Disease
and	O
cpnets	O
share	O
common	O
pathways	O
of	O
oncogenesis	O
related	O
to	O
hsnf5	O
/	O
ini1	O
alteration	O
and	O
that	O
hsnf5	O
/	O
ini1	O
mutations	O
define	O
a	O
genetically	O
homogeneous	O
family	O
of	O
highly	O
aggressive	O
cancers	B-Disease
mainly	O
occurring	O
in	O
young	O
children	O
and	O
frequently	O
,	O
but	O
not	O
always	O
,	O
exhibiting	O
a	O
rhabdoid	B-Disease
phenotype	O
spinocerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
-	I-Disease
3	I-Disease
or	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
sca3	B-Disease
/	O
mjd	B-Disease
)	O
is	O
a	O
member	O
of	O
the	O
cag	B-Disease
/	I-Disease
polyglutamine	I-Disease
repeat	I-Disease
disease	I-Disease
family	O
.	O
	
experimental	O
models	O
of	O
polyglutamine	B-Disease
disease	I-Disease
implicate	O
the	O
nucleus	O
in	O
pathogenesis	O
;	O
however	O
,	O
the	O
link	O
between	O
intranuclear	O
expression	O
of	O
expanded	O
polyglutamine	O
and	O
neuronal	B-Disease
dysfunction	I-Disease
remains	O
unclear	O
.	O
	
here	O
we	O
demonstrate	O
that	O
ataxin	O
-	O
3	O
,	O
the	O
disease	O
protein	O
in	O
sca3	B-Disease
/	O
mjd	B-Disease
,	O
adopts	O
a	O
unique	O
conformation	O
when	O
expressed	O
within	O
the	O
nucleus	O
of	O
transfected	O
cells	O
.	O
	
these	O
data	O
suggest	O
that	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
sca3	B-Disease
/	O
mjd	B-Disease
may	O
be	O
an	O
altered	O
conformation	O
of	O
ataxin	O
-	O
3	O
within	O
the	O
nucleus	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
.	O
	
the	O
human	O
magel2	O
gene	O
and	O
its	O
mouse	O
homologue	O
are	O
paternally	O
expressed	O
and	O
mapped	O
to	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
region	O
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
is	O
a	O
complex	O
neurogenetic	B-Disease
disorder	I-Disease
.	O
	
the	O
phenotype	O
is	O
likely	O
to	O
be	O
a	O
contiguous	B-Disease
gene	I-Disease
syndrome	I-Disease
involving	O
genes	O
which	O
are	O
paternally	O
expressed	O
only	O
,	O
located	O
in	O
the	O
human	O
15q11	O
-	O
q13	O
region	O
.	O
	
four	O
mouse	O
models	O
of	O
pws	B-Disease
have	O
been	O
reported	O
but	O
these	O
do	O
not	O
definitively	O
allow	O
the	O
delineation	O
of	O
the	O
critical	O
region	O
and	O
the	O
associated	O
genes	O
involved	O
in	O
the	O
aetiology	O
of	O
pws	B-Disease
.	O
	
moreover	O
,	O
targeted	O
mutagenesis	O
of	O
mouse	O
homologues	O
of	O
the	O
human	O
candidate	O
pws	B-Disease
genes	O
does	O
not	O
appear	O
to	O
result	O
in	O
any	O
of	O
the	O
features	O
of	O
pws	B-Disease
.	O
	
therefore	O
,	O
the	O
isolation	O
of	O
new	O
genes	O
in	O
this	O
region	O
remains	O
crucial	O
for	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
pws	B-Disease
.	O
	
moreover	O
,	O
magel2	O
/	O
magel2	O
are	O
expressed	O
only	O
from	O
the	O
paternal	O
allele	O
in	O
brain	O
,	O
suggesting	O
a	O
potential	O
role	O
in	O
the	O
aetiology	O
of	O
pws	B-Disease
and	O
its	O
mouse	O
model	O
,	O
respectively	O
.	O
	
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
is	O
an	O
aggressive	O
pediatric	B-Disease
cancer	I-Disease
of	I-Disease
striated	I-Disease
muscle	I-Disease
characterized	O
in	O
60	O
%	O
of	O
cases	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
.	O
	
relevance	O
of	O
this	O
model	O
was	O
suggested	O
by	O
verification	O
that	O
three	O
of	O
these	O
genes	O
(	O
igfbp5	O
,	O
hsix1	O
,	O
and	O
slug	O
)	O
were	O
also	O
expressed	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
cell	O
lines	O
.	O
	
experimental	O
hemochromatosis	B-Disease
due	O
to	O
mhc	O
class	O
i	O
hfe	B-Disease
deficiency	I-Disease
:	O
immune	O
status	O
and	O
iron	O
metabolism	O
.	O
	
the	O
puzzling	O
linkage	O
between	O
genetic	O
hemochromatosis	B-Disease
and	O
histocompatibility	O
loci	O
became	O
even	O
more	O
so	O
when	O
the	O
gene	O
involved	O
,	O
hfe	O
,	O
was	O
identified	O
.	O
	
hfe	B-Disease
-	I-Disease
deficient	I-Disease
animals	O
were	O
analyzed	O
for	O
a	O
comprehensive	O
set	O
of	O
metabolic	O
and	O
immune	O
parameters	O
.	O
	
faithfully	O
mimicking	O
human	O
hemochromatosis	B-Disease
,	O
mice	O
homozygous	O
for	O
this	O
deletion	O
develop	O
iron	O
overload	O
,	O
characterized	O
by	O
a	O
higher	O
plasma	O
iron	O
content	O
and	O
a	O
raised	O
transferrin	O
saturation	O
as	O
well	O
as	O
an	O
elevated	O
hepatic	O
iron	O
load	O
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
is	O
a	O
rare	O
genetic	B-Disease
disorder	I-Disease
associated	O
with	O
immune	B-Disease
deficiency	I-Disease
,	O
chromosome	B-Disease
instability	I-Disease
,	O
and	O
a	O
predisposition	O
to	O
lymphoid	B-Disease
malignancy	I-Disease
.	O
	
these	O
findings	O
as	O
well	O
as	O
data	O
obtained	O
by	O
others	O
for	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
suggest	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
the	O
initial	O
chromosomal	O
change	O
in	O
lymphocyte	O
clones	O
of	O
patients	O
with	O
this	O
disorder	O
.	O
	
chromosomes	O
of	O
lymphocytes	O
from	O
one	O
of	O
the	O
patients	O
were	O
studied	O
before	O
and	O
after	O
the	O
onset	O
of	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
.	O
	
before	O
leukemia	B-Disease
was	O
diagnosed	O
,	O
the	O
patient	O
had	O
a	O
lymphocyte	O
clone	O
with	O
a	O
14q	O
translocation	O
.	O
	
this	O
clone	O
appears	O
to	O
have	O
given	O
rise	O
to	O
the	O
leukemic	B-Disease
cells	O
.	O
	
we	O
hypothesize	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
directly	O
related	O
to	O
abnormal	O
growth	O
of	O
lymphocytes	O
and	O
that	O
it	O
may	O
be	O
a	O
step	O
toward	O
the	O
development	O
of	O
lymphoid	B-Disease
malignancies	I-Disease
.	O
	
increasing	O
evidence	O
,	O
provided	O
by	O
others	O
,	O
for	O
the	O
nonrandom	O
involvement	O
of	O
14q	O
in	O
african	O
-	O
type	O
burkitts	B-Disease
lymphoma	I-Disease
and	O
other	O
lymphoid	B-Disease
neoplasms	I-Disease
further	O
strengthens	O
this	O
hypothesis	O
.	O
	
exon	O
9	O
mutations	O
in	O
the	O
wt1	O
gene	O
,	O
without	O
influencing	O
kts	O
splice	O
isoforms	O
,	O
are	O
also	O
responsible	O
for	O
frasier	B-Disease
syndrome	I-Disease
.	O
	
we	O
report	O
new	O
mutations	O
in	O
exon	O
9	O
of	O
the	O
wt1	O
gene	O
that	O
did	O
not	O
alter	O
the	O
ratio	O
of	O
+	O
/	O
-	O
kts	O
splice	O
isoforms	O
in	O
two	O
unrelated	O
patients	O
with	O
frasier	B-Disease
syndrome	I-Disease
(	O
fs	B-Disease
)	O
.	O
	
the	O
mutations	O
found	O
in	O
our	O
cases	O
occurred	O
in	O
the	O
same	O
exon	O
of	O
the	O
wt1	O
gene	O
as	O
detected	O
in	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
(	O
dds	B-Disease
)	O
and	O
could	O
not	O
be	O
explained	O
by	O
the	O
previously	O
proposed	O
mechanism	O
.	O
	
the	O
results	O
suggest	O
that	O
the	O
two	O
syndromes	O
originate	O
from	O
the	O
same	O
wt1	B-Disease
gene	I-Disease
abnormality	I-Disease
.	O
	
from	O
a	O
molecular	O
biological	O
point	O
of	O
view	O
,	O
we	O
concluded	O
that	O
the	O
two	O
diseases	O
were	O
not	O
separable	O
,	O
and	O
that	O
fs	B-Disease
should	O
be	O
included	O
as	O
an	O
atypical	O
form	O
of	O
dds	B-Disease
.	O
	
splice	O
-	O
site	O
mutation	O
in	O
the	O
pds	B-Disease
gene	O
may	O
result	O
in	O
intrafamilial	O
variability	O
for	O
deafness	B-Disease
in	O
pendred	B-Disease
syndrome	I-Disease
.	O
	
pendred	B-Disease
syndrome	I-Disease
is	O
a	O
recessive	B-Disease
inherited	I-Disease
disorder	I-Disease
that	O
consists	O
of	O
developmental	B-Disease
abnormalities	I-Disease
of	I-Disease
the	I-Disease
cochlea	I-Disease
,	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
,	O
and	O
diffuse	B-Disease
thyroid	I-Disease
enlargement	I-Disease
(	O
goiter	B-Disease
)	O
.	O
	
this	O
disorder	O
may	O
account	O
for	O
up	O
to	O
10	O
%	O
of	O
cases	O
of	O
hereditary	B-Disease
deafness	I-Disease
.	O
	
the	O
disease	O
gene	O
(	O
pds	B-Disease
)	O
has	O
been	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
,	O
and	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O
	
we	O
performed	O
mutation	O
analysis	O
of	O
individual	O
exons	O
of	O
the	O
pds	B-Disease
gene	O
in	O
one	O
spanish	O
family	O
that	O
shows	O
intrafamilial	O
variability	O
of	O
the	O
deafness	B-Disease
phenotype	O
(	O
two	O
patients	O
with	O
profound	O
and	O
one	O
with	O
moderate	O
-	O
severe	O
deafness	B-Disease
)	O
.	O
	
we	O
identified	O
a	O
new	O
splice	O
-	O
site	O
mutation	O
affecting	O
intron	O
4	O
of	O
the	O
pds	B-Disease
gene	O
,	O
at	O
nucleotide	O
position	O
639	O
+	O
7	O
.	O
	
since	O
the	O
newly	O
created	O
donor	O
splice	O
site	O
is	O
likely	O
to	O
compete	O
with	O
the	O
normal	O
one	O
,	O
variations	O
of	O
the	O
levels	O
of	O
normal	O
and	O
aberrant	O
transcripts	O
of	O
the	O
pds	B-Disease
gene	O
in	O
the	O
cochlea	O
may	O
explain	O
the	O
variability	O
in	O
the	O
deafness	B-Disease
presentation	O
.	O
	
the	O
molecular	O
basis	O
of	O
sjogren	B-Disease
-	I-Disease
larsson	I-Disease
syndrome	I-Disease
:	O
mutation	O
analysis	O
of	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene	O
.	O
	
sjogren	B-Disease
-	I-Disease
larsson	I-Disease
syndrome	I-Disease
(	O
sls	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
ichthyosis	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
spasticity	B-Disease
,	O
and	O
deficient	B-Disease
activity	I-Disease
of	I-Disease
fatty	I-Disease
aldehyde	I-Disease
dehydrogenase	I-Disease
(	O
faldh	O
)	O
.	O
	
to	O
define	O
the	O
molecular	O
defects	O
causing	O
sls	B-Disease
,	O
we	O
performed	O
mutation	O
analysis	O
of	O
the	O
faldh	O
gene	O
in	O
probands	O
from	O
63	O
kindreds	O
with	O
sls	B-Disease
.	O
	
all	O
of	O
the	O
patients	O
with	O
sls	B-Disease
were	O
found	O
to	O
carry	O
mutations	O
.	O
	
at	O
least	O
four	O
of	O
the	O
common	O
mutations	O
(	O
551c	O
-	O
-	O
>	O
t	O
,	O
682c	O
-	O
-	O
>	O
t	O
,	O
733g	O
-	O
-	O
>	O
a	O
,	O
and	O
798	O
+	O
1delg	O
)	O
were	O
associated	O
with	O
multiple	O
snp	O
haplotypes	O
,	O
suggesting	O
that	O
these	O
mutations	O
originated	O
independently	O
on	O
more	O
than	O
one	O
occasion	O
or	O
were	O
ancient	O
sls	B-Disease
genes	O
that	O
had	O
undergone	O
intragenic	O
recombination	O
.	O
	
our	O
results	O
demonstrate	O
that	O
sls	B-Disease
is	O
caused	O
by	O
a	O
strikingly	O
heterogeneous	O
group	O
of	O
mutations	O
in	O
the	O
faldh	O
gene	O
and	O
provide	O
a	O
framework	O
for	O
understanding	O
the	O
genetic	O
basis	O
of	O
sls	B-Disease
and	O
the	O
development	O
of	O
dna	O
-	O
based	O
diagnostic	O
tests	O
.	O
	
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
cathepsin	O
c	O
gene	O
result	O
in	O
periodontal	B-Disease
disease	I-Disease
and	O
palmoplantar	B-Disease
keratosis	I-Disease
.	O
	
papillon	B-Disease
-	I-Disease
lefevre	I-Disease
syndrome	I-Disease
,	O
or	O
keratosis	B-Disease
palmoplantaris	I-Disease
with	O
periodontopathia	B-Disease
(	O
pls	B-Disease
,	O
mim	O
245000	O
)	O
,	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	O
periodontitis	B-Disease
that	O
afflicts	O
patients	O
.	O
	
both	O
the	O
deciduous	O
and	O
permanent	O
dentitions	O
are	O
affected	O
,	O
resulting	O
in	O
premature	O
tooth	B-Disease
loss	I-Disease
.	O
	
palmoplantar	B-Disease
keratosis	I-Disease
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	O
to	O
overt	O
hyperkeratosis	B-Disease
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life	O
.	O
	
keratosis	B-Disease
also	O
affects	O
other	O
sites	O
such	O
as	O
elbows	O
and	O
knees	O
.	O
	
most	O
pls	B-Disease
patients	O
display	O
both	O
periodontitis	B-Disease
and	O
hyperkeratosis	B-Disease
.	O
	
some	O
patients	O
have	O
only	O
palmoplantar	B-Disease
keratosis	I-Disease
or	O
periodontitis	B-Disease
,	O
and	O
in	O
rare	O
individuals	O
the	O
periodontitis	B-Disease
is	O
mild	O
and	O
of	O
late	O
onset	O
.	O
	
in	O
two	O
of	O
these	O
families	O
we	O
used	O
a	O
functional	O
assay	O
to	O
demonstrate	O
an	O
almost	O
total	O
loss	O
of	O
cathepsin	O
c	O
activity	O
in	O
pls	B-Disease
patients	O
and	O
reduced	O
activity	O
in	O
obligate	O
carriers	O
.	O
	
confirmation	O
of	O
linkage	O
of	O
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
to	O
chromosome	O
1q32	O
:	O
evidence	O
of	O
association	O
with	O
str	O
alleles	O
suggests	O
possible	O
unique	O
origin	O
of	O
the	O
disease	O
mutation	O
.	O
	
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
(	O
vws	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
craniofacial	I-Disease
disorder	I-Disease
with	O
high	O
penetrance	O
and	O
variable	O
expression	O
.	O
	
its	O
clinical	O
features	O
are	O
variably	O
expressed	O
,	O
but	O
include	O
cleft	B-Disease
lip	I-Disease
and	O
/	O
or	O
cleft	B-Disease
palate	I-Disease
,	O
lip	B-Disease
pits	I-Disease
and	O
hypodontia	B-Disease
.	O
	
all	O
vws	B-Disease
families	O
studied	O
to	O
date	O
map	O
the	O
disease	O
gene	O
to	O
a	O
<	O
2	O
cm	O
region	O
of	O
chromosome	O
1q32	O
,	O
with	O
no	O
evidence	O
of	O
locus	O
heterogeneity	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
refine	O
the	O
localization	O
of	O
the	O
vws	B-Disease
gene	O
and	O
to	O
further	O
assess	O
possible	O
heterogeneity	O
.	O
	
we	O
analyzed	O
four	O
multiplex	O
vws	B-Disease
families	O
.	O
	
all	O
available	O
members	O
were	O
clinically	O
assessed	O
and	O
genotyped	O
for	O
19	O
short	O
tandem	O
repeat	O
markers	O
on	O
chromosome	O
1	O
in	O
the	O
vws	B-Disease
candidate	O
gene	O
region	O
.	O
	
our	O
assay	O
method	O
for	O
short	O
tandem	O
repeat	O
(	O
str	O
)	O
markers	O
provided	O
highly	O
accurate	O
size	O
estimation	O
of	O
marker	O
allele	O
fragment	O
sizes	O
,	O
and	O
therefore	O
enabled	O
us	O
to	O
determine	O
the	O
specific	O
alleles	O
segregating	O
with	O
the	O
vws	B-Disease
gene	O
in	O
each	O
of	O
our	O
four	O
families	O
.	O
	
we	O
observed	O
a	O
striking	O
pattern	O
of	O
str	O
allele	O
sharing	O
at	O
several	O
closely	O
linked	O
loci	O
among	O
our	O
four	O
caucasian	O
vws	B-Disease
families	O
recruited	O
at	O
three	O
different	O
locations	O
in	O
the	O
us	O
.	O
	
these	O
results	O
suggest	O
the	O
possibility	O
of	O
a	O
unique	O
origin	O
for	O
a	O
mutation	O
responsible	O
for	O
many	O
or	O
most	O
cases	O
of	O
vws	B-Disease
.	O
	
a	O
new	O
platelet	O
-	O
specific	O
alloantigen	O
,	O
termed	O
sit	O
(	O
a	O
)	O
,	O
was	O
identified	O
in	O
a	O
severe	O
case	O
of	O
neonatal	B-Disease
alloimmune	I-Disease
thrombocytopenia	I-Disease
.	O
	
mutations	O
of	O
the	O
cathepsin	O
c	O
gene	O
are	O
responsible	O
for	O
papillon	B-Disease
-	I-Disease
lefevre	I-Disease
syndrome	I-Disease
.	O
	
papillon	B-Disease
-	I-Disease
lefevre	I-Disease
syndrome	I-Disease
(	O
pls	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterised	O
by	O
palmoplantar	B-Disease
hyperkeratosis	I-Disease
and	O
severe	O
early	O
onset	O
periodontitis	B-Disease
that	O
results	O
in	O
the	O
premature	O
loss	O
of	O
the	O
primary	O
and	O
secondary	O
dentitions	O
.	O
	
a	O
major	O
gene	O
locus	O
for	O
pls	B-Disease
has	O
been	O
mapped	O
to	O
a	O
2	O
.	O
	
by	O
rt	O
-	O
pcr	O
,	O
we	O
found	O
ctsc	O
is	O
also	O
expressed	O
in	O
epithelial	O
regions	O
commonly	O
affected	O
by	O
pls	B-Disease
,	O
including	O
the	O
palms	O
,	O
soles	O
,	O
knees	O
,	O
and	O
oral	O
keratinised	O
gingiva	O
.	O
	
sequence	O
analysis	O
of	O
ctsc	O
from	O
subjects	O
affected	O
with	O
pls	B-Disease
from	O
five	O
consanguineous	O
turkish	O
families	O
identified	O
four	O
different	O
mutations	O
.	O
	
all	O
pls	B-Disease
patients	O
were	O
homozygous	O
for	O
cathepsin	O
c	O
mutations	O
inherited	O
from	O
a	O
common	O
ancestor	O
.	O
	
parents	O
and	O
sibs	O
heterozygous	O
for	O
cathepsin	O
c	O
mutations	O
do	O
not	O
show	O
either	O
the	O
palmoplantar	B-Disease
hyperkeratosis	I-Disease
or	O
severe	O
early	O
onset	O
periodontitis	B-Disease
characteristic	O
of	O
pls	B-Disease
.	O
	
a	O
more	O
complete	O
understanding	O
of	O
the	O
functional	O
physiology	O
of	O
cathepsin	O
c	O
carries	O
significant	O
implications	O
for	O
understanding	O
normal	O
and	O
abnormal	O
skin	O
development	O
and	O
periodontal	B-Disease
disease	I-Disease
susceptibility	O
mutational	O
analysis	O
of	O
the	O
hgo	O
gene	O
in	O
finnish	O
alkaptonuria	B-Disease
patients	O
.	O
	
alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
,	O
the	O
prototypic	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
,	O
has	O
recently	O
been	O
shown	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
homogentisate	O
-	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
(	O
hgo	O
)	O
.	O
	
so	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
aku	B-Disease
patients	O
of	O
different	O
ethnic	O
origin	O
.	O
	
we	O
describe	O
three	O
novel	O
mutations	O
(	O
r58fs	O
,	O
r330s	O
,	O
and	O
h371r	O
)	O
and	O
one	O
common	O
aku	B-Disease
mutation	O
(	O
m368v	O
)	O
,	O
detected	O
by	O
mutational	O
and	O
polymorphism	O
analysis	O
of	O
the	O
hgo	O
gene	O
in	O
five	O
finnish	O
aku	B-Disease
pedigrees	O
.	O
	
the	O
three	O
novel	O
aku	B-Disease
mutations	O
are	O
most	O
likely	O
specific	O
for	O
the	O
finnish	O
population	O
and	O
have	O
originated	O
recently	O
.	O
	
the	O
identical	O
5	O
'	O
splice	O
-	O
site	O
acceptor	O
mutation	O
in	O
five	O
attenuated	B-Disease
apc	I-Disease
families	O
from	O
newfoundland	O
demonstrates	O
a	O
founder	O
effect	O
.	O
	
inherited	O
mutations	O
of	O
the	O
apc	B-Disease
gene	O
predispose	O
carriers	O
to	O
multiple	O
adenomatous	B-Disease
polyps	I-Disease
of	I-Disease
the	I-Disease
colon	I-Disease
and	I-Disease
rectum	I-Disease
and	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
mutations	O
located	O
at	O
the	O
extreme	O
5	O
end	O
of	O
the	O
apc	B-Disease
gene	O
,	O
however	O
,	O
are	O
associated	O
with	O
a	O
less	O
severe	O
disease	O
known	O
as	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
aapc	B-Disease
)	O
.	O
	
many	O
individuals	O
with	O
aapc	B-Disease
develop	O
relatively	O
few	O
colorectal	B-Disease
polyps	I-Disease
but	O
are	O
still	O
at	O
high	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
we	O
report	O
here	O
the	O
identification	O
of	O
a	O
5	O
apc	B-Disease
germline	O
mutation	O
in	O
five	O
separately	O
ascertained	O
aapc	B-Disease
families	O
from	O
newfoundland	O
,	O
canada	O
.	O
	
this	O
disease	O
-	O
causing	O
mutation	O
is	O
a	O
single	O
basepair	O
change	O
(	O
g	O
to	O
a	O
)	O
in	O
the	O
splice	O
-	O
acceptor	O
region	O
of	O
apc	B-Disease
intron	O
3	O
that	O
creates	O
a	O
mutant	O
rna	O
without	O
exon	O
4	O
of	O
apc	O
.	O
	
the	O
observation	O
of	O
the	O
same	O
apc	B-Disease
mutation	O
in	O
five	O
families	O
from	O
the	O
same	O
geographic	O
area	O
demonstrates	O
a	O
founder	O
effect	O
.	O
	
furthermore	O
,	O
the	O
identification	O
of	O
this	O
germline	O
mutation	O
strengthens	O
the	O
correlation	O
between	O
the	O
5	O
location	O
of	O
an	O
apc	B-Disease
disease	O
-	O
causing	O
mutation	O
and	O
the	O
attenuated	B-Disease
polyposis	I-Disease
phenotype	O
.	O
	
alstrom	B-Disease
syndrome	I-Disease
:	O
further	O
evidence	O
for	O
linkage	O
to	O
human	O
chromosome	O
2p13	O
.	O
	
alstrom	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
retinal	B-Disease
degeneration	I-Disease
,	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
,	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
and	O
non	B-Disease
-	I-Disease
insulin	I-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
.	O
	
the	O
gene	O
for	O
alstrom	B-Disease
syndrome	I-Disease
(	O
alms1	O
)	O
has	O
been	O
previously	O
localized	O
to	O
human	O
chromosome	O
2p13	O
by	O
homozygosity	O
mapping	O
in	O
two	O
distinct	O
isolated	O
populations	O
-	O
french	O
acadian	O
and	O
north	O
african	O
.	O
	
to	O
confirm	O
these	O
findings	O
,	O
a	O
large	O
linkage	O
study	O
was	O
performed	O
in	O
twelve	O
additional	O
families	O
segregating	O
for	O
alstrom	B-Disease
syndrome	I-Disease
.	O
	
pendred	B-Disease
syndrome	I-Disease
:	O
phenotypic	O
variability	O
in	O
two	O
families	O
carrying	O
the	O
same	O
pds	B-Disease
missense	O
mutation	O
.	O
	
pendred	B-Disease
syndrome	I-Disease
comprises	O
congenital	B-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
thyroid	B-Disease
goiter	I-Disease
,	O
and	O
positive	O
perchlorate	O
discharge	O
test	O
.	O
	
recently	O
,	O
this	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
was	O
shown	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
pds	B-Disease
gene	O
,	O
which	O
encodes	O
an	O
anion	O
transporter	O
called	O
pendrin	O
.	O
	
molecular	O
analysis	O
of	O
the	O
pds	B-Disease
gene	O
was	O
performed	O
in	O
two	O
consanguineous	O
large	O
families	O
from	O
southern	O
tunisia	O
comprising	O
a	O
total	O
of	O
23	O
individuals	O
affected	O
with	O
profound	O
congenital	B-Disease
deafness	I-Disease
;	O
the	O
same	O
missense	O
mutation	O
,	O
l445w	O
,	O
was	O
identified	O
in	O
all	O
affected	O
individuals	O
.	O
	
a	O
widened	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
was	O
found	O
in	O
all	O
patients	O
who	O
underwent	O
computed	O
tomography	O
(	O
ct	O
)	O
scan	O
exploration	O
of	O
the	O
inner	O
ear	O
.	O
	
in	O
contrast	O
,	O
goiter	B-Disease
was	O
present	O
in	O
only	O
11	O
affected	O
individuals	O
,	O
who	O
interestingly	O
had	O
a	O
normal	O
result	O
of	O
the	O
perchlorate	O
discharge	O
test	O
whenever	O
performed	O
.	O
	
the	O
present	O
results	O
question	O
the	O
sensitivity	O
of	O
the	O
perchlorate	O
test	O
for	O
the	O
diagnosis	O
of	O
pendred	B-Disease
syndrome	I-Disease
and	O
support	O
the	O
use	O
of	O
a	O
molecular	O
analysis	O
of	O
the	O
pds	B-Disease
gene	O
in	O
the	O
assessment	O
of	O
individuals	O
with	O
severe	O
to	O
profound	O
congenital	B-Disease
hearing	I-Disease
loss	I-Disease
associated	O
with	O
inner	B-Disease
ear	I-Disease
morphological	I-Disease
anomaly	I-Disease
even	O
in	O
the	O
absence	O
of	O
a	O
thyroid	B-Disease
goiter	I-Disease
.	O
	
knobloch	B-Disease
syndrome	I-Disease
involving	O
midline	B-Disease
scalp	I-Disease
defect	I-Disease
of	I-Disease
the	I-Disease
frontal	I-Disease
region	I-Disease
.	O
	
we	O
report	O
on	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
knobloch	B-Disease
syndrome	I-Disease
.	O
	
he	O
has	O
vitreoretinal	B-Disease
degeneration	I-Disease
,	O
high	B-Disease
myopia	I-Disease
,	O
cataract	B-Disease
,	O
telecanthus	B-Disease
,	O
hypertelorism	B-Disease
,	O
and	O
a	O
high	B-Disease
-	I-Disease
arched	I-Disease
palate	I-Disease
.	O
	
he	O
also	O
has	O
a	O
defect	B-Disease
of	I-Disease
the	I-Disease
anterior	I-Disease
midline	I-Disease
scalp	I-Disease
with	O
involvement	O
of	O
the	O
frontal	O
bone	O
as	O
documented	O
by	O
a	O
computed	O
tomography	O
(	O
ct	O
)	O
scan	O
.	O
	
our	O
patient	O
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	O
nervous	O
system	O
pathology	O
whenever	O
midline	B-Disease
scalp	I-Disease
defects	I-Disease
are	O
present	O
.	O
	
.	O
	
the	O
dna	O
double	O
-	O
strand	O
break	O
repair	O
gene	O
hmre11	O
is	O
mutated	O
in	O
individuals	O
with	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
-	I-Disease
like	I-Disease
disorder	I-Disease
.	O
	
we	O
show	O
that	O
hypomorphic	O
mutations	O
in	O
hmre11	O
,	O
but	O
not	O
in	O
atm	O
,	O
are	O
present	O
in	O
certain	O
individuals	O
with	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
-	I-Disease
like	I-Disease
disorder	I-Disease
(	O
atld	B-Disease
)	O
.	O
	
the	O
cellular	O
features	O
resulting	O
from	O
these	O
hmre11	O
mutations	O
are	O
similar	O
to	O
those	O
seen	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
as	O
well	O
as	O
nbs	B-Disease
and	O
include	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
,	O
radioresistant	O
dna	O
synthesis	O
,	O
and	O
abrogation	O
of	O
atm	O
-	O
dependent	O
events	O
,	O
such	O
as	O
the	O
activation	O
of	O
jun	O
kinase	O
following	O
exposure	O
to	O
gamma	O
irradiation	O
.	O
	
these	O
data	O
demonstrate	O
that	O
atm	O
and	O
the	O
hmre11	O
/	O
hrad50	O
/	O
nbs1	O
protein	O
complex	O
act	O
in	O
the	O
same	O
dna	O
damage	O
response	O
pathway	O
and	O
link	O
hmre11	O
to	O
the	O
complex	O
pathology	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
.	O
	
mutations	O
in	O
tnfrsf11a	O
,	O
affecting	O
the	O
signal	O
peptide	O
of	O
rank	O
,	O
cause	O
familial	B-Disease
expansile	I-Disease
osteolysis	I-Disease
.	O
	
familial	B-Disease
expansile	I-Disease
osteolysis	I-Disease
(	O
feo	B-Disease
,	O
mim	O
174810	O
)	O
is	O
a	O
rare	O
,	O
autosomal	B-Disease
dominant	I-Disease
bone	I-Disease
disorder	I-Disease
characterized	O
by	O
focal	O
areas	O
of	O
increased	B-Disease
bone	I-Disease
remodelling	I-Disease
.	O
	
the	O
osteolytic	B-Disease
lesions	I-Disease
,	O
which	O
develop	O
usually	O
in	O
the	O
long	O
bones	O
during	O
early	O
adulthood	O
,	O
show	O
increased	O
osteoblast	O
and	O
osteoclast	O
activity	O
.	O
	
our	O
previous	O
linkage	O
studies	O
mapped	O
the	O
gene	O
responsible	O
for	O
feo	B-Disease
to	O
an	O
interval	O
of	O
less	O
than	O
5	O
cm	O
between	O
d18s64	O
and	O
d18s51	O
on	O
chromosome	O
18q21	O
.	O
	
we	O
identified	O
two	O
heterozygous	O
insertion	O
mutations	O
in	O
exon	O
1	O
of	O
tnfrsf11a	O
in	O
affected	O
members	O
of	O
four	O
families	O
with	O
feo	B-Disease
or	O
familial	B-Disease
paget	I-Disease
disease	I-Disease
of	I-Disease
bone	I-Disease
(	O
pdb	B-Disease
)	O
.	O
	
cardiac	O
na	O
(	O
+	O
)	O
channel	O
dysfunction	O
in	O
brugada	B-Disease
syndrome	I-Disease
is	O
aggravated	O
by	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
.	O
	
background	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	O
cardiac	O
na	O
(	O
+	O
)	O
channel	O
alpha	O
-	O
subunit	O
(	O
hh1	O
)	O
are	O
responsible	O
for	O
chromosome	O
3	O
-	O
linked	O
congenital	B-Disease
long	I-Disease
-	I-Disease
qt	I-Disease
syndrome	I-Disease
(	O
lqt3	B-Disease
)	O
and	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	I-Disease
(	O
ivf	B-Disease
)	O
.	O
	
here	O
,	O
we	O
characterize	O
the	O
altered	O
effects	O
of	O
a	O
human	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
(	O
hbeta	O
(	O
1	O
)	O
)	O
on	O
the	O
heterologously	O
expressed	O
hh1	O
mutation	O
(	O
t1620m	O
)	O
previously	O
associated	O
with	O
ivf	B-Disease
.	O
	
methods	O
and	O
results	O
when	O
expressed	O
alone	O
in	O
xenopus	O
oocytes	O
,	O
t1620m	O
exhibited	O
no	O
persistent	O
currents	O
,	O
in	O
contrast	O
to	O
the	O
lqt3	B-Disease
mutant	O
channels	O
,	O
but	O
the	O
midpoint	O
of	O
steady	O
-	O
state	O
inactivation	O
(	O
v	O
(	O
1	O
/	O
2	O
)	O
)	O
was	O
significantly	O
shifted	O
toward	O
more	O
positive	O
potentials	O
than	O
for	O
wild	O
-	O
type	O
hh1	O
.	O
	
conclusions	O
it	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
exposes	O
a	O
more	O
severe	O
functional	O
defect	O
that	O
results	O
in	O
a	O
greater	O
overlap	O
in	O
the	O
relationship	O
between	O
channel	O
inactivation	O
and	O
activation	O
(	O
window	O
current	O
)	O
in	O
t1620m	O
,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
pathophysiological	O
mechanism	O
of	O
ivf	B-Disease
in	O
vivo	O
.	O
	
meiotic	O
segregation	O
analysis	O
of	O
rb1	O
alleles	O
in	O
retinoblastoma	B-Disease
pedigrees	O
by	O
use	O
of	O
single	O
-	O
sperm	O
typing	O
.	O
	
in	O
hereditary	B-Disease
retinoblastoma	I-Disease
,	O
different	O
epidemiological	O
studies	O
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	O
of	O
mutant	O
retinoblastoma	B-Disease
alleles	O
to	O
offspring	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
meiotic	O
drive	O
.	O
	
to	O
investigate	O
this	O
mechanism	O
,	O
we	O
analyzed	O
sperm	O
samples	O
from	O
six	O
individuals	O
from	O
five	O
unrelated	O
families	O
affected	O
with	O
hereditary	B-Disease
retinoblastoma	I-Disease
.	O
	
single	O
-	O
sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	O
of	O
two	O
informative	O
short	O
tandem	O
repeats	O
located	O
either	O
in	O
or	O
close	O
to	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
rb1	O
)	O
.	O
	
friedreich	B-Disease
ataxia	I-Disease
:	O
an	O
overview	O
.	O
	
friedreich	B-Disease
ataxia	I-Disease
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
,	O
is	O
the	O
most	O
common	O
of	O
the	O
inherited	B-Disease
ataxias	I-Disease
.	O
	
the	O
recent	O
discovery	O
of	O
the	O
gene	O
that	O
is	O
mutated	O
in	O
this	O
condition	O
,	O
frda	O
,	O
has	O
led	O
to	O
rapid	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
friedreich	B-Disease
ataxia	I-Disease
.	O
	
there	O
is	O
mounting	O
evidence	O
to	O
suggest	O
that	O
friedreich	B-Disease
ataxia	I-Disease
is	O
the	O
result	O
of	O
accumulation	O
of	O
iron	O
in	O
mitochondria	O
leading	O
to	O
excess	O
production	O
of	O
free	O
radicals	O
,	O
which	O
then	O
results	O
in	O
cellular	O
damage	O
and	O
death	O
.	O
	
the	O
discovery	O
of	O
the	O
frda	B-Disease
gene	O
and	O
its	O
possible	O
function	O
has	O
raised	O
hope	O
that	O
rational	O
therapeutic	O
strategies	O
will	O
be	O
developed	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
with	O
point	O
mutations	O
in	O
the	O
xlrs1	O
gene	O
.	O
	
background	O
x	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
(	O
xlrs	B-Disease
)	O
is	O
a	O
relatively	O
rare	O
vitreoretinal	B-Disease
dystrophy	I-Disease
that	O
causes	O
visual	B-Disease
loss	I-Disease
in	O
young	O
men	O
.	O
	
objective	O
to	O
analyze	O
japanese	O
patients	O
clinically	O
diagnosed	O
as	O
having	O
xlrs	B-Disease
formutational	O
changes	O
in	O
the	O
xlrs1	O
gene	O
.	O
	
methods	O
ten	O
patients	O
with	O
xlrs	B-Disease
underwent	O
full	O
ophthalmologic	O
examination	O
,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
dilated	O
funduscopy	O
.	O
	
conclusions	O
the	O
discovery	O
of	O
new	O
point	O
mutations	O
in	O
this	O
study	O
increases	O
the	O
available	O
information	O
regarding	O
the	O
spectrum	O
of	O
genetic	B-Disease
abnormalities	I-Disease
and	O
clinical	O
manifestations	O
of	O
xlrs	B-Disease
.	O
	
clinical	O
relevance	O
identification	O
of	O
mutations	O
in	O
the	O
xlrs1	O
gene	O
and	O
expanded	O
information	O
on	O
clinical	O
manifestations	O
will	O
facilitate	O
early	O
diagnosis	O
,	O
appropriate	O
early	O
therapy	O
,	O
and	O
genetic	O
counseling	O
regarding	O
the	O
prognosis	O
of	O
xlrs	B-Disease
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
is	O
a	O
hereditary	B-Disease
multisystemic	I-Disease
disease	I-Disease
resulting	O
from	O
mutations	O
of	O
ataxia	B-Disease
telangiectasia	I-Disease
,	O
mutated	O
(	O
atm	O
)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	B-Disease
,	O
cancer	B-Disease
,	O
immune	B-Disease
defects	I-Disease
,	O
and	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
.	O
	
the	O
molecular	O
details	O
of	O
atm	O
function	O
in	O
the	O
nervous	O
system	O
are	O
unclear	O
,	O
although	O
the	O
neurological	B-Disease
lesion	I-Disease
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
becomes	O
apparent	O
early	O
in	O
life	O
,	O
suggesting	O
a	O
developmental	O
origin	O
.	O
	
haim	B-Disease
-	I-Disease
munk	I-Disease
syndrome	I-Disease
and	O
papillon	B-Disease
-	I-Disease
lefevre	I-Disease
syndrome	I-Disease
are	O
allelic	O
mutations	O
in	O
cathepsin	O
c	O
.	O
	
of	O
the	O
many	O
palmoplantar	B-Disease
keratoderma	I-Disease
(	I-Disease
ppk	I-Disease
)	I-Disease
conditions	I-Disease
,	O
only	O
papillon	B-Disease
-	I-Disease
lefevre	I-Disease
syndrome	I-Disease
(	O
pls	B-Disease
)	O
and	O
haim	B-Disease
-	I-Disease
munk	I-Disease
syndrome	I-Disease
(	O
hms	B-Disease
)	O
are	O
associated	O
with	O
premature	O
periodontal	O
destruction	O
.	O
	
although	O
both	O
pls	B-Disease
and	O
hms	B-Disease
share	O
the	O
cardinal	O
features	O
of	O
ppk	B-Disease
and	O
severe	O
periodontitis	B-Disease
,	O
a	O
number	O
of	O
additional	O
findings	O
are	O
reported	O
in	O
hms	B-Disease
including	O
arachnodactyly	B-Disease
,	O
acro	B-Disease
-	I-Disease
osteolysis	I-Disease
,	O
atrophic	B-Disease
changes	I-Disease
of	I-Disease
the	I-Disease
nails	I-Disease
,	O
and	O
a	O
radiographic	B-Disease
deformity	I-Disease
of	I-Disease
the	I-Disease
fingers	I-Disease
.	O
	
while	O
pls	B-Disease
cases	O
have	O
been	O
identified	O
throughout	O
the	O
world	O
,	O
hms	B-Disease
has	O
only	O
been	O
described	O
among	O
descendants	O
of	O
a	O
religious	O
isolate	O
originally	O
from	O
cochin	O
,	O
india	O
.	O
	
although	O
autosomal	O
recessive	O
transmission	O
of	O
pls	B-Disease
is	O
evident	O
,	O
a	O
more	O
complex	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
with	O
phenotypic	O
influences	O
from	O
a	O
closely	O
linked	O
modifying	O
locus	O
has	O
been	O
hypothesised	O
for	O
hms	B-Disease
.	O
	
recently	O
,	O
mutations	O
of	O
the	O
cathepsin	O
c	O
gene	O
have	O
been	O
identified	O
as	O
the	O
underlying	O
genetic	B-Disease
defect	I-Disease
in	O
pls	B-Disease
.	O
	
to	O
determine	O
if	O
a	O
cathepsin	O
c	O
mutation	O
is	O
also	O
responsible	O
for	O
hms	B-Disease
,	O
we	O
sequenced	O
the	O
gene	O
in	O
affected	O
and	O
unaffected	O
subjects	O
from	O
the	O
cochin	O
isolate	O
in	O
which	O
both	O
the	O
pls	B-Disease
and	O
hms	B-Disease
phenotypes	O
appear	O
.	O
	
this	O
mutation	O
segregates	O
with	O
hms	B-Disease
in	O
four	O
nuclear	O
families	O
.	O
	
this	O
finding	O
supports	O
simple	O
autosomal	O
recessive	O
inheritance	O
for	O
hms	B-Disease
in	O
these	O
families	O
.	O
	
we	O
also	O
report	O
a	O
mutation	O
of	O
the	O
same	O
exon	O
6	O
ctsc	O
codon	O
(	O
2126c	O
-	O
-	O
>	O
t	O
)	O
in	O
a	O
turkish	O
family	O
with	O
classical	O
pls	B-Disease
.	O
	
these	O
findings	O
provide	O
evidence	O
that	O
pls	B-Disease
and	O
hms	B-Disease
are	O
allelic	O
variants	O
of	O
cathepsin	O
c	O
gene	O
mutations	O
.	O
	
atm	O
-	O
heterozygous	O
germline	O
mutations	O
contribute	O
to	O
breast	B-Disease
cancer	I-Disease
-	O
susceptibility	O
.	O
	
mutations	O
in	O
the	O
atm	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
(	O
mim	O
208900	O
)	O
.	O
	
the	O
finding	O
that	O
atm	O
-	O
heterozygotes	O
have	O
an	O
increased	O
relative	O
risk	O
for	O
breast	B-Disease
cancer	I-Disease
was	O
supported	O
by	O
some	O
studies	O
but	O
not	O
confirmed	O
by	O
others	O
.	O
	
in	O
view	O
of	O
this	O
discrepancy	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
atm	O
germline	O
mutations	O
in	O
a	O
selected	O
group	O
of	O
dutch	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
a	O
high	O
percentage	O
of	O
atm	O
germline	O
mutations	O
was	O
demonstrated	O
among	O
patients	O
with	O
sporadic	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
the	O
82	O
patients	O
included	O
in	O
this	O
study	O
had	O
developed	O
breast	B-Disease
cancer	I-Disease
at	O
age	O
<	O
45	O
and	O
had	O
survived	O
>	O
/	O
=	O
5	O
years	O
(	O
mean	O
15	O
years	O
)	O
,	O
and	O
in	O
33	O
(	O
40	O
%	O
)	O
of	O
the	O
patients	O
a	O
contralateral	O
breast	O
tumor	O
had	O
been	O
diagnosed	O
.	O
	
inherited	O
g6pd	B-Disease
deficiency	I-Disease
is	O
associated	O
with	O
either	O
episodic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
triggered	O
by	O
fava	O
beans	O
or	O
other	O
agents	O
)	O
or	O
life	B-Disease
-	I-Disease
long	I-Disease
hemolytic	I-Disease
anemia	I-Disease
.	O
	
from	O
the	O
alignment	O
of	O
the	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
of	O
52	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
g6pd	O
)	O
species	O
from	O
42	O
different	O
organisms	O
,	O
we	O
found	O
a	O
striking	O
correlation	O
between	O
the	O
aa	O
replacements	O
that	O
cause	O
g6pd	B-Disease
deficiency	I-Disease
in	O
humans	O
and	O
the	O
sequence	O
conservation	O
of	O
g6pd	O
two	O
-	O
thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	O
and	O
moderately	O
conserved	O
(	O
50	O
-	O
99	O
%	O
)	O
aa	O
;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	O
aa	O
(	O
where	O
they	O
might	O
be	O
lethal	O
)	O
or	O
in	O
poorly	O
conserved	O
aa	O
,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
constitutive	O
and	O
regulated	O
modes	O
of	O
splicing	O
produce	O
six	O
major	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
(	O
dmpk	O
)	O
isoforms	O
with	O
distinct	O
properties	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
the	O
most	O
prevalent	O
inherited	B-Disease
neuromuscular	I-Disease
disease	I-Disease
in	O
adults	O
.	O
	
the	O
genetic	B-Disease
defect	I-Disease
is	O
a	O
ctg	O
triplet	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
(	O
dmpk	O
)	O
gene	O
,	O
consisting	O
of	O
15	O
exons	O
.	O
	
information	O
on	O
dmpk	O
mrna	O
and	O
protein	O
isoform	O
expression	O
patterns	O
will	O
be	O
useful	O
for	O
recognizing	O
differential	O
effects	O
of	O
(	O
ctg	O
)	O
(	O
n	O
)	O
expansion	O
in	O
dm	B-Disease
manifestation	O
.	O
	
genetic	O
analysis	O
,	O
phenotypic	O
diagnosis	O
,	O
and	O
risk	O
of	O
venous	B-Disease
thrombosis	I-Disease
in	O
families	O
with	O
inherited	O
deficiencies	B-Disease
of	I-Disease
protein	I-Disease
s	I-Disease
.	O
	
protein	B-Disease
s	I-Disease
deficiency	I-Disease
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	B-Disease
thrombosis	I-Disease
.	O
	
of	O
all	O
the	O
inherited	O
thrombophilic	B-Disease
conditions	I-Disease
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	O
variability	O
,	O
which	O
can	O
lead	O
to	O
inconclusive	O
results	O
.	O
	
twenty	O
-	O
eight	O
index	O
patients	O
with	O
protein	B-Disease
s	I-Disease
deficiency	I-Disease
and	O
a	O
pros1	B-Disease
gene	I-Disease
defect	I-Disease
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	O
relatives	O
.	O
	
in	O
this	O
group	O
of	O
relatives	O
,	O
a	O
low	O
free	O
protein	O
s	O
level	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
pros1	B-Disease
gene	I-Disease
defect	I-Disease
(	O
sensitivity	O
97	O
.	O
	
first	O
-	O
degree	O
relatives	O
with	O
a	O
pros1	B-Disease
gene	I-Disease
defect	I-Disease
had	O
a	O
5	O
.	O
	
0	O
-	O
fold	O
higher	O
risk	O
of	O
thrombosis	B-Disease
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
	
8	O
)	O
than	O
those	O
with	O
a	O
normal	O
pros1	O
gene	O
and	O
no	O
other	O
recognized	O
thrombophilic	B-Disease
defect	I-Disease
.	O
	
although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B-Disease
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B-Disease
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous	O
.	O
	
relatives	O
with	O
splice	O
-	O
site	O
or	O
major	O
structural	O
defects	B-Disease
in	I-Disease
the	I-Disease
pros1	I-Disease
gene	I-Disease
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	O
event	O
and	O
had	O
significantly	O
lower	O
total	O
and	O
free	O
protein	O
s	O
levels	O
than	O
those	O
relatives	O
having	O
missense	O
mutations	O
.	O
	
we	O
conclude	O
that	O
persons	O
with	O
pros1	B-Disease
gene	I-Disease
defects	I-Disease
and	O
protein	B-Disease
s	I-Disease
deficiency	I-Disease
are	O
at	O
increased	O
risk	O
of	O
thrombosis	B-Disease
and	O
that	O
free	O
protein	O
s	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	O
.	O
	
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
alps	B-Disease
)	O
in	O
a	O
child	O
from	O
consanguineous	O
parents	O
:	O
a	O
dominant	O
or	O
recessive	O
disease	O
?	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
alps	B-Disease
)	O
is	O
characterized	O
by	O
autoimmune	O
features	O
and	O
lymphoproliferations	O
and	O
is	O
generally	O
caused	O
by	O
defective	O
fas	O
-	O
mediated	O
apoptosis	O
.	O
	
this	O
report	O
describes	O
a	O
child	O
with	O
clinical	O
features	O
of	O
alps	B-Disease
without	O
detectable	O
fas	O
expression	O
on	O
freshly	O
isolated	O
blood	O
leukocytes	O
.	O
	
the	O
patient	O
reported	O
here	O
is	O
a	O
human	O
homologue	O
of	O
the	O
fas	O
-	O
nan	O
mouse	O
,	O
inasmuch	O
as	O
she	O
carries	O
an	O
autosomal	O
homozygous	O
mutation	O
in	O
the	O
fas	O
gene	O
and	O
she	O
shows	O
the	O
severe	O
and	O
accelerated	O
alps	B-Disease
phenotype	O
.	O
	
the	O
heterozygous	O
family	O
members	O
did	O
not	O
have	O
the	O
alps	B-Disease
phenotype	O
,	O
indicating	O
that	O
the	O
disease	O
-	O
causing	O
fas	O
mutation	O
in	O
this	O
family	O
is	O
autosomal	O
recessive	O
.	O
	
identification	O
of	O
novel	O
imprinted	O
transcripts	O
in	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
and	O
angelman	B-Disease
syndrome	I-Disease
deletion	O
region	O
:	O
further	O
evidence	O
for	O
regional	O
imprinting	O
control	O
.	O
	
deletions	O
and	O
other	O
abnormalities	O
of	O
human	O
chromosome	O
15q11	O
-	O
q13	O
are	O
associated	O
with	O
two	O
developmental	O
disorders	O
,	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
and	O
angelman	B-Disease
syndrome	I-Disease
(	O
as	B-Disease
)	O
.	O
	
loss	O
of	O
expression	O
of	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
has	O
been	O
implicated	O
in	O
pws	B-Disease
.	O
	
however	O
,	O
the	O
number	O
of	O
imprinted	O
genes	O
that	O
contribute	O
to	O
pws	B-Disease
,	O
and	O
the	O
range	O
over	O
which	O
the	O
imprinting	O
signal	O
acts	O
to	O
silence	O
one	O
copy	O
of	O
the	O
gene	O
in	O
a	O
parent	O
-	O
of	O
-	O
origin	O
-	O
specific	O
manner	O
,	O
are	O
unknown	O
.	O
	
to	O
identify	O
additional	O
imprinted	O
genes	O
that	O
could	O
contribute	O
to	O
the	O
pws	B-Disease
phenotype	O
and	O
to	O
understand	O
the	O
regional	O
control	O
of	O
imprinting	O
in	O
15q11	O
-	O
q13	O
,	O
we	O
have	O
constructed	O
an	O
imprinted	O
transcript	O
map	O
of	O
the	O
pws	O
-	O
as	O
deletion	O
interval	O
.	O
	
combined	O
analysis	O
of	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
linkage	O
to	O
1q24	O
-	O
25	O
:	O
results	O
from	O
772	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
families	O
from	O
the	O
international	O
consortium	O
for	O
prostate	B-Disease
cancer	I-Disease
genetics	O
.	O
	
a	O
previous	O
linkage	O
study	O
provided	O
evidence	O
for	O
a	O
prostate	B-Disease
cancer	I-Disease
-	O
susceptibility	O
locus	O
at	O
1q24	O
-	O
25	O
.	O
	
in	O
addition	O
,	O
evidence	O
for	O
locus	O
heterogeneity	O
has	O
been	O
provided	O
by	O
the	O
identification	O
of	O
other	O
putative	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
loci	O
on	O
xq27	O
-	O
28	O
,	O
1q42	O
-	O
43	O
,	O
and	O
1p36	O
.	O
	
the	O
present	O
study	O
describes	O
a	O
combined	O
analysis	O
for	O
six	O
markers	O
in	O
the	O
1q24	O
-	O
25	O
region	O
in	O
772	O
families	O
affected	O
by	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
and	O
ascertained	O
by	O
the	O
members	O
of	O
the	O
international	O
consortium	O
for	O
prostate	B-Disease
cancer	I-Disease
genetics	O
(	O
icpcg	O
)	O
from	O
north	O
america	O
,	O
australia	O
,	O
finland	O
,	O
norway	O
,	O
sweden	O
,	O
and	O
the	O
united	O
kingdom	O
.	O
	
these	O
results	O
support	O
the	O
finding	O
of	O
a	O
prostate	B-Disease
cancer	I-Disease
-	O
susceptibility	O
gene	O
linked	O
to	O
1q24	O
-	O
25	O
,	O
albeit	O
in	O
a	O
defined	O
subset	O
of	O
prostate	B-Disease
cancer	I-Disease
families	O
.	O
	
although	O
hpc1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	O
of	O
all	O
families	O
affected	O
by	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
,	O
it	O
appears	O
to	O
play	O
a	O
more	O
prominent	O
role	O
in	O
the	O
subset	O
of	O
families	O
with	O
several	O
members	O
affected	O
at	O
an	O
early	O
age	O
and	O
with	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
.	O
	
a	O
recurrent	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
cag	O
repeats	O
causes	O
huntington	B-Disease
disease	I-Disease
in	O
two	O
sisters	O
.	O
	
large	O
intergenerational	O
repeat	O
expansions	O
of	O
the	O
cag	O
trinucleotide	O
repeat	O
in	O
the	O
hd	B-Disease
gene	O
have	O
been	O
well	O
documented	O
for	O
the	O
male	O
germline	O
.	O
	
we	O
describe	O
a	O
recurrent	O
large	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
cag	O
repeats	O
(	O
to	O
66	O
and	O
57	O
repeats	O
,	O
respectively	O
,	O
in	O
two	O
daughters	O
)	O
associated	O
with	O
onset	O
of	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
in	O
the	O
second	O
and	O
third	O
decade	O
in	O
a	O
family	O
without	O
history	O
of	O
hd	B-Disease
.	O
	
motor	B-Disease
incoordination	I-Disease
,	O
immune	B-Disease
deficiencies	I-Disease
,	O
and	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
are	O
the	O
characteristic	O
features	O
of	O
the	O
hereditary	B-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
atm	O
gene	O
.	O
	
in	O
contrast	O
to	O
other	O
atm	O
mutant	O
mice	O
,	O
atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
show	O
a	O
lower	O
incidence	O
of	O
thymic	B-Disease
lymphoma	I-Disease
and	O
survive	O
beyond	O
a	O
few	O
months	O
of	O
age	O
.	O
	
atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	B-Disease
dysfunction	I-Disease
.	O
	
even	O
though	O
we	O
found	O
no	O
gross	O
cerebellar	B-Disease
degeneration	I-Disease
in	O
older	O
atm	O
(	O
y	O
/	O
y	O
)	O
animals	O
,	O
ectopic	O
and	O
abnormally	O
differentiated	O
purkinje	O
cells	O
were	O
apparent	O
in	O
mutant	O
mice	O
of	O
all	O
ages	O
.	O
	
these	O
findings	O
establish	O
that	O
some	O
neuropathological	B-Disease
abnormalities	I-Disease
seen	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
also	O
are	O
present	O
in	O
atm	O
mutant	O
mice	O
.	O
	
in	O
addition	O
,	O
we	O
report	O
a	O
previously	O
unrecognized	O
effect	O
of	O
atm	B-Disease
deficiency	I-Disease
on	O
development	O
or	O
maintenance	O
of	O
cd4	O
(	O
+	O
)	O
8	O
(	O
+	O
)	O
thymocytes	O
.	O
	
we	O
discuss	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
hypothesis	O
that	O
abnormal	O
development	O
of	O
purkinje	O
cells	O
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
.	O
	
novel	O
mutations	O
of	O
the	O
atp7b	O
gene	O
in	O
japanese	O
patients	O
with	O
wilson	B-Disease
disease	I-Disease
.	O
	
wilson	B-Disease
disease	I-Disease
(	O
wd	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
copper	O
accumulation	O
in	O
the	O
liver	O
,	O
brain	O
,	O
kidneys	O
,	O
and	O
corneas	O
,	O
and	O
culminating	O
in	O
copper	O
toxication	O
in	O
these	O
organs	O
.	O
	
in	O
this	O
study	O
,	O
we	O
analyzed	O
mutations	O
of	O
the	O
responsible	O
gene	O
,	O
atp7b	O
,	O
in	O
four	O
japanese	O
patients	O
with	O
wd	B-Disease
.	O
	
therefore	O
,	O
the	O
accumulation	O
of	O
the	O
types	O
of	O
mutations	O
in	O
japanese	O
patients	O
with	O
wd	B-Disease
will	O
facilitate	O
the	O
fast	O
and	O
effective	O
genetic	O
diagnosis	O
of	O
wd	B-Disease
in	O
japanese	O
patients	O
.	O
	
autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
.	O
	
the	O
rho	O
-	O
family	O
gtpase	O
,	O
cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
(	O
wasp	O
)	O
family	O
members	O
.	O
	
mutations	O
in	O
the	O
brca1	O
(	O
ref	O
.	O
	
1	O
)	O
tumour	B-Disease
suppressor	O
gene	O
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	O
with	O
inherited	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
and	O
about	O
half	O
of	O
the	O
families	O
with	O
only	O
breast	B-Disease
cancer	I-Disease
.	O
	
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
mjd	B-Disease
)	O
belongs	O
to	O
a	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
neurodegenerative	B-Disease
disorders	I-Disease
characterized	O
by	O
progressive	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
.	O
	
in	O
caucasians	O
,	O
repeat	O
expansions	O
in	O
the	O
mjd1	O
gene	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
the	O
clinically	O
distinct	O
autosomal	O
dominant	O
spinocerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
3	I-Disease
(	O
sca3	B-Disease
)	O
.	O
	
analyzing	O
the	O
expression	O
level	O
of	O
the	O
sca3	O
gene	O
in	O
several	O
human	O
brain	O
sections	O
revealed	O
no	O
significant	O
higher	O
mrna	O
level	O
in	O
regions	O
predominantly	O
affected	O
in	O
mjd	B-Disease
.	O
	
thus	O
additional	O
molecules	O
and	O
/	O
or	O
regulatory	O
events	O
are	O
necessary	O
to	O
explain	O
the	O
exclusive	O
degeneration	B-Disease
of	I-Disease
certain	I-Disease
brain	I-Disease
areas	I-Disease
.	O
	
emerin	B-Disease
,	I-Disease
deficiency	I-Disease
of	O
which	O
causes	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
is	O
localized	O
at	O
the	O
inner	O
nuclear	O
membrane	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
edmd	B-Disease
)	O
is	O
an	O
inherited	B-Disease
muscle	I-Disease
disorder	I-Disease
characterized	O
by	O
the	O
clinical	O
triad	O
of	O
progressive	O
wasting	B-Disease
of	I-Disease
humero	I-Disease
-	I-Disease
peroneal	I-Disease
muscles	I-Disease
,	O
early	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
,	I-Disease
achilles	I-Disease
tendons	I-Disease
and	I-Disease
postcervical	I-Disease
muscles	I-Disease
,	O
and	O
cardiac	B-Disease
conduction	I-Disease
block	I-Disease
with	O
a	O
high	O
risk	O
of	O
sudden	B-Disease
death	I-Disease
.	O
	
the	O
gene	O
for	O
edmd	B-Disease
on	O
xq28	O
encodes	O
a	O
novel	O
protein	O
named	O
emerin	O
that	O
localizes	O
at	O
the	O
nuclear	O
membrane	O
of	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
and	O
some	O
other	O
non	O
-	O
muscle	O
tissues	O
.	O
	
locus	O
heterogeneity	O
in	O
friedreich	B-Disease
ataxia	I-Disease
.	O
	
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B-Disease
recessive	I-Disease
ataxia	I-Disease
.	O
	
to	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
frda	B-Disease
.	O
	
we	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
frda	B-Disease
locus	O
.	O
	
studying	O
two	O
siblings	O
with	O
frda	B-Disease
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
stm7	O
/	O
x25	O
.	O
	
although	O
the	O
patients	O
studied	O
had	O
typical	O
frda	B-Disease
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O
	
in	O
order	O
to	O
investigate	O
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	O
of	O
frda	B-Disease
caused	O
by	O
the	O
second	O
locus	O
,	O
frda2	O
,	O
we	O
studied	O
an	O
unrelated	O
frda	B-Disease
patient	O
with	O
retained	O
tendon	O
reflexes	O
.	O
	
the	O
observation	O
of	O
typical	O
mutations	O
in	O
stm7	O
/	O
x25	O
(	O
gaa	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
frda	B-Disease
cannot	O
be	O
distinguished	O
clinically	O
.	O
	
glycerol	O
as	O
a	O
correlate	O
of	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
:	O
dissection	O
of	O
a	O
complex	O
system	O
by	O
use	O
of	O
a	O
simple	O
genetic	O
trait	O
.	O
	
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
igt	B-Disease
)	O
and	O
hypertriglyceridemia	B-Disease
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	B-Disease
mellitus	I-Disease
and	O
cardiovascular	B-Disease
disease	I-Disease
.	O
	
the	O
relationship	O
between	O
glycerol	O
and	O
the	O
risk	O
of	O
igt	B-Disease
,	O
however	O
,	O
is	O
poorly	O
understood	O
.	O
	
family	O
screening	O
in	O
the	O
initial	O
cohort	O
identified	O
18	O
men	O
from	O
five	O
families	O
with	O
severe	O
hyperglycerolemia	B-Disease
(	O
values	O
above	O
2	O
.	O
	
0	O
mmol	O
/	O
liter	O
)	O
and	O
demonstrated	O
an	O
x	O
-	O
linked	O
pattern	O
of	O
inheritance	O
.	O
	
clinical	O
and	O
molecular	O
genetics	O
of	O
primary	B-Disease
dystonias	I-Disease
.	O
	
primary	B-Disease
dystonias	I-Disease
are	O
movement	B-Disease
disorders	I-Disease
with	O
dystonia	B-Disease
as	O
a	O
major	O
symptom	O
.	O
	
to	O
date	O
gene	O
loci	O
have	O
been	O
identified	O
in	O
at	O
least	O
six	O
autosomal	O
dominant	O
forms	O
,	O
i	O
.	O
e	O
.	O
,	O
in	O
idiopathic	B-Disease
torsion	I-Disease
dystonia	I-Disease
(	O
9q34	O
)	O
,	O
focal	B-Disease
dystonia	I-Disease
(	O
18p	O
)	O
,	O
adult	O
-	O
onset	O
idiopathic	B-Disease
torsion	I-Disease
dystonia	I-Disease
of	O
mixed	O
type	O
(	O
8p21	O
-	O
q22	O
)	O
,	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
(	O
14q22	O
.	O
1	O
-	O
q22	O
.	O
2	O
)	O
,	O
and	O
paroxysmal	B-Disease
dystonic	I-Disease
choreoathetosis	I-Disease
(	O
2q25	O
-	O
q33	O
;	O
1p21	O
-	O
p13	O
.	O
	
1	O
in	O
the	O
x	B-Disease
-	I-Disease
linked	I-Disease
dystonia	I-Disease
parkinsonism	I-Disease
syndrome	I-Disease
and	O
to	O
xq22	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
sensorineural	I-Disease
deafness	I-Disease
,	O
dystonia	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
.	O
	
mutations	O
in	O
a	O
gene	O
coding	O
for	O
an	O
atp	O
-	O
binding	O
protein	O
were	O
detected	O
in	O
idiopathic	B-Disease
torsion	I-Disease
dystonia	I-Disease
(	O
dyt1	O
)	O
,	O
and	O
the	O
gtp	O
cyclohydrolase	O
1	O
gene	O
is	O
mutated	O
in	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
(	O
dyt5	O
)	O
.	O
	
in	O
sensorineural	B-Disease
deafness	I-Disease
,	O
dystonia	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
,	O
mutations	O
were	O
found	O
in	O
the	O
gene	O
ddp	O
coding	O
for	O
a	O
polypeptide	O
of	O
unknown	O
function	O
.	O
	
this	O
article	O
reviews	O
the	O
clinical	O
and	O
molecular	O
genetics	O
of	O
primary	B-Disease
dystonias	I-Disease
,	O
critically	O
discusses	O
present	O
findings	O
,	O
and	O
proposes	O
referring	O
to	O
the	O
known	O
forms	O
,	O
most	O
of	O
which	O
can	O
be	O
distinguished	O
by	O
genetic	O
criteria	O
,	O
as	O
dystonias	B-Disease
1	I-Disease
-	I-Disease
12	I-Disease
.	O
	
determination	O
of	O
30	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
mutations	O
,	O
including	O
15	O
not	O
previously	O
described	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
x	B-Disease
-	I-Disease
ald	I-Disease
)	O
is	O
the	O
most	O
frequent	O
peroxisomal	B-Disease
disease	I-Disease
.	O
	
of	O
particular	O
concern	O
are	O
female	O
members	O
of	O
kindreds	O
segregating	O
x	B-Disease
-	I-Disease
ald	I-Disease
mutations	O
,	O
because	O
normal	O
vlcfa	O
levels	O
do	O
not	O
guarantee	O
lack	O
of	O
carrier	O
status	O
.	O
	
we	O
describe	O
a	O
fast	O
method	O
for	O
detection	O
of	O
x	B-Disease
-	I-Disease
ald	I-Disease
mutations	O
.	O
	
using	O
this	O
methodology	O
we	O
have	O
found	O
x	B-Disease
-	I-Disease
ald	I-Disease
mutations	O
in	O
30	O
kindreds	O
,	O
including	O
15	O
not	O
previously	O
reported	O
.	O
	
beta	O
-	O
galactosidase	O
gene	O
mutations	O
affecting	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
elastin	O
-	O
binding	O
protein	O
in	O
gm1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
patients	O
with	O
cardiac	B-Disease
involvement	I-Disease
.	O
	
gm1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
is	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
acid	I-Disease
beta	I-Disease
-	I-Disease
galactosidase	I-Disease
(	O
glb1	O
)	O
.	O
	
six	O
of	O
the	O
eight	O
patients	O
with	O
the	O
infantile	O
,	O
severe	O
form	O
of	O
the	O
disease	O
presented	O
cardiac	B-Disease
involvement	I-Disease
,	O
a	O
feature	O
rarely	O
associated	O
with	O
gm1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
.	O
	
interestingly	O
,	O
all	O
patients	O
with	O
cardiac	B-Disease
involvement	I-Disease
were	O
homozygous	O
for	O
one	O
of	O
these	O
mutations	O
r59h	O
,	O
y591c	O
,	O
y591n	O
,	O
or	O
ivs14	O
-	O
2a	O
>	O
g	O
.	O
	
although	O
we	O
could	O
not	O
directly	O
correlate	O
the	O
presence	O
of	O
cardiac	B-Disease
abnormalities	I-Disease
with	O
specific	O
genetic	B-Disease
lesions	I-Disease
,	O
the	O
mutations	O
identified	O
in	O
patients	O
with	O
cardiomyopathy	B-Disease
fell	O
in	O
the	O
glb1	O
cdna	O
region	O
common	O
to	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
hbeta	O
-	O
gal	O
-	O
related	O
protein	O
,	O
also	O
known	O
as	O
the	O
elastin	O
binding	O
protein	O
(	O
ebp	O
)	O
.	O
	
in	O
vivo	O
modulation	O
of	O
hmgic	O
reduces	O
obesity	B-Disease
.	O
	
it	O
is	O
disrupted	O
and	O
misexpressed	O
in	O
a	O
number	O
of	O
mesenchymal	B-Disease
tumour	I-Disease
cell	O
types	O
,	O
including	O
fat	B-Disease
-	I-Disease
cell	I-Disease
tumours	I-Disease
(	O
lipomas	B-Disease
)	O
.	O
	
to	O
study	O
its	O
role	O
in	O
adipogenesis	O
and	O
obesity	B-Disease
,	O
we	O
examined	O
hmgic	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
adult	O
,	O
obese	B-Disease
mice	O
.	O
	
mice	O
with	O
a	O
partial	B-Disease
or	I-Disease
complete	I-Disease
deficiency	I-Disease
of	I-Disease
hmgic	I-Disease
resisted	O
diet	O
-	O
induced	O
obesity	B-Disease
.	O
	
disruption	O
of	O
hmgic	O
caused	O
a	O
reduction	O
in	O
the	O
obesity	B-Disease
induced	O
by	O
leptin	B-Disease
deficiency	I-Disease
(	O
lepob	O
/	O
lepob	O
)	O
in	O
a	O
gene	O
-	O
dose	O
-	O
dependent	O
manner	O
.	O
	
our	O
studies	O
implicate	O
a	O
role	O
for	O
hmgic	O
in	O
fat	O
-	O
cell	O
proliferation	O
,	O
indicating	O
that	O
it	O
may	O
be	O
an	O
adipose	O
-	O
specific	O
target	O
for	O
the	O
treatment	O
of	O
obesity	B-Disease
.	O
	
molecular	O
analysis	O
of	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
in	O
factor	B-Disease
x	I-Disease
deficiency	I-Disease
.	O
	
factor	B-Disease
x	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
haemorrhagic	B-Disease
condition	I-Disease
,	O
normally	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
in	O
which	O
a	O
variable	O
clinical	O
presentation	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype	O
.	O
	
the	O
factor	O
x	O
(	O
f10	O
)	O
genes	O
of	O
14	O
unrelated	O
individuals	O
with	O
factor	B-Disease
x	I-Disease
deficiency	I-Disease
(	O
12	O
familial	O
and	O
two	O
sporadic	O
cases	O
)	O
were	O
sequenced	O
yielding	O
a	O
total	O
of	O
13	O
novel	O
mutations	O
.	O
	
transgenic	O
mice	O
expressing	O
a	O
truncated	O
form	O
of	O
the	O
high	O
mobility	O
group	O
i	O
-	O
c	O
protein	O
develop	O
adiposity	O
and	O
an	O
abnormally	O
high	O
prevalence	O
of	O
lipomas	B-Disease
.	O
	
chromosomal	O
translocations	O
in	O
human	O
lipomas	B-Disease
frequently	O
create	O
fusion	O
transcripts	O
encoding	O
high	O
mobility	O
group	O
(	O
hmg	O
)	O
i	O
-	O
c	O
dna	O
-	O
binding	O
domains	O
and	O
c	O
-	O
terminal	O
sequences	O
from	O
different	O
presumed	O
transcription	O
factors	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
hmg	O
i	O
-	O
c	O
in	O
the	O
development	O
of	O
lipomas	B-Disease
.	O
	
despite	O
the	O
ubiquitous	O
expression	O
of	O
the	O
truncated	O
hmg	O
i	O
-	O
c	O
protein	O
,	O
the	O
transgenic	O
mice	O
develop	O
a	O
selective	O
abundance	O
of	O
fat	O
tissue	O
early	O
in	O
life	O
,	O
show	O
marked	O
adipose	B-Disease
tissue	I-Disease
inflammation	I-Disease
,	O
and	O
have	O
an	O
abnormally	O
high	O
incidence	O
of	O
lipomas	B-Disease
.	O
	
these	O
findings	O
demonstrate	O
that	O
the	O
dna	O
-	O
binding	O
domains	O
of	O
hmg	O
i	O
-	O
c	O
,	O
in	O
the	O
absence	O
of	O
a	O
c	O
-	O
terminal	O
fusion	O
partner	O
,	O
are	O
sufficient	O
to	O
perturb	O
adipogenesis	O
and	O
predispose	O
to	O
lipomas	B-Disease
.	O
	
we	O
provide	O
data	O
supporting	O
the	O
central	O
utility	O
of	O
this	O
animal	O
model	O
as	O
a	O
tool	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
one	O
of	O
the	O
most	O
common	O
kind	O
of	O
human	O
benign	B-Disease
tumors	I-Disease
.	O
	
the	O
rare	B-Disease
diseases	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
at	B-Disease
)	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
atm	O
gene	O
,	O
and	O
nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
nbs	B-Disease
)	O
,	O
with	O
mutations	O
in	O
the	O
p95	O
/	O
nbs1	O
gene	O
,	O
share	O
a	O
variety	O
of	O
phenotypic	B-Disease
abnormalities	I-Disease
such	O
as	O
chromosomal	B-Disease
instability	I-Disease
,	O
radiation	O
sensitivity	O
and	O
defects	O
in	O
cell	O
-	O
cycle	O
checkpoints	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O
	
here	O
,	O
because	O
of	O
the	O
similarities	O
between	O
at	B-Disease
and	O
nbs	B-Disease
,	O
we	O
evaluated	O
the	O
functional	O
interactions	O
between	O
atm	O
and	O
p95	O
/	O
nbs1	O
.	O
	
activation	O
of	O
the	O
atm	O
kinase	O
by	O
ionizing	O
radiation	O
and	O
induction	O
of	O
atm	O
-	O
dependent	O
responses	O
in	O
nbs	B-Disease
cells	O
indicated	O
that	O
p95	O
/	O
nbs1	O
may	O
not	O
be	O
required	O
for	O
signalling	O
to	O
atm	O
after	O
ionizing	O
radiation	O
.	O
	
a	O
p95	O
/	O
nbs1	O
construct	O
mutated	O
at	O
the	O
atm	O
phosphorylation	O
site	O
abrogated	O
an	O
s	O
-	O
phase	O
checkpoint	O
induced	O
by	O
ionizing	O
radiation	O
in	O
normal	O
cells	O
and	O
failed	O
to	O
compensate	O
for	O
this	O
functional	O
deficiency	O
in	O
nbs	B-Disease
cells	O
.	O
	
understanding	O
the	O
molecular	O
basis	O
of	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
.	O
	
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
a	O
common	O
form	O
of	O
inherited	B-Disease
mental	I-Disease
retardation	I-Disease
,	O
is	O
mainly	O
caused	O
by	O
massive	O
expansion	O
of	O
cgg	O
triplet	O
repeats	O
located	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
of	O
the	O
fragile	B-Disease
x	I-Disease
mental	I-Disease
retardation	I-Disease
-	O
1	O
(	O
fmr1	O
)	O
gene	O
.	O
	
in	O
patients	O
with	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
the	O
expanded	O
cgg	O
triplet	O
repeats	O
are	O
hypermethylated	O
and	O
the	O
expression	O
of	O
the	O
fmr1	O
gene	O
is	O
repressed	O
,	O
which	O
leads	O
to	O
the	O
absence	O
of	O
fmr1	O
protein	O
(	O
fmrp	O
)	O
and	O
subsequent	O
mental	B-Disease
retardation	I-Disease
.	O
	
haploinsufficiency	B-Disease
of	I-Disease
the	I-Disease
transcription	I-Disease
factors	I-Disease
foxc1	I-Disease
and	I-Disease
foxc2	I-Disease
results	O
in	O
aberrant	O
ocular	O
development	O
.	O
	
anterior	B-Disease
segment	I-Disease
developmental	I-Disease
disorders	I-Disease
,	O
including	O
axenfeld	B-Disease
-	I-Disease
rieger	I-Disease
anomaly	I-Disease
(	O
ara	B-Disease
)	O
,	O
variably	O
associate	O
with	O
harmfully	O
elevated	O
intraocular	O
pressure	O
(	O
iop	O
)	O
,	O
which	O
causes	O
glaucoma	B-Disease
.	O
	
clinically	O
observed	O
dysgenesis	O
does	O
not	O
correlate	O
with	O
iop	O
,	O
however	O
,	O
and	O
the	O
etiology	O
of	O
glaucoma	B-Disease
development	O
is	O
not	O
understood	O
.	O
	
mutations	O
in	O
the	O
human	O
homolog	O
of	O
foxc1	O
,	O
fkhl7	O
,	O
cause	O
dominant	O
anterior	B-Disease
segment	I-Disease
defects	I-Disease
and	O
glaucoma	B-Disease
in	O
various	O
families	O
.	O
	
we	O
show	O
that	O
foxc1	O
(	O
+	O
/	O
-	O
)	O
mice	O
have	O
anterior	B-Disease
segment	I-Disease
abnormalities	I-Disease
similar	O
to	O
those	O
reported	O
in	O
human	O
patients	O
.	O
	
these	O
abnormalities	O
include	O
small	O
or	O
absent	O
schlemms	O
canal	O
,	O
aberrantly	O
developed	O
trabecular	O
meshwork	O
,	O
iris	B-Disease
hypoplasia	I-Disease
,	O
severely	O
eccentric	O
pupils	O
and	O
displaced	O
schwalbes	O
line	O
.	O
	
similar	O
abnormalities	O
were	O
found	O
in	O
foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
,	O
but	O
no	O
disease	O
-	O
associated	O
mutations	O
were	O
identified	O
in	O
the	O
human	O
homolog	O
fkhl14	O
in	O
32	O
ara	B-Disease
patients	O
.	O
	
foxc1	O
(	O
+	O
/	O
-	O
)	O
and	O
foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
are	O
useful	O
models	O
for	O
studying	O
anterior	O
segment	O
development	O
and	O
its	O
anomalies	O
,	O
and	O
may	O
allow	O
identification	O
of	O
genes	O
that	O
interact	O
with	O
foxc1	O
and	O
foxc2	O
(	O
or	O
fkhl7	O
and	O
fkhl14	O
)	O
to	O
produce	O
a	O
phenotype	O
with	O
elevated	O
iop	O
and	O
glaucoma	B-Disease
.	O
	
(	O
over	O
)	O
correction	O
of	O
fmr1	B-Disease
deficiency	I-Disease
with	O
yac	O
transgenics	O
:	O
behavioral	O
and	O
physical	O
features	O
.	O
	
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
is	O
a	O
common	O
cause	O
of	O
mental	B-Disease
retardation	I-Disease
involving	O
loss	O
of	O
expression	O
of	O
the	O
fmr1	O
gene	O
.	O
	
fmr1	O
knockout	O
mice	O
exhibit	O
a	O
phenotype	O
with	O
some	O
similarities	O
to	O
humans	O
,	O
such	O
as	O
macroorchidism	B-Disease
and	O
behavioral	O
abnormalities	O
.	O
	
as	O
a	O
step	O
toward	O
understanding	O
the	O
function	O
of	O
fmr1	O
and	O
the	O
determination	O
of	O
the	O
potential	O
for	O
therapeutic	O
approaches	O
to	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
yeast	O
artificial	O
chromosome	O
(	O
yac	O
)	O
transgenic	O
mice	O
were	O
generated	O
in	O
order	O
to	O
determine	O
whether	O
the	O
fmr1	O
knockout	O
mouse	O
phenotype	O
could	O
be	O
rescued	O
.	O
	
given	O
the	O
complex	O
behavioral	O
phenotype	O
in	O
fragile	B-Disease
x	I-Disease
patients	O
and	O
the	O
mild	O
phenotype	O
previously	O
reported	O
for	O
the	O
fmr1	O
knockout	O
mouse	O
,	O
we	O
performed	O
a	O
more	O
thorough	O
evaluation	O
of	O
the	O
fmr1	O
knockout	O
phenotype	O
using	O
additional	O
behavioral	O
assays	O
that	O
had	O
not	O
previously	O
been	O
reported	O
for	O
this	O
animal	O
model	O
.	O
	
the	O
mouse	O
displayed	O
reduced	O
anxiety	B-Disease
-	O
related	O
responses	O
with	O
increased	O
exploratory	O
behavior	O
.	O
	
these	O
findings	O
have	O
significant	O
implications	O
for	O
gene	O
therapy	O
for	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
since	O
overexpression	O
of	O
the	O
gene	O
may	O
harbor	O
its	O
own	O
phenotype	O
.	O
	
transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
expanded	O
ctg	O
repeat	O
mimic	O
closely	O
the	O
dm	B-Disease
ctg	O
repeat	O
intergenerational	O
and	O
somatic	O
instability	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
caused	O
by	O
a	O
ctg	O
repeat	O
expansion	O
in	O
the	O
3utr	O
of	O
the	O
dm	B-Disease
protein	O
kinase	O
(	O
dmpk	O
)	O
gene	O
.	O
	
furthermore	O
,	O
tissues	O
from	O
dm	B-Disease
patients	O
exhibit	O
somatic	O
mosaicism	O
that	O
increases	O
with	O
age	O
.	O
	
we	O
generated	O
transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
20	O
,	O
55	O
or	O
>	O
300	O
ctg	O
,	O
cloned	O
from	O
patients	O
from	O
the	O
same	O
affected	O
dm	B-Disease
family	O
.	O
	
although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(	O
or	O
big	O
jumps	O
over	O
several	O
hundred	O
ctg	O
repeats	O
)	O
as	O
in	O
congenital	O
forms	O
of	O
dm	B-Disease
,	O
our	O
model	O
carrying	O
>	O
300	O
ctg	O
is	O
the	O
first	O
to	O
show	O
instability	O
so	O
close	O
to	O
the	O
human	O
dm	B-Disease
situation	O
.	O
	
inactivation	O
of	O
the	O
friedreich	B-Disease
ataxia	I-Disease
mouse	O
gene	O
leads	O
to	O
early	O
embryonic	B-Disease
lethality	I-Disease
without	O
iron	O
accumulation	O
.	O
	
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
,	O
the	O
most	O
common	O
autosomal	B-Disease
recessive	I-Disease
ataxia	I-Disease
,	O
is	O
caused	O
in	O
almost	O
all	O
cases	O
by	O
homozygous	O
intronic	O
expansions	O
resulting	O
in	O
the	O
loss	O
of	O
frataxin	O
,	O
a	O
mitochondrial	O
protein	O
conserved	O
through	O
evolution	O
,	O
and	O
involved	O
in	O
mitochondrial	O
iron	O
homeostasis	O
.	O
	
yeast	O
knockout	O
models	O
,	O
and	O
histological	O
and	O
biochemical	O
data	O
from	O
patient	O
heart	O
biopsies	O
or	O
autopsies	O
indicate	O
that	O
the	O
frataxin	O
defect	O
causes	O
a	O
specific	O
iron	B-Disease
-	I-Disease
sulfur	I-Disease
protein	I-Disease
deficiency	I-Disease
and	O
mitochondrial	O
iron	O
accumulation	O
leading	O
to	O
the	O
pathological	O
changes	O
.	O
	
to	O
study	O
the	O
mechanism	O
of	O
the	O
disease	O
,	O
we	O
generated	O
a	O
mouse	O
model	O
by	O
deletion	O
of	O
exon	O
4	O
leading	O
to	O
inactivation	O
of	O
the	O
frda	B-Disease
gene	O
product	O
.	O
	
we	O
show	O
that	O
homozygous	O
deletions	O
cause	O
embryonic	B-Disease
lethality	I-Disease
a	O
few	O
days	O
after	O
implantation	O
,	O
demonstrating	O
an	O
important	O
role	O
for	O
frataxin	O
during	O
early	O
development	O
.	O
	
gaucher	B-Disease
disease	I-Disease
:	O
the	O
origins	O
of	O
the	O
ashkenazi	O
jewish	O
n370s	O
and	O
84gg	O
acid	O
beta	O
-	O
glucosidase	O
mutations	O
.	O
	
type	O
1	O
gaucher	B-Disease
disease	I-Disease
(	O
gd	B-Disease
)	O
,	O
a	O
non	O
-	O
neuronopathic	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
,	O
results	O
from	O
the	O
deficient	O
activity	O
of	O
acid	O
beta	O
-	O
glucosidase	O
(	O
gba	O
)	O
.	O
	
hla	O
b27	O
and	O
the	O
genetics	O
of	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O
	
one	O
hundred	O
and	O
twenty	O
-	O
eight	O
of	O
145	O
patients	O
with	O
ankylosing	B-Disease
spondylitis	I-Disease
(	O
as	B-Disease
)	O
were	O
found	O
to	O
be	O
hla	O
b27	O
positive	O
.	O
	
five	O
patients	O
had	O
evidence	O
of	O
a	O
sero	O
-	O
negative	O
peripheral	B-Disease
arthritis	I-Disease
resembling	O
peripheral	B-Disease
psoriatic	I-Disease
arthritis	I-Disease
and	O
3	O
of	O
these	O
were	O
b27	O
negative	O
.	O
	
one	O
further	O
b27	O
negative	O
patients	O
had	O
a	O
sister	O
with	O
ankylosing	B-Disease
spondylitis	I-Disease
and	O
ulcerative	B-Disease
colitis	I-Disease
and	O
a	O
mother	O
with	O
ulcerative	B-Disease
colitis	I-Disease
.	O
	
these	O
findings	O
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	O
of	O
clinical	O
and	O
genetic	O
heterogeneity	O
in	O
ankylosing	B-Disease
spondylitis	I-Disease
with	O
genes	O
for	O
psoriasis	B-Disease
and	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
being	O
important	O
in	O
some	O
individuals	O
,	O
particularly	O
those	O
who	O
are	O
b27	O
negative	O
.	O
	
twenty	O
-	O
five	O
first	O
-	O
degree	O
relatives	O
with	O
ankylosing	B-Disease
spondylitis	I-Disease
were	O
all	O
b27	O
positive	O
.	O
	
the	O
only	O
instance	O
of	O
disassociation	O
of	O
b27	O
and	O
spondylitis	B-Disease
in	O
a	O
family	O
was	O
where	O
the	O
proband	O
had	O
ulcerative	B-Disease
colitis	I-Disease
as	O
well	O
as	O
spondylitis	B-Disease
.	O
	
of	O
13	O
b27	O
positive	O
fathers	O
3	O
could	O
be	O
diagnosed	O
as	O
having	O
definite	O
ankylosing	B-Disease
spondylitis	I-Disease
(	O
23	O
%	O
)	O
.	O
	
these	O
findings	O
are	O
thought	O
to	O
provide	O
evidence	O
against	O
the	O
concept	O
that	O
the	O
gene	O
for	O
ankylosing	B-Disease
spondylitis	I-Disease
is	O
not	O
b27	O
but	O
a	O
closely	O
linked	O
gene	O
and	O
favour	O
the	O
occurrence	O
of	O
an	O
environmental	O
event	O
affecting	O
approximately	O
one	O
-	O
fifth	O
of	O
b27	O
positive	O
males	O
to	O
result	O
in	O
disease	O
.	O
	
founder	O
mutations	O
in	O
the	O
brca1	O
gene	O
in	O
polish	O
families	O
with	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
the	O
study	O
group	O
consisted	O
of	O
66	O
polish	O
families	O
with	O
cancer	B-Disease
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
who	O
had	O
cancer	B-Disease
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O
	
a	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
4	O
families	O
had	O
ovarian	B-Disease
cancers	I-Disease
only	O
,	O
and	O
36	O
families	O
had	O
breast	B-Disease
cancers	I-Disease
only	O
.	O
	
brca1	B-Disease
abnormalities	I-Disease
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B-Disease
cancer	I-Disease
only	O
,	O
in	O
67	O
%	O
of	O
27	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
and	O
in	O
34	O
%	O
of	O
35	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
only	O
.	O
	
the	O
single	O
family	O
with	O
a	O
brca2	O
mutation	O
had	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
.	O
	
three	O
brca1	B-Disease
abnormalities	I-Disease
-	O
5382insc	O
,	O
c61g	O
,	O
and	O
4153dela	O
-	O
accounted	O
for	O
51	O
%	O
,	O
20	O
%	O
,	O
and	O
11	O
%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
.	O
	
molecular	O
basis	O
of	O
very	B-Disease
long	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coa	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
three	O
israeli	O
patients	O
:	O
identification	O
of	O
a	O
complex	O
mutant	O
allele	O
with	O
p65l	O
and	O
k247q	O
mutations	O
,	O
the	O
former	O
being	O
an	O
exonic	O
mutation	O
causing	O
exon	O
3	O
skipping	O
.	O
	
very	B-Disease
long	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coa	I-Disease
dehydrogenase	I-Disease
(	I-Disease
vlcad	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
life	O
-	O
threatening	O
disorder	O
of	O
mitochondrial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O
	
all	O
patients	O
had	O
the	O
severe	O
childhood	O
form	O
of	O
vlcad	B-Disease
deficiency	I-Disease
with	O
early	O
onset	O
and	O
high	O
mortality	O
.	O
	
submicroscopic	O
deletion	O
in	O
cousins	O
with	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
causes	O
a	O
grandmatrilineal	O
inheritance	O
pattern	O
:	O
effects	O
of	O
imprinting	O
.	O
	
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
critical	O
region	O
on	O
15q11	O
-	O
q13	O
is	O
subject	O
to	O
imprinting	O
.	O
	
pws	B-Disease
becomes	O
apparent	O
when	O
genes	O
on	O
the	O
paternally	O
inherited	O
chromosome	O
are	O
not	O
expressed	O
.	O
	
familial	B-Disease
pws	I-Disease
is	O
rare	O
.	O
	
we	O
report	O
on	O
a	O
family	O
in	O
which	O
a	O
male	O
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
pws	B-Disease
with	O
cytogenetically	O
normal	O
karyotypes	O
.	O
	
dna	O
methylation	O
analysis	O
of	O
d15s63	O
is	O
consistent	O
with	O
an	O
abnormality	O
of	O
the	O
imprinting	O
center	O
associated	O
with	O
pws	B-Disease
.	O
	
in	O
this	O
case	O
,	O
pws	B-Disease
does	O
not	O
become	O
evident	O
as	O
long	O
as	O
the	O
deletion	O
is	O
passed	O
through	O
the	O
matrilineal	O
line	O
.	O
	
human	O
glycine	O
decarboxylase	O
gene	O
(	O
gldc	O
)	O
and	O
its	O
highly	O
conserved	O
processed	O
pseudogene	O
(	O
psigldc	O
)	O
:	O
their	O
structure	O
and	O
expression	O
,	O
and	O
the	O
identification	O
of	O
a	O
large	O
deletion	O
in	O
a	O
family	O
with	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
.	O
	
mutations	O
in	O
the	O
glycine	O
decarboxylase	O
gene	O
(	O
gldc	O
)	O
cause	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
(	O
nkh	B-Disease
)	O
,	O
an	O
in	B-Disease
-	I-Disease
born	I-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
characterized	O
by	O
severe	O
neurological	B-Disease
disturbance	I-Disease
.	O
	
we	O
have	O
determined	O
the	O
structure	O
of	O
gldc	O
and	O
of	O
its	O
pseudogene	O
(	O
psigldc	O
)	O
and	O
studied	O
their	O
expression	O
for	O
a	O
molecular	O
analysis	O
of	O
nkh	B-Disease
.	O
	
we	O
have	O
also	O
examined	O
a	O
patient	O
with	O
nkh	B-Disease
with	O
no	O
detectable	O
gldc	O
mrna	O
in	O
his	O
lymphoblasts	O
.	O
	
structural	O
information	O
of	O
gldc	O
and	O
psigldc	O
should	O
facilitate	O
the	O
molecular	O
analysis	O
of	O
nkh	B-Disease
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
is	O
a	O
neurogenetic	B-Disease
disease	I-Disease
characterized	O
by	O
infantile	B-Disease
hypotonia	I-Disease
,	O
gonadal	B-Disease
hypoplasia	I-Disease
,	O
obsessive	O
behaviour	O
and	O
neonatal	O
feeding	O
difficulties	O
followed	O
by	O
hyperphagia	B-Disease
,	O
leading	O
to	O
profound	O
obesity	B-Disease
.	O
	
pws	B-Disease
is	O
due	O
to	O
a	O
lack	O
of	O
paternal	O
genetic	O
information	O
at	O
15q11	O
-	O
q13	O
(	O
ref	O
.	O
	
2	O
)	O
.	O
	
five	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
map	O
to	O
the	O
pws	B-Disease
region	O
,	O
mkrn3	O
(	O
ref	O
.	O
	
deletion	O
of	O
the	O
snrpn	O
promoter	O
/	O
exon	O
1	O
region	O
(	O
the	O
pws	B-Disease
ic	O
element	O
)	O
appears	O
to	O
impair	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
in	O
the	O
male	O
germ	O
line	O
and	O
leads	O
to	O
pws	B-Disease
.	O
	
here	O
we	O
report	O
a	O
pws	B-Disease
family	O
in	O
which	O
the	O
father	O
is	O
mosaic	O
for	O
an	O
ic	O
deletion	O
on	O
his	O
paternal	O
chromosome	O
.	O
	
our	O
studies	O
demonstrate	O
that	O
the	O
pws	B-Disease
ic	O
element	O
is	O
not	O
only	O
required	O
for	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
,	O
but	O
also	O
for	O
its	O
postzygotic	O
maintenance	O
.	O
	
mice	O
deficient	B-Disease
in	I-Disease
six5	I-Disease
develop	O
cataracts	B-Disease
:	O
implications	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
expansion	O
of	O
a	O
ctg	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
utr	O
of	O
the	O
gene	O
dmpk	O
at	O
the	O
dm1	O
locus	O
on	O
chromosome	O
19	O
causes	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
a	O
dominantly	B-Disease
inherited	I-Disease
disease	I-Disease
characterized	O
by	O
skeletal	O
muscle	B-Disease
dystrophy	I-Disease
and	O
myotonia	B-Disease
,	O
cataracts	B-Disease
and	O
cardiac	B-Disease
conduction	I-Disease
defects	I-Disease
.	O
	
targeted	O
deletion	O
of	O
dm15	O
,	O
the	O
mouse	O
orthologue	O
of	O
human	O
dmpk	O
,	O
produced	O
mice	O
with	O
a	O
mild	O
myopathy	B-Disease
and	O
cardiac	B-Disease
conduction	I-Disease
abnormalities	I-Disease
,	O
but	O
without	O
other	O
features	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
such	O
as	O
myotonia	B-Disease
and	O
cataracts	B-Disease
.	O
	
to	O
determine	O
whether	O
six5	B-Disease
deficiency	I-Disease
contributes	O
to	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
phenotype	O
,	O
we	O
disrupted	O
mouse	O
six5	O
by	O
replacing	O
the	O
first	O
exon	O
with	O
a	O
beta	O
-	O
galactosidase	O
reporter	O
.	O
	
homozygous	O
mutant	O
mice	O
had	O
no	O
apparent	O
abnormalities	B-Disease
of	I-Disease
skeletal	I-Disease
muscle	I-Disease
function	I-Disease
,	O
but	O
developed	O
lenticular	B-Disease
opacities	I-Disease
at	O
a	O
higher	O
rate	O
than	O
controls	O
.	O
	
our	O
results	O
suggest	O
that	O
six5	B-Disease
deficiency	I-Disease
contributes	O
to	O
the	O
cataract	B-Disease
phenotype	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
and	O
that	O
myotonic	B-Disease
dystrophy	I-Disease
represents	O
a	O
multigenic	B-Disease
disorder	I-Disease
.	O
	
heterozygous	O
loss	O
of	O
six5	O
in	O
mice	O
is	O
sufficient	O
to	O
cause	O
ocular	O
cataracts	B-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
skeletal	O
muscle	B-Disease
wasting	I-Disease
,	O
myotonia	B-Disease
,	O
cardiac	B-Disease
arrhythmia	I-Disease
,	O
hyperinsulinaemia	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
and	O
ocular	O
cataracts	B-Disease
.	O
	
the	O
genetic	B-Disease
defect	I-Disease
in	O
dm	B-Disease
is	O
a	O
ctg	O
repeat	O
expansion	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
dmpk	O
and	O
5	O
of	O
a	O
homeodomain	O
-	O
encoding	O
gene	O
,	O
six5	O
(	O
formerly	O
dmahp	O
;	O
refs	O
2	O
-	O
5	O
)	O
.	O
	
there	O
are	O
three	O
mechanisms	O
by	O
which	O
ctg	O
expansion	O
can	O
result	O
in	O
dm	B-Disease
.	O
	
previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
dose	O
-	O
dependent	O
loss	O
of	O
dm15	O
(	O
the	O
mouse	O
dmpk	O
homologue	O
)	O
in	O
mice	O
produces	O
a	O
partial	O
dm	B-Disease
phenotype	O
characterized	O
by	O
decreased	O
development	O
of	O
skeletal	O
muscle	O
force	O
and	O
cardiac	B-Disease
conduction	I-Disease
disorders	I-Disease
.	O
	
to	O
test	O
the	O
role	O
of	O
six5	O
loss	O
in	O
dm	B-Disease
,	O
we	O
have	O
analysed	O
a	O
strain	O
of	O
mice	O
in	O
which	O
six5	O
was	O
deleted	O
.	O
	
our	O
results	O
demonstrate	O
that	O
the	O
rate	O
and	O
severity	O
of	O
cataract	B-Disease
formation	O
is	O
inversely	O
related	O
to	O
six5	O
dosage	O
and	O
is	O
temporally	O
progressive	O
.	O
	
thus	O
,	O
altered	O
ion	O
homeostasis	O
within	O
the	O
lens	O
may	O
contribute	O
to	O
cataract	B-Disease
formation	O
.	O
	
as	O
ocular	O
cataracts	B-Disease
are	O
a	O
characteristic	O
feature	O
of	O
dm	B-Disease
,	O
these	O
results	O
demonstrate	O
that	O
decreased	O
six5	O
transcription	O
is	O
important	O
in	O
the	O
aetiology	O
of	O
dm	B-Disease
.	O
	
our	O
data	O
support	O
the	O
hypothesis	O
that	O
dm	B-Disease
is	O
a	O
contiguous	O
gene	O
syndrome	O
associated	O
with	O
the	O
partial	O
loss	O
of	O
both	O
dmpk	O
and	O
six5	O
.	O
	
mutations	O
in	O
the	O
gene	O
atm	O
are	O
responsible	O
for	O
the	O
genetic	B-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
which	O
is	O
characterized	O
by	O
cerebellar	B-Disease
dysfunction	I-Disease
,	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Disease
predisposition	O
.	O
	
both	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
phenotype	O
and	O
the	O
similarity	O
of	O
the	O
atm	O
protein	O
to	O
other	O
dna	O
-	O
damage	O
sensors	O
suggests	O
a	O
role	O
for	O
atm	O
in	O
biochemical	O
pathways	O
involved	O
in	O
the	O
recognition	O
,	O
signalling	O
and	O
repair	O
of	O
dna	O
double	O
-	O
strand	O
breaks	O
(	O
dsbs	O
)	O
.	O
	
there	O
are	O
strong	O
parallels	O
between	O
the	O
pattern	O
of	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Disease
predisposition	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
and	O
that	O
in	O
patients	O
with	O
nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
nbs	B-Disease
)	O
.	O
	
the	O
protein	O
defective	O
in	O
nbs	B-Disease
,	O
nibrin	O
(	O
encoded	O
by	O
nbs1	O
)	O
,	O
forms	O
a	O
complex	O
with	O
mre11	O
and	O
rad50	O
(	O
refs	O
1	O
,	O
2	O
)	O
.	O
	
the	O
overlap	O
between	O
clinical	O
and	O
cellular	O
phenotypes	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
and	O
nbs	B-Disease
suggests	O
that	O
atm	O
and	O
nibrin	O
may	O
function	O
in	O
the	O
same	O
biochemical	O
pathway	O
.	O
	
this	O
response	O
is	O
abrogated	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
that	O
either	O
do	O
not	O
express	O
atm	O
protein	O
or	O
express	O
near	O
full	O
-	O
length	O
mutant	O
protein	O
.	O
	
phosphorylation	O
of	O
this	O
site	O
appears	O
to	O
be	O
functionally	O
important	O
because	O
mutated	O
nibrin	O
(	O
s343a	O
)	O
does	O
not	O
completely	O
complement	O
radiosensitivity	O
in	O
nbs	B-Disease
cells	O
.	O
	
our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
a	B-Disease
-	I-Disease
t	I-Disease
and	O
nbs	B-Disease
.	O
	
clinicopathologic	O
features	O
of	O
brca	B-Disease
-	I-Disease
linked	I-Disease
and	I-Disease
sporadic	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
context	O
most	O
hereditary	B-Disease
ovarian	I-Disease
cancers	I-Disease
are	O
associated	O
with	O
germline	O
mutations	O
in	O
brca1	O
or	O
brca2	O
.	O
	
attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
brca	O
mutation	O
status	O
in	O
ovarian	B-Disease
cancer	I-Disease
have	O
produced	O
conflicting	O
results	O
,	O
especially	O
regarding	O
survival	O
.	O
	
objective	O
to	O
determine	O
whether	O
hereditary	B-Disease
ovarian	I-Disease
cancers	I-Disease
have	O
distinct	O
clinical	O
and	O
pathological	O
features	O
compared	O
with	O
sporadic	B-Disease
(	I-Disease
nonhereditary	I-Disease
)	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
design	O
and	O
setting	O
retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	B-Disease
cancers	I-Disease
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B-Disease
center	O
as	O
designated	O
by	O
the	O
national	O
cancer	B-Disease
institute	O
,	O
over	O
a	O
12	O
-	O
year	O
period	O
(	O
december	O
1986	O
to	O
august	O
1998	O
)	O
.	O
	
the	O
remaining	O
101	O
cases	O
from	O
the	O
same	O
series	O
not	O
associated	O
with	O
a	O
brca	O
mutation	O
and	O
2	O
additional	O
groups	O
(	O
gynecologic	O
oncology	O
group	O
protocols	O
52	O
and	O
111	O
)	O
with	O
ovarian	B-Disease
cancer	I-Disease
from	O
clinical	O
trials	O
(	O
for	O
the	O
survival	O
analysis	O
)	O
were	O
included	O
for	O
comparison	O
.	O
	
results	O
hereditary	B-Disease
cancers	I-Disease
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years	O
,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
brca1	O
-	O
vs	O
brca2	O
-	O
linked	O
patients	O
(	O
54	O
vs	O
62	O
years	O
;	O
p	O
=	O
.	O
	
those	O
with	O
hereditary	B-Disease
cancers	I-Disease
had	O
improved	O
survival	O
compared	O
with	O
the	O
nonhereditary	O
group	O
(	O
p	O
=	O
.	O
	
for	O
stage	B-Disease
iii	I-Disease
cancers	I-Disease
,	O
brca	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(	O
p	O
=	O
.	O
	
conclusions	O
although	O
brca	B-Disease
-	I-Disease
associated	I-Disease
hereditary	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
this	O
population	O
have	O
surgical	O
and	O
pathological	O
characteristics	O
similar	O
to	O
those	O
of	O
sporadic	B-Disease
cancers	I-Disease
,	O
advanced	B-Disease
-	I-Disease
stage	I-Disease
hereditary	I-Disease
cancer	I-Disease
patients	O
survive	O
longer	O
than	O
nonhereditary	B-Disease
cancer	I-Disease
patients	O
.	O
	
age	O
penetrance	O
is	O
greater	O
for	O
brca1	B-Disease
-	I-Disease
linked	I-Disease
than	I-Disease
for	I-Disease
brca2	I-Disease
-	I-Disease
linked	I-Disease
cancers	I-Disease
in	O
this	O
population	O
.	O
	
the	O
gene	O
for	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
,	O
mefv	O
,	O
is	O
expressed	O
in	O
early	O
leukocyte	O
development	O
and	O
is	O
regulated	O
in	O
response	O
to	O
inflammatory	O
mediators	O
.	O
	
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	B-Disease
and	O
neutrophil	B-Disease
-	I-Disease
mediated	I-Disease
serosal	I-Disease
inflammation	I-Disease
.	O
	
we	O
recently	O
identified	O
the	O
gene	O
causing	O
fmf	B-Disease
,	O
designated	O
mefv	O
,	O
and	O
found	O
it	O
to	O
be	O
expressed	O
in	O
mature	O
neutrophils	O
,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
inflammatory	O
regulator	O
.	O
	
in	O
vitro	O
stimulation	O
of	O
monocytes	O
with	O
the	O
proinflammatory	O
agents	O
interferon	O
(	O
ifn	O
)	O
gamma	O
,	O
tumor	B-Disease
necrosis	O
factor	O
,	O
and	O
lipopolysaccharide	O
induced	O
mefv	O
expression	O
,	O
whereas	O
the	O
antiinflammatory	O
cytokines	O
interleukin	O
(	O
il	O
)	O
4	O
,	O
il	O
-	O
10	O
,	O
and	O
transforming	O
growth	O
factor	O
beta	O
inhibited	O
such	O
expression	O
.	O
	
biochemical	O
and	O
structural	O
analysis	O
of	O
missense	O
mutations	O
in	O
n	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
causing	O
mucopolysaccharidosis	B-Disease
iva	I-Disease
phenotypes	O
.	O
	
mucopolysaccharidosis	B-Disease
iva	I-Disease
(	O
mps	B-Disease
iva	I-Disease
;	O
omim	O
#	O
253000	O
)	O
,	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
n	I-Disease
-	I-Disease
acetylgalactosamine	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
sulfate	I-Disease
sulfatase	I-Disease
(	O
galns	O
)	O
,	O
has	O
variable	O
clinical	O
phenotypes	O
.	O
	
to	O
date	O
we	O
have	O
identified	O
65	O
missense	O
mutations	O
in	O
the	O
galns	O
gene	O
from	O
mps	B-Disease
iva	I-Disease
patients	O
,	O
but	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
has	O
remained	O
unclear	O
.	O
	
these	O
studies	O
shed	O
further	O
light	O
on	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
mps	B-Disease
iva	I-Disease
and	O
structure	O
-	O
function	O
relationship	O
in	O
the	O
sulfatase	O
family	O
.	O
	
mutations	O
at	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
locus	O
and	O
clinical	O
phenotypes	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
.	O
	
mutations	O
at	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
locus	O
on	O
chromosome	O
band	O
11q22	O
cause	O
a	O
distinctive	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
in	O
homozygotes	O
and	O
predispose	O
heterozygotes	O
to	O
cancer	B-Disease
,	O
ischemic	B-Disease
heart	I-Disease
disease	I-Disease
,	O
and	O
early	O
mortality	O
.	O
	
pcr	O
amplification	O
from	O
genomic	O
dna	O
and	O
automated	O
sequencing	O
of	O
the	O
entire	O
coding	O
region	O
(	O
66	O
exons	O
)	O
and	O
splice	O
junctions	O
detected	O
77	O
mutations	O
(	O
85	O
%	O
)	O
in	O
90	O
a	B-Disease
-	I-Disease
t	I-Disease
chromosomes	O
.	O
	
heteroduplex	O
analysis	O
detected	O
another	O
42	O
mutations	O
at	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
locus	O
.	O
	
most	O
(	O
58	O
/	O
71	O
,	O
82	O
%	O
)	O
mutations	O
were	O
frameshift	O
and	O
nonsense	O
mutations	O
that	O
are	O
predicted	O
to	O
cause	O
truncation	O
of	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
protein	O
;	O
the	O
less	O
common	O
mutation	O
types	O
were	O
missense	O
(	O
9	O
/	O
71	O
,	O
13	O
%	O
)	O
,	O
splicing	O
(	O
3	O
/	O
71	O
,	O
4	O
%	O
)	O
and	O
one	O
in	O
-	O
frame	O
deletion	O
,	O
2546	O
3	O
(	O
1	O
/	O
71	O
,	O
1	O
%	O
)	O
.	O
	
the	O
mean	O
survival	O
and	O
height	O
distribution	O
of	O
134	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
correlated	O
significantly	O
with	O
the	O
specific	O
mutations	O
present	O
in	O
the	O
patients	O
.	O
	
alterations	O
of	O
the	O
length	O
or	O
amino	O
acid	O
composition	O
of	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
gene	O
product	O
affect	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
clinical	O
phenotype	O
in	O
different	O
ways	O
.	O
	
mutation	O
analysis	O
at	O
the	O
a	B-Disease
-	I-Disease
t	I-Disease
locus	O
may	O
help	O
estimate	O
the	O
prognosis	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
.	O
	
isolation	O
,	O
genomic	O
organization	O
,	O
and	O
expression	O
analysis	O
of	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
mefv	O
,	O
the	O
gene	O
for	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
.	O
	
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	B-Disease
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O
	
recently	O
the	O
fmf	B-Disease
gene	O
(	O
mefv	O
)	O
was	O
cloned	O
;	O
the	O
protein	O
product	O
,	O
pyrin	O
/	O
marenostrin	O
,	O
is	O
thought	O
to	O
regulate	O
inflammation	O
in	O
myeloid	O
cells	O
.	O
	
2	O
domain	O
,	O
in	O
which	O
most	O
fmf	B-Disease
-	O
associated	O
mutations	O
have	O
been	O
found	O
in	O
human	O
mefv	O
.	O
	
additional	O
copies	O
of	O
the	O
proteolipid	O
protein	O
gene	O
causing	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
arise	O
by	O
separate	O
integration	O
into	O
the	O
x	O
chromosome	O
.	O
	
mutations	O
and	O
duplications	O
of	O
this	O
gene	O
are	O
associated	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
.	O
	
here	O
we	O
describe	O
two	O
new	O
families	O
in	O
which	O
males	O
affected	O
with	O
pmd	B-Disease
were	O
found	O
to	O
have	O
a	O
copy	O
of	O
plp	O
on	O
the	O
short	O
arm	O
of	O
the	O
x	O
chromosome	O
,	O
in	O
addition	O
to	O
a	O
normal	O
copy	O
on	O
xq22	O
.	O
	
in	O
a	O
second	O
unrelated	O
family	O
with	O
signs	O
of	O
pmd	B-Disease
,	O
cytogenetic	O
analysis	O
showed	O
a	O
pericentric	O
inversion	O
of	O
the	O
x	O
chromosome	O
.	O
	
the	O
identification	O
of	O
three	O
separate	O
families	O
in	O
which	O
plp	O
is	O
duplicated	O
at	O
a	O
noncontiguous	O
site	O
suggests	O
that	O
such	O
duplications	O
could	O
be	O
a	O
relatively	O
common	O
but	O
previously	O
undetected	O
cause	O
of	O
genetic	B-Disease
disorders	I-Disease
.	O
	
to	O
do	O
this	O
,	O
a	O
collaborative	O
screening	O
study	O
was	O
set	O
up	O
that	O
involved	O
39	O
institutions	O
from	O
19	O
countries	O
and	O
included	O
3	O
,	O
580	O
unrelated	O
individuals	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
and	O
934	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
.	O
	
genotype	O
-	O
phenotype	O
correlations	O
in	O
families	O
with	O
deletions	O
in	O
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	O
vhl	B-Disease
)	O
gene	O
.	O
	
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
disease	I-Disease
is	O
a	O
hereditary	B-Disease
tumor	I-Disease
syndrome	I-Disease
characterized	O
by	O
predisposition	O
for	O
bilateral	B-Disease
and	I-Disease
multi	I-Disease
-	I-Disease
centric	I-Disease
hemangioblastoma	I-Disease
in	O
the	O
retina	O
and	O
central	O
nervous	O
system	O
,	O
pheochromocytoma	B-Disease
,	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
,	O
and	O
cysts	B-Disease
in	I-Disease
the	I-Disease
kidney	I-Disease
,	I-Disease
pancreas	I-Disease
,	I-Disease
and	I-Disease
epididymis	I-Disease
.	O
	
we	O
describe	O
five	O
families	O
for	O
which	O
direct	O
sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
vhl	B-Disease
gene	O
had	O
failed	O
to	O
identify	O
the	O
family	O
-	O
specific	O
mutation	O
.	O
	
further	O
molecular	O
analysis	O
revealed	O
deletions	O
involving	O
the	O
vhl	B-Disease
gene	O
in	O
each	O
of	O
these	O
families	O
.	O
	
in	O
the	O
fifth	O
family	O
,	O
fish	O
analysis	O
demonstrated	O
the	O
deletion	O
of	O
the	O
entire	O
vhl	B-Disease
gene	O
.	O
	
our	O
results	O
show	O
that	O
(	O
quantitative	O
)	O
southern	O
blot	O
analysis	O
is	O
a	O
sensitive	O
method	O
for	O
detecting	O
germline	O
deletions	O
of	O
the	O
vhl	B-Disease
gene	O
and	O
should	O
be	O
implemented	O
in	O
routine	O
dna	O
diagnosis	O
for	O
vhl	B-Disease
disease	I-Disease
.	O
	
our	O
data	O
support	O
the	O
previously	O
established	O
observation	O
that	O
families	O
with	O
a	O
germline	O
deletion	O
have	O
a	O
low	O
risk	O
for	O
pheochromocytoma	B-Disease
.	O
	
further	O
unraveling	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
vhl	B-Disease
disease	I-Disease
has	O
revealed	O
that	O
families	O
with	O
a	O
full	O
or	O
partial	O
deletion	O
of	O
the	O
vhl	B-Disease
gene	O
exhibit	O
a	O
phenotype	O
with	O
a	O
preponderance	O
of	O
central	B-Disease
nervous	I-Disease
system	I-Disease
hemangioblastoma	I-Disease
.	O
	
age	O
of	O
the	O
intronic	O
gaa	O
triplet	O
repeat	O
expansion	O
mutation	O
in	O
friedreich	B-Disease
ataxia	I-Disease
.	O
	
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
,	O
the	O
most	O
frequently	O
inherited	B-Disease
ataxia	I-Disease
,	O
is	O
due	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
to	O
a	O
large	O
expansion	O
of	O
an	O
intronic	O
gaa	O
repeat	O
.	O
	
using	O
linkage	O
disequilibrium	O
analysis	O
based	O
on	O
haplotype	O
data	O
of	O
seven	O
polymorphic	O
markers	O
close	O
to	O
the	O
frataxin	O
gene	O
,	O
the	O
age	O
of	O
frda	B-Disease
founding	O
mutational	O
event	O
(	O
s	O
)	O
is	O
estimated	O
to	O
be	O
at	O
least	O
682	O
+	O
/	O
-	O
203	O
generations	O
(	O
95	O
%	O
confidence	O
interval	O
564	O
-	O
801	O
g	O
)	O
,	O
a	O
dating	O
which	O
is	O
consistent	O
with	O
little	O
or	O
no	O
negative	O
selection	O
and	O
provides	O
further	O
evidence	O
for	O
an	O
ancient	O
spread	O
of	O
a	O
pre	O
-	O
mutation	O
(	O
at	O
-	O
risk	O
alleles	O
)	O
in	O
western	O
europe	O
.	O
	
functional	O
link	O
between	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
and	O
nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
gene	O
products	O
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
and	O
nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
nbs	B-Disease
)	O
are	O
recessive	B-Disease
genetic	I-Disease
disorders	I-Disease
with	O
susceptibility	O
to	O
cancer	B-Disease
and	O
similar	O
cellular	O
phenotypes	O
.	O
	
the	O
protein	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
a	B-Disease
-	I-Disease
t	I-Disease
,	O
designated	O
atm	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
characterized	O
by	O
a	O
carboxy	O
-	O
terminal	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
like	O
domain	O
.	O
	
the	O
nbs1	O
protein	O
is	O
specifically	O
mutated	O
in	O
patients	O
with	O
nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
and	O
forms	O
a	O
complex	O
with	O
the	O
dna	O
repair	O
proteins	O
rad50	O
and	O
mrel1	O
.	O
	
this	O
response	O
includes	O
s	O
-	O
phase	O
checkpoint	O
activation	O
,	O
formation	O
of	O
the	O
nbs1	O
/	O
mrel1	O
/	O
rad50	O
nuclear	O
foci	O
and	O
rescue	O
of	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
.	O
	
together	O
,	O
these	O
results	O
demonstrate	O
a	O
biochemical	O
link	O
between	O
cell	O
-	O
cycle	O
checkpoints	O
activated	O
by	O
dna	O
damage	O
and	O
dna	O
repair	O
in	O
two	O
genetic	B-Disease
diseases	I-Disease
with	O
overlapping	O
phenotypes	O
.	O
	
homozygosity	O
mapping	O
in	O
a	O
family	O
with	O
microcephaly	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
short	B-Disease
stature	I-Disease
to	O
a	O
cohen	B-Disease
syndrome	I-Disease
region	O
on	O
8q21	O
.	O
	
a	O
syndrome	O
of	O
microcephaly	B-Disease
,	O
progressive	O
postnatal	B-Disease
growth	I-Disease
deficiency	I-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
was	O
observed	O
in	O
two	O
brothers	O
and	O
their	O
cousin	O
from	O
a	O
multiply	O
consanguineous	O
kindred	O
of	O
lebanese	O
descent	O
.	O
	
hypotonia	B-Disease
,	O
chorioretinal	B-Disease
dystrophy	I-Disease
,	O
and	O
myopia	B-Disease
were	O
also	O
identified	O
.	O
	
because	O
of	O
absence	O
of	O
a	O
distinctive	O
facial	O
appearance	O
,	O
the	O
degree	O
of	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
short	B-Disease
stature	I-Disease
,	O
the	O
initially	O
considered	O
clinical	O
diagnosis	O
of	O
cohen	B-Disease
syndrome	I-Disease
was	O
withdrawn	O
and	O
a	O
novel	O
genetic	O
entity	O
was	O
assumed	O
.	O
	
intriguingly	O
enough	O
,	O
the	O
identified	O
gene	O
region	O
overlaps	O
the	O
refined	O
gene	O
region	O
for	O
cohen	B-Disease
syndrome	I-Disease
(	O
coh1	O
)	O
[	O
kolehmainen	O
et	O
al	O
.	O
	
this	O
fact	O
encourages	O
the	O
hypothesis	O
that	O
the	O
described	O
kindred	O
segregates	O
for	O
a	O
variant	O
of	O
cohen	B-Disease
syndrome	I-Disease
and	O
suggests	O
a	O
redefinition	O
of	O
its	O
phenotype	O
polymorphisms	O
of	O
the	O
cyp2d6	O
gene	O
increase	O
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O
	
ankylosing	B-Disease
spondylitis	I-Disease
(	O
as	B-Disease
)	O
is	O
a	O
common	O
and	O
highly	O
familial	O
rheumatic	B-Disease
disorder	I-Disease
.	O
	
previous	O
linkage	O
and	O
association	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	O
gene	O
for	O
as	B-Disease
close	O
to	O
,	O
or	O
within	O
,	O
the	O
cytochrome	O
p450	O
2d6	O
gene	O
(	O
cyp2d6	O
,	O
debrisoquine	O
hydroxylase	O
)	O
located	O
at	O
chromosome	O
22q13	O
.	O
	
we	O
performed	O
a	O
linkage	O
study	O
of	O
chromosome	O
22	O
in	O
200	O
families	O
with	O
as	B-Disease
affected	O
sibling	O
-	O
pairs	O
.	O
	
for	O
case	O
-	O
control	O
studies	O
,	O
617	O
unrelated	O
individuals	O
with	O
as	B-Disease
(	O
361	O
probands	O
from	O
sibling	O
-	O
pair	O
and	O
parent	O
-	O
case	O
trio	O
families	O
and	O
256	O
unrelated	O
non	O
-	O
familial	O
sporadic	O
cases	O
)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed	O
.	O
	
homozygosity	O
for	O
poor	O
metabolizer	O
alleles	O
was	O
found	O
to	O
be	O
associated	O
with	O
as	B-Disease
.	O
	
heterozygosity	O
for	O
the	O
most	O
frequent	O
poor	O
metabolizer	O
allele	O
(	O
cyp2d6	O
*	O
4	O
)	O
was	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
as	B-Disease
.	O
	
significant	O
within	O
-	O
family	O
association	O
of	O
cyp2d6	O
*	O
4	O
alleles	O
and	O
as	B-Disease
was	O
demonstrated	O
.	O
	
weak	O
linkage	O
was	O
also	O
demonstrated	O
between	O
cyp2d6	O
and	O
as	B-Disease
.	O
	
we	O
postulate	O
that	O
altered	O
metabolism	O
of	O
a	O
natural	O
toxin	O
or	O
antigen	O
by	O
the	O
cyp2d6	O
gene	O
may	O
increase	O
susceptibility	O
to	O
as	B-Disease
.	O
	
functional	O
differences	O
of	O
the	O
pds	B-Disease
gene	O
product	O
are	O
associated	O
with	O
phenotypic	O
variation	O
in	O
patients	O
with	O
pendred	B-Disease
syndrome	I-Disease
and	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
(	O
dfnb4	B-Disease
)	O
.	O
	
the	O
pds	B-Disease
gene	O
encodes	O
a	O
transmembrane	O
protein	O
,	O
known	O
as	O
pendrin	O
,	O
which	O
functions	O
as	O
a	O
transporter	O
of	O
iodide	O
and	O
chloride	O
.	O
	
mutations	O
in	O
this	O
gene	O
are	O
responsible	O
for	O
pendred	B-Disease
syndrome	I-Disease
and	O
autosomal	B-Disease
recessive	I-Disease
non	I-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
at	O
the	O
dfnb4	B-Disease
locus	O
on	O
chromosome	O
7q31	O
.	O
	
a	O
screen	O
of	O
20	O
individuals	O
from	O
the	O
midwestern	O
usa	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
and	O
dilated	O
vestibular	O
aqueducts	O
identified	O
three	O
people	O
(	O
15	O
%	O
)	O
with	O
pds	B-Disease
mutations	O
.	O
	
to	O
determine	O
whether	O
pds	B-Disease
mutations	O
in	O
individuals	O
with	O
pendred	B-Disease
syndrome	I-Disease
differ	O
functionally	O
from	O
pds	B-Disease
mutations	O
in	O
individuals	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
we	O
compared	O
three	O
common	O
pendred	B-Disease
syndrome	I-Disease
allele	O
variants	O
(	O
l236p	O
,	O
t416p	O
and	O
e384g	O
)	O
,	O
with	O
three	O
pds	B-Disease
mutations	O
reported	O
only	O
in	O
individuals	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
(	O
v480d	O
,	O
v653a	O
and	O
i490l	O
/	O
g497s	O
)	O
.	O
	
the	O
mutations	O
associated	O
with	O
pendred	B-Disease
syndrome	I-Disease
have	O
complete	O
loss	O
of	O
pendrin	O
-	O
induced	O
chloride	O
and	O
iodide	O
transport	O
,	O
while	O
alleles	O
unique	O
to	O
people	O
with	O
dfnb4	B-Disease
are	O
able	O
to	O
transport	O
both	O
iodide	O
and	O
chloride	O
,	O
albeit	O
at	O
a	O
much	O
lower	O
level	O
than	O
wild	O
-	O
type	O
pendrin	O
.	O
	
we	O
hypothesize	O
that	O
this	O
residual	O
level	O
of	O
anion	O
transport	O
is	O
sufficient	O
to	O
eliminate	O
or	O
postpone	O
the	O
onset	O
of	O
goiter	B-Disease
in	O
individuals	O
with	O
dfnb4	B-Disease
.	O
	
germline	O
mutations	O
are	O
the	O
major	O
source	O
of	O
genetic	O
variation	O
that	O
allows	O
a	O
species	O
to	O
evolve	O
over	O
time	O
but	O
at	O
the	O
cost	O
of	O
mendelian	B-Disease
disease	I-Disease
and	O
genetic	O
predisposition	O
to	O
multifactorial	B-Disease
diseases	I-Disease
.	O
	
here	O
,	O
we	O
compare	O
the	O
pattern	O
of	O
germline	O
mutation	O
in	O
a	O
population	O
of	O
hemophilia	B-Disease
b	I-Disease
patients	O
from	O
mainland	O
china	O
(	O
n	O
=	O
66	O
)	O
to	O
that	O
in	O
u	O
.	O
	
heterozygous	O
mutations	O
encoding	O
abnormal	O
forms	O
of	O
the	O
death	O
receptor	O
fas	O
dominantly	O
interfere	O
with	O
fas	O
-	O
induced	O
lymphocyte	O
apoptosis	O
in	O
human	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
.	O
	
determination	O
of	O
carrier	O
status	O
for	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
by	O
flow	O
cytometric	O
analysis	O
of	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
is	O
caused	O
by	O
defects	O
in	O
the	O
was	B-Disease
protein	O
(	O
wasp	O
)	O
gene	O
on	O
the	O
x	O
chromosome	O
.	O
	
previous	O
study	O
disclosed	O
that	O
flow	O
cytometric	O
analysis	O
of	O
intracellular	O
wasp	O
expression	O
(	O
fcm	O
-	O
wasp	O
analysis	O
)	O
in	O
lymphocytes	O
was	O
useful	O
for	O
the	O
diagnosis	O
of	O
was	B-Disease
patients	O
.	O
	
lymphocytes	O
from	O
all	O
was	B-Disease
patients	O
showed	O
waspdim	O
instead	O
of	O
waspbright	O
.	O
	
here	O
we	O
report	O
that	O
fcm	O
-	O
wasp	O
analysis	O
in	O
monocytes	O
could	O
be	O
a	O
useful	O
tool	O
for	O
the	O
was	B-Disease
carrier	O
diagnosis	O
.	O
	
monocytes	O
from	O
all	O
nine	O
was	B-Disease
carriers	O
showed	O
varied	O
population	O
of	O
waspdim	O
together	O
with	O
waspbright	O
.	O
	
the	O
difference	O
of	O
the	O
waspdim	O
population	O
in	O
monocytes	O
and	O
lymphocytes	O
observed	O
in	O
was	B-Disease
carriers	O
suggests	O
that	O
wasp	O
plays	O
a	O
more	O
critical	O
role	O
in	O
the	O
development	O
of	O
lymphocytes	O
than	O
in	O
that	O
of	O
monocytes	O
.	O
	
the	O
present	O
studies	O
suggest	O
that	O
a	O
skewed	O
x	O
-	O
chromosomal	O
inactivation	O
pattern	O
observed	O
in	O
was	B-Disease
carrier	O
peripheral	O
blood	O
cells	O
is	O
not	O
fixed	O
at	O
the	O
hemopoietic	O
stem	O
cell	O
level	O
but	O
progresses	O
after	O
the	O
lineage	O
commitment	O
.	O
	
restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	B-Disease
degeneration	I-Disease
slow	O
mice	O
by	O
gene	O
therapy	O
.	O
	
mutations	O
in	O
prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	B-Disease
dystrophies	I-Disease
,	O
including	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
and	O
macular	B-Disease
dystrophy	I-Disease
.	O
	
a	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function	O
,	O
also	O
seen	O
in	O
the	O
retinal	B-Disease
degeneration	I-Disease
slow	O
(	O
rds	O
or	O
prph2	O
rd2	O
/	O
rd2	O
)	O
mouse	O
,	O
which	O
is	O
homozygous	O
for	O
a	O
nan	O
mutation	O
in	O
prph2	O
.	O
	
mutations	O
in	O
the	O
fibrinogen	O
aalpha	O
gene	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
congenital	B-Disease
afibrinogenemia	I-Disease
.	O
	
congenital	B-Disease
afibrinogenemia	I-Disease
is	O
a	O
rare	O
,	O
autosomal	B-Disease
,	I-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
the	O
complete	O
absence	O
of	O
detectable	O
fibrinogen	O
.	O
	
consequently	O
,	O
86	O
%	O
of	O
afibrinogenemia	B-Disease
alleles	O
analyzed	O
to	O
date	O
have	O
truncating	O
mutations	O
of	O
fga	O
,	O
though	O
mutations	O
in	O
all	O
3	O
fibrinogen	O
genes	O
,	O
fgg	O
,	O
fga	O
,	O
and	O
fgb	O
,	O
might	O
be	O
predicted	O
to	O
cause	O
congenital	B-Disease
afibrinogenemia	I-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
:	O
the	O
role	O
of	O
the	O
cug	O
triplet	O
repeats	O
in	O
splicing	O
of	O
a	O
novel	O
dmpk	O
exon	O
and	O
altered	O
cytoplasmic	O
dmpk	O
mrna	O
isoform	O
ratios	O
.	O
	
the	O
mechanism	O
by	O
which	O
(	O
ctg	O
)	O
n	O
expansion	O
in	O
the	O
3	O
utr	O
of	O
the	O
dmpk	O
gene	O
causes	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
unknown	O
.	O
	
in	O
contrast	O
to	O
(	O
cug	O
)	O
n	O
containing	O
mrnas	O
,	O
the	O
novel	O
isoform	O
is	O
not	O
retained	O
in	O
the	O
nucleus	O
in	O
dm	B-Disease
cells	O
,	O
resulting	O
in	O
imbalances	O
in	O
relative	O
levels	O
of	O
cytoplasmic	O
dmpk	O
mrna	O
isoforms	O
and	O
a	O
new	O
dominant	O
effect	O
of	O
the	O
mutation	O
on	O
dmpk	O
.	O
	
expression	O
and	O
imprinting	O
of	O
magel2	O
suggest	O
a	O
role	O
in	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
and	O
the	O
homologous	O
murine	O
imprinting	O
phenotype	O
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
is	O
caused	O
by	O
the	O
loss	O
of	O
expression	O
of	O
imprinted	O
genes	O
in	O
chromosome	O
15q11	O
-	O
q13	O
.	O
	
affected	O
individuals	O
exhibit	O
neonatal	B-Disease
hypotonia	I-Disease
,	O
developmental	B-Disease
delay	I-Disease
and	O
childhood	B-Disease
-	I-Disease
onset	I-Disease
obesity	I-Disease
.	O
	
necdin	O
,	O
a	O
protein	O
implicated	O
in	O
the	O
terminal	O
differentiation	O
of	O
neurons	O
,	O
is	O
the	O
only	O
pws	B-Disease
candidate	O
gene	O
to	O
reduce	O
viability	O
when	O
disrupted	O
in	O
a	O
mouse	O
model	O
.	O
	
in	O
this	O
study	O
,	O
we	O
have	O
characterized	O
magel2	O
(	O
also	O
known	O
as	O
ndnl1	O
)	O
,	O
a	O
gene	O
with	O
51	O
%	O
amino	O
acid	O
sequence	O
similarity	O
to	O
necdin	O
and	O
located	O
41	O
kb	O
distal	O
to	O
ndn	O
in	O
the	O
pws	B-Disease
deletion	O
region	O
.	O
	
magel2	O
is	O
expressed	O
predominantly	O
in	O
brain	O
,	O
the	O
primary	O
tissue	O
affected	O
in	O
pws	B-Disease
and	O
in	O
several	O
fetal	O
tissues	O
as	O
shown	O
by	O
northern	O
blot	O
analysis	O
.	O
	
magel2	O
is	O
imprinted	O
with	O
monoallelic	O
expression	O
in	O
control	O
brain	O
,	O
and	O
paternal	O
-	O
only	O
expression	O
in	O
the	O
central	O
nervous	O
system	O
as	O
demonstrated	O
by	O
its	O
lack	O
of	O
expression	O
in	O
brain	O
from	O
a	O
pws	B-Disease
-	O
affected	O
individual	O
.	O
	
we	O
hypothesize	O
that	O
,	O
although	O
loss	O
of	O
necdin	O
expression	O
may	O
be	O
important	O
in	O
the	O
neonatal	O
presentation	O
of	O
pws	B-Disease
,	O
loss	O
of	O
magel2	O
may	O
be	O
critical	O
to	O
abnormalities	B-Disease
in	I-Disease
brain	I-Disease
development	I-Disease
and	O
dysmorphic	B-Disease
features	I-Disease
in	O
individuals	O
with	O
pws	B-Disease
.	O
	
retinoschisin	O
,	O
the	O
x	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
protein	O
,	O
is	O
a	O
secreted	O
photoreceptor	O
protein	O
,	O
and	O
is	O
expressed	O
and	O
released	O
by	O
weri	O
-	O
rb1	O
cells	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
is	O
characterized	O
by	O
microcystic	O
-	O
like	O
changes	O
of	O
the	O
macular	O
region	O
and	O
schisis	O
within	O
the	O
inner	O
retinal	O
layers	O
,	O
leading	O
to	O
visual	B-Disease
deterioration	I-Disease
in	O
males	O
.	O
	
furthermore	O
,	O
differentiated	O
retinoblastoma	B-Disease
cells	O
(	O
weri	O
-	O
rb1	O
cells	O
)	O
were	O
found	O
to	O
express	O
rs1	O
mrna	O
and	O
to	O
release	O
retinoschisin	O
.	O
	
thus	O
,	O
x	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
is	O
caused	O
by	O
abnormalities	O
in	O
a	O
putative	O
secreted	O
photoreceptor	O
protein	O
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo	O
-	O
receptor	O
protein	O
associated	O
with	O
a	O
retinal	B-Disease
dystrophy	I-Disease
.	O
	
study	O
of	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
beta	O
1	O
subunit	O
gene	O
(	O
scn1b	O
)	O
in	O
the	O
benign	B-Disease
familial	I-Disease
infantile	I-Disease
convulsions	I-Disease
syndrome	I-Disease
(	O
bfic	B-Disease
)	O
.	O
	
benign	B-Disease
familial	I-Disease
infantile	I-Disease
convulsions	I-Disease
(	O
bfic	B-Disease
)	O
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
epilepsy	I-Disease
syndrome	I-Disease
.	O
	
the	O
seizures	O
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment	O
,	O
leaving	O
no	O
neurological	B-Disease
abnormalities	I-Disease
.	O
	
we	O
have	O
mapped	O
bfic	B-Disease
to	O
chromosome	O
19q	O
in	O
five	O
italian	O
pedigrees	O
.	O
	
the	O
sodium	O
channel	O
beta1	O
subunit	O
gene	O
(	O
scn1b	O
)	O
maps	O
to	O
this	O
candidate	O
region	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
one	O
australian	O
pedigree	O
with	O
generalized	B-Disease
epilepsy	I-Disease
and	I-Disease
febrile	I-Disease
seizures	I-Disease
plus	I-Disease
(	O
gefs	O
+	O
)	O
.	O
	
bfic	B-Disease
and	O
gefs	O
+	O
have	O
clinical	O
features	O
in	O
common	O
,	O
therefore	O
scn1b	O
is	O
a	O
candidate	O
gene	O
for	O
bfic	B-Disease
.	O
	
we	O
studied	O
scn1b	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
using	O
four	O
sscp	O
methods	O
in	O
10	O
caucasian	O
bfic	B-Disease
probands	O
of	O
western	O
europe	O
.	O
	
one	O
variant	O
was	O
identified	O
in	O
intron	O
5	O
(	O
ivs5	O
-	O
10c	O
>	O
g	O
)	O
,	O
which	O
did	O
not	O
segregate	O
with	O
bfic	B-Disease
and	O
was	O
observed	O
in	O
9	O
.	O
	
it	O
was	O
rare	O
,	O
as	O
not	O
observed	O
in	O
controls	O
,	O
but	O
not	O
segregating	O
with	O
the	O
bfic	B-Disease
phenotype	O
.	O
	
inactivation	O
of	O
germline	O
mutant	O
apc	B-Disease
alleles	O
by	O
attenuated	O
somatic	O
mutations	O
:	O
a	O
molecular	O
genetic	O
mechanism	O
for	O
attenuated	B-Disease
familial	I-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O
	
germline	O
mutations	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
apc	I-Disease
)	I-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
result	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
.	O
	
patients	O
with	O
fap	B-Disease
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	B-Disease
colorectal	I-Disease
tumors	I-Disease
and	O
early	O
-	O
onset	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
a	O
subset	O
of	O
germline	O
apc	B-Disease
mutations	O
results	O
in	O
an	O
attenuated	B-Disease
fap	I-Disease
(	O
afap	B-Disease
)	O
phenotype	O
,	O
in	O
which	O
patients	O
develop	O
fewer	O
tumors	B-Disease
and	O
develop	O
them	O
at	O
an	O
older	O
age	O
.	O
	
although	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
locations	O
of	O
apc	B-Disease
germline	O
mutations	O
and	O
the	O
development	O
of	O
afap	B-Disease
has	O
been	O
well	O
documented	O
,	O
the	O
mechanism	O
for	O
afap	B-Disease
has	O
not	O
been	O
well	O
defined	O
.	O
	
we	O
investigated	O
the	O
mechanism	O
for	O
afap	B-Disease
in	O
patients	O
carrying	O
a	O
mutant	O
apc	B-Disease
allele	O
(	O
apc	O
(	O
as9	O
)	O
)	O
that	O
has	O
a	O
mutation	O
in	O
the	O
alternatively	O
spliced	O
region	O
of	O
exon	O
9	O
.	O
	
apc	O
(	O
as9	O
)	O
was	O
found	O
to	O
down	O
-	O
regulate	O
beta	O
-	O
catenin	O
-	O
regulated	O
transcription	O
,	O
the	O
major	O
tumor	B-Disease
-	O
suppressor	O
function	O
of	O
apc	O
,	O
as	O
did	O
the	O
wild	O
-	O
type	O
apc	O
.	O
	
mutation	O
analysis	O
showed	O
that	O
both	O
apc	O
(	O
as9	O
)	O
and	O
the	O
wild	O
-	O
type	O
apc	B-Disease
alleles	O
were	O
somatically	O
mutated	O
in	O
most	O
colorectal	B-Disease
tumors	I-Disease
from	O
these	O
patients	O
.	O
	
functional	O
analysis	O
showed	O
that	O
4666insa	O
,	O
a	O
common	O
somatic	O
mutation	O
in	O
apc	O
(	O
as9	O
)	O
in	O
these	O
tumors	B-Disease
,	O
did	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
apc	O
.	O
	
our	O
results	O
indicate	O
that	O
carriers	O
of	O
apc	O
(	O
as9	O
)	O
develop	O
fewer	O
colorectal	B-Disease
tumors	I-Disease
than	O
do	O
typical	O
patients	O
with	O
fap	B-Disease
because	O
somatic	O
inactivation	O
of	O
both	O
apc	B-Disease
alleles	O
is	O
necessary	O
for	O
colorectal	O
tumorigenesis	O
.	O
	
however	O
,	O
these	O
patients	O
develop	O
colorectal	B-Disease
tumors	I-Disease
more	O
frequently	O
than	O
does	O
the	O
general	O
population	O
because	O
apc	O
(	O
as9	O
)	O
is	O
inactivated	O
by	O
mutations	O
that	O
do	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
apc	O
.	O
	
iron	O
-	O
dependent	O
self	O
-	O
assembly	O
of	O
recombinant	O
yeast	O
frataxin	O
:	O
implications	O
for	O
friedreich	B-Disease
ataxia	I-Disease
.	O
	
frataxin	B-Disease
deficiency	I-Disease
is	O
the	O
primary	O
cause	O
of	O
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
cardiodegenerative	I-Disease
and	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
.	O
	
genetic	O
inactivation	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
(	O
yfh1p	O
)	O
results	O
in	O
mitochondrial	B-Disease
iron	I-Disease
accumulation	I-Disease
and	O
hypersensitivity	B-Disease
to	I-Disease
oxidative	I-Disease
stress	I-Disease
.	O
	
increased	O
iron	O
deposition	O
and	O
evidence	O
of	O
oxidative	O
damage	O
have	O
also	O
been	O
observed	O
in	O
cardiac	O
tissue	O
and	O
cultured	O
fibroblasts	O
from	O
patients	O
with	O
frda	B-Disease
.	O
	
a	O
mutation	O
in	O
the	O
pleckstrin	O
homology	O
(	O
ph	O
)	O
domain	O
of	O
the	O
fgd1	O
gene	O
in	O
an	O
italian	O
family	O
with	O
faciogenital	B-Disease
dysplasia	I-Disease
(	O
aarskog	B-Disease
-	I-Disease
scott	I-Disease
syndrome	I-Disease
)	O
.	O
	
aarskog	B-Disease
-	I-Disease
scott	I-Disease
syndrome	I-Disease
(	O
aas	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
characterised	O
by	O
short	B-Disease
stature	I-Disease
and	O
multiple	O
facial	B-Disease
,	I-Disease
limb	I-Disease
and	I-Disease
genital	I-Disease
abnormalities	I-Disease
.	O
	
a	O
gene	O
,	O
fgd1	O
,	O
altered	O
in	O
a	O
patient	O
with	O
aas	B-Disease
phenotype	O
,	O
has	O
been	O
identified	O
and	O
found	O
to	O
encode	O
a	O
protein	O
with	O
homology	O
to	O
rho	O
/	O
rac	O
guanine	O
nucleotide	O
exchange	O
factors	O
(	O
rho	O
/	O
rac	O
gef	O
)	O
.	O
	
however	O
,	O
since	O
this	O
original	O
report	O
on	O
identification	O
of	O
a	O
mutated	O
fgd1	O
gene	O
in	O
an	O
aas	B-Disease
patient	O
,	O
no	O
additional	O
mutations	O
in	O
the	O
fgd1	O
gene	O
have	O
been	O
described	O
.	O
	
we	O
analysed	O
13	O
independent	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
aas	B-Disease
.	O
	
the	O
mutation	O
was	O
found	O
to	O
segregate	O
with	O
the	O
aas	B-Disease
phenotype	O
in	O
affected	O
males	O
and	O
carrier	O
females	O
in	O
the	O
family	O
of	O
this	O
patient	O
.	O
	
the	O
same	O
residue	O
is	O
often	O
mutated	O
in	O
the	O
brutons	O
tyrosine	O
kinase	O
(	O
btk	O
)	O
gene	O
in	O
patients	O
with	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
agammaglobulinemia	I-Disease
.	O
	
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
is	O
caused	O
by	O
expansion	O
of	O
a	O
glutamine	O
repeat	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
huntingtin	O
.	O
	
here	O
we	O
report	O
that	O
,	O
in	O
mutant	O
mice	O
expressing	O
hd	B-Disease
repeats	O
,	O
the	O
production	O
and	O
aggregation	O
of	O
n	O
-	O
terminal	O
huntingtin	O
fragments	O
preferentially	O
occur	O
in	O
hd	B-Disease
-	O
affected	O
neurons	O
and	O
their	O
processes	O
and	O
axonal	O
terminals	O
.	O
	
n	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
form	O
aggregates	O
and	O
induce	O
neuritic	B-Disease
degeneration	I-Disease
in	O
cultured	O
striatal	O
neurons	O
.	O
	
the	O
specific	O
processing	O
and	O
accumulation	O
of	O
toxic	O
fragments	O
of	O
n	O
-	O
terminal	O
huntingtin	O
in	O
hd	B-Disease
-	O
affected	O
striatal	O
neurons	O
,	O
especially	O
in	O
their	O
neuronal	O
processes	O
and	O
axonal	O
terminals	O
,	O
may	O
contribute	O
to	O
the	O
selective	O
neuropathology	O
of	O
hd	B-Disease
.	O
	
brca1	O
is	O
associated	O
with	O
a	O
human	O
swi	O
/	O
snf	O
-	O
related	O
complex	O
:	O
linking	O
chromatin	O
remodeling	O
to	O
breast	B-Disease
cancer	I-Disease
.	O
	
germline	O
mutations	O
in	O
the	O
tumor	B-Disease
suppressor	O
gene	O
,	O
brca1	O
,	O
predispose	O
individuals	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
moreover	O
,	O
p53	O
-	O
mediated	O
stimulation	O
of	O
transcription	O
by	O
brca1	O
was	O
completely	O
abrogated	O
by	O
either	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
brg1	O
or	O
the	O
cancer	B-Disease
-	O
causing	O
deletion	O
in	O
exon	O
11	O
of	O
brca1	O
.	O
	
asef	O
,	O
a	O
link	O
between	O
the	O
tumor	B-Disease
suppressor	O
apc	O
and	O
g	O
-	O
protein	O
signaling	O
.	O
	
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
gene	O
(	O
apc	O
)	O
is	O
mutated	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
and	O
in	O
sporadic	O
colorectal	B-Disease
tumors	I-Disease
.	O
	
here	O
the	O
apc	B-Disease
gene	O
product	O
is	O
shown	O
to	O
bind	O
through	O
its	O
armadillo	O
repeat	O
domain	O
to	O
a	O
rac	O
-	O
specific	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	O
gef	O
)	O
,	O
termed	O
asef	O
.	O
	
the	O
axonal	O
chemoattractant	O
netrin	O
-	O
1	O
guides	O
spinal	O
commissural	O
axons	O
by	O
activating	O
its	O
receptor	O
dcc	O
(	O
deleted	O
in	O
colorectal	B-Disease
cancer	I-Disease
)	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
cug	O
repeat	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
,	O
the	O
most	O
common	O
form	O
of	O
muscular	B-Disease
dystrophy	I-Disease
in	O
adult	O
humans	O
,	O
results	O
from	O
expansion	O
of	O
a	O
ctg	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
dmpk	O
gene	O
.	O
	
mice	O
that	O
expressed	O
expanded	O
cug	O
repeats	O
developed	O
myotonia	B-Disease
and	O
myopathy	B-Disease
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not	O
.	O
	
thus	O
,	O
transcripts	O
with	O
expanded	O
cug	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
dm	B-Disease
phenotype	O
.	O
	
genomic	O
rearrangements	O
of	O
the	O
apc	B-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O
	
germline	O
mutations	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
apc	I-Disease
)	I-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
result	O
in	O
the	O
hereditary	B-Disease
colorectal	I-Disease
cancer	I-Disease
syndrome	I-Disease
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
.	O
	
almost	O
all	O
apc	B-Disease
mutations	O
that	O
have	O
been	O
identified	O
are	O
single	O
-	O
nucleotide	O
alterations	O
,	O
small	O
insertions	O
,	O
or	O
small	O
deletions	O
that	O
would	O
truncate	O
the	O
protein	O
product	O
of	O
the	O
gene	O
.	O
	
no	O
well	O
-	O
characterized	O
intragenic	O
rearrangement	O
of	O
apc	O
has	O
been	O
described	O
,	O
and	O
the	O
prevalence	O
of	O
this	O
type	O
of	O
mutation	O
in	O
fap	B-Disease
patients	O
is	O
not	O
clear	O
.	O
	
we	O
screened	O
49	O
potential	O
fap	B-Disease
families	O
and	O
identified	O
26	O
different	O
germline	O
apc	B-Disease
mutations	O
in	O
30	O
families	O
.	O
	
the	O
identification	O
of	O
four	O
genomic	O
rearrangements	O
among	O
30	O
mutations	O
suggests	O
that	O
genomic	O
rearrangements	O
are	O
frequent	O
germline	O
apc	B-Disease
mutations	O
.	O
	
detection	O
of	O
a	O
novel	O
missense	O
mutation	O
and	O
second	O
recurrent	O
mutation	O
in	O
the	O
cacna1a	O
gene	O
in	O
individuals	O
with	O
ea	B-Disease
-	I-Disease
2	I-Disease
and	O
fhm	B-Disease
.	O
	
mutations	O
in	O
the	O
brain	O
specific	O
p	O
/	O
q	O
type	O
ca2	O
+	O
channel	O
alpha1	O
subunit	O
gene	O
,	O
cacna1a	O
,	O
have	O
been	O
identified	O
in	O
three	O
clinically	O
distinct	O
disorders	O
,	O
viz	O
.	O
	
episodic	B-Disease
ataxia	I-Disease
type	I-Disease
2	I-Disease
(	O
ea	B-Disease
-	I-Disease
2	I-Disease
)	O
,	O
familial	B-Disease
hemiplegic	I-Disease
migraine	I-Disease
(	O
fhm	B-Disease
)	O
and	O
spinocerebellar	B-Disease
ataxia	I-Disease
6	I-Disease
(	O
sca6	B-Disease
)	O
.	O
	
for	O
individuals	O
with	O
ea	B-Disease
-	I-Disease
2	I-Disease
,	O
the	O
mutations	O
described	O
thus	O
far	O
are	O
presumed	O
to	O
result	O
in	O
a	O
truncated	O
protein	O
product	O
.	O
	
several	O
different	O
missense	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
fhm	B-Disease
.	O
	
we	O
have	O
characterised	O
a	O
novel	O
missense	O
mutation	O
,	O
g5260a	O
,	O
in	O
exon	O
32	O
in	O
a	O
family	O
segregating	O
for	O
ea	B-Disease
-	I-Disease
2	I-Disease
.	O
	
furthermore	O
,	O
this	O
mutation	O
has	O
been	O
detected	O
in	O
a	O
family	O
member	O
with	O
mild	O
clinical	O
signs	O
including	O
only	O
migraine	B-Disease
.	O
	
additionally	O
,	O
a	O
second	O
previously	O
identified	O
recurrent	O
muta	O
tion	O
,	O
c2272t	O
,	O
in	O
exon	O
16	O
has	O
been	O
discovered	O
in	O
a	O
patient	O
with	O
fhm	B-Disease
.	O
	
analbuminemia	B-Disease
in	O
a	O
neonate	O
.	O
	
a	O
small	O
-	O
for	O
-	O
gestational	O
-	O
age	O
infant	O
,	O
found	O
to	O
have	O
analbuminemia	B-Disease
in	O
the	O
neonatal	O
period	O
,	O
is	O
reported	O
and	O
the	O
twelve	O
cases	O
recorded	O
in	O
the	O
world	O
literature	O
are	O
reviewed	O
.	O
	
patients	O
lacking	O
this	O
serum	O
protein	O
are	O
essentially	O
asymptomatic	O
,	O
apart	O
from	O
minimal	O
ankle	B-Disease
edema	I-Disease
and	O
ease	B-Disease
of	I-Disease
fatigue	I-Disease
.	O
	
apparent	O
compensatory	O
mechanisms	O
which	O
come	O
into	O
play	O
when	O
serum	O
albumin	O
is	O
low	O
include	O
prolonged	O
half	O
-	O
life	O
of	O
albumin	O
and	O
transferrin	O
,	O
an	O
increase	O
in	O
serum	O
globulins	O
,	O
beta	O
lipoprotein	O
,	O
and	O
glycoproteins	O
,	O
arterial	B-Disease
hypotension	I-Disease
with	O
reduced	O
capillary	O
hydrostatic	O
pressure	O
,	O
and	O
the	O
ability	O
to	O
respond	O
with	O
rapid	O
sodium	O
and	O
chloride	O
diuresis	O
in	O
response	O
to	O
small	O
volume	O
changes	O
.	O
	
histidinemia	B-Disease
.	O
	
two	O
brothers	O
,	O
6	O
and	O
13	O
years	O
old	O
,	O
had	O
histidinemia	B-Disease
.	O
	
carrier	O
detection	O
of	O
pyruvate	B-Disease
carboxylase	I-Disease
deficiency	I-Disease
in	O
fibroblasts	O
and	O
lymphocytes	O
.	O
	
pyruvate	O
carboxylase	O
activity	O
was	O
determined	O
in	O
the	O
circulating	O
peripheral	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
family	O
of	O
a	O
patient	O
with	O
hepatic	O
,	O
cerebral	O
,	O
renal	O
cortical	O
,	O
leukocyte	O
,	O
and	O
fibroblast	O
pyruvate	B-Disease
carboxylase	I-Disease
deficiency	I-Disease
(	O
pc	B-Disease
portland	I-Disease
deficiency	I-Disease
)	O
.	O
	
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
from	O
italian	O
subjects	O
associated	O
with	O
severe	B-Disease
neonatal	I-Disease
jaundice	I-Disease
.	O
	
screening	O
for	O
the	O
g6pd	B-Disease
deficiency	I-Disease
was	O
carried	O
out	O
at	O
the	O
maternity	O
division	O
of	O
the	O
galliera	O
hospital	O
in	O
genoa	O
,	O
italy	O
.	O
	
two	O
groups	O
of	O
subjects	O
with	O
hyperbilirubinaemia	B-Disease
of	O
non	O
-	O
immunological	O
origin	O
were	O
examined	O
(	O
a	O
)	O
302	O
newborn	O
babies	O
of	O
sardinian	O
extraction	O
(	O
on	O
cord	O
blood	O
)	O
and	O
(	O
b	O
)	O
201	O
newborn	O
babies	O
of	O
south	O
italian	O
ancestry	O
(	O
on	O
peripheral	O
blood	O
)	O
.	O
	
in	O
the	O
present	O
work	O
these	O
three	O
cases	O
,	O
each	O
with	O
severe	B-Disease
neonatal	I-Disease
jaundice	I-Disease
,	O
are	O
reported	O
.	O
	
cytogenetic	O
investigations	O
in	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
chromosomal	O
studies	O
were	O
performed	O
on	O
peripheral	O
blood	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
five	O
israeli	O
-	O
moroccan	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
prenatal	O
diagnosis	O
of	O
wolman	B-Disease
disease	I-Disease
.	O
	
two	O
pregnancies	O
at	O
risk	O
for	O
wolman	B-Disease
disease	I-Disease
were	O
monitored	O
by	O
assay	O
and	O
electrophoresis	O
of	O
acid	O
lipase	O
in	O
cultured	O
amniotic	O
-	O
fluid	O
cells	O
.	O
	
electrophoresis	O
of	O
cell	O
extracts	O
revealed	O
the	O
absence	O
of	O
the	O
a	O
form	O
of	O
acid	O
lipase	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
wolman	B-Disease
disease	I-Disease
.	O
	
the	O
results	O
suggest	O
that	O
the	O
prenatal	O
diagnosis	O
of	O
wolman	B-Disease
disease	I-Disease
be	O
made	O
using	O
the	O
radioassay	O
of	O
acid	O
lipase	O
and	O
/	O
or	O
electrophoresis	O
.	O
	
malignant	B-Disease
neoplasms	I-Disease
in	O
the	O
families	O
of	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
associated	O
with	O
a	O
greatly	O
increased	O
incidence	O
of	O
malignant	B-Disease
neoplasms	I-Disease
in	O
homozygous	O
affected	O
individuals	O
.	O
	
heterozygotes	O
for	O
the	O
gene	O
for	O
a	B-Disease
-	I-Disease
t	I-Disease
are	O
thought	O
to	O
comprise	O
about	O
1	O
%	O
of	O
the	O
general	O
population	O
and	O
,	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	O
also	O
predisposes	O
the	O
heterozygous	O
carrier	O
to	O
cancers	B-Disease
.	O
	
heterozygous	O
carriers	O
of	O
this	O
gene	O
are	O
common	O
among	O
the	O
close	O
relatives	O
of	O
patients	O
with	O
a	B-Disease
-	I-Disease
t	I-Disease
,	O
although	O
individual	O
carriers	O
cannot	O
be	O
identified	O
by	O
any	O
clinical	O
criterion	O
or	O
laboratory	O
test	O
.	O
	
for	O
this	O
reason	O
,	O
we	O
compared	O
the	O
incidence	O
of	O
death	O
from	O
malignant	B-Disease
neoplasms	I-Disease
in	O
2	O
families	O
of	O
patients	O
with	O
a	B-Disease
-	I-Disease
t	I-Disease
to	O
that	O
expected	O
in	O
a	O
random	O
sample	O
of	O
the	O
general	O
population	O
.	O
	
there	O
were	O
59	O
deaths	O
from	O
malignant	B-Disease
neoplasms	I-Disease
in	O
relatives	O
dying	O
before	O
age	O
75	O
,	O
compared	O
to	O
42	O
.	O
	
for	O
a	B-Disease
-	I-Disease
t	I-Disease
heterozygotes	O
younger	O
than	O
age	O
45	O
,	O
the	O
risk	O
of	O
dying	O
from	O
a	O
malignant	B-Disease
neoplasm	I-Disease
was	O
estimated	O
to	O
be	O
greater	O
than	O
5	O
times	O
the	O
risk	O
for	O
the	O
general	O
population	O
.	O
	
a	B-Disease
-	I-Disease
t	I-Disease
heterozygotes	O
may	O
comprise	O
more	O
than	O
5	O
%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	B-Disease
before	O
age	O
45	O
.	O
	
the	O
incidence	O
of	O
ovarian	B-Disease
,	I-Disease
gastric	I-Disease
,	I-Disease
and	I-Disease
biliary	I-Disease
system	I-Disease
carcinomas	I-Disease
and	O
of	O
leukemia	B-Disease
and	O
lymphoma	B-Disease
was	O
increased	O
in	O
these	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
.	O
	
other	O
neoplasms	B-Disease
that	O
may	O
be	O
associated	O
with	O
this	O
gene	O
in	O
heterozygotes	O
include	O
pancreatic	B-Disease
,	I-Disease
basal	I-Disease
cell	I-Disease
,	I-Disease
colonic	I-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
and	I-Disease
cervical	I-Disease
carcinomas	I-Disease
.	O
	
striking	O
prevalence	O
of	O
ankylosing	B-Disease
spondylitis	I-Disease
in	O
healthy	O
w27	O
positive	O
males	O
and	O
females	O
.	O
	
ankylosing	B-Disease
spondylitis	I-Disease
is	O
diagnosed	O
once	O
or	O
twice	O
in	O
each	O
1000	O
males	O
and	O
one	O
tenth	O
as	O
frequently	O
in	O
females	O
,	O
but	O
the	O
TRUE	O
prevalence	O
is	O
unknown	O
.	O
	
evaluation	O
by	O
postal	O
questionnaires	O
,	O
and	O
pelvic	O
radiography	O
of	O
78	O
hl	O
-	O
a	O
27w	O
-	O
positive	O
blood	O
donors	O
selected	O
from	O
a	O
group	O
of	O
apparently	O
healthy	O
subjects	O
revealed	O
14	O
who	O
satisfied	O
the	O
criteria	O
for	O
definite	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O
	
for	O
a	O
person	O
of	O
either	O
sex	O
with	O
hl	O
-	O
a	O
w27	O
,	O
there	O
appears	O
to	O
be	O
about	O
a	O
20	O
per	O
cent	O
chance	O
that	O
ankylosing	B-Disease
spondylitis	I-Disease
will	O
develop	O
,	O
suggesting	O
a	O
prevalence	O
of	O
10	O
to	O
15	O
per	O
thousand	O
.	O
	
analbuminemia	B-Disease
in	O
an	O
american	O
indian	O
girl	O
.	O
	
analbuminemia	B-Disease
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12	O
-	O
year	O
-	O
old	O
american	O
indian	O
girl	O
with	O
atopic	B-Disease
dermatitis	I-Disease
,	O
mild	O
bronchial	B-Disease
asthma	I-Disease
,	O
a	O
mild	O
seizure	B-Disease
disorder	I-Disease
,	O
and	O
hyperlipoproteinemia	B-Disease
with	O
a	O
corneal	B-Disease
arcus	I-Disease
.	O
	
the	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	B-Disease
.	O
	
gc	O
-	O
protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	B-Disease
.	O
	
gc	O
-	O
types	O
in	O
the	O
family	O
were	O
compatible	O
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	O
of	O
analbuminemia	B-Disease
to	O
the	O
gc	O
-	O
locus	O
.	O
	
these	O
findings	O
suggest	O
a	O
thalassemia	B-Disease
-	O
like	O
mutation	O
for	O
this	O
disorder	O
.	O
	
.	O
	
deletion	O
of	O
the	O
kit	O
and	O
pdgfra	O
genes	O
in	O
a	O
patient	O
with	O
piebaldism	B-Disease
.	O
	
we	O
have	O
previously	O
shown	O
that	O
human	O
piebaldism	B-Disease
results	O
from	O
mutations	O
of	O
the	O
kit	O
gene	O
,	O
which	O
encodes	O
the	O
receptor	O
for	O
the	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
and	O
is	O
located	O
in	O
chromosome	O
segment	O
4q12	O
.	O
	
using	O
dna	O
of	O
a	O
patient	O
with	O
piebaldism	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
multiple	B-Disease
congenital	I-Disease
anomalies	I-Disease
associated	O
with	O
a	O
46	O
,	O
xy	O
,	O
del	O
(	O
4	O
)	O
(	O
q12q21	O
.	O
	
1	O
)	O
karyotype	O
,	O
we	O
carried	O
out	O
quantitative	O
southern	O
blot	O
hybridization	O
analyses	O
of	O
the	O
kit	O
gene	O
and	O
the	O
adjacent	O
pdgfra	O
(	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
alpha	O
subunit	O
)	O
genes	O
.	O
	
therefore	O
,	O
deletion	O
of	O
the	O
kit	O
and	O
pdgfra	O
genes	O
may	O
account	O
for	O
the	O
piebald	B-Disease
phenotype	O
in	O
this	O
patient	O
.	O
	
a	O
germ	O
line	O
mutation	O
within	O
the	O
coding	O
sequence	O
for	O
the	O
putative	O
5	O
-	O
phosphoribosyl	O
-	O
1	O
-	O
pyrophosphate	O
binding	O
site	O
of	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
hprt	O
)	O
in	O
a	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
patient	O
:	O
missense	O
mutations	O
within	O
a	O
functionally	O
important	O
region	O
probably	O
cause	O
disease	O
.	O
	
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
caused	O
by	O
a	O
complete	B-Disease
deficiency	I-Disease
of	I-Disease
hypoxanthine	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
(	O
hprt	O
)	O
is	O
the	O
result	O
of	O
a	O
heterogeneous	O
group	O
of	O
germ	O
line	O
mutations	O
.	O
	
we	O
report	O
here	O
a	O
newly	O
identified	O
hprt	O
mutation	O
in	O
a	O
japanese	O
patient	O
with	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
missense	O
mutations	O
in	O
human	O
hprt	B-Disease
deficient	I-Disease
patients	O
thus	O
far	O
reported	O
tend	O
to	O
accumulate	O
in	O
this	O
functionally	O
active	O
region	O
.	O
	
characterisation	O
of	O
a	O
new	O
rare	O
fragile	O
site	O
easily	O
confused	O
with	O
the	O
fragile	B-Disease
x	I-Disease
.	O
	
the	O
fragile	O
site	O
is	O
not	O
associated	O
with	O
mental	B-Disease
retardation	I-Disease
,	O
it	O
does	O
not	O
give	O
abnormal	O
results	O
when	O
subjected	O
to	O
southern	O
analysis	O
with	O
probe	O
pfxa3	O
which	O
detects	O
the	O
unstable	O
dna	O
sequence	O
characteristic	O
of	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
.	O
	
the	O
distinction	O
between	O
the	O
two	O
fragile	O
sites	O
is	O
important	O
clinically	O
since	O
cytogenetic	O
detection	O
of	O
fraxe	O
,	O
without	O
molecular	O
analysis	O
,	O
could	O
result	O
in	O
misdiagnosis	O
of	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
.	O
	
the	O
norrie	B-Disease
disease	I-Disease
gene	O
maps	O
to	O
a	O
150	O
kb	O
region	O
on	O
chromosome	O
xp11	O
.	O
	
norrie	B-Disease
disease	I-Disease
is	O
a	O
human	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disorder	I-Disease
of	O
unknown	O
etiology	O
characterized	O
by	O
congenital	B-Disease
blindness	I-Disease
,	O
sensory	B-Disease
neural	I-Disease
deafness	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
.	O
	
we	O
report	O
here	O
fine	O
physical	O
mapping	O
of	O
the	O
obligate	O
region	O
containing	O
the	O
norrie	B-Disease
disease	I-Disease
gene	O
(	O
ndp	O
)	O
defined	O
by	O
a	O
recombination	O
and	O
by	O
the	O
smallest	O
submicroscopic	O
chromosomal	O
deletion	O
associated	O
with	O
norrie	B-Disease
disease	I-Disease
identified	O
to	O
date	O
.	O
	
molecular	O
basis	O
of	O
phenylketonuria	B-Disease
and	O
related	O
hyperphenylalaninemias	B-Disease
:	O
mutations	O
and	O
polymorphisms	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
.	O
	
mutations	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
producing	O
phenylketonuria	B-Disease
or	O
hyperphenylalaninemia	B-Disease
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O
	
a	O
glycine250	O
-	O
-	O
>	O
aspartate	O
substitution	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
hexosaminidase	O
a	O
causes	O
juvenile	O
-	O
onset	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
in	O
a	O
lebanese	O
-	O
canadian	O
family	O
.	O
	
the	O
mutation	O
causing	O
juvenile	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
in	O
two	O
sibs	O
of	O
lebanese	O
-	O
maronite	O
origin	O
is	O
described	O
.	O
	
the	O
predicted	O
protein	O
environment	O
in	O
which	O
the	O
mutation	O
occurs	O
is	O
compared	O
to	O
that	O
of	O
the	O
adult	O
-	O
onset	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
mutation	O
caused	O
by	O
a	O
gly269	O
-	O
-	O
>	O
ser	O
substitution	O
in	O
exon	O
7	O
.	O
	
novel	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
mutations	O
from	O
china	O
.	O
	
we	O
describe	O
three	O
hexa	O
mutations	O
associated	O
with	O
infantile	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
in	O
three	O
unrelated	O
nonconsanguineous	O
chinese	O
families	O
.	O
	
it	O
has	O
been	O
reported	O
in	O
an	O
italian	O
tsd	B-Disease
proband	O
and	O
causes	O
defective	O
intracellular	O
transport	O
of	O
the	O
alpha	O
-	O
subunit	O
from	O
the	O
rough	O
endoplasmic	O
reticulum	O
to	O
the	O
golgi	O
apparatus	O
.	O
	
two	O
missense	O
mutations	O
causing	O
mild	O
hyperphenylalaninemia	B-Disease
associated	O
with	O
dna	O
haplotype	O
12	O
.	O
	
the	O
genetic	B-Disease
defects	I-Disease
responsible	O
for	O
most	O
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
and	O
hyperphenylalaninemia	B-Disease
(	O
hpa	B-Disease
)	O
cases	O
are	O
located	O
in	O
the	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
gene	O
.	O
	
we	O
hypothesized	O
that	O
there	O
is	O
at	O
least	O
one	O
mild	O
mutation	O
linked	O
to	O
haplotype	O
12	O
in	O
the	O
swedish	O
pku	B-Disease
/	O
hpa	B-Disease
population	O
,	O
since	O
7	O
of	O
8	O
patients	O
carrying	O
haplotype	O
12	O
had	O
mild	O
hpa	B-Disease
.	O
	
mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
locus	O
are	O
the	O
major	O
cause	O
of	O
hyperphenylalaninemia	B-Disease
.	O
	
here	O
we	O
report	O
(	O
1	O
)	O
identification	O
of	O
another	O
mutation	O
,	O
on	O
a	O
haplotype	O
9	O
chromosome	O
,	O
which	O
converts	O
codon	O
65	O
from	O
isoleucine	O
(	O
att	O
)	O
to	O
threonine	O
(	O
act	O
)	O
,	O
(	O
2	O
)	O
expression	O
analysis	O
of	O
the	O
i65t	O
mutation	O
in	O
cos	O
cells	O
demonstrating	O
75	O
%	O
loss	O
of	O
both	O
immunoreactive	O
protein	O
and	O
enzyme	O
activity	O
,	O
and	O
(	O
3	O
)	O
expression	O
analysis	O
of	O
the	O
most	O
prevalent	O
pku	B-Disease
allele	O
(	O
m1v	O
)	O
in	O
eastern	O
quebec	O
,	O
showing	O
nondetectable	O
levels	O
of	O
pah	O
protein	O
and	O
activity	O
,	O
a	O
finding	O
compatible	O
with	O
a	O
mutation	O
in	O
the	O
translation	O
initiation	O
codon	O
.	O
	
homozygosity	O
for	O
m1v	O
and	O
codominant	O
inheritance	O
of	O
i65t	O
/	O
r408w	O
were	O
both	O
associated	O
with	O
classical	B-Disease
phenylketonuria	I-Disease
.	O
	
molecular	O
basis	O
of	O
hexosaminidase	B-Disease
a	I-Disease
deficiency	I-Disease
and	O
pseudodeficiency	O
in	O
the	O
berks	O
county	O
pennsylvania	O
dutch	O
.	O
	
following	O
the	O
birth	O
of	O
two	O
infants	O
with	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
,	O
a	O
non	O
-	O
jewish	O
,	O
pennsylvania	O
dutch	O
kindred	O
was	O
screened	O
for	O
tsd	B-Disease
carriers	O
using	O
the	O
biochemical	O
assay	O
.	O
	
a	O
high	O
frequency	O
of	O
individuals	O
who	O
appeared	O
to	O
be	O
tsd	B-Disease
heterozygotes	O
was	O
detected	O
(	O
kelly	O
et	O
al	O
.	O
	
one	O
allele	O
,	O
reported	O
originally	O
in	O
a	O
french	O
tsd	B-Disease
patient	O
(	O
akli	O
et	O
al	O
.	O
	
,	O
1991	O
)	O
,	O
is	O
a	O
gt	O
-	O
-	O
>	O
at	O
transition	O
at	O
the	O
donor	O
splice	O
-	O
site	O
of	O
intron	O
9	O
.	O
	
a	O
mutation	O
common	O
in	O
non	O
-	O
jewish	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
:	O
frequency	O
and	O
rna	O
studies	O
.	O
	
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
resulting	O
from	O
mutation	O
of	O
the	O
hexa	O
gene	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
n	O
-	O
acetylhexosaminidase	O
a	O
(	O
hex	O
a	O
)	O
.	O
	
we	O
have	O
discovered	O
that	O
a	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
mutation	O
,	O
ivs	O
-	O
9	O
+	O
1	O
g	O
-	O
-	O
>	O
a	O
,	O
first	O
detected	O
by	O
akli	O
et	O
al	O
.	O
	
it	O
was	O
not	O
identified	O
among	O
12	O
black	O
american	O
tsd	B-Disease
alleles	O
or	O
in	O
any	O
of	O
18	O
ashkenazi	O
jewish	O
,	O
enzyme	O
-	O
defined	O
carriers	O
who	O
did	O
not	O
carry	O
any	O
of	O
the	O
mutations	O
common	O
to	O
this	O
population	O
.	O
	
together	O
with	O
a	O
recently	O
identified	O
allele	O
responsible	O
for	O
hex	O
a	O
pseudodeficiency	O
(	O
triggs	O
-	O
raine	O
et	O
al	O
.	O
	
am	O
j	O
hum	O
genet	O
,	O
1992	O
)	O
,	O
these	O
two	O
alleles	O
accounted	O
for	O
almost	O
50	O
%	O
(	O
29	O
/	O
64	O
)	O
of	O
tsd	B-Disease
or	O
carrier	O
alleles	O
ascertained	O
by	O
enzyme	O
screening	O
tests	O
in	O
non	O
-	O
jewish	O
caucasians	O
.	O
	
aberrant	O
splicing	O
of	O
the	O
chm	B-Disease
gene	O
is	O
a	O
significant	O
cause	O
of	O
choroideremia	B-Disease
.	O
	
choroideremia	B-Disease
(	O
chm	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
progressive	I-Disease
degeneration	I-Disease
of	I-Disease
the	I-Disease
choroid	I-Disease
and	I-Disease
retina	I-Disease
.	O
	
12	O
%	O
of	O
unrelated	O
male	O
patients	O
carry	O
deletions	O
of	O
the	O
partially	O
cloned	O
chm	B-Disease
gene	O
.	O
	
in	O
finland	O
,	O
there	O
are	O
more	O
than	O
120	O
living	O
chm	B-Disease
patients	O
belonging	O
to	O
eight	O
apparently	O
unrelated	O
pedigrees	O
.	O
	
molecular	O
deletions	O
involving	O
the	O
chm	B-Disease
gene	O
have	O
been	O
detected	O
in	O
three	O
families	O
.	O
	
our	O
findings	O
provide	O
additional	O
evidence	O
for	O
the	O
pathogenetic	O
role	O
of	O
chm	B-Disease
mutations	O
and	O
provide	O
a	O
diagnostic	O
tool	O
for	O
one	O
fifth	O
of	O
the	O
worlds	O
known	O
chm	B-Disease
patients	O
.	O
	
germline	O
intronic	O
and	O
exonic	O
mutations	O
in	O
the	O
wilms	B-Disease
'	I-Disease
tumour	I-Disease
gene	O
(	O
wt1	O
)	O
affecting	O
urogenital	O
development	O
.	O
	
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
human	O
developmental	B-Disease
disorder	I-Disease
affecting	O
the	O
urogenital	O
system	O
and	O
leading	O
to	O
renal	B-Disease
failure	I-Disease
,	O
intersex	B-Disease
disorders	I-Disease
and	O
wilms	B-Disease
tumour	I-Disease
.	O
	
in	O
this	O
report	O
,	O
four	O
individuals	O
with	O
this	O
syndrome	O
are	O
described	O
carrying	O
germline	O
point	O
mutations	O
in	O
the	O
wilms	B-Disease
tumour	I-Disease
suppressor	O
gene	O
,	O
wt1	O
.	O
	
characterization	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
region	O
predicts	O
multiple	O
protein	O
isoform	O
-	O
encoding	O
mrnas	O
.	O
	
the	O
mutation	O
underlying	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
has	O
been	O
identified	O
as	O
an	O
expansion	O
of	O
a	O
polymorphic	O
ctg	O
-	O
repeat	O
in	O
a	O
gene	O
encoding	O
protein	O
kinase	O
activity	O
.	O
	
characterization	O
of	O
the	O
dm	B-Disease
region	O
of	O
both	O
species	O
reveals	O
another	O
active	O
gene	O
(	O
dmr	O
-	O
n9	O
)	O
in	O
close	O
proximity	O
to	O
the	O
kinase	O
gene	O
.	O
	
clinical	O
manifestation	O
of	O
dm	B-Disease
may	O
be	O
caused	O
by	O
the	O
expanded	O
ctg	O
-	O
repeat	O
compromising	O
the	O
(	O
alternative	O
)	O
expression	O
of	O
dm	O
-	O
kinase	O
or	O
dmr	O
-	O
n9	O
proteins	O
.	O
	
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
without	O
ccg	O
amplification	O
has	O
an	O
fmr1	O
deletion	O
.	O
	
we	O
describe	O
a	O
patient	O
with	O
typical	O
clinical	O
features	O
of	O
the	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
but	O
without	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B-Disease
x	I-Disease
or	O
an	O
amplified	O
ccg	O
trinucleotide	O
repeat	O
fragment	O
.	O
	
this	O
finding	O
confirms	O
that	O
the	O
fragile	B-Disease
x	I-Disease
phenotype	O
can	O
exist	O
,	O
without	O
amplification	O
of	O
the	O
ccg	O
repeat	O
or	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B-Disease
x	I-Disease
,	O
and	O
that	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
is	O
a	O
genetically	O
homogeneous	O
disorder	O
involving	O
fmr1	O
.	O
	
cloning	O
of	O
the	O
huntington	B-Disease
disease	I-Disease
region	O
in	O
yeast	O
artificial	O
chromosomes	O
.	O
	
the	O
gene	O
responsible	O
for	O
huntington	B-Disease
disease	I-Disease
has	O
been	O
localized	O
to	O
a	O
2	O
.	O
	
as	O
part	O
of	O
a	O
strategy	O
to	O
clone	O
the	O
hd	B-Disease
gene	O
on	O
the	O
basis	O
of	O
its	O
chromosomal	O
location	O
,	O
we	O
isolated	O
genomic	O
dna	O
from	O
the	O
hd	B-Disease
region	O
as	O
a	O
set	O
of	O
overlapping	O
yeast	O
artificial	O
chromosome	O
(	O
yac	O
)	O
clones	O
.	O
	
we	O
assembled	O
the	O
yac	O
clones	O
into	O
overlapping	O
sets	O
by	O
hybridizing	O
them	O
to	O
a	O
large	O
number	O
of	O
dna	O
probes	O
from	O
the	O
hd	B-Disease
region	O
,	O
including	O
the	O
stss	O
.	O
	
2	O
mb	O
of	O
the	O
hd	B-Disease
region	O
in	O
yacs	O
,	O
including	O
one	O
continuous	O
segment	O
of	O
2	O
.	O
	
0	O
mb	O
covering	O
the	O
region	O
that	O
most	O
likely	O
contains	O
the	O
hd	B-Disease
gene	O
.	O
	
these	O
clones	O
provide	O
reagents	O
for	O
the	O
complete	O
characterization	O
of	O
this	O
region	O
of	O
the	O
genome	O
and	O
for	O
the	O
eventual	O
isolation	O
of	O
the	O
hd	B-Disease
gene	O
.	O
	
characterization	O
of	O
a	O
yac	O
containing	O
part	O
or	O
all	O
of	O
the	O
norrie	B-Disease
disease	I-Disease
locus	O
.	O
	
a	O
series	O
of	O
subclones	O
prepared	O
from	O
a	O
phage	O
library	O
(	O
lambda	O
dash	O
ii	O
)	O
of	O
the	O
yac	O
have	O
been	O
characterised	O
and	O
have	O
been	O
employed	O
to	O
determine	O
the	O
end	O
point	O
of	O
the	O
deletion	O
of	O
a	O
norrie	B-Disease
disease	I-Disease
(	O
ndp	B-Disease
)	O
patient	O
who	O
has	O
been	O
shown	O
to	O
lack	O
both	O
dxs7	O
and	O
mao	O
coding	O
sequences	O
.	O
	
both	O
mutations	O
in	O
g6pd	O
a	O
-	O
are	O
necessary	O
to	O
produce	O
the	O
g6pd	B-Disease
deficient	I-Disease
phenotype	O
.	O
	
the	O
high	O
prevalence	O
of	O
glucose	B-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
african	O
populations	O
is	O
due	O
almost	O
entirely	O
to	O
the	O
enzyme	O
variant	O
a	O
-	O
,	O
which	O
differs	O
from	O
the	O
wild	O
-	O
type	O
g6pd	O
b	O
by	O
two	O
amino	O
acid	O
replacements	O
,	O
68	O
val	O
-	O
-	O
>	O
met	O
and	O
126	O
asn	O
-	O
-	O
>	O
asp	O
.	O
	
this	O
could	O
be	O
because	O
the	O
68	O
val	O
-	O
-	O
>	O
met	O
mutation	O
happened	O
to	O
arise	O
in	O
an	O
a	O
gene	O
in	O
the	O
first	O
instance	O
,	O
or	O
because	O
the	O
68	O
val	O
-	O
-	O
>	O
met	O
mutation	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
we	O
infer	O
that	O
the	O
coexistence	O
of	O
the	O
two	O
mutations	O
is	O
responsible	O
for	O
enzyme	B-Disease
deficiency	I-Disease
in	I-Disease
g6pd	I-Disease
a	O
-	O
because	O
they	O
act	O
synergistically	O
in	O
causing	O
instability	O
of	O
the	O
enzyme	O
.	O
	
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
snrpn	O
)	O
,	O
an	O
expressed	O
gene	O
in	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
critical	O
region	O
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
is	O
associated	O
with	O
paternally	O
derived	O
chromosomal	O
deletions	O
in	O
region	O
15q11	O
-	O
13	O
or	O
with	O
maternal	B-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
15	I-Disease
.	O
	
therefore	O
,	O
loss	O
of	O
the	O
expressed	O
paternal	O
alleles	O
of	O
maternally	O
imprinted	O
genes	O
must	O
be	O
responsible	O
for	O
the	O
pws	B-Disease
phenotype	O
.	O
	
furthermore	O
,	O
snrpn	O
was	O
mapped	O
to	O
the	O
minimal	O
deletion	O
interval	O
that	O
is	O
critical	O
for	O
pws	B-Disease
.	O
	
the	O
fact	O
that	O
the	O
mouse	O
snrpn	O
gene	O
is	O
maternally	O
imprinted	O
in	O
brain	O
suggests	O
that	O
loss	O
of	O
the	O
paternally	O
derived	O
snrpn	O
allele	O
may	O
be	O
involved	O
in	O
the	O
pws	B-Disease
phenotype	O
.	O
	
the	O
presence	O
of	O
two	O
different	O
infantile	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
mutations	O
in	O
a	O
cajun	O
population	O
.	O
	
a	O
study	O
was	O
undertaken	O
to	O
characterize	O
the	O
mutation	O
(	O
s	O
)	O
responsible	O
for	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
in	O
a	O
cajun	O
population	O
in	O
southwest	O
louisiana	O
and	O
to	O
identify	O
the	O
origins	O
of	O
these	O
mutations	O
.	O
	
eleven	O
of	O
12	O
infantile	O
tsd	B-Disease
alleles	O
examined	O
in	O
six	O
families	O
had	O
the	O
beta	O
-	O
hexosaminidase	O
a	O
(	O
hex	O
a	O
)	O
alpha	O
-	O
subunit	O
exon	O
11	O
insertion	O
mutation	O
that	O
is	O
present	O
in	O
approximately	O
70	O
%	O
of	O
ashkenazi	O
jewish	O
tsd	B-Disease
heterozygotes	O
.	O
	
to	O
determine	O
the	O
origins	O
of	O
these	O
two	O
mutations	O
in	O
the	O
cajun	O
population	O
,	O
the	O
tsd	B-Disease
carrier	O
status	O
was	O
enzymatically	O
determined	O
for	O
90	O
members	O
of	O
four	O
of	O
the	O
six	O
families	O
,	O
and	O
extensive	O
pedigrees	O
were	O
constructed	O
for	O
all	O
carriers	O
.	O
	
mutations	O
in	O
the	O
candidate	O
gene	O
for	O
norrie	B-Disease
disease	I-Disease
.	O
	
recently	O
,	O
we	O
and	O
others	O
have	O
isolated	O
a	O
candidate	O
gene	O
for	O
x	B-Disease
linked	I-Disease
norrie	I-Disease
disease	I-Disease
(	O
nd	B-Disease
)	O
which	O
was	O
found	O
to	O
be	O
deleted	O
or	O
disrupted	O
in	O
several	O
patients	O
.	O
	
as	O
a	O
prerequisite	O
for	O
the	O
identification	O
of	O
point	O
mutations	O
in	O
the	O
nd	B-Disease
gene	O
we	O
have	O
established	O
the	O
exon	O
-	O
intron	O
structure	O
of	O
this	O
gene	O
.	O
	
these	O
findings	O
,	O
and	O
the	O
absence	O
of	O
functionally	O
relevant	O
base	O
changes	O
in	O
healthy	O
controls	O
,	O
emphasize	O
the	O
causal	O
role	O
of	O
this	O
candidate	O
gene	O
in	O
norrie	B-Disease
disease	I-Disease
and	O
pave	O
the	O
way	O
for	O
reliable	O
diagnosis	O
and	O
carrier	O
detection	O
.	O
	
co	O
-	O
amplification	O
of	O
11	O
exons	O
from	O
genomic	O
dna	O
of	O
duchenne	B-Disease
and	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
/	O
bmd	B-Disease
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
sscp	O
analysis	O
.	O
	
we	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
duchenne	B-Disease
patient	O
identified	O
by	O
this	O
approach	O
.	O
	
high	O
level	O
expression	O
of	O
the	O
nm23	O
-	O
h1	O
gene	O
,	O
which	O
encodes	O
for	O
a	O
nucleoside	O
diphosphate	O
kinase	O
,	O
has	O
been	O
found	O
to	O
correlate	O
with	O
diminished	O
metastasis	O
in	O
some	O
tumors	B-Disease
but	O
not	O
in	O
others	O
.	O
	
in	O
neuroblastoma	B-Disease
,	O
higher	O
levels	O
of	O
p19	O
/	O
nm23	O
,	O
which	O
are	O
associated	O
with	O
amplification	O
of	O
the	O
n	O
-	O
myc	O
oncogene	O
,	O
large	O
tumor	B-Disease
mass	O
,	O
and	O
metastasis	O
,	O
were	O
observed	O
in	O
advanced	O
stage	O
tumors	B-Disease
compared	O
with	O
limited	O
stage	O
disease	O
.	O
	
because	O
of	O
the	O
variable	O
expression	O
of	O
nm23	O
-	O
h1	O
in	O
different	O
tumors	B-Disease
,	O
we	O
have	O
investigated	O
the	O
relationship	O
between	O
amounts	O
of	O
the	O
protein	O
and	O
cell	O
proliferation	O
.	O
	
the	O
levels	O
of	O
p19	O
/	O
nm23	O
were	O
compared	O
between	O
resting	O
and	O
mitotically	O
stimulated	O
normal	O
human	O
pbls	O
and	O
in	O
leukemia	B-Disease
cells	O
.	O
	
in	O
leukemia	B-Disease
cells	O
obtained	O
from	O
patients	O
with	O
different	O
subtypes	O
of	O
acute	B-Disease
leukemia	I-Disease
,	O
p19	O
/	O
nm23	O
levels	O
were	O
also	O
increased	O
relative	O
to	O
resting	O
normal	O
lymphocytes	O
.	O
	
treatment	O
of	O
mitotically	O
stimulated	O
lymphocytes	O
with	O
cyclosporin	O
,	O
which	O
inhibits	O
proliferation	O
,	O
blocked	O
the	O
increase	O
in	O
p19	O
/	O
nm23	O
;	O
treatment	O
of	O
the	O
leukemia	B-Disease
cell	O
line	O
hl	O
-	O
60	O
with	O
dimethylsulfoxide	O
,	O
which	O
induces	O
terminal	O
differentiation	O
,	O
resulted	O
in	O
diminished	O
levels	O
of	O
p19	O
/	O
nm23	O
.	O
	
an	O
intrachromosomal	O
insertion	O
causing	O
5q22	O
deletion	O
and	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
in	O
two	O
generations	O
.	O
	
we	O
report	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
fapc	B-Disease
)	O
with	O
epidermoid	B-Disease
cysts	I-Disease
,	O
osteomata	B-Disease
,	O
and	O
areas	O
of	O
congenital	B-Disease
hypertrophy	I-Disease
of	I-Disease
the	I-Disease
retinal	I-Disease
pigment	I-Disease
epithelium	I-Disease
(	O
chrpes	B-Disease
)	O
in	O
a	O
male	O
patient	O
and	O
his	O
maternal	O
aunt	O
,	O
both	O
of	O
whom	O
suffered	O
a	O
mild	O
to	O
moderate	O
degree	O
of	O
mental	B-Disease
handicap	I-Disease
.	O
	
as	O
expected	O
,	O
the	O
molecular	O
analyses	O
indicate	O
loss	O
of	O
one	O
allele	O
at	O
the	O
mcc	O
and	O
apc	B-Disease
loci	O
.	O
	
the	O
apc	B-Disease
gene	O
is	O
located	O
within	O
band	O
5q22	O
.	O
	
chromosome	O
mapping	O
of	O
the	O
rod	O
photoreceptor	O
cgmp	O
phosphodiesterase	O
beta	O
-	O
subunit	O
gene	O
in	O
mouse	O
and	O
human	O
:	O
tight	O
linkage	O
to	O
the	O
huntington	B-Disease
disease	I-Disease
region	O
(	O
4p16	O
.	O
	
the	O
retinal	B-Disease
degeneration	I-Disease
mouse	O
(	O
gene	O
symbol	O
,	O
rd	O
)	O
is	O
an	O
animal	O
model	O
for	O
certain	O
forms	O
of	O
human	O
hereditary	B-Disease
retinopathies	I-Disease
.	O
	
3	O
,	O
very	O
close	O
to	O
the	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
region	O
.	O
	
analysis	O
of	O
the	O
comparative	O
map	O
for	O
mice	O
and	O
humans	O
shows	O
that	O
the	O
mouse	O
homologue	O
of	O
the	O
hd	B-Disease
gene	O
will	O
reside	O
on	O
chromosome	O
5	O
.	O
	
3	O
region	O
is	O
maintained	O
but	O
gene	O
order	O
is	O
not	O
,	O
suggesting	O
at	O
least	O
three	O
possible	O
sites	O
for	O
the	O
corresponding	O
mouse	O
hd	B-Disease
gene	O
.	O
	
coincident	O
kaposi	B-Disease
sarcoma	I-Disease
and	O
t	B-Disease
-	I-Disease
cell	I-Disease
lymphoma	I-Disease
in	O
a	O
patient	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
a	O
24	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
eczema	B-Disease
,	O
recurrent	O
mild	O
infections	O
,	O
and	O
thrombocytopenia	B-Disease
consistent	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
presented	O
with	O
a	O
mediastinal	O
mass	O
,	O
generalized	O
lymphadenopathy	B-Disease
,	O
splenomegaly	B-Disease
,	O
and	O
severe	O
thrombocytopenia	B-Disease
.	O
	
however	O
,	O
their	O
proliferative	O
responses	O
to	O
anti	O
-	O
cd43	O
antibody	O
and	O
periodate	O
were	O
diminished	O
,	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
was	B-Disease
.	O
	
an	O
initial	O
inguinal	O
lymph	O
node	O
biopsy	O
surprisingly	O
revealed	O
kaposi	B-Disease
sarcoma	I-Disease
.	O
	
however	O
,	O
following	O
splenectomy	O
to	O
increase	O
the	O
platelet	O
count	O
,	O
biopsy	O
of	O
the	O
mediastinal	O
mass	O
revealed	O
t	B-Disease
-	I-Disease
cell	I-Disease
large	I-Disease
cell	I-Disease
lymphoma	I-Disease
.	O
	
studies	O
of	O
biopsied	O
tissue	O
for	O
the	O
presence	O
of	O
epstein	B-Disease
-	I-Disease
barr	I-Disease
virus	I-Disease
and	O
cytomegalovirus	B-Disease
were	O
negative	O
,	O
as	O
were	O
studies	O
of	O
blood	O
,	O
including	O
the	O
polymerase	O
chain	O
reaction	O
,	O
for	O
the	O
presence	O
of	O
the	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	O
hiv	B-Disease
)	O
.	O
	
this	O
is	O
the	O
first	O
report	O
of	O
kaposi	B-Disease
sarcoma	I-Disease
arising	O
in	O
a	O
patient	O
with	O
a	O
congenital	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
.	O
	
although	O
kaposi	B-Disease
sarcoma	I-Disease
can	O
arise	O
in	O
the	O
face	O
of	O
the	O
severe	O
immunosuppression	O
that	O
follows	O
allograft	O
transplantation	O
and	O
in	O
patients	O
infected	O
with	O
hiv	B-Disease
,	O
we	O
postulate	O
that	O
longevity	O
in	O
the	O
face	O
of	O
mild	O
immunosuppression	O
was	O
the	O
major	O
factor	O
in	O
the	O
development	O
of	O
kaposi	B-Disease
sarcoma	I-Disease
in	O
this	O
patient	O
.	O
	
the	O
apc	B-Disease
gene	O
,	O
responsible	O
for	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
,	O
is	O
mutated	O
in	O
human	O
gastric	B-Disease
cancer	I-Disease
.	O
	
although	O
gastric	B-Disease
cancer	I-Disease
is	O
the	O
most	O
common	O
cancer	B-Disease
in	O
the	O
world	O
,	O
genetic	O
changes	O
during	O
its	O
carcinogenesis	O
are	O
not	O
well	O
understood	O
.	O
	
since	O
some	O
gastric	B-Disease
cancers	I-Disease
are	O
considered	O
to	O
originate	O
from	O
the	O
intestinal	O
metaplasia	O
,	O
it	O
is	O
likely	O
that	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
,	O
the	O
mutation	O
of	O
which	O
causes	O
adenomatous	B-Disease
polyps	I-Disease
in	I-Disease
the	I-Disease
colon	I-Disease
,	O
is	O
associated	O
with	O
carcinogenesis	O
of	O
gastric	B-Disease
cancer	I-Disease
.	O
	
based	O
on	O
this	O
idea	O
,	O
dnas	O
isolated	O
from	O
gastric	B-Disease
cancers	I-Disease
were	O
examined	O
by	O
means	O
of	O
a	O
rnase	O
protection	O
analysis	O
coupled	O
with	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products	O
.	O
	
by	O
screening	O
nearly	O
one	O
-	O
half	O
of	O
the	O
coding	O
region	O
of	O
the	O
apc	B-Disease
gene	O
in	O
44	O
tumors	B-Disease
,	O
somatic	O
mutations	O
were	O
detected	O
in	O
three	O
tumors	B-Disease
a	O
missense	O
mutation	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
5	O
-	O
base	O
pair	O
deletion	O
resulting	O
in	O
a	O
frame	O
shift	O
which	O
causes	O
truncation	O
of	O
the	O
gene	O
product	O
.	O
	
these	O
results	O
suggest	O
that	O
the	O
mutation	O
of	O
the	O
apc	B-Disease
gene	O
also	O
plays	O
an	O
important	O
role	O
during	O
the	O
carcinogenesis	O
of	O
at	O
least	O
some	O
gastric	B-Disease
cancers	I-Disease
.	O
	
.	O
	
a	O
71	O
-	O
kilodalton	O
protein	O
is	O
a	O
major	O
product	O
of	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
.	O
	
the	O
known	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
products	O
,	O
the	O
muscle	O
-	O
and	O
brain	O
-	O
type	O
dystrophin	O
isoforms	O
,	O
are	O
427	O
-	O
kda	O
proteins	O
translated	O
from	O
14	O
-	O
kilobase	O
(	O
kb	O
)	O
mrnas	O
.	O
	
5	O
-	O
kb	O
mrna	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
dmd	B-Disease
gene	O
.	O
	
8	O
-	O
kda	O
protein	O
that	O
is	O
a	O
major	O
product	O
of	O
the	O
dmd	B-Disease
gene	O
.	O
	
this	O
protein	O
is	O
the	O
major	O
dmd	B-Disease
gene	O
product	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
but	O
is	O
undetectable	O
in	O
skeletal	O
muscle	O
extracts	O
.	O
	
correlation	O
between	O
the	O
location	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
apc	B-Disease
gene	O
and	O
the	O
number	O
of	O
colorectal	B-Disease
polyps	I-Disease
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
.	O
	
recently	O
we	O
have	O
isolated	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
which	O
causes	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
,	O
and	O
its	O
germ	O
-	O
line	O
mutations	O
in	O
a	O
substantial	O
number	O
of	O
fap	B-Disease
patients	O
have	O
been	O
identified	O
.	O
	
on	O
the	O
basis	O
of	O
this	O
information	O
,	O
we	O
compared	O
the	O
location	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
apc	B-Disease
gene	O
in	O
22	O
unrelated	O
patients	O
(	O
12	O
of	O
whom	O
have	O
been	O
reported	O
previously	O
)	O
with	O
the	O
number	O
of	O
colorectal	B-Disease
polyps	I-Disease
developed	O
in	O
fap	B-Disease
patients	O
;	O
17	O
were	O
sparse	O
types	O
and	O
five	O
were	O
profuse	O
types	O
.	O
	
the	O
location	O
of	O
the	O
germ	O
-	O
line	O
mutations	O
seems	O
to	O
correlate	O
with	O
the	O
two	O
clinical	O
types	O
;	O
germ	O
-	O
line	O
mutations	O
in	O
five	O
fap	B-Disease
patients	O
with	O
profuse	O
polyps	B-Disease
were	O
observed	O
between	O
codon	O
1250	O
and	O
codon	O
1464	O
,	O
whereas	O
mutations	O
in	O
17	O
fap	B-Disease
patients	O
with	O
fewer	O
polyps	B-Disease
were	O
observed	O
in	O
the	O
other	O
regions	O
of	O
the	O
apc	B-Disease
gene	O
.	O
	
the	O
result	O
suggests	O
that	O
the	O
number	O
of	O
colorectal	B-Disease
polyps	I-Disease
in	O
fap	B-Disease
patients	O
may	O
be	O
associated	O
with	O
a	O
difference	O
in	O
the	O
stability	O
or	O
biological	O
function	O
of	O
the	O
truncated	O
apc	B-Disease
protein	O
.	O
	
.	O
	
identification	O
and	O
rapid	O
detection	O
of	O
three	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
mutations	O
in	O
the	O
moroccan	O
jewish	O
population	O
.	O
	
infantile	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
hexa	O
gene	O
that	O
result	O
in	O
the	O
complete	O
absence	O
of	O
beta	O
-	O
hexosaminidase	O
a	O
activity	O
.	O
	
it	O
is	O
well	O
known	O
that	O
an	O
elevated	O
frequency	O
of	O
tsd	B-Disease
mutations	O
exists	O
among	O
ashkenazi	O
jews	O
.	O
	
more	O
recently	O
it	O
has	O
become	O
apparent	O
that	O
elevated	O
carrier	O
frequencies	O
for	O
tsd	B-Disease
also	O
occur	O
in	O
several	O
other	O
ethnic	O
groups	O
,	O
including	O
moroccan	O
jews	O
,	O
a	O
subgroup	O
of	O
sephardic	O
jews	O
.	O
	
elsewhere	O
we	O
reported	O
an	O
in	O
-	O
frame	O
deletion	O
of	O
one	O
of	O
the	O
two	O
adjacent	O
phenylalanine	O
codons	O
at	O
position	O
304	O
or	O
305	O
(	O
delta	O
f304	O
/	O
305	O
)	O
in	O
one	O
hexa	O
allele	O
of	O
a	O
moroccan	O
jewish	O
tsd	B-Disease
patient	O
and	O
in	O
three	O
obligate	O
carriers	O
from	O
six	O
unrelated	O
moroccan	O
jewish	O
families	O
.	O
	
we	O
have	O
now	O
identified	O
two	O
additional	O
mutations	O
within	O
exon	O
5	O
of	O
the	O
hexa	O
gene	O
that	O
account	O
for	O
the	O
remaining	O
tsd	B-Disease
alleles	O
in	O
the	O
patient	O
and	O
carriers	O
.	O
	
this	O
mutation	O
is	O
at	O
a	O
cpg	O
site	O
in	O
a	O
japanese	O
infant	O
with	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
and	O
was	O
described	O
elsewhere	O
.	O
	
molecular	O
characterization	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
by	O
natural	O
and	O
amplification	O
created	O
restriction	O
sites	O
:	O
five	O
mutations	O
account	O
for	O
most	O
g6pd	B-Disease
deficiency	I-Disease
cases	O
in	O
taiwan	O
.	O
	
we	O
have	O
developed	O
a	O
rapid	O
and	O
simple	O
method	O
to	O
diagnose	O
the	O
molecular	O
defects	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
chinese	O
in	O
taiwan	O
.	O
	
ninety	O
-	O
four	O
chinese	O
males	O
with	O
g6pd	B-Disease
deficiency	I-Disease
were	O
studied	O
.	O
	
these	O
results	O
show	O
that	O
the	O
former	O
five	O
mutations	O
account	O
for	O
more	O
than	O
90	O
%	O
of	O
g6pd	B-Disease
deficiency	I-Disease
cases	O
in	O
taiwan	O
.	O
	
eight	O
novel	O
inactivating	O
germ	O
line	O
mutations	O
at	O
the	O
apc	B-Disease
gene	O
identified	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
	
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
is	O
a	O
dominantly	O
inherited	O
condition	O
predisposing	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
the	O
recent	O
isolation	O
of	O
the	O
responsible	O
gene	O
(	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
or	O
apc	B-Disease
)	O
has	O
facilitated	O
the	O
search	O
for	O
germ	O
line	O
mutations	O
in	O
affected	O
individuals	O
.	O
	
dgge	O
analysis	O
of	O
10	O
apc	B-Disease
exons	O
(	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
and	O
part	O
of	O
15	O
)	O
in	O
33	O
unrelated	O
dutch	O
fap	B-Disease
patients	O
has	O
led	O
to	O
the	O
identification	O
of	O
eight	O
novel	O
germ	O
line	O
mutations	O
resulting	O
in	O
stop	O
codons	O
or	O
frameshifts	O
.	O
	
the	O
results	O
reported	O
here	O
indicate	O
that	O
(	O
1	O
)	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
is	O
caused	O
by	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
point	O
mutations	O
;	O
(	O
2	O
)	O
all	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
chain	O
terminating	O
;	O
and	O
(	O
3	O
)	O
dgge	O
represents	O
a	O
rapid	O
and	O
sensitive	O
technique	O
for	O
the	O
detection	O
of	O
mutations	O
in	O
the	O
unusually	O
large	O
apc	B-Disease
gene	O
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
occurrence	O
of	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
mutations	O
spread	O
throughout	O
the	O
entire	O
length	O
of	O
the	O
large	O
apc	B-Disease
gene	O
among	O
the	O
fap	B-Disease
patients	O
indicates	O
that	O
this	O
approach	O
may	O
not	O
be	O
useful	O
as	O
a	O
rapid	O
presymptomatic	O
diagnostic	O
procedure	O
in	O
a	O
routine	O
laboratory	O
.	O
	
such	O
intragenic	O
polymorphisms	O
offer	O
a	O
practical	O
approach	O
to	O
a	O
more	O
rapid	O
procedure	O
for	O
presymptomatic	O
diagnosis	O
of	O
fap	B-Disease
by	O
linkage	O
analysis	O
in	O
informative	O
families	O
.	O
	
yeast	O
artificial	O
chromosomes	O
for	O
the	O
molecular	O
analysis	O
of	O
the	O
familial	B-Disease
polyposis	I-Disease
apc	I-Disease
gene	O
region	O
.	O
	
1	O
megabase	O
pairs	O
of	O
dna	O
around	O
the	O
mcc	O
(	O
for	O
mutated	O
in	O
colorectal	B-Disease
carcinoma	I-Disease
)	O
and	O
apc	B-Disease
(	O
for	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
)	O
genes	O
at	O
5q21	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O
	
starting	O
from	O
the	O
mcc	O
gene	O
,	O
a	O
strategy	O
was	O
undertaken	O
to	O
identify	O
constitutional	O
submicroscopic	O
deletions	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
that	O
might	O
considerably	O
narrow	O
down	O
the	O
position	O
of	O
the	O
apc	B-Disease
gene	O
.	O
	
this	O
screening	O
approach	O
led	O
to	O
the	O
confirmation	O
of	O
a	O
small	O
heterozygous	O
deletion	O
in	O
a	O
polyposis	B-Disease
patient	O
that	O
overlaps	O
one	O
of	O
the	O
two	O
isolated	O
yacs	O
.	O
	
this	O
yac	O
has	O
been	O
shown	O
to	O
contain	O
the	O
entire	O
apc	B-Disease
gene	O
,	O
in	O
addition	O
to	O
a	O
significant	O
portion	O
of	O
dna	O
flanking	O
the	O
5	O
end	O
of	O
the	O
gene	O
,	O
and	O
should	O
therefore	O
prove	O
a	O
valuable	O
resource	O
for	O
functional	O
studies	O
by	O
transfer	O
to	O
colorectal	B-Disease
tumor	I-Disease
-	O
derived	O
cell	O
lines	O
.	O
	
inherited	O
wt1	O
mutation	O
in	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
.	O
	
patients	O
with	O
the	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
(	O
wilms	B-Disease
tumor	I-Disease
,	O
genital	B-Disease
anomalies	I-Disease
,	O
and	O
nephropathy	B-Disease
)	O
have	O
been	O
demonstrated	O
to	O
carry	O
de	O
novo	O
constitutional	O
mutations	O
in	O
wt1	O
,	O
the	O
wilms	B-Disease
tumor	I-Disease
gene	O
at	O
chromosome	O
11p13	O
.	O
	
this	O
observation	O
indicates	O
that	O
the	O
wt1	O
exon	O
9	O
mutation	O
affecting	O
394arg	O
demonstrated	O
in	O
over	O
one	O
-	O
half	O
of	O
the	O
patients	O
with	O
the	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
may	O
exhibit	O
incomplete	O
penetrance	O
.	O
	
submicroscopic	O
deletions	O
at	O
the	O
wagr	B-Disease
locus	O
,	O
revealed	O
by	O
nonradioactive	O
in	O
situ	O
hybridization	O
.	O
	
fluorescence	O
in	O
situ	O
hybridization	O
(	O
fish	O
)	O
with	O
biotin	O
-	O
labeled	O
probes	O
mapping	O
to	O
11p13	O
has	O
been	O
used	O
for	O
the	O
molecular	O
analysis	O
of	O
deletions	O
of	O
the	O
wagr	B-Disease
(	O
wilms	B-Disease
tumor	I-Disease
,	O
aniridia	B-Disease
,	O
genitourinary	B-Disease
abnormalities	I-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
)	O
locus	O
.	O
	
we	O
have	O
detected	O
a	O
submicroscopic	O
11p13	O
deletion	O
in	O
a	O
child	O
with	O
inherited	O
aniridia	B-Disease
who	O
subsequently	O
presented	O
with	O
wilms	B-Disease
tumor	I-Disease
in	O
a	O
horseshoe	O
kidney	O
,	O
only	O
revealed	O
at	O
surgery	O
.	O
	
the	O
mother	O
,	O
who	O
has	O
aniridia	B-Disease
,	O
was	O
also	O
found	O
to	O
carry	O
a	O
deletion	O
including	O
both	O
the	O
aniridia	B-Disease
candidate	O
gene	O
(	O
an2	O
)	O
and	O
the	O
wilms	B-Disease
tumor	I-Disease
predisposition	O
gene	O
(	O
wt1	O
)	O
.	O
	
this	O
is	O
therefore	O
a	O
rare	O
case	O
of	O
an	O
inherited	O
wagr	B-Disease
deletion	O
.	O
	
wilms	B-Disease
tumor	I-Disease
has	O
so	O
far	O
only	O
been	O
associated	O
with	O
sporadic	O
de	O
novo	O
aniridia	B-Disease
cases	O
.	O
	
we	O
have	O
shown	O
that	O
a	O
cosmid	O
probe	O
for	O
a	O
candidate	O
aniridia	B-Disease
gene	O
,	O
homologous	O
to	O
the	O
mouse	O
pax	O
-	O
6	O
gene	O
,	O
is	O
deleted	O
in	O
cell	O
lines	O
from	O
aniridia	B-Disease
patients	O
with	O
previously	O
characterized	O
deletions	O
at	O
11p13	O
,	O
while	O
another	O
cosmid	O
marker	O
mapping	O
between	O
two	O
aniridia	B-Disease
-	O
associated	O
translocation	O
breakpoints	O
(	O
and	O
hence	O
a	O
second	O
candidate	O
marker	O
)	O
is	O
present	O
on	O
both	O
chromosomes	O
.	O
	
linkage	O
of	O
gene	O
for	O
c2	B-Disease
deficiency	I-Disease
and	O
the	O
major	O
histocompatibility	O
complex	O
mhc	O
in	O
man	O
.	O
	
close	O
linkage	O
between	O
hl	O
-	O
a	O
and	O
c2	B-Disease
deficiency	I-Disease
was	O
first	O
reported	O
by	O
fu	O
and	O
co	O
-	O
workers	O
in	O
1974	O
.	O
	
we	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
c2	B-Disease
-	I-Disease
deficient	I-Disease
individual	O
with	O
clinical	O
manifestations	O
of	O
hodgkins	B-Disease
disease	I-Disease
.	O
	
in	O
addition	O
to	O
close	O
linkage	O
between	O
hl	O
-	O
a	O
and	O
c2	B-Disease
deficiency	I-Disease
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
bf	O
(	O
hl	O
-	O
a	O
linked	O
,	O
electrophoretic	O
variation	O
of	O
b	O
)	O
.	O
	
the	O
two	O
hl	O
-	O
a	O
haplotypes	O
closely	O
linked	O
to	O
c2	B-Disease
deficiency	I-Disease
are	O
different	O
2	O
,	O
w18	O
and	O
w24	O
,	O
w18	O
.	O
	
screening	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
:	O
61	O
new	O
patients	O
and	O
a	O
summary	O
of	O
150	O
unrelated	O
patients	O
.	O
	
we	O
report	O
here	O
the	O
result	O
of	O
a	O
screening	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
in	O
61	O
new	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
patients	O
as	O
well	O
as	O
a	O
summary	O
of	O
the	O
results	O
of	O
150	O
patients	O
.	O
	
examination	O
of	O
the	O
entire	O
coding	O
region	O
of	O
the	O
apc	B-Disease
gene	O
,	O
based	O
on	O
a	O
ribonuclease	O
protection	O
assay	O
coupled	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
pcr	O
)	O
,	O
disclosed	O
mutations	O
that	O
were	O
considered	O
to	O
cause	O
significant	O
defects	O
in	O
the	O
apc	B-Disease
product	O
in	O
97	O
of	O
150	O
unrelated	O
fap	B-Disease
patients	O
.	O
	
our	O
findings	O
revealed	O
the	O
following	O
characteristics	O
of	O
the	O
germ	O
-	O
line	O
mutations	O
of	O
apc	O
1	O
)	O
the	O
great	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
to	O
truncate	O
the	O
apc	B-Disease
product	O
;	O
2	O
)	O
almost	O
all	O
of	O
the	O
mutations	O
were	O
located	O
within	O
the	O
first	O
half	O
of	O
the	O
coding	O
region	O
;	O
3	O
)	O
no	O
correlation	O
was	O
observed	O
between	O
the	O
locations	O
of	O
germ	O
-	O
line	O
mutations	O
and	O
extracolonic	O
manifestations	O
in	O
fap	B-Disease
patients	O
;	O
4	O
)	O
more	O
than	O
80	O
%	O
of	O
base	O
substitutions	O
in	O
the	O
apc	B-Disease
gene	O
were	O
from	O
cytosine	O
to	O
other	O
nucleotides	O
,	O
nearly	O
one	O
-	O
third	O
of	O
which	O
occurred	O
at	O
the	O
gpg	O
site	O
.	O
	
our	O
results	O
provide	O
information	O
helpful	O
to	O
an	O
understanding	O
of	O
the	O
apc	B-Disease
gene	O
and	O
will	O
also	O
contribute	O
to	O
presymptomatic	O
diagnosis	O
of	O
members	O
in	O
fap	B-Disease
families	O
.	O
	
somatic	O
mutations	O
of	O
the	O
apc	B-Disease
gene	O
in	O
colorectal	B-Disease
tumors	I-Disease
:	O
mutation	O
cluster	O
region	O
in	O
the	O
apc	B-Disease
gene	O
.	O
	
we	O
examined	O
somatic	O
mutations	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
in	O
63	O
colorectal	B-Disease
tumors	I-Disease
(	O
16	O
adenomas	B-Disease
and	O
47	O
carcinomas	B-Disease
)	O
developed	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
and	O
non	O
-	O
fap	O
patients	O
.	O
	
in	O
addition	O
to	O
loss	O
of	O
heterozygosity	O
(	O
loh	O
)	O
at	O
the	O
apc	B-Disease
locus	O
in	O
30	O
tumors	B-Disease
,	O
43	O
other	O
somatic	O
mutations	O
were	O
detected	O
.	O
	
twenty	O
-	O
two	O
tumors	B-Disease
had	O
frameshift	O
mutations	O
due	O
to	O
deletion	O
or	O
insertion	O
;	O
nineteen	O
of	O
them	O
were	O
deletions	O
of	O
one	O
to	O
31	O
bp	O
and	O
three	O
were	O
a	O
1	O
-	O
bp	O
insertion	O
.	O
	
one	O
tumor	B-Disease
had	O
a	O
1	O
-	O
bp	O
deletion	O
in	O
an	O
intron	O
near	O
the	O
splicing	O
site	O
.	O
	
hence	O
,	O
41	O
(	O
95	O
%	O
)	O
of	O
43	O
mutations	O
resulted	O
in	O
truncation	O
of	O
the	O
apc	B-Disease
protein	O
.	O
	
over	O
60	O
%	O
of	O
the	O
somatic	O
mutations	O
in	O
the	O
apc	B-Disease
gene	O
were	O
clustered	O
within	O
a	O
small	O
region	O
of	O
exon	O
15	O
,	O
designated	O
as	O
mcr	O
(	O
mutation	O
cluster	O
region	O
)	O
,	O
which	O
accounted	O
for	O
less	O
than	O
10	O
%	O
of	O
the	O
coding	O
region	O
.	O
	
combining	O
these	O
data	O
and	O
the	O
results	O
of	O
loh	O
,	O
more	O
than	O
80	O
%	O
of	O
tumors	B-Disease
(	O
14	O
adenomas	B-Disease
and	O
39	O
carcinomas	B-Disease
)	O
had	O
at	O
least	O
one	O
mutation	O
in	O
the	O
apc	B-Disease
gene	O
,	O
of	O
which	O
more	O
than	O
60	O
%	O
(	O
9	O
adenomas	B-Disease
and	O
23	O
carcinomas	B-Disease
)	O
had	O
two	O
mutations	O
.	O
	
these	O
results	O
strongly	O
suggest	O
that	O
somatic	O
mutations	O
of	O
the	O
apc	B-Disease
gene	O
are	O
associated	O
with	O
development	O
of	O
a	O
great	O
majority	O
of	O
colorectal	B-Disease
tumors	I-Disease
.	O
	
constitutional	O
mutations	O
in	O
the	O
wt1	O
gene	O
in	O
patients	O
with	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
.	O
	
the	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
is	O
characterised	O
by	O
a	O
typical	O
nephropathy	B-Disease
,	O
genital	B-Disease
abnormalities	I-Disease
and	O
also	O
predisposes	O
to	O
the	O
development	O
of	O
wilms	B-Disease
tumor	I-Disease
.	O
	
these	O
patients	O
eventually	O
go	O
into	O
end	O
stage	O
renal	B-Disease
failure	I-Disease
.	O
	
a	O
candidate	O
wilms	B-Disease
tumor	I-Disease
gene	O
,	O
wt1	O
,	O
from	O
the	O
11p13	O
chromosome	O
region	O
has	O
recently	O
been	O
cloned	O
.	O
	
linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
founder	O
populations	O
:	O
diastrophic	B-Disease
dysplasia	I-Disease
in	O
finland	O
.	O
	
using	O
these	O
methods	O
,	O
we	O
report	O
striking	O
linkage	O
disequilibrium	O
for	O
diastrophic	B-Disease
dysplasia	I-Disease
(	O
dtd	B-Disease
)	O
in	O
finland	O
indicating	O
that	O
the	O
dtd	B-Disease
gene	O
should	O
lie	O
within	O
0	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
:	O
refinement	O
of	O
the	O
localization	O
on	O
xp	O
and	O
identification	O
of	O
another	O
closely	O
linked	O
marker	O
locus	O
,	O
oatl1	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
has	O
previously	O
been	O
mapped	O
to	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
x	O
chromosome	O
between	O
the	O
dxs14	O
and	O
dxs7	O
loci	O
.	O
	
in	O
this	O
study	O
,	O
further	O
segregation	O
analysis	O
has	O
been	O
performed	O
using	O
a	O
newly	O
identified	O
was	B-Disease
family	O
as	O
well	O
as	O
an	O
additional	O
marker	O
probe	O
,	O
hoatl1	O
.	O
	
the	O
results	O
indicate	O
close	O
linkage	O
between	O
the	O
was	B-Disease
and	O
oatl1	O
loci	O
(	O
z	O
=	O
6	O
.	O
	
8	O
at	O
theta	O
=	O
0	O
.	O
	
0	O
)	O
and	O
localize	O
the	O
timp	O
,	O
oatl1	O
,	O
dxs255	O
,	O
and	O
was	B-Disease
loci	O
distal	O
to	O
dxs146	O
and	O
the	O
oatl1	O
and	O
was	B-Disease
loci	O
proximal	O
to	O
timp	O
.	O
	
these	O
linkage	O
data	O
narrow	O
the	O
boundaries	O
within	O
which	O
the	O
was	B-Disease
locus	O
maps	O
to	O
the	O
chromosomal	O
region	O
bracketed	O
by	O
timp	O
and	O
dxs146	O
and	O
support	O
the	O
loci	O
order	O
xpter	O
-	O
dxs7	O
-	O
timp	O
-	O
(	O
oatl1	O
,	O
was	O
,	O
dxs255	O
)	O
-	O
dxs146	O
.	O
	
detection	O
of	O
an	O
unstable	O
fragment	O
of	O
dna	O
specific	O
to	O
individuals	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
,	O
with	O
a	O
prevalence	O
of	O
2	O
-	O
14	O
per	O
100	O
,	O
0	O
individuals	O
.	O
	
the	O
disease	O
is	O
characterized	O
by	O
progressive	O
muscle	B-Disease
weakness	I-Disease
and	O
sustained	B-Disease
muscle	I-Disease
contraction	I-Disease
,	O
often	O
with	O
a	O
wide	O
range	O
of	O
accompanying	O
symptoms	O
.	O
	
it	O
is	O
flanked	O
by	O
the	O
tightly	O
linked	O
genetic	O
markers	O
ercc1	O
proximally	O
and	O
d19s51	O
distally	O
;	O
these	O
define	O
the	O
dm	B-Disease
critical	O
region	O
.	O
	
we	O
postulate	O
that	O
this	O
unstable	O
dna	O
sequence	O
is	O
the	O
molecular	O
feature	O
that	O
underlies	O
dm	B-Disease
.	O
	
to	O
learn	O
about	O
causative	O
mechanisms	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
breakpoints	O
of	O
a	O
cytologically	O
balanced	O
constitutional	O
reciprocal	O
translocation	O
,	O
t	O
(	O
x	O
;	O
4	O
)	O
(	O
p21	O
.	O
22	O
)	O
,	O
present	O
in	O
a	O
girl	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
physical	O
mapping	O
of	O
the	O
derivative	O
chromosomes	O
,	O
after	O
their	O
separation	O
in	O
somatic	O
cell	O
hybrids	O
,	O
reveals	O
that	O
the	O
translocation	O
disrupts	O
the	O
dmd	B-Disease
gene	O
in	O
xp21	O
within	O
the	O
18	O
-	O
kb	O
intron	O
16	O
.	O
	
a	O
genetic	O
etiology	O
for	O
digeorge	B-Disease
syndrome	I-Disease
:	O
consistent	O
deletions	O
and	O
microdeletions	O
of	O
22q11	O
.	O
	
digeorge	B-Disease
syndrome	I-Disease
(	O
dgs	B-Disease
)	O
,	O
a	O
developmental	O
field	O
defect	O
of	O
the	O
third	O
and	O
fourth	O
pharyngeal	O
pouches	O
,	O
is	O
characterized	O
by	O
aplasia	B-Disease
or	I-Disease
hypoplasia	I-Disease
of	I-Disease
the	I-Disease
thymus	I-Disease
and	I-Disease
parathyroid	I-Disease
glands	I-Disease
and	O
by	O
conotruncal	B-Disease
cardiac	I-Disease
malformations	I-Disease
.	O
	
cytogenetic	O
studies	O
support	O
the	O
presence	O
of	O
a	O
dgs	B-Disease
critical	O
region	O
in	O
band	O
22q11	O
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
results	O
of	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
studies	O
of	O
14	O
patients	O
with	O
dgs	B-Disease
.	O
	
a	O
third	O
locus	O
,	O
d22s66	O
,	O
is	O
deleted	O
in	O
the	O
eight	O
dgs	B-Disease
probands	O
tested	O
.	O
	
on	O
the	O
basis	O
of	O
these	O
families	O
,	O
and	O
of	O
six	O
maternally	O
and	O
five	O
paternally	O
derived	O
unbalanced	O
-	O
translocation	O
dgs	B-Disease
probands	O
in	O
the	O
literature	O
,	O
parent	O
of	O
origin	O
or	O
imprinting	O
does	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
dgs	B-Disease
.	O
	
deletion	O
of	O
the	O
same	O
three	O
loci	O
in	O
all	O
14	O
dgs	B-Disease
probands	O
begins	O
to	O
delineate	O
the	O
region	O
of	O
chromosome	O
22	O
critical	O
for	O
dgs	B-Disease
and	O
confirms	O
the	O
hypothesis	O
that	O
submicroscopic	O
deletions	O
of	O
22q11	O
are	O
etiologic	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
.	O
	
.	O
	
loss	O
of	O
normal	O
allele	O
of	O
the	O
apc	B-Disease
gene	O
in	O
an	O
adrenocortical	B-Disease
carcinoma	I-Disease
from	O
a	O
patient	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O
	
endocrine	B-Disease
neoplasms	I-Disease
have	O
been	O
reported	O
occasionally	O
in	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
.	O
	
an	O
adrenocorotical	B-Disease
carcinoma	I-Disease
was	O
studied	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
fap	B-Disease
.	O
	
loss	O
of	O
heterozygosity	O
(	O
loh	O
)	O
in	O
the	O
region	O
close	O
to	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
was	O
detected	O
in	O
this	O
carcinoma	B-Disease
,	O
and	O
evidence	O
was	O
obtained	O
that	O
there	O
was	O
a	O
loss	O
of	O
the	O
normal	O
allele	O
of	O
the	O
apc	B-Disease
gene	O
.	O
	
this	O
is	O
the	O
first	O
demonstration	O
of	O
loh	O
at	O
the	O
apc	B-Disease
locus	O
in	O
adrenocortical	B-Disease
tumors	I-Disease
.	O
	
the	O
present	O
results	O
and	O
our	O
previous	O
data	O
on	O
loh	O
in	O
a	O
recurring	O
desmoid	B-Disease
tumor	I-Disease
suggest	O
that	O
the	O
heterozygous	O
mutant	O
/	O
wild	O
-	O
type	O
condition	O
of	O
the	O
apc	B-Disease
gene	O
may	O
give	O
rise	O
to	O
benign	B-Disease
tumors	I-Disease
,	O
and	O
that	O
functional	O
loss	O
of	O
this	O
gene	O
leads	O
to	O
development	O
of	O
tumors	B-Disease
not	O
only	O
in	O
the	O
colon	O
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
fap	B-Disease
patients	O
.	O
	
oncogenic	O
point	O
mutations	O
in	O
exon	O
20	O
of	O
the	O
rb1	O
gene	O
in	O
families	O
showing	O
incomplete	O
penetrance	O
and	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B-Disease
phenotype	O
.	O
	
the	O
retinoblastoma	B-Disease
-	O
predisposition	O
gene	O
,	O
rb1	O
,	O
segregates	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
high	O
(	O
90	O
%	O
)	O
penetrance	O
.	O
	
certain	O
families	O
,	O
however	O
,	O
show	O
an	O
unusual	O
low	O
-	O
penetrance	O
phenotype	O
with	O
many	O
individuals	O
being	O
unaffected	O
,	O
unilaterally	O
affected	O
,	O
or	O
with	O
evidence	O
of	O
spontaneously	O
regressed	O
tumors	B-Disease
.	O
	
late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O
	
we	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
.	O
	
in	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
mld	B-Disease
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
arsa	O
activity	O
.	O
	
a	O
comparison	O
of	O
genotypes	O
,	O
arsa	O
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
mld	B-Disease
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
arsa	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
mld	B-Disease
.	O
	
trisomy	B-Disease
15	I-Disease
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
due	O
to	O
maternal	B-Disease
disomy	I-Disease
.	O
	
uniparental	B-Disease
disomy	I-Disease
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
we	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B-Disease
disomy	I-Disease
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	B-Disease
disomy	I-Disease
in	O
a	O
fetus	O
.	O
	
chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	B-Disease
15	I-Disease
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O
	
the	O
child	O
was	O
hypotonic	B-Disease
at	O
birth	O
,	O
and	O
high	O
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11	O
-	O
13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-	O
70	O
%	O
of	O
patients	O
with	O
pws	B-Disease
.	O
	
over	O
time	O
,	O
typical	O
features	O
of	O
pws	B-Disease
developed	O
.	O
	
maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B-Disease
disomy	I-Disease
in	O
this	O
case	O
of	O
pws	B-Disease
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
.	O
	
genetic	O
heterogeneity	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
.	O
	
3	O
encodes	O
for	O
the	O
enamel	O
protein	O
amelogenin	O
and	O
has	O
been	O
implicated	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
inherited	B-Disease
dental	I-Disease
abnormality	I-Disease
x	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
(	O
xai	B-Disease
)	O
.	O
	
three	O
families	O
with	O
xai	B-Disease
have	O
been	O
investigated	O
using	O
polymorphic	O
dna	O
markers	O
flanking	O
the	O
position	O
of	O
amelx	O
.	O
	
using	O
two	O
-	O
point	O
linkage	O
analysis	O
,	O
linkage	O
was	O
established	O
between	O
xai	B-Disease
and	O
several	O
of	O
these	O
markers	O
in	O
two	O
families	O
,	O
with	O
a	O
combined	O
lod	O
score	O
of	O
6	O
.	O
	
this	O
supports	O
the	O
involvement	O
of	O
amelx	O
,	O
located	O
close	O
to	O
dxs16	O
,	O
in	O
the	O
xai	B-Disease
disease	I-Disease
process	O
(	O
aih1	O
)	O
in	O
those	O
families	O
.	O
	
there	O
was	O
significant	O
evidence	O
against	O
linkage	O
to	O
this	O
region	O
in	O
the	O
third	O
family	O
,	O
indicating	O
locus	O
heterogeneity	O
in	O
xai	B-Disease
.	O
	
multiple	O
origins	O
for	O
phenylketonuria	B-Disease
in	O
europe	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
,	O
a	O
disorder	B-Disease
of	I-Disease
amino	I-Disease
acid	I-Disease
metabolism	I-Disease
prevalent	O
among	O
caucasians	O
and	O
other	O
ethnic	O
groups	O
,	O
is	O
caused	O
primarily	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hepatic	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
pku	B-Disease
is	O
a	O
highly	O
heterogeneous	O
disorder	O
,	O
with	O
more	O
than	O
60	O
molecular	O
lesions	O
identified	O
in	O
the	O
pah	O
gene	O
.	O
	
the	O
haplotype	O
associations	O
,	O
relative	O
frequencies	O
,	O
and	O
distributions	O
of	O
five	O
prevalent	O
pah	O
mutations	O
(	O
r158q	O
,	O
r261q	O
,	O
ivs10nt546	O
,	O
r408w	O
,	O
and	O
ivs12n1	O
)	O
were	O
established	O
in	O
a	O
comprehensive	O
european	O
sample	O
population	O
and	O
subsequently	O
were	O
examined	O
to	O
determine	O
the	O
potential	O
roles	O
of	O
several	O
genetic	O
mechanisms	O
in	O
explaining	O
the	O
present	O
distribution	O
of	O
the	O
major	O
pku	B-Disease
alleles	O
.	O
	
together	O
,	O
these	O
data	O
suggest	O
that	O
there	O
were	O
multiple	O
,	O
geographically	O
and	O
ethnically	O
distinct	O
origins	O
for	O
pku	B-Disease
within	O
the	O
european	O
population	O
.	O
	
complement	B-Disease
factor	I-Disease
2	I-Disease
deficiency	I-Disease
:	O
a	O
clinical	O
and	O
serological	O
family	O
study	O
.	O
	
inherited	B-Disease
complement	I-Disease
deficiencies	I-Disease
are	O
associated	O
with	O
a	O
variety	O
of	O
connective	O
tissue	O
diseases	O
.	O
	
a	O
family	O
with	O
inherited	B-Disease
deficiency	I-Disease
of	I-Disease
complement	I-Disease
factor	I-Disease
2	I-Disease
(	O
c2	O
)	O
is	O
described	O
in	O
which	O
two	O
family	O
members	O
with	O
homozygous	O
c2	B-Disease
deficiency	I-Disease
developed	O
cutaneous	B-Disease
vasculitis	I-Disease
and	O
sicca	B-Disease
syndrome	I-Disease
.	O
	
the	O
other	O
family	O
members	O
had	O
heterozygous	O
c2	B-Disease
deficiency	I-Disease
and	O
each	O
member	O
had	O
the	O
hla	O
-	O
a25	O
,	O
b18	O
,	O
dr2	O
(	O
w15	O
)	O
haplotype	O
.	O
	
the	O
mother	O
had	O
seropositive	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
.	O
	
new	O
variant	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
(	O
plp	O
)	O
gene	O
in	O
a	O
family	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
a	O
c	O
-	O
-	O
greater	O
than	O
g	O
transversion	O
has	O
been	O
found	O
in	O
exon	O
3	O
of	O
the	O
plp	O
gene	O
of	O
affected	O
males	O
and	O
their	O
mother	O
in	O
a	O
single	O
sibship	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
.	O
	
the	O
cause	O
of	O
disease	O
in	O
this	O
family	O
remains	O
unknown	O
,	O
but	O
the	O
association	O
between	O
this	O
rare	O
mutation	O
and	O
pmd	B-Disease
is	O
intriguing	O
.	O
	
uncoupling	O
of	O
hypomyelination	B-Disease
and	O
glial	B-Disease
cell	I-Disease
death	I-Disease
by	O
a	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
gene	O
.	O
	
neurological	O
mutant	O
mice	O
can	O
often	O
provide	O
model	O
systems	O
for	O
human	O
genetic	B-Disease
disorders	I-Disease
.	O
	
mutations	O
of	O
the	O
x	O
-	O
chromosome	O
-	O
linked	O
plp	O
gene	O
are	O
lethal	O
,	O
identified	O
first	O
in	O
the	O
jimpy	O
mouse	O
and	O
subsequently	O
in	O
patients	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
the	O
unexplained	O
phenotype	O
of	O
these	O
mutations	O
includes	O
degeneration	B-Disease
and	I-Disease
premature	I-Disease
cell	I-Disease
death	I-Disease
of	I-Disease
oligodendrocytes	I-Disease
with	O
associated	O
hypomyelination	B-Disease
.	O
	
surprisingly	O
,	O
rumpshaker	O
mice	O
,	O
although	O
myelin	B-Disease
-	I-Disease
deficient	I-Disease
,	O
have	O
normal	O
longevity	O
and	O
a	O
full	O
complement	O
of	O
morphologically	O
normal	O
oligodendrocytes	O
.	O
	
hypomyelination	B-Disease
can	O
thus	O
be	O
genetically	O
separated	O
from	O
the	O
plp	O
-	O
dependent	O
oligodendrocyte	B-Disease
degeneration	I-Disease
.	O
	
we	O
suggest	O
that	O
plp	O
has	O
a	O
vital	O
function	O
in	O
glial	O
cell	O
development	O
,	O
distinct	O
from	O
its	O
later	O
role	O
in	O
myelin	O
assembly	O
,	O
and	O
that	O
this	O
dichotomy	O
of	O
action	O
may	O
explain	O
the	O
clinical	O
spectrum	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
a	O
pseudodeficiency	O
allele	O
common	O
in	O
non	O
-	O
jewish	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
carriers	O
:	O
implications	O
for	O
carrier	O
screening	O
.	O
	
deficiency	B-Disease
of	I-Disease
beta	I-Disease
-	I-Disease
hexosaminidase	I-Disease
a	I-Disease
(	O
hex	O
a	O
)	O
activity	O
typically	O
results	O
in	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
.	O
	
however	O
,	O
healthy	O
subjects	O
found	O
to	O
be	O
deficient	B-Disease
in	I-Disease
hex	I-Disease
a	I-Disease
activity	O
(	O
i	O
.	O
	
,	O
pseudodeficient	O
)	O
by	O
means	O
of	O
in	O
vitro	O
biochemical	O
tests	O
have	O
been	O
described	O
.	O
	
we	O
analyzed	O
the	O
hexa	O
gene	O
of	O
one	O
pseudodeficient	O
subject	O
and	O
identified	O
both	O
a	O
c739	O
-	O
to	O
-	O
t	O
substitution	O
that	O
changes	O
arg247	O
-	O
-	O
-	O
-	O
trp	O
on	O
one	O
allele	O
and	O
a	O
previously	O
identified	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
mutation	O
on	O
the	O
second	O
allele	O
.	O
	
this	O
allele	O
accounted	O
for	O
32	O
%	O
(	O
20	O
/	O
62	O
)	O
of	O
non	O
-	O
jewish	O
enzyme	O
-	O
defined	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
carriers	O
but	O
for	O
none	O
of	O
36	O
jewish	O
enzyme	O
-	O
defined	O
carriers	O
who	O
did	O
not	O
have	O
one	O
of	O
three	O
known	O
mutations	O
common	O
to	O
this	O
group	O
.	O
	
the	O
c739	O
-	O
to	O
-	O
t	O
allele	O
,	O
together	O
with	O
a	O
TRUE	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
allele	O
,	O
causes	O
hex	O
a	O
pseudodeficiency	O
.	O
	
given	O
both	O
the	O
large	O
proportion	O
of	O
non	O
-	O
jewish	O
carriers	O
with	O
this	O
allele	O
and	O
that	O
standard	O
biochemical	O
screening	O
cannot	O
differentiate	O
between	O
heterozygotes	O
for	O
the	O
c739	O
-	O
to	O
-	O
t	O
mutations	O
and	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
carriers	O
,	O
dna	O
testing	O
for	O
this	O
mutation	O
in	O
at	O
-	O
risk	O
couples	O
is	O
essential	O
.	O
	
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
:	O
detection	O
of	O
mutations	O
thr181	O
-	O
-	O
-	O
-	O
pro	O
and	O
leu223	O
-	O
-	O
-	O
-	O
pro	O
in	O
the	O
proteolipid	O
protein	O
gene	O
,	O
and	O
prenatal	O
diagnosis	O
.	O
	
a	O
family	O
with	O
an	O
apparent	O
history	O
of	O
x	O
-	O
linked	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
presented	O
for	O
genetic	O
counseling	O
,	O
requesting	O
carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
.	O
	
these	O
results	O
provide	O
further	O
examples	O
of	O
mutations	O
in	O
plp	O
that	O
cause	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
and	O
illustrate	O
the	O
value	O
of	O
sscp	O
in	O
genetic	O
analysis	O
.	O
	
von	B-Disease
willebrand	I-Disease
disease	I-Disease
type	I-Disease
b	I-Disease
:	O
a	O
missense	O
mutation	O
selectively	O
abolishes	O
ristocetin	O
-	O
induced	O
von	B-Disease
willebrand	I-Disease
factor	O
binding	O
to	O
platelet	O
glycoprotein	O
ib	O
.	O
	
von	B-Disease
willebrand	I-Disease
factor	O
(	O
vwf	O
)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
mediates	O
the	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
by	O
binding	O
to	O
platelet	O
glycoprotein	O
ib	O
.	O
	
a	O
missense	O
mutation	O
,	O
gly	O
-	O
561	O
-	O
-	O
>	O
ser	O
,	O
was	O
identified	O
within	O
the	O
proposed	O
glycoprotein	O
ib	O
binding	O
domain	O
of	O
vwf	O
in	O
the	O
proband	O
with	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
type	I-Disease
b	I-Disease
,	O
a	O
unique	O
variant	O
characterized	O
by	O
no	O
ristocetin	O
-	O
induced	O
,	O
but	O
normal	O
botrocetin	O
-	O
induced	O
,	O
binding	O
to	O
glycoprotein	O
ib	O
.	O
	
the	O
corresponding	O
mutant	O
recombinant	O
protein	O
,	O
rvwf	O
(	O
g561s	O
)	O
,	O
formed	O
normal	O
multimers	O
and	O
exhibited	O
the	O
same	O
functional	O
defect	O
as	O
the	O
patients	O
plasma	O
vwf	O
,	O
confirming	O
that	O
this	O
mutation	O
causes	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
type	I-Disease
b	I-Disease
.	O
	
the	O
normal	O
botrocetin	O
-	O
induced	O
binding	O
and	O
the	O
defective	O
ristocetin	O
-	O
induced	O
binding	O
of	O
rvwf	O
(	O
g561s	O
)	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
type	I-Disease
b	I-Disease
may	O
be	O
a	O
failure	O
of	O
normal	O
allosteric	O
regulation	O
of	O
the	O
glycoprotein	O
ib	O
binding	O
function	O
of	O
vwf	O
.	O
	
typical	O
and	O
partial	O
cat	B-Disease
eye	I-Disease
syndrome	I-Disease
:	O
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
fish	O
.	O
	
three	O
children	O
are	O
reported	O
with	O
typical	O
cat	B-Disease
eye	I-Disease
syndrome	I-Disease
(	O
ces	B-Disease
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
ces	B-Disease
because	O
of	O
absence	O
of	O
coloboma	O
,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
fish	O
.	O
	
using	O
a	O
genomic	O
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B-Disease
was	O
shown	O
in	O
all	O
cases	O
.	O
	
[	O
genetic	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
:	O
mutant	O
alleles	O
of	O
g6pd	O
in	O
the	O
shekii	O
district	O
of	O
azerbaijan	O
]	O
examination	O
on	O
g6pd	B-Disease
deficiency	I-Disease
in	O
349	O
patients	O
of	O
shekii	O
district	O
hospital	O
(	O
azerbaijan	O
)	O
revealed	O
16	O
hemi	O
-	O
,	O
4	O
homo	O
-	O
and	O
9	O
heterozygotic	O
carriers	O
of	O
the	O
defect	O
.	O
	
carriers	O
of	O
g6pd	B-Disease
deficiency	I-Disease
are	O
residents	O
of	O
11	O
villages	O
located	O
in	O
alasani	O
-	O
aphtalan	O
valley	O
,	O
highly	O
endemic	O
with	O
malaria	B-Disease
in	O
the	O
past	O
;	O
nearly	O
all	O
marriages	O
are	O
endogamic	O
.	O
	
craniofrontonasal	B-Disease
dysplasia	I-Disease
.	O
	
we	O
report	O
on	O
nine	O
patients	O
with	O
craniofrontonasal	B-Disease
dysplasia	I-Disease
(	O
cfnd	B-Disease
)	O
.	O
	
seven	O
classical	O
cases	O
had	O
facial	O
features	O
suggestive	O
of	O
frontonasal	B-Disease
dysplasia	I-Disease
and	O
coronal	B-Disease
craniosynostosis	I-Disease
.	O
	
extracranial	B-Disease
abnormalities	I-Disease
such	O
as	O
brittle	B-Disease
nails	I-Disease
with	I-Disease
prominent	I-Disease
longitudinal	I-Disease
grooves	I-Disease
or	O
syndactyly	B-Disease
of	I-Disease
fingers	I-Disease
and	I-Disease
toes	I-Disease
were	O
observed	O
in	O
individual	O
patients	O
.	O
	
hypotonia	B-Disease
and	O
laxity	B-Disease
of	I-Disease
joints	I-Disease
are	O
common	O
and	O
may	O
necessitate	O
supportive	O
measures	O
.	O
	
mild	O
developmental	B-Disease
delay	I-Disease
was	O
noted	O
in	O
three	O
out	O
of	O
six	O
classical	O
cases	O
studied	O
in	O
detail	O
.	O
	
unlike	O
almost	O
all	O
other	O
x	B-Disease
-	I-Disease
linked	I-Disease
disorders	I-Disease
,	O
clinical	O
expression	O
in	O
cfnd	B-Disease
is	O
generally	O
much	O
more	O
severe	O
in	O
females	O
than	O
in	O
males	O
.	O
	
the	O
intron	O
7	O
donor	O
splice	O
site	O
transition	O
:	O
a	O
second	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
mutation	O
in	O
french	O
canada	O
.	O
	
mutations	O
at	O
the	O
hexosaminidase	O
a	O
(	O
hexa	O
)	O
gene	O
which	O
cause	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
have	O
elevated	O
frequency	O
in	O
the	O
ashkenazi	O
jewish	O
and	O
french	O
-	O
canadian	O
populations	O
.	O
	
we	O
report	O
a	O
novel	O
tsd	B-Disease
allele	O
in	O
the	O
french	O
-	O
canadian	O
population	O
associated	O
with	O
the	O
infantile	O
form	O
of	O
the	O
disease	O
.	O
	
the	O
intron	O
7	O
+	O
1	O
mutation	O
occurs	O
in	O
the	O
base	O
adjacent	O
to	O
the	O
site	O
of	O
the	O
adult	O
-	O
onset	O
tsd	B-Disease
mutation	O
(	O
g805a	O
)	O
.	O
	
this	O
mutation	O
thus	O
has	O
a	O
different	O
geographic	O
centre	O
of	O
diffusion	O
and	O
is	O
probably	O
less	O
common	O
than	O
the	O
exon	O
1	O
deletion	O
tsd	B-Disease
mutation	O
in	O
french	O
canadians	O
.	O
	
aspartylglucosaminuria	B-Disease
(	O
agu	B-Disease
)	O
is	O
a	O
recessive	O
autosomally	O
inherited	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
due	O
to	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
enzyme	I-Disease
aspartylglucosaminidase	I-Disease
(	O
aga	O
)	O
.	O
	
resolution	O
of	O
the	O
two	O
loci	O
for	O
autosomal	O
dominant	O
aniridia	B-Disease
,	O
an1	O
and	O
an2	O
,	O
to	O
a	O
single	O
locus	O
on	O
chromosome	O
11p13	O
.	O
	
two	O
distinct	O
loci	O
have	O
been	O
proposed	O
for	O
aniridia	B-Disease
;	O
an1	O
for	O
autosomal	O
dominant	O
aniridia	B-Disease
on	O
chromosome	O
2p	O
and	O
an2	O
for	O
the	O
aniridia	B-Disease
in	O
the	O
wagr	B-Disease
contiguous	I-Disease
gene	I-Disease
syndrome	I-Disease
on	O
chromosome	O
11p13	O
.	O
	
in	O
this	O
report	O
,	O
the	O
kindred	O
segregating	O
for	O
autosomal	O
dominant	O
aniridia	B-Disease
,	O
which	O
suggested	O
linkage	O
to	O
acid	O
phosphatase	O
-	O
1	O
(	O
acp1	O
)	O
and	O
led	O
to	O
the	O
assignment	O
of	O
the	O
an1	O
locus	O
on	O
chromosome	O
2p	O
,	O
has	O
been	O
updated	O
and	O
expanded	O
.	O
	
linkage	O
analysis	O
between	O
the	O
aniridia	B-Disease
phenotype	O
and	O
acp1	O
does	O
not	O
support	O
the	O
original	O
linkage	O
results	O
,	O
excluding	O
linkage	O
up	O
to	O
theta	O
=	O
0	O
.	O
	
apob	O
,	O
d2s71	O
,	O
d2s5	O
,	O
and	O
d2s1	O
,	O
also	O
excluded	O
linkage	O
to	O
aniridia	B-Disease
.	O
	
markers	O
that	O
have	O
been	O
isolated	O
from	O
the	O
chromosome	O
11p13	O
region	O
were	O
then	O
analyzed	O
in	O
this	O
aniridia	B-Disease
family	O
.	O
	
these	O
data	O
suggest	O
that	O
a	O
locus	O
for	O
aniridia	B-Disease
(	O
an1	O
)	O
on	O
chromosome	O
2p	O
has	O
been	O
misassigned	O
and	O
that	O
this	O
autosomal	O
dominant	O
aniridia	B-Disease
family	O
is	O
segregating	O
for	O
an	O
aniridia	B-Disease
mutation	O
linked	O
to	O
markers	O
in	O
the	O
11p13	O
region	O
.	O
	
fatal	O
pyoderma	B-Disease
gangrenosum	I-Disease
in	O
association	O
with	O
c7	B-Disease
deficiency	I-Disease
.	O
	
although	O
pyoderma	B-Disease
gangrenosum	I-Disease
(	O
pg	B-Disease
)	O
is	O
often	O
associated	O
with	O
systemic	B-Disease
diseases	I-Disease
,	O
it	O
has	O
not	O
been	O
reported	O
in	O
association	O
with	O
congenital	B-Disease
complement	I-Disease
deficiencies	I-Disease
.	O
	
we	O
describe	O
an	O
aggressive	O
and	O
ultimately	O
fatal	O
case	O
of	O
pg	B-Disease
in	O
a	O
patient	O
with	O
a	O
congenital	O
c7	B-Disease
deficiency	I-Disease
.	O
	
deficiencies	B-Disease
of	I-Disease
c7	I-Disease
can	O
be	O
associated	O
with	O
decreased	O
neutrophil	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
opsonization	O
,	O
similar	O
to	O
the	O
immunologic	B-Disease
abnormalities	I-Disease
described	O
in	O
patients	O
with	O
pg	B-Disease
.	O
	
our	O
patients	O
decreased	O
complement	O
level	O
,	O
if	O
not	O
directly	O
related	O
to	O
the	O
development	O
of	O
pg	B-Disease
,	O
may	O
have	O
contributed	O
to	O
the	O
aggressive	O
nature	O
of	O
her	O
disease	O
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
;	I-Disease
ec	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
the	O
most	O
common	O
human	O
enzymopathy	B-Disease
,	O
affecting	O
more	O
than	O
200	O
million	O
people	O
worldwide	O
.	O
	
although	O
greater	O
than	O
400	O
variants	O
have	O
been	O
described	O
based	O
on	O
clinical	O
and	O
biochemical	O
criteria	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
basis	O
of	O
these	O
g6pd	B-Disease
deficiencies	I-Disease
.	O
	
the	O
1376	O
g	O
-	O
-	O
-	O
-	O
t	O
mutation	O
seems	O
to	O
be	O
the	O
dominant	O
allele	O
that	O
causes	O
g6pd	B-Disease
deficiency	I-Disease
in	O
taiwan	O
.	O
	
our	O
studies	O
provide	O
the	O
direct	O
proof	O
of	O
the	O
genetic	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
in	O
the	O
chinese	O
populations	O
of	O
taiwan	O
and	O
the	O
pcr	O
/	O
re	O
digestion	O
method	O
is	O
suitable	O
for	O
simultaneous	O
detection	O
of	O
the	O
487	O
g	O
-	O
-	O
-	O
-	O
a	O
and	O
493	O
a	O
-	O
-	O
-	O
-	O
g	O
mutations	O
.	O
	
an	O
error	O
in	O
dystrophin	O
mrna	O
processing	O
in	O
golden	B-Disease
retriever	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
an	O
animal	O
homologue	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
golden	B-Disease
retriever	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
grmd	B-Disease
)	O
is	O
a	O
spontaneous	O
,	O
x	O
-	O
linked	O
,	O
progressively	O
fatal	O
disease	O
of	O
dogs	O
and	O
is	O
also	O
a	O
homologue	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
two	O
-	O
thirds	O
of	O
dmd	B-Disease
patients	O
carry	O
detectable	O
deletions	O
in	O
their	O
dystrophin	O
gene	O
.	O
	
the	O
defect	O
underlying	O
the	O
remaining	O
one	O
-	O
third	O
of	O
dmd	B-Disease
patients	O
is	O
undetermined	O
.	O
	
analysis	O
of	O
the	O
canine	O
dystrophin	O
gene	O
in	O
normal	O
and	O
grmd	B-Disease
dogs	O
has	O
failed	O
to	O
demonstrate	O
any	O
detectable	O
loss	O
of	O
exons	O
.	O
	
here	O
,	O
we	O
have	O
demonstrated	O
a	O
rna	O
processing	O
error	O
in	O
grmd	B-Disease
that	O
results	O
from	O
a	O
single	O
base	O
change	O
in	O
the	O
3	O
consensus	O
splice	O
site	O
of	O
intron	O
6	O
.	O
	
this	O
is	O
the	O
first	O
example	O
of	O
dystrophin	B-Disease
deficiency	I-Disease
caused	O
by	O
a	O
splice	O
-	O
site	O
mutation	O
.	O
	
type	B-Disease
i	I-Disease
human	I-Disease
complement	I-Disease
c2	I-Disease
deficiency	I-Disease
.	O
	
two	O
variants	O
of	O
a	O
genetic	O
deficiency	B-Disease
of	I-Disease
complement	I-Disease
protein	I-Disease
c2	I-Disease
(	O
c2d	O
)	O
have	O
been	O
previously	O
identified	O
.	O
	
type	B-Disease
i	I-Disease
c2	I-Disease
deficiency	I-Disease
was	O
described	O
in	O
a	O
family	O
in	O
which	O
the	O
c2	O
nan	O
allele	O
(	O
c2q0	O
)	O
is	O
associated	O
with	O
the	O
major	O
histocompatibility	O
haplotype	O
/	O
complotype	O
hla	O
-	O
a25	O
,	O
b18	O
,	O
c2q0	O
,	O
bfs	O
,	O
c4a4	O
,	O
c4b2	O
,	O
drw2	O
;	O
this	O
extended	O
haplotype	O
occurs	O
in	O
over	O
90	O
%	O
of	O
c2	B-Disease
-	I-Disease
deficient	I-Disease
individuals	O
(	O
common	O
complotype	O
/	O
haplotype	O
)	O
.	O
	
to	O
determine	O
the	O
molecular	O
basis	O
of	O
type	B-Disease
i	I-Disease
c2	I-Disease
deficiency	I-Disease
,	O
the	O
c2	O
gene	O
and	O
cdna	O
were	O
characterized	O
from	O
a	O
homozygous	O
type	B-Disease
i	I-Disease
c2	I-Disease
-	I-Disease
deficient	I-Disease
individual	O
with	O
the	O
common	O
associated	O
haplotype	O
/	O
complotype	O
.	O
	
in	O
studies	O
of	O
eight	O
kindred	O
,	O
the	O
28	O
-	O
base	O
pair	O
deletion	O
was	O
observed	O
in	O
all	O
c2q0	O
alleles	O
associated	O
with	O
the	O
common	O
type	O
i	O
deficient	O
complotype	O
/	O
haplotype	O
;	O
this	O
deletion	O
was	O
not	O
present	O
in	O
normal	O
c2	O
nor	O
in	O
type	B-Disease
ii	I-Disease
c2	I-Disease
-	I-Disease
deficient	I-Disease
genes	O
.	O
	
these	O
data	O
demonstrate	O
that	O
1	O
)	O
type	B-Disease
i	I-Disease
human	I-Disease
complement	I-Disease
c2	I-Disease
deficiency	I-Disease
is	O
caused	O
by	O
a	O
28	O
-	O
base	O
pair	O
genomic	O
deletion	O
that	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
rna	O
splicing	O
,	O
resulting	O
in	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
,	O
2	O
)	O
the	O
28	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
type	O
i	O
c2q0	O
gene	O
is	O
strongly	O
associated	O
with	O
the	O
hla	O
haplotype	O
/	O
complotype	O
a25	O
,	O
b18	O
,	O
c2q0	O
,	O
bfs	O
,	O
c4a4	O
,	O
c4b2	O
,	O
drw2	O
,	O
suggesting	O
that	O
all	O
c2	B-Disease
-	I-Disease
deficient	I-Disease
individuals	O
with	O
this	O
haplotype	O
/	O
complotype	O
will	O
harbor	O
the	O
28	O
-	O
base	O
pair	O
c2	O
gene	O
deletion	O
,	O
and	O
3	O
)	O
type	B-Disease
ii	I-Disease
c2	I-Disease
deficiency	I-Disease
is	O
caused	O
by	O
a	O
different	O
,	O
as	O
yet	O
uncharacterized	O
,	O
molecular	O
genetic	B-Disease
defect	I-Disease
.	O
	
molecular	O
characterization	O
of	O
two	O
galactosemia	B-Disease
mutations	O
and	O
one	O
polymorphism	O
:	O
implications	O
for	O
structure	O
-	O
function	O
analysis	O
of	O
human	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
.	O
	
we	O
report	O
here	O
the	O
molecular	O
characterization	O
of	O
two	O
galactosemia	B-Disease
mutations	O
,	O
l74p	O
and	O
f171s	O
,	O
and	O
one	O
polymorphism	O
,	O
s135l	O
,	O
in	O
human	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
.	O
	
both	O
galactosemia	B-Disease
mutations	O
result	O
in	O
reduced	O
enzymatic	O
activity	O
when	O
reconstructed	O
in	O
the	O
cdna	O
and	O
overexpressed	O
.	O
	
our	O
data	O
further	O
support	O
the	O
notion	O
of	O
molecular	O
heterogeneity	O
of	O
galactosemia	B-Disease
and	O
suggest	O
that	O
galactosemia	B-Disease
mutations	O
and	O
galt	O
polymorphisms	O
may	O
be	O
useful	O
tools	O
in	O
highlighting	O
different	O
functional	O
domains	O
in	O
human	O
galt	O
.	O
	
linkage	O
relationship	O
of	O
c2	B-Disease
deficiency	I-Disease
,	O
hla	O
and	O
glyoxalase	O
i	O
loci	O
.	O
	
immunogenetic	O
analysis	O
of	O
a	O
homozygous	O
c2	B-Disease
-	I-Disease
deficient	I-Disease
individual	O
and	O
family	O
members	O
demonstrated	O
linkage	O
of	O
hla	O
-	O
a25	O
,	O
b18	O
and	O
c2o	O
.	O
	
hla	O
-	O
d	O
typing	O
showed	O
that	O
5	O
members	O
typed	O
with	O
homozygous	O
dw2	O
typing	O
cells	O
from	O
an	O
individual	O
with	O
c2	B-Disease
deficiency	I-Disease
but	O
not	O
with	O
dw2	O
typing	O
cells	O
from	O
2	O
individuals	O
with	O
normal	O
c2	O
.	O
	
the	O
homozygous	O
c2	B-Disease
-	I-Disease
deficient	I-Disease
propositus	O
and	O
brother	O
were	O
hla	O
-	O
a	O
and	O
b	O
homozygous	O
but	O
heterozygous	O
at	O
the	O
hla	O
-	O
d	O
and	O
glyoxalase	O
i	O
loci	O
.	O
	
germline	O
mutations	O
in	O
the	O
wilms	B-Disease
'	I-Disease
tumor	I-Disease
suppressor	O
gene	O
are	O
associated	O
with	O
abnormal	O
urogenital	O
development	O
in	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
.	O
	
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
human	O
condition	O
in	O
which	O
severe	O
urogenital	B-Disease
aberrations	I-Disease
result	O
in	O
renal	B-Disease
failure	I-Disease
,	O
pseudohermaphroditism	B-Disease
,	O
and	O
wilms	B-Disease
tumor	I-Disease
(	O
nephroblastoma	B-Disease
)	O
.	O
	
to	O
investigate	O
its	O
possible	O
role	O
,	O
we	O
have	O
analyzed	O
the	O
coding	O
exons	O
of	O
the	O
wilms	B-Disease
tumor	I-Disease
suppressor	O
gene	O
(	O
wt1	O
)	O
for	O
germline	O
mutations	O
.	O
	
in	O
ten	O
independent	O
cases	O
of	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
,	O
point	O
mutations	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
one	O
wt1	O
gene	O
copy	O
were	O
found	O
.	O
	
wilms	B-Disease
tumors	I-Disease
from	O
three	O
individuals	O
and	O
one	O
juvenile	O
granulosa	O
cell	O
tumor	B-Disease
demonstrate	O
reduction	O
to	O
homozygosity	O
for	O
the	O
mutated	O
wt1	O
allele	O
.	O
	
our	O
results	O
provide	O
evidence	O
of	O
a	O
direct	O
role	O
for	O
wt1	O
in	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
and	O
thus	O
urogenital	O
system	O
development	O
.	O
	
linkage	O
analysis	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
and	O
application	O
in	O
post	O
-	O
and	O
prenatal	O
diagnosis	O
.	O
	
we	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
dna	O
markers	O
dxs52	O
and	O
the	O
clotting	O
factor	O
viii	O
gene	O
(	O
f8c	O
)	O
,	O
in	O
several	O
large	O
families	O
with	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ald	B-Disease
)	O
.	O
	
f8c	O
was	O
also	O
tightly	O
linked	O
to	O
ald	B-Disease
with	O
a	O
maximal	O
lod	O
score	O
of	O
7	O
.	O
	
multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
dxs304	O
,	O
dxs52	O
,	O
and	O
f8c	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ald	B-Disease
and	O
for	O
f8c	O
are	O
distal	O
to	O
dxs52	O
.	O
	
in	O
four	O
patients	O
with	O
ald	B-Disease
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
xqter	O
region	O
was	O
observed	O
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B-Disease
in	I-Disease
the	I-Disease
vision	I-Disease
blindness	I-Disease
genes	I-Disease
.	O
	
two	O
distinct	O
mutations	O
at	O
a	O
single	O
bamhi	O
site	O
in	O
phenylketonuria	B-Disease
.	O
	
classical	B-Disease
phenylketonuria	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
the	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
pku	B-Disease
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
pah	B-Disease
deficiencies	I-Disease
.	O
	
a	O
detailed	O
10	O
-	O
point	O
map	O
of	O
the	O
4p16	O
region	O
constructed	O
from	O
the	O
ceph	O
panel	O
provides	O
evidence	O
for	O
heterogeneity	O
in	O
the	O
linkage	O
maps	O
constructed	O
from	O
families	O
segregating	O
for	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
.	O
	
carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
using	O
a	O
combination	O
of	O
anonymous	O
dna	O
polymorphisms	O
and	O
the	O
proteolipid	O
protein	O
(	O
plp	O
)	O
gene	O
cdna	O
.	O
	
we	O
report	O
carrier	O
identification	O
and	O
a	O
prenatal	O
diagnosis	O
using	O
dna	O
polymorphisms	O
in	O
2	O
families	O
with	O
x	B-Disease
-	I-Disease
linked	I-Disease
pelizaeus	I-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
.	O
	
in	O
the	O
case	O
of	O
the	O
prenatal	O
diagnosis	O
,	O
the	O
fetus	O
was	O
shown	O
by	O
cytogenetic	O
analysis	O
to	O
be	O
a	O
female	O
,	O
who	O
we	O
predict	O
will	O
be	O
a	O
noncarrier	O
of	O
pmd	B-Disease
based	O
on	O
her	O
genotype	O
with	O
the	O
plp	O
intragenic	O
polymorphism	O
.	O
	
identification	O
of	O
deletion	O
mutations	O
and	O
three	O
new	O
genes	O
at	O
the	O
familial	B-Disease
polyposis	I-Disease
locus	O
.	O
	
small	O
(	O
100	O
-	O
260	O
kb	O
)	O
,	O
nested	O
deletions	O
were	O
characterized	O
in	O
dna	O
from	O
two	O
unrelated	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
.	O
	
exclusion	O
of	O
linkage	O
between	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
and	O
the	O
human	O
serum	O
amyloid	O
a	O
(	O
saa	O
)	O
gene	O
cluster	O
.	O
	
we	O
studied	O
the	O
relationship	O
between	O
the	O
autosomal	O
recessive	O
trait	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
and	O
the	O
serum	O
amyloid	O
a	O
(	O
saa	O
)	O
genes	O
by	O
comparing	O
alleles	O
of	O
a	O
highly	O
polymorphic	O
dinucleotide	O
repeat	O
and	O
a	O
conventional	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
rflp	O
)	O
in	O
the	O
saa	O
gene	O
cluster	O
in	O
israeli	O
fmf	B-Disease
kindreds	O
.	O
	
by	O
haplotype	O
analysis	O
,	O
our	O
data	O
indicate	O
a	O
minimum	O
crossover	O
frequency	O
of	O
22	O
%	O
between	O
the	O
saa	O
gene	O
marker	O
and	O
fmf	B-Disease
.	O
	
4	O
cm	O
including	O
and	O
surrounding	O
the	O
saa	O
gene	O
cluster	O
as	O
the	O
site	O
of	O
the	O
fmf	B-Disease
mutation	O
although	O
saa	O
proteins	O
are	O
prominent	O
physiologic	O
markers	O
of	O
the	O
acute	O
attacks	O
.	O
	
prad1	O
,	O
a	O
candidate	O
bcl1	O
oncogene	O
:	O
mapping	O
and	O
expression	O
in	O
centrocytic	B-Disease
lymphoma	I-Disease
.	O
	
rearrangement	O
of	O
the	O
bcl1	O
(	O
b	O
-	O
cell	O
lymphoma	O
1	O
)	O
region	O
on	O
chromosome	O
11q13	O
appears	O
to	O
be	O
highly	O
characteristic	O
of	O
centrocytic	B-Disease
lymphoma	I-Disease
and	O
also	O
is	O
found	O
infrequently	O
in	O
other	O
b	B-Disease
-	I-Disease
cell	I-Disease
neoplasms	I-Disease
.	O
	
prad1	O
,	O
previously	O
designated	O
d11s287e	O
,	O
was	O
identified	O
on	O
11q13	O
as	O
a	O
chromosomal	O
breakpoint	O
region	O
rearranged	O
with	O
the	O
parathyroid	O
hormone	O
gene	O
in	O
a	O
subset	O
of	O
parathyroid	B-Disease
adenomas	I-Disease
;	O
this	O
highly	O
conserved	O
putative	O
oncogene	O
,	O
which	O
encodes	O
a	O
novel	O
cyclin	O
,	O
has	O
been	O
linked	O
to	O
bcl1	O
and	O
implicated	O
also	O
in	O
subsets	O
of	O
breast	B-Disease
and	I-Disease
squamous	I-Disease
cell	I-Disease
neoplasms	I-Disease
with	O
11q13	O
amplification	O
.	O
	
prad1	O
mrna	O
is	O
abundantly	O
expressed	O
in	O
seven	O
of	O
seven	O
centrocytic	B-Disease
lymphomas	I-Disease
(	O
kiel	O
classification	O
)	O
,	O
in	O
contrast	O
to	O
13	O
closely	O
related	O
but	O
noncentrocytic	B-Disease
lymphomas	I-Disease
.	O
	
three	O
of	O
the	O
seven	O
centrocytic	B-Disease
lymphomas	I-Disease
had	O
detectable	O
bcl1	O
dna	O
rearrangement	O
.	O
	
its	O
overexpression	O
may	O
be	O
a	O
key	O
consequence	O
of	O
rearrangement	O
of	O
the	O
bcl1	O
vicinity	O
in	O
b	B-Disease
-	I-Disease
cell	I-Disease
neoplasms	I-Disease
and	O
a	O
unifying	O
pathogenetic	O
feature	O
in	O
centrocytic	B-Disease
lymphoma	I-Disease
.	O
	
two	O
new	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
mutations	O
in	O
a	O
juvenile	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
patient	O
.	O
	
fragments	O
of	O
the	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
gene	O
from	O
a	O
patient	O
with	O
juvenile	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
were	O
amplified	O
by	O
pcr	O
and	O
ligated	O
into	O
mp13	O
cloning	O
vectors	O
.	O
	
a	O
collection	O
of	O
dna	O
samples	O
from	O
known	O
or	O
suspected	O
mld	B-Disease
patients	O
,	O
members	O
of	O
their	O
families	O
,	O
and	O
normal	O
controls	O
was	O
screened	O
for	O
these	O
mutations	O
.	O
	
four	O
additional	O
individuals	O
carrying	O
each	O
of	O
the	O
mutations	O
were	O
found	O
among	O
the	O
nearly	O
100	O
mld	B-Disease
patients	O
in	O
the	O
sample	O
.	O
	
however	O
,	O
combinations	O
with	O
other	O
mld	B-Disease
mutations	O
suggest	O
that	O
the	O
point	O
mutation	O
in	O
exon	O
3	O
does	O
result	O
in	O
some	O
residual	O
enzyme	O
activity	O
and	O
is	O
associated	O
with	O
late	O
-	O
onset	O
forms	O
of	O
the	O
disease	O
.	O
	
the	O
splice	O
-	O
site	O
mutation	O
following	O
exon	O
7	O
produces	O
late	O
-	O
infantile	O
mld	B-Disease
when	O
combined	O
with	O
other	O
enzyme	O
-	O
nan	O
mutations	O
,	O
implying	O
that	O
it	O
is	O
completely	O
silent	O
enzymatically	O
.	O
	
analysis	O
of	O
x	O
-	O
chromosome	O
inactivation	O
and	O
presumptive	O
expression	O
of	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
gene	O
in	O
hematopoietic	O
cell	O
lineages	O
of	O
a	O
thrombocytopenic	O
carrier	O
female	O
of	O
was	B-Disease
.	O
	
we	O
report	O
on	O
a	O
thrombocytopenic	B-Disease
female	O
belonging	O
to	O
a	O
pedigree	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
.	O
	
restriction	O
fragment	O
length	O
polymorphism	O
(	O
rflp	O
)	O
analysis	O
with	O
probe	O
m27	O
beta	O
,	O
closely	O
linked	O
to	O
the	O
was	B-Disease
gene	O
,	O
demonstrated	O
that	O
she	O
is	O
a	O
carrier	O
of	O
was	B-Disease
.	O
	
both	O
small	O
-	O
sized	O
and	O
normal	O
-	O
sized	O
platelets	O
were	O
present	O
,	O
suggesting	O
that	O
,	O
unlike	O
the	O
vast	O
majority	O
of	O
was	B-Disease
carriers	O
,	O
she	O
does	O
not	O
manifest	O
nonrandom	O
x	O
-	O
chromosome	O
inactivation	O
in	O
the	O
thrombopoietic	O
cell	O
lineage	O
.	O
	
while	O
this	O
is	O
the	O
first	O
complete	O
report	O
on	O
the	O
occurrence	O
of	O
thrombocytopenia	B-Disease
in	O
a	O
carrier	O
female	O
of	O
was	B-Disease
as	O
the	O
result	O
of	O
atypical	O
lyonization	O
,	O
it	O
also	O
suggests	O
that	O
expression	O
of	O
the	O
was	B-Disease
gene	O
occurs	O
at	O
(	O
or	O
extends	O
up	O
to	O
)	O
a	O
later	O
stage	O
than	O
the	O
multipotent	O
stem	O
cell	O
along	O
the	O
hematopoietic	O
differentiation	O
pathway	O
.	O
	
a	O
new	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
(	O
plp	O
)	O
gene	O
in	O
a	O
german	O
family	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
a	O
c	O
-	O
to	O
-	O
t	O
transition	O
in	O
exon	O
4	O
of	O
the	O
plp	O
gene	O
was	O
found	O
in	O
2	O
affected	O
males	O
and	O
two	O
obligate	O
carriers	O
in	O
a	O
german	O
family	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
a	O
3	O
-	O
base	O
pair	O
in	O
-	O
frame	O
deletion	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
results	O
in	O
a	O
kinetic	O
variant	O
of	O
phenylketonuria	B-Disease
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
due	O
to	O
deficiency	B-Disease
of	I-Disease
a	I-Disease
hepatic	I-Disease
enzyme	I-Disease
,	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
the	O
absence	O
of	O
pah	O
activity	O
results	O
in	O
typical	O
pku	B-Disease
while	O
persistence	O
of	O
a	O
residual	O
enzyme	O
activity	O
gives	O
rise	O
to	O
variant	O
forms	O
of	O
the	O
disease	O
.	O
	
finally	O
,	O
since	O
none	O
of	O
the	O
98	O
pku	B-Disease
patients	O
tested	O
were	O
found	O
to	O
carry	O
this	O
particular	O
deletion	O
,	O
our	O
study	O
suggests	O
that	O
this	O
molecular	O
event	O
probably	O
occurred	O
recently	O
on	O
the	O
background	O
of	O
a	O
haplotype	O
2	O
gene	O
in	O
portugal	O
.	O
	
mutation	O
of	O
the	O
kit	O
(	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
receptor	O
)	O
protooncogene	O
in	O
human	O
piebaldism	B-Disease
.	O
	
piebaldism	B-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
genetic	I-Disease
disorder	I-Disease
characterized	O
by	O
cogenital	O
patches	O
of	O
skin	O
and	O
hair	O
from	O
which	O
melanocytes	O
are	O
completely	O
absent	O
.	O
	
we	O
identified	O
a	O
kit	O
gene	O
mutation	O
in	O
a	O
proband	O
with	O
classic	O
autosomal	O
dominant	O
piebaldism	B-Disease
.	O
	
this	O
substitution	O
was	O
not	O
seen	O
in	O
any	O
normal	O
individuals	O
and	O
was	O
completely	O
linked	O
to	O
the	O
piebald	B-Disease
phenotype	O
in	O
the	O
probands	O
family	O
.	O
	
piebaldism	B-Disease
in	O
this	O
family	O
thus	O
appears	O
to	O
be	O
the	O
human	O
homologue	O
to	O
dominant	O
white	O
spotting	O
(	O
w	O
)	O
of	O
the	O
mouse	O
.	O
	
genetic	O
analysis	O
of	O
a	O
japanese	O
family	O
with	O
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
indicates	O
a	O
lack	O
of	O
linkage	O
to	O
the	O
apolipoprotein	O
b	O
gene	O
.	O
	
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
is	O
a	O
rare	O
familial	B-Disease
disorder	I-Disease
characterized	O
by	O
an	O
isolated	O
deficiency	B-Disease
of	I-Disease
apob	I-Disease
-	I-Disease
100	I-Disease
.	O
	
to	O
elucidate	O
the	O
genetic	B-Disease
abnormalities	I-Disease
in	O
this	O
family	O
,	O
we	O
studied	O
the	O
linkage	O
of	O
apob	O
gene	O
using	O
three	O
genetic	O
markers	O
.	O
	
localisation	O
of	O
the	O
gene	O
for	O
norrie	B-Disease
disease	I-Disease
to	O
between	O
dxs7	O
and	O
dxs426	O
on	O
xp	O
.	O
	
23	O
,	O
has	O
been	O
used	O
to	O
refine	O
further	O
the	O
localisation	O
of	O
the	O
gene	O
for	O
norrie	B-Disease
disease	I-Disease
(	O
ndp	B-Disease
)	O
.	O
	
the	O
results	O
from	O
a	O
multiply	O
informative	O
crossover	O
localize	O
the	O
ndp	B-Disease
gene	O
proximal	O
to	O
dxs7	O
.	O
	
in	O
conjunction	O
with	O
information	O
from	O
2	O
ndp	B-Disease
patients	O
who	O
have	O
a	O
deletion	O
for	O
dxs7	O
but	O
not	O
for	O
dsx426	O
,	O
our	O
data	O
indicate	O
that	O
the	O
ndp	B-Disease
gene	O
lies	O
between	O
dxs7	O
and	O
dxs426	O
on	O
proximal	O
xp	O
.	O
	
aberrant	O
splicing	O
of	O
phenylalanine	O
hydroxylase	O
mrna	O
:	O
the	O
major	O
cause	O
for	O
phenylketonuria	B-Disease
in	O
parts	O
of	O
southern	O
europe	O
.	O
	
because	O
of	O
the	O
high	O
frequency	O
of	O
these	O
particular	O
haplotypes	O
in	O
bulgaria	O
,	O
italy	O
,	O
and	O
turkey	O
,	O
it	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequent	O
defects	O
in	O
the	O
pah	O
gene	O
causing	O
classical	O
phenylketonuria	B-Disease
in	O
this	O
part	O
of	O
europe	O
.	O
	
gardner	B-Disease
syndrome	I-Disease
in	O
a	O
boy	O
with	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O
	
we	O
described	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
gardner	B-Disease
syndrome	I-Disease
(	O
gs	B-Disease
)	O
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
craniofacial	B-Disease
abnormalities	I-Disease
.	O
	
the	O
breakpoints	O
in	O
the	O
present	O
case	O
and	O
in	O
3	O
previously	O
reported	O
5q	O
-	O
patients	O
with	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
suggest	O
that	O
the	O
gene	O
responsible	O
for	O
gs	B-Disease
/	O
or	O
familial	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
fpc	B-Disease
)	O
is	O
in	O
the	O
5q22	O
region	O
,	O
a	O
result	O
consistent	O
with	O
the	O
findings	O
of	O
linkage	O
studies	O
huntington	B-Disease
disease	I-Disease
and	O
childhood	O
-	O
onset	O
tourette	B-Disease
syndrome	I-Disease
.	O
	
a	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
childhood	O
-	O
onset	O
tourette	B-Disease
syndrome	I-Disease
(	O
ts	B-Disease
)	O
developed	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
.	O
	
we	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood	O
-	O
onset	O
ts	B-Disease
with	O
adult	O
onset	O
hd	B-Disease
.	O
	
sequence	O
of	O
dna	O
flanking	O
the	O
exons	O
of	O
the	O
hexa	O
gene	O
,	O
and	O
identification	O
of	O
mutations	O
in	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
.	O
	
the	O
rapid	O
identification	O
of	O
mutations	O
causing	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
requires	O
the	O
capacity	O
to	O
readily	O
screen	O
the	O
regions	O
of	O
the	O
hexa	O
gene	O
most	O
likely	O
to	O
be	O
affected	O
by	O
mutation	O
.	O
	
five	O
novel	O
mutations	O
from	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
patients	O
were	O
detected	O
a	O
5	O
-	O
bp	O
deletion	O
of	O
tctcc	O
in	O
ivs	O
-	O
9	O
;	O
a	O
2	O
-	O
bp	O
deletion	O
of	O
tg	O
in	O
exon	O
5	O
;	O
g78	O
to	O
a	O
,	O
giving	O
a	O
stop	O
codon	O
in	O
exon	O
1	O
;	O
g533	O
to	O
t	O
in	O
exon	O
5	O
,	O
producing	O
the	O
third	O
amino	O
acid	O
substitution	O
detected	O
at	O
this	O
site	O
;	O
and	O
g	O
to	O
c	O
at	O
position	O
1	O
of	O
ivs	O
-	O
2	O
,	O
expected	O
to	O
produce	O
abnormal	O
splicing	O
.	O
	
molecular	O
characterization	O
of	O
two	O
galactosemia	B-Disease
mutations	O
:	O
correlation	O
of	O
mutations	O
with	O
highly	O
conserved	O
domains	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
.	O
	
galactosemia	B-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	I-Disease
human	I-Disease
galactose	I-Disease
metabolism	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
enzyme	I-Disease
galactose	I-Disease
-	I-Disease
1	I-Disease
-	I-Disease
phosphate	I-Disease
uridyl	I-Disease
transferase	I-Disease
(	O
galt	O
)	O
.	O
	
the	O
arginine	O
188	O
mutation	O
is	O
the	O
most	O
common	O
galactosemia	B-Disease
mutation	O
characterized	O
to	O
date	O
.	O
	
it	O
accounts	O
for	O
one	O
-	O
fourth	O
of	O
the	O
galactosemia	B-Disease
alleles	O
studied	O
.	O
	
our	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
heterogeneity	O
of	O
galactosemia	B-Disease
at	O
the	O
molecular	O
level	O
,	O
heterogeneity	O
which	O
might	O
be	O
related	O
to	O
the	O
variable	O
clinical	O
outcome	O
observed	O
in	O
this	O
disorder	O
.	O
	
hypoxanthine	B-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
deficiency	I-Disease
:	O
analysis	O
of	O
hprt	O
mutations	O
by	O
direct	O
sequencing	O
and	O
allele	O
-	O
specific	O
amplification	O
.	O
	
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
is	O
a	O
severe	O
x	B-Disease
chromosome	I-Disease
-	I-Disease
linked	I-Disease
human	I-Disease
disease	I-Disease
caused	O
by	O
a	O
virtual	O
absence	B-Disease
of	I-Disease
hypoxanthine	I-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
(	I-Disease
hprt	I-Disease
)	I-Disease
activity	I-Disease
.	O
	
a	O
partial	O
deficiency	O
in	O
the	O
activity	O
of	O
this	O
enzyme	O
can	O
result	O
in	O
gouty	B-Disease
arthritis	I-Disease
.	O
	
to	O
determine	O
the	O
genetic	O
basis	O
for	O
reduction	O
or	O
loss	O
of	O
enzyme	O
activity	O
,	O
we	O
have	O
amplified	O
and	O
sequenced	O
the	O
coding	O
region	O
of	O
hprt	O
cdna	O
from	O
four	O
patients	O
one	O
with	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
(	O
hprtperth	O
)	O
and	O
three	O
with	O
partial	B-Disease
deficiencies	I-Disease
of	I-Disease
hprt	I-Disease
activity	I-Disease
,	O
which	O
have	O
been	O
designated	O
hprturangan	O
,	O
hprtswan	O
and	O
hprttoowong	O
.	O
	
molecular	O
and	O
metabolic	O
basis	O
for	O
the	O
metabolic	B-Disease
disorder	I-Disease
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
.	O
	
we	O
have	O
previously	O
described	O
a	O
disorder	O
,	O
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
,	O
that	O
is	O
characterized	O
by	O
the	O
virtual	O
absence	O
of	O
plasma	O
low	O
density	O
lipoproteins	O
and	O
complete	O
absence	O
of	O
apob	O
-	O
100	O
,	O
but	O
with	O
apparently	O
normal	O
secretion	O
of	O
triglyceride	O
-	O
rich	O
lipoproteins	O
containing	O
apob	O
-	O
48	O
.	O
	
thus	O
,	O
this	O
is	O
a	O
rare	O
example	O
of	O
homozygous	B-Disease
hypobetalipoproteinemia	I-Disease
.	O
	
a	O
single	O
origin	O
of	O
phenylketonuria	B-Disease
in	O
yemenite	O
jews	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
a	O
metabolic	B-Disease
disease	I-Disease
caused	O
by	O
recessive	O
mutations	O
of	O
the	O
gene	O
encoding	O
the	O
hepatic	O
enzyme	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
.	O
	
the	O
incidence	O
of	O
pku	B-Disease
varies	O
widely	O
across	O
different	O
geographic	O
areas	O
,	O
and	O
is	O
highest	O
(	O
about	O
1	O
in	O
5	O
,	O
0	O
live	O
births	O
)	O
in	O
ireland	O
and	O
western	O
scotland	O
,	O
and	O
among	O
yemenite	O
jews	O
.	O
	
a	O
limited	O
number	O
of	O
point	O
mutations	O
account	O
for	O
most	O
of	O
the	O
pku	B-Disease
cases	O
in	O
the	O
european	O
population	O
.	O
	
here	O
we	O
report	O
that	O
a	O
single	O
molecular	O
defect	O
-	O
-	O
a	O
deletion	O
spanning	O
the	O
third	O
exon	O
of	O
the	O
pah	O
gene	O
-	O
-	O
is	O
responsible	O
for	O
all	O
the	O
pku	B-Disease
cases	O
among	O
the	O
yemenite	O
jews	O
.	O
	
although	O
the	O
deleted	O
pah	O
gene	O
was	O
traced	O
to	O
25	O
different	O
locations	O
throughout	O
yemen	O
,	O
family	O
histories	O
and	O
official	O
documents	O
of	O
the	O
yemenite	O
jewish	O
community	O
showed	O
that	O
the	O
common	O
ancestor	O
of	O
all	O
the	O
carriers	O
of	O
this	O
genetic	B-Disease
defect	I-Disease
lived	O
in	O
sana	O
,	O
the	O
capital	O
of	O
yemen	O
,	O
before	O
the	O
eighteenth	O
century	O
.	O
	
linkage	O
of	O
aspartylglucosaminuria	B-Disease
(	O
agu	B-Disease
)	O
to	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
.	O
	
aspartylglucosaminuria	B-Disease
(	O
agu	B-Disease
)	O
is	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
enzyme	O
aspartylglucosaminidase	O
(	O
aga	O
)	O
.	O
	
restriction	O
fragment	O
length	O
polymorphism	O
alleles	O
for	O
the	O
adh2	O
,	O
adh3	O
,	O
egf	O
,	O
fg	O
alpha	O
and	O
fg	O
beta	O
loci	O
and	O
blood	O
group	O
antigens	O
for	O
the	O
mns	O
locus	O
were	O
determined	O
in	O
a	O
panel	O
of	O
12	O
finnish	O
agu	B-Disease
families	O
.	O
	
loose	O
linkage	O
of	O
the	O
agu	B-Disease
locus	O
to	O
the	O
fg	O
and	O
mns	O
loci	O
was	O
observed	O
(	O
z	O
=	O
1	O
.	O
	
linkage	O
relationships	O
of	O
the	O
apolipoprotein	O
c1	O
gene	O
and	O
a	O
cytochrome	O
p450	O
gene	O
(	O
cyp2a	O
)	O
to	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
we	O
have	O
studied	O
the	O
genetic	O
linkage	O
of	O
two	O
markers	O
,	O
the	O
apolipoprotein	O
c1	O
(	O
apoc1	O
)	O
gene	O
and	O
a	O
cytochrome	O
p450	O
(	O
cyp2a	O
)	O
gene	O
,	O
in	O
relation	O
to	O
the	O
gene	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
.	O
	
genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
dna	O
markers	O
around	O
the	O
gene	O
for	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
on	O
chromosome	O
5	O
.	O
	
a	O
genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
dna	O
markers	O
close	O
to	O
the	O
gene	O
(	O
apc	O
)	O
for	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
on	O
chromosome	O
5q	O
is	O
reported	O
.	O
	
one	O
hundred	O
fifty	O
-	O
five	O
typed	O
members	O
of	O
nine	O
fap	B-Disease
kindred	O
provided	O
more	O
than	O
90	O
meioses	O
for	O
linkage	O
analysis	O
.	O
	
48	O
,	O
but	O
published	O
deletion	O
mapping	O
in	O
colorectal	B-Disease
carcinomas	I-Disease
and	O
linkage	O
analysis	O
in	O
fap	B-Disease
suggest	O
that	O
yn5	O
.	O
	
44	O
locus	O
lies	O
very	O
close	O
to	O
the	O
apc	B-Disease
gene	O
.	O
	
these	O
data	O
not	O
only	O
allow	O
use	O
of	O
flanking	O
markers	O
for	O
presymptomatic	O
diagnosis	O
of	O
fap	B-Disease
but	O
also	O
provide	O
a	O
high	O
-	O
density	O
map	O
of	O
the	O
region	O
for	O
isolation	O
of	O
the	O
apc	B-Disease
gene	O
itself	O
and	O
for	O
further	O
assessment	O
of	O
the	O
role	O
of	O
chromosome	O
5	O
deletions	O
in	O
the	O
biology	O
of	O
sporadic	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
serum	O
amyloid	O
a	O
and	O
p	O
protein	O
genes	O
in	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
.	O
	
two	O
recent	O
studies	O
have	O
suggested	O
the	O
involvement	O
of	O
serum	O
amyloid	O
a	O
(	O
saa	O
)	O
and	O
p	O
(	O
apcs	O
)	O
genes	O
in	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
mef	B-Disease
)	O
.	O
	
to	O
test	O
the	O
role	O
of	O
saa	O
and	O
apcs	O
in	O
mef	B-Disease
and	O
mef	B-Disease
-	I-Disease
amyloidosis	I-Disease
,	O
we	O
studied	O
17	O
informative	O
families	O
(	O
15	O
armenians	O
,	O
2	O
non	O
-	O
ashkenazi	O
jews	O
)	O
and	O
8	O
mef	B-Disease
patients	O
with	O
amyloidosis	B-Disease
using	O
a	O
candidate	O
gene	O
approach	O
.	O
	
no	O
evidence	O
for	O
any	O
mef	B-Disease
-	O
associated	O
polymorphism	O
was	O
found	O
in	O
any	O
of	O
the	O
41	O
armenian	O
and	O
jewish	O
mef	B-Disease
patients	O
tested	O
.	O
	
our	O
family	O
studies	O
allowed	O
us	O
to	O
rule	O
out	O
tight	O
linkage	O
between	O
saa	O
and	O
mef	B-Disease
(	O
lod	O
score	O
=	O
-	O
2	O
.	O
	
for	O
apcs	O
we	O
found	O
that	O
the	O
allele	O
frequency	O
in	O
the	O
mef	B-Disease
-	I-Disease
amyloidosis	I-Disease
patients	O
was	O
similar	O
to	O
that	O
in	O
18	O
unrelated	O
mef	B-Disease
patients	O
without	O
amyloidosis	B-Disease
and	O
their	O
33	O
healthy	O
parents	O
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
appears	O
to	O
be	O
fairly	O
common	O
in	O
mexico	O
.	O
	
two	O
other	O
mexican	O
males	O
with	O
g6pd	B-Disease
deficiency	I-Disease
were	O
found	O
to	O
have	O
the	O
same	O
mutation	O
.	O
	
hereditary	O
deficiency	B-Disease
of	I-Disease
c5	I-Disease
in	O
association	O
with	O
discoid	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O
	
a	O
29	O
-	O
year	O
-	O
old	O
woman	O
with	O
discoid	B-Disease
lupus	I-Disease
erythematosus	I-Disease
had	O
undetectable	O
classic	O
pathway	O
complement	O
activity	O
.	O
	
hypocomplementemia	B-Disease
was	O
due	O
to	O
selective	O
deficiency	B-Disease
of	I-Disease
c5	I-Disease
.	O
	
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
documented	O
case	O
of	O
an	O
association	O
between	O
discoid	B-Disease
lupus	I-Disease
erythematosus	I-Disease
and	O
c5	B-Disease
deficiency	I-Disease
.	O
	
founder	O
effect	O
of	O
a	O
prevalent	O
phenylketonuria	B-Disease
mutation	O
in	O
the	O
oriental	O
population	O
.	O
	
a	O
missense	O
mutation	O
has	O
been	O
identified	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
[	O
pah	O
;	O
phenylalanine	O
4	O
-	O
monooxygenase	O
;	O
l	O
-	O
phenylalanine	O
,	O
tetrahydrobiopterin	O
oxygen	O
oxidoreductase	O
(	O
4	O
-	O
hydroxylating	O
)	O
,	O
ec	O
1	O
.	O
	
1	O
]	O
gene	O
in	O
a	O
chinese	O
patient	O
with	O
classic	O
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
.	O
	
this	O
mutation	O
(	O
r413p	O
)	O
results	O
in	O
negligible	O
enzymatic	O
activity	O
when	O
expressed	O
in	O
heterologous	O
mammalian	O
cells	O
and	O
is	O
compatible	O
with	O
a	O
classic	O
pku	B-Disease
phenotype	O
in	O
the	O
patient	O
.	O
	
8	O
%	O
of	O
northern	O
chinese	O
and	O
27	O
%	O
of	O
japanese	O
pku	B-Disease
alleles	O
,	O
but	O
it	O
is	O
rare	O
in	O
southern	O
chinese	O
(	O
2	O
.	O
	
2	O
%	O
)	O
and	O
is	O
absent	O
in	O
the	O
caucasian	O
population	O
.	O
	
our	O
results	O
are	O
compatible	O
with	O
this	O
hypothesis	O
in	O
that	O
the	O
pku	B-Disease
mutation	O
might	O
have	O
occurred	O
in	O
northern	O
mongoloids	O
and	O
subsequently	O
spread	O
to	O
the	O
chinese	O
and	O
japanese	O
populations	O
.	O
	
glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
caused	O
by	O
a	O
defect	O
in	O
the	O
na	O
+	O
/	O
glucose	O
cotransporter	O
.	O
	
glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
(	O
ggm	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
manifesting	O
within	O
the	O
first	O
weeks	O
of	O
life	O
and	O
characterized	O
by	O
a	O
selective	O
failure	O
to	O
absorb	O
dietary	O
glucose	O
and	O
galactose	O
from	O
the	O
intestine	O
.	O
	
the	O
consequent	O
severe	O
diarrhoea	B-Disease
and	O
dehydration	B-Disease
are	O
usually	O
fatal	O
unless	O
these	O
sugars	O
are	O
eliminated	O
from	O
the	O
diet	O
.	O
	
intestinal	O
biopsies	O
of	O
ggm	B-Disease
patients	O
have	O
revealed	O
a	O
specific	O
defect	O
in	O
na	O
(	O
+	O
)	O
-	O
dependent	O
absorption	O
of	O
glucose	O
in	O
the	O
brush	O
border	O
.	O
	
we	O
have	O
now	O
amplified	O
sglt1	O
complementary	O
dna	O
and	O
genomic	O
dna	O
from	O
members	O
of	O
a	O
family	O
affected	O
with	O
ggm	B-Disease
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
	
sequence	O
analysis	O
of	O
the	O
amplified	O
products	O
has	O
revealed	O
a	O
single	O
missense	O
mutation	O
in	O
sglt1	O
which	O
cosegregates	O
with	O
the	O
ggm	B-Disease
phenotype	O
and	O
results	O
in	O
a	O
complete	O
loss	O
of	O
na	O
(	O
+	O
)	O
-	O
dependent	O
glucose	O
transport	O
in	O
xenopus	O
oocytes	O
injected	O
with	O
this	O
complementary	O
rna	O
.	O
	
a	O
de	O
novo	O
unbalanced	O
reciprocal	O
translocation	O
identified	O
as	O
paternal	O
in	O
origin	O
in	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
.	O
	
interstitial	O
cytogenetic	O
deletions	O
involving	O
the	O
paternally	O
derived	O
chromosome	O
15q11	O
-	O
13	O
have	O
been	O
described	O
in	O
patients	O
with	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
we	O
report	O
a	O
child	O
with	O
pws	B-Disease
and	O
a	O
de	O
novo	O
unbalanced	O
karyotype	O
-	O
45	O
,	O
xy	O
,	O
-	O
9	O
,	O
-	O
15	O
,	O
+	O
der	O
(	O
9	O
)	O
t	O
(	O
9	O
;	O
15	O
)	O
(	O
q34	O
;	O
q13	O
)	O
.	O
	
molecular	O
studies	O
with	O
the	O
dna	O
probe	O
pml34	O
confirmed	O
that	O
only	O
a	O
single	O
prader	B-Disease
willi	I-Disease
critical	O
region	O
(	O
pwcr	O
15q11	O
.	O
2	O
-	O
q12	O
)	O
copy	O
was	O
present	O
.	O
	
localisation	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
to	O
19q13	O
.	O
	
2	O
-	O
19q13	O
.	O
	
3	O
and	O
its	O
relationship	O
to	O
twelve	O
polymorphic	O
loci	O
on	O
19q	O
.	O
	
we	O
report	O
here	O
the	O
linkage	O
relationship	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
locus	O
to	O
twelve	O
of	O
these	O
markers	O
as	O
studied	O
in	O
45	O
families	O
with	O
dm	B-Disease
.	O
	
ten	O
of	O
the	O
twelve	O
markers	O
have	O
been	O
shown	O
to	O
be	O
proximal	O
to	O
the	O
dm	B-Disease
gene	O
and	O
two	O
,	O
prkcg	O
and	O
d19s22	O
,	O
distal	O
but	O
at	O
distances	O
of	O
approximately	O
25	O
cm	O
and	O
15	O
cm	O
,	O
respectively	O
.	O
	
the	O
closest	O
proximal	O
markers	O
are	O
apoc2	O
(	O
apolipoprotein	O
c	O
-	O
ii	O
)	O
and	O
ckm	O
(	O
creatine	O
kinase	O
,	O
muscle	O
)	O
approximately	O
3	O
cm	O
and	O
2	O
cm	O
from	O
the	O
dm	B-Disease
gene	O
respectively	O
,	O
in	O
the	O
order	O
apoc2	O
-	O
ckm	O
-	O
dm	O
.	O
	
the	O
distance	O
between	O
apoc2	O
,	O
ckm	O
and	O
dm	B-Disease
(	O
of	O
the	O
order	O
of	O
2	O
million	O
base	O
pairs	O
)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	O
walking	O
and	O
jumping	O
.	O
	
the	O
data	O
presented	O
here	O
should	O
enable	O
us	O
to	O
determine	O
whether	O
or	O
not	O
new	O
markers	O
are	O
distal	O
to	O
apoc2	O
/	O
ckm	O
and	O
thus	O
potentially	O
flank	O
the	O
dm	B-Disease
gene	O
.	O
	
the	O
human	O
gene	O
for	O
histidase	O
(	O
histidine	O
ammonia	O
-	O
lyase	O
;	O
hal	O
)	O
,	O
the	O
enzyme	O
deficient	O
in	O
histidinemia	B-Disease
,	O
was	O
assigned	O
to	O
human	O
chromosome	O
12	O
by	O
southern	O
blot	O
analysis	O
of	O
human	O
x	O
mouse	O
somatic	O
cell	O
hybrid	O
dna	O
.	O
	
determination	O
of	O
the	O
mutations	O
responsible	O
for	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
in	O
17	O
subjects	O
.	O
	
the	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
product	O
of	O
reverse	O
-	O
transcribed	O
hprt	O
mrna	O
enabled	O
the	O
rapid	O
identification	O
of	O
the	O
mutations	O
found	O
in	O
17	O
previously	O
uncharacterized	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
linkage	O
of	O
dna	O
markers	O
at	O
xq28	O
to	O
adrenoleukodystrophy	B-Disease
and	O
adrenomyeloneuropathy	B-Disease
present	O
within	O
the	O
same	O
family	O
.	O
	
we	O
present	O
a	O
large	O
kindred	O
that	O
contained	O
patients	O
with	O
either	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
or	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
.	O
	
the	O
pedigree	O
clearly	O
supported	O
the	O
x	O
-	O
linked	O
mode	O
of	O
inheritance	O
of	O
the	O
nonneonatal	O
form	O
of	O
ald	B-Disease
/	O
amn	B-Disease
.	O
	
analysis	O
with	O
dna	O
markers	O
at	O
xq28	O
suggested	O
segregation	O
of	O
both	O
ald	B-Disease
and	O
amn	B-Disease
with	O
an	O
identical	O
haplotype	O
.	O
	
this	O
indicated	O
that	O
nonneonatal	O
ald	B-Disease
and	O
amn	B-Disease
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
same	O
gene	O
at	O
xq28	O
.	O
	
it	O
showed	O
,	O
furthermore	O
,	O
that	O
phenotypic	O
differences	O
between	O
ald	B-Disease
and	O
amn	B-Disease
are	O
not	O
necessarily	O
the	O
consequence	O
of	O
allelic	O
heterogeneity	O
due	O
to	O
different	O
mutations	O
within	O
the	O
same	O
gene	O
.	O
	
the	O
maximal	O
lod	O
score	O
for	O
linkage	O
of	O
the	O
ald	B-Disease
/	O
amn	B-Disease
gene	O
and	O
the	O
multiallelic	O
anonymous	O
dna	O
marker	O
at	O
dxs52	O
was	O
3	O
.	O
	
skewed	O
x	O
inactivation	O
in	O
a	O
female	O
mz	O
twin	O
results	O
in	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
one	O
of	O
female	O
mz	O
twins	O
presented	O
with	O
muscular	B-Disease
dystrophy	I-Disease
.	O
	
physical	O
examination	O
,	O
creatine	O
phosphokinase	O
levels	O
,	O
and	O
muscle	O
biopsy	O
were	O
consistent	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
however	O
,	O
because	O
of	O
her	O
sex	O
she	O
was	O
diagnosed	O
as	O
having	O
limb	B-Disease
-	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
with	O
cdna	O
probes	O
to	O
the	O
dmd	B-Disease
gene	O
,	O
a	O
gene	O
deletion	O
was	O
detected	O
in	O
the	O
twins	O
and	O
their	O
mother	O
.	O
	
these	O
data	O
indicate	O
that	O
the	O
affected	O
twin	O
is	O
a	O
manifesting	O
carrier	O
of	O
an	O
abnormal	O
dmd	B-Disease
gene	O
,	O
her	O
myopathy	B-Disease
being	O
a	O
direct	O
result	O
of	O
underexpression	O
of	O
dystrophin	O
.	O
	
cytogenetic	O
analysis	O
revealed	O
normal	O
karyotypes	O
,	O
eliminating	O
the	O
possibility	O
of	O
a	O
translocation	O
affecting	O
dmd	B-Disease
gene	O
function	O
.	O
	
both	O
linkage	O
analysis	O
and	O
dna	O
fingerprint	O
analysis	O
revealed	O
that	O
each	O
twin	O
has	O
two	O
different	O
x	O
chromosomes	O
,	O
eliminating	O
the	O
possibility	O
of	O
uniparental	B-Disease
disomy	I-Disease
as	O
a	O
mechanism	O
for	O
dmd	B-Disease
expression	O
.	O
	
adrenoleukodystrophy	B-Disease
and	O
adrenomyeloneuropathy	B-Disease
associated	O
with	O
partial	O
adrenal	B-Disease
insufficiency	I-Disease
in	O
three	O
generations	O
of	O
a	O
kindred	O
.	O
	
four	O
cases	O
of	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
and	O
one	O
case	O
of	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
have	O
developed	O
in	O
a	O
kindred	O
over	O
three	O
generations	O
demonstrating	O
that	O
amn	B-Disease
is	O
a	O
clinical	O
variant	O
of	O
ald	B-Disease
.	O
	
pituitary	O
-	O
adrenal	O
function	O
studies	O
were	O
performed	O
in	O
10	O
family	O
members	O
,	O
including	O
two	O
affected	O
males	O
and	O
four	O
females	O
identified	O
as	O
carriers	O
of	O
ald	B-Disease
/	O
amn	B-Disease
.	O
	
no	O
pituitary	B-Disease
-	I-Disease
adrenal	I-Disease
abnormality	I-Disease
was	O
found	O
in	O
the	O
carriers	O
.	O
	
however	O
,	O
basal	O
morning	O
plasma	O
adrenocorticotropic	O
hormone	O
(	O
acth	O
)	O
levels	O
were	O
markedly	O
elevated	O
in	O
the	O
two	O
males	O
with	O
ald	B-Disease
and	O
amn	B-Disease
,	O
despite	O
the	O
fact	O
that	O
they	O
had	O
no	O
clinical	O
signs	O
of	O
adrenal	B-Disease
insufficiency	I-Disease
and	O
that	O
morning	O
plasma	O
cortisol	O
levels	O
and	O
their	O
response	O
to	O
maximal	O
exogenous	O
acth	O
stimulation	O
appeared	O
to	O
be	O
normal	O
.	O
	
thus	O
,	O
people	O
with	O
ald	B-Disease
and	O
amn	B-Disease
may	O
have	O
subclinical	O
partial	O
adrenocrotical	B-Disease
insufficiency	I-Disease
.	O
	
no	O
other	O
endocrinologic	B-Disease
dysfunction	I-Disease
was	O
identified	O
.	O
	
regional	O
localisation	O
of	O
the	O
friedreich	B-Disease
ataxia	I-Disease
locus	O
to	O
human	O
chromosome	O
9q13	O
-	O
-	O
-	O
-	O
q21	O
.	O
	
we	O
have	O
previously	O
assigned	O
the	O
friedreich	B-Disease
ataxia	I-Disease
locus	O
(	O
frda	O
)	O
to	O
chromosome	O
9	O
;	O
the	O
current	O
maximal	O
lod	O
score	O
between	O
frda	O
and	O
mct112	O
(	O
d9s15	O
)	O
is	O
greater	O
than	O
50	O
at	O
a	O
recombination	O
fraction	O
of	O
theta	O
=	O
0	O
.	O
	
we	O
recently	O
described	O
a	O
japanese	O
family	O
with	O
increased	O
hdl	O
levels	O
and	O
cetp	B-Disease
deficiency	I-Disease
due	O
to	O
a	O
splicing	O
defect	O
of	O
the	O
cetp	O
gene	O
.	O
	
family	O
members	O
homozygous	O
for	O
cetp	B-Disease
deficiency	I-Disease
(	O
n	O
=	O
10	O
)	O
had	O
moderate	O
hypercholesterolemia	B-Disease
(	O
mean	O
total	O
cholesterol	O
level	O
[	O
+	O
/	O
-	O
sd	O
]	O
,	O
7	O
.	O
83	O
mmol	O
per	O
liter	O
)	O
,	O
markedly	O
increased	O
levels	O
of	O
hdl	O
cholesterol	O
(	O
4	O
.	O
24	O
+	O
/	O
-	O
1	O
.	O
1	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	O
a	O
-	O
i	O
,	O
and	O
decreased	O
levels	O
of	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
80	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	O
b	O
.	O
	
cetp	B-Disease
deficiency	I-Disease
was	O
not	O
found	O
in	O
six	O
unrelated	O
subjects	O
with	O
elevated	O
hdl	O
cholesterol	O
levels	O
who	O
were	O
from	O
different	O
parts	O
of	O
the	O
united	O
states	O
.	O
	
cetp	B-Disease
deficiency	I-Disease
appears	O
to	O
be	O
a	O
frequent	O
cause	O
of	O
increased	O
hdl	O
levels	O
in	O
the	O
population	O
of	O
japan	O
,	O
possibly	O
because	O
of	O
a	O
founder	O
effect	O
.	O
	
there	O
was	O
no	O
evidence	O
of	O
premature	B-Disease
atherosclerosis	I-Disease
in	O
the	O
families	O
with	O
cetp	B-Disease
deficiency	I-Disease
.	O
	
in	O
fact	O
,	O
the	O
lipoprotein	O
profile	O
of	O
persons	O
with	O
cetp	B-Disease
deficiency	I-Disease
is	O
potentially	O
antiatherogenic	O
and	O
may	O
be	O
associated	O
with	O
an	O
increased	O
life	O
span	O
.	O
	
further	O
mapping	O
of	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
locus	O
to	O
the	O
chromosome	O
11q23	O
region	O
.	O
	
we	O
recently	O
mapped	O
the	O
gene	O
for	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
group	O
a	O
(	O
ata	O
)	O
to	O
chromosome	O
11q22	O
-	O
23	O
by	O
linkage	O
analysis	O
,	O
using	O
the	O
genetic	O
markers	O
thy1	O
and	O
pynb3	O
.	O
	
the	O
present	O
paper	O
describes	O
further	O
mapping	O
of	O
the	O
at	B-Disease
locus	O
by	O
means	O
of	O
a	O
panel	O
of	O
10	O
markers	O
that	O
span	O
approximately	O
60	O
cm	O
in	O
the	O
11q22	O
-	O
23	O
region	O
centered	O
around	O
s144	O
and	O
thy1	O
.	O
	
location	O
scores	O
indicate	O
that	O
three	O
contiguous	O
subsegments	O
within	O
the	O
[	O
s144	O
-	O
thy1	O
]	O
segment	O
,	O
as	O
well	O
as	O
three	O
contiguous	O
segments	O
telomeric	O
to	O
thy1	O
,	O
are	O
each	O
unlikely	O
to	O
contain	O
the	O
at	B-Disease
locus	O
,	O
while	O
the	O
more	O
centromeric	O
[	O
stmy	O
-	O
s144	O
]	O
segment	O
is	O
most	O
likely	O
to	O
contain	O
the	O
at	B-Disease
locus	O
.	O
	
these	O
data	O
,	O
together	O
with	O
recent	O
refinements	O
in	O
the	O
linkage	O
and	O
physical	O
maps	O
of	O
11q22	O
-	O
23	O
,	O
place	O
the	O
at	B-Disease
locus	O
at	O
11q23	O
.	O
	
recurrent	O
meningitis	B-Disease
in	O
a	O
patient	O
with	O
congenital	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
c9	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
.	O
	
first	O
case	O
of	O
c9	B-Disease
deficiency	I-Disease
in	O
europe	O
.	O
	
we	O
describe	O
the	O
first	O
cases	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
c9	B-Disease
deficiency	I-Disease
in	O
europe	O
that	O
were	O
detected	O
in	O
a	O
swiss	O
family	O
,	O
of	O
which	O
two	O
members	O
-	O
-	O
one	O
with	O
a	O
complete	O
deficiency	O
and	O
the	O
other	O
with	O
approximately	O
half	O
-	O
normal	O
c9	O
levels	O
-	O
-	O
experienced	O
bacterial	B-Disease
meningitis	I-Disease
.	O
	
the	O
index	O
patient	O
,	O
a	O
56	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
a	O
history	O
of	O
purulent	B-Disease
meningitis	I-Disease
at	O
the	O
age	O
of	O
23	O
years	O
,	O
presented	O
with	O
an	O
acute	B-Disease
meningococcal	I-Disease
meningitis	I-Disease
.	O
	
no	O
impairment	B-Disease
of	I-Disease
cellular	I-Disease
immunity	I-Disease
or	O
immunoglobulin	B-Disease
deficiency	I-Disease
could	O
be	O
found	O
.	O
	
complement	O
assays	O
showed	O
a	O
complete	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
c9	I-Disease
component	I-Disease
,	O
while	O
the	O
other	O
individual	O
component	O
levels	O
were	O
normal	O
and	O
the	O
hemolytic	O
activity	O
(	O
measured	O
using	O
the	O
ch50	O
assay	O
)	O
was	O
only	O
slightly	O
reduced	O
.	O
	
a	O
family	O
study	O
revealed	O
complete	B-Disease
c9	I-Disease
deficiency	I-Disease
in	O
the	O
patients	O
healthy	O
brother	O
and	O
half	O
-	O
normal	O
c9	O
concentrations	O
in	O
his	O
sister	O
,	O
his	O
son	O
(	O
who	O
also	O
had	O
experienced	O
an	O
episode	O
of	O
bacterial	B-Disease
meningitis	I-Disease
)	O
,	O
and	O
his	O
niece	O
,	O
consistent	O
with	O
an	O
inherited	O
c9	B-Disease
deficiency	I-Disease
.	O
	
this	O
first	O
case	O
of	O
recurrent	B-Disease
meningitis	I-Disease
in	O
a	O
white	O
patient	O
with	O
complete	B-Disease
c9	I-Disease
deficiency	I-Disease
suggests	O
that	O
this	O
complement	B-Disease
defect	I-Disease
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
bacterial	B-Disease
,	I-Disease
especially	I-Disease
neisserial	I-Disease
,	I-Disease
infections	I-Disease
.	O
	
detection	O
of	O
98	O
%	O
of	O
dmd	B-Disease
/	O
bmd	B-Disease
gene	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
.	O
	
when	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set	O
,	O
these	O
two	O
multiplex	O
reactions	O
detect	O
about	O
98	O
%	O
of	O
deletions	O
in	O
patients	O
with	O
duchenne	B-Disease
or	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
,	O
bmd	B-Disease
)	O
.	O
	
thus	O
,	O
use	O
of	O
these	O
pcr	O
-	O
based	O
assays	O
will	O
allow	O
deletion	O
detection	O
and	O
prenatal	O
diagnosis	O
for	O
most	O
dmd	B-Disease
/	O
bmd	B-Disease
patients	O
in	O
a	O
fraction	O
of	O
the	O
time	O
required	O
for	O
southern	O
blot	O
analysis	O
.	O
	
of	O
these	O
,	O
31	O
had	O
severe	O
g6pd	B-Disease
deficiency	I-Disease
,	O
nine	O
had	O
mild	O
to	O
moderate	O
deficiency	O
,	O
and	O
three	O
had	O
a	O
non	O
-	O
deficient	O
electrophoretic	O
variant	O
.	O
	
the	O
overall	O
rate	O
of	O
g6pd	B-Disease
deficiency	I-Disease
was	O
2	O
.	O
	
the	O
frequency	O
of	O
g6pd	B-Disease
deficiency	I-Disease
,	O
ranging	O
from	O
7	O
.	O
	
biochemical	O
characterization	O
has	O
shown	O
that	O
most	O
of	O
the	O
g6pd	B-Disease
deficiency	I-Disease
in	O
this	O
population	O
is	O
accounted	O
for	O
by	O
g6pd	O
mediterranean	O
.	O
	
these	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
marked	O
genetic	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
within	O
a	O
relatively	O
narrow	O
geographic	O
area	O
and	O
they	O
prove	O
the	O
presence	O
in	O
the	O
italian	O
peninsula	O
of	O
a	O
gene	O
(	O
gda	O
-	O
)	O
regarded	O
as	O
characteristically	O
african	O
.	O
	
deficiency	B-Disease
of	I-Disease
the	I-Disease
murine	I-Disease
fifth	I-Disease
complement	I-Disease
component	I-Disease
(	I-Disease
c5	I-Disease
)	I-Disease
.	O
	
to	O
ascertain	O
the	O
molecular	O
mechanism	O
that	O
causes	O
murine	O
c5	B-Disease
deficiency	I-Disease
,	O
genomic	O
and	O
cdna	O
libraries	O
were	O
constructed	O
from	O
mouse	O
liver	O
dna	O
and	O
mrna	O
employing	O
the	O
congenic	O
strains	O
b10	O
.	O
	
d2	O
/	O
osnj	O
that	O
are	O
sufficient	O
and	O
deficient	B-Disease
for	I-Disease
c5	I-Disease
,	O
respectively	O
.	O
	
genomic	O
fragments	O
were	O
isolated	O
which	O
correspond	O
to	O
pvuii	O
and	O
hindiii	O
restriction	O
fragment	O
length	O
polymorphisms	O
associated	O
with	O
c5	B-Disease
deficiency	I-Disease
.	O
	
sequence	O
analyses	O
demonstrated	O
that	O
each	O
of	O
these	O
polymorphisms	O
resulted	O
from	O
single	O
base	O
pair	O
substitutions	O
and	O
that	O
neither	O
substitution	O
would	O
probably	O
cause	O
or	O
contribute	O
to	O
the	O
c5	B-Disease
deficiency	I-Disease
.	O
	
six	O
c5	B-Disease
-	I-Disease
deficient	I-Disease
strains	O
,	O
a	O
/	O
hej	O
,	O
akr	O
/	O
j	O
,	O
dba	O
/	O
2j	O
,	O
nzb	O
/	O
b1nj	O
,	O
swr	O
/	O
j	O
,	O
and	O
b10	O
.	O
	
these	O
data	O
demonstrate	O
that	O
1	O
)	O
there	O
is	O
an	O
identical	O
2	O
-	O
base	O
pair	O
deletion	O
in	O
an	O
exon	O
of	O
the	O
c5	O
gene	O
in	O
several	O
different	O
c5	B-Disease
-	I-Disease
deficient	I-Disease
mouse	O
strains	O
;	O
2	O
)	O
the	O
mrna	O
transcribed	O
from	O
the	O
c5d	O
gene	O
retains	O
this	O
deletion	O
;	O
and	O
3	O
)	O
this	O
mutation	O
should	O
result	O
in	O
c5	B-Disease
protein	I-Disease
deficiency	I-Disease
.	O
	
molecular	O
genetics	O
of	O
pku	B-Disease
in	O
eastern	O
europe	O
:	O
a	O
nonsense	O
mutation	O
associated	O
with	O
haplotype	O
4	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
a	O
genetic	B-Disease
disorder	I-Disease
secondary	O
to	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
a	O
new	O
molecular	B-Disease
lesion	I-Disease
has	O
been	O
identified	O
in	O
exon	O
7	O
of	O
the	O
pah	O
gene	O
in	O
a	O
hungarian	O
pku	B-Disease
patient	O
by	O
direct	O
sequencing	O
of	O
pcr	O
-	O
amplified	O
dna	O
.	O
	
the	O
red	O
-	O
green	O
visual	O
pigment	O
gene	O
region	O
in	O
adrenoleukodystrophy	B-Disease
.	O
	
although	O
recent	O
data	O
established	O
that	O
a	O
specific	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acyl	O
-	O
coa	O
synthetase	O
is	O
defective	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ald	B-Disease
)	O
,	O
the	O
ald	B-Disease
gene	O
is	O
still	O
unidentified	O
.	O
	
the	O
ald	B-Disease
locus	O
has	O
been	O
mapped	O
to	O
xq28	O
,	O
like	O
the	O
red	O
and	O
green	O
color	O
pigment	O
genes	O
.	O
	
abnormal	B-Disease
color	I-Disease
vision	I-Disease
has	O
been	O
observed	O
in	O
12	O
of	O
27	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
,	O
a	O
milder	O
form	O
of	O
ald	B-Disease
.	O
	
furthermore	O
,	O
rearrangements	O
of	O
the	O
color	O
vision	O
gene	O
cluster	O
were	O
found	O
in	O
four	O
of	O
eight	O
ald	B-Disease
kindreds	O
.	O
	
this	O
led	O
us	O
to	O
propose	O
that	O
a	O
single	O
dna	O
rearrangement	O
could	O
underlie	O
both	O
ald	B-Disease
and	O
abnormal	B-Disease
color	I-Disease
vision	I-Disease
in	O
these	O
patients	O
.	O
	
study	O
of	O
34	O
french	O
ald	B-Disease
patients	O
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	O
of	O
green	O
/	O
red	O
visual	O
pigment	O
rearrangements	O
3	O
to	O
the	O
red	O
/	O
green	O
color	O
vision	O
gene	O
complex	O
.	O
	
the	O
previous	O
report	O
of	O
such	O
rearrangements	O
was	O
based	O
on	O
small	O
numbers	O
and	O
lack	O
of	O
knowledge	O
that	O
the	O
frequency	O
of	O
abnormal	O
color	O
vision	O
arrays	O
on	O
molecular	O
analysis	O
was	O
twice	O
as	O
high	O
as	O
expected	O
on	O
the	O
basis	O
of	O
the	O
frequency	O
of	O
phenotypic	B-Disease
color	I-Disease
vision	I-Disease
defects	I-Disease
.	O
	
the	O
r	O
/	O
gcp	O
region	O
was	O
also	O
analyzed	O
in	O
29	O
french	O
and	O
seven	O
north	O
american	O
ald	B-Disease
patients	O
by	O
using	O
six	O
genomic	O
dna	O
probes	O
,	O
isolated	O
from	O
a	O
cosmid	O
walk	O
,	O
that	O
flank	O
the	O
color	O
vision	O
genes	O
.	O
	
one	O
of	O
the	O
eight	O
previously	O
reported	O
ald	B-Disease
individuals	O
has	O
a	O
long	O
deletion	O
5	O
of	O
the	O
red	O
pigment	O
gene	O
,	O
a	O
deletion	O
causing	O
blue	O
cone	O
monochromacy	O
.	O
	
this	O
finding	O
and	O
the	O
previous	O
findings	O
of	O
a	O
45	O
%	O
frequency	O
of	O
phenotypic	O
color	O
vision	O
defects	O
in	O
patients	O
with	O
amn	B-Disease
may	O
suggest	O
that	O
the	O
ald	B-Disease
/	O
amn	B-Disease
gene	O
lies	O
5	O
to	O
the	O
red	O
pigment	O
gene	O
and	O
that	O
the	O
frequent	O
phenotypic	O
color	B-Disease
vision	I-Disease
anomalies	I-Disease
owe	O
their	O
origin	O
to	O
deleted	O
dna	O
that	O
includes	O
regulatory	O
genes	O
for	O
color	O
vision	O
.	O
	
it	O
is	O
possible	O
,	O
however	O
,	O
that	O
phenotypic	O
color	B-Disease
vision	I-Disease
anomalies	I-Disease
in	O
amn	B-Disease
may	O
be	O
phenocopies	O
secondary	O
to	O
retinal	O
or	O
neural	O
involvement	O
by	O
the	O
disease	O
.	O
	
paroxysmal	B-Disease
nocturnal	I-Disease
haemoglobinuria	I-Disease
with	O
coexisting	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
:	O
lack	O
of	O
massive	O
haemolytic	B-Disease
attack	I-Disease
.	O
	
a	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
haemoglobinuria	I-Disease
(	O
pnh	B-Disease
)	O
was	O
found	O
to	O
have	O
an	O
inherited	B-Disease
deficiency	I-Disease
in	I-Disease
the	I-Disease
ninth	I-Disease
complement	I-Disease
component	I-Disease
(	O
c9	O
)	O
.	O
	
surprisingly	O
,	O
she	O
has	O
suffered	O
only	O
mild	O
haemolysis	B-Disease
and	O
has	O
never	O
experienced	O
massive	O
spontaneous	O
haemolysis	B-Disease
.	O
	
gross	O
haemoglobinuria	B-Disease
and	O
jaundice	B-Disease
occurred	O
only	O
after	O
receiving	O
postoperative	O
transfusion	O
of	O
whole	O
blood	O
.	O
	
these	O
observations	O
indicated	O
that	O
c9	O
may	O
play	O
a	O
critical	O
role	O
in	O
haemolytic	B-Disease
attacks	I-Disease
in	O
patients	O
with	O
pnh	B-Disease
and	O
that	O
characteristic	O
haemolysis	B-Disease
in	O
pnh	B-Disease
may	O
be	O
tempered	O
by	O
coexisting	O
c9	B-Disease
deficiency	I-Disease
.	O
	
duplicational	O
mutation	O
at	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
locus	O
:	O
its	O
frequency	O
,	O
distribution	O
,	O
origin	O
,	O
and	O
phenotypegenotype	O
correlation	O
.	O
	
partial	O
gene	O
deletion	O
is	O
the	O
major	O
cause	O
of	O
mutation	O
leading	O
to	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
and	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
bmd	B-Disease
)	O
.	O
	
we	O
have	O
conducted	O
a	O
survey	O
for	O
duplication	O
in	O
72	O
unrelated	O
nondeletion	O
patients	O
,	O
analyzed	O
by	O
southern	O
blot	O
hybridization	O
with	O
clones	O
representing	O
the	O
entire	O
dmd	B-Disease
cdna	O
.	O
	
a	O
shift	O
of	O
the	O
reading	O
frame	O
was	O
predicted	O
in	O
four	O
of	O
the	O
six	O
dmd	B-Disease
cases	O
and	O
in	O
one	O
of	O
the	O
two	O
intermediate	O
cases	O
,	O
while	O
the	O
reading	O
frame	O
remained	O
uninterrupted	O
in	O
both	O
bmd	B-Disease
cases	O
.	O
	
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
:	O
gd	O
(	O
+	O
)	O
alexandra	O
associated	O
with	O
neonatal	B-Disease
jaundice	I-Disease
and	O
gd	O
(	O
-	O
)	O
camperdown	O
in	O
a	O
young	O
man	O
with	O
lamellar	B-Disease
cataracts	I-Disease
.	O
	
the	O
first	O
,	O
of	O
italian	O
extraction	O
,	O
suffered	O
from	O
severe	O
neonatal	B-Disease
jaundice	I-Disease
following	O
maternal	O
ingestion	O
of	O
fresh	O
broad	O
beans	O
(	O
vicia	O
fava	O
)	O
both	O
prenatally	O
and	O
postnatally	O
the	O
expression	O
of	O
the	O
enzymatic	O
defect	O
was	O
much	O
more	O
severe	O
in	O
the	O
neonatal	O
period	O
than	O
on	O
retesting	O
in	O
adolescence	O
,	O
when	O
biochemical	O
characterization	O
showed	O
unique	O
features	O
which	O
justify	O
designation	O
as	O
a	O
new	O
variant	O
gd	O
(	O
+	O
)	O
alexandra	O
.	O
	
the	O
second	O
patient	O
,	O
a	O
boy	O
of	O
maltese	O
extraction	O
who	O
was	O
found	O
to	O
have	O
bilateral	B-Disease
lamellar	I-Disease
cataracts	I-Disease
at	O
the	O
age	O
of	O
4	O
years	O
,	O
was	O
identified	O
as	O
g6pd	B-Disease
deficient	I-Disease
only	O
as	O
a	O
result	O
of	O
a	O
survey	O
of	O
children	O
of	O
mediterranean	O
origin	O
with	O
unexplained	O
cataract	B-Disease
formation	O
;	O
he	O
has	O
approximately	O
15	O
%	O
of	O
normal	O
enzyme	O
activity	O
,	O
with	O
another	O
unique	O
combination	O
of	O
biochemical	O
characteristics	O
which	O
has	O
led	O
to	O
its	O
designation	O
as	O
gd	O
(	O
-	O
)	O
camperdown	O
.	O
	
although	O
this	O
association	O
may	O
be	O
coincidental	O
,	O
it	O
prompts	O
further	O
attention	O
to	O
the	O
possibility	O
that	O
under	O
certain	O
circumstances	O
g6pd	B-Disease
deficiency	I-Disease
may	O
favor	O
cataract	B-Disease
formation	O
.	O
	
statistical	O
analysis	O
of	O
the	O
two	O
stage	O
mutation	O
model	O
in	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
,	O
and	O
in	O
sporadic	B-Disease
cerebellar	I-Disease
haemangioblastoma	I-Disease
and	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
	
analysis	O
of	O
the	O
age	O
incidence	O
curves	O
for	O
unilateral	B-Disease
and	I-Disease
bilateral	I-Disease
retinoblastoma	I-Disease
led	O
knudson	O
to	O
propose	O
that	O
hereditary	B-Disease
tumours	I-Disease
may	O
arise	O
by	O
a	O
single	O
event	O
and	O
sporadic	B-Disease
tumours	I-Disease
by	O
a	O
two	O
stage	O
mutation	O
process	O
.	O
	
it	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
may	O
arise	O
from	O
a	O
two	O
stage	O
mutation	O
process	O
.	O
	
we	O
analysed	O
the	O
age	O
incidence	O
curves	O
for	O
symptomatic	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
n	O
=	O
26	O
)	O
and	O
cerebellar	B-Disease
haemangioblastoma	I-Disease
(	O
n	O
=	O
68	O
)	O
in	O
109	O
patients	O
with	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
disease	I-Disease
,	O
and	O
compared	O
them	O
to	O
104	O
patients	O
with	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
43	O
patients	O
with	O
sporadic	B-Disease
cerebellar	I-Disease
haemangioblastoma	I-Disease
.	O
	
the	O
age	O
incidence	O
curves	O
for	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
cerebellar	B-Disease
haemangioblastoma	I-Disease
in	O
vhl	B-Disease
disease	I-Disease
were	O
compatible	O
with	O
a	O
single	O
mutation	O
model	O
,	O
whereas	O
the	O
age	O
incidence	O
curves	O
for	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
cerebellar	B-Disease
haemangioblastoma	I-Disease
suggested	O
a	O
two	O
stage	O
mutation	O
process	O
.	O
	
these	O
data	O
are	O
compatible	O
with	O
the	O
vhl	B-Disease
gene	O
functioning	O
as	O
a	O
recessive	O
tumour	B-Disease
suppressor	O
gene	O
.	O
	
sporadic	B-Disease
cerebellar	I-Disease
haemangioblastoma	I-Disease
and	O
some	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
may	O
arise	O
from	O
somatic	O
mutations	O
inactivating	O
both	O
alleles	O
at	O
the	O
vhl	B-Disease
locus	O
.	O
	
screening	O
for	O
carriers	O
of	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
among	O
ashkenazi	O
jews	O
.	O
	
the	O
prevention	O
of	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
gm2	B-Disease
gangliosidosis	I-Disease
,	I-Disease
type	I-Disease
1	I-Disease
)	O
depends	O
on	O
the	O
identification	O
of	O
carriers	O
of	O
the	O
gene	O
for	O
this	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
.	O
	
we	O
compared	O
the	O
enzyme	O
-	O
based	O
test	O
widely	O
used	O
in	O
screening	O
for	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
with	O
a	O
test	O
based	O
on	O
analysis	O
of	O
dna	O
.	O
	
we	O
developed	O
methods	O
to	O
detect	O
the	O
three	O
mutations	O
in	O
the	O
hexa	O
gene	O
that	O
occur	O
with	O
high	O
frequency	O
among	O
ashkenazi	O
jews	O
two	O
mutations	O
cause	O
infantile	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
,	O
and	O
the	O
third	O
causes	O
the	O
adult	O
-	O
onset	O
form	O
of	O
the	O
disease	O
.	O
	
among	O
62	O
ashkenazi	O
obligate	O
carriers	O
of	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
,	O
the	O
three	O
specific	O
mutations	O
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	O
alleles	O
(	O
98	O
percent	O
)	O
.	O
	
the	O
increased	O
specificity	O
and	O
predictive	O
value	O
of	O
the	O
dna	O
-	O
based	O
test	O
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	O
tests	O
currently	O
used	O
to	O
screen	O
for	O
carriers	O
of	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
.	O
	
total	B-Disease
deficiency	I-Disease
of	I-Disease
plasma	I-Disease
cholesteryl	I-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
in	O
subjects	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
intron	O
14	O
splicing	O
defect	O
.	O
	
the	O
molecular	O
basis	O
of	O
cholesteryl	B-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
(	I-Disease
cetp	I-Disease
)	I-Disease
deficiency	I-Disease
was	O
investigated	O
in	O
4	O
unrelated	O
cetp	B-Disease
-	I-Disease
deficient	I-Disease
families	O
.	O
	
thus	O
,	O
other	O
genetic	B-Disease
defects	I-Disease
or	O
metabolic	O
factors	O
influencing	O
cetp	O
expression	O
are	O
implicated	O
.	O
	
the	O
data	O
suggest	O
that	O
the	O
g	O
-	O
to	O
-	O
a	O
mutation	O
may	O
be	O
common	O
in	O
human	O
plasma	O
cetp	B-Disease
deficiency	I-Disease
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
;	I-Disease
e	I-Disease
.	I-Disease
c	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
the	O
most	O
common	O
human	O
enzymopathy	B-Disease
;	O
more	O
than	O
300	O
different	O
biochemical	O
variants	O
of	O
the	O
enzyme	O
have	O
been	O
described	O
.	O
	
in	O
many	O
parts	O
of	O
the	O
world	O
the	O
mediterranean	O
type	O
of	O
g6pd	B-Disease
deficiency	I-Disease
is	O
prevalent	O
.	O
	
a	O
normal	O
male	O
with	O
an	O
inherited	O
deletion	O
of	O
one	O
exon	O
within	O
the	O
dmd	B-Disease
gene	O
.	O
	
we	O
describe	O
two	O
brothers	O
with	O
identical	O
inherited	O
deletions	O
of	O
one	O
single	O
exon	O
within	O
the	O
middle	O
of	O
the	O
dmd	B-Disease
gene	O
;	O
one	O
brother	O
has	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
diagnosed	O
at	O
11	O
years	O
of	O
age	O
,	O
whereas	O
the	O
older	O
brother	O
is	O
normal	O
at	O
18	O
.	O
	
these	O
results	O
have	O
implications	O
for	O
genetic	O
counselling	O
and	O
prenatal	O
diagnosis	O
in	O
families	O
with	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
expression	O
in	O
normal	O
and	O
diseased	O
human	O
muscle	O
.	O
	
a	O
probe	O
for	O
the	O
5	O
end	O
of	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
was	O
used	O
to	O
study	O
expression	O
of	O
the	O
gene	O
in	O
normal	O
human	O
muscle	O
,	O
myogenic	O
cell	O
cultures	O
,	O
and	O
muscle	O
from	O
patients	O
with	O
dmd	B-Disease
.	O
	
in	O
dmd	B-Disease
muscle	O
,	O
expression	O
of	O
this	O
portion	O
of	O
the	O
gene	O
was	O
also	O
revealed	O
by	O
in	O
situ	O
rna	O
hybridization	O
,	O
particularly	O
in	O
regenerating	O
muscle	O
fibers	O
.	O
	
molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
.	O
	
eighty	O
unrelated	O
individuals	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
or	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
bmd	B-Disease
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
dmd	B-Disease
locus	O
.	O
	
thirty	O
-	O
eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
dmd	B-Disease
,	O
bmd	B-Disease
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O
	
of	O
these	O
,	O
eight	O
bmd	B-Disease
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
dmd	B-Disease
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
bmd	B-Disease
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O
	
chromosome	O
translocations	O
involving	O
11p13	O
have	O
been	O
associated	O
with	O
familial	B-Disease
aniridia	I-Disease
in	O
two	O
kindreds	O
highlighting	O
the	O
chromosomal	O
localization	O
of	O
the	O
an2	O
locus	O
.	O
	
this	O
locus	O
is	O
also	O
part	O
of	O
the	O
wagr	B-Disease
complex	O
(	O
wilms	B-Disease
tumor	I-Disease
,	O
aniridia	B-Disease
,	O
genitourinary	B-Disease
abnormalities	I-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
)	O
.	O
	
linkage	O
analysis	O
of	O
the	O
apolipoprotein	O
c2	O
gene	O
and	O
myotonic	B-Disease
dystrophy	I-Disease
on	O
human	O
chromosome	O
19	O
reveals	O
linkage	O
disequilibrium	O
in	O
a	O
french	O
-	O
canadian	O
population	O
.	O
	
the	O
gene	O
for	O
human	O
apolipoprotein	O
c2	O
(	O
apoc2	O
)	O
,	O
situated	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
19	O
,	O
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
,	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
.	O
	
we	O
have	O
conducted	O
a	O
comprehensive	O
dm	B-Disease
linkage	O
study	O
utilizing	O
all	O
six	O
rflps	O
and	O
involving	O
50	O
families	O
and	O
372	O
individuals	O
.	O
	
this	O
represents	O
the	O
first	O
evidence	O
of	O
linkage	O
disequilibrium	O
between	O
apoc2	O
and	O
the	O
dm	B-Disease
locus	O
.	O
	
phenylalanine	O
hydroxylase	O
gene	O
haplotypes	O
in	O
polynesians	O
:	O
evolutionary	O
origins	O
and	O
absence	O
of	O
alleles	O
associated	O
with	O
severe	O
phenylketonuria	B-Disease
.	O
	
the	O
absence	O
of	O
severe	O
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
in	O
both	O
polynesians	O
and	O
southeast	O
asians	O
is	O
consistent	O
with	O
the	O
lack	O
of	O
pah	O
haplotypes	O
2	O
and	O
3	O
,	O
on	O
which	O
the	O
severe	O
pku	B-Disease
mutants	O
have	O
arisen	O
among	O
caucasians	O
.	O
	
preferential	O
germline	O
mutation	O
of	O
the	O
paternal	O
allele	O
in	O
retinoblastoma	B-Disease
.	O
	
the	O
event	O
triggering	O
malignant	O
proliferation	O
in	O
70	O
%	O
of	O
retinoblastoma	B-Disease
tumours	I-Disease
is	O
loss	O
of	O
heterozygosity	O
for	O
chromosome	O
13q14	O
,	O
whereby	O
the	O
normal	O
retinoblastoma	B-Disease
gene	O
(	O
rb1	O
)	O
allele	O
is	O
lost	O
and	O
an	O
already	O
mutated	O
rb1	O
allele	O
remains	O
in	O
the	O
tumour	B-Disease
.	O
	
most	O
bilateral	O
patients	O
have	O
no	O
family	O
history	O
of	O
retinoblastoma	B-Disease
and	O
are	O
presumed	O
to	O
have	O
new	O
germline	O
mutations	O
which	O
arose	O
in	O
the	O
egg	O
,	O
sperm	O
or	O
early	O
embryo	O
.	O
	
we	O
have	O
determined	O
the	O
parental	O
origin	O
of	O
the	O
retained	O
allele	O
in	O
nine	O
retinoblastoma	B-Disease
tumours	I-Disease
from	O
eight	O
unrelated	O
non	O
-	O
familial	O
cases	O
by	O
using	O
rb1	O
-	O
linked	O
genetic	O
markers	O
.	O
	
six	O
tumours	B-Disease
retained	O
the	O
paternal	O
allele	O
and	O
three	O
retained	O
the	O
maternal	O
allele	O
.	O
	
of	O
the	O
three	O
unilateral	B-Disease
tumours	I-Disease
,	O
only	O
one	O
retained	O
the	O
paternal	O
rb1	O
allele	O
.	O
	
thus	O
,	O
there	O
is	O
no	O
evidence	O
that	O
the	O
paternal	O
rb1	O
allele	O
is	O
preferentially	O
retained	O
in	O
retinoblastoma	B-Disease
,	O
as	O
has	O
been	O
suggested	O
to	O
be	O
the	O
case	O
in	O
osteosarcoma	B-Disease
.	O
	
by	O
contrast	O
,	O
tumours	B-Disease
from	O
four	O
of	O
the	O
five	O
bilateral	O
patients	O
retained	O
the	O
paternal	O
rb1	O
allele	O
.	O
	
haplotype	O
analysis	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
turkish	O
phenylketonuria	B-Disease
families	O
.	O
	
we	O
have	O
estimated	O
the	O
haplotype	O
distribution	O
of	O
mutant	O
and	O
normal	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
alleles	O
for	O
17	O
turkish	O
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
families	O
20	O
normal	O
and	O
27	O
mutated	O
pah	O
alleles	O
could	O
be	O
identified	O
.	O
	
two	O
of	O
the	O
eight	O
polymorphic	O
sites	O
were	O
in	O
association	O
with	O
pku	B-Disease
.	O
	
huntington	B-Disease
disease	I-Disease
:	O
no	O
evidence	O
for	O
locus	O
heterogeneity	O
.	O
	
a	O
total	O
of	O
63	O
families	O
with	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
were	O
examined	O
for	O
linkage	O
between	O
hd	B-Disease
and	O
g8	O
(	O
d4s10	O
)	O
.	O
	
these	O
data	O
suggest	O
that	O
there	O
is	O
only	O
one	O
hd	B-Disease
locus	O
,	O
although	O
a	O
second	O
rare	O
locus	O
cannot	O
be	O
ruled	O
out	O
.	O
	
haplotype	O
and	O
multipoint	O
linkage	O
analysis	O
in	O
finnish	O
choroideremia	B-Disease
families	O
.	O
	
multipoint	O
linkage	O
analysis	O
of	O
choroideremia	B-Disease
(	O
tcd	B-Disease
)	O
and	O
seven	O
x	O
chromosomal	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
rflps	O
)	O
was	O
carried	O
out	O
in	O
18	O
finnish	O
tcd	B-Disease
families	O
.	O
	
the	O
data	O
place	O
tcd	B-Disease
distal	O
to	O
pgk	O
and	O
dxs72	O
,	O
very	O
close	O
to	O
dxys1	O
and	O
dxys5	O
(	O
zmax	O
=	O
24	O
at	O
theta	O
=	O
0	O
)	O
and	O
proximal	O
to	O
dxys4	O
and	O
dxys12	O
.	O
	
all	O
the	O
tcd	B-Disease
males	O
and	O
carrier	O
females	O
studied	O
have	O
the	O
same	O
dxys1	O
allele	O
in	O
coupling	O
with	O
tcd	B-Disease
.	O
	
in	O
northeastern	O
finland	O
,	O
66	O
/	O
69	O
chromosomes	O
carrying	O
tcd	B-Disease
had	O
the	O
same	O
haplotype	O
at	O
loci	O
dxs72	O
,	O
dxys1	O
,	O
dxys4	O
,	O
and	O
dxys12	O
.	O
	
the	O
same	O
haplotype	O
is	O
seen	O
in	O
only	O
15	O
/	O
99	O
chromosomes	O
not	O
carrying	O
tcd	B-Disease
.	O
	
moreover	O
,	O
in	O
71	O
/	O
104	O
non	O
-	O
tcd	O
chromosomes	O
,	O
the	O
haplotype	O
at	O
six	O
marker	O
loci	O
is	O
different	O
from	O
those	O
seen	O
in	O
any	O
of	O
the	O
76	O
tcd	B-Disease
chromosomes	O
.	O
	
this	O
supports	O
the	O
previously	O
described	O
hypothesis	O
that	O
the	O
large	O
northern	O
finnish	O
choroideremia	B-Disease
pedigrees	O
,	O
comprising	O
a	O
total	O
of	O
over	O
80	O
living	O
patients	O
representing	O
more	O
than	O
a	O
fifth	O
of	O
all	O
tcd	B-Disease
patients	O
described	O
worldwide	O
,	O
carry	O
the	O
same	O
mutation	O
.	O
	
autosomal	O
dominant	O
aniridia	B-Disease
linked	O
to	O
the	O
chromosome	O
11p13	O
markers	O
catalase	O
and	O
d11s151	O
in	O
a	O
large	O
dutch	O
family	O
.	O
	
in	O
a	O
large	O
pedigree	O
with	O
autosomal	O
dominant	O
aniridia	B-Disease
,	O
we	O
found	O
close	O
linkage	O
between	O
the	O
aniridia	B-Disease
locus	O
an2	O
and	O
the	O
markers	O
catalase	O
(	O
cat	O
)	O
(	O
zeta	O
=	O
7	O
.	O
27	O
at	O
theta	O
=	O
0	O
.	O
0	O
)	O
and	O
d11s151	O
(	O
zeta	O
=	O
3	O
.	O
86	O
at	O
theta	O
=	O
0	O
.	O
10	O
)	O
flanking	O
the	O
an2	O
locus	O
on	O
11p13	O
.	O
	
we	O
conclude	O
that	O
the	O
autosomal	O
dominant	O
aniridia	B-Disease
in	O
this	O
family	O
is	O
due	O
to	O
a	O
mutation	O
at	O
the	O
an2	O
locus	O
on	O
11p13	O
.	O
	
we	O
have	O
excluded	O
linkage	O
(	O
zeta	O
less	O
than	O
-	O
2	O
at	O
theta	O
less	O
than	O
0	O
.	O
	
18	O
)	O
between	O
the	O
aniridia	B-Disease
and	O
the	O
chromosome	O
2p25	O
marker	O
d2s1	O
(	O
linked	O
to	O
acp1	O
)	O
.	O
	
recombination	O
events	O
that	O
locate	O
myotonic	B-Disease
dystrophy	I-Disease
distal	O
to	O
apoc2	O
on	O
19q	O
.	O
	
we	O
previously	O
reported	O
a	O
recombination	O
in	O
an	O
individual	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
which	O
placed	O
the	O
markers	O
d19s19	O
and	O
apoc2	O
on	O
the	O
same	O
side	O
of	O
the	O
dm	B-Disease
locus	O
.	O
	
haplotyping	O
of	O
this	O
family	O
with	O
more	O
recently	O
characterized	O
probes	O
which	O
are	O
either	O
tightly	O
linked	O
to	O
dm	B-Disease
or	O
distal	O
to	O
the	O
linkage	O
group	O
at	O
q13	O
.	O
	
2	O
shows	O
that	O
the	O
dm	B-Disease
locus	O
is	O
distal	O
to	O
apoc2	O
.	O
	
this	O
is	O
confirmed	O
by	O
other	O
recombinants	O
where	O
dm	B-Disease
segregates	O
with	O
distal	O
probes	O
.	O
	
additional	O
marker	O
to	O
marker	O
recombinations	O
in	O
unaffected	O
individuals	O
are	O
reported	O
and	O
support	O
the	O
order	O
and	O
orientation	O
of	O
the	O
dm	B-Disease
linkage	O
group	O
as	O
pter	O
-	O
(	O
insr	O
,	O
ldlr	O
,	O
s9	O
)	O
-	O
(	O
s19	O
,	O
bcl3	O
,	O
apoc2	O
)	O
-	O
(	O
ckmm	O
,	O
dm	O
)	O
-	O
(	O
s22	O
,	O
+	O
+	O
+	O
prkcg	O
)	O
-	O
qter	O
.	O
	
the	O
data	O
presented	O
here	O
cannot	O
determine	O
whether	O
dm	B-Disease
is	O
proximal	O
or	O
distal	O
to	O
ckmm	O
.	O
	
the	O
consequences	O
of	O
this	O
probe	O
order	O
for	O
antenatal	O
diagnosis	O
and	O
future	O
research	O
aiming	O
to	O
isolate	O
the	O
gene	O
which	O
is	O
affected	O
in	O
dm	B-Disease
are	O
discussed	O
.	O
	
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
rb1	O
gene	O
during	O
normal	O
retinal	O
development	O
initiates	O
the	O
formation	O
of	O
a	O
retinoblastoma	B-Disease
(	I-Disease
rb	I-Disease
)	I-Disease
tumor	I-Disease
.	O
	
to	O
identify	O
the	O
mutations	O
which	O
inactivate	O
rb1	O
,	O
21	O
rb	B-Disease
tumors	I-Disease
isolated	O
from	O
19	O
patients	O
were	O
analyzed	O
with	O
the	O
polymerase	O
chain	O
reaction	O
or	O
an	O
rnase	O
protection	O
assay	O
or	O
both	O
.	O
	
mutations	O
were	O
identified	O
in	O
13	O
of	O
21	O
rb	B-Disease
tumors	I-Disease
;	O
in	O
8	O
tumors	B-Disease
,	O
the	O
precise	O
errors	O
in	O
nucleotide	O
sequence	O
were	O
characterized	O
.	O
	
we	O
were	O
unable	O
to	O
detect	O
expression	O
of	O
the	O
mutant	O
allele	O
in	O
lymphoblasts	O
of	O
three	O
bilaterally	O
affected	O
patients	O
,	O
although	O
the	O
mutation	O
was	O
present	O
in	O
the	O
genomic	O
dna	O
and	O
transcripts	O
containing	O
the	O
mutations	O
were	O
obvious	O
in	O
the	O
rb	B-Disease
tumors	I-Disease
in	O
the	O
absence	O
of	O
a	O
normal	O
rb1	O
allele	O
.	O
	
partial	O
deletion	O
8q	O
without	O
langer	B-Disease
-	I-Disease
giedion	I-Disease
syndrome	I-Disease
:	O
a	O
recognisable	O
syndrome	O
.	O
	
the	O
clinical	O
features	O
were	O
similar	O
and	O
there	O
were	O
no	O
obvious	O
stigmata	O
of	O
langer	B-Disease
-	I-Disease
giedion	I-Disease
syndrome	I-Disease
(	O
lgs	B-Disease
)	O
.	O
	
there	O
are	O
three	O
other	O
cases	O
reported	O
with	O
a	O
deletion	O
of	O
chromosome	O
8	O
at	O
approximately	O
the	O
same	O
breakpoint	O
,	O
one	O
without	O
lgs	B-Disease
and	O
some	O
similarities	O
to	O
our	O
cases	O
,	O
the	O
other	O
two	O
with	O
lgs	B-Disease
.	O
	
our	O
findings	O
would	O
support	O
the	O
observation	O
that	O
the	O
critical	O
segment	O
for	O
the	O
assignment	O
of	O
lgs	B-Disease
is	O
proximal	O
to	O
or	O
involves	O
the	O
proximal	O
part	O
of	O
8q24	O
.	O
	
1	O
,	O
but	O
a	O
review	O
of	O
published	O
reports	O
suggests	O
that	O
the	O
aetiology	O
of	O
lgs	B-Disease
may	O
be	O
a	O
more	O
complex	O
issue	O
myotonic	B-Disease
dystrophy	I-Disease
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
muscle	O
-	O
type	O
creatine	O
kinase	O
(	O
ckmm	O
)	O
.	O
	
we	O
have	O
studied	O
genetic	O
linkage	O
between	O
the	O
gene	O
for	O
creatine	O
kinase	O
muscle	O
type	O
(	O
ckmm	O
)	O
and	O
the	O
gene	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
.	O
	
in	O
a	O
panel	O
of	O
65	O
myotonic	B-Disease
dystrophy	I-Disease
families	O
from	O
canada	O
and	O
the	O
netherlands	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
zmax	O
)	O
of	O
22	O
.	O
	
this	O
establishes	O
ckmm	O
as	O
a	O
useful	O
marker	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
color	B-Disease
vision	I-Disease
defects	I-Disease
in	O
adrenomyeloneuropathy	B-Disease
.	O
	
the	O
relationship	O
between	O
abnormal	B-Disease
color	I-Disease
vision	I-Disease
and	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
was	O
investigated	O
in	O
27	O
amn	B-Disease
patients	O
and	O
31	O
age	O
-	O
matched	O
controls	O
by	O
using	O
the	O
farnsworth	O
-	O
munsell	O
100	O
hue	O
test	O
.	O
	
the	O
axes	O
of	O
bipolarity	O
determined	O
by	O
the	O
testing	O
differed	O
widely	O
between	O
the	O
patients	O
with	O
abnormal	O
scores	O
,	O
compatible	O
with	O
the	O
notion	O
that	O
different	O
alterations	O
in	O
visual	O
pigment	O
genes	O
occur	O
in	O
different	O
amn	B-Disease
kindreds	O
.	O
	
these	O
observations	O
confirm	O
our	O
earlier	O
impression	O
that	O
the	O
frequency	O
of	O
abnormal	B-Disease
color	I-Disease
vision	I-Disease
is	O
increased	O
in	O
these	O
kindreds	O
,	O
and	O
it	O
supports	O
our	O
contentions	O
that	O
(	O
1	O
)	O
amn	B-Disease
(	O
and	O
its	O
companion	O
,	O
adrenoleukodystrophy	B-Disease
)	O
are	O
very	O
closely	O
linked	O
to	O
the	O
visual	O
pigment	O
loci	O
at	O
xq28	O
and	O
(	O
2	O
)	O
this	O
proximity	O
might	O
provide	O
the	O
opportunity	O
to	O
observe	O
contiguous	B-Disease
gene	I-Disease
defects	I-Disease
.	O
	
molecular	O
analysis	O
of	O
a	O
female	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
patient	O
.	O
	
we	O
report	O
the	O
identification	O
of	O
a	O
female	O
patient	O
with	O
the	O
x	O
-	O
linked	O
recessive	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
(	O
hypoxanthine	B-Disease
phosphoribosyltransferase	I-Disease
[	I-Disease
hprt	I-Disease
]	I-Disease
deficiency	I-Disease
)	O
.	O
	
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
:	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
neurologic	I-Disease
disorder	I-Disease
of	I-Disease
myelin	I-Disease
metabolism	I-Disease
with	O
a	O
novel	O
mutation	O
in	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
.	O
	
the	O
nosology	O
of	O
the	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
myelin	I-Disease
metabolism	I-Disease
has	O
been	O
stymied	O
by	O
the	O
lack	O
of	O
molecular	O
genetic	O
analysis	O
.	O
	
historically	O
,	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
has	O
encompassed	O
a	O
host	O
of	O
neurologic	B-Disease
disorders	I-Disease
that	O
present	O
with	O
a	O
deficit	B-Disease
of	I-Disease
myelin	I-Disease
,	O
the	O
membrane	O
elaborated	O
by	O
glial	O
cells	O
that	O
encircles	O
and	O
successively	O
enwraps	O
axons	O
.	O
	
we	O
describe	O
here	O
a	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
pedigree	O
of	O
the	O
classical	O
type	O
,	O
with	O
x	O
-	O
linked	O
inheritance	O
,	O
a	O
typical	O
clinical	O
progression	O
,	O
and	O
a	O
pathologic	O
loss	O
of	O
myelinating	O
cells	O
and	O
myelin	O
in	O
the	O
central	O
nervous	O
system	O
.	O
	
to	O
discriminate	O
variants	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
,	O
a	O
set	O
of	O
oligonucleotide	O
primers	O
was	O
constructed	O
to	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
pcr	O
)	O
amplify	O
and	O
sequence	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
(	O
plp	O
)	O
,	O
a	O
structural	O
protein	O
that	O
comprises	O
half	O
of	O
the	O
protein	O
of	O
the	O
myelin	O
sheath	O
.	O
	
our	O
results	O
delineate	O
the	O
clinical	O
features	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
,	O
define	O
the	O
possible	O
molecular	O
pathology	O
of	O
this	O
dysmyelinating	B-Disease
disorder	I-Disease
,	O
and	O
address	O
the	O
molecular	O
classification	O
of	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
myelin	I-Disease
metabolism	I-Disease
.	O
	
patients	O
with	O
the	O
classical	O
form	O
(	O
type	O
i	O
)	O
and	O
the	O
more	O
severely	O
affected	O
,	O
connatal	O
variant	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	I-Disease
type	I-Disease
ii	I-Disease
)	I-Disease
would	O
be	O
predicted	O
to	O
display	O
mutation	O
at	O
the	O
plp	O
locus	O
.	O
	
the	O
other	O
variants	O
(	O
types	O
iii	O
-	O
vi	O
)	O
,	O
which	O
have	O
sometimes	O
been	O
categorized	O
as	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
,	O
may	O
represent	O
mutations	O
in	O
genes	O
encoding	O
other	O
structural	O
myelin	O
proteins	O
or	O
proteins	O
critical	O
to	O
myelination	O
.	O
	
molecular	O
basis	O
of	O
human	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
:	O
analysis	O
of	O
platelet	O
von	B-Disease
willebrand	I-Disease
factor	O
mrna	O
.	O
	
von	B-Disease
willebrand	I-Disease
disease	I-Disease
(	O
vwd	B-Disease
)	O
,	O
the	O
most	O
common	O
inherited	B-Disease
bleeding	I-Disease
disorder	I-Disease
in	O
humans	O
,	O
can	O
result	O
from	O
either	O
a	O
quantitative	O
or	O
a	O
qualitative	O
defect	O
in	O
the	O
adhesive	O
glycoprotein	O
,	O
von	B-Disease
willebrand	I-Disease
factor	O
(	O
vwf	O
)	O
.	O
	
molecular	O
studies	O
of	O
vwd	B-Disease
have	O
been	O
limited	O
by	O
the	O
large	O
size	O
of	O
the	O
vwf	O
gene	O
and	O
difficulty	O
in	O
obtaining	O
the	O
vwf	O
mrna	O
from	O
patients	O
.	O
	
in	O
two	O
type	B-Disease
iia	I-Disease
vwd	I-Disease
patients	O
,	O
two	O
different	O
but	O
adjacent	O
missense	O
mutations	O
were	O
identified	O
,	O
the	O
locations	O
of	O
which	O
may	O
identify	O
an	O
important	O
vwf	O
functional	O
domain	O
.	O
	
expression	O
in	O
heterologous	O
cells	O
of	O
recombinant	O
vwf	O
containing	O
one	O
of	O
these	O
latter	O
mutations	O
reproduced	O
the	O
characteristic	O
structural	O
abnormality	O
seen	O
in	O
type	B-Disease
iia	I-Disease
vwd	I-Disease
plasma	O
.	O
	
familial	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
associated	O
with	O
recurrent	O
meningococcal	B-Disease
infections	I-Disease
.	O
	
we	O
describe	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
suffering	O
from	O
recurrent	B-Disease
meningitis	I-Disease
with	O
a	O
complete	O
absence	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c7	O
)	O
.	O
	
the	O
relatives	O
(	O
parents	O
and	O
one	O
sister	O
)	O
had	O
half	O
-	O
normal	O
levels	O
of	O
both	O
immunochemically	O
and	O
functionally	O
determined	O
c7	O
,	O
indicating	O
a	O
heterozygous	O
state	O
for	O
c7	B-Disease
deficiency	I-Disease
.	O
	
translocation	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
	
1	O
;	O
p13	O
)	O
associated	O
with	O
familial	O
isolated	B-Disease
aniridia	I-Disease
.	O
	
a	O
father	O
and	O
daughter	O
with	O
isolated	B-Disease
aniridia	I-Disease
were	O
observed	O
to	O
have	O
an	O
apparently	O
balanced	O
,	O
reciprocal	O
translocation	O
involving	O
chromosomes	O
5	O
and	O
11	O
[	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
1	O
;	O
p13	O
)	O
]	O
.	O
	
this	O
finding	O
,	O
in	O
association	O
with	O
3	O
other	O
instances	O
of	O
single	O
breaks	O
at	O
11p13	O
and	O
aniridia	B-Disease
,	O
supports	O
the	O
assignment	O
of	O
an2	O
to	O
11p13	O
.	O
	
homozygous	B-Disease
hypobetalipoproteinemia	I-Disease
:	O
a	O
disease	O
distinct	O
from	O
abetalipoproproteinemia	B-Disease
at	O
the	O
molecular	O
level	O
.	O
	
apob	O
dna	O
,	O
rna	O
,	O
and	O
protein	O
from	O
two	O
patients	O
with	O
homozygous	B-Disease
hypobetalipoproteinemia	I-Disease
(	O
hbl	B-Disease
)	O
were	O
evaluated	O
and	O
compared	O
with	O
normal	O
individuals	O
.	O
	
northern	O
and	O
slot	O
blot	O
analyses	O
of	O
total	O
liver	O
mrna	O
from	O
hbl	B-Disease
patients	O
documented	O
a	O
normal	O
size	O
apob	O
mrna	O
that	O
was	O
present	O
in	O
greatly	O
reduced	O
quantities	O
.	O
	
apob	O
protein	O
was	O
detected	O
within	O
hbl	B-Disease
hepatocytes	O
utilizing	O
immunohistochemical	O
techniques	O
;	O
however	O
,	O
it	O
was	O
markedly	O
reduced	O
in	O
quantity	O
when	O
compared	O
with	O
control	O
samples	O
.	O
	
no	O
apob	O
was	O
detectable	O
in	O
the	O
plasma	O
of	O
hbl	B-Disease
individuals	O
with	O
an	O
elisa	O
assay	O
.	O
	
these	O
data	O
are	O
most	O
consistent	O
with	O
a	O
mutation	O
in	O
the	O
coding	O
portion	O
of	O
the	O
apob	O
gene	O
in	O
hbl	B-Disease
patients	O
,	O
leading	O
to	O
an	O
abnormal	O
apob	O
protein	O
and	O
apob	O
mrna	O
instability	O
.	O
	
these	O
results	O
are	O
distinct	O
from	O
those	O
previously	O
noted	O
in	O
abetalipoproteinemia	B-Disease
,	O
which	O
was	O
characterized	O
by	O
an	O
elevated	O
level	O
of	O
hepatic	O
apob	O
mrna	O
and	O
accumulation	O
of	O
intracellular	O
hepatic	O
apob	O
protein	O
.	O
	
spontaneous	O
reversion	O
of	O
novel	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
mutation	O
by	O
hprt	O
gene	O
rearrangement	O
.	O
	
molecular	O
analysis	O
of	O
an	O
unusual	O
patient	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
has	O
suggested	O
that	O
the	O
mutation	O
is	O
due	O
to	O
a	O
partial	O
hprt	O
gene	O
duplication	O
.	O
	
growth	O
of	O
epstein	B-Disease
-	I-Disease
barr	I-Disease
virus	O
-	O
transformed	O
lymphoblasts	O
from	O
this	O
patient	O
in	O
selective	O
medium	O
has	O
permitted	O
isolation	O
of	O
spontaneous	O
hprt	O
+	O
revertants	O
of	O
this	O
mutation	O
.	O
	
this	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	O
of	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
exhibited	O
by	O
this	O
patient	O
.	O
	
complex	B-Disease
glycerol	I-Disease
kinase	I-Disease
deficiency	I-Disease
:	O
molecular	O
-	O
genetic	O
,	O
cytogenetic	O
,	O
and	O
clinical	O
studies	O
of	O
five	O
japanese	O
patients	O
.	O
	
five	O
male	O
japanese	O
patients	O
with	O
complex	B-Disease
glycerol	I-Disease
kinase	I-Disease
deficiency	I-Disease
(	O
cgkd	B-Disease
)	O
and	O
their	O
relatives	O
were	O
studied	O
clinically	O
,	O
cytogenetically	O
,	O
and	O
molecular	O
-	O
genetically	O
.	O
	
all	O
patients	O
had	O
muscular	B-Disease
dystrophy	I-Disease
or	O
muscle	B-Disease
weakness	I-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
congenital	B-Disease
adrenal	I-Disease
hypoplasia	I-Disease
,	O
and	O
glycerol	B-Disease
kinase	I-Disease
deficiency	I-Disease
.	O
	
a	O
comparison	O
of	O
the	O
clinical	O
manifestations	O
of	O
the	O
present	O
five	O
patients	O
and	O
reported	O
cgkd	B-Disease
or	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
patients	O
with	O
dna	O
deletion	O
suggests	O
the	O
existence	O
of	O
a	O
certain	O
gene	O
responsible	O
for	O
gonadotropin	B-Disease
deficiency	I-Disease
(	O
gtd	B-Disease
)	O
.	O
	
the	O
result	O
of	O
the	O
present	O
study	O
and	O
results	O
of	O
previous	O
studies	O
suggest	O
that	O
genes	O
for	O
ornithine	O
transcarbamylase	O
(	O
otc	O
)	O
,	O
dmd	B-Disease
,	O
and	O
gk	O
and	O
putative	O
genes	O
responsible	O
for	O
congenital	B-Disease
adrenal	I-Disease
hypoplasia	I-Disease
(	O
ahc	B-Disease
)	O
and	O
gtd	B-Disease
are	O
arranged	O
from	O
telomere	O
to	O
centromere	O
as	O
pter	O
-	O
-	O
gtd	O
-	O
-	O
ahc	O
-	O
-	O
gk	O
-	O
-	O
dmd	O
-	O
-	O
otc	O
-	O
-	O
cen	O
genetically	O
determined	O
low	O
c4	O
:	O
a	O
predisposing	O
factor	O
to	O
autoimmune	B-Disease
chronic	I-Disease
active	I-Disease
hepatitis	I-Disease
.	O
	
of	O
26	O
patients	O
with	O
autoimmune	B-Disease
chronic	I-Disease
active	I-Disease
hepatitis	I-Disease
(	O
cah	B-Disease
)	O
starting	O
in	O
childhood	O
18	O
(	O
69	O
%	O
)	O
had	O
low	O
c4	O
and	O
5	O
(	O
19	O
%	O
)	O
had	O
low	O
c3	O
serum	O
levels	O
.	O
	
these	O
results	O
suggest	O
that	O
low	O
c4	O
levels	O
in	O
cah	B-Disease
are	O
genetically	O
determined	O
.	O
	
c4	O
phenotyping	O
in	O
20	O
patients	O
and	O
in	O
26	O
parents	O
showed	O
that	O
90	O
%	O
and	O
81	O
%	O
,	O
respectively	O
,	O
had	O
nan	O
allotypes	O
at	O
either	O
the	O
c4a	O
or	O
c4b	O
locus	O
compared	O
with	O
59	O
%	O
in	O
controls	O
,	O
indicating	O
that	O
defective	O
expression	O
of	O
structural	O
genes	O
may	O
contribute	O
to	O
the	O
observed	O
c4	B-Disease
deficiency	I-Disease
.	O
	
.	O
	
an	O
amino	O
-	O
acid	O
substitution	O
involved	O
in	O
phenylketonuria	B-Disease
is	O
in	O
linkage	O
disequilibrium	O
with	O
dna	O
haplotype	O
2	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
human	I-Disease
genetic	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
,	O
phenylalanine	O
4	O
-	O
monooxygenase	O
,	O
ec	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O
	
pku	B-Disease
is	O
a	O
common	O
inborn	B-Disease
error	I-Disease
of	I-Disease
amino	I-Disease
-	I-Disease
acid	I-Disease
metabolism	I-Disease
in	O
caucasian	O
populations	O
and	O
approximately	O
1	O
in	O
50	O
individuals	O
are	O
carriers	O
of	O
a	O
pku	B-Disease
allele	O
.	O
	
to	O
define	O
the	O
molecular	O
basis	O
of	O
pku	B-Disease
,	O
we	O
characterized	O
twelve	O
restriction	O
fragment	O
-	O
length	O
polymorphism	O
(	O
rflp	O
)	O
haplotypes	O
of	O
the	O
pah	O
locus	O
in	O
the	O
northern	O
european	O
population	O
and	O
observed	O
that	O
90	O
%	O
of	O
the	O
pku	B-Disease
alleles	O
in	O
this	O
population	O
are	O
confined	O
to	O
four	O
common	O
rflp	O
haplotypes	O
.	O
	
we	O
now	O
report	O
the	O
molecular	B-Disease
lesion	I-Disease
associated	O
with	O
the	O
rflp	O
haplotype	O
2	O
mutant	O
allele	O
.	O
	
choroideremia	B-Disease
:	O
close	O
linkage	O
to	O
dxys1	O
and	O
dxys12	O
demonstrated	O
by	O
segregation	O
analysis	O
and	O
historical	O
-	O
genealogical	O
evidence	O
.	O
	
linkage	O
studies	O
using	O
restriction	O
fragment	O
length	O
polymorphisms	O
were	O
conducted	O
in	O
the	O
x	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
,	O
choroideremia	B-Disease
,	O
designated	O
tcd	B-Disease
for	O
progressive	B-Disease
tapeto	I-Disease
-	I-Disease
choroidal	I-Disease
dystrophy	I-Disease
.	O
	
in	O
addition	O
,	O
locus	O
dxys12	O
was	O
found	O
to	O
be	O
closely	O
linked	O
with	O
tcd	B-Disease
(	O
lod	O
3	O
.	O
31	O
at	O
0	O
recombination	O
distance	O
)	O
.	O
	
all	O
36	O
patients	O
and	O
48	O
carriers	O
tested	O
from	O
the	O
three	O
kindreds	O
had	O
the	O
same	O
haplotype	O
(	O
tcd	B-Disease
/	O
dxys1	O
,	O
11kb	O
/	O
dxys12	O
,	O
1	O
.	O
6kb	O
)	O
.	O
	
given	O
that	O
at	O
least	O
105	O
female	O
meioses	O
transmitting	O
tcd	B-Disease
have	O
occurred	O
since	O
1650	O
in	O
these	O
kindreds	O
,	O
extremely	O
close	O
linkage	O
between	O
tcd	B-Disease
,	O
dxys1	O
and	O
dxys12	O
is	O
suggested	O
.	O
	
the	O
above	O
haplotype	O
is	O
a	O
very	O
useful	O
diagnostic	O
tool	O
in	O
these	O
tcd	B-Disease
families	O
.	O
	
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
maps	O
to	O
the	O
region	O
of	O
chromosome	O
3	O
associated	O
with	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
	
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
(	O
vhl	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
with	O
inherited	O
susceptibility	O
to	O
various	O
forms	O
of	O
cancer	B-Disease
,	O
including	O
hemangioblastomas	B-Disease
of	O
the	O
central	O
nervous	O
system	O
,	O
phaeochromocytomas	B-Disease
,	O
pancreatic	B-Disease
malignancies	I-Disease
,	O
and	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
constitute	O
a	O
particularly	O
frequent	O
cause	O
of	O
death	O
in	O
this	O
disorder	O
,	O
occurring	O
as	O
bilateral	B-Disease
and	I-Disease
multifocal	I-Disease
tumours	I-Disease
,	O
and	O
presenting	O
at	O
an	O
earlier	O
age	O
than	O
in	O
sporadic	O
,	O
non	O
-	O
familial	O
cases	O
of	O
this	O
tumour	B-Disease
type	O
.	O
	
we	O
report	O
here	O
that	O
the	O
vhl	B-Disease
gene	O
is	O
linked	O
to	O
the	O
locus	O
encoding	O
the	O
human	O
homologoue	O
of	O
the	O
raf1	O
oncogene	O
,	O
which	O
maps	O
to	O
chromosome	O
3p25	O
(	O
ref	O
.	O
4	O
)	O
.	O
	
crossovers	O
with	O
the	O
vhl	B-Disease
locus	O
suggest	O
that	O
the	O
defect	O
responsible	O
for	O
the	O
vhl	B-Disease
phenotype	O
is	O
not	O
a	O
mutation	O
in	O
the	O
raf1	O
gene	O
itself	O
.	O
	
an	O
alternative	O
or	O
prior	O
event	O
to	O
oncogene	O
activation	O
in	O
tumour	B-Disease
formation	O
may	O
be	O
the	O
inactivation	O
of	O
a	O
putative	O
tumour	B-Disease
suppressor	O
which	O
can	O
be	O
associated	O
with	O
both	O
the	O
inherited	B-Disease
and	I-Disease
sporadic	I-Disease
forms	I-Disease
of	I-Disease
the	I-Disease
cancer	I-Disease
.	O
	
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
have	O
previously	O
been	O
associated	O
with	O
the	O
loss	O
of	O
regions	O
on	O
chromosome	O
3p	O
(	O
refs	O
5	O
,	O
6	O
)	O
.	O
	
consequently	O
,	O
sporadic	O
and	O
vhl	O
-	O
associated	O
forms	O
of	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
might	O
both	O
result	O
from	O
alterations	O
causing	O
loss	O
of	O
function	O
of	O
the	O
same	O
tumour	B-Disease
suppressor	O
gene	O
on	O
this	O
chromosome	O
.	O
	
tightly	O
linked	O
flanking	O
markers	O
for	O
the	O
lowe	B-Disease
oculocerebrorenal	I-Disease
syndrome	I-Disease
,	O
with	O
application	O
to	O
carrier	O
assessment	O
.	O
	
the	O
lowe	B-Disease
oculocerebrorenal	I-Disease
syndrome	I-Disease
(	O
ocrl	B-Disease
)	O
is	O
characterized	O
by	O
congenital	O
cataract	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
defective	B-Disease
renal	I-Disease
tubular	I-Disease
function	I-Disease
.	O
	
a	O
map	O
assignment	O
of	O
ocrl	B-Disease
to	O
xq24	O
-	O
q26	O
has	O
been	O
made	O
previously	O
by	O
linkage	O
analysis	O
with	O
dxs42	O
at	O
xq24	O
-	O
q26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
5	O
.	O
	
9	O
)	O
and	O
with	O
dxs10	O
at	O
xq26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
6	O
.	O
45	O
)	O
.	O
	
with	O
additional	O
ocrl	B-Disease
families	O
made	O
informative	O
for	O
dxs42	O
,	O
theta	O
remained	O
0	O
with	O
z	O
=	O
6	O
.	O
	
evidence	O
for	O
placing	O
ocrl	O
at	O
xq25	O
also	O
comes	O
from	O
a	O
female	O
with	O
lowe	B-Disease
syndrome	I-Disease
and	O
an	O
x	O
;	O
3	O
translocation	O
.	O
	
the	O
markers	O
dxs10	O
and	O
dxs42	O
therefore	O
show	O
tight	O
linkage	O
with	O
ocrl	B-Disease
in	O
six	O
families	O
and	O
flank	O
the	O
xq25	O
breakpoint	O
in	O
a	O
female	O
patient	O
with	O
an	O
x	O
;	O
3	O
translocation	O
.	O
	
linkage	O
analysis	O
with	O
flanking	O
markers	O
was	O
used	O
to	O
assess	O
ocrl	B-Disease
carrier	O
status	O
in	O
women	O
at	O
risk	O
.	O
	
identification	O
of	O
a	O
single	O
nucleotide	O
change	O
in	O
the	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
gene	O
(	O
hprtyale	O
)	O
responsible	O
for	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
complete	O
deficiency	B-Disease
of	I-Disease
hypoxanthine	I-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
(	O
hprt	O
)	O
causes	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
previous	O
characterization	O
of	O
a	O
mutant	O
form	O
of	O
hprt	O
,	O
hprtyale	O
,	O
from	O
a	O
subject	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
revealed	O
normal	O
mrna	O
and	O
protein	O
concentrations	O
,	O
no	O
residual	O
catalytic	O
activity	O
,	O
and	O
cathodal	O
migration	O
upon	O
page	O
.	O
	
g6pd	B-Disease
deficiency	I-Disease
in	O
different	O
geographical	O
areas	O
appears	O
to	O
have	O
arisen	O
through	O
independent	O
mutational	O
events	O
,	O
but	O
within	O
the	O
same	O
population	O
it	O
may	O
also	O
be	O
heterogeneous	O
.	O
	
we	O
cloned	O
and	O
sequenced	O
the	O
four	O
g6pd	O
variants	O
from	O
sardinia	O
and	O
found	O
that	O
only	O
two	O
mutations	O
are	O
responsible	O
for	O
g6pd	B-Disease
deficiency	I-Disease
in	O
this	O
area	O
one	O
mutation	O
is	O
the	O
cause	O
of	O
the	O
g6pd	B-Disease
seattle	I-Disease
-	I-Disease
like	I-Disease
phenotype	I-Disease
,	O
a	O
milder	O
form	O
of	O
g6pd	B-Disease
deficiency	I-Disease
;	O
the	O
other	O
mutation	O
is	O
responsible	O
for	O
all	O
forms	O
of	O
very	O
severe	O
g6pd	B-Disease
deficiency	I-Disease
in	O
sardinia	O
and	O
,	O
possibly	O
,	O
in	O
the	O
mediterranean	O
.	O
	
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
cnsha	B-Disease
)	O
and	O
glucose	B-Disease
6	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
a	O
patient	O
with	O
familial	B-Disease
amyloidotic	I-Disease
polyneuropathy	I-Disease
(	O
fap	B-Disease
)	O
.	O
	
a	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
g6pd	O
)	O
variant	O
with	O
severe	O
erythrocytic	B-Disease
g6pd	I-Disease
deficiency	I-Disease
and	O
a	O
unique	O
ph	O
optimum	O
is	O
described	O
in	O
a	O
young	O
patient	O
with	O
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
cnsha	B-Disease
)	O
and	O
familial	B-Disease
amyloidotic	I-Disease
polyneuropathy	I-Disease
(	O
fap	B-Disease
)	O
.	O
	
chronic	B-Disease
hemolysis	I-Disease
was	O
present	O
in	O
the	O
absence	O
of	O
infections	O
,	O
oxidant	O
drugs	O
or	O
ingestion	O
of	O
faba	O
beans	O
.	O
	
molecular	O
detection	O
of	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
putative	O
retinoblastoma	B-Disease
susceptibility	O
locus	O
.	O
	
a	O
candidate	O
dna	O
sequence	O
with	O
many	O
of	O
the	O
properties	O
predicted	O
for	O
the	O
retinoblastoma	B-Disease
susceptibility	O
(	O
rb1	O
)	O
locus	O
has	O
been	O
cloned	O
(	O
s	O
.	O
h	O
.	O
friend	O
,	O
r	O
.	O
bernards	O
,	O
s	O
.	O
rogelj	O
,	O
r	O
.	O
a	O
.	O
weinberg	O
,	O
j	O
.	O
m	O
.	O
rapaport	O
,	O
d	O
.	O
m	O
.	O
albert	O
,	O
and	O
t	O
.	O
p	O
.	O
dryja	O
,	O
nature	O
[	O
london	O
]	O
323	O
643	O
-	O
645	O
,	O
1986	O
)	O
.	O
	
here	O
we	O
used	O
field	O
inversion	O
gel	O
electrophoresis	O
(	O
fige	O
)	O
to	O
construct	O
a	O
restriction	O
map	O
of	O
approximately	O
1	O
,	O
0	O
kb	O
of	O
dna	O
surrounding	O
the	O
rb1	O
locus	O
and	O
to	O
detect	O
the	O
translocation	O
breakpoints	O
in	O
three	O
retinoblastoma	B-Disease
patients	O
.	O
	
the	O
detection	O
and	O
mapping	O
of	O
the	O
translocation	O
breakpoints	O
of	O
all	O
three	O
retinoblastoma	B-Disease
patients	O
to	O
within	O
the	O
putative	O
rb1	O
gene	O
substantiated	O
the	O
authenticity	O
of	O
this	O
candidate	O
sequence	O
and	O
demonstrated	O
the	O
utility	O
of	O
fige	O
in	O
detecting	O
chromosomal	O
rearrangements	O
affecting	O
this	O
locus	O
.	O
	
inherited	O
c3	B-Disease
deficiency	I-Disease
with	O
recurrent	O
infections	O
and	O
glomerulonephritis	B-Disease
.	O
	
a	O
10	O
-	O
year	O
-	O
old	O
laotian	O
boy	O
had	O
homozygous	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
third	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
and	O
recurrent	O
bacterial	B-Disease
infections	I-Disease
beginning	O
at	O
age	O
5	O
months	O
.	O
	
in	O
vitro	O
addition	O
of	O
purified	O
c3	O
to	O
patient	O
serum	O
restored	O
hemolytic	O
complement	O
to	O
normal	O
levels	O
,	O
and	O
plasma	O
infusion	O
during	O
each	O
of	O
four	O
episodes	O
of	O
pneumonia	B-Disease
significantly	O
enhanced	O
serum	O
opsonic	O
activity	O
for	O
as	O
long	O
as	O
36	O
hours	O
.	O
	
a	O
renal	O
biopsy	O
specimen	O
revealed	O
mesangiopathic	B-Disease
glomerulonephritis	I-Disease
,	O
although	O
significant	O
levels	O
of	O
circulating	O
igg	O
immune	O
complexes	O
were	O
not	O
detected	O
.	O
	
these	O
findings	O
further	O
support	O
the	O
association	O
of	O
c3	B-Disease
deficiency	I-Disease
with	O
immune	B-Disease
-	I-Disease
complex	I-Disease
disease	I-Disease
and	O
suggest	O
that	O
plasma	O
infusion	O
may	O
be	O
an	O
adjunct	O
to	O
antibiotic	O
therapy	O
in	O
the	O
management	O
of	O
severe	O
pyogenic	B-Disease
infections	I-Disease
in	O
patients	O
with	O
c3	B-Disease
deficiency	I-Disease
.	O
	
a	O
deficiency	B-Disease
of	I-Disease
aat	I-Disease
in	O
individuals	O
homozygous	O
for	O
the	O
pi	O
z	O
allele	O
occurs	O
in	O
about	O
1	O
in	O
2	O
,	O
0	O
-	O
8	O
,	O
0	O
caucasians	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
early	O
adult	O
onset	O
emphysema	B-Disease
and	O
liver	B-Disease
disease	I-Disease
in	O
childhood	O
.	O
	
segregation	O
analysis	O
of	O
a	O
marker	O
localised	O
xp21	O
.	O
	
2	O
-	O
xp21	O
.	O
	
3	O
in	O
duchenne	B-Disease
and	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
families	O
.	O
	
3	O
,	O
has	O
been	O
studied	O
in	O
kindreds	O
segregating	O
for	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
and	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
bmd	B-Disease
)	O
.	O
	
in	O
dmd	B-Disease
families	O
four	O
crossovers	O
were	O
observed	O
in	O
38	O
informative	O
meioses	O
between	O
c7	O
and	O
the	O
dmd	B-Disease
locus	O
(	O
theta	O
=	O
0	O
.	O
12	O
,	O
z	O
max	O
=	O
+	O
2	O
.	O
72	O
)	O
.	O
	
in	O
bmd	B-Disease
families	O
no	O
recombinants	O
were	O
observed	O
in	O
the	O
16	O
informative	O
meioses	O
studied	O
.	O
	
c7	O
and	O
754	O
thus	O
provide	O
good	O
bridging	O
markers	O
for	O
the	O
diagnosis	O
of	O
dmd	B-Disease
and	O
bmd	B-Disease
isolation	O
of	O
molecular	O
probes	O
associated	O
with	O
the	O
chromosome	O
15	O
instability	O
in	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
.	O
	
flow	O
cytometry	O
and	O
recombinant	O
dna	O
techniques	O
have	O
been	O
used	O
to	O
obtain	O
reagents	O
for	O
a	O
molecular	O
analysis	O
of	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
2	O
and	O
are	O
shown	O
to	O
be	O
deleted	O
in	O
dna	O
of	O
one	O
of	O
two	O
patients	O
examined	O
with	O
the	O
pws	B-Disease
.	O
	
2	O
may	O
elucidate	O
the	O
molecular	O
basis	O
for	O
the	O
instability	O
of	O
this	O
chromosomal	O
region	O
in	O
patients	O
with	O
the	O
pws	B-Disease
or	O
other	O
diseases	O
associated	O
with	O
chromosomal	B-Disease
abnormalities	I-Disease
in	O
the	O
proximal	O
long	O
arm	O
of	O
human	O
chromosome	O
15	O
analysis	O
of	O
deletions	O
in	O
dna	O
from	O
patients	O
with	O
becker	B-Disease
and	I-Disease
duchenne	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
for	O
which	O
the	O
biochemical	O
defect	O
is	O
as	O
yet	O
unknown	O
.	O
	
both	O
of	O
these	O
cloned	O
segments	O
were	O
described	O
as	O
tightly	O
linked	O
to	O
the	O
locus	O
and	O
were	O
capable	O
of	O
detecting	O
deletions	O
in	O
the	O
dna	O
of	O
boys	O
affected	O
with	O
dmd	B-Disease
.	O
	
in	O
an	O
attempt	O
to	O
determine	O
more	O
precisely	O
the	O
occurrence	O
of	O
these	O
deletions	O
within	O
a	O
large	O
population	O
of	O
dmd	B-Disease
patients	O
and	O
the	O
accuracy	O
of	O
one	O
of	O
the	O
segments	O
,	O
dxs164	O
(	O
pert87	O
)	O
,	O
in	O
determining	O
the	O
inheritance	O
of	O
the	O
dmd	B-Disease
x	O
chromosome	O
,	O
the	O
subclones	O
1	O
,	O
8	O
and	O
15	O
were	O
made	O
available	O
to	O
many	O
investigators	O
throughout	O
the	O
world	O
.	O
	
here	O
we	O
describe	O
the	O
combined	O
results	O
of	O
more	O
than	O
20	O
research	O
laboratories	O
with	O
respect	O
to	O
the	O
occurrence	O
of	O
deletions	O
at	O
the	O
dxs164	O
locus	O
in	O
dna	O
samples	O
isolated	O
from	O
patients	O
with	O
dmd	B-Disease
and	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
bmd	B-Disease
)	O
.	O
	
the	O
results	O
indicate	O
that	O
the	O
dxs164	O
locus	O
apparently	O
recombines	O
with	O
dmd	B-Disease
5	O
%	O
of	O
the	O
time	O
,	O
but	O
is	O
probably	O
located	O
between	O
independent	O
sites	O
of	O
mutation	O
which	O
yield	O
dmd	B-Disease
.	O
	
the	O
breakpoints	O
of	O
some	O
deletions	O
are	O
delineated	O
within	O
the	O
dxs164	O
locus	O
,	O
and	O
it	O
is	O
evident	O
that	O
the	O
deletions	O
at	O
the	O
dmd	B-Disease
locus	O
are	O
frequent	O
and	O
extremely	O
large	O
.	O
	
a	O
potential	O
animal	O
model	O
for	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
through	O
introduction	O
of	O
hprt	O
mutations	O
into	O
mice	O
.	O
	
the	O
human	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
neurological	B-Disease
and	I-Disease
behavioural	I-Disease
disorder	I-Disease
,	O
affecting	O
only	O
males	O
,	O
which	O
is	O
caused	O
by	O
an	O
inherited	B-Disease
deficiency	I-Disease
in	O
the	O
level	O
of	O
activity	O
of	O
the	O
purine	O
salvage	O
enzyme	O
hypoxanthine	O
-	O
guanosine	O
phosphoribosyl	O
transferase	O
(	O
hprt	O
)	O
.	O
	
how	O
the	O
resulting	O
alterations	O
in	O
purine	O
metabolism	O
lead	O
to	O
the	O
severe	O
symptoms	O
characteristic	O
of	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
patients	O
is	O
still	O
not	O
understood	O
.	O
	
to	O
derive	O
an	O
animal	O
model	O
for	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
,	O
we	O
have	O
used	O
cultured	O
mouse	O
embryonic	O
stem	O
cells	O
,	O
mutagenized	O
by	O
retroviral	O
insertion	O
and	O
selected	O
for	O
loss	O
of	O
hprt	O
activity	O
,	O
to	O
construct	O
chimaeric	O
mice	O
.	O
	
two	O
clonal	O
lines	O
carrying	O
different	O
mutant	O
hprt	O
alleles	O
have	O
given	O
rise	O
to	O
germ	O
cells	O
in	O
chimaeras	O
,	O
allowing	O
the	O
derivation	O
of	O
strains	O
of	O
mutant	O
mice	O
having	O
the	O
same	O
biochemical	O
defect	O
as	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
patients	O
.	O
	
re	O
-	O
evaluation	O
of	O
the	O
sublocalization	O
of	O
esterase	O
d	O
and	O
its	O
relation	O
to	O
the	O
retinoblastoma	B-Disease
locus	O
by	O
in	O
situ	O
hybridization	O
.	O
	
a	O
deletion	O
in	O
an	O
individual	O
with	O
retinoblastoma	B-Disease
was	O
reported	O
to	O
separate	O
the	O
closely	O
linked	O
esd	O
and	O
retinoblastoma	B-Disease
(	O
rb1	O
)	O
loci	O
,	O
placing	O
esd	O
proximal	O
to	O
rb1	O
.	O
	
hereditary	B-Disease
c2	I-Disease
deficiency	I-Disease
associated	O
with	O
common	O
variable	O
immunodeficiency	B-Disease
.	O
	
homozygous	O
c2	B-Disease
deficiency	I-Disease
in	O
a	O
19	O
-	O
year	O
-	O
old	O
boy	O
was	O
associated	O
with	O
variable	O
immunodeficiency	B-Disease
manifested	O
by	O
marked	O
hypoimmunoglobulinemia	B-Disease
and	O
impaired	O
antibody	O
responses	O
,	O
normal	O
circulating	O
b	O
lymphocytes	O
,	O
and	O
subnormal	O
t	O
-	O
cell	O
functions	O
.	O
	
neither	O
antilymphocytic	O
autoantibodies	O
nor	O
chromosomal	B-Disease
abnormalities	I-Disease
were	O
found	O
.	O
	
serum	O
immunoglobulin	O
levels	O
were	O
within	O
normal	O
limits	O
in	O
his	O
parents	O
and	O
brother	O
who	O
were	O
heterozygous	O
for	O
c2	B-Disease
deficiency	I-Disease
.	O
	
mild	O
and	O
severe	O
muscular	B-Disease
dystrophy	I-Disease
associated	O
with	O
deletions	O
in	O
xp21	O
of	O
the	O
human	O
x	O
chromosome	O
.	O
	
we	O
have	O
analysed	O
over	O
300	O
patients	O
suffering	O
from	O
duchenne	B-Disease
or	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
or	O
bmd	B-Disease
)	O
.	O
	
these	O
loci	O
have	O
been	O
shown	O
to	O
lie	O
within	O
the	O
dmd	B-Disease
region	O
covering	O
several	O
hundred	O
kilobases	O
(	O
kb	O
)	O
of	O
dna	O
.	O
	
one	O
mildly	O
affected	O
bmd	B-Disease
patient	O
possesses	O
a	O
deletion	O
of	O
at	O
least	O
110	O
kb	O
including	O
exons	O
of	O
the	O
dmd	B-Disease
gene	O
.	O
	
other	O
patients	O
with	O
similar	O
exon	O
deletions	O
,	O
or	O
smaller	O
deletions	O
,	O
show	O
the	O
more	O
severe	O
phenotype	O
typical	O
of	O
dmd	B-Disease
.	O
	
patterns	O
of	O
exon	O
deletions	O
in	O
duchenne	B-Disease
and	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
a	O
panel	O
of	O
patients	O
with	O
duchenne	B-Disease
and	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
and	O
bmd	B-Disease
)	O
has	O
been	O
screened	O
with	O
the	O
cdna	O
probes	O
cf56a	O
and	O
cf23a	O
,	O
which	O
detect	O
exons	O
in	O
the	O
central	O
part	O
of	O
the	O
dmd	B-Disease
gene	O
.	O
	
the	O
deletions	O
were	O
mapped	O
and	O
prove	O
to	O
be	O
heterogeneous	O
in	O
size	O
and	O
extent	O
,	O
particularly	O
in	O
dmd	B-Disease
.	O
	
deletions	O
specific	O
to	O
dmd	B-Disease
and	O
to	O
bmd	B-Disease
are	O
described	O
.	O
	
half	O
of	O
all	O
bmd	B-Disease
patients	O
have	O
a	O
deletion	O
of	O
one	O
particular	O
small	O
group	O
of	O
exons	O
;	O
smaller	O
deletions	O
within	O
this	O
same	O
group	O
produce	O
the	O
more	O
severe	O
dmd	B-Disease
.	O
	
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
third	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
a	O
child	O
with	O
fever	B-Disease
,	O
skin	B-Disease
rash	I-Disease
,	O
and	O
arthralgias	B-Disease
:	O
response	O
to	O
transfusion	O
of	O
whole	O
blood	O
.	O
	
a	O
previously	O
well	O
34	O
-	O
month	O
-	O
old	O
male	O
presenting	O
with	O
fever	B-Disease
,	O
skin	B-Disease
rash	I-Disease
,	O
and	O
arthralgias	B-Disease
was	O
found	O
to	O
lack	O
c3	O
by	O
immunochemical	O
(	O
undetectable	O
)	O
and	O
hemolytic	O
(	O
1	O
%	O
normal	O
)	O
assays	O
.	O
	
a	O
transfusion	O
of	O
320	O
ml	O
1	O
-	O
hour	O
-	O
old	O
normal	O
whole	O
blood	O
on	O
the	O
fifty	O
-	O
second	O
day	O
resulted	O
in	O
transitory	O
elevation	O
of	O
the	O
c3	O
level	O
to	O
25	O
mg	O
/	O
dl	O
with	O
a	O
fall	O
-	O
off	O
(	O
approximately	O
2	O
1	O
/	O
2	O
%	O
per	O
hour	O
)	O
to	O
undetectable	O
levels	O
by	O
69	O
hours	O
;	O
it	O
was	O
followed	O
by	O
disappearance	O
of	O
the	O
skin	B-Disease
rash	I-Disease
and	O
arthralgias	B-Disease
and	O
return	O
to	O
normal	O
of	O
the	O
previously	O
elevated	O
temperature	O
and	O
crp	O
levels	O
.	O
	
c3	O
levels	O
in	O
family	O
members	O
(	O
seven	O
of	O
24	O
half	O
-	O
normal	O
)	O
,	O
lack	O
of	O
anti	O
-	O
c3	O
activity	O
,	O
normal	O
c3b	O
-	O
ina	O
levels	O
and	O
a	O
normal	O
rate	O
of	O
catabolism	O
of	O
transfused	O
c3	O
indicated	O
that	O
the	O
deficiency	O
was	O
inherited	O
with	O
autosomal	O
codominance	O
and	O
involved	O
decreased	B-Disease
synthesis	I-Disease
of	I-Disease
c3	I-Disease
.	O
	
thus	O
,	O
this	O
child	O
is	O
a	O
unique	O
individual	O
with	O
inherited	B-Disease
c3	I-Disease
deficiency	I-Disease
presenting	O
with	O
absence	O
of	O
repeated	O
infections	O
,	O
whose	O
symptoms	O
of	O
fever	B-Disease
,	O
skin	B-Disease
rash	I-Disease
,	O
and	O
arthralgia	B-Disease
were	O
abated	O
by	O
whole	O
blood	O
transfusion	O
.	O
	
erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
g6pd	O
)	O
was	O
characterized	O
in	O
blood	O
samples	O
obtained	O
from	O
97	O
randomly	O
selected	O
males	O
with	O
enzyme	B-Disease
deficiency	I-Disease
from	O
various	O
regions	O
of	O
guangdong	O
province	O
,	O
china	O
.	O
	
the	O
results	O
demonstrated	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
was	O
high	O
in	O
this	O
area	O
.	O
	
homozygous	O
and	O
heterozygous	O
deletions	O
of	O
the	O
von	B-Disease
willebrand	I-Disease
factor	O
gene	O
in	O
patients	O
and	O
carriers	O
of	O
severe	B-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
.	O
	
severe	B-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
is	O
characterized	O
by	O
undetectable	O
or	O
trace	O
quantities	O
of	O
von	B-Disease
willebrand	I-Disease
factor	O
in	O
plasma	O
and	O
tissue	O
stores	O
.	O
	
the	O
second	O
group	O
was	O
comprised	O
of	O
a	O
family	O
in	O
which	O
there	O
was	O
a	O
complete	O
heterozygous	O
deletion	O
of	O
the	O
vwf	O
gene	O
in	O
the	O
proband	O
and	O
one	O
asymptomatic	O
parent	O
,	O
suggesting	O
that	O
a	O
different	O
type	O
of	O
genetic	B-Disease
abnormality	I-Disease
was	O
inherited	O
from	O
the	O
other	O
parent	O
.	O
	
thus	O
,	O
the	O
patient	O
appeared	O
to	O
be	O
doubly	O
heterozygous	O
for	O
interacting	O
genetic	B-Disease
abnormalities	I-Disease
affecting	O
vwf	O
expression	O
.	O
	
these	O
techniques	O
should	O
prove	O
useful	O
in	O
identifying	O
carriers	O
of	O
severe	B-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
and	O
also	O
in	O
defining	O
patients	O
predictably	O
at	O
risk	O
of	O
developing	O
alloantibodies	O
to	O
vwf	O
.	O
	
sjogren	B-Disease
-	I-Disease
larsson	I-Disease
syndrome	I-Disease
.	O
	
lipid	O
metabolism	O
was	O
studied	O
in	O
cultured	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
the	O
inherited	B-Disease
disorder	I-Disease
,	O
sjogren	B-Disease
-	I-Disease
larsson	I-Disease
syndrome	I-Disease
(	O
sls	B-Disease
)	O
.	O
	
intact	O
sls	B-Disease
fibroblasts	O
incubated	O
in	O
the	O
presence	O
of	O
[	O
1	O
-	O
14c	O
]	O
palmitate	O
accumulated	O
more	O
radioactive	O
hexadecanol	O
than	O
did	O
normal	O
cells	O
,	O
whereas	O
incorporation	O
of	O
radioactivity	O
into	O
other	O
cellular	O
lipids	O
was	O
unaltered	O
.	O
	
the	O
hexadecanol	O
content	O
of	O
sls	B-Disease
fibroblasts	O
was	O
abnormally	O
elevated	O
.	O
	
the	O
half	O
-	O
life	O
of	O
intracellular	O
hexadecanol	O
loaded	O
into	O
sls	B-Disease
fibroblasts	O
was	O
increased	O
(	O
70	O
min	O
)	O
compared	O
with	O
normal	O
(	O
15	O
min	O
)	O
,	O
and	O
intact	O
sls	B-Disease
fibroblasts	O
showed	O
impaired	O
oxidation	O
of	O
[	O
14c	O
]	O
-	O
hexadecanol	O
to	O
fatty	O
acid	O
.	O
	
fatty	O
alcohol	O
nad	O
+	O
oxidoreductase	O
,	O
the	O
enzyme	O
catalyzing	O
this	O
reaction	O
,	O
was	O
deficient	O
in	O
sls	B-Disease
fibroblasts	O
.	O
	
mean	O
total	O
activity	O
in	O
sls	B-Disease
fibroblasts	O
(	O
n	O
=	O
5	O
)	O
was	O
13	O
%	O
of	O
that	O
in	O
normal	O
fibroblasts	O
,	O
and	O
palmitoyl	O
coa	O
-	O
inhibitable	O
activity	O
was	O
1	O
%	O
of	O
normal	O
.	O
	
fibroblasts	O
from	O
two	O
obligate	O
sls	B-Disease
heterozygotes	O
had	O
enzyme	O
activities	O
intermediate	O
between	O
that	O
in	O
normal	O
fibroblasts	O
and	O
individuals	O
with	O
sls	B-Disease
.	O
	
these	O
results	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
sls	B-Disease
is	O
deficiency	B-Disease
of	I-Disease
fatty	I-Disease
alcohol	I-Disease
nad	I-Disease
+	I-Disease
oxidoreductase	I-Disease
.	O
	
sls	B-Disease
represents	O
the	O
first	O
inherited	B-Disease
disorder	I-Disease
in	O
man	O
associated	O
with	O
an	O
isolated	O
abnormality	B-Disease
in	I-Disease
fatty	I-Disease
alcohol	I-Disease
metabolism	I-Disease
.	O
	
germinal	O
mosaicism	O
in	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
we	O
have	O
identified	O
a	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
pedigree	O
where	O
the	O
disease	O
is	O
associated	O
with	O
a	O
molecular	O
deletion	O
within	O
the	O
dmd	B-Disease
locus	O
.	O
	
nebulin	O
seen	O
in	O
dmd	B-Disease
males	O
including	O
one	O
patient	O
with	O
a	O
large	O
dna	O
deletion	O
encompassing	O
the	O
dmd	B-Disease
gene	O
.	O
	
the	O
presence	O
of	O
nebulin	O
in	O
a	O
muscle	O
specimen	O
from	O
a	O
patient	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
due	O
to	O
a	O
large	O
deletion	O
precludes	O
the	O
possibility	O
that	O
this	O
protein	O
is	O
the	O
dmd	B-Disease
gene	O
product	O
.	O
	
expression	O
of	O
the	O
murine	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
in	O
muscle	O
and	O
brain	O
.	O
	
5	O
kilobases	O
of	O
the	O
murine	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	O
)	O
messenger	O
rna	O
(	O
mrna	O
)	O
.	O
	
dmd	O
mrna	O
is	O
also	O
present	O
,	O
but	O
at	O
much	O
lower	O
than	O
normal	O
levels	O
,	O
in	O
both	O
the	O
muscle	O
and	O
brain	O
of	O
three	O
different	O
strains	O
of	O
dystrophic	B-Disease
mdx	O
mice	O
.	O
	
the	O
identification	O
of	O
dmd	O
mrna	O
in	O
brain	O
raises	O
the	O
possibility	O
of	O
a	O
relation	O
between	O
human	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
expression	O
and	O
the	O
mental	B-Disease
retardation	I-Disease
found	O
in	O
some	O
dmd	B-Disease
males	O
.	O
	
glucose	B-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
and	O
incidence	O
of	O
hematologic	B-Disease
malignancy	I-Disease
.	O
	
we	O
have	O
evaluated	O
the	O
hypothesis	O
of	O
a	O
negative	O
association	O
between	O
glucose	B-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
and	O
cancer	B-Disease
in	O
a	O
cohort	O
of	O
481	O
sardinian	O
males	O
with	O
hematological	B-Disease
malignancies	I-Disease
.	O
	
the	O
frequency	O
of	O
g6pd	B-Disease
deficiency	I-Disease
in	O
the	O
patients	O
was	O
not	O
different	O
from	O
the	O
incidence	O
in	O
a	O
group	O
of	O
16	O
,	O
219	O
controls	O
.	O
	
the	O
same	O
conclusion	O
resulted	O
from	O
the	O
comparison	O
of	O
the	O
frequency	O
of	O
expression	O
of	O
the	O
gdb	O
gene	O
in	O
23	O
heterozygous	O
women	O
having	O
a	O
clonal	O
hematologic	B-Disease
disease	I-Disease
and	O
a	O
control	O
group	O
of	O
37	O
healthy	O
heterozygotes	O
.	O
	
therefore	O
at	O
present	O
there	O
is	O
no	O
evidence	O
that	O
g6pd	B-Disease
deficiency	I-Disease
has	O
a	O
protective	O
effect	O
against	O
development	O
of	O
hematologic	B-Disease
neoplasms	I-Disease
.	O
	
.	O
	
hepatoblastoma	B-Disease
,	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
and	O
jaw	B-Disease
lesions	I-Disease
in	O
gardner	B-Disease
syndrome	I-Disease
.	O
	
hepatoblastoma	B-Disease
is	O
a	O
rare	O
neoplasm	B-Disease
of	O
infants	O
and	O
children	O
only	O
recently	O
documented	O
in	O
association	O
with	O
hereditary	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
of	I-Disease
the	I-Disease
colon	I-Disease
[	O
kingston	O
et	O
al	O
.	O
,	O
1983	O
]	O
.	O
	
we	O
report	O
four	O
children	O
with	O
hepatoblastoma	B-Disease
from	O
four	O
unrelated	O
families	O
with	O
gardner	B-Disease
syndrome	I-Disease
(	O
gs	B-Disease
)	O
.	O
	
one	O
child	O
,	O
now	O
19	O
years	O
old	O
,	O
survived	O
after	O
a	O
resection	O
of	O
a	O
hepatoblastoma	B-Disease
in	O
infancy	O
and	O
recently	O
was	O
found	O
to	O
have	O
gs	B-Disease
.	O
	
he	O
has	O
an	O
associated	O
odontoma	B-Disease
and	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
,	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
be	O
clinical	O
markers	O
of	O
gs	B-Disease
.	O
	
many	O
individuals	O
in	O
these	O
four	O
gs	B-Disease
families	O
,	O
both	O
affected	O
and	O
at	O
risk	O
,	O
have	O
osteomatous	B-Disease
jaw	I-Disease
lesions	I-Disease
and	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
.	O
	
a	O
search	O
for	O
colonic	B-Disease
polyps	I-Disease
should	O
be	O
made	O
in	O
families	O
of	O
infants	O
and	O
children	O
with	O
hepatoblastoma	B-Disease
.	O
	
if	O
the	O
child	O
survives	O
,	O
he	O
or	O
she	O
should	O
be	O
monitored	O
for	O
the	O
later	O
appearance	O
of	O
colonic	B-Disease
polyps	I-Disease
.	O
	
the	O
finding	O
of	O
jaw	B-Disease
lesions	I-Disease
and	O
/	O
or	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
in	O
relatives	O
at	O
risk	O
are	O
indications	O
of	O
the	O
possible	O
presence	O
of	O
the	O
gs	B-Disease
gene	O
.	O
	
identification	O
of	O
an	O
altered	O
splice	O
site	O
in	O
ashkenazi	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
.	O
	
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
resulting	O
from	O
mutation	O
of	O
the	O
hexa	O
gene	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
n	O
-	O
acetylhexosaminidase	O
a	O
(	O
ref	O
.	O
1	O
)	O
.	O
	
a	O
test	O
for	O
the	O
mutant	O
allele	O
based	O
on	O
amplification	O
of	O
dna	O
by	O
the	O
polymerase	O
chain	O
rection	O
and	O
cleavage	O
of	O
a	O
ddei	O
restriction	O
site	O
generated	O
by	O
the	O
mutation	O
revealed	O
that	O
this	O
case	O
and	O
two	O
other	O
cases	O
of	O
the	O
ashkenazi	O
,	O
infantile	O
form	O
of	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
are	O
heterozygous	O
for	O
two	O
different	O
mutations	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
mus	O
musculus	O
.	O
	
a	O
mouse	O
with	O
x	B-Disease
-	I-Disease
linked	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1	O
-	O
ethyl	O
-	O
1	O
-	O
nitrosourea	O
-	O
treated	O
male	O
mice	O
.	O
	
this	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
x	B-Disease
-	I-Disease
linked	I-Disease
g6pd	I-Disease
deficiency	I-Disease
in	O
humans	O
.	O
	
diverse	O
point	O
mutations	O
in	O
the	O
human	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
cause	O
enzyme	B-Disease
deficiency	I-Disease
and	O
mild	O
or	O
severe	O
hemolytic	B-Disease
anemia	I-Disease
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
;	I-Disease
ec	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
common	O
genetic	B-Disease
abnormality	I-Disease
affecting	O
an	O
estimated	O
400	O
million	O
people	O
worldwide	O
.	O
	
the	O
other	O
six	O
mutants	O
investigated	O
were	O
all	O
associated	O
with	O
enzyme	B-Disease
deficiency	I-Disease
.	O
	
in	O
one	O
of	O
the	O
commonest	O
,	O
g6pd	O
mediterranean	O
,	O
which	O
is	O
associated	O
with	O
favism	B-Disease
among	O
other	O
clinical	O
manifestations	O
,	O
a	O
single	O
amino	O
acid	O
replacement	O
was	O
found	O
(	O
serine	O
-	O
-	O
-	O
-	O
phenylalanine	O
)	O
it	O
must	O
be	O
responsible	O
for	O
the	O
decreased	O
stability	O
and	O
the	O
reduced	O
catalytic	O
efficiency	O
of	O
this	O
enzyme	O
.	O
	
single	O
point	O
mutations	O
were	O
also	O
found	O
in	O
g6pd	O
metaponto	O
(	O
southern	O
italy	O
)	O
and	O
in	O
g6pd	O
ilesha	O
(	O
nigeria	O
)	O
,	O
which	O
are	O
asymptomatic	O
,	O
and	O
in	O
g6pd	O
chatham	O
,	O
which	O
was	O
observed	O
in	O
an	O
indian	O
boy	O
with	O
neonatal	B-Disease
jaundice	I-Disease
.	O
	
in	O
g6pd	O
santiago	O
,	O
a	O
de	O
novo	O
mutation	O
(	O
glycine	O
-	O
-	O
-	O
-	O
arginine	O
)	O
is	O
associated	O
with	O
severe	O
chronic	O
hemolytic	B-Disease
anemia	I-Disease
.	O
	
thus	O
,	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
the	O
phenotypic	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
tight	O
linkage	O
between	O
myotonic	B-Disease
dystrophy	I-Disease
and	O
apolipoprotein	O
e	O
genes	O
revealed	O
with	O
allele	O
-	O
specific	O
oligonucleotides	O
.	O
	
in	O
16	O
families	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
a	O
novel	O
approach	O
based	O
on	O
use	O
of	O
allele	O
-	O
specific	O
oligonucleotides	O
has	O
been	O
employed	O
to	O
study	O
the	O
linkage	O
relationship	O
between	O
the	O
apolipoprotein	O
e	O
(	O
apoe	O
)	O
gene	O
and	O
dm	B-Disease
.	O
	
these	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
apoc2	O
,	O
apoe	O
is	O
a	O
useful	O
marker	O
for	O
presymptomatic	O
dm	B-Disease
diagnosis	O
.	O
	
regional	O
localization	O
of	O
polymorphic	O
dna	O
loci	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
x	O
chromosome	O
using	O
deletions	O
associated	O
with	O
choroideremia	B-Disease
.	O
	
in	O
two	O
unrelated	O
families	O
,	O
males	O
have	O
been	O
identified	O
who	O
suffer	O
from	O
choroideremia	B-Disease
and	O
at	O
the	O
same	O
time	O
have	O
an	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
x	O
chromosome	O
.	O
	
by	O
southern	O
blot	O
analysis	O
we	O
have	O
mapped	O
ten	O
different	O
polymorphic	O
dna	O
loci	O
relative	O
to	O
the	O
position	O
of	O
the	O
deletion	O
and	O
the	O
choroideremia	B-Disease
locus	O
tcd	O
.	O
	
retroviral	O
-	O
mediated	O
gene	O
transfer	O
of	O
human	O
phenylalanine	O
hydroxylase	O
into	O
nih	O
3t3	O
and	O
hepatoma	B-Disease
cells	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
caused	O
by	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hepatic	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
the	O
recombinant	O
virus	O
is	O
also	O
capable	O
of	O
infecting	O
a	O
mouse	O
hepatoma	B-Disease
cell	O
line	O
that	O
does	O
not	O
normally	O
synthesize	O
pah	O
.	O
	
pah	O
activity	O
is	O
present	O
in	O
the	O
cellular	O
extracts	O
and	O
the	O
entire	O
hydroxylation	O
system	O
is	O
reconstituted	O
in	O
the	O
hepatoma	B-Disease
cells	O
infected	O
with	O
the	O
recombinant	O
viruses	O
.	O
	
thus	O
,	O
recombinant	O
viruses	O
containing	O
human	O
pah	O
cdna	O
provide	O
a	O
means	O
for	O
introducing	O
functional	O
pah	O
into	O
mammalian	O
cells	O
of	O
hepatic	O
origin	O
and	O
can	O
potentially	O
be	O
introduced	O
into	O
whole	O
animals	O
as	O
a	O
model	O
for	O
somatic	O
gene	O
therapy	O
for	O
pku	B-Disease
.	O
	
estimation	O
of	O
the	O
male	O
to	O
female	O
ratio	O
of	O
mutation	O
rates	O
from	O
the	O
segregation	O
of	O
x	O
-	O
chromosomal	O
dna	O
haplotypes	O
in	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
families	O
.	O
	
a	O
novel	O
procedure	O
is	O
presented	O
to	O
estimate	O
the	O
ratio	O
of	O
male	O
to	O
female	O
mutation	O
rates	O
for	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
x	O
-	O
specific	O
restriction	O
fragment	O
length	O
polymorphisms	O
are	O
used	O
to	O
establish	O
dna	O
haplotypes	O
in	O
three	O
-	O
generation	O
dmd	B-Disease
families	O
.	O
	
from	O
the	O
proportion	O
of	O
dmd	B-Disease
patients	O
who	O
have	O
inherited	O
their	O
maternal	O
grandfathers	O
x	O
chromosome	O
,	O
the	O
ratio	O
of	O
mutation	O
rates	O
can	O
be	O
calculated	O
.	O
	
deletions	O
of	O
a	O
dna	O
sequence	O
in	O
retinoblastomas	B-Disease
and	O
mesenchymal	B-Disease
tumors	I-Disease
:	O
organization	O
of	O
the	O
sequence	O
and	O
its	O
encoded	O
protein	O
.	O
	
retinoblastoma	B-Disease
is	O
a	O
childhood	B-Disease
tumor	I-Disease
that	O
can	O
arise	O
because	O
of	O
mutant	O
alleles	O
acquired	O
as	O
somatic	O
or	O
germinal	O
mutations	O
.	O
	
we	O
have	O
reported	O
isolation	O
of	O
a	O
cdna	O
fragment	O
that	O
recognizes	O
chromosomal	O
sequences	O
possessing	O
many	O
of	O
the	O
attributes	O
of	O
the	O
retinoblastoma	B-Disease
gene	O
associated	O
with	O
the	O
rb1	O
locus	O
.	O
	
we	O
now	O
report	O
that	O
this	O
segment	O
is	O
additionally	O
the	O
target	O
of	O
somatic	O
mutations	O
in	O
mesenchymal	B-Disease
tumors	I-Disease
among	O
patients	O
having	O
no	O
apparent	O
predisposition	O
to	O
retinoblastoma	B-Disease
and	O
no	O
previous	O
evidence	O
of	O
retinoblastoma	B-Disease
.	O
	
these	O
tumors	B-Disease
provide	O
additional	O
evidence	O
that	O
the	O
cloned	O
sequences	O
are	O
representative	O
of	O
a	O
gene	O
that	O
is	O
a	O
frequent	O
target	O
of	O
inactivation	O
during	O
tumorigenesis	O
.	O
	
treatment	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
with	O
growth	O
hormone	O
inhibitors	O
.	O
	
a	O
controlled	O
,	O
double	O
-	O
blind	O
therapeutic	O
trial	O
with	O
the	O
drug	O
mazindol	O
,	O
a	O
growth	O
hormone	O
inhibitor	O
,	O
was	O
performed	O
in	O
a	O
pair	O
of	O
7	O
1	O
/	O
2	O
year	O
-	O
old	O
monozygotic	O
twins	O
,	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
the	O
rationale	O
for	O
this	O
trial	O
was	O
based	O
on	O
a	O
patient	O
(	O
reported	O
previously	O
)	O
affected	O
simultaneously	O
with	O
dmd	B-Disease
and	O
growth	B-Disease
hormone	I-Disease
(	I-Disease
gh	I-Disease
)	I-Disease
deficiency	I-Disease
,	O
who	O
is	O
showing	O
a	O
benign	O
course	O
of	O
the	O
dystrophic	B-Disease
process	I-Disease
and	O
is	O
still	O
walking	O
at	O
18	O
years	O
.	O
	
these	O
results	O
strongly	O
suggest	O
that	O
treatment	O
with	O
a	O
gh	O
inhibitor	O
is	O
beneficial	O
for	O
dmd	B-Disease
patients	O
.	O
	
identification	O
and	O
localization	O
of	O
mutations	O
at	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
locus	O
by	O
ribonuclease	O
a	O
cleavage	O
.	O
	
the	O
recently	O
described	O
ribonuclease	O
a	O
cleavage	O
procedure	O
,	O
with	O
a	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
chromatography	O
step	O
,	O
has	O
been	O
used	O
to	O
identify	O
the	O
mutational	O
lesions	O
in	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
(	O
hprt	O
)	O
messenger	O
rnas	O
of	O
patients	O
with	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
distinctive	O
ribonuclease	O
a	O
cleavage	O
patterns	O
were	O
identified	O
in	O
messenger	O
rna	O
from	O
5	O
of	O
14	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
patients	O
who	O
were	O
chosen	O
because	O
no	O
hprt	O
southern	O
or	O
northern	O
blotting	O
pattern	O
changes	O
had	O
been	O
found	O
.	O
	
this	O
approach	O
now	O
allows	O
hprt	O
mutation	O
detection	O
in	O
50	O
percent	O
of	O
the	O
cases	O
of	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
two	O
new	O
variants	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
associated	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
spherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
:	O
g6pd	O
wayne	O
and	O
g6pd	O
huron	O
.	O
	
two	O
new	O
deficient	O
variants	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
g6pd	O
)	O
causing	O
hereditary	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
hnsha	B-Disease
)	O
are	O
described	O
.	O
	
the	O
patients	O
with	O
g6pd	O
huron	O
were	O
under	O
medical	O
observation	O
for	O
a	O
considerable	O
period	O
of	O
time	O
without	O
the	O
diagnosis	O
of	O
g6pd	B-Disease
deficiency	I-Disease
being	O
entertained	O
because	O
the	O
family	O
was	O
of	O
northern	O
european	O
origin	O
.	O
	
since	O
sporadic	O
variants	O
of	O
g6pd	O
causing	O
hnsha	B-Disease
show	O
no	O
special	O
racial	O
predilection	O
,	O
the	O
diagnosis	O
of	O
g6pd	B-Disease
deficiency	I-Disease
should	O
always	O
be	O
considered	O
in	O
patients	O
with	O
this	O
syndrome	O
.	O
	
sialophorin	O
,	O
a	O
surface	O
sialoglycoprotein	O
defective	O
in	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
,	O
is	O
involved	O
in	O
human	O
t	O
lymphocyte	O
proliferation	O
.	O
	
the	O
mab	O
l10	O
was	O
used	O
to	O
determine	O
the	O
distribution	O
and	O
the	O
function	O
of	O
sialophorin	O
,	O
the	O
heavily	O
glycosylated	O
surface	O
molecule	O
that	O
is	O
deficient	O
/	O
defective	O
in	O
lymphocytes	O
of	O
patients	O
with	O
the	O
x	B-Disease
-	I-Disease
linked	I-Disease
immunodeficiency	I-Disease
wiskott	I-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
hypopigmentation	B-Disease
in	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
.	O
	
cutaneous	B-Disease
and	I-Disease
ocular	I-Disease
pigmentation	I-Disease
were	O
evaluated	O
in	O
29	O
individuals	O
with	O
the	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
criteria	O
for	O
hypopigmentation	B-Disease
included	O
the	O
presence	O
of	O
type	O
i	O
or	O
ii	O
skin	O
,	O
the	O
lightest	O
skin	O
type	O
in	O
the	O
family	O
by	O
history	O
,	O
and	O
iris	O
translucency	O
on	O
globe	O
transillumination	O
.	O
	
on	O
the	O
basis	O
of	O
these	O
criteria	O
,	O
48	O
%	O
of	O
the	O
pws	B-Disease
individuals	O
were	O
hypopigmented	B-Disease
.	O
	
the	O
presence	O
of	O
hypopigmentation	B-Disease
correlated	O
with	O
a	O
small	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
;	O
however	O
,	O
this	O
deletion	O
was	O
also	O
found	O
in	O
individuals	O
who	O
did	O
not	O
meet	O
the	O
full	O
criteria	O
for	O
hypopigmentation	B-Disease
.	O
	
hairbulb	O
tyrosinase	O
activity	O
and	O
glutathione	O
content	O
,	O
as	O
well	O
as	O
urine	O
cysteinyldopa	O
excretion	O
,	O
were	O
low	O
in	O
pws	B-Disease
individuals	O
with	O
and	O
without	O
hypopigmentation	B-Disease
and	O
did	O
not	O
separate	O
these	O
two	O
groups	O
.	O
	
we	O
conclude	O
that	O
hypopigmentation	B-Disease
is	O
found	O
in	O
a	O
significant	O
proportion	O
of	O
individuals	O
with	O
pws	B-Disease
and	O
that	O
the	O
hypopigmentation	B-Disease
may	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
15	O
.	O
the	O
mechanism	O
for	O
the	O
hypopigmentation	B-Disease
is	O
unknown	O
.	O
	
phenotype	O
heterogeneity	O
among	O
hemizygotes	O
in	O
a	O
family	O
biochemically	O
screened	O
for	O
adrenoleukodystrophy	B-Disease
.	O
	
we	O
report	O
on	O
two	O
clinically	O
,	O
neurologically	O
normal	O
relatives	O
of	O
a	O
boy	O
affected	O
by	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
;	O
they	O
were	O
found	O
repeatedly	O
to	O
have	O
the	O
biochemical	O
defect	O
of	O
an	O
ald	B-Disease
hemizygote	O
.	O
	
while	O
no	O
evidence	O
of	O
neurologic	B-Disease
disease	I-Disease
(	O
leukodystrophy	B-Disease
or	O
myeloneuropathy	B-Disease
)	O
was	O
present	O
in	O
these	O
hemizygotes	O
,	O
adrenocortical	B-Disease
insufficiency	I-Disease
provoking	O
compensatory	O
high	O
acth	O
release	O
was	O
found	O
in	O
both	O
.	O
	
these	O
findings	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
counseling	O
families	O
in	O
which	O
cases	O
with	O
clinically	O
expressed	O
ald	B-Disease
are	O
represented	O
in	O
several	O
generations	O
.	O
	
the	O
mapping	O
of	O
a	O
cdna	O
from	O
the	O
human	O
x	B-Disease
-	I-Disease
linked	I-Disease
duchenne	I-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
to	O
the	O
mouse	O
x	O
chromosome	O
.	O
	
the	O
recent	O
discovery	O
of	O
sequences	O
at	O
the	O
site	O
of	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
in	O
humans	O
has	O
opened	O
up	O
the	O
possibility	O
of	O
a	O
detailed	O
molecular	O
analysis	O
of	O
the	O
genes	O
in	O
humans	O
and	O
in	O
related	O
mammalian	O
species	O
.	O
	
until	O
relatively	O
recently	O
,	O
there	O
was	O
no	O
obvious	O
mouse	O
model	O
of	O
this	O
genetic	B-Disease
disease	I-Disease
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
.	O
	
the	O
identification	O
of	O
a	O
mouse	O
x	O
-	O
linked	O
mutant	O
showing	O
muscular	B-Disease
dystrophy	I-Disease
,	O
mdx	O
,	O
has	O
provided	O
a	O
candidate	O
mouse	O
genetic	O
homologue	O
to	O
the	O
dmd	B-Disease
locus	O
;	O
the	O
relatively	O
mild	O
pathological	O
features	O
of	O
mdx	O
suggest	O
it	O
may	O
have	O
more	O
in	O
common	O
with	O
mutations	O
of	O
the	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
type	O
at	O
the	O
same	O
human	O
locus	O
,	O
however	O
.	O
	
but	O
the	O
close	O
genetic	O
linkage	O
of	O
mdx	O
to	O
g6pd	O
and	O
hprt	O
on	O
the	O
mouse	O
x	O
chromosome	O
,	O
coupled	O
with	O
its	O
comparatively	O
mild	O
pathology	O
,	O
have	O
suggested	O
that	O
the	O
mdx	O
mutation	O
may	O
instead	O
correspond	O
to	O
emery	B-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
which	O
itself	O
is	O
closely	O
linked	O
to	O
dna	O
markers	O
at	O
xq28	O
-	O
qter	O
in	O
the	O
region	O
of	O
g6pd	O
on	O
the	O
human	O
x	O
chromosome	O
.	O
	
using	O
an	O
interspecific	O
mouse	O
domesticus	O
/	O
spretus	O
cross	O
,	O
segregating	O
for	O
a	O
variety	O
of	O
markers	O
on	O
the	O
mouse	O
x	O
chromosome	O
,	O
we	O
have	O
positioned	O
on	O
the	O
mouse	O
x	O
chromosome	O
sequences	O
homologous	O
to	O
a	O
dmd	B-Disease
cdna	O
clone	O
.	O
	
these	O
sequences	O
map	O
provocatively	O
close	O
to	O
the	O
mdx	O
mutation	O
and	O
unexpectedly	O
distant	O
from	O
sparse	O
fur	O
,	O
spf	O
,	O
the	O
mouse	O
homologue	O
of	O
otc	O
(	O
ornithine	O
transcarbamylase	O
)	O
which	O
is	O
closely	O
linked	O
to	O
dmd	B-Disease
on	O
the	O
human	O
x	O
chromosome	O
.	O
	
localization	O
of	O
the	O
region	O
homologous	O
to	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
locus	O
on	O
the	O
mouse	O
x	O
chromosome	O
.	O
	
recent	O
progress	O
has	O
resulted	O
in	O
part	O
of	O
the	O
gene	O
mutated	O
in	O
duchenne	B-Disease
and	I-Disease
the	I-Disease
milder	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophies	I-Disease
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	O
itself	O
extends	O
over	O
1	O
,	O
0	O
to	O
2	O
,	O
0	O
kilobases	O
(	O
kb	O
)	O
.	O
	
the	O
mouse	O
mdx	O
mutation	O
affects	O
muscle	O
and	O
confers	O
a	O
mild	O
dystrophic	B-Disease
syndrome	I-Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	O
is	O
equivalent	O
to	O
duchenne	B-Disease
/	I-Disease
becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
man	O
.	O
	
here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
that	O
cross	O
-	O
hybridize	O
to	O
mouse	O
x	O
-	O
linked	O
sequences	O
to	O
localize	O
the	O
gene	O
homologous	O
to	O
dmd	B-Disease
in	O
the	O
mouse	O
.	O
	
by	O
analogy	O
with	O
the	O
human	O
x	O
-	O
chromosome	O
,	O
we	O
conclude	O
that	O
the	O
region	O
in	O
the	O
mouse	O
around	O
the	O
g6pd	O
and	O
st14	O
-	O
1	O
loci	O
may	O
contain	O
two	O
genes	O
corresponding	O
to	O
distinct	O
human	O
myopathies	B-Disease
emery	B-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
which	O
is	O
known	O
to	O
be	O
closely	O
linked	O
to	O
st14	O
-	O
1	O
in	O
man	O
and	O
the	O
dmd	B-Disease
homologue	O
described	O
here	O
.	O
	
gt	O
to	O
at	O
transition	O
at	O
a	O
splice	O
donor	O
site	O
causes	O
skipping	O
of	O
the	O
preceding	O
exon	O
in	O
phenylketonuria	B-Disease
.	O
	
classical	B-Disease
phenylketonuria	I-Disease
(	O
pku	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
human	I-Disease
genetic	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
we	O
isolated	O
several	O
mutant	O
pah	O
cdna	O
clones	O
from	O
a	O
pku	B-Disease
carrier	O
individual	O
and	O
showed	O
that	O
they	O
contained	O
an	O
internal	O
116	O
base	O
pair	O
deletion	O
,	O
corresponding	O
precisely	O
to	O
exon	O
12	O
of	O
the	O
human	O
chromosomal	O
pah	O
gene	O
.	O
	
conservation	O
of	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
in	O
mice	O
and	O
humans	O
.	O
	
a	O
portion	O
of	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
gene	O
transcript	O
from	O
human	O
fetal	O
skeletal	O
muscle	O
and	O
mouse	O
adult	O
heart	O
was	O
sequenced	O
,	O
representing	O
approximately	O
25	O
percent	O
of	O
the	O
total	O
,	O
14	O
-	O
kb	O
dmd	B-Disease
transcript	O
.	O
	
the	O
amino	O
acid	O
sequence	O
that	O
is	O
predicted	O
from	O
this	O
portion	O
of	O
the	O
dmd	B-Disease
gene	O
indicates	O
that	O
the	O
protein	O
product	O
might	O
serve	O
a	O
structural	O
role	O
in	O
muscle	O
,	O
but	O
the	O
abundance	O
and	O
tissue	O
distribution	O
of	O
the	O
messenger	O
rna	O
suggests	O
that	O
the	O
dmd	B-Disease
protein	O
is	O
not	O
nebulin	O
.	O
	
familial	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
with	O
apparently	O
normal	O
chromosomes	O
.	O
	
we	O
report	O
on	O
4	O
sibs	O
(	O
2f	O
,	O
2m	O
)	O
with	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
the	O
other	O
child	O
had	O
died	O
at	O
age	O
10	O
months	O
with	O
a	O
history	O
and	O
clinical	O
findings	O
typical	O
of	O
first	O
phase	O
of	O
pws	B-Disease
.	O
	
the	O
implications	O
of	O
this	O
unusual	O
familial	O
occurrence	O
for	O
our	O
understanding	O
of	O
pws	B-Disease
are	O
discussed	O
.	O
	
nebulin	O
and	O
titin	O
expression	O
in	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
appears	O
normal	O
.	O
	
monoclonal	O
antibodies	O
which	O
recognize	O
different	O
epitopes	O
on	O
either	O
titin	O
or	O
nebulin	O
show	O
normal	O
staining	O
patterns	O
on	O
frozen	O
sections	O
of	O
three	O
muscle	O
biopsies	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
since	O
the	O
donor	O
of	O
one	O
of	O
these	O
biopsies	O
has	O
a	O
large	O
deletion	O
of	O
the	O
5	O
-	O
region	O
of	O
the	O
dmd	B-Disease
gene	O
,	O
our	O
results	O
argue	O
against	O
the	O
recent	O
proposal	O
that	O
nebulin	O
is	O
the	O
gene	O
mutated	O
in	O
dmd	B-Disease
.	O
	
heterozygous	B-Disease
c2	I-Disease
deficiency	I-Disease
associated	O
with	O
angioedema	B-Disease
,	O
myasthenia	B-Disease
gravis	I-Disease
,	O
and	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O
	
we	O
describe	O
a	O
patient	O
with	O
myasthenia	B-Disease
gravis	I-Disease
,	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
,	O
and	O
angioedema	B-Disease
associated	O
with	O
heterozygous	O
complement	B-Disease
factor	I-Disease
2	I-Disease
(	I-Disease
c2	I-Disease
)	I-Disease
deficiency	I-Disease
.	O
	
the	O
significance	O
of	O
this	O
association	O
is	O
controversial	O
,	O
though	O
the	O
association	O
of	O
c2	B-Disease
deficiency	I-Disease
with	O
certain	O
histocompatibility	O
antigens	O
suggests	O
possible	O
linkage	O
to	O
immune	O
response	O
genes	O
.	O
	
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
heterozygous	O
c2	B-Disease
deficiency	I-Disease
in	O
association	O
with	O
this	O
combination	O
of	O
autoimmune	B-Disease
disorders	I-Disease
,	O
and	O
we	O
discuss	O
the	O
aetiological	O
implications	O
.	O
	
genetic	O
analysis	O
of	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
third	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
brittany	O
spaniel	O
dogs	O
.	O
	
genetically	O
determined	O
c3	B-Disease
deficiency	I-Disease
in	O
brittany	O
spaniel	O
dogs	O
shares	O
a	O
number	O
of	O
biochemical	O
and	O
clinical	O
characteristics	O
with	O
the	O
human	O
disorder	O
.	O
	
in	O
humans	O
,	O
the	O
gene	O
for	O
c3	B-Disease
deficiency	I-Disease
is	O
a	O
nan	O
gene	O
that	O
is	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
c3	O
and	O
is	O
not	O
linked	O
to	O
the	O
major	O
histocompatibility	O
locus	O
.	O
	
the	O
current	O
study	O
used	O
allotype	O
analysis	O
of	O
canine	O
c3	O
in	O
order	O
to	O
demonstrate	O
that	O
the	O
gene	O
for	O
c3	B-Disease
deficiency	I-Disease
in	O
these	O
dogs	O
is	O
also	O
a	O
nan	O
gene	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
c3	O
.	O
	
in	O
addition	O
,	O
preliminary	O
pedigree	O
analysis	O
suggests	O
that	O
the	O
gene	O
for	O
canine	O
c3	B-Disease
deficiency	I-Disease
is	O
apparently	O
not	O
closely	O
linked	O
to	O
the	O
major	O
histocompatibility	O
complex	O
of	O
the	O
dog	O
.	O
	
thus	O
,	O
it	O
appears	O
that	O
c3	B-Disease
deficiency	I-Disease
in	O
brittany	O
spaniel	O
dogs	O
not	O
only	O
shares	O
biochemical	O
and	O
clinical	O
features	O
with	O
c3	B-Disease
deficiency	I-Disease
in	O
humans	O
,	O
but	O
also	O
shares	O
some	O
genetic	O
characteristics	O
with	O
the	O
human	O
disorder	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
caused	O
by	O
a	O
genetic	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
these	O
results	O
support	O
the	O
use	O
of	O
the	O
human	O
pah	O
probe	O
in	O
prenatal	O
diagnosis	O
and	O
detection	O
of	O
carriers	O
,	O
to	O
provide	O
new	O
opportunities	O
for	O
the	O
biochemical	O
characterization	O
of	O
normal	O
and	O
mutant	O
enzymes	O
,	O
and	O
in	O
the	O
investigation	O
of	O
alternative	O
genetic	O
therapies	O
for	O
pku	B-Disease
.	O
	
regional	O
mapping	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
and	O
the	O
phenylketonuria	B-Disease
locus	O
in	O
the	O
human	O
genome	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	O
amino	O
acid	O
metabolism	O
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hepatic	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
;	O
phenylalanine	O
4	O
-	O
monooxygenase	O
,	O
ec	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O
	
results	O
of	O
these	O
experiments	O
demonstrated	O
that	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
pah	O
gene	O
and	O
the	O
pku	B-Disease
locus	O
in	O
man	O
is	O
12q22	O
-	O
-	O
-	O
-	O
12q24	O
.	O
	
heterogeneity	O
of	O
type	B-Disease
i	I-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
:	O
evidence	O
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	B-Disease
willebrand	I-Disease
factor	O
.	O
	
type	B-Disease
i	I-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
(	O
vwd	B-Disease
)	O
is	O
characterized	O
by	O
equally	O
low	O
plasma	O
concentrations	O
of	O
von	B-Disease
willebrand	I-Disease
factor	O
antigen	O
(	O
vwf	O
ag	O
)	O
and	O
ristocetin	O
cofactor	O
(	O
ricof	O
)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vwf	O
multimers	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
sds	O
)	O
-	O
agarose	O
gel	O
electrophoresis	O
.	O
	
these	O
findings	O
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vwf	O
(	O
ricof	O
less	O
than	O
vwf	O
ag	O
)	O
even	O
in	O
type	B-Disease
i	I-Disease
vwd	I-Disease
,	O
coexisting	O
with	O
a	O
complete	O
set	O
of	O
vwf	O
multimers	O
(	O
platelet	O
discordant	O
)	O
;	O
that	O
the	O
abnormal	O
vwf	O
can	O
be	O
shown	O
more	O
clearly	O
in	O
platelets	O
than	O
in	O
plasma	O
or	O
else	O
in	O
plasma	O
after	O
ddavp	O
infusion	O
;	O
and	O
that	O
ddavp	O
normalizes	O
the	O
bt	O
only	O
in	O
those	O
patients	O
with	O
normal	O
platelet	O
levels	O
of	O
both	O
vwf	O
ag	O
and	O
ricof	O
(	O
platelet	O
normal	O
)	O
.	O
	
genetic	O
analysis	O
in	O
families	O
with	O
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
.	O
	
we	O
have	O
brought	O
together	O
information	O
on	O
864	O
affected	O
individuals	O
in	O
164	O
families	O
(	O
including	O
three	O
new	O
pedigrees	O
)	O
reported	O
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
demarquay	O
first	O
described	O
a	O
family	O
with	O
what	O
was	O
later	O
called	O
van	B-Disease
der	I-Disease
woude	I-Disease
syndrome	I-Disease
(	O
vws	B-Disease
)	O
.	O
	
both	O
types	O
of	O
oral	B-Disease
cleft	I-Disease
,	O
cleft	B-Disease
palate	I-Disease
(	O
cp	B-Disease
)	O
and	O
cleft	B-Disease
lip	I-Disease
with	O
or	O
without	O
cp	B-Disease
(	O
clp	B-Disease
)	O
,	O
segregate	O
in	O
these	O
families	O
together	O
with	O
lower	O
lip	B-Disease
pits	I-Disease
or	O
fistulae	B-Disease
in	O
an	O
autosomal	O
dominant	O
mode	O
with	O
high	O
penetrance	O
estimated	O
to	O
be	O
k	O
=	O
.	O
	
cleft	O
types	O
(	O
clp	B-Disease
and	O
cp	B-Disease
)	O
occur	O
in	O
vws	B-Disease
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	O
non	O
-	O
vws	O
population	O
,	O
ie	O
,	O
about	O
twice	O
as	O
many	O
cleft	O
-	O
bearing	O
individuals	O
have	O
clp	B-Disease
as	O
have	O
cp	B-Disease
.	O
	
on	O
the	O
other	O
hand	O
,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	O
excess	O
of	O
females	O
with	O
cp	B-Disease
and	O
excess	O
of	O
males	O
with	O
clp	B-Disease
;	O
in	O
vws	B-Disease
the	O
sex	O
ratios	O
are	O
more	O
nearly	O
equal	O
.	O
	
lip	B-Disease
pits	I-Disease
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes	O
.	O
	
affected	O
males	O
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
vws	B-Disease
.	O
	
the	O
expression	O
of	O
vws	B-Disease
is	O
significantly	O
modified	O
by	O
the	O
genetic	O
background	O
more	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	O
more	O
extreme	O
expression	O
in	O
their	O
children	O
.	O
	
for	O
a	O
vws	B-Disease
gene	O
carrier	O
the	O
relative	O
risk	O
of	O
transmitting	O
a	O
cleft	O
is	O
26	O
.	O
	
45	O
%	O
;	O
that	O
of	O
transmitting	O
lower	O
lip	B-Disease
pits	I-Disease
is	O
23	O
.	O
	
three	O
pedigrees	O
of	O
lip	B-Disease
pits	I-Disease
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	O
number	O
of	O
affected	O
individuals	O
.	O
	
control	O
of	O
gene	O
expression	O
in	O
vws	B-Disease
in	O
the	O
three	O
target	O
tissues	O
appears	O
to	O
be	O
independent	O
and	O
separately	O
designated	O
.	O
	
mutation	O
rate	O
of	O
the	O
vws	B-Disease
gene	O
is	O
calculated	O
to	O
be	O
1	O
.	O
	
hereditary	B-Disease
c7	I-Disease
deficiency	I-Disease
.	O
	
the	O
serum	O
of	O
a	O
44	O
-	O
yr	O
-	O
old	O
woman	O
of	O
french	O
-	O
canadian	O
descent	O
having	O
a	O
b	O
-	O
27	O
positive	O
ankylosing	B-Disease
spondylitis	I-Disease
was	O
deficient	B-Disease
in	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c7	O
)	O
as	O
determined	O
by	O
hemolytic	O
and	O
immunochemical	O
methods	O
.	O
	
the	O
seven	O
other	O
siblings	O
were	O
heterozygous	O
for	O
c7	B-Disease
deficiency	I-Disease
,	O
while	O
the	O
paternal	O
aunt	O
had	O
a	O
normal	O
c7	O
level	O
.	O
	
studies	O
of	O
the	O
hla	O
antigens	O
in	O
all	O
the	O
22	O
subjects	O
and	O
in	O
three	O
spouses	O
indicated	O
no	O
close	O
linkage	O
between	O
the	O
cm	B-Disease
deficienty	I-Disease
and	O
the	O
hla	O
system	O
.	O
	
in	O
addition	O
,	O
the	O
simultaneous	O
occurrence	O
of	O
two	O
hereditary	O
complement	B-Disease
deficiencies	I-Disease
(	I-Disease
c2	I-Disease
and	I-Disease
c7	I-Disease
)	I-Disease
was	O
discovered	O
in	O
one	O
family	O
of	O
this	O
remarkable	O
kindred	O
.	O
	
genetic	O
defect	B-Disease
in	I-Disease
secretion	I-Disease
of	I-Disease
complement	I-Disease
c5	I-Disease
in	O
mice	O
.	O
	
a	O
genetic	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
(	I-Disease
c5	I-Disease
)	I-Disease
component	I-Disease
of	I-Disease
complement1	I-Disease
-	I-Disease
3	I-Disease
,	O
a	O
serum	O
glycoprotein	O
of	O
molecular	O
weight	O
(	O
mw	O
)	O
220	O
,	O
0	O
(	O
ref	O
.	O
	
4	O
)	O
,	O
has	O
been	O
found	O
in	O
39	O
%	O
of	O
inbred	O
strains	O
of	O
mice3	O
.	O
	
using	O
similar	O
methods	O
,	O
we	O
now	O
find	O
that	O
c5	B-Disease
deficiency	I-Disease
in	O
each	O
of	O
five	O
different	O
mouse	O
strains	O
(	O
akr	O
,	O
swr	O
,	O
dba	O
/	O
2j8	O
a	O
/	O
hej	O
and	O
b10	O
.	O
	
d2	O
/	O
old	O
line	O
)	O
is	O
due	O
to	O
a	O
failure	O
in	O
secretion	O
of	O
c5	O
protein	O
and	O
not	O
to	O
a	O
failure	O
in	O
biosynthesis	O
of	O
pro	O
-	O
c5	O
recurrent	O
meningococcal	B-Disease
meningitis	I-Disease
with	O
absence	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
:	O
an	O
evaluation	O
of	O
underlying	O
immunologic	O
mechanisms	O
.	O
	
a	O
51	O
/	O
2	O
-	O
year	O
-	O
old	O
black	O
girl	O
with	O
recurrent	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
absence	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c6	O
)	O
is	O
reported	O
.	O
	
to	O
explore	O
the	O
pathogenesis	O
of	O
recurrent	O
neisserial	B-Disease
infections	I-Disease
in	O
c6	B-Disease
deficiency	I-Disease
,	O
a	O
detailed	O
analysis	O
of	O
her	O
immune	O
competence	O
was	O
conducted	O
.	O
	
in	O
addition	O
,	O
her	O
c6	B-Disease
-	I-Disease
deficient	I-Disease
serum	O
was	O
indistinguishable	O
from	O
normal	O
serum	O
in	O
a	O
complement	O
-	O
dependent	O
assay	O
of	O
phagocyte	O
bactericidal	O
activity	O
.	O
	
absent	O
bacteriolysis	O
remains	O
the	O
only	O
consistent	O
defect	O
associated	O
with	O
recurrent	O
neisserial	B-Disease
infections	I-Disease
and	O
absence	O
of	O
one	O
of	O
the	O
late	O
-	O
acting	O
complement	O
components	O
.	O
	
deficiency	B-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
human	O
subjects	O
.	O
	
the	O
discovery	O
of	O
a	O
large	O
kindred	O
with	O
a	O
heritable	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c5	O
)	O
has	O
permitted	O
the	O
accumulation	O
of	O
new	O
clinical	O
,	O
genetic	O
and	O
immunologic	O
data	O
concerning	O
the	O
role	O
of	O
c5	O
in	O
human	O
subjects	O
.	O
	
the	O
proband	O
,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	B-Disease
infection	I-Disease
,	O
has	O
a	O
hemolytic	O
c5	O
level	O
of	O
approximately	O
0	O
.	O
	
no	O
chemotactic	O
activity	O
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
c5	B-Disease
-	I-Disease
deficient	I-Disease
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	O
or	O
alternative	O
pathways	O
,	O
again	O
demonstrating	O
the	O
importance	O
of	O
c5	O
in	O
human	O
subjects	O
for	O
the	O
production	O
of	O
chemotactic	O
factors	O
.	O
	
no	O
linkage	O
for	O
c5	B-Disease
deficiency	I-Disease
and	O
the	O
a	O
or	O
b	O
loci	O
of	O
the	O
major	O
histocompatibility	O
complex	O
could	O
be	O
found	O
.	O
	
these	O
data	O
suggest	O
an	O
autosomal	O
codominant	O
mode	O
of	O
inheritance	O
of	O
c5	B-Disease
deficiency	I-Disease
.	O
	
deficiency	B-Disease
of	I-Disease
c5	I-Disease
is	O
compatible	O
with	O
good	O
health	O
,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	B-Disease
infection	I-Disease
a	O
total	O
of	O
3000	O
men	O
living	O
in	O
yamaguchi	O
were	O
screened	O
for	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
using	O
beutlers	O
spot	O
test	O
and	O
three	O
types	O
of	O
starch	O
gel	O
electrophoresis	O
.	O
	
fifteen	O
g6pd	B-Disease
-	I-Disease
deficient	I-Disease
variants	O
were	O
found	O
at	O
the	O
rate	O
of	O
0	O
.	O
	
these	O
three	O
variants	O
had	O
a	O
mild	O
to	O
moderate	O
g6pd	B-Disease
deficiency	I-Disease
and	O
were	O
not	O
associated	O
with	O
any	O
clinical	O
signs	O
.	O
	
utilization	O
of	O
purines	O
by	O
an	O
hprt	O
variant	O
in	O
an	O
intelligent	O
,	O
nonmutilative	O
patient	O
with	O
features	O
of	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
b	O
.	O
,	O
was	O
among	O
the	O
first	O
reported	O
with	O
hyperuricemia	B-Disease
and	O
central	B-Disease
nervous	I-Disease
system	I-Disease
symptoms	I-Disease
.	O
	
he	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
hprt	O
;	O
e	O
.	O
c	O
.	O
2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
distinct	O
from	O
the	O
enzyme	O
present	O
in	O
patients	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
the	O
patient	O
had	O
chroeoathetosis	B-Disease
,	O
spasticity	B-Disease
,	O
dysarthric	B-Disease
speech	I-Disease
,	O
and	O
hyperuricemia	B-Disease
.	O
	
in	O
contrast	O
,	O
cells	O
from	O
patients	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	O
to	O
nucleotides	O
.	O
	
the	O
growth	O
of	O
the	O
cultured	O
fibroblasts	O
of	O
this	O
patient	O
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	O
aminopterin	O
thymidine	O
(	O
hat	O
)	O
,	O
whereas	O
the	O
growth	O
of	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
cells	O
was	O
inhibited	O
and	O
normal	O
cells	O
grew	O
normally	O
.	O
	
similarly	O
in	O
8	O
-	O
azaguanine	O
,	O
6	O
-	O
thioguanine	O
,	O
and	O
8	O
-	O
azahypoxanthine	O
,	O
the	O
growth	O
of	O
the	O
patients	O
cells	O
was	O
intermediate	O
between	O
normal	O
and	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
cells	O
.	O
	
they	O
document	O
that	O
this	O
famous	O
patient	O
did	O
not	O
have	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
localisation	O
of	O
the	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
on	O
the	O
short	O
arm	O
of	O
the	O
x	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
dna	O
sequences	O
.	O
	
a	O
linkage	O
study	O
in	O
30	O
becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
bmd	B-Disease
)	O
kindreds	O
using	O
three	O
cloned	O
dna	O
sequences	O
from	O
the	O
x	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
rflps	O
)	O
,	O
suggests	O
that	O
the	O
bmd	B-Disease
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
x	O
chromosome	O
,	O
in	O
the	O
p21	O
region	O
.	O
	
the	O
genes	O
for	O
becker	B-Disease
and	I-Disease
duchenne	I-Disease
dystrophies	I-Disease
must	O
therefore	O
be	O
closely	O
linked	O
,	O
if	O
not	O
allelic	O
,	O
and	O
any	O
future	O
dna	O
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	O
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O
	
molecular	O
evidence	O
for	O
new	O
mutation	O
at	O
the	O
hprt	O
locus	O
in	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
patients	O
.	O
	
partial	O
hprt	B-Disease
deficiencies	I-Disease
are	O
associated	O
with	O
gouty	B-Disease
arthritis	I-Disease
,	O
while	O
absence	O
of	O
activity	O
results	O
in	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
(	O
l	B-Disease
-	I-Disease
n	I-Disease
)	O
.	O
	
l	B-Disease
-	I-Disease
n	I-Disease
patients	O
fail	O
to	O
reproduce	O
and	O
the	O
heterozygous	O
state	O
appears	O
to	O
confer	O
no	O
selective	O
advantage	O
.	O
	
thus	O
,	O
haldanes	O
principle	O
predicts	O
that	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
must	O
occur	O
frequently	O
in	O
order	O
for	O
l	B-Disease
-	I-Disease
n	I-Disease
syndrome	I-Disease
to	O
be	O
maintained	O
in	O
the	O
population	O
.	O
	
this	O
constant	O
introduction	O
of	O
new	O
mutations	O
would	O
be	O
expected	O
to	O
result	O
in	O
a	O
heterogeneous	O
collection	O
of	O
genetic	B-Disease
lesions	I-Disease
,	O
some	O
of	O
which	O
may	O
be	O
novel	O
.	O
	
as	O
we	O
report	O
here	O
,	O
the	O
mutations	O
in	O
the	O
hprt	O
gene	O
of	O
seven	O
l	B-Disease
-	I-Disease
n	I-Disease
patients	O
,	O
selected	O
from	O
an	O
initial	O
survey	O
of	O
28	O
patients	O
,	O
have	O
been	O
characterized	O
and	O
all	O
were	O
found	O
to	O
be	O
distinctly	O
different	O
,	O
as	O
predicted	O
.	O
	
allelic	O
exclusion	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
t	O
lymphocytes	O
from	O
a	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
carrier	O
.	O
	
an	O
obligate	O
carrier	O
of	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
who	O
was	O
also	O
heterozygous	O
for	O
the	O
a	O
and	O
b	O
types	O
of	O
x	O
-	O
linked	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
was	O
found	O
.	O
	
with	O
her	O
it	O
became	O
possible	O
to	O
determine	O
whether	O
allelic	O
exclusion	O
occurs	O
in	O
particular	O
cell	O
-	O
types	O
of	O
the	O
was	B-Disease
carrier	O
.	O
	
these	O
findings	O
suggest	O
that	O
selection	O
against	O
the	O
was	B-Disease
gene	O
occurs	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
t	O
lymphocytes	O
and	O
that	O
the	O
defects	O
associated	O
with	O
was	B-Disease
expressed	O
in	O
these	O
cell	O
-	O
types	O
may	O
be	O
implicated	O
in	O
the	O
genesis	O
of	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
complement	B-Disease
deficiency	I-Disease
and	O
nephritis	B-Disease
.	O
	
a	O
family	O
is	O
described	O
in	O
which	O
three	O
children	O
had	O
homozygous	O
deficiency	B-Disease
of	I-Disease
c3	I-Disease
and	O
in	O
which	O
both	O
parents	O
and	O
two	O
other	O
children	O
were	O
heterozygous	O
for	O
the	O
c3	O
nan	O
gene	O
.	O
	
one	O
child	O
with	O
heterozygous	O
c3	B-Disease
deficiency	I-Disease
was	O
found	O
to	O
have	O
membranoproliferative	O
glomerulonephritis	B-Disease
;	O
proteinuria	B-Disease
and	O
/	O
or	O
microscopical	O
haematuria	B-Disease
was	O
present	O
in	O
all	O
three	O
homozygous	O
c3	B-Disease
-	I-Disease
deficient	I-Disease
children	O
.	O
	
all	O
children	O
with	O
homozygous	O
or	O
heterozygous	O
c3	B-Disease
deficiency	I-Disease
were	O
,	O
to	O
a	O
varying	O
degree	O
,	O
susceptible	O
to	O
infection	O
.	O
	
the	O
only	O
child	O
of	O
the	O
family	O
with	O
normal	O
complement	O
had	O
no	O
increased	O
risk	O
of	O
infection	O
and	O
no	O
renal	B-Disease
disease	I-Disease
.	O
	
this	O
family	O
study	O
provides	O
further	O
support	O
for	O
the	O
proposal	O
that	O
c3	B-Disease
deficiency	I-Disease
predisposes	O
to	O
nephritis	B-Disease
.	O
	
heterogeneity	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
algeria	O
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
was	O
found	O
in	O
3	O
.	O
	
g6pd	B-Disease
deficiency	I-Disease
is	O
heterogeneous	O
in	O
northern	O
algeria	O
where	O
autochtonous	O
variants	O
seem	O
to	O
prevail	O
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
inhibits	O
in	O
vitro	O
growth	O
of	O
plasmodium	O
falciparum	O
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
;	I-Disease
ec	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
-	I-Disease
deficient	I-Disease
red	O
blood	O
cells	O
from	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
from	O
the	O
island	O
of	O
sardinia	O
were	O
studied	O
for	O
their	O
ability	O
to	O
support	O
growth	O
in	O
vitro	O
of	O
the	O
malaria	B-Disease
-	O
causing	O
organism	O
plasmodium	O
falciparum	O
.	O
	
parasite	O
growth	O
was	O
approximately	O
one	O
-	O
third	O
of	O
normal	O
in	O
both	O
hemi	O
-	O
and	O
heterozygotes	O
for	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
in	O
sardinians	O
with	O
the	O
beta	O
0	O
-	O
thalassemia	O
trait	O
,	O
parasite	O
growth	O
was	O
normal	O
except	O
when	O
g6pd	B-Disease
deficiency	I-Disease
occurred	O
together	O
with	O
the	O
thalassemia	B-Disease
trait	O
.	O
	
the	O
data	O
support	O
the	O
hypothesis	O
that	O
g6pd	B-Disease
deficiency	I-Disease
may	O
confer	O
a	O
selective	O
advantage	O
in	O
a	O
malarious	B-Disease
area	O
;	O
the	O
female	O
heterozygote	O
may	O
be	O
at	O
a	O
particular	O
advantage	O
because	O
resistance	O
to	O
malaria	B-Disease
equals	O
that	O
of	O
male	O
hemizygotes	O
,	O
but	O
the	O
risk	O
of	O
fatal	B-Disease
hemolysis	I-Disease
may	O
be	O
less	O
.	O
	
bone	O
marrow	O
transplant	O
in	O
adrenoleukodystrophy	B-Disease
.	O
	
an	O
allogeneic	O
bone	O
marrow	O
transplant	O
(	O
bmt	O
)	O
from	O
a	O
normal	O
hla	O
identical	O
sibling	O
donor	O
was	O
performed	O
in	O
a	O
13	O
-	O
year	O
-	O
old	O
boy	O
with	O
rapidly	O
progressive	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
.	O
	
engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	O
within	O
4	O
weeks	O
,	O
but	O
neurologic	B-Disease
deterioration	I-Disease
continued	O
.	O
	
the	O
patient	O
died	O
of	O
an	O
adenovirus	B-Disease
infection	I-Disease
141	O
days	O
after	O
bmt	O
.	O
	
ald	B-Disease
is	O
characterized	O
by	O
abnormally	O
high	O
plasma	O
levels	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
vlcfa	O
)	O
as	O
a	O
result	O
of	O
impaired	O
capacity	O
to	O
degrade	O
them	O
.	O
	
in	O
28	O
families	O
with	O
g6pd	B-Disease
deficiency	I-Disease
living	O
in	O
3	O
settlements	O
of	O
shekii	O
district	O
of	O
azerbaijan	O
11	O
g6pd	O
variants	O
of	O
ii	O
and	O
iii	O
classes	O
differing	O
by	O
kinetic	O
properties	O
were	O
identified	O
according	O
who	O
program	O
.	O
	
adrenoleukodystrophy	B-Disease
:	O
survey	O
of	O
303	O
cases	O
:	O
biochemistry	O
,	O
diagnosis	O
,	O
and	O
therapy	O
.	O
	
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
is	O
a	O
genetically	O
determined	O
disorder	O
associated	O
with	O
progressive	B-Disease
central	I-Disease
demyelination	I-Disease
and	O
adrenal	B-Disease
cortical	I-Disease
insufficiency	I-Disease
.	O
	
this	O
degradation	O
normally	O
takes	O
place	O
in	O
a	O
subcellular	O
organelle	O
called	O
the	O
peroxisome	O
,	O
and	O
ald	B-Disease
,	O
together	O
with	O
zellwegers	B-Disease
cerebrohepatorenal	I-Disease
syndrome	I-Disease
,	O
is	O
now	O
considered	O
to	O
belong	O
to	O
the	O
newly	O
formed	O
category	O
of	O
peroxisomal	B-Disease
disorders	I-Disease
.	O
	
we	O
have	O
identified	O
303	O
patients	O
with	O
ald	B-Disease
in	O
217	O
kindreds	O
.	O
	
sixty	O
percent	O
of	O
patients	O
had	O
childhood	O
ald	B-Disease
and	O
17	O
%	O
adrenomyeloneuropathy	B-Disease
,	O
both	O
of	O
which	O
are	O
x	O
-	O
linked	O
,	O
with	O
the	O
gene	O
mapped	O
to	O
xq28	O
.	O
	
neonatal	B-Disease
ald	I-Disease
,	O
a	O
distinct	O
entity	O
with	O
autosomal	O
recessive	O
inheritance	O
and	O
points	O
of	O
resemblance	O
to	O
zellwegers	B-Disease
syndrome	I-Disease
,	O
accounted	O
for	O
7	O
%	O
of	O
the	O
cases	O
.	O
	
although	O
excess	O
c26	O
0	O
in	O
the	O
brain	O
of	O
patients	O
with	O
ald	B-Disease
is	O
partially	O
of	O
dietary	O
origin	O
,	O
dietary	O
c26	O
0	O
restriction	O
did	O
not	O
produce	O
clear	O
benefit	O
.	O
	
considerable	O
genetic	O
heterogeneity	O
in	O
g6pd	O
was	O
found	O
in	O
the	O
bulgarian	O
population	O
-	O
14	O
g6pd	O
variants	O
isolated	O
from	O
117	O
hemizygous	O
carriers	O
of	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
clinical	O
use	O
of	O
dna	O
markers	O
linked	O
to	O
the	O
gene	O
for	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
seventy	O
families	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
known	O
to	O
the	O
institute	O
of	O
child	O
health	O
fall	O
into	O
three	O
categories	O
with	O
respect	O
to	O
potential	O
linkage	O
analysis	O
with	O
the	O
x	O
chromosome	O
dna	O
markers	O
rc8	O
and	O
l1	O
.	O
	
28	O
that	O
bridge	O
the	O
dmd	B-Disease
gene	O
.	O
	
here	O
prediction	O
and	O
exclusion	O
of	O
dmd	B-Disease
gene	O
transmission	O
may	O
be	O
possible	O
,	O
the	O
accuracy	O
being	O
dependent	O
on	O
the	O
closeness	O
of	O
the	O
linkage	O
of	O
the	O
dna	O
marker	O
(	O
s	O
)	O
to	O
the	O
dmd	B-Disease
gene	O
;	O
an	O
illustrative	O
case	O
is	O
reported	O
.	O
	
given	O
an	O
informative	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
rflp	O
)	O
,	O
the	O
probability	O
that	O
the	O
boy	O
represents	O
a	O
new	O
mutation	O
can	O
be	O
reassessed	O
;	O
it	O
is	O
also	O
possible	O
to	O
exclude	O
the	O
dmd	B-Disease
gene	O
in	O
a	O
sister	O
.	O
	
here	O
exclusion	O
of	O
the	O
dmd	B-Disease
gene	O
in	O
a	O
sister	O
may	O
be	O
possible	O
.	O
	
the	O
linkage	O
analysis	O
required	O
is	O
described	O
,	O
and	O
the	O
need	O
to	O
check	O
dmd	B-Disease
families	O
for	O
informative	O
rflps	O
is	O
stressed	O
.	O
	
family	O
studies	O
in	O
bechterew	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
(	O
ankylosing	B-Disease
spondylitis	I-Disease
)	O
iii	O
.	O
	
the	O
results	O
of	O
segregation	O
analyses	O
in	O
75	O
families	O
where	O
the	O
proband	O
had	O
ankylosing	B-Disease
spondylitis	I-Disease
,	O
are	O
presented	O
.	O
	
the	O
results	O
were	O
in	O
agreement	O
with	O
our	O
hypothesis	O
that	O
ankylosing	B-Disease
spondylitis	I-Disease
is	O
part	O
of	O
a	O
syndrome	O
where	O
different	O
genetic	O
factors	O
interact	O
.	O
	
such	O
known	O
factors	O
are	O
hla	O
b27	O
associated	O
disease	O
susceptibility	O
,	O
susceptibility	O
to	O
psoriatic	B-Disease
arthropathy	I-Disease
and	O
susceptibility	O
to	O
entero	B-Disease
-	I-Disease
arthropathy	I-Disease
.	O
	
radiographical	O
sacro	B-Disease
-	I-Disease
iliitis	I-Disease
was	O
restricted	O
to	O
hla	O
b27	O
positive	O
relatives	O
,	O
and	O
was	O
more	O
frequently	O
found	O
in	O
relatives	O
to	O
probands	O
with	O
psoriasis	B-Disease
than	O
in	O
relatives	O
to	O
probands	O
without	O
psoriasis	B-Disease
.	O
	
the	O
phenotypic	O
expressions	O
of	O
the	O
different	O
genetic	O
predispositions	O
involved	O
,	O
include	O
sacro	B-Disease
-	I-Disease
iliitis	I-Disease
,	O
psoriasis	B-Disease
,	O
acute	B-Disease
anterior	I-Disease
uveitis	I-Disease
,	O
peripheral	O
arthropathy	B-Disease
and	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
.	O
	
we	O
suggest	O
the	O
descriptive	O
name	O
hereditary	B-Disease
multifocal	I-Disease
relapsing	I-Disease
inflammation	I-Disease
(	O
hemri	B-Disease
)	O
for	O
this	O
syndrome	O
.	O
	
ankylosing	B-Disease
spondylitis	I-Disease
,	O
psoriatic	B-Disease
arthropathy	I-Disease
and	O
entero	B-Disease
-	I-Disease
arthropathy	I-Disease
may	O
be	O
regarded	O
as	O
clinical	O
sub	O
-	O
types	O
of	O
the	O
syndrome	O
.	O
	
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
and	O
chromosome	O
15	O
.	O
	
a	O
chromosome	B-Disease
15	I-Disease
anomaly	I-Disease
was	O
observed	O
in	O
12	O
of	O
20	O
patients	O
,	O
17	O
of	O
whom	O
were	O
clinically	O
suspected	O
of	O
having	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
the	O
clinical	O
features	O
of	O
eight	O
cases	O
with	O
15q11	O
-	O
12	O
deletion	O
were	O
very	O
similar	O
to	O
those	O
originally	O
described	O
in	O
pws	B-Disease
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
group	O
of	O
normal	O
karyotype	O
patients	O
is	O
heterogeneous	O
,	O
and	O
their	O
features	O
do	O
not	O
strictly	O
correspond	O
to	O
the	O
clinical	O
definition	O
of	O
pws	B-Disease
.	O
	
however	O
,	O
the	O
hypothesis	O
that	O
pws	B-Disease
is	O
associated	O
with	O
deletion	O
of	O
15q11	O
-	O
12	O
can	O
neither	O
explain	O
the	O
apparently	O
balanced	O
translocations	O
of	O
chromosome	O
15	O
nor	O
account	O
for	O
the	O
small	O
supernumerary	O
metacentric	O
chromosomes	O
corresponding	O
to	O
an	O
isochromosome	O
15	O
for	O
band	O
15q11	O
observed	O
in	O
some	O
cases	O
.	O
	
the	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
gene	O
in	O
north	O
american	O
jewish	O
populations	O
:	O
geographic	O
variations	O
and	O
origin	O
.	O
	
from	O
data	O
collected	O
in	O
a	O
north	O
american	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
heterozygote	O
screening	O
program	O
,	O
the	O
tsd	B-Disease
carrier	O
frequency	O
among	O
46	O
,	O
304	O
jewish	O
individuals	O
was	O
found	O
to	O
be	O
.	O
	
this	O
frequency	O
is	O
consistent	O
with	O
earlier	O
estimates	O
based	O
on	O
tsd	B-Disease
incidence	O
data	O
.	O
	
tsd	B-Disease
carrier	O
frequencies	O
were	O
then	O
examined	O
by	O
single	O
country	O
and	O
single	O
region	O
of	O
origin	O
in	O
28	O
,	O
29	O
jews	O
within	O
this	O
sample	O
for	O
whom	O
such	O
data	O
were	O
available	O
for	O
analysis	O
.	O
	
jews	O
with	O
polish	O
and	O
/	O
or	O
russian	O
ancestry	O
constituted	O
88	O
%	O
of	O
this	O
sample	O
and	O
had	O
a	O
tsd	B-Disease
carrier	O
frequency	O
of	O
.	O
	
no	O
tsd	B-Disease
carriers	O
were	O
observed	O
among	O
the	O
166	O
jews	O
of	O
near	O
eastern	O
origins	O
.	O
	
relative	O
to	O
jews	O
of	O
polish	O
and	O
russian	O
origins	O
,	O
there	O
was	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
the	O
tsd	B-Disease
carrier	O
frequency	O
in	O
jews	O
of	O
austrian	O
,	O
hungarian	O
,	O
and	O
czechoslovakian	O
origins	O
(	O
p	O
less	O
than	O
.	O
5	O
)	O
.	O
	
these	O
findings	O
suggest	O
that	O
the	O
tsd	B-Disease
gene	O
proliferated	O
among	O
the	O
antecedents	O
of	O
modern	O
ashkenazi	O
jewry	O
after	O
the	O
second	O
diaspora	O
(	O
70	O
a	O
.	O
d	O
.	O
)	O
and	O
before	O
their	O
major	O
migrations	O
to	O
regions	O
of	O
poland	O
and	O
russia	O
(	O
before	O
1100	O
a	O
.	O
d	O
.	O
)	O
.	O
	
human	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
a	O
patient	O
with	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
no	O
haemostasis	B-Disease
abnormality	I-Disease
.	O
	
a	O
case	O
of	O
human	O
complete	O
c6	B-Disease
deficiency	I-Disease
is	O
reported	O
.	O
	
the	O
patient	O
,	O
a	O
31	O
year	O
old	O
white	O
male	O
,	O
was	O
seen	O
on	O
the	O
occasion	O
of	O
an	O
isolated	O
episode	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
.	O
	
no	O
hemostatic	B-Disease
abnormalities	I-Disease
were	O
observed	O
.	O
	
absence	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
a	O
patient	O
with	O
chronic	B-Disease
meningococcemia	I-Disease
presenting	O
as	O
vasculitis	B-Disease
.	O
	
a	O
previously	O
healthy	O
40	O
-	O
year	O
-	O
old	O
man	O
presenting	O
with	O
fever	B-Disease
,	O
arthritis	B-Disease
,	O
and	O
cutaneous	B-Disease
vasculitis	I-Disease
was	O
found	O
to	O
have	O
chronic	B-Disease
meningococcemia	I-Disease
.	O
	
evaluation	O
of	O
his	O
complement	O
system	O
showed	O
an	O
absence	O
of	O
functional	O
and	O
antigenic	O
c7	O
,	O
compatible	O
with	O
a	O
complete	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
.	O
	
study	O
of	O
the	O
patients	O
family	O
spanning	O
four	O
generations	O
showed	O
heterozygous	O
deficiency	B-Disease
of	I-Disease
c7	I-Disease
in	O
five	O
members	O
.	O
	
chronic	B-Disease
neisserial	I-Disease
infection	I-Disease
can	O
be	O
associated	O
with	O
c7	B-Disease
deficiency	I-Disease
and	O
must	O
be	O
distinguished	O
from	O
other	O
causes	O
of	O
cutaneous	B-Disease
vasculitis	I-Disease
.	O
	
familial	B-Disease
discoid	I-Disease
lupus	I-Disease
erythematosus	I-Disease
associated	O
with	O
heterozygote	O
c2	B-Disease
deficiency	I-Disease
.	O
	
two	O
siblings	O
with	O
chronic	B-Disease
discoid	I-Disease
lupus	I-Disease
erythematosus	I-Disease
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
c2	B-Disease
deficiency	I-Disease
.	O
	
linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
c2	B-Disease
deficiency	I-Disease
gene	O
and	O
genes	O
coding	O
for	O
b18	O
,	O
dw2	O
,	O
and	O
bfs	O
antigens	O
.	O
	
severe	B-Disease
-	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
associated	O
with	O
chronic	O
hemolytic	B-Disease
anemia	I-Disease
,	O
granulocyte	B-Disease
dysfunction	I-Disease
,	O
and	O
increased	O
susceptibility	O
to	O
infections	O
:	O
description	O
of	O
a	O
new	O
molecular	O
variant	O
(	O
g6pd	O
barcelona	O
)	O
.	O
	
molecular	O
,	O
kinetic	O
,	O
and	O
functional	O
studies	O
were	O
carried	O
out	O
on	O
erythrocytes	O
and	O
leukocytes	O
in	O
a	O
spanish	O
male	O
with	O
g6pd	B-Disease
deficiency	I-Disease
,	O
congenital	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
cnsha	B-Disease
)	O
,	O
and	O
increased	O
susceptibility	O
to	O
infections	O
.	O
	
the	O
molecular	O
characteristics	O
of	O
g6pd	O
in	O
the	O
patient	O
differed	O
from	O
those	O
of	O
all	O
previously	O
reported	O
variants	O
associated	O
with	O
cnsha	B-Disease
,	O
so	O
the	O
present	O
variant	O
was	O
provisionally	O
called	O
g6pd	O
barcelona	O
to	O
distinguish	O
it	O
from	O
other	O
g6pd	O
variants	O
previously	O
described	O
.	O
	
possible	O
mechanisms	O
for	O
the	O
severe	O
deficiency	B-Disease
of	I-Disease
g6pd	I-Disease
in	O
erythrocytes	O
and	O
granulocytes	O
was	O
investigated	O
by	O
studies	O
on	O
the	O
immunologic	O
specific	O
activity	O
of	O
the	O
mutant	O
enzyme	O
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
papua	O
new	O
guinea	O
.	O
	
twenty	O
-	O
six	O
g6pd	B-Disease
deficient	I-Disease
individuals	O
were	O
identified	O
.	O
	
this	O
study	O
illustrates	O
the	O
extreme	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
among	O
the	O
people	O
of	O
papua	O
new	O
guinea	O
.	O
	
heterogeneity	O
of	O
mediterranean	O
type	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
spain	O
and	O
description	O
of	O
two	O
new	O
variants	O
associated	O
with	O
favism	B-Disease
.	O
	
subjects	O
were	O
from	O
multiple	O
geographic	O
regions	O
within	O
spain	O
,	O
and	O
all	O
suffered	O
from	O
hemolytic	B-Disease
anemia	I-Disease
,	O
either	O
acute	O
(	O
34	O
cases	O
)	O
or	O
chronic	O
nonspherocytic	O
(	O
2	O
cases	O
)	O
.	O
	
the	O
present	O
study	O
constitutes	O
the	O
first	O
attempt	O
to	O
characterize	O
the	O
deficient	B-Disease
g6pd	I-Disease
variants	O
found	O
in	O
spain	O
and	O
supplies	O
new	O
data	O
on	O
the	O
relationship	O
between	O
molecular	O
characteristics	O
of	O
deficient	O
variants	O
and	O
their	O
clinical	O
manifestations	O
.	O
	
the	O
most	O
important	O
findings	O
can	O
be	O
summarized	O
as	O
follows	O
(	O
1	O
)	O
the	O
spanish	O
population	O
is	O
characterized	O
by	O
an	O
important	O
heterogeneity	O
in	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
(	O
3	O
)	O
favism	B-Disease
has	O
been	O
observed	O
associated	O
with	O
all	O
kinds	O
of	O
variants	O
described	O
here	O
.	O
	
(	O
4	O
)	O
g6pd	O
betica	O
,	O
which	O
is	O
the	O
most	O
frequent	O
variant	O
found	O
in	O
subjects	O
of	O
southern	O
spanish	O
origin	O
,	O
has	O
been	O
observed	O
associated	O
with	O
favism	B-Disease
in	O
all	O
cases	O
except	O
one	O
.	O
	
a	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variant	O
(	O
g6pd	O
nagano	O
)	O
associated	O
with	O
congenital	B-Disease
hemolytic	I-Disease
anemia	I-Disease
.	O
	
a	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
g6pd	O
)	O
variant	O
associated	O
with	O
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
was	O
reported	O
.	O
	
the	O
patient	O
,	O
a	O
6	O
-	O
year	O
-	O
old	O
japanese	O
male	O
,	O
was	O
noticed	O
to	O
have	O
hemolytic	B-Disease
anemia	I-Disease
soon	O
after	O
birth	O
,	O
and	O
a	O
diagnosis	O
of	O
g6pd	B-Disease
deficiency	I-Disease
was	O
made	O
at	O
the	O
age	O
of	O
2	O
.	O
	
he	O
had	O
episodes	O
of	O
hemolytic	B-Disease
crisis	I-Disease
several	O
times	O
after	O
upper	B-Disease
respiratory	I-Disease
infection	I-Disease
.	O
	
infection	O
-	O
induced	O
hemolysis	B-Disease
and	O
chronic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
seem	O
to	O
be	O
due	O
to	O
markedly	O
impaired	O
enzyme	O
activity	O
and	O
thermal	O
instability	O
.	O
	
heterozygous	O
c2	B-Disease
-	I-Disease
deficiency	I-Disease
and	O
myasthenia	B-Disease
gravis	I-Disease
.	O
	
complement	B-Disease
deficiency	I-Disease
states	O
in	O
myasthenia	B-Disease
gravis	I-Disease
(	O
mg	B-Disease
)	O
have	O
not	O
been	O
reported	O
previously	O
.	O
	
we	O
describe	O
a	O
19	O
-	O
year	O
-	O
old	O
woman	O
with	O
typical	O
mg	B-Disease
and	O
heterozygous	O
c2	B-Disease
deficiency	I-Disease
,	O
along	O
with	O
hla	O
typing	O
of	O
the	O
patient	O
and	O
her	O
immediate	O
family	O
.	O
	
adrenoleukodystrophy	B-Disease
:	O
increased	O
plasma	O
content	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
.	O
	
with	O
a	O
new	O
method	O
we	O
measured	O
the	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
the	O
plasma	O
of	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
hemizygotes	O
,	O
ald	B-Disease
heterozygotes	O
,	O
and	O
controls	O
.	O
	
ald	B-Disease
hemizygotes	O
showed	O
increased	O
levels	O
of	O
hexacosanoate	O
(	O
c26	O
fatty	O
acid	O
)	O
which	O
represented	O
0	O
.	O
	
c26	O
levels	O
were	O
also	O
increased	O
in	O
most	O
ald	B-Disease
heterozygotes	O
,	O
with	O
a	O
mean	O
level	O
0	O
.	O
	
abnormal	O
high	O
density	O
lipoproteins	O
in	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
.	O
	
the	O
plasma	O
lipoprotein	O
profiles	O
and	O
high	O
density	O
lipoproteins	O
(	O
hdl	O
)	O
were	O
characterized	O
in	O
patients	O
with	O
the	O
genetic	B-Disease
disease	I-Disease
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
.	O
	
abnormalities	B-Disease
in	I-Disease
the	I-Disease
hdl	I-Disease
may	O
contribute	O
to	O
their	O
increased	O
atherogenesis	O
and	O
excessive	O
deposits	O
of	O
tissue	O
sterols	O
in	O
the	O
presence	O
of	O
low	O
or	O
low	O
-	O
normal	O
concentrations	O
of	O
plasma	O
cholesterol	O
(	O
165	O
+	O
/	O
-	O
25	O
mg	O
/	O
dl	O
)	O
and	O
low	O
density	O
lipoproteins	O
(	O
ldl	O
)	O
.	O
	
the	O
mean	O
hdl	O
-	O
cholesterol	O
concentration	O
in	O
the	O
ctx	B-Disease
plasmas	O
was	O
14	O
.	O
	
the	O
ratio	O
of	O
apoprotein	O
(	O
apo	O
)	O
to	O
total	O
cholesterol	O
in	O
the	O
hdl	O
of	O
ctx	B-Disease
was	O
two	O
to	O
three	O
times	O
greater	O
than	O
normal	O
.	O
	
in	O
the	O
ctx	B-Disease
hdl	O
,	O
the	O
ratio	O
of	O
apoai	O
to	O
apoaii	O
was	O
high	O
,	O
the	O
proportion	O
of	O
apoc	O
low	O
,	O
and	O
a	O
normally	O
minor	O
form	O
of	O
apoai	O
increased	O
relative	O
to	O
other	O
forms	O
.	O
	
the	O
abnormalities	O
in	O
lipoprotein	O
distribution	O
profile	O
and	O
composition	O
of	O
the	O
plasma	O
hdl	O
result	O
from	O
metabolic	O
defects	O
that	O
are	O
not	O
understood	O
but	O
may	O
be	O
linked	O
to	O
the	O
genetic	B-Disease
defect	I-Disease
in	O
bile	O
acid	O
synthesis	O
in	O
ctx	B-Disease
.	O
	
genetics	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
:	O
an	O
autosomal	O
recessive	O
trait	O
with	O
high	O
gene	O
frequency	O
in	O
sephardim	O
of	O
moroccan	O
origin	O
.	O
	
we	O
described	O
6	O
patients	O
(	O
from	O
3	O
families	O
)	O
affected	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
.	O
	
in	O
view	O
of	O
the	O
small	O
number	O
of	O
ctx	B-Disease
patients	O
diagnosed	O
in	O
the	O
world	O
(	O
a	O
total	O
of	O
50	O
including	O
our	O
6	O
patients	O
)	O
,	O
we	O
are	O
probably	O
dealing	O
with	O
an	O
ethnic	O
subgroup	O
with	O
a	O
high	O
ctx	O
gene	O
frequency	O
,	O
which	O
we	O
have	O
estimated	O
to	O
be	O
1	O
/	O
108	O
.	O
	
since	O
there	O
are	O
differences	O
in	O
expression	O
in	O
this	O
disease	O
,	O
we	O
recommend	O
cholestanol	O
study	O
in	O
cases	O
of	O
undiagnosed	O
cataract	B-Disease
or	O
tendinous	B-Disease
xanthomas	I-Disease
in	O
childhood	O
or	O
early	O
adolescence	O
.	O
	
the	O
diagnosis	O
in	O
ctx	B-Disease
is	O
important	O
not	O
only	O
for	O
genetic	O
counseling	O
,	O
but	O
also	O
in	O
veiw	O
of	O
possible	O
treatment	O
.	O
	
all	O
of	O
them	O
were	O
found	O
in	O
italian	O
males	O
and	O
all	O
were	O
associated	O
with	O
enzyme	B-Disease
deficiency	I-Disease
,	O
but	O
only	O
two	O
with	O
signs	O
of	O
haemolysis	B-Disease
.	O
	
these	O
and	O
other	O
variants	O
reported	O
in	O
the	O
literature	O
,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic	O
,	O
are	O
found	O
to	O
map	O
in	O
parts	O
of	O
italy	O
where	O
common	O
types	O
of	O
g6pd	B-Disease
deficiency	I-Disease
are	O
also	O
prevalent	O
.	O
	
ten	O
variants	O
of	O
erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
were	O
identified	O
in	O
22	O
patients	O
with	O
g6pd	B-Disease
deficiency	I-Disease
from	O
three	O
districts	O
of	O
bulgaria	O
.	O
	
nephropathy	B-Disease
in	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
nephropathy	B-Disease
was	O
detected	O
in	O
five	O
of	O
32	O
patients	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
who	O
were	O
participating	O
in	O
a	O
study	O
of	O
transfer	O
factor	O
(	O
tf	O
)	O
therapy	O
.	O
	
in	O
two	O
patients	O
,	O
nephropathy	B-Disease
was	O
present	O
before	O
tf	O
and	O
did	O
not	O
appear	O
changed	O
by	O
tf	O
therapy	O
.	O
	
one	O
of	O
these	O
patients	O
subsequently	O
developed	O
progressive	O
renal	B-Disease
failure	I-Disease
requiring	O
dialysis	O
beginning	O
5	O
1	O
/	O
2	O
years	O
after	O
tf	O
therapy	O
.	O
	
an	O
additional	O
patient	O
was	O
identified	O
who	O
died	O
with	O
renal	B-Disease
failure	I-Disease
without	O
having	O
received	O
tf	O
.	O
	
the	O
results	O
suggest	O
that	O
renal	B-Disease
failure	I-Disease
occurs	O
in	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
tf	O
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	B-Disease
disease	I-Disease
in	O
patients	O
with	O
this	O
syndrome	O
.	O
	
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
:	O
cellular	O
impairments	O
and	O
their	O
implication	O
for	O
carrier	O
detection	O
.	O
	
a	O
family	O
in	O
which	O
two	O
male	O
siblings	O
were	O
affected	O
with	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
was	O
studied	O
using	O
g	O
-	O
6	O
-	O
pd	O
isoenzymes	O
as	O
an	O
x	O
-	O
linked	O
marker	O
in	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
cellular	O
abnormalities	O
.	O
	
isolated	O
peripheral	O
blood	O
cell	O
types	O
from	O
the	O
doubly	O
heterozygous	O
mother	O
of	O
the	O
affected	O
males	O
seemingly	O
failed	O
to	O
express	O
the	O
g	O
-	O
6	O
-	O
pd	O
allele	O
in	O
cis	O
position	O
with	O
the	O
was	B-Disease
allele	O
while	O
her	O
cultured	O
skin	O
fibroblasts	O
expressed	O
both	O
g	O
-	O
6	O
-	O
pd	O
alleles	O
.	O
	
in	O
vitro	O
culture	O
of	O
hemopoietic	O
progenitor	O
cells	O
of	O
the	O
heterozygous	O
mother	O
showed	O
that	O
the	O
majority	O
of	O
progenitor	O
cells	O
did	O
not	O
express	O
the	O
was	B-Disease
allele	O
.	O
	
however	O
,	O
a	O
small	O
number	O
of	O
cells	O
expressing	O
the	O
g	O
-	O
6	O
-	O
pd	O
type	O
linked	O
with	O
the	O
was	B-Disease
allele	O
were	O
detected	O
.	O
	
this	O
observation	O
suggests	O
that	O
selection	O
against	O
cells	O
expressing	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
defect	I-Disease
takes	O
place	O
in	O
the	O
hemopoietic	O
system	O
of	O
the	O
heterozygous	O
female	O
and	O
offers	O
a	O
possible	O
means	O
of	O
carrier	O
detection	O
in	O
some	O
women	O
.	O
	
linkage	O
studies	O
in	O
this	O
family	O
revealed	O
one	O
example	O
of	O
probable	O
recombination	O
between	O
the	O
loci	O
for	O
was	B-Disease
and	O
g	O
-	O
6	O
-	O
pd	O
among	O
three	O
informative	O
subjects	O
,	O
suggesting	O
that	O
these	O
two	O
loci	O
may	O
not	O
be	O
closely	O
linked	O
on	O
the	O
x	O
-	O
chromosome	O
.	O
	
a	O
new	O
ct	O
pattern	O
in	O
adrenoleukodystrophy	B-Disease
.	O
	
a	O
new	O
ct	O
pattern	O
was	O
observed	O
in	O
2	O
patients	O
with	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
.	O
	
this	O
is	O
different	O
from	O
numerous	O
previous	O
descriptions	O
of	O
the	O
ct	O
pattern	O
in	O
ald	B-Disease
.	O
	
type	B-Disease
ii	I-Disease
ald	I-Disease
does	O
not	O
appear	O
to	O
have	O
been	O
seen	O
in	O
any	O
other	O
leukoencephalopathy	B-Disease
and	O
is	O
probably	O
specific	O
for	O
a	O
phenotypic	O
variant	O
or	O
an	O
evolving	O
stage	O
of	O
ald	B-Disease
.	O
	
further	O
evidence	O
for	O
heterogeneity	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
papua	O
new	O
guinea	O
.	O
	
th	O
data	O
presented	O
here	O
together	O
with	O
those	O
of	O
previously	O
published	O
studies	O
demonstrate	O
a	O
degree	O
of	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
that	O
is	O
much	O
higher	O
than	O
that	O
in	O
other	O
regions	O
of	O
the	O
world	O
where	O
g6pd	B-Disease
deficiency	I-Disease
is	O
common	O
.	O
	
increased	O
incidence	O
of	O
cataracts	B-Disease
in	O
male	O
subjects	O
deficient	B-Disease
in	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
rbcs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	O
cataractous	B-Disease
patients	O
than	O
in	O
672	O
control	O
subjects	O
of	O
sardinian	O
origin	O
.	O
	
the	O
frequency	O
of	O
the	O
deficiency	O
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	B-Disease
.	O
	
in	O
the	O
g6pd	B-Disease
-	I-Disease
deficient	I-Disease
group	O
,	O
the	O
incidence	O
of	O
cortical	B-Disease
and	I-Disease
total	I-Disease
cataracts	I-Disease
was	O
also	O
increased	O
.	O
	
moreover	O
,	O
g6pd	B-Disease
deficiency	I-Disease
should	O
be	O
added	O
to	O
other	O
conditions	O
,	O
such	O
as	O
the	O
galactosemic	B-Disease
states	O
and	O
riboflavin	B-Disease
deficiency	I-Disease
,	O
where	O
cataracts	B-Disease
represent	O
a	O
sensitive	O
indicator	O
of	O
metabolic	B-Disease
abnormalities	I-Disease
of	O
the	O
rbc	O
.	O
	
molecular	O
basis	O
of	O
human	O
mitochondrial	O
very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coa	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
causing	O
cardiomyopathy	B-Disease
and	O
sudden	B-Disease
death	I-Disease
in	O
childhood	O
.	O
	
defects	O
in	O
enzymes	O
of	O
the	O
beta	O
-	O
oxidation	O
pathway	O
cause	O
sudden	B-Disease
,	I-Disease
unexplained	I-Disease
death	I-Disease
in	O
childhood	O
,	O
acute	O
hepatic	B-Disease
encephalopathy	I-Disease
or	O
liver	B-Disease
failure	I-Disease
,	O
skeletal	B-Disease
myopathy	I-Disease
,	O
and	O
cardiomyopathy	B-Disease
.	O
	
polymerase	O
chain	O
reaction	O
amplification	O
of	O
vlcad	O
mrna	O
and	O
genomic	O
exons	O
defined	O
the	O
molecular	O
defects	O
in	O
two	O
patients	O
with	O
vlcad	B-Disease
deficiency	I-Disease
who	O
presented	O
with	O
unexplained	O
cardiac	B-Disease
arrest	I-Disease
and	O
cardiomyopathy	B-Disease
.	O
	
this	O
initial	O
delineation	O
of	O
human	O
mutations	O
in	O
vlcad	O
suggests	O
that	O
vlcad	B-Disease
deficiency	I-Disease
reduces	O
myocardial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
and	O
energy	O
production	O
and	O
is	O
associated	O
with	O
cardiomyopathy	B-Disease
and	O
sudden	B-Disease
death	I-Disease
in	O
childhood	O
.	O
	
aberrant	O
subcellular	O
localization	O
of	O
brca1	O
in	O
breast	B-Disease
cancer	I-Disease
.	O
	
the	O
brca1	O
gene	O
product	O
was	O
identified	O
as	O
a	O
220	O
-	O
kilodalton	O
nuclear	O
phosphoprotein	O
in	O
normal	O
cells	O
,	O
including	O
breast	O
ductal	O
epithelial	O
cells	O
,	O
and	O
in	O
18	O
of	O
20	O
tumor	B-Disease
cell	O
lines	O
derived	O
from	O
tissues	O
other	O
than	O
breast	O
and	O
ovary	O
.	O
	
in	O
16	O
of	O
17	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
lines	O
and	O
17	O
of	O
17	O
samples	O
of	O
cells	O
obtained	O
from	O
malignant	O
effusions	O
,	O
however	O
,	O
brca1	O
localized	O
mainly	O
in	O
cytoplasm	O
.	O
	
absence	O
of	O
brca1	O
or	O
aberrant	O
subcellular	O
location	O
was	O
also	O
observed	O
to	O
a	O
variable	O
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	B-Disease
cancer	I-Disease
biopsies	O
.	O
	
these	O
findings	O
suggest	O
that	O
brca1	B-Disease
abnormalities	I-Disease
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
breast	B-Disease
cancers	I-Disease
,	O
sporadic	O
as	O
well	O
as	O
familial	O
.	O
	
mapping	O
of	O
the	O
mouse	O
homologue	O
of	O
the	O
wilson	B-Disease
disease	I-Disease
gene	O
to	O
mouse	O
chromosome	O
8	O
.	O
	
atp7b	O
,	O
the	O
gene	O
altered	O
in	O
wilson	B-Disease
disease	I-Disease
(	O
wd	B-Disease
)	O
patients	O
,	O
lies	O
in	O
a	O
block	O
of	O
homology	O
shared	O
between	O
human	O
chromosome	O
13q14	O
and	O
the	O
central	O
region	O
of	O
mouse	O
chromosome	O
14	O
.	O
	
this	O
assignment	O
suggests	O
a	O
possible	O
location	O
for	O
the	O
toxic	O
milk	O
mutation	O
in	O
the	O
mouse	O
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
homologue	O
of	O
wd	B-Disease
.	O
	
germline	O
mutations	O
of	O
the	O
brca1	O
gene	O
in	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
provide	O
evidence	O
for	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O
	
mutations	O
in	O
the	O
brca1	O
gene	O
,	O
discovered	O
in	O
1994	O
,	O
are	O
associated	O
with	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
we	O
have	O
analysed	O
60	O
families	O
with	O
a	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
for	O
germline	O
mutations	O
in	O
brca1	O
.	O
	
we	O
observed	O
a	O
significant	O
correlation	O
between	O
the	O
location	O
of	O
the	O
mutation	O
in	O
the	O
gene	O
and	O
the	O
ratio	O
of	O
breast	B-Disease
to	I-Disease
ovarian	I-Disease
cancer	I-Disease
incidence	O
within	O
each	O
family	O
.	O
	
our	O
data	O
suggest	O
a	O
transition	O
in	O
risk	O
such	O
that	O
mutations	O
in	O
the	O
3	O
third	O
of	O
the	O
gene	O
are	O
associated	O
with	O
a	O
lower	O
proportion	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
hereditary	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
and	O
recurrent	O
meningococcal	B-Disease
infection	I-Disease
:	O
investigations	O
of	O
an	O
irish	O
family	O
using	O
a	O
novel	O
haemolytic	O
screening	O
assay	O
for	O
complement	O
activity	O
and	O
c7	O
m	O
/	O
n	O
allotyping	O
.	O
	
terminal	B-Disease
complement	I-Disease
component	I-Disease
deficiency	I-Disease
predisposes	O
to	O
meningococcal	B-Disease
infection	I-Disease
and	O
is	O
inherited	O
in	O
an	O
autosomal	O
co	O
-	O
dominant	O
manner	O
.	O
	
an	O
irish	O
family	O
is	O
described	O
,	O
in	O
which	O
2	O
of	O
3	O
brothers	O
had	O
recurrent	O
meningococcal	B-Disease
infection	I-Disease
.	O
	
a	O
novel	O
screening	O
assay	O
was	O
used	O
to	O
investigate	O
for	O
terminal	B-Disease
complement	I-Disease
deficiency	I-Disease
and	O
the	O
2	O
affected	O
brothers	O
were	O
found	O
to	O
be	O
completely	B-Disease
deficient	I-Disease
in	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c7	O
)	O
.	O
	
c7	O
m	O
/	O
n	O
protein	O
polymorphism	O
allotyping	O
,	O
used	O
to	O
investigate	O
the	O
segregation	O
of	O
the	O
c7	B-Disease
deficiency	I-Disease
genes	O
,	O
showed	O
that	O
the	O
apparently	O
complement	O
sufficient	O
brother	O
was	O
heterozygous	O
c7	B-Disease
deficient	I-Disease
and	O
a	O
carrier	O
of	O
one	O
of	O
the	O
deficiency	O
genes	O
.	O
	
complement	O
screening	O
should	O
be	O
carried	O
out	O
in	O
any	O
individual	O
suffering	O
recurrent	O
meningococcal	B-Disease
infection	I-Disease
or	O
infection	O
with	O
an	O
uncommon	O
meningococcal	B-Disease
serogroup	O
.	O
	
identification	O
of	O
complement	B-Disease
deficient	I-Disease
patients	O
allows	O
the	O
implementation	O
of	O
strategies	O
to	O
prevent	O
recurrent	O
infection	O
.	O
	
molecular	O
basis	O
of	O
subtotal	B-Disease
complement	I-Disease
c6	I-Disease
deficiency	I-Disease
.	O
	
individuals	O
with	O
subtotal	B-Disease
complement	I-Disease
c6	I-Disease
deficiency	I-Disease
possess	O
a	O
c6	O
molecule	O
that	O
is	O
14	O
%	O
shorter	O
than	O
normal	O
c6	O
and	O
present	O
in	O
low	O
but	O
detectable	O
concentrations	O
(	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
mean	O
)	O
.	O
	
interestingly	O
,	O
all	O
three	O
subjects	O
were	O
probably	O
heterozygous	O
for	O
both	O
subtotal	B-Disease
c6	I-Disease
and	I-Disease
complete	I-Disease
c6	I-Disease
deficiency	I-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
:	O
evidence	O
for	O
a	O
possible	O
dominant	O
-	O
negative	O
rna	O
mutation	O
.	O
	
the	O
trinucleotide	O
expansion	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
is	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
gene	O
.	O
	
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
expanded	O
repeat	O
causes	O
the	O
clinically	O
variable	O
and	O
multisystemic	B-Disease
disease	I-Disease
,	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
are	O
not	O
understood	O
.	O
	
here	O
we	O
use	O
muscle	O
biopsies	O
from	O
classical	O
adult	O
-	O
onset	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
to	O
study	O
the	O
accumulation	O
of	O
transcripts	O
from	O
both	O
the	O
normal	O
and	O
expanded	O
dm	B-Disease
kinase	O
genes	O
in	O
patient	O
muscle	O
,	O
and	O
compare	O
the	O
results	O
to	O
normal	O
and	O
myopathic	B-Disease
controls	O
.	O
	
we	O
found	O
relatively	O
small	O
decreases	O
of	O
dm	B-Disease
kinase	O
rna	O
in	O
the	O
total	O
rna	O
pool	O
from	O
muscle	O
;	O
however	O
,	O
these	O
reductions	O
were	O
not	O
disease	O
specific	O
.	O
	
analysis	O
of	O
poly	O
(	O
a	O
)	O
+	O
rna	O
showed	O
dramatic	O
decreases	O
of	O
both	O
the	O
mutant	O
and	O
normal	O
dm	B-Disease
kinase	O
rnas	O
,	O
and	O
these	O
changes	O
were	O
disease	O
-	O
specific	O
.	O
	
our	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
molecular	O
pathogenetic	O
mechanism	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
both	O
the	O
normal	O
and	O
expanded	O
dm	B-Disease
kinase	O
genes	O
are	O
transcribed	O
in	O
patient	O
muscle	O
,	O
but	O
the	O
abnormal	O
expansion	O
-	O
containing	O
rna	O
has	O
a	O
dominant	O
effect	O
on	O
rna	O
metabolism	O
by	O
preventing	O
the	O
accumulation	O
of	O
poly	O
(	O
a	O
)	O
+	O
rna	O
.	O
	
the	O
ability	O
of	O
the	O
expansion	O
mutation	O
to	O
alter	O
accumulation	O
of	O
poly	O
(	O
a	O
)	O
+	O
rna	O
in	O
trans	O
suggests	O
that	O
myotonic	B-Disease
dystrophy	I-Disease
may	O
be	O
the	O
first	O
example	O
of	O
a	O
dominant	O
-	O
negative	O
mutation	O
manifested	O
at	O
the	O
rna	O
level	O
.	O
	
a	O
strong	O
candidate	O
for	O
the	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
.	O
	
a	O
strong	O
candidate	O
for	O
the	O
17q	O
-	O
linked	O
brca1	O
gene	O
,	O
which	O
influences	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
has	O
been	O
identified	O
by	O
positional	O
cloning	O
methods	O
.	O
	
identification	O
of	O
brca1	O
should	O
facilitate	O
early	O
diagnosis	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
in	O
some	O
individuals	O
as	O
well	O
as	O
a	O
better	O
understanding	O
of	O
breast	B-Disease
cancer	I-Disease
biology	O
.	O
	
molecular	O
characterization	O
of	O
galactosemia	B-Disease
(	O
type	O
1	O
)	O
mutations	O
in	O
japanese	O
.	O
	
we	O
characterized	O
two	O
novel	O
mutations	O
of	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
gene	O
in	O
two	O
japanese	O
patients	O
with	O
galt	B-Disease
deficiency	I-Disease
and	O
identified	O
n314d	O
and	O
r333w	O
mutations	O
,	O
previously	O
found	O
in	O
caucasians	O
.	O
	
in	O
seven	O
japanese	O
families	O
(	O
14	O
alleles	O
for	O
classic	O
form	O
and	O
one	O
allele	O
for	O
duarte	O
variant	O
)	O
with	O
galt	B-Disease
deficiency	I-Disease
,	O
the	O
r231h	O
and	O
318a	O
-	O
-	O
>	O
g	O
mutations	O
were	O
found	O
only	O
on	O
both	O
alleles	O
of	O
the	O
proband	O
.	O
	
we	O
speculate	O
that	O
classic	B-Disease
galactosemia	I-Disease
mutations	O
appear	O
to	O
differ	O
between	O
japanese	O
and	O
caucasian	O
patients	O
.	O
	
our	O
limited	O
data	O
set	O
on	O
galactosemia	B-Disease
mutations	O
in	O
japanese	O
suggests	O
that	O
the	O
n314d	O
galt	O
mutation	O
encoding	O
the	O
duarte	O
variant	O
arose	O
before	O
asian	O
and	O
caucasian	O
people	O
diverged	O
and	O
that	O
classic	B-Disease
galactosemia	I-Disease
mutations	O
arose	O
and	O
/	O
or	O
accumulated	O
after	O
the	O
divergence	O
of	O
asian	O
and	O
caucasian	O
populations	O
.	O
	
three	O
novel	O
aniridia	B-Disease
mutations	O
in	O
the	O
human	O
pax6	O
gene	O
.	O
	
aniridia	B-Disease
(	O
iris	B-Disease
hypoplasia	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
congenital	I-Disease
disorder	I-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
.	O
	
mutations	O
in	O
the	O
human	O
aniridia	B-Disease
(	O
pax6	O
)	O
gene	O
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O
	
in	O
the	O
study	O
reported	O
here	O
we	O
describe	O
pax6	O
mutations	O
in	O
one	O
sporadic	O
and	O
five	O
familial	O
cases	O
with	O
aniridia	B-Disease
.	O
	
one	O
pax6	O
mutation	O
found	O
in	O
the	O
pst	O
region	O
was	O
associated	O
with	O
cataracts	B-Disease
in	O
an	O
aniridia	B-Disease
family	O
.	O
	
another	O
splice	O
mutation	O
in	O
the	O
pst	O
domain	O
occurred	O
in	O
an	O
aniridia	B-Disease
patient	O
with	O
anosmia	B-Disease
(	O
inability	O
to	O
smell	O
)	O
.	O
	
the	O
six	O
new	O
aniridia	B-Disease
cases	O
reported	O
here	O
have	O
mutations	O
predicted	O
to	O
generate	O
incomplete	O
pax6	O
proteins	O
.	O
	
these	O
results	O
support	O
the	O
theory	O
that	O
human	O
aniridia	B-Disease
is	O
caused	O
by	O
haploinsufficiency	B-Disease
of	I-Disease
pax6	I-Disease
.	O
	
since	O
brca1	O
,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
in	O
high	O
-	O
risk	O
pedigrees	O
,	O
female	O
carriers	O
of	O
brca1	O
mutations	O
have	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
and	O
a	O
40	O
-	O
50	O
%	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
however	O
,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
has	O
not	O
been	O
determined	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	B-Disease
as	O
in	O
individuals	O
from	O
the	O
high	O
-	O
risk	O
families	O
studied	O
so	O
far	O
.	O
	
following	O
the	O
finding	O
of	O
a	O
185delag	O
frameshift	O
mutation	O
in	O
several	O
ashkenazi	O
jewish	O
breast	O
/	O
ovarian	O
families	O
,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	B-Disease
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin	O
.	O
	
our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
the	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
phenotype	O
is	O
associated	O
with	O
expansion	O
of	O
a	O
trinucleotide	O
repeat	O
in	O
the	O
it15	O
gene	O
,	O
which	O
is	O
predicted	O
to	O
encode	O
a	O
348	O
-	O
kda	O
protein	O
named	O
huntington	O
.	O
	
in	O
lymphoblastoid	O
cell	O
lines	O
from	O
juvenile	O
-	O
onset	O
heterozygote	O
hd	B-Disease
cases	O
,	O
both	O
normal	O
and	O
mutant	O
huntingtin	O
are	O
expressed	O
,	O
and	O
increasing	O
repeat	O
expansion	O
leads	O
to	O
lower	O
levels	O
of	O
the	O
mutant	O
protein	O
.	O
	
in	O
the	O
human	O
striatum	O
,	O
huntingtin	O
is	O
enriched	O
in	O
a	O
patch	O
-	O
like	O
distribution	O
,	O
potentially	O
corresponding	O
to	O
the	O
first	O
areas	O
affected	O
in	O
hd	B-Disease
.	O
	
marked	O
phenotypic	O
heterogeneity	O
associated	O
with	O
expansion	O
of	O
a	O
cag	O
repeat	O
sequence	O
at	O
the	O
spinocerebellar	B-Disease
ataxia	I-Disease
3	I-Disease
/	I-Disease
machado	I-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
locus	O
.	O
	
the	O
spinocerebellar	B-Disease
ataxia	I-Disease
3	I-Disease
locus	O
(	O
sca3	B-Disease
)	O
for	O
type	B-Disease
i	I-Disease
autosomal	I-Disease
dominant	I-Disease
cerebellar	I-Disease
ataxia	I-Disease
(	O
adca	B-Disease
type	I-Disease
i	I-Disease
)	O
,	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	B-Disease
disorders	I-Disease
,	O
has	O
been	O
mapped	O
to	O
chromosome	O
14q32	O
.	O
	
adca	B-Disease
type	I-Disease
i	I-Disease
patients	O
from	O
families	O
segregating	O
sca3	B-Disease
share	O
clinical	O
features	O
in	O
common	O
with	O
those	O
with	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
mjd	B-Disease
)	O
,	O
the	O
gene	O
of	O
which	O
maps	O
to	O
the	O
same	O
region	O
.	O
	
we	O
show	O
here	O
that	O
the	O
disease	O
gene	O
segregating	O
in	O
each	O
of	O
three	O
french	O
adca	B-Disease
type	I-Disease
i	I-Disease
kindreds	O
and	O
in	O
a	O
french	O
family	O
with	O
neuropathological	O
findings	O
suggesting	O
the	O
ataxochoreic	O
form	O
of	O
dentatorubropallidoluysian	B-Disease
atrophy	I-Disease
carries	O
an	O
expanded	O
cag	O
repeat	O
sequence	O
located	O
at	O
the	O
same	O
locus	O
as	O
that	O
for	O
mjd	B-Disease
.	O
	
overexpression	O
of	O
dm20	O
messenger	O
rna	O
in	O
two	O
brothers	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
is	O
a	O
rare	B-Disease
,	I-Disease
sex	I-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
,	I-Disease
dysmyelinating	I-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
that	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
myelin	O
proteolipid	O
protein	O
(	O
plp	O
)	O
gene	O
.	O
	
only	O
25	O
%	O
of	O
patients	O
studied	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
have	O
exonic	O
mutations	O
in	O
this	O
gene	O
,	O
the	O
underlying	O
cause	O
of	O
the	O
disease	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O
	
we	O
studied	O
cultured	O
skin	O
fibroblasts	O
from	O
2	O
brothers	O
with	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
who	O
exhibited	O
no	O
detectable	O
exonic	O
mutation	O
of	O
the	O
plp	O
gene	O
.	O
	
our	O
findings	O
suggest	O
that	O
in	O
some	O
patients	O
,	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
is	O
caused	O
by	O
overexpression	O
of	O
plp	O
gene	O
transcripts	O
,	O
and	O
that	O
in	O
these	O
families	O
a	O
50	O
%	O
increase	O
of	O
dm20	O
messenger	O
rna	O
in	O
females	O
,	O
relative	O
to	O
the	O
increase	O
in	O
affected	O
males	O
,	O
can	O
identify	O
a	O
female	O
carrier	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
and	O
x	B-Disease
-	I-Disease
linked	I-Disease
congenital	I-Disease
thrombocytopenia	I-Disease
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
thrombocytopenia	B-Disease
,	O
small	O
platelets	O
,	O
eczema	B-Disease
,	O
recurrent	O
infections	O
,	O
and	O
immunodeficiency	B-Disease
.	O
	
besides	O
the	O
classic	O
was	B-Disease
phenotype	O
,	O
there	O
is	O
a	O
group	O
of	O
patients	O
with	O
congenital	B-Disease
x	I-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
(	O
xlt	B-Disease
)	O
who	O
have	O
small	O
platelets	O
but	O
only	O
transient	O
eczema	B-Disease
,	O
if	O
any	O
,	O
and	O
minimal	O
immune	B-Disease
deficiency	I-Disease
.	O
	
because	O
the	O
gene	O
responsible	O
for	O
was	B-Disease
has	O
been	O
sequenced	O
,	O
it	O
was	O
possible	O
to	O
correlate	O
the	O
was	B-Disease
phenotypes	O
with	O
was	B-Disease
gene	O
mutations	O
.	O
	
using	O
a	O
fingerprinting	O
screening	O
technique	O
,	O
we	O
determined	O
the	O
approximate	O
location	O
of	O
the	O
mutation	O
in	O
13	O
unrelated	O
was	B-Disease
patients	O
with	O
mild	O
to	O
severe	O
clinical	O
symptoms	O
.	O
	
direct	O
sequence	O
analysis	O
of	O
cdna	O
and	O
genomic	O
dna	O
obtained	O
from	O
patient	O
-	O
derived	O
cell	O
lines	O
showed	O
12	O
unique	O
mutations	O
distributed	O
throughout	O
the	O
was	B-Disease
gene	O
,	O
including	O
insertions	O
,	O
deletions	O
,	O
and	O
point	O
mutations	O
resulting	O
in	O
amino	O
acid	O
substitutions	O
,	O
termination	O
,	O
exon	O
skipping	O
,	O
or	O
splicing	O
defects	O
.	O
	
of	O
4	O
unrelated	O
patients	O
with	O
the	O
xlt	B-Disease
phenotype	O
,	O
3	O
had	O
missense	O
mutations	O
affecting	O
exon	O
2	O
and	O
1	O
had	O
a	O
splice	O
-	O
site	O
mutation	O
affecting	O
exon	O
9	O
.	O
	
patients	O
with	O
classic	O
was	B-Disease
had	O
more	O
complex	O
mutations	O
,	O
resulting	O
in	O
termination	O
codons	O
,	O
frameshift	O
,	O
and	O
early	O
termination	O
.	O
	
these	O
findings	O
provide	O
direct	O
evidence	O
that	O
xlt	B-Disease
and	O
was	B-Disease
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene	O
and	O
suggest	O
that	O
severe	O
clinical	O
phenotypes	O
are	O
associated	O
with	O
complex	O
mutations	O
.	O
	
myotonia	B-Disease
levior	I-Disease
is	O
a	O
chloride	B-Disease
channel	I-Disease
disorder	I-Disease
.	O
	
the	O
group	O
of	O
dominant	B-Disease
non	I-Disease
-	I-Disease
dystrophic	I-Disease
myotonias	I-Disease
,	O
comprising	O
disorders	O
characterized	O
by	O
clinically	O
similar	O
forms	O
of	O
myogenic	O
muscle	O
stiffness	O
,	O
is	O
genetically	O
inhomogeneous	O
.	O
	
dominant	B-Disease
myotonia	I-Disease
congenita	I-Disease
(	O
thomsens	B-Disease
disease	I-Disease
)	O
is	O
linked	O
to	O
clcn1	O
,	O
the	O
gene	O
encoding	O
the	O
major	O
muscle	O
chloride	O
channel	O
,	O
localized	O
on	O
chromosome	O
7q35	O
.	O
	
in	O
contrast	O
,	O
dominant	B-Disease
myotonias	I-Disease
sensitive	O
to	O
potassium	O
are	O
caused	O
by	O
point	O
mutations	O
in	O
scn4a	O
on	O
chromosome	O
17q	O
,	O
the	O
gene	O
for	O
the	O
alpha	O
subunit	O
of	O
the	O
adult	O
skeletal	O
muscle	O
sodium	O
channel	O
.	O
	
no	O
linkage	O
or	O
molecular	O
genetic	O
data	O
are	O
as	O
yet	O
available	O
on	O
myotonia	B-Disease
levior	I-Disease
characterized	O
by	O
milder	O
symptoms	O
and	O
later	O
onset	O
of	O
myotonia	B-Disease
than	O
in	O
thomsens	B-Disease
disease	I-Disease
,	O
and	O
absence	O
of	O
muscle	B-Disease
hypertrophy	I-Disease
.	O
	
we	O
report	O
a	O
clcn1	O
gln	O
-	O
552	O
-	O
arg	O
substitution	O
for	O
a	O
family	O
with	O
dominant	O
inheritance	O
previously	O
diagnosed	O
to	O
have	O
myotonia	B-Disease
levior	I-Disease
.	O
	
thus	O
,	O
this	O
disorder	O
appears	O
as	O
a	O
variant	O
of	O
thomsens	B-Disease
disease	I-Disease
due	O
to	O
mutations	O
leading	O
to	O
low	O
clinical	O
expressivity	O
.	O
	
in	O
another	O
family	O
previously	O
diagnosed	O
as	O
having	O
thomsens	B-Disease
disease	I-Disease
,	O
we	O
unexpectedly	O
found	O
a	O
clcn1	O
14	O
bp	O
deletion	O
known	O
to	O
cause	O
recessive	B-Disease
myotonia	I-Disease
,	O
and	O
a	O
rare	O
trp	O
-	O
118	O
-	O
gly	O
polymorphism	O
.	O
	
southern	O
analysis	O
reveals	O
a	O
large	O
deletion	O
at	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
locus	O
in	O
a	O
patient	O
with	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
whole	O
genomic	O
hprt	O
clones	O
were	O
used	O
in	O
southern	O
analysis	O
to	O
screen	O
the	O
integrity	O
of	O
the	O
hprt	O
gene	O
in	O
a	O
family	O
that	O
includes	O
a	O
patient	O
with	O
hprt	B-Disease
enzyme	I-Disease
deficiency	I-Disease
causal	O
to	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
characterisation	O
of	O
molecular	O
defects	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
(	O
aih1	O
)	O
.	O
	
disturbances	O
of	O
enamel	O
formation	O
occur	O
in	O
amelogenesis	B-Disease
imperfecta	I-Disease
,	O
a	O
clinically	O
heterogenous	O
group	O
of	O
inherited	B-Disease
disorders	I-Disease
characterised	O
by	O
defective	O
enamel	O
biomineralisation	O
.	O
	
an	O
amelogenin	O
gene	O
,	O
amgx	O
,	O
has	O
been	O
mapped	O
to	O
the	O
short	O
of	O
the	O
x	O
chromosome	O
(	O
xp22	O
.	O
	
1	O
-	O
p22	O
.	O
	
3	O
)	O
and	O
has	O
been	O
implicated	O
in	O
the	O
molecular	O
pathology	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
(	O
aih1	B-Disease
)	O
.	O
	
we	O
have	O
identified	O
three	O
families	O
exhibiting	O
aih1	B-Disease
and	O
screened	O
the	O
amgx	O
gene	O
for	O
mutations	O
using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
dna	O
sequencing	O
.	O
	
frequency	O
of	O
exon	O
15	O
missense	O
mutation	O
(	O
442d	O
:	O
g	O
)	O
in	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
in	O
hyperalphalipoproteinemic	B-Disease
japanese	O
subjects	O
.	O
	
the	O
hyperalphalipoproteinemia	B-Disease
caused	O
by	O
cetp	B-Disease
deficiency	I-Disease
is	O
fairly	O
common	O
in	O
japan	O
and	O
one	O
of	O
the	O
most	O
common	O
mutations	O
in	O
the	O
cetp	O
gene	O
is	O
the	O
splicing	O
defect	O
of	O
the	O
intron	O
14	O
,	O
the	O
allelic	O
frequency	O
of	O
which	O
has	O
been	O
shown	O
to	O
be	O
0	O
.	O
	
in	O
the	O
current	O
study	O
,	O
we	O
determined	O
the	O
frequency	O
of	O
this	O
new	O
mutation	O
in	O
japanese	O
hyperalphalipoproteinemic	B-Disease
(	O
hdl	O
-	O
cholesterol	O
>	O
or	O
=	O
100	O
mg	O
/	O
dl	O
)	O
subjects	O
.	O
	
among	O
117	O
japanese	O
hyperalphalipoproteinemic	B-Disease
subjects	O
(	O
hdl	O
-	O
cholesterol	O
;	O
116	O
.	O
	
7	O
+	O
/	O
-	O
16	O
.	O
	
5	O
mg	O
/	O
dl	O
,	O
mean	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
)	O
without	O
the	O
intron	O
14	O
splice	O
defect	O
,	O
three	O
homozygotes	O
(	O
2	O
.	O
5	O
%	O
)	O
and	O
34	O
heterozygotes	O
(	O
29	O
.	O
1	O
%	O
)	O
were	O
found	O
to	O
have	O
the	O
442d	O
g	O
mutation	O
.	O
	
one	O
of	O
the	O
homozygotes	O
for	O
the	O
442d	O
g	O
mutation	O
was	O
the	O
patient	O
previously	O
described	O
by	O
us	O
as	O
having	O
hyperalphalipoproteinemia	B-Disease
with	O
corneal	B-Disease
opacity	I-Disease
and	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
	
this	O
was	O
the	O
first	O
reported	O
subject	O
homozygous	O
for	O
the	O
cetp	B-Disease
deficiency	I-Disease
who	O
also	O
demonstrated	O
atherosclerotic	B-Disease
symptoms	I-Disease
.	O
	
mucopolysaccharidosis	B-Disease
type	I-Disease
iva	I-Disease
:	O
common	O
double	O
deletion	O
in	O
the	O
n	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfatase	O
gene	O
(	O
galns	O
)	O
.	O
	
mucopolysaccharidosis	B-Disease
iva	I-Disease
(	O
mps	B-Disease
iva	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
in	I-Disease
n	I-Disease
-	I-Disease
acetylgalactosamine	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
sulfatase	I-Disease
(	O
galns	O
)	O
.	O
	
detection	O
of	O
eight	O
brca1	O
mutations	O
in	O
10	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
,	O
including	O
1	O
family	O
with	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
genetic	O
epidemiological	O
evidence	O
suggests	O
that	O
mutations	O
in	O
brca1	O
may	O
be	O
responsible	O
for	O
approximately	O
one	O
half	O
of	O
early	O
onset	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
and	O
the	O
majority	O
of	O
familial	B-Disease
breast	I-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
the	O
recent	O
cloning	O
of	O
brca1	O
allows	O
for	O
the	O
direct	O
detection	O
of	O
mutations	O
,	O
but	O
the	O
feasibility	O
of	O
presymptomatic	O
screening	O
for	O
cancer	B-Disease
susceptibility	O
is	O
unknown	O
.	O
	
we	O
analyzed	O
genomic	O
dna	O
from	O
one	O
affected	O
individual	O
from	O
each	O
of	O
24	O
families	O
with	O
at	O
least	O
three	O
cases	O
of	O
ovarian	B-Disease
or	I-Disease
breast	I-Disease
cancer	I-Disease
,	O
using	O
sscp	O
assays	O
.	O
	
a	O
frameshift	O
mutation	O
was	O
detected	O
in	O
a	O
male	O
proband	O
affected	O
with	O
both	O
breast	B-Disease
and	I-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
a	O
40	O
-	O
bp	O
deletion	O
was	O
detected	O
in	O
a	O
patient	O
who	O
developed	O
intra	B-Disease
-	I-Disease
abdominal	I-Disease
carcinomatosis	I-Disease
1	O
year	O
after	O
prophylactic	O
oophorectomy	O
.	O
	
these	O
results	O
provide	O
further	O
evidence	O
that	O
inherited	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
can	O
occur	O
as	O
a	O
consequence	O
of	O
a	O
wide	O
array	O
of	O
brca1	O
mutations	O
.	O
	
the	O
finding	O
of	O
a	O
mutation	O
in	O
a	O
family	O
with	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
not	O
previously	O
thought	O
to	O
be	O
related	O
to	O
brca1	O
,	O
also	O
illustrates	O
the	O
potential	O
difficulties	O
of	O
genetic	O
counseling	O
for	O
individuals	O
known	O
to	O
carry	O
mutations	O
.	O
	
natural	O
selection	O
of	O
hemi	O
-	O
and	O
heterozygotes	O
for	O
g6pd	B-Disease
deficiency	I-Disease
in	O
africa	O
by	O
resistance	O
to	O
severe	O
malaria	B-Disease
.	O
	
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
,	O
the	O
most	O
common	O
enzymopathy	B-Disease
of	O
humans	O
,	O
affects	O
over	O
400	O
million	O
people	O
.	O
	
the	O
geographical	O
correlation	O
of	O
its	O
distribution	O
with	O
the	O
historical	O
endemicity	O
of	O
malaria	B-Disease
suggests	O
that	O
this	O
disorder	O
has	O
risen	O
in	O
frequency	O
through	O
natural	O
selection	O
by	O
malaria	B-Disease
.	O
	
however	O
,	O
attempts	O
to	O
confirm	O
that	O
g6pd	B-Disease
deficiency	I-Disease
is	O
protective	O
in	O
case	O
-	O
control	O
studies	O
of	O
malaria	B-Disease
have	O
yielded	O
conflicting	O
results	O
.	O
	
hence	O
,	O
for	O
this	O
x	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
are	O
protected	O
or	O
,	O
as	O
frequently	O
suggested	O
,	O
only	O
females	O
.	O
	
here	O
we	O
report	O
that	O
,	O
in	O
two	O
large	O
case	O
-	O
control	O
studies	O
of	O
over	O
2	O
,	O
0	O
african	O
children	O
,	O
the	O
common	O
african	O
form	O
of	O
g6pd	B-Disease
deficiency	I-Disease
(	O
g6pd	B-Disease
a	I-Disease
-	I-Disease
)	O
is	O
associated	O
with	O
a	O
46	O
-	O
58	O
%	O
reduction	O
in	O
risk	O
of	O
severe	O
malaria	B-Disease
for	O
both	O
female	O
heterozygotes	O
and	O
male	O
hemizygotes	O
.	O
	
a	O
mathematical	O
model	O
incorporating	O
the	O
measured	O
selective	O
advantage	O
against	O
malaria	B-Disease
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage	O
,	O
associated	O
with	O
this	O
enzyme	B-Disease
deficiency	I-Disease
,	O
has	O
retarded	O
its	O
rise	O
in	O
frequency	O
in	O
malaria	B-Disease
-	O
endemic	O
regions	O
.	O
	
although	O
g6pd	B-Disease
deficiency	I-Disease
is	O
now	O
regarded	O
as	O
a	O
generally	O
benign	O
disorder	O
,	O
in	O
earlier	O
environmental	O
conditions	O
it	O
could	O
have	O
been	O
significantly	O
disadvantageous	O
.	O
	
the	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
pax3	O
/	O
fkhr	O
fusion	O
protein	O
is	O
a	O
transcriptional	O
activator	O
.	O
	
chimeric	O
transcription	O
factors	O
,	O
created	O
by	O
gene	O
fusions	O
as	O
the	O
result	O
of	O
chromosomal	O
translocations	O
,	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
pathologically	O
disparate	O
solid	B-Disease
tumors	I-Disease
.	O
	
the	O
pax3	O
/	O
fkhr	O
fusion	O
gene	O
,	O
formed	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
,	O
encodes	O
a	O
hybrid	O
protein	O
that	O
contains	O
both	O
pax3	O
dna	O
binding	O
domains	O
,	O
the	O
paired	O
box	O
and	O
homeodomain	O
,	O
linked	O
to	O
the	O
bisected	O
dna	O
binding	O
domain	O
of	O
fkhr	O
,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors	O
.	O
	
we	O
show	O
that	O
the	O
native	O
pax3	O
/	O
fkhr	O
protein	O
present	O
in	O
tumor	B-Disease
cells	O
with	O
this	O
translocation	O
has	O
transcriptional	O
characteristics	O
similar	O
to	O
the	O
in	O
vitro	O
expressed	O
protein	O
.	O
	
a	O
p16ink4a	O
-	O
insensitive	O
cdk4	O
mutant	O
targeted	O
by	O
cytolytic	O
t	O
lymphocytes	O
in	O
a	O
human	O
melanoma	B-Disease
.	O
	
a	O
mutated	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
(	O
cdk4	O
)	O
was	O
identified	O
as	O
a	O
tumor	B-Disease
-	O
specific	O
antigen	O
recognized	O
by	O
hla	O
-	O
a2	O
.	O
	
1	O
-	O
restricted	O
autologous	O
cytolytic	O
t	O
lymphocytes	O
(	O
ctls	O
)	O
in	O
a	O
human	O
melanoma	B-Disease
.	O
	
the	O
mutated	O
cdk4	O
allele	O
was	O
present	O
in	O
autologous	O
cultured	O
melanoma	B-Disease
cells	O
and	O
metastasis	O
tissue	O
,	O
but	O
not	O
in	O
the	O
patients	O
lymphocytes	O
.	O
	
the	O
same	O
mutation	O
was	O
found	O
in	O
one	O
additional	O
melanoma	B-Disease
among	O
28	O
melanomas	B-Disease
analyzed	O
.	O
	
these	O
results	O
suggest	O
that	O
mutation	O
of	O
cdk4	O
can	O
create	O
a	O
tumor	B-Disease
-	O
specific	O
antigen	O
and	O
can	O
disrupt	O
the	O
cell	O
-	O
cycle	O
regulation	O
exerted	O
by	O
the	O
tumor	B-Disease
suppressor	O
p16ink4a	O
.	O
	
more	O
than	O
75	O
%	O
of	O
the	O
reported	O
mutations	O
in	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
,	O
brca1	O
,	O
result	O
in	O
truncated	O
proteins	O
.	O
	
in	O
45	O
patients	O
from	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
we	O
found	O
six	O
novel	O
mutations	O
two	O
single	O
nucleotide	O
insertions	O
,	O
three	O
small	O
deletions	O
(	O
1	O
-	O
5	O
bp	O
)	O
and	O
a	O
nonsense	O
mutation	O
identified	O
two	O
unrelated	O
families	O
.	O
	
pcr	O
-	O
amplified	O
vlcad	O
cdnas	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
vlcad	B-Disease
-	I-Disease
deficient	I-Disease
patients	O
.	O
	
this	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
vlcad	B-Disease
deficiency	I-Disease
.	O
	
quantitative	O
cdna	O
expression	O
of	O
normal	O
human	O
vlcad	O
was	O
performed	O
in	O
the	O
patients	O
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
normal	I-Disease
vlcad	I-Disease
protein	I-Disease
causes	O
impaired	O
long	O
-	O
chain	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	O
fibroblasts	O
.	O
	
in	O
patient	O
fibroblasts	O
,	O
raising	O
vlcad	O
activity	O
to	O
approximately	O
20	O
%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	O
acid	O
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
vlcad	B-Disease
deficiency	I-Disease
.	O
	
brain	B-Disease
disease	I-Disease
and	O
molecular	O
analysis	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
abnormal	O
amplification	O
of	O
a	O
ctg	O
repeat	O
on	O
chromosome	O
19	O
is	O
the	O
molecular	O
basis	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
.	O
	
we	O
performed	O
extensive	O
cognitive	O
testing	O
,	O
cerebral	O
magnetic	O
resonance	O
imaging	O
(	O
mri	O
)	O
and	O
a	O
molecular	O
analysis	O
in	O
28	O
cases	O
of	O
dm	B-Disease
to	O
determine	O
the	O
relationship	O
between	O
the	O
molecular	O
defect	O
and	O
brain	B-Disease
disease	I-Disease
.	O
	
fourteen	O
patients	O
had	O
subcortical	O
white	B-Disease
matter	I-Disease
lesions	I-Disease
on	O
mri	O
,	O
14	O
had	O
cerebral	B-Disease
atrophy	I-Disease
.	O
	
disease	O
duration	O
influenced	O
the	O
appearance	O
and	O
amount	O
of	O
white	B-Disease
matter	I-Disease
lesions	I-Disease
on	O
mri	O
.	O
	
quantification	O
of	O
ctg	O
repeat	O
size	O
may	O
allow	O
an	O
early	O
estimate	O
on	O
the	O
probability	O
of	O
brain	O
involvement	O
in	O
dm	B-Disease
;	O
cognitive	B-Disease
dysfunction	I-Disease
is	O
associated	O
with	O
white	B-Disease
matter	I-Disease
lesions	I-Disease
and	O
cerebral	B-Disease
atrophy	I-Disease
later	O
on	O
in	O
the	O
course	O
.	O
	
mutations	O
in	O
the	O
gene	O
for	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
in	O
patients	O
with	O
different	O
clinical	O
phenotypes	O
.	O
	
recently	O
,	O
the	O
gene	O
for	O
the	O
most	O
common	O
peroxisomal	B-Disease
disorder	I-Disease
,	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
x	B-Disease
-	I-Disease
ald	I-Disease
)	O
,	O
has	O
been	O
described	O
encoding	O
a	O
peroxisomal	O
membrane	O
transporter	O
protein	O
.	O
	
we	O
analyzed	O
the	O
entire	O
protein	O
-	O
coding	O
sequence	O
of	O
this	O
gene	O
by	O
reverse	O
-	O
transcription	O
pcr	O
,	O
sscp	O
,	O
and	O
dna	O
sequencing	O
in	O
five	O
patients	O
with	O
different	O
clinical	O
expression	O
of	O
x	B-Disease
-	I-Disease
ald	I-Disease
and	O
in	O
their	O
female	O
relatives	O
;	O
these	O
clinical	O
expressions	O
were	O
cerebral	O
childhood	O
ald	B-Disease
,	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
,	O
and	O
addison	B-Disease
disease	I-Disease
only	I-Disease
(	O
ado	B-Disease
)	O
phenotype	O
.	O
	
in	O
the	O
three	O
patients	O
exhibiting	O
the	O
classical	O
picture	O
of	O
severe	O
childhood	O
ald	B-Disease
we	O
identified	O
in	O
the	O
5	O
portion	O
of	O
the	O
x	B-Disease
-	I-Disease
ald	I-Disease
gene	O
a	O
38	O
-	O
bp	O
deletion	O
that	O
causes	O
a	O
frameshift	O
mutation	O
,	O
a	O
3	O
-	O
bp	O
deletion	O
leading	O
to	O
a	O
deletion	O
of	O
an	O
amino	O
acid	O
in	O
the	O
atp	O
-	O
binding	O
domain	O
of	O
the	O
ald	B-Disease
protein	O
,	O
and	O
a	O
missense	O
mutation	O
.	O
	
in	O
the	O
patient	O
with	O
the	O
clinical	O
phenotype	O
of	O
amn	B-Disease
,	O
a	O
nonsense	O
mutation	O
in	O
codon	O
212	O
,	O
along	O
with	O
a	O
second	O
site	O
mutation	O
at	O
codon	O
178	O
,	O
was	O
observed	O
.	O
	
analysis	O
of	O
the	O
patient	O
with	O
the	O
ado	B-Disease
phenotype	O
revealed	O
a	O
further	O
missense	O
mutation	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
aldp	O
/	O
pmp70	O
comparison	O
.	O
	
the	O
disruptive	O
nature	O
of	O
two	O
mutations	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
frameshift	O
and	O
the	O
nonsense	O
mutation	O
)	O
in	O
patients	O
with	O
biochemically	O
proved	O
childhood	O
ald	B-Disease
and	O
amn	B-Disease
further	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
alterations	O
in	O
this	O
gene	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
x	B-Disease
-	I-Disease
ald	I-Disease
.	O
	
since	O
the	O
current	O
biochemical	O
techniques	O
for	O
x	B-Disease
-	I-Disease
ald	I-Disease
carrier	O
detection	O
in	O
affected	O
families	O
lack	O
sufficient	O
reliability	O
,	O
our	O
procedure	O
described	O
for	O
systematic	O
mutation	O
scanning	O
is	O
also	O
capable	O
of	O
improving	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
myotonic	B-Disease
dystrophy	I-Disease
in	O
the	O
same	O
patient	O
.	O
	
we	O
report	O
on	O
the	O
first	O
patient	O
identified	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
and	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
the	O
family	O
of	O
the	O
propositus	O
had	O
a	O
strong	O
history	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
and	O
there	O
was	O
an	O
intrafamilial	O
pathological	O
expansion	O
of	O
the	O
responsible	O
ctg	O
repeat	O
between	O
the	O
mildly	O
affected	O
mother	O
(	O
160	O
repeats	O
;	O
normal	O
27	O
repeats	O
)	O
and	O
her	O
more	O
severely	O
affected	O
son	O
(	O
650	O
repeats	O
)	O
,	O
and	O
his	O
sister	O
(	O
650	O
repeats	O
)	O
.	O
	
the	O
propositus	O
was	O
an	O
isolated	O
case	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
with	O
marked	O
dystrophin	B-Disease
deficiency	I-Disease
in	O
muscle	O
biopsy	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
could	O
interfere	O
to	O
some	O
extent	O
with	O
the	O
progression	O
of	O
duchenne	B-Disease
dystrophy	I-Disease
.	O
	
twelve	O
percent	O
of	O
dystrophin	O
revertant	O
fibers	O
as	O
observed	O
by	O
immunohistochemistry	O
could	O
be	O
sufficient	O
to	O
ameliorate	O
typical	O
dmd	B-Disease
clinical	O
severity	O
,	O
or	O
the	O
patient	O
may	O
present	O
a	O
somatic	O
mosaic	O
.	O
	
age	O
at	O
diagnosis	O
as	O
an	O
indicator	O
of	O
eligibility	O
for	O
brca1	O
dna	O
testing	O
in	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
we	O
searched	O
for	O
criteria	O
that	O
could	O
indicate	O
breast	B-Disease
cancer	I-Disease
families	O
with	O
a	O
high	O
prior	O
probability	O
of	O
being	O
caused	O
by	O
the	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
locus	O
brca1	O
on	O
chromosome	O
17	O
.	O
	
to	O
this	O
end	O
,	O
we	O
performed	O
a	O
linkage	O
study	O
with	O
59	O
consecutively	O
collected	O
dutch	O
breast	B-Disease
cancer	I-Disease
families	O
,	O
including	O
16	O
with	O
at	O
least	O
one	O
case	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
we	O
used	O
an	O
intake	O
cut	O
-	O
off	O
of	O
at	O
least	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
at	O
any	O
age	O
.	O
	
significant	O
evidence	O
for	O
linkage	O
was	O
found	O
only	O
among	O
the	O
13	O
breast	B-Disease
cancer	I-Disease
families	O
with	O
a	O
mean	O
age	O
at	O
diagnosis	O
of	O
less	O
than	O
45	O
years	O
.	O
	
an	O
unexpectedly	O
low	O
proportion	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
brca1	O
,	O
which	O
could	O
be	O
due	O
to	O
a	O
founder	O
effect	O
in	O
the	O
dutch	O
population	O
.	O
	
given	O
the	O
expected	O
logistical	O
problems	O
in	O
clinical	O
management	O
now	O
that	O
brca1	O
has	O
been	O
identified	O
,	O
we	O
propose	O
an	O
interim	O
period	O
in	O
which	O
only	O
families	O
with	O
a	O
strong	O
positive	O
family	O
history	O
for	O
early	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
will	O
be	O
offered	O
brca1	O
mutation	O
testing	O
.	O
	
linkage	O
analysis	O
of	O
26	O
canadian	O
breast	B-Disease
and	I-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
we	O
have	O
examined	O
26	O
canadian	O
families	O
with	O
hereditary	B-Disease
breast	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
for	O
linkage	O
to	O
markers	O
flanking	O
the	O
brca1	O
gene	O
on	O
chromosome	O
17q12	O
-	O
q21	O
.	O
	
of	O
the	O
15	O
families	O
that	O
contain	O
cases	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
94	O
%	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
brca1	O
.	O
	
in	O
contrast	O
,	O
there	O
was	O
no	O
overall	O
evidence	O
of	O
linkage	O
in	O
the	O
group	O
of	O
10	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
without	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
a	O
genetic	O
recombinant	O
in	O
a	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
family	O
indicates	O
a	O
placement	O
of	O
brca1	O
telomeric	O
to	O
d17s776	O
,	O
and	O
helps	O
to	O
define	O
the	O
region	O
of	O
assignment	O
of	O
the	O
cancer	B-Disease
susceptibility	O
gene	O
.	O
	
other	O
cancers	B-Disease
of	O
interest	O
that	O
appeared	O
in	O
the	O
brca1	O
-	O
linked	O
families	O
included	O
primary	B-Disease
peritoneal	I-Disease
cancer	I-Disease
,	O
cancer	B-Disease
of	I-Disease
the	I-Disease
fallopian	I-Disease
tube	I-Disease
,	O
and	O
malignant	B-Disease
melanoma	I-Disease
.	O
	
structural	O
analysis	O
of	O
the	O
5	O
'	O
region	O
of	O
mouse	O
and	O
human	O
huntington	B-Disease
disease	I-Disease
genes	O
reveals	O
conservation	O
of	O
putative	O
promoter	O
region	O
and	O
di	O
-	O
and	O
trinucleotide	O
polymorphisms	O
.	O
	
we	O
have	O
previously	O
cloned	O
and	O
characterized	O
the	O
murine	O
homologue	O
of	O
the	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
gene	O
and	O
shown	O
that	O
it	O
maps	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O
	
here	O
we	O
present	O
a	O
detailed	O
comparison	O
of	O
the	O
sequence	O
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	O
of	O
the	O
5	O
genomic	O
region	O
of	O
the	O
murine	O
(	O
hdh	O
)	O
and	O
human	O
hd	B-Disease
genes	O
encompassing	O
the	O
first	O
five	O
exons	O
.	O
	
two	O
dinucleotide	O
(	O
ct	O
)	O
and	O
one	O
trinucleotide	O
intronic	O
polymorphism	O
in	O
hdh	O
and	O
an	O
intronic	O
ca	O
polymorphism	O
in	O
the	O
hd	B-Disease
gene	O
were	O
identified	O
.	O
	
comparison	O
of	O
940	O
-	O
bp	O
sequence	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
reveals	O
a	O
highly	O
conserved	O
region	O
(	O
78	O
.	O
	
8	O
%	O
nucleotide	O
identity	O
)	O
between	O
hdh	O
and	O
the	O
hd	B-Disease
gene	O
from	O
nucleotide	O
-	O
56	O
to	O
-	O
206	O
(	O
of	O
hdh	O
)	O
.	O
	
neither	O
hdh	O
nor	O
the	O
hd	B-Disease
gene	O
have	O
typical	O
tata	O
or	O
ccaat	O
elements	O
,	O
but	O
both	O
show	O
one	O
putative	O
ap2	O
binding	O
site	O
and	O
numerous	O
potential	O
sp1	O
binding	O
sites	O
.	O
	
the	O
high	O
sequence	O
identity	O
between	O
hdh	O
and	O
the	O
hd	B-Disease
gene	O
for	O
approximately	O
200	O
bp	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
the	O
huntington	B-Disease
disease	I-Disease
gene	O
the	O
protein	O
deficient	O
in	O
lowe	B-Disease
syndrome	I-Disease
is	O
a	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
5	O
-	O
phosphatase	O
.	O
	
lowe	B-Disease
syndrome	I-Disease
,	O
also	O
known	O
as	O
oculocerebrorenal	B-Disease
syndrome	I-Disease
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
x	O
chromosome	O
-	O
encoded	O
ocrl	O
gene	O
.	O
	
deficiency	O
of	O
this	O
enzyme	O
apparently	O
causes	O
the	O
protean	O
manifestations	O
of	O
lowe	B-Disease
syndrome	I-Disease
.	O
	
new	O
founder	O
haplotypes	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
in	O
southern	O
africa	O
.	O
	
the	O
association	O
between	O
normal	O
alleles	O
at	O
the	O
ctg	O
repeat	O
and	O
two	O
nearby	O
polymorphisms	O
in	O
the	O
myotonin	O
protein	O
kinase	O
gene	O
,	O
the	O
alu	O
insertion	O
/	O
deletion	O
polymorphism	O
and	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
kinase	O
(	O
dmk	O
)	O
(	O
g	O
/	O
t	O
)	O
intron	O
9	O
/	O
hinfi	O
polymorphism	O
,	O
has	O
been	O
analyzed	O
in	O
south	O
african	O
negroids	O
,	O
a	O
population	O
in	O
which	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
has	O
not	O
been	O
described	O
.	O
	
these	O
data	O
provide	O
support	O
for	O
the	O
out	O
of	O
africa	O
model	O
for	O
the	O
origin	O
of	O
modern	O
humans	O
and	O
suggest	O
that	O
the	O
rare	O
ancestral	O
dm	B-Disease
mutation	O
event	O
may	O
have	O
occurred	O
after	O
the	O
migration	O
from	O
africa	O
,	O
hence	O
the	O
absence	O
of	O
dm	B-Disease
in	O
sub	O
-	O
saharan	O
negroid	O
peoples	O
.	O
	
discordant	O
clinical	O
outcome	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
relatives	O
showing	O
(	O
ctg	O
)	O
n	O
>	O
700	O
repeats	O
.	O
	
a	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
family	O
is	O
described	O
in	O
which	O
discordant	O
dm	B-Disease
phenotypes	O
were	O
found	O
in	O
the	O
children	O
of	O
two	O
affected	O
sisters	O
with	O
similar	O
ctg	O
expansion	O
and	O
clinical	O
manifestations	O
.	O
	
in	O
this	O
family	O
,	O
congenital	O
as	O
well	O
as	O
early	O
severe	O
childhood	O
and	O
later	O
childhood	O
onset	O
dm	B-Disease
coexist	O
.	O
	
this	O
observation	O
strengthens	O
the	O
limited	O
ability	O
of	O
lymphocytes	O
ctg	O
repeat	O
number	O
analysis	O
in	O
predicting	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
dm	B-Disease
patients	O
.	O
	
the	O
seven	O
deficient	O
fibroblast	O
lines	O
were	O
characterized	O
by	O
measuring	O
acyl	O
-	O
coenzyme	O
a	O
dehydrogenation	O
activities	O
,	O
overall	O
palmitic	O
acid	O
oxidation	O
,	O
and	O
vlcad	O
protein	O
synthesis	O
using	O
pulse	O
-	O
chase	O
,	O
further	O
confirming	O
the	O
diagnosis	O
of	O
vlcad	B-Disease
deficiency	I-Disease
.	O
	
clinically	O
,	O
all	O
patients	O
with	O
vlcad	B-Disease
deficiency	I-Disease
exhibited	O
cardiac	B-Disease
disease	I-Disease
.	O
	
at	O
least	O
four	O
of	O
them	O
presented	O
with	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
.	O
	
this	O
frequency	O
(	O
>	O
57	O
%	O
)	O
was	O
much	O
higher	O
than	O
that	O
observed	O
in	O
patients	O
with	O
other	O
disorders	O
of	O
mitochondrial	O
long	O
-	O
chain	O
fatty	O
acid	O
oxidation	O
that	O
may	O
be	O
accompanied	O
by	O
cardiac	B-Disease
disease	I-Disease
in	O
infants	O
.	O
	
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
man	O
.	O
	
biological	O
properties	O
of	O
c5	B-Disease
-	I-Disease
deficient	I-Disease
human	O
serum	O
.	O
	
the	O
first	O
known	O
human	O
kindred	O
with	O
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c5	O
)	O
was	O
documented	O
in	O
the	O
accompanying	O
report	O
.	O
	
this	O
study	O
examines	O
several	O
biological	O
properties	O
of	O
c5	B-Disease
-	I-Disease
deficient	I-Disease
(	O
c5d	B-Disease
)	O
human	O
serum	O
,	O
particularly	O
sera	O
obtained	O
from	O
two	O
c5d	B-Disease
homozygotes	O
.	O
	
the	O
proband	O
,	O
who	O
has	O
inactive	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
is	O
completely	O
lacking	O
c5	O
,	O
while	O
her	O
healthy	O
half	O
-	O
sister	O
has	O
1	O
-	O
2	O
%	O
of	O
normal	O
levels	O
.	O
	
sera	O
from	O
eight	O
family	O
members	O
who	O
were	O
apparently	O
heterozygous	O
for	O
c5	B-Disease
deficiency	I-Disease
gave	O
normal	O
chemotactic	O
scores	O
.	O
	
the	O
ability	O
of	O
c5d	B-Disease
serum	O
to	O
opsonize	O
saccharomyces	O
cerevisiae	O
(	O
bakers	O
yeast	O
)	O
or	O
candida	O
albicans	O
for	O
ingestion	O
by	O
normal	O
neutrophils	O
was	O
completely	O
normal	O
.	O
	
in	O
addition	O
,	O
c5d	B-Disease
serum	O
was	O
capable	O
of	O
promoting	O
normal	O
phagocytosis	O
and	O
intracellular	O
killing	O
of	O
staphylococcus	O
aureus	O
.	O
	
the	O
probands	O
serum	O
was	O
incapable	O
of	O
mediating	O
lysis	O
of	O
erythrocytes	O
from	O
a	O
patient	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
in	O
both	O
the	O
sucrose	O
hemolysia	O
and	O
acid	O
hemolysis	O
tests	O
,	O
and	O
also	O
lacked	O
bactericidal	O
activity	O
against	O
sensitized	O
or	O
unsensitized	O
salmonella	O
typhi	O
.	O
	
human	O
peroxisomal	O
targeting	O
signal	O
-	O
1	O
receptor	O
restores	O
peroxisomal	O
protein	O
import	O
in	O
cells	O
from	O
patients	O
with	O
fatal	O
peroxisomal	B-Disease
disorders	I-Disease
.	O
	
human	O
patients	O
with	O
fatal	O
generalized	O
peroxisomal	B-Disease
deficiency	I-Disease
disorders	I-Disease
fall	O
into	O
at	O
least	O
nine	O
genetic	O
complementation	O
groups	O
.	O
	
the	O
pts1r	O
cdna	O
also	O
complements	O
the	O
pts1	B-Disease
protein	I-Disease
-	I-Disease
import	I-Disease
defect	I-Disease
in	O
skin	O
fibroblasts	O
from	O
patients	O
-	O
-	O
belonging	O
to	O
complementation	O
group	O
two	O
-	O
-	O
diagnosed	O
as	O
having	O
neonatal	B-Disease
adrenoleukodystrophy	I-Disease
or	O
zellweger	B-Disease
syndrome	I-Disease
.	O
	
the	O
pts1r	O
gene	O
has	O
been	O
localized	O
to	O
a	O
chromosomal	O
location	O
where	O
no	O
other	O
peroxisomal	B-Disease
disorder	I-Disease
genes	O
are	O
known	O
to	O
map	O
.	O
	
our	O
findings	O
represent	O
the	O
only	O
case	O
in	O
which	O
the	O
molecular	O
basis	O
of	O
the	O
protein	B-Disease
-	I-Disease
import	I-Disease
deficiency	I-Disease
in	O
human	O
peroxisomal	B-Disease
disorders	I-Disease
is	O
understood	O
.	O
	
spectrum	O
of	O
germline	O
mutations	O
in	O
the	O
rb1	O
gene	O
:	O
a	O
study	O
of	O
232	O
patients	O
with	O
hereditary	B-Disease
and	I-Disease
non	I-Disease
hereditary	I-Disease
retinoblastoma	I-Disease
.	O
	
germline	O
mutations	O
in	O
the	O
rb1	O
gene	O
confer	O
hereditary	O
predisposition	O
to	O
retinoblastoma	B-Disease
.	O
	
we	O
have	O
performed	O
a	O
mutation	O
survey	O
of	O
the	O
rb1	O
gene	O
in	O
232	O
patients	O
with	O
hereditary	B-Disease
or	I-Disease
non	I-Disease
hereditary	I-Disease
retinoblastoma	I-Disease
.	O
	
the	O
spectrum	O
of	O
mutations	O
presented	O
here	O
should	O
help	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
retinoblastoma	B-Disease
and	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
leading	O
to	O
tumorigenesis	O
.	O
	
aniridia	B-Disease
-	O
associated	O
cytogenetic	O
rearrangements	O
suggest	O
that	O
a	O
position	O
effect	O
may	O
cause	O
the	O
mutant	O
phenotype	O
.	O
	
current	O
evidence	O
suggests	O
that	O
aniridia	B-Disease
(	O
absence	B-Disease
of	I-Disease
iris	I-Disease
)	O
is	O
caused	O
by	O
loss	O
of	O
function	O
of	O
one	O
copy	O
of	O
the	O
pax6	O
gene	O
,	O
which	O
maps	O
to	O
11p13	O
.	O
	
we	O
present	O
the	O
further	O
characterisation	O
of	O
two	O
aniridia	B-Disease
pedigrees	O
in	O
which	O
the	O
disease	O
segregates	O
with	O
chromosomal	O
rearrangements	O
which	O
involve	O
11p13	O
but	O
do	O
not	O
disrupt	O
the	O
pax6	O
gene	O
.	O
	
somatic	O
mutations	O
in	O
the	O
brca1	O
gene	O
in	O
sporadic	B-Disease
ovarian	I-Disease
tumours	I-Disease
.	O
	
the	O
brca1	O
gene	O
on	O
chromosome	O
17q21	O
is	O
responsible	O
for	O
an	O
autosomal	B-Disease
dominant	I-Disease
syndrome	I-Disease
of	O
increased	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
but	O
no	O
somatic	O
mutations	O
in	O
tumours	B-Disease
have	O
yet	O
been	O
described	O
.	O
	
to	O
study	O
the	O
potential	O
role	O
of	O
brca1	O
in	O
sporadic	O
carcinogenesis	O
,	O
we	O
analysed	O
the	O
genomic	O
dna	O
of	O
tumour	B-Disease
and	O
normal	O
fractions	O
of	O
47	O
ovarian	B-Disease
cancers	I-Disease
for	O
mutations	O
in	O
brca1	O
using	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O
	
we	O
now	O
describe	O
somatic	O
mutations	O
in	O
the	O
dna	O
of	O
four	O
tumours	B-Disease
which	O
also	O
had	O
loss	O
of	O
heterozygosity	O
(	O
loh	O
)	O
at	O
a	O
brca1	O
intragenic	O
marker	O
.	O
	
our	O
data	O
support	O
a	O
tumour	B-Disease
suppressor	O
mechanism	O
for	O
brca1	O
;	O
somatic	O
mutations	O
and	O
loh	O
may	O
result	O
in	O
inactivation	O
of	O
brca1	O
in	O
at	O
least	O
a	O
small	O
number	O
of	O
ovarian	B-Disease
cancers	I-Disease
.	O
	
decreased	O
expression	O
of	O
brca1	O
accelerates	O
growth	O
and	O
is	O
often	O
present	O
during	O
sporadic	B-Disease
breast	I-Disease
cancer	I-Disease
progression	O
.	O
	
we	O
have	O
characterized	O
expression	O
of	O
the	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
,	O
brca1	O
,	O
in	O
cases	O
of	O
non	B-Disease
-	I-Disease
hereditary	I-Disease
(	I-Disease
sporadic	I-Disease
)	I-Disease
breast	I-Disease
cancer	I-Disease
and	O
analyzed	O
the	O
effect	O
of	O
antisense	O
inhibition	O
of	O
brca1	O
on	O
the	O
proliferative	O
rate	O
of	O
mammary	O
epithelial	O
cells	O
.	O
	
brca1	O
mrna	O
levels	O
are	O
markedly	O
decreased	O
during	O
the	O
transition	O
from	O
carcinoma	B-Disease
in	I-Disease
situ	I-Disease
to	O
invasive	B-Disease
cancer	I-Disease
.	O
	
these	O
studies	O
suggest	O
that	O
brca1	O
may	O
normally	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
mammary	O
epithelial	O
cell	O
growth	O
whose	O
function	O
is	O
compromised	O
in	O
breast	B-Disease
cancer	I-Disease
either	O
by	O
direct	O
mutation	O
or	O
alterations	O
in	O
gene	O
expression	O
.	O
	
additional	O
case	O
of	O
female	O
monozygotic	O
twins	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
due	O
to	O
opposite	O
x	O
-	O
chromosome	O
inactivation	O
.	O
	
a	O
pair	O
of	O
female	O
monozygotic	O
(	O
mz	O
)	O
twins	O
,	O
heterozygous	O
carriers	O
for	O
a	O
deletion	O
in	O
the	O
dmd	B-Disease
gene	O
and	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
were	O
analyzed	O
by	O
molecular	O
studies	O
,	O
in	O
situ	O
hybridization	O
,	O
and	O
methylation	O
pattern	O
of	O
x	O
chromosomes	O
to	O
search	O
for	O
opposite	O
x	O
inactivation	O
as	O
an	O
explanation	O
of	O
their	O
clinical	O
discordance	O
.	O
	
a	O
review	O
shows	O
that	O
mz	O
female	O
twins	O
discordant	O
for	O
x	B-Disease
-	I-Disease
linked	I-Disease
diseases	I-Disease
are	O
not	O
uncommon	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ald	B-Disease
)	O
:	O
a	O
novel	O
mutation	O
of	O
the	O
ald	B-Disease
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes	O
.	O
	
fragments	O
of	O
the	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
cdna	O
from	O
a	O
patient	O
with	O
adolescent	B-Disease
ald	I-Disease
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned	O
.	O
	
bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ald	B-Disease
gene	O
disclosed	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
at	O
nucleotide	O
1451	O
in	O
exon	O
five	O
,	O
resulting	O
in	O
substitution	O
of	O
proline	O
484	O
by	O
arginine	O
.	O
	
five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	O
,	O
comprising	O
two	O
cerebral	B-Disease
ald	I-Disease
,	O
one	O
adrenomyeloneuropathy	B-Disease
,	O
one	O
addison	B-Disease
only	I-Disease
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	O
long	O
chain	O
fatty	O
acids	O
)	O
carried	O
this	O
mutation	O
,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
,	O
in	O
five	O
unrelated	O
ald	B-Disease
patients	O
,	O
and	O
in	O
twenty	O
controls	O
.	O
	
novel	O
mutation	O
at	O
the	O
initiation	O
codon	O
in	O
the	O
norrie	B-Disease
disease	I-Disease
gene	O
in	O
two	O
japanese	O
families	O
.	O
	
we	O
have	O
identified	O
a	O
new	O
mutation	O
of	O
norrie	B-Disease
disease	I-Disease
(	O
nd	B-Disease
)	O
gene	O
in	O
two	O
japanese	O
males	O
from	O
unrelated	O
families	O
;	O
they	O
showed	O
typical	O
ocular	O
features	O
of	O
nd	B-Disease
but	O
no	O
mental	B-Disease
retardation	I-Disease
or	O
hearing	B-Disease
impairment	I-Disease
.	O
	
a	O
mutation	O
was	O
found	O
in	O
both	O
patients	O
at	O
the	O
initiation	O
codon	O
of	O
exon	O
2	O
of	O
the	O
nd	B-Disease
gene	O
(	O
atg	O
to	O
gtg	O
)	O
,	O
with	O
otherwise	O
normal	O
nucleotide	O
sequences	O
.	O
	
the	O
mutation	O
of	O
the	O
initiation	O
codon	O
would	O
cause	O
the	O
failure	O
of	O
nd	B-Disease
gene	O
expression	O
or	O
a	O
defect	O
in	O
translation	O
thereby	O
truncating	O
the	O
amino	O
terminus	O
of	O
nd	B-Disease
protein	O
.	O
	
in	O
view	O
of	O
the	O
rarity	O
and	O
marked	O
heterogeneity	O
of	O
mutations	O
in	O
the	O
nd	B-Disease
gene	O
,	O
the	O
present	O
apparently	O
unrelated	O
japanese	O
families	O
who	O
have	O
lived	O
in	O
the	O
same	O
area	O
for	O
over	O
two	O
centuries	O
presumably	O
share	O
the	O
origin	O
of	O
the	O
mutation	O
.	O
	
anticipation	O
resulting	O
in	O
elimination	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
gene	O
:	O
a	O
follow	O
up	O
study	O
of	O
one	O
extended	O
family	O
.	O
	
we	O
have	O
re	O
-	O
examined	O
an	O
extended	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
family	O
,	O
previously	O
described	O
in	O
1955	O
,	O
in	O
order	O
to	O
study	O
the	O
long	O
term	O
effects	O
of	O
anticipation	O
in	O
dm	B-Disease
and	O
in	O
particular	O
the	O
implications	O
for	O
families	O
affected	O
by	O
this	O
disease	O
.	O
	
clinical	O
anticipation	O
,	O
defined	O
as	O
the	O
cascade	O
of	O
mild	O
,	O
adult	O
,	O
childhood	O
,	O
or	O
congenital	B-Disease
disease	I-Disease
in	O
subsequent	O
generations	O
,	O
appeared	O
to	O
be	O
a	O
relentless	O
process	O
,	O
occurring	O
in	O
all	O
affected	O
branches	O
of	O
the	O
family	O
.	O
	
gene	O
loss	O
in	O
the	O
patient	O
group	O
was	O
complete	O
,	O
owing	O
to	O
infertility	B-Disease
of	O
the	O
male	O
patients	O
with	O
adult	O
onset	O
disease	O
and	O
the	O
fact	O
that	O
mentally	B-Disease
retarded	I-Disease
patients	O
did	O
not	O
procreate	O
.	O
	
therefore	O
it	O
is	O
highly	O
probable	O
that	O
the	O
dm	B-Disease
gene	O
will	O
be	O
eliminated	O
from	O
this	O
pedigree	O
within	O
one	O
generation	O
.	O
	
the	O
high	O
population	O
frequency	O
of	O
dm	B-Disease
can	O
at	O
present	O
not	O
be	O
explained	O
by	O
the	O
contribution	O
of	O
asymptomatic	O
cases	O
in	O
the	O
younger	O
generations	O
of	O
known	O
families	O
,	O
but	O
is	O
probably	O
caused	O
by	O
the	O
events	O
in	O
the	O
ancestral	O
generations	O
.	O
	
the	O
gene	O
for	O
spinal	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
3	O
(	O
sca3	O
)	O
is	O
located	O
in	O
a	O
region	O
of	O
approximately	O
3	O
cm	O
on	O
chromosome	O
14q24	O
.	O
3	O
-	O
q32	O
.	O
2	O
.	O
	
sca3	O
,	O
the	O
gene	O
for	O
spinal	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
3	O
,	O
was	O
recently	O
mapped	O
to	O
a	O
15	O
-	O
cm	O
interval	O
between	O
d14s67	O
and	O
d14s81	O
on	O
chromosome	O
14q	O
,	O
by	O
linkage	O
analysis	O
in	O
two	O
families	O
of	O
french	O
ancestry	O
.	O
	
2	O
containing	O
the	O
gene	O
for	O
the	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
,	O
which	O
is	O
clinically	O
related	O
to	O
the	O
phenotype	O
determined	O
by	O
sca3	O
,	O
but	O
it	O
cannot	O
yet	O
be	O
concluded	O
that	O
both	O
diseases	O
result	O
from	O
alterations	O
of	O
the	O
same	O
gene	O
an	O
evaluation	O
of	O
genetic	O
heterogeneity	O
in	O
145	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
breast	B-Disease
cancer	I-Disease
linkage	O
consortium	O
.	O
	
the	O
breast	B-Disease
-	I-Disease
ovary	I-Disease
cancer	I-Disease
-	I-Disease
family	I-Disease
syndrome	I-Disease
is	O
a	O
dominant	O
predisposition	O
to	O
cancer	B-Disease
of	I-Disease
the	I-Disease
breast	I-Disease
and	I-Disease
ovaries	I-Disease
which	O
has	O
been	O
mapped	O
to	O
chromosome	O
region	O
17q12	O
-	O
q21	O
.	O
	
the	O
majority	O
,	O
but	O
not	O
all	O
,	O
of	O
breast	B-Disease
-	I-Disease
ovary	I-Disease
cancer	I-Disease
families	O
show	O
linkage	O
to	O
this	O
susceptibility	O
locus	O
,	O
designated	O
brca1	O
.	O
	
we	O
report	O
here	O
the	O
results	O
of	O
a	O
linkage	O
analysis	O
of	O
145	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
these	O
families	O
contain	O
either	O
a	O
total	O
of	O
three	O
or	O
more	O
cases	O
of	O
early	O
-	O
onset	O
(	O
before	O
age	O
60	O
years	O
)	O
breast	B-Disease
cancer	I-Disease
or	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
all	O
families	O
contained	O
at	O
least	O
one	O
case	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
none	O
of	O
the	O
13	O
families	O
with	O
cases	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
appear	O
to	O
be	O
linked	O
,	O
but	O
it	O
is	O
estimated	O
that	O
92	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
76	O
%	O
-	O
100	O
%	O
)	O
of	O
families	O
with	O
no	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
and	O
with	O
two	O
or	O
more	O
ovarian	B-Disease
cancers	I-Disease
are	O
linked	O
to	O
brca1	O
.	O
	
these	O
data	O
suggest	O
that	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
-	I-Disease
family	I-Disease
syndrome	I-Disease
is	O
genetically	O
heterogeneous	O
.	O
	
however	O
,	O
the	O
large	O
majority	O
of	O
families	O
with	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
and	O
with	O
two	O
or	O
more	O
cases	O
of	O
ovarian	B-Disease
cancer	I-Disease
are	O
likely	O
to	O
be	O
due	O
to	O
brca1	O
mutations	O
.	O
	
molecular	O
basis	O
of	O
essential	B-Disease
fructosuria	I-Disease
:	O
molecular	O
cloning	O
and	O
mutational	O
analysis	O
of	O
human	O
ketohexokinase	O
(	O
fructokinase	O
)	O
.	O
	
essential	B-Disease
fructosuria	I-Disease
is	O
one	O
of	O
the	O
oldest	O
known	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
metabolism	I-Disease
.	O
	
it	O
is	O
a	O
benign	O
condition	O
which	O
is	O
believed	O
to	O
result	O
from	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
fructokinase	I-Disease
(	O
ketohexokinase	O
,	O
khk	O
,	O
e	O
.	O
c	O
.	O
2	O
.	O
7	O
.	O
1	O
.	O
3	O
)	O
.	O
	
despite	O
the	O
early	O
recognition	O
of	O
this	O
disorder	O
,	O
the	O
primary	O
structure	O
of	O
human	O
khk	O
and	O
the	O
molecular	O
basis	O
of	O
essential	B-Disease
fructosuria	I-Disease
have	O
not	O
been	O
previously	O
defined	O
.	O
	
direct	O
evidence	O
that	O
mutation	O
of	O
the	O
khk	O
structural	O
gene	O
is	O
the	O
cause	O
of	O
essential	B-Disease
fructosuria	I-Disease
was	O
also	O
obtained	O
.	O
	
in	O
a	O
well	O
-	O
characterized	O
family	O
,	O
in	O
which	O
three	O
of	O
eight	O
siblings	O
have	O
fructosuria	B-Disease
,	O
all	O
affected	O
individuals	O
are	O
compound	O
heterozygotes	O
for	O
two	O
mutations	O
gly40arg	O
and	O
ala43thr	O
.	O
	
homozygous	O
presence	O
of	O
the	O
crossover	O
(	O
fusion	O
gene	O
)	O
mutation	O
identified	O
in	O
a	O
type	B-Disease
ii	I-Disease
gaucher	I-Disease
disease	I-Disease
fetus	O
:	O
is	O
this	O
analogous	O
to	O
the	O
gaucher	O
knock	O
-	O
out	O
mouse	O
model	O
?	O
gaucher	B-Disease
disease	I-Disease
(	O
gd	B-Disease
)	O
is	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
beta	I-Disease
-	I-Disease
glucocerebrosidase	I-Disease
(	O
ec	O
3	O
.	O
1	O
.	O
2	O
.	O
45	O
,	O
gene	O
symbol	O
gba	O
)	O
.	O
	
in	O
type	B-Disease
i	I-Disease
gd	I-Disease
,	O
the	O
cns	O
is	O
not	O
involved	O
(	O
nonneuronopathic	O
)	O
,	O
whereas	O
in	O
type	B-Disease
ii	I-Disease
gd	I-Disease
(	O
acute	O
neuronopathic	O
)	O
cns	O
involvement	O
is	O
early	O
and	O
rapidly	O
progressive	O
,	O
while	O
in	O
type	B-Disease
iii	I-Disease
gd	I-Disease
(	O
subacute	O
neuronopathic	O
)	O
cns	O
involvement	O
occurs	O
later	O
and	O
is	O
slowly	O
progressive	O
.	O
	
the	O
t6433c	O
(	O
l444p	O
)	O
substitution	O
is	O
prevalent	O
in	O
type	B-Disease
gd	I-Disease
ii	I-Disease
.	O
	
using	O
this	O
procedure	O
we	O
demonstrated	O
the	O
fusion	O
gene	O
in	O
homozygous	O
form	O
for	O
the	O
first	O
time	O
,	O
in	O
a	O
macedonian	O
/	O
ashkenazi	O
jewish	O
gd	B-Disease
type	I-Disease
ii	I-Disease
fetus	O
.	O
	
a	O
previous	O
conceptus	O
in	O
this	O
family	O
was	O
stillborn	B-Disease
at	O
36	O
weeks	O
,	O
with	O
features	O
of	O
severe	O
type	B-Disease
ii	I-Disease
gd	I-Disease
.	O
	
late	O
infantile	O
metachromatic	B-Disease
leukodystrophy	I-Disease
in	O
israel	O
.	O
	
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
is	O
a	O
neurodegenerative	B-Disease
disease	I-Disease
in	O
which	O
the	O
lysosomal	O
enzyme	O
,	O
aryl	O
sulfatase	O
a	O
(	O
arsa	O
)	O
is	O
deficient	O
.	O
	
the	O
gene	O
of	O
arsa	O
has	O
been	O
cloned	O
and	O
up	O
to	O
now	O
eight	O
mutations	O
causing	O
mld	B-Disease
have	O
been	O
reported	O
.	O
	
in	O
israel	O
,	O
late	O
infantile	O
mld	B-Disease
was	O
found	O
to	O
be	O
very	O
frequent	O
in	O
a	O
small	O
jewish	O
isolate	O
,	O
the	O
habbanite	O
jews	O
(	O
1	O
/	O
75	O
live	O
births	O
)	O
.	O
	
mld	B-Disease
is	O
also	O
frequent	O
among	O
moslem	O
arabs	O
in	O
jerusalem	O
.	O
	
this	O
mutation	O
has	O
been	O
reported	O
in	O
patients	O
with	O
the	O
late	O
infantile	O
mld	B-Disease
from	O
different	O
ethnic	O
groups	O
.	O
	
knowledge	O
of	O
the	O
different	O
mutations	O
causing	O
mld	B-Disease
in	O
these	O
defined	O
populations	O
will	O
allow	O
a	O
carrier	O
screening	O
program	O
to	O
be	O
carried	O
out	O
and	O
prevent	O
the	O
birth	O
of	O
additional	O
affected	O
children	O
.	O
	
a	O
single	O
amino	O
acid	O
substitution	O
(	O
g103d	O
)	O
in	O
the	O
type	O
ii	O
collagen	O
triple	O
helix	O
produces	O
kniest	B-Disease
dysplasia	I-Disease
.	O
	
kniest	B-Disease
dysplasia	I-Disease
is	O
a	O
moderately	O
severe	O
chondrodysplasia	B-Disease
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
ii	O
collagen	O
,	O
col2a1	O
.	O
	
characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	B-Disease
trunk	I-Disease
and	I-Disease
extremities	I-Disease
,	O
mid	B-Disease
-	I-Disease
face	I-Disease
hypoplasia	I-Disease
,	O
cleft	B-Disease
palate	I-Disease
,	O
myopia	B-Disease
,	O
retinal	B-Disease
detachment	I-Disease
,	O
and	O
hearing	B-Disease
loss	I-Disease
.	O
	
recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
kniest	B-Disease
dysplasia	I-Disease
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
kniest	B-Disease
dysplasia	I-Disease
phenotype	O
.	O
	
we	O
used	O
sscp	O
to	O
analyze	O
an	O
amplified	O
genomic	O
dna	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
kniest	B-Disease
dysplasia	I-Disease
.	O
	
these	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
kniest	B-Disease
dysplasia	I-Disease
and	O
further	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
domain	O
,	O
which	O
includes	O
the	O
region	O
encoded	O
by	O
exon	O
12	O
,	O
in	O
the	O
type	O
ii	O
collagen	O
protein	O
leads	O
to	O
this	O
disorder	O
.	O
	
cag	O
expansions	O
in	O
a	O
novel	O
gene	O
for	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
at	O
chromosome	O
14q32	O
.	O
1	O
.	O
	
1	O
,	O
the	O
genetic	O
locus	O
for	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
mjd	B-Disease
)	O
.	O
	
in	O
normal	O
individuals	O
the	O
gene	O
contains	O
between	O
13	O
and	O
36	O
cag	O
repeats	O
,	O
whereas	O
most	O
of	O
the	O
clinically	O
diagnosed	O
patients	O
and	O
all	O
of	O
the	O
affected	O
members	O
of	O
a	O
family	O
with	O
the	O
clinical	O
and	O
pathological	O
diagnosis	O
of	O
mjd	B-Disease
show	O
expansion	O
of	O
the	O
repeat	O
-	O
number	O
(	O
from	O
68	O
-	O
79	O
)	O
.	O
	
these	O
results	O
raise	O
the	O
possibility	O
that	O
similar	O
abnormalities	O
in	O
related	O
genes	O
may	O
give	O
rise	O
to	O
diseases	O
similar	O
to	O
mjd	B-Disease
.	O
	
mutations	O
in	O
the	O
brca1	O
gene	O
in	O
families	O
with	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
we	O
analysed	O
50	O
probands	O
with	O
a	O
family	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
for	O
germline	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
brca1	O
candidate	O
gene	O
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
sscp	O
)	O
analysis	O
on	O
pcr	O
-	O
amplified	O
genomic	O
dna	O
.	O
	
these	O
data	O
are	O
consistent	O
with	O
a	O
tumour	B-Disease
suppressor	O
model	O
,	O
and	O
support	O
the	O
notion	O
that	O
this	O
candidate	O
gene	O
is	O
in	O
fact	O
brca1	O
.	O
	
confirmation	O
of	O
brca1	O
by	O
analysis	O
of	O
germline	O
mutations	O
linked	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
ten	O
families	O
.	O
	
we	O
provide	O
genetic	O
evidence	O
supporting	O
the	O
identity	O
of	O
the	O
candidate	O
gene	O
for	O
brca1	O
through	O
the	O
characterization	O
of	O
germline	O
mutations	O
in	O
63	O
breast	B-Disease
cancer	I-Disease
patients	O
and	O
10	O
ovarian	B-Disease
cancer	I-Disease
patients	O
in	O
ten	O
families	O
with	O
cancer	B-Disease
linked	O
to	O
chromosome	O
17q21	O
.	O
	
the	O
four	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
had	O
chain	O
termination	O
mutations	O
in	O
the	O
n	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
.	O
	
high	O
resolution	O
genetic	O
analysis	O
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	O
for	O
the	O
origin	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
mutation	O
.	O
	
the	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
has	O
been	O
identified	O
as	O
an	O
amplification	O
of	O
an	O
unstable	O
trinucleotide	O
(	O
ctg	O
)	O
n	O
repeat	O
in	O
over	O
99	O
%	O
of	O
the	O
global	O
dm	B-Disease
population	O
.	O
	
it	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
an	O
alu	O
element	O
polymorphism	O
within	O
the	O
dm	B-Disease
kinase	O
gene	O
,	O
suggesting	O
that	O
dm	B-Disease
is	O
a	O
consequence	O
of	O
one	O
or	O
few	O
ancestral	O
mutations	O
.	O
	
a	O
recent	O
analysis	O
utilizing	O
this	O
polymorphism	O
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	O
marker	O
,	O
suggested	O
that	O
similar	O
to	O
fragile	B-Disease
x	I-Disease
syndrome	I-Disease
,	O
dm	B-Disease
exhibited	O
a	O
founder	O
effect	O
(	O
imbert	O
et	O
al	O
.	O
,	O
1993	O
nature	O
genet	O
.	O
4	O
,	O
72	O
-	O
76	O
)	O
.	O
	
in	O
contrast	O
,	O
the	O
low	O
reproductive	O
fitness	O
of	O
individuals	O
with	O
congenital	O
dm	B-Disease
(	O
the	O
endpoint	O
of	O
genetic	O
anticipation	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
)	O
suggests	O
a	O
higher	O
rate	O
of	O
new	O
mutations	O
.	O
	
we	O
present	O
a	O
high	O
resolution	O
genetic	O
analysis	O
of	O
the	O
dm	B-Disease
locus	O
using	O
pcr	O
based	O
assays	O
of	O
nine	O
polymorphisms	O
,	O
spanning	O
a	O
physical	O
distance	O
of	O
30	O
kb	O
,	O
within	O
and	O
immediately	O
flanking	O
the	O
dm	B-Disease
kinase	O
gene	O
.	O
	
the	O
persistent	O
complete	O
allelic	O
association	O
of	O
the	O
dm	B-Disease
mutation	O
with	O
all	O
these	O
polymorphisms	O
provides	O
further	O
support	O
to	O
previous	O
observations	O
and	O
suggests	O
more	O
strongly	O
that	O
the	O
dm	B-Disease
mutation	O
occurred	O
on	O
the	O
background	O
of	O
a	O
particular	O
haplotype	O
in	O
which	O
the	O
(	O
ctg	O
)	O
n	O
repeat	O
became	O
inherently	O
unstable	O
and	O
therefore	O
predisposed	O
to	O
amplification	O
.	O
	
genetic	O
instability	O
in	O
human	O
ovarian	B-Disease
cancer	I-Disease
cell	O
lines	O
.	O
	
we	O
have	O
analyzed	O
the	O
stability	O
of	O
microsatellites	O
in	O
cell	O
lines	O
derived	O
from	O
human	O
ovarian	B-Disease
cancers	I-Disease
and	O
found	O
that	O
5	O
out	O
of	O
10	O
of	O
the	O
ovarian	B-Disease
tumor	I-Disease
cell	O
lines	O
are	O
genetically	O
unstable	O
at	O
the	O
majority	O
of	O
the	O
loci	O
analyzed	O
.	O
	
in	O
clones	O
and	O
subclones	O
derived	O
serially	O
from	O
one	O
of	O
these	O
cell	O
lines	O
(	O
2774	O
;	O
serous	B-Disease
cystadenocarcinoma	I-Disease
)	O
,	O
a	O
very	O
high	O
proportion	O
of	O
microsatellites	O
distributed	O
in	O
many	O
different	O
regions	O
of	O
the	O
genome	O
change	O
their	O
size	O
in	O
a	O
mercurial	O
fashion	O
.	O
	
we	O
conclude	O
that	O
genomic	O
instability	O
in	O
ovarian	B-Disease
tumors	I-Disease
is	O
a	O
dynamic	O
and	O
ongoing	O
process	O
whose	O
high	O
frequency	O
may	O
have	O
been	O
previously	O
underestimated	O
by	O
pcr	O
-	O
based	O
allelotyping	O
of	O
bulk	O
tumor	B-Disease
tissue	O
.	O
	
we	O
have	O
identified	O
the	O
source	O
of	O
the	O
genetic	O
instability	O
in	O
one	O
ovarian	B-Disease
tumor	I-Disease
as	O
a	O
point	O
mutation	O
(	O
r524p	O
)	O
in	O
the	O
human	O
mismatch	O
-	O
repair	O
gene	O
msh2	O
(	O
salmonella	O
muts	O
homologue	O
)	O
,	O
which	O
has	O
recently	O
been	O
shown	O
to	O
be	O
involved	O
in	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
however	O
the	O
wild	O
-	O
type	O
allele	O
was	O
lost	O
at	O
some	O
point	O
early	O
during	O
tumorigenesis	O
so	O
that	O
dna	O
isolated	O
either	O
from	O
the	O
patients	O
ovarian	B-Disease
tumor	I-Disease
or	O
from	O
the	O
2774	O
cell	O
line	O
carries	O
only	O
the	O
mutant	O
allele	O
of	O
the	O
human	O
msh2	O
gene	O
.	O
	
the	O
genetic	O
instability	O
observed	O
in	O
the	O
tumor	B-Disease
and	O
cell	O
line	O
dna	O
,	O
together	O
with	O
the	O
germ	O
-	O
line	O
mutation	O
in	O
a	O
mismatch	O
-	O
repair	O
gene	O
,	O
suggest	O
that	O
the	O
msh2	O
gene	O
is	O
involved	O
in	O
the	O
onset	O
and	O
/	O
or	O
progression	O
in	O
a	O
subset	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
brca1	O
mutations	O
in	O
primary	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
carcinomas	I-Disease
.	O
	
loss	O
of	O
heterozygosity	O
data	O
from	O
familial	B-Disease
tumors	I-Disease
suggest	O
that	O
brca1	O
,	O
a	O
gene	O
that	O
confers	O
susceptibility	O
to	O
ovarian	B-Disease
and	I-Disease
early	I-Disease
-	I-Disease
onset	I-Disease
breast	B-Disease
cancer	I-Disease
,	O
encodes	O
a	O
tumor	B-Disease
suppressor	O
.	O
	
the	O
brca1	O
region	O
is	O
also	O
subject	O
to	O
allelic	O
loss	O
in	O
sporadic	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
an	O
indication	O
that	O
brca1	O
mutations	O
may	O
occur	O
somatically	O
in	O
these	O
tumors	B-Disease
.	O
	
the	O
brca1	O
coding	O
region	O
was	O
examined	O
for	O
mutations	O
in	O
primary	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
tumors	I-Disease
that	O
show	O
allele	O
loss	O
at	O
the	O
brca1	O
locus	O
.	O
	
mutations	O
were	O
detected	O
in	O
3	O
of	O
32	O
breast	O
and	O
1	O
of	O
12	O
ovarian	B-Disease
carcinomas	I-Disease
;	O
all	O
four	O
mutations	O
were	O
germline	O
alterations	O
and	O
occurred	O
in	O
early	O
-	O
onset	O
cancers	B-Disease
.	O
	
these	O
results	O
suggest	O
that	O
mutation	O
of	O
brca1	O
may	O
not	O
be	O
critical	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
that	O
arise	O
in	O
the	O
absence	O
of	O
a	O
mutant	O
germline	O
allele	O
.	O
	
pax6	O
gene	O
dosage	O
effect	O
in	O
a	O
family	O
with	O
congenital	B-Disease
cataracts	I-Disease
,	O
aniridia	B-Disease
,	O
anophthalmia	B-Disease
and	O
central	B-Disease
nervous	I-Disease
system	I-Disease
defects	I-Disease
.	O
	
the	O
human	O
eye	O
malformation	O
aniridia	B-Disease
results	O
from	O
haploinsufficiency	B-Disease
of	I-Disease
pax6	I-Disease
,	O
a	O
paired	O
box	O
dna	O
-	O
binding	O
protein	O
.	O
	
to	O
study	O
this	O
dosage	O
effect	O
,	O
we	O
characterized	O
two	O
pax6	O
mutations	O
in	O
a	O
family	O
segregating	O
aniridia	B-Disease
and	O
a	O
milder	O
syndrome	O
consisting	O
of	O
congenital	B-Disease
cataracts	I-Disease
and	O
late	O
onset	O
corneal	B-Disease
dystrophy	I-Disease
.	O
	
a	O
compound	O
heterozygote	O
had	O
severe	O
craniofacial	B-Disease
and	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
defects	I-Disease
and	O
no	B-Disease
eyes	I-Disease
.	O
	
we	O
have	O
constructed	O
a	O
physical	O
map	O
of	O
a	O
4	O
cm	O
region	O
on	O
chromosome	O
17q12	O
-	O
21	O
that	O
contains	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
brca1	O
.	O
	
two	O
genes	O
that	O
lie	O
within	O
a	O
narrow	O
region	O
defined	O
by	O
meiotic	O
breakpoints	O
in	O
brca1	O
patients	O
have	O
been	O
sequenced	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
without	O
revealing	O
any	O
deleterious	O
mutations	O
.	O
	
the	O
lec	O
rat	O
has	O
a	O
deletion	O
in	O
the	O
copper	O
transporting	O
atpase	O
gene	O
homologous	O
to	O
the	O
wilson	B-Disease
disease	I-Disease
gene	O
.	O
	
the	O
long	O
-	O
evans	O
cinnamon	O
(	O
lec	O
)	O
rat	O
shows	O
similarity	O
to	O
wilson	B-Disease
disease	I-Disease
in	O
many	O
clinical	O
and	O
biochemical	O
features	O
.	O
	
we	O
have	O
cloned	O
cdnas	O
for	O
the	O
rat	O
gene	O
(	O
atp7b	O
)	O
homologous	O
to	O
the	O
human	O
wilson	B-Disease
disease	I-Disease
gene	O
(	O
atp7b	O
)	O
and	O
have	O
used	O
them	O
to	O
identify	O
a	O
partial	O
deletion	O
in	O
the	O
atp7b	O
gene	O
in	O
the	O
lec	O
rat	O
.	O
	
our	O
results	O
provide	O
convincing	O
evidence	O
for	O
defining	O
the	O
lec	O
rat	O
as	O
an	O
animal	O
model	O
for	O
wilson	B-Disease
disease	I-Disease
.	O
	
this	O
model	O
will	O
be	O
important	O
for	O
studying	O
liver	O
pathophysiology	O
,	O
for	O
developing	O
therapy	O
for	O
wilson	B-Disease
disease	I-Disease
and	O
for	O
studying	O
the	O
pathway	O
of	O
copper	O
transport	O
and	O
its	O
possible	O
interaction	O
with	O
other	O
heavy	O
metals	O
.	O
	
genomic	O
organization	O
of	O
the	O
adrenoleukodystrophy	B-Disease
gene	O
.	O
	
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
,	O
the	O
most	O
frequent	O
peroxisomal	B-Disease
disorder	I-Disease
,	O
is	O
a	O
severe	O
neurodegenerative	B-Disease
disease	I-Disease
associated	O
with	O
an	O
impairment	B-Disease
of	I-Disease
very	I-Disease
long	I-Disease
chain	I-Disease
fatty	I-Disease
acids	I-Disease
beta	I-Disease
-	I-Disease
oxidation	I-Disease
.	O
	
we	O
have	O
recently	O
identified	O
by	O
positional	O
cloning	O
the	O
gene	O
responsible	O
for	O
ald	B-Disease
,	O
located	O
in	O
xq28	O
.	O
	
we	O
report	O
here	O
a	O
detailed	O
characterization	O
of	O
the	O
ald	B-Disease
gene	O
structure	O
.	O
	
to	O
facilitate	O
the	O
detection	O
of	O
mutations	O
in	O
ald	B-Disease
patients	O
,	O
we	O
have	O
determined	O
the	O
intronic	O
sequences	O
flanking	O
the	O
exons	O
as	O
well	O
as	O
the	O
sequence	O
of	O
the	O
3	O
untranslated	O
region	O
and	O
of	O
the	O
immediate	O
5	O
promoter	O
region	O
.	O
	
the	O
ald	B-Disease
gene	O
has	O
been	O
positioned	O
on	O
a	O
pulsed	O
-	O
field	O
map	O
between	O
dxs15	O
and	O
the	O
l1cam	O
gene	O
,	O
about	O
650	O
kb	O
upstream	O
from	O
the	O
color	O
pigment	O
genes	O
.	O
	
the	O
frequent	O
occurrence	O
of	O
color	O
vision	O
anomalies	O
observed	O
in	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
(	O
the	O
adult	O
onset	O
form	O
of	O
ald	B-Disease
)	O
thus	O
does	O
not	O
represent	O
a	O
contiguous	B-Disease
gene	I-Disease
syndrome	I-Disease
but	O
a	O
secondary	O
manifestation	O
of	O
ald	B-Disease
.	O
	
the	O
murine	O
homologues	O
of	O
the	O
huntington	B-Disease
disease	I-Disease
gene	O
(	O
hdh	O
)	O
and	O
the	O
alpha	O
-	O
adducin	O
gene	O
(	O
add1	O
)	O
map	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O
3	O
.	O
	
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
is	O
a	O
severe	O
autosomal	B-Disease
dominant	I-Disease
neurodegenerative	I-Disease
disorder	I-Disease
associated	O
with	O
a	O
novel	O
gene	O
(	O
it15	O
)	O
.	O
	
genetic	O
cholesteryl	B-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
deficiency	I-Disease
caused	O
by	O
two	O
prevalent	O
mutations	O
as	O
a	O
major	O
determinant	O
of	O
increased	O
levels	O
of	O
high	O
density	O
lipoprotein	O
cholesterol	O
.	O
	
we	O
previously	O
described	O
plasma	O
cholesteryl	B-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
(	I-Disease
cetp	I-Disease
)	I-Disease
deficiency	I-Disease
due	O
to	O
an	O
intron	O
14	O
g	O
(	O
+	O
1	O
)	O
-	O
to	O
-	O
a	O
mutation	O
(	O
int14	O
a	O
)	O
in	O
several	O
families	O
with	O
very	O
high	O
hdl	O
-	O
c	O
levels	O
in	O
japan	O
.	O
	
cetp	B-Disease
deficiency	I-Disease
,	O
reflecting	O
two	O
prevalent	O
mutations	O
(	O
d442g	O
and	O
int14	O
a	O
)	O
,	O
is	O
the	O
first	O
example	O
of	O
a	O
genetic	B-Disease
deficiency	I-Disease
state	O
which	O
is	O
sufficiently	O
common	O
to	O
explain	O
a	O
significant	O
fraction	O
of	O
the	O
variation	O
in	O
hdl	O
-	O
c	O
in	O
the	O
general	O
population	O
.	O
	
treatment	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
:	O
effects	O
of	O
chenodeoxycholic	O
acid	O
,	O
pravastatin	O
,	O
and	O
combined	O
use	O
.	O
	
treatments	O
by	O
oral	O
administration	O
of	O
chenodeoxycholic	O
acid	O
(	O
cdca	O
)	O
alone	O
,	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
(	O
hmg	O
)	O
coa	O
reductase	O
inhibitor	O
(	O
pravastatin	O
)	O
alone	O
,	O
and	O
combination	O
of	O
the	O
two	O
drugs	O
were	O
attempted	O
for	O
7	O
patients	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
.	O
	
the	O
combination	O
of	O
cdca	O
and	O
pravastatin	O
was	O
a	O
good	O
treatment	O
for	O
ctx	B-Disease
,	O
based	O
on	O
the	O
improvement	O
of	O
serum	O
lipoprotein	O
metabolism	O
,	O
the	O
suppression	O
of	O
cholesterol	O
synthesis	O
,	O
and	O
reductions	O
of	O
cholestanol	O
and	O
plant	O
sterol	O
levels	O
.	O
	
in	O
all	O
of	O
7	O
patients	O
,	O
the	O
progression	O
of	O
disease	O
was	O
arrested	O
,	O
but	O
dramatic	O
effects	O
on	O
clinical	O
manifestations	O
,	O
xanthoma	B-Disease
,	O
and	O
electrophysiological	O
findings	O
could	O
not	O
be	O
found	O
after	O
the	O
treatment	O
of	O
these	O
drugs	O
mutation	O
spectrum	O
in	O
the	O
chm	B-Disease
gene	O
of	O
danish	O
and	O
swedish	O
choroideremia	B-Disease
patients	O
.	O
	
the	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	B-Disease
(	O
chm	B-Disease
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	B-Disease
.	O
	
causative	O
mutations	O
in	O
the	O
chm	B-Disease
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families	O
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach	O
.	O
	
thus	O
,	O
in	O
one	O
patient	O
,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon	O
,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
chm	B-Disease
gene	O
.	O
	
interestingly	O
,	O
all	O
chm	B-Disease
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	B-Disease
patients	O
give	O
rise	O
to	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
codon	O
.	O
	
predominance	O
of	O
the	O
adrenomyeloneuropathy	B-Disease
phenotype	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
in	O
the	O
netherlands	O
:	O
a	O
survey	O
of	O
30	O
kindreds	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
x	B-Disease
-	I-Disease
ald	I-Disease
)	O
is	O
an	O
inherited	B-Disease
disorder	I-Disease
of	O
peroxisomal	O
beta	O
-	O
oxidation	O
associated	O
with	O
accumulation	O
of	O
saturated	O
very	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
results	O
in	O
central	O
and	O
peripheral	O
demyelination	B-Disease
and	O
in	O
impaired	B-Disease
function	I-Disease
of	I-Disease
adrenal	I-Disease
cortex	I-Disease
and	I-Disease
testes	I-Disease
.	O
	
the	O
phenotypic	O
expression	O
is	O
highly	O
variable	O
,	O
childhood	B-Disease
cerebral	I-Disease
ald	I-Disease
(	O
ccald	B-Disease
)	O
and	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
being	O
the	O
main	O
variants	O
.	O
	
we	O
explored	O
the	O
30	O
dutch	O
kindreds	O
well	O
known	O
to	O
the	O
dutch	O
x	B-Disease
-	I-Disease
ald	I-Disease
/	O
amn	B-Disease
study	O
group	O
and	O
phenotyped	O
77	O
male	O
patients	O
35	O
(	O
46	O
%	O
)	O
had	O
amn	B-Disease
and	O
24	O
(	O
31	O
%	O
)	O
ccald	B-Disease
or	O
adolescent	B-Disease
cerebral	I-Disease
ald	I-Disease
(	O
adolcald	B-Disease
)	O
.	O
	
these	O
percentages	O
differ	O
significantly	O
from	O
previous	O
reports	O
,	O
in	O
which	O
25	O
to	O
28	O
%	O
of	O
the	O
patients	O
developed	O
amn	B-Disease
and	O
53	O
to	O
57	O
%	O
ccald	B-Disease
or	O
adolcald	B-Disease
.	O
	
our	O
findings	O
indicate	O
that	O
-	O
-	O
at	O
least	O
in	O
the	O
netherlands	O
-	O
-	O
amn	B-Disease
may	O
be	O
the	O
most	O
frequent	O
phenotype	O
of	O
x	B-Disease
-	I-Disease
ald	I-Disease
.	O
	
adrenoleukodystrophy	B-Disease
gene	O
encodes	O
an	O
80	O
kda	O
membrane	O
protein	O
.	O
	
an	O
antibody	O
against	O
the	O
synthetic	O
c	O
-	O
terminal	O
peptides	O
deduced	O
from	O
the	O
cdna	O
of	O
the	O
gene	O
responsible	O
for	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ald	B-Disease
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ald	B-Disease
gene	O
.	O
	
the	O
antibody	O
reacted	O
with	O
the	O
80	O
kda	O
band	O
protein	O
in	O
control	O
fibroblasts	O
,	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	O
with	O
ald	B-Disease
(	O
#	O
163	O
)	O
,	O
in	O
which	O
mrna	O
of	O
the	O
ald	B-Disease
gene	O
was	O
undetectable	O
based	O
on	O
northern	O
blot	O
analysis	O
.	O
	
these	O
data	O
thus	O
indicate	O
that	O
the	O
ald	B-Disease
gene	O
encodes	O
an	O
80	O
kda	O
membrane	O
protein	O
.	O
	
isolation	O
of	O
the	O
gene	O
for	O
mcleod	B-Disease
syndrome	I-Disease
that	O
encodes	O
a	O
novel	O
membrane	O
transport	O
protein	O
.	O
	
mcleod	B-Disease
syndrome	I-Disease
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
multisystem	I-Disease
disorder	I-Disease
characterized	O
by	O
abnormalities	O
in	O
the	O
neuromuscular	O
and	O
hematopoietic	O
systems	O
.	O
	
we	O
have	O
assembled	O
a	O
cosmid	O
contig	O
of	O
360	O
kb	O
that	O
encompasses	O
the	O
mcleod	B-Disease
gene	O
locus	O
.	O
	
the	O
mrna	O
expression	O
pattern	O
of	O
one	O
of	O
them	O
,	O
designated	O
as	O
xk	O
,	O
correlates	O
closely	O
to	O
the	O
mcleod	B-Disease
phenotype	O
.	O
	
nucleotide	O
sequence	O
analysis	O
of	O
xk	O
from	O
two	O
unrelated	O
mcleod	B-Disease
patients	O
has	O
identified	O
point	O
mutations	O
at	O
conserved	O
splice	O
donor	O
and	O
acceptor	O
sites	O
.	O
	
these	O
findings	O
provide	O
direct	O
evidence	O
that	O
xk	O
is	O
responsible	O
for	O
mcleod	B-Disease
syndrome	I-Disease
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
spastic	I-Disease
paraplegia	I-Disease
and	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
are	O
allelic	B-Disease
disorders	I-Disease
at	O
the	O
proteolipid	O
protein	O
locus	O
.	O
	
three	O
forms	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
spastic	I-Disease
paraplegia	I-Disease
(	O
spg	B-Disease
)	O
have	O
been	O
defined	O
.	O
	
a	O
rare	O
x	B-Disease
-	I-Disease
linked	I-Disease
dysmyelinating	I-Disease
disorder	I-Disease
of	O
the	O
central	O
nervous	O
system	O
,	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
,	O
has	O
also	O
been	O
mapped	O
to	O
xq21	O
-	O
q22	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(	O
plp	O
)	O
which	O
encodes	O
two	O
myelin	O
proteins	O
,	O
plp	O
and	O
dm20	O
.	O
	
it	O
appears	O
,	O
therefore	O
,	O
that	O
spg2	O
and	O
pmd	B-Disease
are	O
allelic	B-Disease
disorders	I-Disease
canavan	B-Disease
disease	I-Disease
:	O
mutations	O
among	O
jewish	O
and	O
non	O
-	O
jewish	O
patients	O
.	O
	
canavan	B-Disease
disease	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
leukodystrophy	I-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
aspartoacylase	I-Disease
(	O
aspa	O
)	O
.	O
	
of	O
the	O
128	O
unrelated	O
canavan	B-Disease
chromosomes	O
analyzed	O
,	O
88	O
were	O
from	O
probands	O
of	O
ashkenazi	O
jewish	O
descent	O
.	O
	
8	O
%	O
of	O
the	O
canavan	B-Disease
chromosomes	O
of	O
ashkenazi	O
jewish	O
origin	O
.	O
	
predominant	O
occurrence	O
of	O
certain	O
mutations	O
among	O
ashkenazi	O
jewish	O
and	O
non	O
-	O
jewish	O
patients	O
with	O
canavan	B-Disease
disease	I-Disease
would	O
suggest	O
a	O
founding	O
-	O
father	O
effect	O
in	O
propagation	O
of	O
these	O
mutant	O
chromosomes	O
intelligence	O
quotient	O
profile	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
intergenerational	O
deficit	O
,	O
and	O
correlation	O
with	O
ctg	O
amplification	O
.	O
	
an	O
abbreviated	O
wechsler	O
adult	O
intelligence	O
scale	O
revised	O
(	O
wais	O
-	O
r	O
)	O
was	O
used	O
to	O
assess	O
verbal	O
and	O
arithmetical	O
cognitive	O
performance	O
in	O
55	O
subjects	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
,	O
covering	O
all	O
grades	O
of	O
disease	O
severity	O
,	O
and	O
31	O
controls	O
at	O
50	O
%	O
risk	O
of	O
inheriting	O
dm	B-Disease
.	O
	
significant	O
iq	O
differences	O
were	O
found	O
between	O
(	O
1	O
)	O
all	O
55	O
dm	B-Disease
subjects	O
(	O
mean	O
90	O
.	O
2	O
,	O
sd	O
16	O
.	O
1	O
)	O
and	O
31	O
controls	O
(	O
102	O
.	O
6	O
,	O
sd	O
9	O
.	O
4	O
)	O
,	O
with	O
no	O
sex	O
differences	O
in	O
either	O
group	O
;	O
(	O
2	O
)	O
15	O
affected	O
parents	O
(	O
99	O
.	O
3	O
,	O
sd	O
12	O
.	O
2	O
)	O
and	O
their	O
affected	O
children	O
(	O
88	O
.	O
1	O
,	O
sd	O
17	O
.	O
2	O
)	O
,	O
where	O
significance	O
was	O
dependent	O
on	O
parental	O
sex	O
being	O
female	O
;	O
and	O
(	O
3	O
)	O
15	O
pairs	O
of	O
affected	O
sibs	O
(	O
89	O
.	O
6	O
,	O
sd	O
13	O
.	O
2	O
)	O
and	O
their	O
normal	O
sibs	O
(	O
100	O
.	O
2	O
,	O
sd	O
7	O
.	O
6	O
)	O
.	O
	
the	O
correlation	O
of	O
iq	O
difference	O
and	O
ctg	O
expansion	O
difference	O
in	O
both	O
the	O
dm	B-Disease
parent	O
-	O
child	O
pairs	O
and	O
normal	O
sib	O
-	O
affected	O
sib	O
pairs	O
was	O
poor	O
,	O
indicating	O
that	O
ctg	O
expansion	O
is	O
not	O
a	O
reliable	O
predictor	O
of	O
iq	O
either	O
in	O
individual	O
persons	O
or	O
families	O
.	O
	
further	O
analysis	O
of	O
cognitive	O
function	O
in	O
dm	B-Disease
is	O
required	O
to	O
clarify	O
specific	O
deficits	O
characteristic	O
of	O
this	O
patient	O
group	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
and	O
a	O
cytogenetic	O
deletion	O
of	O
chromosome	O
5	O
resulting	O
from	O
a	O
maternal	O
intrachromosomal	O
insertion	O
.	O
	
we	O
present	O
the	O
clinical	O
and	O
laboratory	O
findings	O
in	O
an	O
institutionalised	O
adult	O
patient	O
originally	O
referred	O
for	O
autism	B-Disease
.	O
	
a	O
high	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
predicted	O
when	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
,	O
del	O
(	O
5	O
)	O
(	O
q15q22	O
.	O
	
3	O
)	O
,	O
was	O
detected	O
in	O
her	O
lymphocytes	O
and	O
deletion	O
of	O
the	O
mcc	O
and	O
apc	B-Disease
genes	O
confirmed	O
by	O
molecular	O
analysis	O
.	O
	
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
and	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
rectum	I-Disease
were	O
subsequently	O
diagnosed	O
in	O
the	O
patient	O
.	O
	
she	O
was	O
profoundly	O
mentally	B-Disease
retarded	I-Disease
,	O
autistic	B-Disease
,	O
and	O
had	O
minor	O
dysmorphic	B-Disease
features	I-Disease
consistent	O
with	O
those	O
of	O
previous	O
patients	O
with	O
similar	O
deletions	O
.	O
	
this	O
family	O
further	O
confirms	O
the	O
cytogenetic	O
mapping	O
of	O
both	O
mcc	O
and	O
apc	B-Disease
genes	O
to	O
5q22	O
and	O
comparison	O
with	O
other	O
recent	O
cases	O
suggests	O
that	O
both	O
genes	O
and	O
their	O
closely	O
linked	O
markers	O
lie	O
within	O
the	O
5q22	O
.	O
	
familial	B-Disease
male	I-Disease
breast	I-Disease
cancer	I-Disease
is	O
not	O
linked	O
to	O
the	O
brca1	O
locus	O
on	O
chromosome	O
17q	O
.	O
	
breast	B-Disease
cancer	I-Disease
in	O
men	O
is	O
about	O
a	O
hundredfold	O
less	O
common	O
than	O
in	O
women	O
and	O
this	O
has	O
hindered	O
research	O
into	O
its	O
genetic	O
basis	O
.	O
	
we	O
have	O
examined	O
22	O
families	O
with	O
at	O
least	O
one	O
case	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
for	O
linkage	O
to	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
locus	O
,	O
brca1	O
,	O
on	O
chromosome	O
17q	O
.	O
	
our	O
results	O
indicate	O
that	O
there	O
is	O
a	O
gene	O
(	O
s	O
)	O
other	O
than	O
brca1	O
which	O
predisposes	O
to	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
in	O
women	O
and	O
which	O
confers	O
a	O
higher	O
risk	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
identification	O
of	O
additional	O
pedigrees	O
that	O
include	O
cases	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
may	O
therefore	O
facilitate	O
the	O
mapping	O
and	O
isolation	O
of	O
this	O
gene	O
.	O
	
the	O
ews	O
gene	O
,	O
involved	O
in	O
ewing	B-Disease
family	I-Disease
of	I-Disease
tumors	I-Disease
,	O
malignant	B-Disease
melanoma	I-Disease
of	I-Disease
soft	I-Disease
parts	I-Disease
and	O
desmoplastic	B-Disease
small	I-Disease
round	I-Disease
cell	I-Disease
tumors	I-Disease
,	O
codes	O
for	O
an	O
rna	O
binding	O
protein	O
with	O
novel	O
regulatory	O
domains	O
.	O
	
the	O
ews	O
gene	O
,	O
which	O
maps	O
to	O
band	O
q12	O
of	O
human	O
chromosome	O
22	O
,	O
is	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
human	O
solid	B-Disease
tumors	I-Disease
including	O
ewing	B-Disease
sarcoma	I-Disease
,	O
related	O
primitive	O
neuroectodermal	B-Disease
tumors	I-Disease
,	O
malignant	B-Disease
melanoma	I-Disease
of	I-Disease
soft	I-Disease
parts	I-Disease
and	O
desmoplastic	B-Disease
small	I-Disease
round	I-Disease
cell	I-Disease
tumors	I-Disease
.	O
	
in	O
these	O
tumors	B-Disease
,	O
the	O
ews	O
is	O
fused	O
to	O
genes	O
encoding	O
transcriptional	O
activators	O
/	O
repressors	O
,	O
like	O
fli	O
-	O
1	O
or	O
erg	O
or	O
atf	O
1	O
or	O
wt1	O
.	O
	
an	O
ews	O
-	O
erg	O
chimeric	O
protein	O
,	O
which	O
is	O
found	O
in	O
ewings	B-Disease
sarcoma	I-Disease
cells	O
,	O
functions	O
as	O
a	O
transcriptional	O
activator	O
.	O
	
canavan	B-Disease
disease	I-Disease
:	O
genomic	O
organization	O
and	O
localization	O
of	O
human	O
aspa	O
to	O
17p13	O
-	O
ter	O
and	O
conservation	O
of	O
the	O
aspa	O
gene	O
during	O
evolution	O
.	O
	
canavan	B-Disease
disease	I-Disease
,	O
or	O
spongy	B-Disease
degeneration	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
,	O
is	O
a	O
severe	O
leukodystrophy	B-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
aspartoacylase	I-Disease
(	O
aspa	O
)	O
.	O
	
recently	O
,	O
a	O
missense	O
mutation	O
was	O
identified	O
in	O
human	O
aspa	O
coding	O
sequence	O
from	O
patients	O
with	O
canavan	B-Disease
disease	I-Disease
.	O
	
it	O
should	O
now	O
be	O
possible	O
to	O
identify	O
mutations	O
in	O
the	O
noncoding	O
genomic	O
sequences	O
that	O
lead	O
to	O
canavan	B-Disease
disease	I-Disease
and	O
to	O
study	O
the	O
regulation	O
of	O
aspa	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
:	O
size	O
-	O
and	O
sex	O
-	O
dependent	O
dynamics	O
of	O
ctg	O
meiotic	O
instability	O
,	O
and	O
somatic	O
mosaicism	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
a	O
progressive	O
neuromuscular	B-Disease
disorder	I-Disease
which	O
results	O
from	O
elongations	O
of	O
an	O
unstable	O
(	O
ctg	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
dm	B-Disease
gene	O
.	O
	
our	O
observation	O
of	O
differently	O
sized	O
repeats	O
in	O
various	O
dm	B-Disease
tissues	O
from	O
the	O
same	O
individual	O
may	O
explain	O
why	O
the	O
size	O
of	O
the	O
mutation	O
observed	O
in	O
lymphocytes	O
does	O
not	O
necessarily	O
correlate	O
with	O
the	O
severity	O
and	O
nature	O
of	O
symptoms	O
.	O
	
through	O
a	O
molecular	O
and	O
genetic	O
study	O
of	O
142	O
families	O
including	O
418	O
dm	B-Disease
patients	O
,	O
we	O
have	O
investigated	O
the	O
dynamics	O
of	O
the	O
ctg	O
repeat	O
meiotic	O
instability	O
.	O
	
illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
lymphocytes	O
for	O
identification	O
of	O
mutations	O
in	O
phenylketonuria	B-Disease
.	O
	
taking	O
advantage	O
of	O
the	O
illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
gene	O
,	O
we	O
have	O
been	O
able	O
to	O
analyse	O
the	O
pah	O
cdna	O
sequence	O
of	O
hyperphenylalaninemic	B-Disease
children	O
in	O
circulating	O
lymphocytes	O
.	O
	
the	O
present	O
study	O
supports	O
the	O
view	O
that	O
circulating	O
lymphocytes	O
give	O
easy	O
access	O
to	O
pah	O
gene	O
transcripts	O
whose	O
nucleotide	O
sequence	O
is	O
identical	O
to	O
that	O
reported	O
in	O
liver	O
and	O
therefore	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	O
genetic	O
studies	O
in	O
phenylketonuria	B-Disease
.	O
	
high	O
residual	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
activity	O
in	O
a	O
patient	O
with	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
.	O
	
we	O
identified	O
a	O
patient	O
suffering	O
from	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
who	O
has	O
a	O
residual	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
activity	O
of	O
about	O
10	O
%	O
.	O
	
fibroblasts	O
of	O
the	O
patient	O
show	O
significant	O
sulfatide	O
degradation	O
activity	O
exceeding	O
that	O
of	O
adult	B-Disease
mld	I-Disease
patients	O
.	O
	
these	O
findings	O
are	O
in	O
contrast	O
to	O
previous	O
results	O
showing	O
that	O
the	O
late	B-Disease
-	I-Disease
infantile	I-Disease
type	I-Disease
of	I-Disease
mld	I-Disease
is	O
always	O
associated	O
with	O
the	O
complete	O
absence	O
of	O
arsa	O
activity	O
.	O
	
an	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
missense	O
mutation	O
(	O
t274m	O
)	O
causing	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
.	O
	
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
arylsulfatase	I-Disease
a	I-Disease
(	O
arsa	O
;	O
ec	O
3	O
.	O
1	O
.	O
6	O
.	O
8	O
)	O
.	O
	
the	O
8	O
arsa	O
exons	O
and	O
adjacent	O
intron	O
boundaries	O
from	O
a	O
patient	O
with	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
were	O
polymerase	O
chain	O
reaction	O
(	O
pcr	O
)	O
amplified	O
in	O
seven	O
discrete	O
reactions	O
.	O
	
analysis	O
of	O
a	O
further	O
29	O
mld	B-Disease
patients	O
revealed	O
the	O
presence	O
of	O
five	O
additional	O
homozygotes	O
for	O
t274m	O
.	O
	
mutations	O
in	O
the	O
pax6	O
gene	O
in	O
patients	O
with	O
hereditary	O
aniridia	B-Disease
.	O
	
the	O
14	O
exons	O
of	O
the	O
pax6	O
gene	O
have	O
been	O
analysed	O
exon	O
-	O
by	O
-	O
exon	O
using	O
sscp	O
in	O
6	O
aniridia	B-Disease
families	O
.	O
	
this	O
data	O
strongly	O
supports	O
the	O
candidature	O
of	O
pax6	O
as	O
the	O
gene	O
responsible	O
for	O
hereditary	O
aniridia	B-Disease
.	O
	
three	O
novel	O
mutations	O
in	O
five	O
unrelated	O
subjects	O
with	O
hereditary	O
protein	B-Disease
s	I-Disease
deficiency	I-Disease
type	I-Disease
i	I-Disease
.	O
	
a	O
panel	O
of	O
eight	O
unrelated	O
subjects	O
with	O
inherited	O
type	B-Disease
i	I-Disease
protein	I-Disease
s	I-Disease
deficiency	I-Disease
was	O
screened	O
for	O
mutations	O
in	O
the	O
pros1	O
gene	O
.	O
	
the	O
latter	O
indicates	O
that	O
a	O
mrna	O
based	O
approach	O
is	O
not	O
feasible	O
for	O
the	O
genetic	O
analysis	O
of	O
protein	B-Disease
s	I-Disease
deficiency	I-Disease
type	I-Disease
i	I-Disease
.	O
	
characteristics	O
of	O
intergenerational	O
contractions	O
of	O
the	O
ctg	O
repeat	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
in	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
,	O
the	O
size	O
of	O
a	O
ctg	O
repeat	O
in	O
the	O
dm	B-Disease
kinase	O
gene	O
generally	O
increases	O
in	O
successive	O
generations	O
with	O
clinical	O
evidence	O
of	O
anticipation	O
.	O
	
we	O
examined	O
1	O
,	O
489	O
dm	B-Disease
parent	O
-	O
offspring	O
pairs	O
,	O
of	O
which	O
95	O
(	O
6	O
.	O
	
4	O
%	O
)	O
showed	O
such	O
contractions	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
pbl	O
)	O
.	O
	
it	O
is	O
surprising	O
that	O
anticipation	O
occurred	O
in	O
27	O
(	O
48	O
%	O
)	O
of	O
these	O
56	O
pairs	O
,	O
while	O
none	O
clearly	O
showed	O
a	O
later	O
onset	O
of	O
dm	B-Disease
in	O
the	O
symptomatic	O
offspring	O
.	O
	
sixteen	O
dm	B-Disease
parents	O
had	O
multiple	O
dm	B-Disease
offspring	O
with	O
the	O
ctg	O
repeat	O
contractions	O
.	O
	
this	O
frequency	O
was	O
higher	O
than	O
the	O
frequency	O
expected	O
from	O
the	O
probability	O
of	O
the	O
repeat	O
contractions	O
(	O
6	O
.	O
	
4	O
%	O
)	O
and	O
the	O
size	O
of	O
dm	B-Disease
sib	O
population	O
(	O
1	O
.	O
	
54	O
dm	B-Disease
offspring	O
per	O
dm	B-Disease
parent	O
,	O
in	O
968	O
dm	B-Disease
parents	O
)	O
.	O
	
we	O
conclude	O
that	O
(	O
1	O
)	O
intergenerational	O
contractions	O
of	O
the	O
ctg	O
repeat	O
in	O
leukocyte	O
dna	O
frequently	O
accompanies	O
apparent	O
anticipation	O
,	O
especially	O
when	O
dm	B-Disease
is	O
maternally	O
transmitted	O
,	O
and	O
(	O
2	O
)	O
the	O
paternal	O
origin	O
of	O
the	O
repeat	O
and	O
the	O
presence	O
of	O
the	O
repeat	O
contraction	O
in	O
a	O
sibling	O
increase	O
the	O
probability	O
of	O
the	O
ctg	O
repeat	O
contraction	O
gonosomal	O
mosaicism	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
:	O
involvement	O
of	O
mitotic	O
events	O
in	O
(	O
ctg	O
)	O
n	O
repeat	O
variation	O
and	O
selection	O
against	O
extreme	O
expansion	O
in	O
sperm	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
caused	O
by	O
abnormal	O
expansion	O
of	O
a	O
polymorphic	O
(	O
ctg	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
dm	B-Disease
protein	O
kinase	O
gene	O
.	O
	
we	O
determined	O
the	O
(	O
ctg	O
)	O
n	O
repeat	O
lengths	O
in	O
a	O
broad	O
range	O
of	O
tissue	O
dnas	O
from	O
patients	O
with	O
mild	O
,	O
classical	O
,	O
or	O
congenital	O
manifestation	O
of	O
dm	B-Disease
.	O
	
differences	O
in	O
the	O
repeat	O
length	O
were	O
seen	O
in	O
somatic	O
tissues	O
from	O
single	O
dm	B-Disease
individuals	O
and	O
twins	O
.	O
	
we	O
conclude	O
that	O
dm	B-Disease
patients	O
can	O
be	O
considered	O
gonosomal	O
mosaics	O
,	O
i	O
.	O
	
a	O
model	O
explaining	O
mitotic	O
instability	O
and	O
sex	O
-	O
dependent	O
segregation	O
phenomena	O
in	O
dm	B-Disease
manifestation	O
is	O
discussed	O
regionally	O
clustered	O
apc	B-Disease
mutations	O
are	O
associated	O
with	O
a	O
severe	O
phenotype	O
and	O
occur	O
at	O
a	O
high	O
frequency	O
in	O
new	O
mutation	O
cases	O
of	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O
	
germline	O
mutation	O
in	O
apc	O
at	O
5q21	O
-	O
22	O
results	O
in	O
the	O
dominantly	O
inherited	O
syndrome	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
.	O
	
eighteen	O
patients	O
had	O
no	O
family	O
history	O
of	O
the	O
disease	O
;	O
of	O
these	O
11	O
were	O
classified	O
as	O
having	O
a	O
severe	O
phenotype	O
,	O
based	O
on	O
an	O
early	O
age	O
at	O
presentation	O
or	O
cancer	B-Disease
development	O
.	O
	
a	O
5	O
bp	O
deletion	O
at	O
codon	O
1309	O
reported	O
to	O
occur	O
in	O
10	O
-	O
15	O
%	O
of	O
unselected	O
apc	B-Disease
patients	O
worldwide	O
,	O
was	O
found	O
in	O
5	O
of	O
the	O
18	O
new	O
mutation	O
cases	O
and	O
4	O
of	O
the	O
27	O
familial	O
cases	O
all	O
nine	O
were	O
classed	O
as	O
severe	O
.	O
	
in	O
contrast	O
all	O
of	O
the	O
apc	B-Disease
mutations	O
detected	O
in	O
affected	O
individuals	O
with	O
an	O
average	O
phenotype	O
were	O
located	O
prior	O
to	O
codon	O
1309	O
.	O
	
mutations	O
at	O
the	O
pax6	O
locus	O
are	O
found	O
in	O
heterogeneous	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
peters	B-Disease
'	I-Disease
anomaly	I-Disease
.	O
	
mutation	O
or	O
deletion	O
of	O
the	O
pax6	O
gene	O
underlies	O
many	O
cases	O
of	O
aniridia	B-Disease
.	O
	
three	O
lines	O
of	O
evidence	O
now	O
converge	O
to	O
implicate	O
pax6	O
more	O
widely	O
in	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
peters	B-Disease
anomaly	I-Disease
.	O
	
first	O
,	O
a	O
child	O
with	O
peters	B-Disease
anomaly	I-Disease
is	O
deleted	O
for	O
one	O
copy	O
of	O
pax6	O
.	O
	
second	O
,	O
affected	O
members	O
of	O
a	O
family	O
with	O
dominantly	O
inherited	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
,	O
including	O
peters	B-Disease
anomaly	I-Disease
are	O
heterozygous	O
for	O
an	O
r26g	O
mutation	O
in	O
the	O
pax6	O
paired	O
box	O
.	O
	
third	O
,	O
a	O
proportion	O
of	O
sey	O
/	O
+	O
smalleye	O
mice	O
,	O
heterozygous	O
for	O
a	O
nonsense	O
mutation	O
in	O
murine	O
pax	O
-	O
6	O
,	O
have	O
an	O
ocular	O
phenotype	O
resembling	O
peters	B-Disease
anomaly	I-Disease
.	O
	
we	O
therefore	O
propose	O
that	O
a	O
variety	O
of	O
anterior	B-Disease
segment	I-Disease
anomalies	I-Disease
may	O
be	O
associated	O
with	O
pax6	O
mutations	O
.	O
	
huntington	B-Disease
disease	I-Disease
without	O
cag	O
expansion	O
:	O
phenocopies	O
or	O
errors	O
in	O
assignment	O
?	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
expanded	O
cag	O
repeat	O
within	O
a	O
novel	O
gene	O
on	O
4p16	O
.	O
	
the	O
reasons	O
for	O
not	O
observing	O
expansion	O
in	O
affected	O
individuals	O
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	O
length	O
both	O
for	O
diagnosis	O
of	O
affected	O
patients	O
and	O
for	O
predictive	O
testing	O
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
hd	B-Disease
.	O
	
the	O
remaining	O
12	O
patients	O
represent	O
possible	O
phenocopies	O
for	O
hd	B-Disease
.	O
	
mutations	O
in	O
the	O
hd	B-Disease
gene	O
that	O
are	O
other	O
than	O
cag	O
expansion	O
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases	O
;	O
however	O
,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons	O
,	O
retrospective	O
review	O
of	O
these	O
patients	O
clinical	O
features	O
identified	O
characteristics	O
not	O
typical	O
for	O
hd	B-Disease
.	O
	
this	O
study	O
shows	O
that	O
on	O
rare	O
occasions	O
mutations	O
in	O
other	O
,	O
as	O
-	O
yet	O
-	O
undefined	O
genes	O
can	O
present	O
with	O
a	O
clinical	O
phenotype	O
very	O
similar	O
to	O
that	O
of	O
hd	B-Disease
frequent	O
detection	O
of	O
codon	O
877	O
mutation	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
advanced	B-Disease
prostate	I-Disease
cancers	I-Disease
.	O
	
prostatic	O
tissue	O
specimens	O
derived	O
from	O
transurethral	O
resections	O
of	O
patients	O
with	O
metastatic	B-Disease
prostate	I-Disease
cancer	I-Disease
were	O
analyzed	O
for	O
genetic	O
alterations	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
androgen	O
receptor	O
(	O
ar	O
)	O
gene	O
.	O
	
this	O
same	O
ar	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
a	O
metastatic	B-Disease
prostate	I-Disease
cancer	I-Disease
cell	O
line	O
,	O
lncap	O
,	O
where	O
this	O
mutation	O
confers	O
upon	O
the	O
ar	O
an	O
altered	O
ligand	O
-	O
binding	O
specificity	O
which	O
is	O
stimulated	O
by	O
estrogens	O
,	O
progestagens	O
,	O
and	O
antiandrogens	O
.	O
	
it	O
is	O
possible	O
that	O
analogous	O
to	O
an	O
activated	O
/	O
altered	O
growth	O
factor	O
receptor	O
oncogene	O
,	O
codon	O
877	O
mutant	O
ar	O
with	O
altered	O
ligand	O
binding	O
may	O
provide	O
a	O
selective	O
growth	O
advantage	O
in	O
the	O
genesis	O
of	O
a	O
subset	O
of	O
advanced	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
although	O
estrogens	O
are	O
used	O
infrequently	O
,	O
antiandrogens	O
are	O
used	O
increasingly	O
in	O
hormonal	O
therapy	O
for	O
patients	O
with	O
advanced	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
the	O
human	O
gene	O
for	O
alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
maps	O
to	O
chromosome	O
3q	O
.	O
	
alkaptonuria	B-Disease
(	O
aku	B-Disease
;	O
mckusick	O
no	O
.	O
	
203500	O
)	O
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
the	O
lack	O
of	O
homogentisic	O
acid	O
oxidase	O
activity	O
.	O
	
ochronosis	B-Disease
is	O
the	O
predominant	O
clinical	O
complication	O
of	O
the	O
disease	O
leading	O
to	O
ochronotic	B-Disease
arthropathy	I-Disease
,	O
dark	O
urine	O
,	O
pigment	O
changes	O
of	O
the	O
skin	O
,	O
and	O
other	O
clinical	O
features	O
.	O
	
a	O
mutation	O
causing	O
alkaptonuria	B-Disease
in	O
the	O
mouse	O
has	O
mapped	O
to	O
chromosome	O
16	O
.	O
	
considering	O
conserved	O
synteny	O
,	O
we	O
were	O
able	O
to	O
map	O
the	O
human	O
gene	O
to	O
chromosome	O
3q	O
in	O
six	O
alkaptonuria	B-Disease
pedigrees	O
of	O
slovak	O
origin	O
.	O
	
an	O
sglt1	O
missense	O
mutation	O
underlies	O
hereditary	B-Disease
glucose	I-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
,	O
characterized	O
by	O
potentially	O
fatal	O
diarrhea	B-Disease
;	O
conversely	O
,	O
oral	O
rehydration	O
therapy	O
exploits	O
normal	O
transport	O
to	O
alleviate	O
life	O
-	O
threatening	O
diarrhea	B-Disease
of	O
infectious	O
origin	O
.	O
	
a	O
new	O
missense	O
mutation	O
in	O
exon	O
1	O
causing	O
glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
is	O
also	O
described	O
.	O
	
these	O
data	O
facilitate	O
the	O
search	O
for	O
new	O
glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
-	O
related	O
mutations	O
in	O
this	O
important	O
gene	O
and	O
provide	O
a	O
basis	O
for	O
future	O
evolutionary	O
comparisons	O
with	O
other	O
na	O
(	O
+	O
)	O
-	O
dependent	O
cotransporters	O
.	O
	
four	O
novel	O
pepd	O
alleles	O
causing	O
prolidase	B-Disease
deficiency	I-Disease
.	O
	
mutations	O
at	O
the	O
pepd	O
locus	O
cause	O
prolidase	B-Disease
deficiency	I-Disease
(	O
mckusick	O
170100	O
)	O
,	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
iminodipeptiduria	B-Disease
,	O
skin	B-Disease
ulcers	I-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
recurrent	O
infections	O
.	O
	
our	O
results	O
indicate	O
that	O
the	O
severe	O
form	O
of	O
prolidase	B-Disease
deficiency	I-Disease
is	O
caused	O
by	O
multiple	O
pepd	O
alleles	O
.	O
	
recombinations	O
in	O
individuals	O
homozygous	O
by	O
descent	O
localize	O
the	O
friedreich	B-Disease
ataxia	I-Disease
locus	O
in	O
a	O
cloned	O
450	O
-	O
kb	O
interval	O
.	O
	
the	O
locus	O
for	O
friedreich	B-Disease
ataxia	I-Disease
(	O
frda	B-Disease
)	O
,	O
a	O
severe	O
neurodegenerative	B-Disease
disease	I-Disease
,	O
is	O
tightly	O
linked	O
to	O
markers	O
d9s5	O
and	O
d9s15	O
,	O
and	O
analysis	O
of	O
rare	O
recombination	O
events	O
has	O
suggested	O
the	O
order	O
cen	O
-	O
frda	O
-	O
d9s5	O
-	O
d9s15	O
-	O
qter	O
.	O
	
in	O
order	O
to	O
map	O
these	O
markers	O
with	O
respect	O
to	O
the	O
frda	B-Disease
locus	O
,	O
all	O
within	O
a	O
1	O
-	O
cm	O
confidence	O
interval	O
,	O
we	O
sought	O
to	O
increase	O
the	O
genetic	O
information	O
of	O
available	O
frda	B-Disease
families	O
by	O
considering	O
homozygosity	O
by	O
descent	O
and	O
association	O
with	O
founder	O
haplotypes	O
in	O
isolated	O
populations	O
.	O
	
this	O
approach	O
allowed	O
us	O
to	O
identify	O
one	O
phase	O
-	O
known	O
recombination	O
and	O
one	O
probable	O
historic	O
recombination	O
on	O
haplotypes	O
from	O
reunion	O
island	O
patients	O
,	O
both	O
of	O
which	O
place	O
three	O
of	O
the	O
five	O
markers	O
proximal	O
to	O
frda	B-Disease
.	O
	
this	O
represents	O
the	O
first	O
identification	O
of	O
close	O
frda	B-Disease
flanking	O
markers	O
on	O
the	O
centromeric	O
side	O
.	O
	
taken	O
together	O
,	O
the	O
results	O
place	O
the	O
frda	B-Disease
locus	O
in	O
a	O
450	O
-	O
kb	O
interval	O
,	O
which	O
is	O
small	O
enough	O
for	O
direct	O
search	O
of	O
candidate	O
genes	O
.	O
	
investigation	O
of	O
thermoregulatory	O
characteristics	O
in	O
patients	O
with	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
.	O
	
a	O
survey	O
instrument	O
is	O
used	O
to	O
assess	O
temperature	O
regulation	O
characteristics	O
in	O
children	O
with	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
compared	O
to	O
3	O
control	O
groups	O
sibs	O
of	O
pws	B-Disease
patients	O
(	O
sib	O
)	O
,	O
neurodevelopmentally	B-Disease
handicapped	I-Disease
children	O
(	O
nd	O
)	O
,	O
and	O
age	O
and	O
gender	O
matched	O
well	O
children	O
(	O
wc	O
)	O
.	O
	
significant	O
differences	O
were	O
found	O
between	O
pws	B-Disease
patients	O
,	O
sib	O
controls	O
,	O
and	O
wc	O
controls	O
in	O
the	O
prevalence	O
of	O
febrile	O
convulsions	O
,	O
fever	O
-	O
associated	O
symptoms	O
,	O
and	O
temperature	O
less	O
than	O
94	O
degrees	O
f	O
.	O
	
no	O
differences	O
were	O
noted	O
in	O
any	O
variable	O
between	O
the	O
pws	B-Disease
patients	O
and	O
the	O
nd	O
controls	O
,	O
suggesting	O
that	O
these	O
abnormalities	O
are	O
not	O
unique	O
to	O
pws	B-Disease
,	O
but	O
can	O
occur	O
in	O
any	O
neurodevelopmentally	B-Disease
handicapped	I-Disease
individual	O
,	O
further	O
suggesting	O
these	O
do	O
not	O
necessarily	O
reflect	O
syndrome	O
-	O
specific	O
hypothalamic	B-Disease
abnormalities	I-Disease
.	O
	
phenotypic	O
variation	O
including	O
retinitis	B-Disease
pigmentosa	I-Disease
,	O
pattern	B-Disease
dystrophy	I-Disease
,	O
and	O
fundus	B-Disease
flavimaculatus	I-Disease
in	O
a	O
single	O
family	O
with	O
a	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
rds	O
gene	O
.	O
	
background	O
and	O
objectives	O
mutations	O
of	O
the	O
peripherin	O
/	O
rds	O
gene	O
have	O
been	O
reported	O
in	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
,	O
pattern	O
macular	B-Disease
dystrophy	I-Disease
,	O
and	O
retinitis	B-Disease
punctata	I-Disease
albescens	I-Disease
.	O
	
results	O
the	O
mother	O
presented	O
at	O
age	O
63	O
years	O
with	O
a	O
profoundly	O
abnormal	O
electroretinogram	O
(	O
erg	O
)	O
and	O
adult	O
-	O
onset	O
retinitis	B-Disease
pigmentosa	I-Disease
that	O
progressed	O
dramatically	O
over	O
12	O
years	O
,	O
with	O
marked	O
loss	O
of	O
peripheral	O
visual	O
field	O
.	O
	
one	O
daughter	O
developed	O
pattern	B-Disease
macular	I-Disease
dystrophy	I-Disease
at	O
age	O
31	O
years	O
.	O
	
another	O
daughter	O
presented	O
at	O
age	O
42	O
years	O
with	O
macular	B-Disease
degeneration	I-Disease
and	O
over	O
10	O
years	O
developed	O
the	O
clinical	O
picture	O
of	O
fundus	B-Disease
flavimaculatus	I-Disease
.	O
	
the	O
son	O
had	O
onset	O
of	O
macular	B-Disease
degeneration	I-Disease
at	O
age	O
44	O
years	O
.	O
	
pericentral	B-Disease
scotomas	I-Disease
were	O
present	O
and	O
the	O
erg	O
was	O
markedly	O
abnormal	O
.	O
	
in	O
two	O
patients	O
with	O
the	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
glucose	I-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	O
mutation	O
in	O
sglt1	O
,	O
and	O
the	O
asp28	O
-	O
-	O
>	O
asn	O
change	O
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
sglt1	O
transport	O
activity	O
.	O
	
1	O
,	O
and	O
provide	O
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
sglt1	O
probe	O
as	O
a	O
diagnostic	O
for	O
genetic	B-Disease
diseases	I-Disease
associated	O
with	O
translocations	O
of	O
chromosome	O
22	O
.	O
	
restriction	O
of	O
ocular	O
fundus	O
lesions	O
to	O
a	O
specific	O
subgroup	O
of	O
apc	B-Disease
mutations	O
in	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
patients	O
.	O
	
in	O
humans	O
,	O
alteration	O
of	O
the	O
tumor	B-Disease
suppressor	O
gene	O
,	O
apc	B-Disease
,	O
causes	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
,	O
a	O
condition	O
causing	O
predisposition	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
the	O
syndrome	O
inconsistently	O
associates	O
characteristic	O
patches	O
of	O
congenital	B-Disease
hypertrophy	I-Disease
of	I-Disease
the	I-Disease
retinal	I-Disease
pigment	I-Disease
epithelium	I-Disease
(	O
chrpe	B-Disease
)	O
.	O
	
ocular	O
examination	O
revealed	O
that	O
patients	O
expressing	O
chrpe	B-Disease
tend	O
to	O
cluster	O
within	O
specific	O
families	O
.	O
	
the	O
exact	O
apc	B-Disease
mutation	O
was	O
identified	O
in	O
42	O
unrelated	O
patients	O
.	O
	
the	O
extent	O
of	O
chrpe	B-Disease
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
position	O
of	O
the	O
mutation	O
along	O
the	O
coding	O
sequence	O
.	O
	
chrpe	B-Disease
lesions	O
are	O
almost	O
always	O
absent	O
if	O
the	O
mutation	O
occurs	O
before	O
exon	O
9	O
,	O
but	O
are	O
systematically	O
present	O
if	O
it	O
occurs	O
after	O
this	O
exon	O
.	O
	
thus	O
,	O
the	O
range	O
of	O
phenotypic	O
expression	O
observed	O
among	O
affected	O
patients	O
may	O
result	O
in	O
part	O
from	O
different	O
allelic	O
manifestations	O
of	O
apc	B-Disease
mutations	O
.	O
	
the	O
authors	O
earlier	O
findings	O
of	O
a	O
negative	O
electroretinogram	O
(	O
erg	O
)	O
in	O
a	O
boy	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
led	O
them	O
to	O
investigate	O
dystrophin	O
gene	O
deletions	O
and	O
ergs	O
in	O
five	O
boys	O
with	O
dmd	B-Disease
.	O
	
the	O
authors	O
wanted	O
to	O
determined	O
whether	O
there	O
were	O
similar	O
erg	O
findings	O
in	O
an	O
animal	O
model	O
for	O
dmd	B-Disease
,	O
the	O
mdx	O
mouse	O
.	O
	
ganzfeld	O
ergs	O
were	O
recorded	O
in	O
five	O
boys	O
with	O
dmd	B-Disease
after	O
a	O
complete	O
ophthalmic	O
examination	O
.	O
	
the	O
authors	O
believe	O
the	O
unique	O
erg	O
recorded	O
for	O
the	O
human	O
subjects	O
is	O
a	O
manifestation	O
of	O
dmd	B-Disease
associated	O
with	O
defects	O
at	O
the	O
dystrophin	O
gene	O
locus	O
and	O
represents	O
a	O
new	O
clinical	O
entity	O
.	O
	
the	O
erg	O
shows	O
promise	O
of	O
becoming	O
a	O
noninvasive	O
diagnostic	O
tool	O
for	O
dmd	B-Disease
and	O
its	O
milder	O
allelic	O
forms	O
.	O
	
association	O
of	O
the	O
apc	B-Disease
tumor	I-Disease
suppressor	O
protein	O
with	O
catenins	O
.	O
	
mutations	O
of	O
apc	O
appear	O
to	O
initiate	O
sporadic	O
and	O
inherited	O
forms	O
of	O
human	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
although	O
these	O
mutations	O
have	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
apc	B-Disease
gene	O
product	O
.	O
	
two	O
cellular	O
proteins	O
that	O
associate	O
with	O
apc	B-Disease
were	O
identified	O
by	O
nucleotide	O
sequence	O
analysis	O
and	O
peptide	O
mapping	O
as	O
the	O
e	O
-	O
cadherin	O
-	O
associated	O
proteins	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
.	O
	
these	O
results	O
suggest	O
an	O
important	O
link	O
between	O
tumor	B-Disease
initiation	O
and	O
cell	O
adhesion	O
.	O
	
difference	O
in	O
methylation	O
patterns	O
within	O
the	O
d15s9	O
region	O
of	O
chromosome	O
15q11	O
-	O
13	O
in	O
first	O
cousins	O
with	O
angelman	B-Disease
syndrome	I-Disease
and	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
.	O
	
abnormalities	O
of	O
chromosome	O
region	O
15q11	O
-	O
13	O
are	O
associated	O
with	O
angelman	B-Disease
syndrome	I-Disease
(	O
as	B-Disease
)	O
and	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
differences	O
between	O
the	O
methylation	O
patterns	O
of	O
the	O
region	O
of	O
chromosome	O
15q11	O
-	O
13	O
which	O
hybridizes	O
to	O
the	O
highly	O
conserved	O
dna	O
,	O
dn34	O
,	O
in	O
normal	O
individuals	O
and	O
in	O
patients	O
with	O
as	B-Disease
and	O
pws	B-Disease
have	O
been	O
described	O
.	O
	
we	O
report	O
on	O
a	O
family	O
in	O
which	O
first	O
cousins	O
are	O
affected	O
by	O
as	B-Disease
and	O
pws	B-Disease
as	O
a	O
result	O
of	O
a	O
familial	O
paracentric	O
inversion	O
of	O
15q11	O
-	O
q13	O
.	O
	
haplotype	O
studies	O
in	O
wilson	B-Disease
disease	I-Disease
.	O
	
in	O
51	O
families	O
with	O
wilson	B-Disease
disease	I-Disease
,	O
we	O
have	O
studied	O
dna	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(	O
ca	O
repeats	O
)	O
in	O
the	O
13q14	O
.	O
	
3	O
region	O
,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
wilson	B-Disease
disease	I-Disease
gene	O
(	O
wnd	B-Disease
)	O
.	O
	
in	O
addition	O
to	O
a	O
marker	O
(	O
d13s133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(	O
d13s314	O
,	O
d13s315	O
,	O
and	O
d13s316	O
)	O
close	O
to	O
the	O
wnd	B-Disease
locus	O
.	O
	
we	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
d13s314	O
,	O
d13s133	O
,	O
and	O
d13s316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
wnd	B-Disease
mutation	O
.	O
	
we	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
wnd	B-Disease
and	O
normal	O
haplotypes	O
in	O
northern	O
european	O
families	O
.	O
	
these	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
wilson	B-Disease
disease	I-Disease
.	O
	
we	O
have	O
analyzed	O
a	O
single	O
multi	O
-	O
affected	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
pedigree	O
(	O
bov3	O
)	O
and	O
have	O
shown	O
consistent	O
inheritance	O
of	O
markers	O
on	O
chromosome	O
17q	O
with	O
the	O
disease	O
confirming	O
that	O
this	O
family	O
is	O
due	O
to	O
the	O
brca1	O
gene	O
.	O
	
analysis	O
of	O
17q	O
haplotypes	O
shows	O
a	O
recombination	O
event	O
in	O
a	O
bilateral	O
breast	B-Disease
cancer	I-Disease
case	O
which	O
suggests	O
that	O
the	O
brca1	O
gene	O
lies	O
distal	O
to	O
d17s857	O
;	O
d17s857	O
is	O
thus	O
the	O
new	O
proximal	O
boundary	O
for	O
the	O
region	O
containing	O
brca1	O
.	O
	
all	O
seven	O
breast	B-Disease
tumour	I-Disease
/	O
blood	O
pairs	O
examined	O
from	O
this	O
family	O
show	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tumours	B-Disease
.	O
	
the	O
allel	O
retained	O
in	O
each	O
tumour	B-Disease
was	O
from	O
the	O
disease	O
-	O
bearing	O
chromosome	O
implicating	O
brca1	O
as	O
a	O
tumour	B-Disease
suppressor	O
gene	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
kinase	O
is	O
a	O
component	O
of	O
neuromuscular	O
junctions	O
.	O
	
the	O
clinical	O
manifestation	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
correlated	O
to	O
the	O
extent	O
of	O
expansion	O
of	O
an	O
unstable	O
[	O
ctg	O
]	O
n	O
dna	O
motif	O
.	O
	
recent	O
studies	O
have	O
demonstrated	O
that	O
this	O
trinucleotide	O
motif	O
forms	O
part	O
of	O
the	O
last	O
,	O
3	O
untranslated	O
exon	O
of	O
a	O
gene	O
which	O
potentially	O
encodes	O
multiple	O
protein	O
isoforms	O
of	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
(	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
,	O
dm	O
-	O
pk	O
)	O
.	O
	
immunoreactive	O
dm	O
-	O
kinase	O
protein	O
of	O
53	O
kd	O
is	O
present	O
at	O
low	O
levels	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
extracts	O
of	O
dm	B-Disease
patients	O
and	O
normal	O
controls	O
.	O
	
strikingly	O
,	O
presence	O
of	O
the	O
protein	O
can	O
also	O
be	O
demonstrated	O
for	O
nmjs	O
of	O
muscular	O
tissues	O
of	O
adult	O
and	O
congenital	O
cases	O
of	O
dm	B-Disease
,	O
with	O
no	O
gross	O
changes	O
in	O
structural	O
organisation	O
.	O
	
our	O
findings	O
provide	O
a	O
basis	O
for	O
further	O
characterisation	O
of	O
the	O
role	O
of	O
the	O
kinase	O
in	O
protein	O
assembly	O
processes	O
or	O
signal	O
mediation	O
at	O
synaptic	O
sites	O
and	O
ultimately	O
for	O
the	O
understanding	O
of	O
the	O
complex	O
pathophysiology	O
of	O
dm	B-Disease
.	O
	
markedly	O
accelerated	O
catabolism	O
of	O
apolipoprotein	O
a	O
-	O
ii	O
(	O
apoa	O
-	O
ii	O
)	O
and	O
high	O
density	O
lipoproteins	O
containing	O
apoa	O
-	O
ii	O
in	O
classic	O
lecithin	O
:	O
cholesterol	B-Disease
acyltransferase	I-Disease
deficiency	I-Disease
and	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
.	O
	
classic	B-Disease
(	I-Disease
complete	I-Disease
)	I-Disease
lecithin	I-Disease
cholesterol	I-Disease
acyltransferase	I-Disease
(	I-Disease
lcat	I-Disease
)	I-Disease
deficiency	I-Disease
and	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
(	O
partial	B-Disease
lcat	I-Disease
deficiency	I-Disease
)	O
are	O
genetic	O
syndromes	O
associated	O
with	O
markedly	O
decreased	O
plasma	O
levels	O
of	O
high	O
density	O
lipoprotein	O
(	O
hdl	O
)	O
cholesterol	O
but	O
not	O
with	O
an	O
increased	O
risk	O
of	O
atherosclerotic	B-Disease
cardiovascular	I-Disease
disease	I-Disease
.	O
	
we	O
investigated	O
the	O
metabolism	O
of	O
the	O
hdl	O
apolipoproteins	O
(	O
apo	O
)	O
apoa	O
-	O
i	O
and	O
apoa	O
-	O
ii	O
in	O
a	O
total	O
of	O
five	O
patients	O
with	O
lcat	B-Disease
deficiency	I-Disease
,	O
one	O
with	O
classic	B-Disease
lcat	I-Disease
deficiency	I-Disease
and	O
four	O
with	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
.	O
	
in	O
summary	O
,	O
genetic	O
syndromes	O
of	O
either	O
complete	B-Disease
or	I-Disease
partial	I-Disease
lcat	I-Disease
deficiency	I-Disease
result	O
in	O
low	O
levels	O
of	O
hdl	O
through	O
preferential	O
hypercatabolism	O
of	O
apoa	O
-	O
ii	O
and	O
hdl	O
particles	O
containing	O
apoa	O
-	O
ii	O
.	O
	
because	O
lpa	O
-	O
i	O
has	O
been	O
proposed	O
to	O
be	O
more	O
protective	O
than	O
lpa	O
-	O
i	O
a	O
-	O
ii	O
against	O
atherosclerosis	B-Disease
,	O
this	O
selective	O
effect	O
on	O
the	O
metabolism	O
of	O
lpa	O
-	O
i	O
a	O
-	O
ii	O
may	O
provide	O
a	O
potential	O
explanation	O
why	O
patients	O
with	O
classic	B-Disease
lcat	I-Disease
deficiency	I-Disease
and	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
are	O
not	O
at	O
increased	O
risk	O
for	O
premature	O
atherosclerosis	B-Disease
despite	O
markedly	O
decreased	O
levels	O
of	O
hdl	O
cholesterol	O
and	O
apoa	O
-	O
i	O
x	B-Disease
linked	I-Disease
recessive	I-Disease
thrombocytopenia	I-Disease
.	O
	
a	O
saudi	O
arab	O
boy	O
presented	O
in	O
early	O
childhood	O
with	O
thrombocytopenia	B-Disease
,	O
morphologically	O
large	O
and	O
normal	O
sized	O
platelets	O
,	O
increased	O
mean	O
platelet	O
volume	O
,	O
and	O
a	O
hypermegakaryocytic	O
bone	O
marrow	O
.	O
	
there	O
was	O
no	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
any	O
significant	O
immunological	B-Disease
abnormalities	I-Disease
.	O
	
similar	O
findings	O
in	O
two	O
other	O
brothers	O
suggested	O
strongly	O
that	O
they	O
were	O
all	O
suffering	O
from	O
an	O
x	B-Disease
linked	I-Disease
recessive	I-Disease
thrombocytopenic	I-Disease
disorder	I-Disease
.	O
	
results	O
of	O
dna	O
analysis	O
with	O
the	O
probe	O
m27	O
beta	O
are	O
consistent	O
with	O
x	O
linkage	O
and	O
indicate	O
also	O
that	O
the	O
locus	O
of	O
the	O
relevant	O
gene	O
lies	O
close	O
to	O
or	O
is	O
identical	O
to	O
the	O
locus	O
of	O
the	O
gene	O
for	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
.	O
	
because	O
of	O
various	O
features	O
which	O
include	O
the	O
presence	O
of	O
large	O
and	O
normal	O
sized	O
platelets	O
(	O
rather	O
than	O
small	O
platelets	O
)	O
and	O
freedom	O
from	O
significant	O
immune	B-Disease
deficiencies	I-Disease
,	O
it	O
is	O
likely	O
that	O
the	O
x	B-Disease
linked	I-Disease
recessive	I-Disease
thrombocytopenia	I-Disease
in	O
this	O
family	O
is	O
an	O
isolated	O
entity	O
quite	O
distinct	O
from	O
the	O
classical	O
was	B-Disease
phenotype	O
.	O
	
however	O
,	O
a	O
modified	O
expression	O
of	O
the	O
was	B-Disease
gene	O
producing	O
a	O
mild	O
phenotypic	O
variant	O
cannot	O
be	O
excluded	O
entirely	O
.	O
	
macular	B-Disease
dystrophy	I-Disease
associated	O
with	O
mutations	O
at	O
codon	O
172	O
in	O
the	O
human	O
retinal	B-Disease
degeneration	I-Disease
slow	O
gene	O
.	O
	
background	O
recently	O
,	O
mutations	O
in	O
the	O
retinal	B-Disease
degeneration	I-Disease
slow	O
(	O
rds	O
)	O
gene	O
which	O
codes	O
for	O
peripherin	O
-	O
rds	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
.	O
	
mutations	O
at	O
codon	O
172	O
of	O
the	O
rds	O
gene	O
have	O
been	O
identified	O
in	O
three	O
families	O
with	O
autosomal	O
dominantly	O
inherited	O
,	O
progressive	O
macular	B-Disease
dystrophy	I-Disease
.	O
	
results	O
in	O
all	O
but	O
one	O
affected	O
member	O
,	O
symptoms	O
of	O
progressive	O
central	O
visual	B-Disease
loss	I-Disease
developed	O
in	O
the	O
third	O
or	O
fourth	O
decade	O
of	O
life	O
accompanied	O
by	O
central	B-Disease
scotoma	I-Disease
and	O
well	O
-	O
demarcated	O
atrophy	B-Disease
of	I-Disease
the	I-Disease
retinal	I-Disease
pigment	I-Disease
epithelium	I-Disease
and	O
choriocapillaris	B-Disease
of	I-Disease
the	I-Disease
macula	I-Disease
.	O
	
conclusion	O
these	O
results	O
indicate	O
that	O
mutations	O
in	O
the	O
rds	O
gene	O
can	O
be	O
expressed	O
as	O
a	O
macular	B-Disease
dystrophy	I-Disease
,	O
with	O
evidence	O
of	O
primary	O
cone	B-Disease
dysfunction	I-Disease
and	O
preservation	O
of	O
peripheral	O
rod	O
function	O
.	O
	
anonymous	O
marker	O
loci	O
within	O
400	O
kb	O
of	O
hla	O
-	O
a	O
generate	O
haplotypes	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
hemochromatosis	B-Disease
gene	O
(	O
hfe	O
)	O
the	O
hemochromatosis	B-Disease
gene	O
(	O
hfe	O
)	O
maps	O
to	O
6p21	O
.	O
	
the	O
unambiguous	O
identification	O
of	O
a	O
crossover	O
event	O
within	O
hemochromatosis	B-Disease
families	O
is	O
very	O
difficult	O
;	O
it	O
is	O
particularly	O
hampered	O
by	O
the	O
variability	O
of	O
the	O
phenotypic	O
expression	O
as	O
well	O
as	O
by	O
the	O
sex	O
-	O
and	O
age	O
-	O
related	O
penetrance	O
of	O
the	O
disease	O
.	O
	
in	O
the	O
present	O
report	O
,	O
66	O
hemochromatosis	B-Disease
families	O
yielding	O
151	O
hemochromatosis	B-Disease
chromosomes	O
and	O
182	O
normal	O
chromosomes	O
were	O
rflp	O
-	O
typed	O
with	O
a	O
battery	O
of	O
probes	O
,	O
including	O
two	O
newly	O
derived	O
polymorphic	O
markers	O
from	O
the	O
6	O
.	O
	
additionally	O
,	O
hemochromatosis	B-Disease
haplotypes	O
possessing	O
hla	O
-	O
a11	O
and	O
the	O
low	O
-	O
frequency	O
hla	O
-	O
f	O
polymorphism	O
(	O
allele	O
2	O
)	O
are	O
supportive	O
of	O
a	O
separate	O
founder	O
chromosome	O
containing	O
a	O
second	O
,	O
independently	O
arising	O
mutant	O
allele	O
.	O
	
overall	O
,	O
the	O
establishment	O
of	O
a	O
likely	O
hemochromatosis	B-Disease
critical	O
region	O
centromeric	O
boundary	O
and	O
the	O
identification	O
of	O
a	O
linkage	O
-	O
disequilibrium	O
zone	O
both	O
significantly	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
dna	O
required	O
to	O
be	O
searched	O
for	O
novel	O
coding	O
sequences	O
constituting	O
the	O
hfe	B-Disease
defect	I-Disease
genomic	O
structure	O
of	O
the	O
ews	O
gene	O
and	O
its	O
relationship	O
to	O
ewsr1	O
,	O
a	O
site	O
of	O
tumor	B-Disease
-	O
associated	O
chromosome	O
translocation	O
.	O
	
the	O
ews	O
gene	O
has	O
been	O
identified	O
based	O
on	O
its	O
location	O
at	O
the	O
chromosome	O
22	O
breakpoint	O
of	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
(	O
q24	O
;	O
q12	O
)	O
translocation	O
that	O
characterizes	O
ewing	B-Disease
sarcoma	I-Disease
and	O
related	O
neuroectodermal	B-Disease
tumors	I-Disease
.	O
	
positions	O
of	O
the	O
chromosome	O
22	O
breakpoints	O
were	O
determined	O
for	O
19	O
ewing	B-Disease
tumors	I-Disease
.	O
	
norrie	B-Disease
disease	I-Disease
gene	O
:	O
characterization	O
of	O
deletions	O
and	O
possible	O
function	O
.	O
	
positional	O
cloning	O
experiments	O
have	O
resulted	O
recently	O
in	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
norrie	B-Disease
disease	I-Disease
(	O
pseudoglioma	B-Disease
;	O
ndp	B-Disease
)	O
,	O
a	O
severe	O
x	B-Disease
-	I-Disease
linked	I-Disease
neurodevelopmental	I-Disease
disorder	I-Disease
.	O
	
here	O
we	O
report	O
the	O
isolation	O
and	O
analysis	O
of	O
human	O
genomic	O
dna	O
clones	O
encompassing	O
the	O
ndp	B-Disease
gene	O
.	O
	
detailed	O
analysis	O
of	O
genomic	O
deletions	O
in	O
norrie	B-Disease
patients	O
shows	O
that	O
they	O
are	O
heterogeneous	O
,	O
both	O
in	O
size	O
and	O
in	O
position	O
.	O
	
by	O
pcr	O
analysis	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
ndp	B-Disease
gene	O
was	O
not	O
confined	O
to	O
the	O
eye	O
or	O
to	O
the	O
brain	O
.	O
	
an	O
extensive	O
dna	O
and	O
protein	O
sequence	O
comparison	O
between	O
the	O
human	O
ndp	B-Disease
gene	O
and	O
related	O
genes	O
from	O
the	O
database	O
revealed	O
homology	O
with	O
cysteine	O
-	O
rich	O
protein	O
-	O
binding	O
domains	O
of	O
immediate	O
-	O
-	O
early	O
genes	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
.	O
	
the	O
normal	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
allele	O
,	O
or	O
a	O
closely	O
linked	O
gene	O
,	O
influences	O
age	O
at	O
onset	O
of	O
hd	B-Disease
.	O
	
we	O
evaluated	O
the	O
hypothesis	O
that	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
is	O
influenced	O
by	O
the	O
normal	O
hd	B-Disease
allele	O
by	O
comparing	O
transmission	O
patterns	O
of	O
genetically	O
linked	O
markers	O
at	O
the	O
d4s10	O
locus	O
in	O
the	O
normal	O
parent	O
against	O
age	O
at	O
onset	O
in	O
the	O
affected	O
offspring	O
.	O
	
these	O
findings	O
suggest	O
that	O
the	O
expression	O
of	O
hd	B-Disease
is	O
modulated	O
by	O
the	O
normal	O
hd	B-Disease
allele	O
or	O
by	O
a	O
closely	O
linked	O
locus	O
.	O
	
further	O
investigation	O
of	O
the	O
hexa	O
gene	O
intron	O
9	O
donor	O
splice	O
site	O
mutation	O
frequently	O
found	O
in	O
non	O
-	O
jewish	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
patients	O
from	O
the	O
british	O
isles	O
.	O
	
in	O
a	O
previous	O
study	O
we	O
found	O
that	O
a	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
causing	O
mutation	O
in	O
the	O
intron	O
9	O
donor	O
splice	O
site	O
of	O
the	O
hexa	O
gene	O
occurs	O
at	O
high	O
frequency	O
in	O
non	O
-	O
jewish	O
patients	O
and	O
carriers	O
from	O
the	O
british	O
isles	O
.	O
	
we	O
have	O
now	O
tested	O
,	O
in	O
a	O
blind	O
study	O
,	O
26	O
american	O
tsd	B-Disease
carriers	O
and	O
28	O
non	O
-	O
carriers	O
who	O
have	O
british	O
ancestry	O
for	O
the	O
intron	O
9	O
splice	O
site	O
mutation	O
.	O
	
all	O
six	O
had	O
irish	O
ancestry	O
,	O
compared	O
with	O
nine	O
of	O
the	O
20	O
other	O
(	O
intron	O
9	O
mutation	O
negative	O
)	O
tsd	B-Disease
carriers	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
.	O
	
these	O
results	O
confirm	O
the	O
previously	O
found	O
high	O
frequency	O
of	O
the	O
intron	O
9	O
mutation	O
in	O
non	O
-	O
jewish	O
tsd	B-Disease
families	O
of	O
british	O
isles	O
,	O
particularly	O
irish	O
,	O
origin	O
,	O
and	O
reinforce	O
the	O
need	O
to	O
screen	O
such	O
families	O
for	O
this	O
mutation	O
.	O
	
molecular	O
mechanisms	O
of	O
oncogenic	O
mutations	O
in	O
tumors	B-Disease
from	O
patients	O
with	O
bilateral	B-Disease
and	I-Disease
unilateral	I-Disease
retinoblastoma	I-Disease
.	O
	
the	O
rb1	O
gene	O
from	O
12	O
human	O
retinoblastoma	B-Disease
tumors	I-Disease
has	O
been	O
analyzed	O
exon	O
-	O
by	O
-	O
exon	O
with	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O
	
mutations	O
were	O
found	O
in	O
all	O
tumors	B-Disease
,	O
and	O
one	O
-	O
third	O
of	O
the	O
tumors	B-Disease
had	O
independent	O
mutations	O
in	O
both	O
alleles	O
neither	O
of	O
which	O
were	O
found	O
in	O
the	O
germ	O
line	O
,	O
confirming	O
their	O
TRUE	O
sporadic	O
nature	O
.	O
	
in	O
the	O
remaining	O
two	O
-	O
thirds	O
of	O
the	O
tumors	B-Disease
only	O
one	O
mutation	O
was	O
found	O
,	O
consistent	O
with	O
the	O
loss	O
-	O
of	O
-	O
heterozygosity	O
theory	O
of	O
tumorigenesis	O
.	O
	
pax6	O
mutations	O
in	O
aniridia	B-Disease
.	O
	
aniridia	B-Disease
is	O
a	O
congenital	B-Disease
malformation	I-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
,	O
chiefly	O
characterised	O
by	O
iris	B-Disease
hypoplasia	I-Disease
,	O
which	O
can	O
cause	O
blindness	B-Disease
.	O
	
the	O
pax6	O
gene	O
was	O
isolated	O
as	O
a	O
candidate	O
aniridia	B-Disease
gene	O
by	O
positional	O
cloning	O
from	O
the	O
smallest	O
region	O
of	O
overlap	O
of	O
aniridia	B-Disease
-	O
associated	O
deletions	O
.	O
	
subsequently	O
pax6	O
intragenic	O
mutations	O
were	O
demonstrated	O
in	O
smalleye	O
,	O
a	O
mouse	O
mutant	O
which	O
is	O
an	O
animal	O
model	O
for	O
aniridia	B-Disease
,	O
and	O
six	O
human	O
aniridia	B-Disease
patients	O
.	O
	
in	O
this	O
paper	O
we	O
describe	O
four	O
additional	O
pax6	O
point	O
mutations	O
in	O
aniridia	B-Disease
patients	O
,	O
both	O
sporadic	O
and	O
familial	O
.	O
	
in	O
addition	O
,	O
the	O
frequency	O
at	O
which	O
we	O
have	O
found	O
pax6	O
mutations	O
suggests	O
that	O
lesions	O
in	O
pax6	O
will	O
account	O
for	O
most	O
cases	O
of	O
aniridia	B-Disease
.	O
	
autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
a	O
familial	O
form	O
of	O
diabetes	B-Disease
insipidus	I-Disease
.	O
	
this	O
disorder	O
is	O
associated	O
with	O
variable	O
levels	O
of	O
arginine	O
vasopressin	O
(	O
avp	O
)	O
and	O
diabetes	B-Disease
insipidus	I-Disease
of	O
varying	O
severity	O
,	O
which	O
responds	O
to	O
exogenous	O
avp	O
.	O
	
to	O
determine	O
the	O
molecular	O
basis	O
of	O
autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
the	O
avp	O
genes	O
of	O
members	O
of	O
a	O
large	O
kindred	O
were	O
analyzed	O
.	O
	
germinal	O
mosaicism	O
in	O
a	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
family	O
:	O
implications	O
for	O
genetic	O
counselling	O
.	O
	
in	O
this	O
study	O
we	O
describe	O
a	O
three	O
-	O
generation	O
family	O
in	O
which	O
two	O
siblings	O
were	O
affected	O
by	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
.	O
	
immunohistochemical	O
analysis	O
of	O
muscle	O
dystrophin	O
and	O
haplotype	O
analysis	O
of	O
the	O
dmd	B-Disease
locus	O
revealed	O
that	O
the	O
x	O
chromosome	O
carrying	O
the	O
dmd	B-Disease
gene	O
was	O
transmitted	O
from	O
the	O
healthy	O
maternal	O
grandfather	O
to	O
his	O
three	O
daughters	O
,	O
including	O
the	O
probands	O
mother	O
.	O
	
these	O
findings	O
indicate	O
that	O
the	O
grandfather	O
was	O
a	O
germinal	O
mosaic	O
for	O
the	O
dmd	B-Disease
gene	O
.	O
	
genetic	O
mapping	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
to	O
a	O
small	O
interval	O
on	O
chromosome	O
17q12	O
-	O
21	O
:	O
exclusion	O
of	O
candidate	O
genes	O
edh17b2	O
and	O
rara	O
.	O
	
a	O
susceptibility	O
gene	O
for	O
hereditary	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
brca1	O
,	O
has	O
been	O
assigned	O
by	O
linkage	O
analysis	O
to	O
chromosome	O
17q21	O
.	O
	
we	O
have	O
typed	O
22	O
breast	B-Disease
and	I-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
with	O
eight	O
polymorphisms	O
from	O
the	O
chromosome	O
17q12	O
-	O
21	O
region	O
,	O
including	O
two	O
in	O
the	O
edh17b2	O
gene	O
.	O
	
genetic	O
recombination	O
with	O
the	O
breast	B-Disease
cancer	I-Disease
trait	O
excludes	O
rara	O
from	O
further	O
consideration	O
as	O
a	O
candidate	O
gene	O
for	O
brca1	O
.	O
	
mutations	O
in	O
the	O
edh17b2	O
gene	O
,	O
therefore	O
do	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
hereditary	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
.	O
	
plasma	O
hdl	O
are	O
a	O
negative	O
risk	O
factor	O
for	O
atherosclerosis	B-Disease
.	O
	
subjects	O
with	O
homozygous	O
cetp	B-Disease
deficiency	I-Disease
caused	O
by	O
a	O
gene	O
splicing	O
defect	O
have	O
markedly	O
elevated	O
hdl	O
;	O
however	O
,	O
heterozygotes	O
have	O
only	O
mild	O
increases	O
in	O
hdl	O
.	O
	
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
in	O
the	O
colchicine	O
era	O
:	O
the	O
fate	O
of	O
one	O
family	O
.	O
	
in	O
order	O
to	O
demonstrate	O
the	O
effect	O
of	O
prophylactic	O
colchicine	O
treatment	O
on	O
the	O
natural	O
history	O
of	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
,	O
a	O
family	O
is	O
presented	O
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	O
by	O
fmf	B-Disease
.	O
	
each	O
patient	O
represents	O
a	O
different	O
stage	O
of	O
the	O
amyloidotic	B-Disease
kidney	I-Disease
disease	I-Disease
of	O
fmf	B-Disease
and	O
the	O
effect	O
of	O
continuous	O
colchicine	O
treatment	O
on	O
its	O
course	O
.	O
	
detection	O
of	O
a	O
new	O
submicroscopic	O
norrie	B-Disease
disease	I-Disease
deletion	O
interval	O
with	O
a	O
novel	O
dna	O
probe	O
isolated	O
by	O
differential	O
alu	O
pcr	O
fingerprint	O
cloning	O
.	O
	
this	O
novel	O
sequence	O
,	O
cpxr318	O
(	O
dxs742	O
)	O
,	O
detects	O
a	O
new	O
submicroscopic	O
deletion	O
interval	O
at	O
the	O
norrie	B-Disease
disease	I-Disease
locus	O
(	O
ndp	O
)	O
.	O
	
finally	O
,	O
dxs742	O
,	O
dsx7	O
,	O
dxs77	O
,	O
and	O
maoa	O
were	O
integrated	O
into	O
a	O
physical	O
map	O
spanning	O
the	O
norrie	B-Disease
disease	I-Disease
locus	O
putative	O
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
gene	O
shares	O
unexpected	O
homology	O
with	O
abc	O
transporters	O
.	O
	
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
is	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
disease	I-Disease
affecting	O
1	O
/	O
20	O
,	O
0	O
males	O
either	O
as	O
cerebral	B-Disease
ald	I-Disease
in	O
childhood	O
or	O
as	O
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
in	O
adults	O
.	O
	
childhood	O
ald	B-Disease
is	O
the	O
more	O
severe	O
form	O
,	O
with	O
onset	O
of	O
neurological	O
symptoms	O
between	O
5	O
-	O
12	O
years	O
of	O
age	O
.	O
	
central	B-Disease
nervous	I-Disease
system	I-Disease
demyelination	I-Disease
progresses	O
rapidly	O
and	O
death	O
occurs	O
within	O
a	O
few	O
years	O
.	O
	
amn	B-Disease
is	O
a	O
milder	O
form	O
of	O
the	O
disease	O
with	O
onset	O
at	O
15	O
-	O
30	O
years	O
of	O
age	O
and	O
a	O
more	O
progressive	O
course	O
.	O
	
adrenal	B-Disease
insufficiency	I-Disease
(	O
addisons	B-Disease
disease	I-Disease
)	O
may	O
remain	O
the	O
only	O
clinical	O
manifestation	O
of	O
ald	B-Disease
.	O
	
the	O
principal	O
biochemical	O
abnormality	O
of	O
ald	B-Disease
is	O
the	O
accumulation	O
of	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
vlcfa	O
)	O
because	O
of	O
impaired	O
beta	O
-	O
oxidation	O
in	O
peroxisomes	O
.	O
	
the	O
normal	O
oxidation	O
of	O
vlcfa	O
-	O
coa	O
in	O
patients	O
fibroblasts	O
suggested	O
that	O
the	O
gene	O
coding	O
for	O
the	O
vlcfa	O
-	O
coa	O
synthetase	O
could	O
be	O
a	O
candidate	O
gene	O
for	O
ald	B-Disease
.	O
	
here	O
we	O
use	O
positional	O
cloning	O
to	O
identify	O
a	O
gene	O
partially	O
deleted	O
in	O
6	O
of	O
85	O
independent	O
patients	O
with	O
ald	B-Disease
.	O
	
an	O
identical	O
deletion	O
was	O
detected	O
in	O
two	O
brothers	O
presenting	O
with	O
different	O
clinical	O
ald	B-Disease
phenotypes	O
.	O
	
targeted	O
modification	O
of	O
the	O
apolipoprotein	O
b	O
gene	O
results	O
in	O
hypobetalipoproteinemia	B-Disease
and	O
developmental	B-Disease
abnormalities	I-Disease
in	O
mice	O
.	O
	
familial	B-Disease
hypobetalipoproteinemia	I-Disease
is	O
an	O
autosomal	B-Disease
codominant	I-Disease
disorder	I-Disease
resulting	O
in	O
a	O
dramatic	O
reduction	O
in	O
plasma	O
concentrations	O
of	O
apolipoprotein	O
(	O
apo	O
)	O
b	O
,	O
cholesterol	O
,	O
and	O
beta	O
-	O
migrating	O
lipoproteins	O
.	O
	
a	O
benefit	O
of	O
hypobetalipoproteinemia	B-Disease
is	O
that	O
mildly	O
affected	O
individuals	O
may	O
be	O
protected	O
from	O
coronary	B-Disease
vascular	I-Disease
disease	I-Disease
.	O
	
mice	O
containing	O
this	O
allele	O
display	O
all	O
of	O
the	O
hallmarks	O
of	O
human	O
hypobetalipoproteinemia	B-Disease
they	O
produce	O
a	O
truncated	O
apob	O
protein	O
,	O
apob70	O
,	O
and	O
have	O
markedly	O
decreased	O
plasma	O
concentrations	O
of	O
apob	O
,	O
beta	O
-	O
lipoproteins	O
,	O
and	O
total	O
cholesterol	O
.	O
	
in	O
addition	O
,	O
the	O
mice	O
manifest	O
several	O
characteristics	O
that	O
are	O
occasionally	O
observed	O
in	O
human	O
hypobetalipoproteinemia	B-Disease
,	O
including	O
reduced	O
plasma	O
triglyceride	O
concentrations	O
,	O
fasting	O
chylomicronemia	B-Disease
,	O
and	O
reduced	O
high	O
density	O
lipoprotein	O
cholesterol	O
.	O
	
an	O
unexpected	O
finding	O
is	O
that	O
the	O
modified	O
apob	O
allele	O
is	O
strongly	O
associated	O
with	O
exencephalus	B-Disease
and	O
hydrocephalus	B-Disease
.	O
	
these	O
mice	O
should	O
help	O
increase	O
our	O
understanding	O
of	O
hypobetalipoproteinemia	B-Disease
,	O
atherogenesis	B-Disease
,	O
and	O
the	O
etiology	O
of	O
exencephalus	B-Disease
and	O
hydrocephalus	B-Disease
.	O
	
.	O
	
a	O
novel	O
disease	O
with	O
deficiency	B-Disease
of	I-Disease
mitochondrial	I-Disease
very	I-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coa	I-Disease
dehydrogenase	I-Disease
.	O
	
two	O
of	O
the	O
patients	O
,	O
4	O
-	O
5	O
month	O
old	O
boys	O
,	O
were	O
found	O
to	O
have	O
a	O
novel	O
disease	O
,	O
vlcad	B-Disease
deficiency	I-Disease
,	O
as	O
judged	O
from	O
the	O
results	O
of	O
very	O
low	O
palmitoyl	O
-	O
coa	O
dehydrogenase	O
activity	O
and	O
the	O
lack	O
of	O
immunoreactivity	O
toward	O
antibody	O
raised	O
to	O
purified	O
vlcad	O
.	O
	
.	O
	
molecular	O
characterization	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
patients	O
of	O
chinese	O
descent	O
and	O
identification	O
of	O
new	O
base	O
substitutions	O
in	O
the	O
human	O
g6pd	O
gene	O
.	O
	
the	O
underlying	O
dna	O
changes	O
associated	O
with	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
-	I-Disease
deficient	I-Disease
asians	O
have	O
not	O
been	O
extensively	O
investigated	O
.	O
	
to	O
fill	O
this	O
gap	O
,	O
we	O
sequenced	O
the	O
g6pd	O
gene	O
of	O
43	O
g6pd	B-Disease
-	I-Disease
deficient	I-Disease
chinese	O
whose	O
g6pd	O
was	O
well	O
characterized	O
biochemically	O
.	O
	
these	O
five	O
nucleotide	O
substitutions	O
account	O
for	O
over	O
83	O
%	O
of	O
our	O
43	O
g6pd	B-Disease
-	I-Disease
deficient	I-Disease
samples	O
and	O
these	O
substitutions	O
have	O
not	O
been	O
reported	O
in	O
non	O
-	O
asians	O
.	O
	
the	O
substitutions	O
at	O
cdna	O
1376	O
and	O
1388	O
account	O
for	O
over	O
50	O
%	O
of	O
the	O
43	O
samples	O
examined	O
indicating	O
a	O
high	O
prevalence	O
of	O
these	O
two	O
alleles	O
among	O
g6pd	B-Disease
-	I-Disease
deficient	I-Disease
chinese	O
.	O
	
our	O
findings	O
add	O
support	O
to	O
the	O
notion	O
that	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
much	O
of	O
the	O
phenotypic	O
heterogeneity	O
of	O
g6pd	B-Disease
deficiency	I-Disease
.	O
	
.	O
	
identification	O
of	O
mutations	O
in	O
danish	O
choroideremia	B-Disease
families	O
.	O
	
we	O
have	O
searched	O
for	O
mutations	O
in	O
the	O
choroideremia	B-Disease
gene	O
(	O
chm	B-Disease
)	O
in	O
patients	O
from	O
12	O
danish	O
families	O
in	O
which	O
chm	B-Disease
is	O
segregating	O
.	O
	
structure	O
and	O
genomic	O
sequence	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
kinase	O
)	O
gene	O
.	O
	
the	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
ctg	O
trinucleotide	O
repeat	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
gene	O
encoding	O
for	O
a	O
protein	O
with	O
putative	O
serine	O
-	O
threonine	O
protein	O
kinase	O
activity	O
.	O
	
in	O
this	O
report	O
we	O
present	O
the	O
genomic	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
dm	B-Disease
kinase	O
gene	O
.	O
	
a	O
comparison	O
of	O
these	O
sequences	O
with	O
each	O
other	O
and	O
with	O
known	O
cdna	O
sequences	O
from	O
both	O
species	O
,	O
led	O
us	O
to	O
predict	O
a	O
translation	O
initiation	O
codon	O
,	O
as	O
well	O
as	O
determine	O
the	O
organization	O
of	O
the	O
dm	B-Disease
kinase	O
gene	O
.	O
	
several	O
polymorphisms	O
within	O
the	O
human	O
dm	B-Disease
kinase	O
gene	O
have	O
been	O
identified	O
,	O
and	O
pcr	O
assays	O
to	O
detect	O
two	O
of	O
these	O
are	O
described	O
.	O
	
the	O
complete	O
sequence	O
and	O
characterization	O
of	O
the	O
structure	O
of	O
the	O
dm	B-Disease
kinase	O
gene	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
novel	O
polymorphisms	O
within	O
the	O
gene	O
,	O
represent	O
an	O
important	O
step	O
in	O
a	O
further	O
understanding	O
of	O
the	O
genetics	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
and	O
the	O
molecular	O
biology	O
of	O
the	O
gene	O
.	O
	
.	O
	
autosomal	O
recessive	O
transmission	O
of	O
hemophilia	B-Disease
a	I-Disease
due	O
to	O
a	O
von	B-Disease
willebrand	I-Disease
factor	O
mutation	O
.	O
	
the	O
differential	O
diagnosis	O
of	O
the	O
genetic	B-Disease
bleeding	I-Disease
disorders	I-Disease
,	O
hemophilia	B-Disease
a	I-Disease
and	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
,	O
is	O
occasionally	O
confounded	O
by	O
the	O
close	O
molecular	O
relationship	O
of	O
coagulation	O
factor	O
viii	O
and	O
von	B-Disease
willebrand	I-Disease
factor	O
(	O
vwf	O
)	O
.	O
	
this	O
report	O
describes	O
the	O
autosomal	O
inheritance	O
of	O
a	O
hemophilia	B-Disease
a	I-Disease
phenotype	O
due	O
to	O
a	O
mutation	O
of	O
vwf	O
that	O
results	O
in	O
defective	O
factor	O
viii	O
binding	O
.	O
	
however	O
,	O
the	O
mutant	O
failed	O
to	O
bind	O
factor	O
viii	O
,	O
demonstrating	O
that	O
the	O
mutation	O
was	O
functionally	O
related	O
to	O
the	O
observed	O
hemophilia	B-Disease
phenotype	O
.	O
	
the	O
family	O
we	O
describe	O
demonstrates	O
the	O
recessive	O
inheritance	O
of	O
a	O
recently	O
recognized	O
class	O
of	O
genetic	O
bleeding	O
disorders	O
,	O
we	O
call	O
autosomal	O
hemophilia	B-Disease
.	O
	
we	O
conclude	O
that	O
vwf	O
mutation	O
may	O
be	O
an	O
under	O
recognized	O
cause	O
of	O
hemophilia	B-Disease
,	O
especially	O
in	O
cases	O
where	O
the	O
inheritance	O
pattern	O
is	O
not	O
consistent	O
with	O
x	O
-	O
linked	O
transmission	O
.	O
	
somatic	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
mutation	O
in	O
clear	O
cell	O
papillary	B-Disease
cystadenoma	I-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
.	O
	
papillary	B-Disease
cystadenoma	I-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
is	O
an	O
uncommon	O
benign	O
lesion	O
that	O
may	O
occur	O
sporadically	O
or	O
as	O
a	O
manifestation	O
of	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
disease	I-Disease
.	O
	
neither	O
immunohistochemical	O
studies	O
nor	O
molecular	O
genetic	O
analyses	O
of	O
the	O
vhl	B-Disease
gene	O
have	O
been	O
reported	O
previously	O
for	O
this	O
lesion	O
.	O
	
the	O
authors	O
describe	O
two	O
cases	O
of	O
clear	O
cell	O
papillary	B-Disease
cystadenoma	I-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
,	O
both	O
of	O
which	O
were	O
initially	O
confused	O
with	O
metastatic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
	
because	O
clear	O
cell	O
papillary	B-Disease
cystadenoma	I-Disease
is	O
similar	O
to	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
histologically	O
,	O
and	O
because	O
both	O
occur	O
as	O
components	O
of	O
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
complex	O
,	O
the	O
authors	O
analyzed	O
both	O
cases	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
vhl	B-Disease
gene	O
.	O
	
a	O
somatic	O
vhl	B-Disease
gene	O
mutation	O
was	O
detected	O
in	O
one	O
of	O
the	O
two	O
tumors	B-Disease
by	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
	
as	O
the	O
vhl	B-Disease
gene	O
is	O
believed	O
to	O
function	O
as	O
a	O
tumor	B-Disease
suppressor	O
gene	O
,	O
vhl	B-Disease
gene	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
tumorigenesis	O
in	O
sporadic	O
cystadenomas	B-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
.	O
	
identification	O
of	O
wasp	O
mutations	O
in	O
patients	O
with	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
and	O
isolated	B-Disease
thrombocytopenia	I-Disease
reveals	O
allelic	O
heterogeneity	O
at	O
the	O
was	B-Disease
locus	O
.	O
	
mutation	O
in	O
the	O
gene	O
encoding	O
the	O
recently	O
isolated	O
wasp	O
protein	O
has	O
now	O
been	O
identified	O
as	O
the	O
genetic	B-Disease
defect	I-Disease
responsible	O
for	O
the	O
x	B-Disease
-	I-Disease
linked	I-Disease
wiskott	I-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
,	O
a	O
primary	O
immunodeficiency	B-Disease
disease	I-Disease
associated	O
with	O
extensive	O
phenotypic	O
variability	O
.	O
	
to	O
elucidate	O
the	O
range	O
of	O
wasp	O
mutations	O
responsible	O
for	O
was	B-Disease
,	O
we	O
used	O
pcr	O
-	O
sscp	O
analysis	O
to	O
screen	O
for	O
wasp	O
gene	O
mutation	O
in	O
19	O
unrelated	O
boys	O
with	O
the	O
diagnosis	O
of	O
classical	O
or	O
attenuated	O
was	B-Disease
or	O
isolated	B-Disease
thrombocytopenia	I-Disease
.	O
	
however	O
,	O
a	O
missense	O
mutation	O
which	O
results	O
in	O
substitution	O
of	O
the	O
arginine	O
at	O
was	B-Disease
codon	O
86	O
was	O
identified	O
in	O
three	O
boys	O
with	O
severe	O
was	B-Disease
as	O
well	O
as	O
in	O
one	O
boy	O
presenting	O
with	O
thrombocytopenia	B-Disease
alone	O
.	O
	
while	O
the	O
three	O
mutations	O
found	O
in	O
the	O
isolated	B-Disease
thrombocytopenia	I-Disease
patients	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
about	O
one	O
-	O
half	O
of	O
the	O
gene	O
alterations	O
detected	O
in	O
both	O
severe	O
and	O
attenuated	O
was	B-Disease
patients	O
result	O
in	O
frameshifted	O
transcript	O
and	O
premature	O
translation	O
termination	O
.	O
	
these	O
findings	O
therefore	O
confirm	O
the	O
association	O
of	O
was	B-Disease
with	O
wasp	O
mutation	O
and	O
identify	O
wasp	O
mutation	O
as	O
a	O
cause	O
for	O
isolated	O
congenital	B-Disease
thrombocytopenia	I-Disease
in	O
males	O
.	O
	
while	O
the	O
wasp	O
gene	O
defects	O
responsible	O
for	O
isolated	B-Disease
thrombocytopenia	I-Disease
and	O
other	O
mild	O
presentations	O
of	O
was	B-Disease
do	O
not	O
appear	O
distinct	O
from	O
those	O
resulting	O
in	O
severe	O
was	B-Disease
,	O
these	O
data	O
indicate	O
that	O
analysis	O
of	O
wasp	O
gene	O
mutation	O
provides	O
a	O
valuable	O
tool	O
for	O
distinguishing	O
the	O
spectrum	O
of	O
was	B-Disease
patients	O
and	O
the	O
subset	O
of	O
males	O
with	O
isolated	B-Disease
thrombocytopenia	I-Disease
who	O
represent	O
mild	O
cases	O
of	O
was	B-Disease
.	O
	
.	O
	
wasp	O
gene	O
mutations	O
in	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
and	O
x	B-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
.	O
	
23	O
and	O
shown	O
to	O
be	O
mutated	O
in	O
three	O
patients	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
.	O
	
four	O
amino	O
acid	O
substitutions	O
,	O
leu27phe	O
,	O
thr48ile	O
,	O
val75met	O
and	O
arg477lys	O
,	O
were	O
found	O
in	O
patients	O
with	O
congenital	B-Disease
thrombocytopenia	I-Disease
and	O
no	O
clinically	O
evident	O
immune	O
defect	O
indicating	O
that	O
the	O
wasp	O
gene	O
is	O
the	O
site	O
for	O
mutations	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
as	O
well	O
as	O
in	O
was	B-Disease
.	O
	
a	O
t	O
-	O
cell	O
line	O
from	O
a	O
was	B-Disease
patient	O
contained	O
two	O
independent	O
dna	O
alterations	O
,	O
a	O
constitutional	O
frameshift	O
mutation	O
,	O
also	O
present	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
patient	O
,	O
and	O
compensatory	O
splice	O
site	O
mutation	O
unique	O
to	O
the	O
cell	O
line	O
.	O
	
evidence	O
for	O
inter	O
-	O
generational	O
instability	O
in	O
the	O
cag	O
repeat	O
in	O
the	O
mjd1	O
gene	O
and	O
for	O
conserved	O
haplotypes	O
at	O
flanking	O
markers	O
amongst	O
japanese	O
and	O
caucasian	O
subjects	O
with	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
.	O
	
the	O
size	O
of	O
the	O
(	O
cag	O
)	O
n	O
repeat	O
array	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
mjd1	O
gene	O
and	O
the	O
haplotype	O
at	O
a	O
series	O
of	O
microsatellite	O
markers	O
surrounding	O
the	O
mjd1	O
gene	O
were	O
examined	O
in	O
a	O
large	O
cohort	O
of	O
japanese	O
and	O
caucasian	O
subjects	O
affected	O
with	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
mjd	B-Disease
)	O
.	O
	
first	O
,	O
mjd	B-Disease
is	O
associated	O
with	O
expansion	O
fo	O
the	O
array	O
from	O
the	O
normal	O
range	O
of	O
14	O
-	O
37	O
repeats	O
to	O
68	O
-	O
84	O
repeats	O
in	O
most	O
japanese	O
and	O
caucasian	O
subjects	O
,	O
but	O
no	O
subjects	O
were	O
observed	O
with	O
expansions	O
intermediate	O
in	O
size	O
between	O
those	O
of	O
the	O
normal	O
and	O
mjd	B-Disease
affected	O
groups	O
.	O
	
second	O
,	O
the	O
expanded	O
allele	O
associated	O
with	O
mjd	B-Disease
displays	O
inter	O
-	O
generational	O
instability	O
,	O
particularly	O
in	O
male	O
meioses	O
,	O
and	O
this	O
instability	O
was	O
associated	O
with	O
the	O
clinical	O
phenomenon	O
of	O
anticipation	O
.	O
	
third	O
,	O
the	O
size	O
of	O
the	O
expanded	O
allele	O
is	O
not	O
only	O
inversely	O
correlated	O
with	O
the	O
age	O
-	O
of	O
-	O
onset	O
of	O
mjd	B-Disease
(	O
r	O
=	O
-	O
0	O
.	O
	
738	O
,	O
p	O
<	O
0	O
.	O
	
1	O
)	O
,	O
but	O
is	O
also	O
correlated	O
with	O
the	O
frequency	O
of	O
other	O
clinical	O
features	O
[	O
e	O
.	O
	
g	O
.	O
	
pseudoexophthalmos	O
and	O
pyramidal	O
signs	O
were	O
more	O
frequent	O
in	O
subjects	O
with	O
large	O
repeats	O
(	O
p	O
<	O
0	O
.	O
	
1	O
and	O
p	O
<	O
0	O
.	O
	
5	O
respectively	O
)	O
]	O
.	O
	
fourth	O
,	O
the	O
disease	O
phenotype	O
is	O
significantly	O
more	O
severe	O
and	O
had	O
an	O
early	O
age	O
of	O
onset	O
(	O
16	O
years	O
)	O
in	O
a	O
subject	O
homozygous	O
for	O
the	O
expanded	O
allele	O
,	O
which	O
contrasts	O
with	O
huntington	B-Disease
disease	I-Disease
and	O
suggests	O
that	O
the	O
expanded	O
allele	O
in	O
the	O
mjd1	O
gene	O
could	O
exert	O
its	O
effect	O
either	O
by	O
a	O
dominant	O
negative	O
effect	O
(	O
putatively	O
excluded	O
in	O
hd	B-Disease
)	O
or	O
by	O
a	O
gain	O
of	O
function	O
effect	O
as	O
proposed	O
for	O
hd	B-Disease
.	O
	
finally	O
,	O
japanese	O
and	O
caucasian	O
subjects	O
affected	O
with	O
mjd	B-Disease
share	O
haplotypes	O
at	O
several	O
markers	O
surrounding	O
the	O
mjd1	O
gene	O
,	O
which	O
are	O
uncommon	O
in	O
the	O
normal	O
japanese	O
and	O
caucasian	O
population	O
,	O
and	O
which	O
suggests	O
the	O
existence	O
either	O
of	O
common	O
founders	O
in	O
these	O
populations	O
or	O
of	O
chromosomes	O
susceptible	O
to	O
pathologic	O
expansion	O
of	O
the	O
cag	O
repeat	O
in	O
the	O
mjd1	O
gene	O
.	O
	
a	O
4	O
-	O
megabase	O
yac	O
contig	O
that	O
spans	O
the	O
langer	B-Disease
-	I-Disease
giedion	I-Disease
syndrome	I-Disease
region	O
on	O
human	O
chromosome	O
8q24	O
.	O
	
1	O
:	O
use	O
in	O
refining	O
the	O
location	O
of	O
the	O
trichorhinophalangeal	B-Disease
syndrome	I-Disease
and	O
multiple	O
exostoses	O
genes	O
(	O
trps1	O
and	O
ext1	O
)	O
.	O
	
1	O
and	O
used	O
this	O
map	O
to	O
refine	O
the	O
locations	O
of	O
the	O
genes	O
responsible	O
for	O
langer	B-Disease
-	I-Disease
giedion	I-Disease
syndrome	I-Disease
.	O
	
the	O
minimal	O
region	O
of	O
overlap	O
of	O
langer	B-Disease
-	I-Disease
giedion	I-Disease
syndrome	I-Disease
deletions	O
,	O
previously	O
identified	O
by	O
analysis	O
of	O
15	O
patients	O
,	O
was	O
placed	O
on	O
the	O
map	O
by	O
analysis	O
of	O
2	O
patients	O
whose	O
deletions	O
define	O
the	O
endpoints	O
.	O
	
the	O
chromosome	O
8	O
breakpoint	O
of	O
a	O
balanced	O
t	O
(	O
8	O
;	O
9	O
)	O
(	O
q24	O
.	O
	
11	O
;	O
q33	O
.	O
	
3	O
)	O
translocation	O
from	O
a	O
patient	O
with	O
trichorhinophalangeal	B-Disease
syndrome	I-Disease
(	O
trps	B-Disease
i	O
)	O
was	O
found	O
to	O
be	O
located	O
just	O
within	O
the	O
proximal	O
end	O
of	O
the	O
minimal	O
deletion	O
region	O
.	O
	
3	O
in	O
a	O
patient	O
with	O
multiple	O
exostoses	O
was	O
found	O
to	O
overlap	O
the	O
distal	O
end	O
of	O
the	O
lgs	B-Disease
deletion	O
region	O
,	O
indicating	O
that	O
the	O
ext1	O
gene	O
is	O
distal	O
to	O
the	O
trps1	O
gene	O
and	O
supporting	O
the	O
hypothesis	O
that	O
langer	B-Disease
-	I-Disease
giedion	I-Disease
syndrome	I-Disease
is	O
due	O
to	O
loss	O
of	O
functional	O
copies	O
of	O
both	O
the	O
trps1	O
and	O
the	O
ext1	O
genes	O
brca1	O
mutations	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
young	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
inherited	O
mutations	O
in	O
the	O
brca1	O
gene	O
are	O
associated	O
with	O
a	O
high	O
risk	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
some	O
families	O
.	O
	
however	O
,	O
little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
brca1	O
mutations	O
to	O
breast	B-Disease
cancer	I-Disease
in	O
the	O
general	O
population	O
.	O
	
we	O
analyzed	O
dna	O
samples	O
from	O
women	O
enrolled	O
in	O
a	O
population	O
-	O
based	O
study	O
of	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
to	O
assess	O
the	O
spectrum	O
and	O
frequency	O
of	O
germ	O
-	O
line	O
brca1	O
mutations	O
in	O
young	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
we	O
studied	O
80	O
women	O
in	O
whom	O
breast	B-Disease
cancer	I-Disease
was	O
diagnosed	O
before	O
the	O
age	O
of	O
35	O
,	O
and	O
who	O
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
family	O
history	O
.	O
	
two	O
of	O
the	O
mutations	O
and	O
three	O
of	O
the	O
rare	O
sequence	O
variants	O
were	O
found	O
among	O
the	O
39	O
women	O
who	O
reported	O
no	O
family	O
history	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
alterations	O
in	O
brca1	O
were	O
identified	O
in	O
approximately	O
10	O
percent	O
of	O
this	O
cohort	O
of	O
young	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
the	O
risk	O
of	O
harboring	O
a	O
mutation	O
was	O
not	O
limited	O
to	O
women	O
with	O
family	O
histories	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
thirty	O
-	O
seven	O
families	O
with	O
four	O
or	O
more	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
or	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
were	O
analyzed	O
for	O
mutations	O
in	O
brca1	O
.	O
	
expressivity	O
of	O
185delag	O
in	O
these	O
families	O
varied	O
,	O
from	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
without	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
in	O
one	O
family	O
,	O
penetrance	O
was	O
complete	O
,	O
with	O
females	O
developing	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
or	O
ovarian	B-Disease
cancer	I-Disease
and	O
the	O
male	O
carrier	O
developing	O
prostatic	B-Disease
cancer	I-Disease
,	O
whereas	O
,	O
in	O
the	O
other	O
family	O
,	O
penetrance	O
was	O
incomplete	O
and	O
only	O
breast	B-Disease
cancer	I-Disease
occurred	O
,	O
diagnosed	O
at	O
ages	O
38	O
-	O
81	O
years	O
.	O
	
two	O
novel	O
nonsense	O
mutations	O
led	O
to	O
the	O
loss	O
of	O
mutant	O
brca1	O
transcript	O
in	O
families	O
with	O
10	O
and	O
6	O
cases	O
of	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
overall	O
in	O
our	O
series	O
,	O
brca1	O
mutations	O
have	O
been	O
detected	O
in	O
26	O
families	O
16	O
with	O
positive	O
brca1	O
lod	O
scores	O
,	O
7	O
with	O
negative	O
lod	O
scores	O
(	O
reflecting	O
multiple	O
sporadic	O
breast	B-Disease
cancers	I-Disease
)	O
,	O
and	O
3	O
not	O
tested	O
for	O
linkage	O
.	O
	
deficiency	B-Disease
of	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	O
g6pd	O
)	O
is	O
usually	O
found	O
at	O
high	O
frequencies	O
in	O
areas	O
of	O
the	O
world	O
where	O
malaria	B-Disease
has	O
been	O
endemic	O
.	O
	
the	O
frequency	O
and	O
genetic	O
basis	O
of	O
g6pd	B-Disease
deficiency	I-Disease
have	O
been	O
studied	O
in	O
africa	O
,	O
around	O
the	O
mediterranean	O
,	O
and	O
in	O
the	O
far	O
east	O
,	O
but	O
little	O
such	O
information	O
is	O
available	O
about	O
the	O
situation	O
in	O
india	O
.	O
	
to	O
determine	O
the	O
extent	O
of	O
heterogeneity	O
of	O
g6pd	O
,	O
we	O
have	O
studied	O
several	O
different	O
indian	O
populations	O
by	O
screening	O
for	O
g6pd	B-Disease
deficiency	I-Disease
,	O
followed	O
by	O
molecular	O
analysis	O
of	O
deficient	O
alleles	O
.	O
	
the	O
frequency	O
of	O
g6pd	B-Disease
deficiency	I-Disease
varies	O
between	O
3	O
%	O
and	O
15	O
%	O
in	O
different	O
tribal	O
and	O
urban	O
groups	O
.	O
	
remarkably	O
,	O
a	O
previously	O
unreported	O
deficient	O
variant	O
,	O
g6pd	O
orissa	O
(	O
44	O
ala	O
-	O
-	O
>	O
gly	O
)	O
,	O
is	O
responsible	O
for	O
most	O
of	O
the	O
g6pd	B-Disease
deficiency	I-Disease
in	O
tribal	O
indian	O
populations	O
but	O
is	O
not	O
found	O
in	O
urban	O
populations	O
,	O
where	O
most	O
of	O
the	O
g6pd	B-Disease
deficiency	I-Disease
is	O
due	O
to	O
the	O
g6pd	O
mediterranean	O
(	O
188	O
ser	O
-	O
-	O
>	O
phe	O
)	O
variant	O
.	O
	
evidence	O
for	O
linkage	O
of	O
bipolar	B-Disease
disorder	I-Disease
to	O
chromosome	O
18	O
with	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
.	O
	
a	O
susceptibility	O
gene	O
on	O
chromosome	O
18	O
and	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
have	O
been	O
suggested	O
for	O
bipolar	B-Disease
affective	I-Disease
disorder	I-Disease
(	O
bpad	B-Disease
)	O
.	O
	
we	O
have	O
studied	O
28	O
nuclear	O
families	O
selected	O
for	O
apparent	O
unilineal	O
transmission	O
of	O
the	O
bpad	B-Disease
phenotype	O
,	O
by	O
using	O
31	O
polymorphic	O
markers	O
spanning	O
chromosome	O
18	O
.	O
	
our	O
results	O
provide	O
further	O
support	O
for	O
linkage	O
of	O
bpad	B-Disease
to	O
chromosome	O
18	O
and	O
the	O
first	O
molecular	O
evidence	O
for	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
operating	O
in	O
this	O
disorder	O
.	O
	
a	O
prevalent	O
mutation	O
for	O
galactosemia	B-Disease
among	O
black	O
americans	O
.	O
	
objective	O
to	O
define	O
the	O
mutation	O
causing	O
galactosemia	B-Disease
in	O
patients	O
of	O
black	O
american	O
origin	O
who	O
have	O
no	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
activity	O
in	O
erythrocytes	O
but	O
good	O
clinical	O
outcome	O
.	O
	
results	O
we	O
found	O
a	O
48	O
%	O
prevalence	O
of	O
the	O
s135l	O
mutation	O
among	O
17	O
black	O
american	O
patients	O
with	O
classic	B-Disease
galactosemia	I-Disease
and	O
a	O
1	O
%	O
prevalence	O
in	O
a	O
population	O
of	O
50	O
black	O
americans	O
without	O
galactosemia	B-Disease
.	O
	
the	O
s135l	O
mutation	O
was	O
not	O
found	O
in	O
84	O
white	O
patients	O
with	O
g	O
/	O
g	O
galactosemia	B-Disease
nor	O
in	O
87	O
white	O
control	O
subjects	O
without	O
galactosemia	B-Disease
.	O
	
conclusions	O
the	O
s135l	O
mutation	O
in	O
the	O
galt	O
gene	O
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	B-Disease
among	O
black	O
patients	O
.	O
	
a	O
high	O
incidence	O
of	O
brca1	O
mutations	O
in	O
20	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
we	O
have	O
analyzed	O
20	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
,	O
the	O
majority	O
of	O
which	O
show	O
positive	O
evidence	O
of	O
linkage	O
to	O
chromosome	O
17q12	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
brca1	O
gene	O
.	O
	
brca1	O
mutations	O
cosegregating	O
with	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
were	O
identified	O
in	O
16	O
families	O
,	O
including	O
1	O
family	O
with	O
a	O
case	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
it	O
is	O
expected	O
that	O
the	O
majority	O
of	O
clear	O
examples	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
syndrome	I-Disease
will	O
be	O
associated	O
with	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
brca1	O
.	O
	
.	O
	
brca1	B-Disease
deficiency	I-Disease
results	O
in	O
early	O
embryonic	B-Disease
lethality	I-Disease
characterized	O
by	O
neuroepithelial	B-Disease
abnormalities	I-Disease
.	O
	
the	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
,	O
brca1	O
,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc	O
-	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O
	
mutations	O
in	O
brca1	O
account	O
for	O
at	O
least	O
80	O
%	O
of	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
as	O
well	O
as	O
some	O
non	O
-	O
familial	O
sporadic	O
ovarian	B-Disease
cancers	I-Disease
.	O
	
the	O
loss	O
of	O
wild	O
-	O
type	O
brca1	O
in	O
tumours	B-Disease
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
brca1	O
allele	O
suggests	O
that	O
brca1	O
encodes	O
a	O
tumour	B-Disease
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells	O
.	O
	
to	O
examine	O
the	O
role	O
of	O
brca1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation	O
,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	B-Disease
susceptibility	O
associated	O
with	O
loss	O
of	O
brca1	O
function	O
,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
brca1	O
allele	O
.	O
	
abnormalities	O
in	O
brca1	B-Disease
-	I-Disease
deficient	I-Disease
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	B-Disease
bifida	I-Disease
and	O
anencephaly	B-Disease
.	O
	
in	O
addition	O
,	O
the	O
neuroepithelium	O
in	O
brca1	B-Disease
-	I-Disease
deficient	I-Disease
embryos	O
appeared	O
disorganized	O
,	O
with	O
signs	O
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	O
death	O
.	O
	
.	O
	
identification	O
of	O
mutations	O
in	O
the	O
ald	O
-	O
gene	O
of	O
20	O
families	O
with	O
adrenoleukodystrophy	B-Disease
/	O
adrenomyeloneuropathy	B-Disease
.	O
	
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
,	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
inherited	I-Disease
metabolic	I-Disease
disorder	I-Disease
,	O
is	O
the	O
most	O
frequent	O
inborn	B-Disease
peroxisomal	I-Disease
disease	I-Disease
.	O
	
it	O
leads	O
to	O
demyelination	B-Disease
in	I-Disease
the	I-Disease
central	I-Disease
and	I-Disease
peripheral	I-Disease
nervous	I-Disease
system	I-Disease
.	O
	
the	O
ald	B-Disease
gene	O
has	O
been	O
recently	O
identified	O
and	O
encodes	O
a	O
745	O
-	O
amino	O
-	O
acid	O
protein	O
.	O
	
we	O
screened	O
patients	O
with	O
adrenoleukodystrophy	B-Disease
/	O
adrenomyeloneuropathy	B-Disease
(	O
ald	B-Disease
/	O
amn	B-Disease
)	O
from	O
20	O
kindreds	O
for	O
mutations	O
in	O
the	O
ald	B-Disease
gene	O
.	O
	
eleven	O
missense	O
and	O
two	O
nonsense	O
mutations	O
,	O
five	O
deletions	O
,	O
and	O
one	O
insertion	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
eight	O
reverse	O
transcribed	O
fragments	O
of	O
the	O
ald	B-Disease
-	O
gene	O
mrna	O
.	O
	
the	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
ald	B-Disease
gene	O
of	O
30	O
healthy	O
persons	O
.	O
	
.	O
	
the	O
murine	O
homolog	O
of	O
the	O
human	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
maps	O
to	O
mouse	O
chromosome	O
11d	O
.	O
	
the	O
recently	O
cloned	O
human	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
,	O
brca1	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
17q21	O
.	O
	
atelosteogenesis	B-Disease
type	I-Disease
ii	I-Disease
is	O
caused	O
by	O
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
-	O
transporter	O
gene	O
(	O
dtdst	O
)	O
:	O
evidence	O
for	O
a	O
phenotypic	O
series	O
involving	O
three	O
chondrodysplasias	B-Disease
.	O
	
atelosteogenesis	B-Disease
type	I-Disease
ii	I-Disease
(	O
ao	B-Disease
ii	I-Disease
)	O
is	O
a	O
neonatally	O
lethal	O
chondrodysplasia	B-Disease
whose	O
clinical	O
and	O
histological	O
characteristics	O
resemble	O
those	O
of	O
another	O
chondrodysplasia	B-Disease
,	O
the	O
much	O
less	O
severe	O
diastrophic	B-Disease
dysplasia	I-Disease
(	O
dtd	B-Disease
)	O
.	O
	
dtd	B-Disease
is	O
caused	O
by	O
mutations	O
in	O
the	O
recently	O
identified	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
-	O
transporter	O
gene	O
(	O
dtdst	O
)	O
.	O
	
here	O
,	O
we	O
report	O
that	O
aoii	B-Disease
patients	O
also	O
have	O
dtdst	O
mutations	O
,	O
which	O
lead	O
to	O
defective	O
uptake	O
of	O
inorganic	O
sulfate	O
and	O
insufficient	O
sulfation	O
of	O
macromolecules	O
by	O
patient	O
mesenchymal	O
cells	O
in	O
vitro	O
.	O
	
together	O
with	O
our	O
recent	O
observation	O
that	O
a	O
third	O
even	O
more	O
severe	O
chondrodysplasia	B-Disease
,	O
achondrogenesis	O
type	O
ib	O
,	O
is	O
also	O
caused	O
by	O
mutations	O
in	O
dtdst	O
,	O
these	O
results	O
demonstrate	O
a	O
phenotypic	O
series	O
of	O
three	O
chondrodysplasias	B-Disease
of	O
increasing	O
severity	O
caused	O
by	O
lesions	O
in	O
a	O
single	O
sulfate	O
-	O
transporter	O
gene	O
.	O
	
several	O
brca1	O
mutations	O
have	O
now	O
been	O
found	O
to	O
occur	O
in	O
geographically	O
diverse	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
to	O
investigate	O
mutation	O
origin	O
and	O
mutation	O
-	O
specific	O
phenotypes	O
due	O
to	O
brca1	O
,	O
we	O
constructed	O
a	O
haplotype	O
of	O
nine	O
polymorphic	O
markers	O
within	O
or	O
immediately	O
flanking	O
the	O
brca1	O
locus	O
in	O
a	O
set	O
of	O
61	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
selected	O
for	O
having	O
one	O
of	O
six	O
recurrent	O
brca1	O
mutations	O
.	O
	
a	O
comparison	O
of	O
the	O
six	O
mutations	O
in	O
the	O
relative	O
proportions	O
of	O
cases	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
was	O
suggestive	O
of	O
an	O
effect	O
(	O
p	O
=	O
.	O
	
69	O
)	O
,	O
with	O
57	O
%	O
of	O
women	O
presumed	O
affected	O
because	O
of	O
the	O
1294	O
del	O
40	O
brca1	O
mutation	O
having	O
ovarian	B-Disease
cancer	I-Disease
,	O
compared	O
with	O
14	O
%	O
of	O
affected	O
women	O
with	O
the	O
splice	O
-	O
site	O
mutation	O
in	O
intron	O
5	O
of	O
brca1	O
.	O
	
the	O
brca1	O
gene	O
is	O
in	O
large	O
part	O
responsible	O
for	O
hereditary	B-Disease
human	I-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
the	O
isolation	O
of	O
the	O
mouse	O
brca1	O
homologue	O
will	O
facilitate	O
the	O
creation	O
of	O
mouse	O
models	O
for	O
germline	O
brca1	B-Disease
defects	I-Disease
.	O
	
.	O
	
emerin	B-Disease
deficiency	I-Disease
at	O
the	O
nuclear	O
membrane	O
in	O
patients	O
with	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
mutations	O
in	O
the	O
sta	O
gene	O
at	O
the	O
xq28	O
locus	O
have	O
been	O
found	O
in	O
patients	O
with	O
x	B-Disease
-	I-Disease
linked	I-Disease
emery	I-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
edmd	B-Disease
)	O
.	O
	
using	O
both	O
antisera	O
,	O
we	O
found	O
positive	O
nuclear	O
membrane	O
staining	O
in	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
in	O
the	O
normal	O
controls	O
and	O
in	O
patients	O
with	O
neuromuscular	B-Disease
diseases	I-Disease
other	O
than	O
edmd	B-Disease
.	O
	
in	O
contrast	O
,	O
a	O
deficiency	O
in	O
immunofluorescent	O
staining	O
of	O
skeletal	O
and	O
cardiac	O
muscle	O
from	O
edmd	B-Disease
patients	O
was	O
observed	O
.	O
	
together	O
,	O
our	O
findings	O
suggest	O
the	O
specific	O
deficiency	B-Disease
of	I-Disease
emerin	I-Disease
in	O
the	O
nuclear	O
membrane	O
of	O
muscle	O
cells	O
in	O
patients	O
with	O
edmd	B-Disease
.	O
	
.	O
	
growth	B-Disease
retardation	I-Disease
and	O
tumour	B-Disease
inhibition	O
by	O
brca1	O
.	O
	
inherited	O
mutations	O
in	O
brca1	O
predispose	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
but	O
the	O
role	O
of	O
brca1	O
in	O
sporadic	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
has	O
previously	O
been	O
elusive	O
.	O
	
here	O
,	O
we	O
show	O
that	O
retroviral	O
transfer	O
of	O
the	O
wild	O
-	O
type	O
brca1	O
gene	O
inhibits	O
growth	O
in	O
vitro	O
of	O
all	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
cell	O
lines	O
tested	O
,	O
but	O
not	O
colon	B-Disease
or	I-Disease
lung	I-Disease
cancer	I-Disease
cells	O
or	O
fibroblasts	O
.	O
	
mutant	O
brca1	O
has	O
no	O
effect	O
on	O
growth	O
of	O
breast	B-Disease
cancer	I-Disease
cells	O
;	O
ovarian	B-Disease
cancer	I-Disease
cell	O
growth	O
is	O
not	O
affected	O
by	O
brca1	O
mutations	O
in	O
the	O
5	O
portion	O
of	O
the	O
gene	O
,	O
but	O
is	O
inhibited	O
by	O
3	O
brca1	O
mutations	O
.	O
	
development	O
of	O
mcf	B-Disease
-	I-Disease
7	I-Disease
tumours	I-Disease
in	O
nude	O
mice	O
is	O
inhibited	O
when	O
mcf	O
-	O
7	O
cells	O
are	O
transfected	O
with	O
wild	O
-	O
type	O
,	O
but	O
not	O
mutant	O
,	O
brca1	O
.	O
	
most	O
importantly	O
,	O
among	O
mice	O
with	O
established	O
mcf	B-Disease
-	I-Disease
7	I-Disease
tumours	I-Disease
,	O
peritoneal	O
treatment	O
with	O
a	O
retroviral	O
vector	O
expressing	O
wild	O
-	O
type	O
brca1	O
significantly	O
inhibits	O
tumour	B-Disease
growth	O
and	O
increased	O
survival	O
.	O
	
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
in	O
a	O
sporadic	B-Disease
t	I-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
is	O
a	O
recessive	B-Disease
multi	I-Disease
-	I-Disease
system	I-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
atm	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
	
3	O
)	O
.	O
	
the	O
risk	O
of	O
cancer	B-Disease
,	O
especially	O
lymphoid	B-Disease
neoplasias	I-Disease
,	O
is	O
substantially	O
elevated	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O
	
by	O
analysing	O
tumour	B-Disease
dna	O
from	O
patients	O
with	O
sporadic	B-Disease
t	I-Disease
-	I-Disease
cell	I-Disease
prolymphocytic	I-Disease
leukaemia	I-Disease
(	O
t	B-Disease
-	I-Disease
pll	I-Disease
)	O
,	O
a	O
rare	O
clonal	B-Disease
malignancy	I-Disease
with	O
similarities	O
to	O
a	O
mature	B-Disease
t	I-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
seen	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
atm	O
mutations	O
in	O
t	B-Disease
-	I-Disease
pll	I-Disease
.	O
	
in	O
marked	O
contrast	O
to	O
the	O
atm	O
mutation	O
pattern	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B-Disease
were	O
missense	O
mutations	O
.	O
	
two	O
of	O
seventeen	O
mutated	O
t	B-Disease
-	I-Disease
pll	I-Disease
samples	O
had	O
a	O
previously	O
reported	O
a	B-Disease
-	I-Disease
t	I-Disease
allele	O
.	O
	
in	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B-Disease
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B-Disease
.	O
	
occasional	O
missense	O
mutations	O
in	O
atm	O
were	O
also	O
found	O
in	O
tumour	B-Disease
dna	O
from	O
patients	O
with	O
b	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
hodgkins	I-Disease
lymphomas	I-Disease
(	O
b	B-Disease
-	I-Disease
nhl	I-Disease
)	O
and	O
a	O
b	B-Disease
-	I-Disease
nhl	I-Disease
cell	O
line	O
.	O
	
the	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
atm	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B-Disease
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-Disease
t	I-Disease
-	I-Disease
pll	I-Disease
and	O
suggests	O
that	O
atm	O
acts	O
as	O
a	O
tumour	B-Disease
suppressor	O
.	O
	
as	O
constitutional	O
dna	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
t	B-Disease
-	I-Disease
pll	I-Disease
will	O
require	O
further	O
investigation	O
.	O
	
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
,	O
the	O
most	O
prevalent	O
muscular	B-Disease
disorder	I-Disease
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
ctg	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
dm	B-Disease
protein	O
kinase	O
;	O
dmpk	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O
	
constitutional	O
rb1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	I-Disease
.	O
	
in	O
most	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	I-Disease
,	O
tumor	B-Disease
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
rb1	O
gene	O
.	O
	
however	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B-Disease
predisposition	O
to	O
their	O
offspring	O
.	O
	
to	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
rb1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	I-Disease
,	O
we	O
analyzed	O
dna	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B-Disease
tissue	O
.	O
	
the	O
analysis	O
of	O
tumors	B-Disease
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
loh	O
)	O
at	O
intragenic	O
loci	O
.	O
	
for	O
39	O
randomly	O
selected	O
tumors	B-Disease
,	O
sscp	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O
	
mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	B-Disease
with	O
loh	O
.	O
	
in	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B-Disease
without	O
loh	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B-Disease
without	O
loh	O
,	O
both	O
mutations	O
were	O
found	O
.	O
	
thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B-Disease
of	O
36	O
patients	O
.	O
	
in	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	B-Disease
and	O
the	O
other	O
later	O
developed	O
bilateral	B-Disease
retinoblastoma	I-Disease
.	O
	
in	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B-Disease
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
.	O
	
.	O
	
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
man	O
.	O
	
the	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c5	O
)	O
is	O
described	O
.	O
	
the	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O
	
c5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
c5	B-Disease
deficiency	I-Disease
.	O
	
normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
c5	B-Disease
-	I-Disease
deficient	I-Disease
(	O
c5d	B-Disease
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
c5	O
.	O
	
in	O
specific	O
c5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
c5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
c5d	B-Disease
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O
	
further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
c5d	B-Disease
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
c5	O
,	O
rather	O
than	O
a	O
TRUE	O
c5	O
inhibitor	O
or	O
inactivator	O
.	O
	
of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B-Disease
,	O
vasculitis	B-Disease
,	O
and	O
arthritis	B-Disease
in	O
an	O
individual	O
lacking	O
c5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B-Disease
infections	I-Disease
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O
	
other	O
observations	O
indicate	O
that	O
the	O
c5d	B-Disease
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B-Disease
infection	I-Disease
.	O
	
.	O
	
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
hla	O
,	O
and	O
the	O
environment	O
.	O
	
objective	O
to	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
(	O
as	B-Disease
)	O
.	O
	
methods	O
twins	O
with	O
as	B-Disease
were	O
identified	O
from	O
the	O
royal	O
national	O
hospital	O
for	O
rheumatic	B-Disease
diseases	I-Disease
database	O
.	O
	
genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
as	B-Disease
.	O
	
conclusion	O
susceptibility	O
to	O
as	B-Disease
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O
	
hla	O
-	O
b27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
as	B-Disease
.	O
	
germ	O
-	O
line	O
mutations	O
of	O
the	O
brca1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B-Disease
suppressor	O
.	O
	
this	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
bard1	O
and	O
brca1	O
indicates	O
a	O
role	O
for	O
bard1	O
in	O
brca1	O
-	O
mediated	O
tumor	B-Disease
suppression	O
.	O
	
recent	O
studies	O
have	O
shown	O
that	O
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
hh	B-Disease
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
cys282tyr	O
mutation	O
in	O
the	O
hfe	O
gene	O
located	O
4	O
.	O
	
comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
hh	B-Disease
showed	O
some	O
disagreements	O
with	O
the	O
rflp	O
data	O
,	O
particularly	O
in	O
finns	O
.	O
	
the	O
newly	O
described	O
hfe	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
hh	B-Disease
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
hfe	O
tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B-Disease
autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
gly23	O
-	O
-	O
>	O
val	O
in	O
neurophysin	O
ii	O
.	O
	
autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
adndi	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disease	I-Disease
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
avp	O
)	O
.	O
	
affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B-Disease
insipidus	I-Disease
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O
	
the	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
avp	O
-	O
neurophysin	O
ii	O
(	O
npii	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
adndi	B-Disease
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
avp	O
-	O
npii	O
precursor	O
and	O
within	O
npii	O
itself	O
.	O
	
this	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B-Disease
inherited	I-Disease
neurodegeneration	I-Disease
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
	
.	O
	
frequent	O
inactivation	O
of	O
pten	O
/	O
mmac1	O
in	O
primary	O
prostate	B-Disease
cancer	I-Disease
.	O
	
sporadic	B-Disease
prostate	I-Disease
carcinoma	I-Disease
is	O
the	O
most	O
common	O
male	B-Disease
cancer	I-Disease
in	O
the	O
western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B-Disease
remain	O
to	O
be	O
elucidated	O
.	O
	
numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
a	O
new	O
tumor	B-Disease
suppressor	O
gene	O
,	O
pten	O
/	O
mmac1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B-Disease
cancer	I-Disease
cell	O
lines	O
.	O
	
we	O
screened	O
80	O
prostate	B-Disease
tumors	I-Disease
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O
	
the	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B-Disease
establishes	O
pten	O
/	O
mmac1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
.	O
	
risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
huntington	B-Disease
disease	I-Disease
.	O
	
the	O
first	O
predictive	O
testing	O
for	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
dna	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
hd	B-Disease
.	O
	
with	O
direct	O
tests	O
for	O
the	O
hd	B-Disease
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O
	
a	O
novel	O
common	O
missense	O
mutation	O
g301c	O
in	O
the	O
n	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B-Disease
iva	I-Disease
.	O
	
mucopolysaccharidosis	B-Disease
iva	I-Disease
(	O
mps	B-Disease
iva	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
n	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
galns	O
)	O
.	O
	
to	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
galns	O
gene	O
in	O
colombian	O
mps	B-Disease
iva	I-Disease
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
dna	O
(	O
mtdna	O
)	O
lineages	O
.	O
	
three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
colombian	O
mps	B-Disease
iva	I-Disease
unrelated	O
alleles	O
account	O
for	O
84	O
.	O
	
low	O
frequency	O
of	O
brca1	O
germline	O
mutations	O
in	O
45	O
german	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
in	O
this	O
study	O
we	O
investigated	O
45	O
german	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
for	O
germline	O
mutations	O
in	O
the	O
brca1	O
gene	O
.	O
	
we	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B-Disease
cancer	I-Disease
families	O
and	O
in	O
one	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
family	O
.	O
	
among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O
	
these	O
findings	O
show	O
that	O
brca1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O
paternal	O
transmission	O
of	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	I-Disease
.	O
	
we	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
.	O
	
the	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B-Disease
retarded	I-Disease
male	O
who	O
suffers	O
severe	O
muscular	B-Disease
weakness	I-Disease
.	O
	
his	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
dm	B-Disease
.	O
	
their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
dm	B-Disease
,	O
with	O
onset	O
around	O
30	O
years	O
.	O
	
only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B-Disease
dm	I-Disease
have	O
been	O
reported	O
recently	O
.	O
	
we	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B-Disease
dm	I-Disease
.	O
	
decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
dm	B-Disease
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B-Disease
dm	I-Disease
.	O
	
also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
ctg	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B-Disease
dm	I-Disease
.	O
	
we	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B-Disease
dm	I-Disease
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
dm	B-Disease
past	O
30	O
years	O
in	O
the	O
father	O
.	O
	
.	O
	
the	O
rb1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B-Disease
intracranial	I-Disease
retinoblastoma	I-Disease
.	O
	
the	O
rb1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B-Disease
intracranial	I-Disease
retinoblastoma	I-Disease
using	O
dna	O
obtained	O
from	O
both	O
the	O
pineal	B-Disease
and	I-Disease
retinal	I-Disease
tumours	I-Disease
of	O
the	O
patient	O
.	O
	
a	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
rb1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B-Disease
and	I-Disease
the	I-Disease
pineal	I-Disease
tumours	I-Disease
.	O
	
the	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B-Disease
.	O
	
.	O
	
appreciable	O
beta	O
hexosaminidase	O
a	O
(	O
hex	O
a	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B-Disease
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B-Disease
of	I-Disease
hex	I-Disease
a	I-Disease
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
.	O
	
previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
tsd	B-Disease
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O
	
heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
tsd	B-Disease
mutant	O
.	O
	
however	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
a	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
FALSE	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
tsd	B-Disease
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B-Disease
a	I-Disease
deficiency	I-Disease
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O
the	O
tumor	B-Disease
suppressor	O
gene	O
smad4	O
/	O
dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O
	
mutations	O
in	O
the	O
smad4	O
/	O
dpc4	O
tumor	B-Disease
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
tgfbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B-Disease
cancers	I-Disease
.	O
	
growth	B-Disease
retardation	I-Disease
of	O
the	O
smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O
	
aggregation	O
of	O
mutant	O
smad4	O
es	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B-Disease
defect	I-Disease
.	O
	
these	O
results	O
indicate	O
that	O
smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B-Disease
defect	I-Disease
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O
	
prevalence	O
of	O
p16	O
and	O
cdk4	O
germline	O
mutations	O
in	O
48	O
melanoma	B-Disease
-	O
prone	O
families	O
in	O
france	O
.	O
	
the	O
french	O
familial	B-Disease
melanoma	I-Disease
study	O
group	O
.	O
	
germline	O
mutations	O
in	O
the	O
p16	O
and	O
cdk4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B-Disease
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O
	
we	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
french	O
melanoma	B-Disease
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O
	
in	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B-Disease
melanoma	I-Disease
and	O
confirm	O
the	O
role	O
of	O
the	O
cdk4	O
gene	O
as	O
a	O
melanoma	B-Disease
-	O
predisposing	O
gene	O
.	O
	
.	O
	
progression	O
of	O
somatic	O
ctg	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
.	O
	
the	O
genetic	O
basis	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
ctg	O
repeat	O
in	O
the	O
34	O
utr	O
of	O
the	O
dm	B-Disease
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O
	
one	O
of	O
the	O
principal	O
features	O
of	O
the	O
dm	B-Disease
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O
	
in	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
dm	B-Disease
ctg	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
ctg	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O
	
aspartylglucosaminuria	B-Disease
among	O
palestinian	O
arabs	O
.	O
	
aspartylglucosaminuria	B-Disease
(	O
agu	B-Disease
)	O
is	O
a	O
rare	O
disorder	B-Disease
of	I-Disease
glycoprotein	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
lysosomal	I-Disease
enzyme	I-Disease
aspartylglucosaminidase	I-Disease
(	O
aga	O
)	O
.	O
	
agu	B-Disease
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O
	
while	O
very	O
few	O
patients	O
with	O
agu	B-Disease
have	O
been	O
reported	O
from	O
non	O
-	O
finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
palestinian	O
arabs	O
from	O
the	O
region	O
of	O
jerusalem	O
.	O
	
the	O
clinical	O
diagnosis	O
of	O
agu	B-Disease
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O
	
detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
atm	O
)	O
gene	O
by	O
g2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O
	
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
atm	O
,	O
result	O
in	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B-Disease
.	O
	
heterozygotes	O
for	O
the	O
atm	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
but	O
may	O
be	O
cancer	B-Disease
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O
	
we	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
g2	O
-	O
phase	O
lymphocytes	O
from	O
7	O
unrelated	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
,	O
13	O
obligate	O
a	B-Disease
-	I-Disease
t	I-Disease
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
x	O
-	O
irradiation	O
with	O
1	O
gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
atm	O
carriers	O
.	O
	
both	O
a	B-Disease
-	I-Disease
t	I-Disease
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls	O
.	O
	
these	O
results	O
show	O
that	O
the	O
g2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
heterozygotes	O
.	O
	
in	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B-Disease
and	I-Disease
sporadic	I-Disease
cancers	I-Disease
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
atm	O
mutations	O
in	O
tumor	B-Disease
risk	O
or	O
development	O
.	O
	
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
atm	O
gene	O
in	O
ethnic	O
populations	O
.	O
	
to	O
facilitate	O
the	O
evaluation	O
of	O
atm	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B-Disease
cancer	I-Disease
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O
	
these	O
assays	O
should	O
facilitate	O
screening	O
for	O
a	B-Disease
-	I-Disease
t	I-Disease
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
	
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
tumor	I-Disease
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O
	
the	O
inactivation	O
of	O
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
tumor	I-Disease
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
vhl	B-Disease
cancer	I-Disease
syndrome	I-Disease
and	O
is	O
associated	O
with	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
(	O
rcc	B-Disease
)	O
and	O
brain	B-Disease
hemangioblastomas	I-Disease
.	O
	
vhl	O
-	O
negative	O
786	O
-	O
0	O
rcc	B-Disease
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
vhl	B-Disease
.	O
	
the	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B-Disease
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O
	
here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
vhl	B-Disease
gene	O
restores	O
the	O
ability	O
of	O
vhl	O
-	O
negative	O
rcc	B-Disease
cancer	I-Disease
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
g0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O
	
both	O
vhl	O
-	O
positive	O
and	O
vhl	O
-	O
negative	O
rcc	B-Disease
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O
	
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
vhl	B-Disease
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O
	
we	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
vhl	B-Disease
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B-Disease
formation	O
.	O
	
this	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
vhl	B-Disease
,	O
implicating	O
vhl	B-Disease
as	O
the	O
first	O
tumor	B-Disease
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
.	O
	
.	O
	
piebaldism	B-Disease
with	O
deafness	B-Disease
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O
	
in	O
a	O
south	O
african	O
girl	O
of	O
xhosa	O
stock	O
with	O
severe	O
piebaldism	B-Disease
and	O
profound	O
congenital	O
sensorineural	B-Disease
deafness	I-Disease
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
kit	O
proto	O
-	O
oncogene	O
,	O
r796g	O
.	O
	
though	O
auditory	B-Disease
anomalies	I-Disease
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
w	O
)	O
due	O
to	O
kit	O
mutations	O
,	O
deafness	B-Disease
is	O
not	O
typical	O
in	O
human	O
piebaldism	B-Disease
.	O
	
thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B-Disease
deafness	I-Disease
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B-Disease
due	O
to	O
kit	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B-Disease
and	O
the	O
various	O
forms	O
of	O
waardenburg	B-Disease
syndrome	I-Disease
.	O
	
.	O
	
cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
col17a1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
.	O
	
patients	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
often	O
show	O
decreased	O
expression	O
of	O
type	O
xvii	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
col17a1	O
.	O
	
this	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
col17a1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mrna	O
splice	O
variants	O
.	O
	
a	O
deletion	O
mutation	O
in	O
col17a1	O
in	O
five	O
austrian	O
families	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O
	
patients	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
have	O
generalized	O
blistering	B-Disease
,	O
nail	B-Disease
dystrophy	I-Disease
,	O
patchy	B-Disease
alopecia	I-Disease
,	O
and	O
dental	B-Disease
abnormalities	I-Disease
.	O
	
skin	B-Disease
fragility	I-Disease
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
xvii	O
collagen	O
(	O
col17a1	O
)	O
.	O
	
recently	O
,	O
we	O
reported	O
five	O
austrian	O
families	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
who	O
share	O
the	O
same	O
col17a1	O
mutation	O
.	O
	
the	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B-Disease
.	O
	
we	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B-Disease
.	O
	
southern	O
blot	O
and	O
pcr	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B-Disease
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
hp	O
to	O
hpr	O
alpha	O
but	O
not	O
to	O
hpr	O
beta	O
(	O
hpdel	O
)	O
.	O
	
in	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B-Disease
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
hp2	O
/	O
hpdel	O
.	O
	
the	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B-Disease
(	O
hp2	O
)	O
and	O
hp2	O
/	O
hpdel	O
,	O
the	O
mother	O
to	O
be	O
hp2	O
-	O
1	O
and	O
hp1	O
/	O
hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B-Disease
(	O
hp2	O
)	O
and	O
hp2	O
/	O
hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
hp1	O
and	O
hp1	O
/	O
hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
hp	O
phenotypes	O
in	O
the	O
child	O
with	O
hp1	O
.	O
	
on	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B-Disease
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
hp	O
phenotypes	O
were	O
well	O
explained	O
.	O
	
however	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B-Disease
remains	O
unknown	O
atm	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
families	O
in	O
the	O
british	O
isles	O
:	O
expression	O
of	O
mutant	O
atm	O
and	O
the	O
risk	O
of	O
leukemia	B-Disease
,	O
lymphoma	B-Disease
,	O
and	O
breast	B-Disease
cancer	I-Disease
.	O
	
we	O
report	O
the	O
spectrum	O
of	O
59	O
atm	O
mutations	O
observed	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
patients	O
in	O
the	O
british	O
isles	O
.	O
	
of	O
51	O
atm	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
british	O
isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B-Disease
degeneration	I-Disease
and	O
cellular	O
features	O
.	O
	
we	O
report	O
,	O
in	O
two	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
,	O
an	O
atm	O
mutation	O
(	O
7271t	O
-	O
-	O
>	O
g	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
	
7	O
;	O
p	O
=	O
.	O
	
25	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
a	B-Disease
-	I-Disease
t	I-Disease
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B-Disease
degeneration	I-Disease
.	O
	
in	O
addition	O
,	O
we	O
have	O
studied	O
18	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B-Disease
,	O
lymphoma	B-Disease
,	O
preleukemic	O
t	O
-	O
cell	O
proliferation	O
,	O
or	O
hodgkin	B-Disease
lymphoma	I-Disease
,	O
mostly	O
in	O
childhood	O
.	O
	
we	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
atm	O
protein	O
.	O
	
the	O
dmpk	O
gene	O
of	O
severely	O
affected	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
ctg	O
repeat	O
.	O
	
using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
ctg	O
repeat	O
in	O
the	O
dmpk	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
showing	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O
	
the	O
hemochromatosis	B-Disease
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O
	
we	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B-Disease
hemochromatosis	I-Disease
called	O
hfe	O
.	O
	
these	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
hfe	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
tfr	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
.	O
	
.	O
	
the	O
ube3a	O
gene	O
encodes	O
the	O
e6	O
-	O
ap	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
angelman	B-Disease
syndrome	I-Disease
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B-Disease
disomy	I-Disease
.	O
	
mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
cowden	B-Disease
disease	I-Disease
and	O
bannayan	B-Disease
-	I-Disease
zonana	I-Disease
syndrome	I-Disease
,	O
two	O
hamartoma	B-Disease
syndromes	I-Disease
with	O
germline	O
pten	O
mutation	O
.	O
	
the	O
tumour	B-Disease
suppressor	O
gene	O
pten	O
,	O
which	O
maps	O
to	O
10q23	O
.	O
	
3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
ptpase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B-Disease
.	O
	
somatic	O
pten	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B-Disease
breast	I-Disease
,	I-Disease
brain	I-Disease
,	I-Disease
prostate	I-Disease
and	I-Disease
kidney	I-Disease
cancer	I-Disease
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B-Disease
such	O
as	O
endometrial	B-Disease
carcinomas	I-Disease
,	O
malignant	B-Disease
melanoma	I-Disease
and	O
thyroid	B-Disease
tumours	I-Disease
.	O
	
in	O
addition	O
,	O
pten	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B-Disease
syndromes	I-Disease
cowden	B-Disease
disease	I-Disease
(	O
cd	B-Disease
;	O
mim	O
158350	O
)	O
and	O
bannayan	B-Disease
-	I-Disease
zonana	I-Disease
(	I-Disease
bzs	I-Disease
)	I-Disease
or	I-Disease
ruvalcaba	I-Disease
-	I-Disease
riley	I-Disease
-	I-Disease
smith	I-Disease
syndrome	I-Disease
(	O
mim	O
153480	O
)	O
.	O
	
constitutive	O
dna	O
from	O
37	O
cd	B-Disease
families	O
and	O
seven	O
bzs	B-Disease
families	O
was	O
screened	O
for	O
germline	O
pten	O
mutations	O
.	O
	
pten	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
cd	B-Disease
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
.	O
	
a	O
hot	O
spot	O
for	O
pten	O
mutation	O
in	O
cd	B-Disease
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
ptpase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
cd	B-Disease
mutations	O
identified	O
in	O
this	O
exon	O
.	O
	
germline	O
pten	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
bzs	B-Disease
families	O
studied	O
.	O
	
it	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
r233x	O
,	O
was	O
observed	O
in	O
the	O
germline	O
dna	O
from	O
two	O
unrelated	O
cd	B-Disease
families	O
and	O
one	O
bzs	B-Disease
family	O
.	O
	
genotype	O
-	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
bzs	B-Disease
families	O
.	O
	
however	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
cd	B-Disease
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O
	
the	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
cd	B-Disease
families	O
with	O
breast	B-Disease
disease	I-Disease
.	O
	
specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
pten	O
mutation	O
and	O
malignant	B-Disease
breast	I-Disease
disease	I-Disease
.	O
	
however	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
cd	B-Disease
families	O
.	O
	
molecular	O
defects	O
leading	O
to	O
human	O
complement	B-Disease
component	I-Disease
c6	I-Disease
deficiency	I-Disease
in	O
an	O
african	O
-	O
american	O
family	O
.	O
	
complement	B-Disease
component	I-Disease
c6	I-Disease
deficiency	I-Disease
(	O
c6d	B-Disease
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
african	O
-	O
american	O
male	O
with	O
meningococcal	B-Disease
meningitis	I-Disease
.	O
	
the	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
c6d	B-Disease
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B-Disease
or	O
other	O
neisserial	B-Disease
infection	I-Disease
.	O
	
the	O
first	O
,	O
1195delc	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delg	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
c6d	B-Disease
in	O
an	O
unrelated	O
african	O
-	O
american	O
individual	O
.	O
	
mutations	O
in	O
pax6	O
are	O
responsible	O
for	O
human	O
aniridia	B-Disease
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
peters	B-Disease
anomaly	I-Disease
,	O
with	O
congenital	B-Disease
cataracts	I-Disease
,	O
with	O
autosomal	B-Disease
dominant	I-Disease
keratitis	I-Disease
,	O
and	O
with	O
isolated	B-Disease
foveal	I-Disease
hypoplasia	I-Disease
.	O
	
no	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B-Disease
,	O
and	O
pax6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O
	
genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
brca1	O
and	O
brca2	O
genes	O
in	O
breast	B-Disease
cancer	I-Disease
families	O
.	O
	
the	O
breast	B-Disease
cancer	I-Disease
linkage	O
consortium	O
.	O
	
the	O
contribution	O
of	O
brca1	O
and	O
brca2	O
to	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
collected	O
by	O
the	O
breast	B-Disease
cancer	I-Disease
linkage	O
consortium	O
.	O
	
families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B-Disease
or	I-Disease
other	I-Disease
cancers	I-Disease
.	O
	
the	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
were	O
due	O
to	O
brca1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O
brca2	O
.	O
	
conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B-Disease
and	I-Disease
female	I-Disease
breast	I-Disease
cancer	I-Disease
were	O
due	O
to	O
brca2	O
(	O
76	O
%	O
)	O
.	O
	
the	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B-Disease
cancer	I-Disease
only	O
.	O
	
the	O
estimated	O
cumulative	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
reached	O
28	O
%	O
(	O
95	O
%	O
ci	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
ci	O
43	O
%	O
-	O
95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O
	
the	O
corresponding	O
ovarian	B-Disease
cancer	I-Disease
risks	O
were	O
0	O
.	O
	
the	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
appears	O
similar	O
to	O
the	O
risk	O
in	O
brca1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
brca2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O
	
eye	B-Disease
movement	I-Disease
abnormalities	I-Disease
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
i	I-Disease
.	O
	
we	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B-Disease
ataxias	I-Disease
type	I-Disease
i	I-Disease
spinocerebellar	B-Disease
ataxias	I-Disease
1	I-Disease
and	I-Disease
2	I-Disease
(	O
sca1	B-Disease
,	O
n	O
=	O
11	O
;	O
sca2	B-Disease
,	O
n	O
=	O
10	O
)	O
and	O
sca3	B-Disease
/	O
machado	B-Disease
-	I-Disease
joseph	I-Disease
disease	I-Disease
(	O
mjd	B-Disease
)	O
(	O
n	O
=	O
16	O
)	O
.	O
	
in	O
sca1	B-Disease
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B-Disease
.	O
	
in	O
sca2	B-Disease
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O
	
in	O
sca3	B-Disease
,	O
gaze	B-Disease
-	I-Disease
evoked	I-Disease
nystagmus	I-Disease
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O
	
three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B-Disease
-	I-Disease
evoked	I-Disease
nystagmus	I-Disease
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
sca1	B-Disease
,	O
90	O
%	O
of	O
the	O
sca2	B-Disease
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
sca3	B-Disease
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
sca1	B-Disease
,	O
sca2	B-Disease
,	O
and	O
sca3	B-Disease
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
	
.	O
	
genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	I-Disease
.	O
	
ventricular	B-Disease
fibrillation	I-Disease
causes	O
more	O
than	O
300	O
,	O
0	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
usa	O
alone	O
.	O
	
in	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	I-Disease
(	O
ivf	B-Disease
)	O
.	O
	
a	O
distinct	O
group	O
of	O
ivf	B-Disease
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O
	
because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B-Disease
death	I-Disease
,	O
however	O
,	O
molecular	O
genetic	O
studies	O
of	O
ivf	B-Disease
have	O
not	O
yet	O
been	O
done	O
.	O
	
because	O
ivf	B-Disease
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
scn5a	O
.	O
	
we	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
scn5a	O
in	O
three	O
ivf	B-Disease
families	O
.	O
	
our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
ivf	B-Disease
.	O
	
.	O
	
molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B-Disease
iva	I-Disease
in	O
australia	O
and	O
northern	O
ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
t312s	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O
	
mucopolysaccharidosis	B-Disease
iva	I-Disease
(	O
mps	B-Disease
iva	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
n	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
galns	O
)	O
.	O
	
previous	O
studies	O
of	O
patients	O
from	O
a	O
british	O
-	O
irish	O
population	O
showed	O
that	O
the	O
i113f	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
mps	B-Disease
iva	I-Disease
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O
	
we	O
studied	O
mutations	O
in	O
the	O
galns	O
gene	O
from	O
23	O
additional	O
mps	B-Disease
iva	I-Disease
patients	O
(	O
15	O
from	O
australia	O
,	O
8	O
from	O
northern	O
ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O
	
these	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
mps	B-Disease
iva	I-Disease
in	O
british	O
-	O
irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
australia	O
by	O
british	O
-	O
irish	O
migrants	O
.	O
	
.	O
	
identification	O
of	O
constitutional	O
wt1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O
	
constitutional	O
mutations	O
of	O
the	O
wt1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
(	O
dds	B-Disease
)	O
,	O
or	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
(	O
dms	B-Disease
)	O
associated	O
with	O
pseudohermaphroditism	B-Disease
and	O
/	O
or	O
wilms	B-Disease
tumor	I-Disease
(	O
wt	B-Disease
)	O
.	O
	
most	O
mutations	O
in	O
dds	B-Disease
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
r394w	O
)	O
in	O
exon	O
9	O
.	O
	
we	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B-Disease
dms	I-Disease
(	O
idms	B-Disease
)	O
,	O
10	O
with	O
dds	B-Disease
,	O
and	O
4	O
with	O
urogenital	B-Disease
abnormalities	I-Disease
and	O
/	O
or	O
wt	B-Disease
.	O
	
we	O
report	O
wt1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
idms	B-Disease
.	O
	
one	O
male	O
and	O
two	O
female	O
idms	B-Disease
patients	O
with	O
wt1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O
	
two	O
mutations	O
associated	O
with	O
idms	B-Disease
are	O
different	O
from	O
those	O
described	O
in	O
dds	B-Disease
patients	O
.	O
	
no	O
wt1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
idms	B-Disease
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O
	
this	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
dms	B-Disease
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
dms	B-Disease
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
xy	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
xy	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
.	O
	
.	O
	
the	O
185delag	O
mutation	O
in	O
brca1	O
is	O
detected	O
in	O
ashkenazi	O
jews	O
both	O
in	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
in	O
the	O
general	O
population	O
.	O
	
brca1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
ashkenazi	O
185delag	O
mutation	O
carriers	O
who	O
had	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
crystal	O
structure	O
of	O
the	O
hemochromatosis	B-Disease
protein	O
hfe	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O
	
hfe	O
is	O
an	O
mhc	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B-Disease
-	I-Disease
overload	I-Disease
disease	I-Disease
hereditary	B-Disease
hemochromatosis	I-Disease
.	O
	
6	O
a	O
crystal	O
structure	O
of	O
hfe	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B-Disease
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
ph	O
-	O
dependent	O
interactions	O
.	O
	
identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
arg778leu	O
mutation	O
in	O
korean	O
patients	O
with	O
wilson	B-Disease
disease	I-Disease
.	O
	
four	O
mutations	O
-	O
-	O
r778l	O
,	O
a874v	O
,	O
l1083f	O
,	O
and	O
2304delc	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
p	O
-	O
type	O
atpase	O
(	O
atp7b	O
)	O
,	O
were	O
identified	O
in	O
korean	O
patients	O
with	O
wilson	B-Disease
disease	I-Disease
.	O
	
since	O
a	O
mutation	O
at	O
cdna	O
nucleotide	O
2302	O
(	O
2302insc	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
atp7b	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
wilson	B-Disease
disease	I-Disease
.	O
	
disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
cug	O
-	O
binding	O
protein	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
caused	O
by	O
a	O
ctg	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
dm	B-Disease
gene	O
.	O
	
one	O
model	O
of	O
dm	B-Disease
pathogenesis	O
suggests	O
that	O
rnas	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
cug	O
repeats	O
.	O
	
splicing	O
of	O
ctnt	O
was	O
disrupted	O
in	O
dm	B-Disease
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
cug	O
repeats	O
.	O
	
altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
cug	O
-	O
bp	O
therefore	O
may	O
contribute	O
to	O
dm	B-Disease
pathogenesis	O
.	O
	
.	O
	
identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
ii	O
gene	O
in	O
two	O
spanish	O
kindreds	O
with	O
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O
	
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
fndi	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
avp	O
)	O
encoded	O
by	O
the	O
avp	O
-	O
neurophysin	O
ii	O
(	O
avp	O
-	O
npii	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O
	
in	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
fndi	B-Disease
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
dna	O
sequencing	O
of	O
pcr	O
-	O
amplified	O
avp	O
-	O
npii	O
dna	O
.	O
	
this	O
missense	O
mutation	O
,	O
which	O
replaces	O
ala	O
with	O
thr	O
,	O
is	O
frequent	O
among	O
fndi	B-Disease
patients	O
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
	
.	O
	
genetic	O
heterogeneity	O
of	O
saethre	B-Disease
-	I-Disease
chotzen	I-Disease
syndrome	I-Disease
,	O
due	O
to	O
twist	O
and	O
fgfr	O
mutations	O
.	O
	
thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
saethre	B-Disease
-	I-Disease
chotzen	I-Disease
syndrome	I-Disease
,	O
a	O
common	O
autosomal	B-Disease
dominant	I-Disease
condition	I-Disease
of	O
craniosynostosis	B-Disease
and	O
limb	B-Disease
anomalies	I-Disease
,	O
were	O
screened	O
for	O
mutations	O
in	O
twist	O
,	O
fgfr2	O
,	O
and	O
fgfr3	O
.	O
	
to	O
date	O
,	O
our	O
detection	O
rate	O
for	O
twist	O
or	O
fgfr	O
mutations	O
is	O
68	O
%	O
in	O
our	O
saethre	B-Disease
-	I-Disease
chotzen	I-Disease
syndrome	I-Disease
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
twist	O
mutations	O
.	O
	
the	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
twist	O
mutations	O
,	O
are	O
coronal	B-Disease
synostosis	I-Disease
,	O
brachycephaly	B-Disease
,	O
low	B-Disease
frontal	I-Disease
hairline	I-Disease
,	O
facial	B-Disease
asymmetry	I-Disease
,	O
ptosis	B-Disease
,	O
hypertelorism	B-Disease
,	O
broad	B-Disease
great	I-Disease
toes	I-Disease
,	O
and	O
clinodactyly	B-Disease
.	O
	
the	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B-Disease
condition	I-Disease
-	O
such	O
as	O
saethre	B-Disease
-	I-Disease
chotzen	I-Disease
,	I-Disease
crouzon	I-Disease
,	I-Disease
and	I-Disease
pfeiffer	I-Disease
syndromes	I-Disease
-	O
support	O
the	O
hypothesis	O
that	O
twist	O
and	O
fgfrs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
	
.	O
	
mutation	O
analysis	O
of	O
ube3a	O
in	O
angelman	B-Disease
syndrome	I-Disease
patients	O
.	O
	
angelman	B-Disease
syndrome	I-Disease
(	O
as	B-Disease
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B-Disease
disomy	I-Disease
(	O
upd	B-Disease
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
ube3a	O
gene	O
.	O
	
here	O
we	O
describe	O
ube3a	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
sscp	O
analysis	O
in	O
13	O
as	B-Disease
individuals	O
or	O
families	O
.	O
	
in	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
ube3a	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
as	B-Disease
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
as	B-Disease
first	O
cousins	O
,	O
and	O
in	O
the	O
mother	O
of	O
an	O
as	B-Disease
daughter	O
.	O
	
the	O
hemochromatosis	B-Disease
845	O
g	O
-	O
-	O
>	O
a	O
and	O
187	O
c	O
-	O
-	O
>	O
g	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
caucasian	O
populations	O
.	O
	
hemochromatosis	B-Disease
,	O
the	O
inherited	B-Disease
disorder	I-Disease
of	I-Disease
iron	I-Disease
metabolism	I-Disease
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B-Disease
overload	I-Disease
and	O
premature	B-Disease
death	I-Disease
.	O
	
the	O
hemochromatosis	B-Disease
gene	O
,	O
hfe	O
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cdna	O
nucleotides	O
845	O
g	O
-	O
-	O
>	O
a	O
(	O
c282y	O
)	O
and	O
187	O
c	O
-	O
-	O
>	O
g	O
(	O
h63d	O
)	O
.	O
	
although	O
hemochromatosis	B-Disease
is	O
common	O
in	O
caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
european	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O
	
genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
.	O
	
germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B-Disease
suppressor	O
apc	O
are	O
implicated	O
in	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
aapc	B-Disease
)	O
,	O
a	O
variant	O
of	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
.	O
	
aapc	B-Disease
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B-Disease
adenomas	I-Disease
and	O
a	O
later	O
onset	O
of	O
colorectal	B-Disease
cancer	I-Disease
(	O
age	O
>	O
40	O
years	O
)	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
aapc	B-Disease
families	O
.	O
	
by	O
protein	O
-	O
truncation	O
test	O
(	O
ptt	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
apc	B-Disease
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
aapc	B-Disease
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O
	
five	O
novel	O
germ	O
-	O
line	O
apc	B-Disease
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O
	
mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
apc	B-Disease
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O
	
variability	O
in	O
the	O
number	O
of	O
colorectal	B-Disease
adenomas	I-Disease
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O
	
in	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B-Disease
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O
	
in	O
all	O
aapc	B-Disease
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B-Disease
adenomas	I-Disease
and	O
rectal	B-Disease
polyp	I-Disease
sparing	O
was	O
observed	O
.	O
	
no	O
desmoid	B-Disease
tumors	I-Disease
were	O
found	O
in	O
these	O
kindreds	O
.	O
	
our	O
data	O
suggest	O
that	O
,	O
in	O
aapc	B-Disease
families	O
,	O
the	O
location	O
of	O
the	O
apc	B-Disease
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O
	
this	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
fap	B-Disease
patients	O
.	O
	
.	O
	
wilms	B-Disease
'	I-Disease
tumor	I-Disease
1	O
and	O
dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
sf	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O
	
products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
sf	O
-	O
1	O
)	O
and	O
wilms	B-Disease
tumor	I-Disease
1	O
(	O
wt1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O
	
in	O
contrast	O
,	O
wt1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B-Disease
pseudohermaphroditism	I-Disease
in	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
,	O
fail	O
to	O
synergize	O
with	O
sf	O
-	O
1	O
.	O
	
a	O
mouse	O
model	O
for	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
imprinting	O
-	O
centre	O
mutations	O
.	O
	
deletion	O
of	O
this	O
ic	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
we	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
pws	B-Disease
and	O
the	O
mechanism	O
of	O
this	O
ic	O
.	O
	
mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
snrpn	O
are	O
not	O
sufficient	O
to	O
induce	O
pws	B-Disease
.	O
	
mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
snrpn	O
and	O
the	O
putative	O
pws	O
-	O
ic	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
zfp127	O
(	O
mouse	O
homologue	O
of	O
znf127	O
)	O
,	O
ndn	O
and	O
ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
pws	B-Disease
infants	O
.	O
	
mutations	O
of	O
the	O
atm	O
gene	O
detected	O
in	O
japanese	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O
	
3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
.	O
	
in	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
atm	O
mutations	O
in	O
japanese	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
rna	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
japanese	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O
	
w474c	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
a	O
and	O
is	O
associated	O
with	O
subacute	O
g	B-Disease
(	I-Disease
m2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
.	O
	
mutations	O
in	O
the	O
hexa	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
a	O
(	O
hex	O
a	O
)	O
,	O
that	O
abolish	O
hex	O
a	O
enzyme	O
activity	O
cause	O
tay	B-Disease
-	I-Disease
sachs	I-Disease
disease	I-Disease
(	O
tsd	B-Disease
)	O
,	O
the	O
fatal	O
infantile	B-Disease
form	I-Disease
of	I-Disease
g	I-Disease
(	I-Disease
m2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
,	I-Disease
type	I-Disease
1	I-Disease
.	O
	
we	O
identified	O
a	O
1422	O
g	O
-	O
-	O
>	O
c	O
(	O
amino	O
acid	O
w474c	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
hexa	O
of	O
a	O
non	O
-	O
jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
g	B-Disease
(	I-Disease
m2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
.	O
	
when	O
the	O
w474c	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
hex	O
a	O
(	O
alphabeta	O
)	O
in	O
cos	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
tsd	B-Disease
.	O
	
we	O
conclude	O
that	O
the	O
1422	O
g	O
-	O
-	O
>	O
c	O
mutation	O
is	O
the	O
cause	O
of	O
hex	B-Disease
a	I-Disease
enzyme	I-Disease
deficiency	I-Disease
in	O
the	O
proband	O
.	O
	
the	O
resulting	O
w474c	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
hex	B-Disease
a	I-Disease
deficiency	I-Disease
in	O
this	O
proband	O
.	O
	
.	O
	
two	O
frequent	O
missense	O
mutations	O
in	O
pendred	B-Disease
syndrome	I-Disease
.	O
	
pendred	B-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
early	O
childhood	O
deafness	B-Disease
and	O
goiter	B-Disease
.	O
	
we	O
performed	O
mutation	O
analysis	O
of	O
the	O
pds	B-Disease
gene	O
in	O
patients	O
from	O
14	O
pendred	B-Disease
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O
	
pendred	B-Disease
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
l236p	O
and	O
t416p	O
.	O
	
the	O
identification	O
of	O
two	O
frequent	O
pds	B-Disease
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
pendred	B-Disease
syndrome	I-Disease
.	O
	
insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
l1	O
,	O
in	O
the	O
dmd	B-Disease
gene	O
results	O
in	O
x	B-Disease
-	I-Disease
linked	I-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
(	O
xldcm	B-Disease
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B-Disease
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B-Disease
involvement	I-Disease
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B-Disease
myopathy	I-Disease
.	O
	
to	O
date	O
,	O
several	O
mutations	O
in	O
the	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
,	O
dmd	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
xldcm	B-Disease
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
dmd	O
with	O
the	O
xldcm	B-Disease
phenotype	O
has	O
remained	O
to	O
be	O
elucidated	O
.	O
	
we	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
l1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
dmd	O
in	O
three	O
xldcm	B-Disease
patients	O
from	O
two	O
unrelated	O
japanese	O
families	O
.	O
	
we	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
l1	O
sequence	O
in	O
dmd	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
japanese	O
patients	O
with	O
xldcm	B-Disease
.	O
	
.	O
	
severe	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
adrenal	B-Disease
insufficiency	I-Disease
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
pomc	O
mutations	O
in	O
humans	O
.	O
	
while	O
a	O
few	O
cases	O
of	O
isolated	O
acth	B-Disease
deficiency	I-Disease
have	O
been	O
reported	O
(	O
omim	O
201400	O
)	O
,	O
an	O
inherited	O
pomc	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O
	
recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
msh	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
mc4	O
-	O
r	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	B-Disease
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
pomc	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
pomc	O
with	O
human	O
obesity	B-Disease
.	O
	
the	O
dual	O
role	O
of	O
alpha	O
-	O
msh	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
pomc	O
function	O
would	O
include	O
obesity	B-Disease
,	O
alteration	O
in	O
pigmentation	O
and	O
acth	B-Disease
deficiency	I-Disease
.	O
	
these	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B-Disease
defect	I-Disease
within	O
the	O
pomc	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B-Disease
endocrine	I-Disease
disorder	I-Disease
resulting	O
in	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
adrenal	B-Disease
insufficiency	I-Disease
and	O
red	O
hair	O
pigmentation	O
.	O
	
.	O
	
a	O
european	O
multicenter	O
study	O
of	O
phenylalanine	B-Disease
hydroxylase	I-Disease
deficiency	I-Disease
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O
	
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
and	O
mild	B-Disease
hyperphenylalaninemia	I-Disease
(	O
mhp	B-Disease
)	O
are	O
allelic	B-Disease
disorders	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
pah	O
)	O
.	O
	
previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
pah	B-Disease
deficiency	I-Disease
correlate	O
with	O
pah	O
genotypes	O
.	O
	
our	O
data	O
indicate	O
that	O
the	O
pah	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
pah	B-Disease
deficiency	I-Disease
.	O
	
in	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
pah	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
0	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B-Disease
in	O
newborns	O
.	O
	
somatic	O
instability	O
of	O
the	O
ctg	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O
	
a	O
(	O
ctg	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
utr	O
)	O
of	O
the	O
dm	O
protein	O
kinase	O
gene	O
(	O
dmpk	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
.	O
	
the	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
dm	B-Disease
and	O
other	O
human	O
genetic	B-Disease
diseases	I-Disease
are	O
unknown	O
.	O
	
we	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
ctg	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
ctg	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
dm	B-Disease
region	O
,	O
using	O
small	O
-	O
pool	O
pcr	O
.	O
	
as	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
dm	B-Disease
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O
	
a	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B-Disease
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B-Disease
phenotype	O
.	O
	
we	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
rb1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B-Disease
phenotype	O
.	O
	
in	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B-Disease
tumors	I-Disease
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O
	
analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B-Disease
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O
	
maternal	B-Disease
disomy	I-Disease
and	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
	
2	O
)	O
.	O
	
maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
(	I-Disease
upd	I-Disease
)	I-Disease
for	I-Disease
chromosome	I-Disease
15	I-Disease
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
we	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B-Disease
disomy	I-Disease
15	I-Disease
in	O
pws	B-Disease
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
	
2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O
	
the	O
patient	O
(	O
j	O
.	O
	
b	O
.	O
	
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	O
pws	B-Disease
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O
	
fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
pws	B-Disease
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
pws	B-Disease
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
j	O
.	O
	
maternal	B-Disease
disomy	I-Disease
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
gabrb3	O
)	O
locus	O
.	O
	
uniparental	B-Disease
disomy	I-Disease
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
pws	B-Disease
.	O
	
furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
TRUE	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B-Disease
upd	I-Disease
15	I-Disease
and	O
pws	B-Disease
schwartz	B-Disease
-	I-Disease
jampel	I-Disease
syndrome	I-Disease
type	I-Disease
2	I-Disease
and	O
stuve	B-Disease
-	I-Disease
wiedemann	I-Disease
syndrome	I-Disease
:	O
a	O
case	O
for	O
lumping	O
.	O
	
recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
schwartz	B-Disease
-	I-Disease
jampel	I-Disease
syndrome	I-Disease
(	O
sjs	B-Disease
)	O
of	O
myotonia	B-Disease
and	O
skeletal	B-Disease
dysplasia	I-Disease
,	O
which	O
we	O
called	O
sjs	B-Disease
type	I-Disease
2	I-Disease
.	O
	
this	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
stuve	B-Disease
-	I-Disease
wiedemann	I-Disease
syndrome	I-Disease
(	O
sws	B-Disease
)	O
,	O
which	O
comprises	O
campomelia	B-Disease
at	O
birth	O
with	O
skeletal	B-Disease
dysplasia	I-Disease
,	O
contractures	B-Disease
,	O
and	O
early	B-Disease
death	I-Disease
.	O
	
to	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
sjs	B-Disease
type	I-Disease
2	I-Disease
at	O
age	O
10	O
years	O
and	O
another	O
with	O
sws	B-Disease
at	O
age	O
7	O
years	O
.	O
	
patients	O
reported	O
as	O
having	O
either	O
neonatal	O
sjs	B-Disease
or	O
sws	B-Disease
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B-Disease
disorder	I-Disease
(	O
with	O
congenital	B-Disease
joint	I-Disease
contractures	I-Disease
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B-Disease
,	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B-Disease
-	I-Disease
metaphyseal	I-Disease
skeletal	I-Disease
dysplasia	I-Disease
.	O
	
the	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B-Disease
dysplasia	I-Disease
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
sjs	B-Disease
type	I-Disease
2	I-Disease
,	O
one	O
with	O
sws	B-Disease
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O
	
the	O
hypothesis	O
that	O
sws	B-Disease
and	O
sjs	B-Disease
type	I-Disease
2	I-Disease
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
	
.	O
	
a	O
mouse	O
model	O
of	O
severe	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B-Disease
.	O
	
von	B-Disease
willebrand	I-Disease
factor	I-Disease
(	I-Disease
vwf	I-Disease
)	I-Disease
deficiency	I-Disease
causes	O
severe	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
in	O
humans	O
.	O
	
vwf	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O
	
neither	O
vwf	O
nor	O
vwf	O
propolypeptide	O
(	O
von	B-Disease
willebrand	I-Disease
antigen	O
ii	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O
	
defective	O
thrombosis	B-Disease
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B-Disease
injury	I-Disease
.	O
	
we	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B-Disease
willebrand	I-Disease
disease	I-Disease
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vwf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
	
.	O
	
oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
hereditary	B-Disease
ovarian	I-Disease
cancer	I-Disease
clinical	O
study	O
group	O
.	O
	
background	O
women	O
with	O
mutations	O
in	O
either	O
the	O
brca1	O
or	O
the	O
brca2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
	
oral	O
contraceptives	O
protect	O
against	O
ovarian	B-Disease
cancer	I-Disease
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B-Disease
forms	I-Disease
of	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
methods	O
we	O
enrolled	O
207	O
women	O
with	O
hereditary	B-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O
	
results	O
the	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B-Disease
cancer	I-Disease
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O
	
oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B-Disease
cancer	I-Disease
both	O
for	O
carriers	O
of	O
the	O
brca1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
	
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
	
3	O
to	O
0	O
.	O
	
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
brca2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
	
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
	
2	O
to	O
1	O
.	O
	
1	O
)	O
.	O
	
conclusions	O
oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
brca1	O
or	O
brca2	O
gene	O
a	O
japanese	O
family	O
with	O
adrenoleukodystrophy	B-Disease
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O
	
we	O
report	O
a	O
japanese	O
family	O
with	O
adrenoleukodystrophy	B-Disease
(	O
ald	B-Disease
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delgag	O
291	O
)	O
in	O
the	O
ald	B-Disease
gene	O
.	O
	
while	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ald	B-Disease
type	O
.	O
	
the	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
csf	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
alzheimers	B-Disease
disease	I-Disease
(	O
ad	B-Disease
)	O
.	O
	
his	O
brain	O
magnetic	O
resonance	O
image	O
(	O
mri	O
)	O
showed	O
abnormalities	B-Disease
in	I-Disease
the	I-Disease
bilateral	I-Disease
cerebellar	I-Disease
hemispheres	I-Disease
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
pet	O
)	O
.	O
	
in	O
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B-Disease
of	I-Disease
the	I-Disease
cerebral	I-Disease
white	I-Disease
matter	I-Disease
with	O
sparing	O
of	O
the	O
u	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ald	B-Disease
.	O
	
the	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delgag291	O
is	O
part	O
of	O
the	O
cause	O
of	O
japanese	O
ald	B-Disease
with	O
phenotypic	O
variations	O
.	O
	
moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
pet	O
can	O
detect	O
an	O
insidious	B-Disease
lesion	I-Disease
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
ct	O
)	O
or	O
mri	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B-Disease
degeneration	I-Disease
in	O
ald	B-Disease
.	O
	
nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
c9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
japanese	O
complement	B-Disease
c9	I-Disease
deficiency	I-Disease
.	O
	
deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
c9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	I-Disease
in	O
japan	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O
	
we	O
studied	O
the	O
molecular	O
basis	O
of	O
c9	B-Disease
deficiency	I-Disease
in	O
four	O
japanese	O
c9	B-Disease
-	I-Disease
deficient	I-Disease
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B-Disease
meningitis	I-Disease
.	O
	
direct	O
sequencing	O
of	O
amplified	O
c9	O
cdna	O
and	O
dna	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
cga	O
-	O
-	O
>	O
tga	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
c9	B-Disease
-	I-Disease
deficient	I-Disease
individuals	O
.	O
	
the	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
japanese	O
c9	B-Disease
deficiency	I-Disease
.	O
	
.	O
	
the	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O
	
here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B-Disease
in	I-Disease
brca1	I-Disease
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
dna	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O
	
heterozygous	O
mutations	O
in	O
the	O
human	O
pax6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B-Disease
,	O
peters	B-Disease
anomaly	I-Disease
,	O
autosomal	B-Disease
dominant	I-Disease
keratitis	I-Disease
,	O
and	O
familial	B-Disease
foveal	I-Disease
dysplasia	I-Disease
.	O
	
it	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
pax6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B-Disease
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O
	
however	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
c	O
-	O
terminal	O
half	O
of	O
pax6	O
in	O
patients	O
with	O
aniridia	B-Disease
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
dna	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O
	
these	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
pax6	O
in	O
causing	O
aniridia	B-Disease
.	O
	
.	O
	
reversal	O
of	O
severe	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coenzyme	I-Disease
a	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
.	O
	
very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coenzyme	I-Disease
a	I-Disease
dehydrogenase	I-Disease
(	I-Disease
vlcad	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O
	
we	O
describe	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
vlcad	B-Disease
deficiency	I-Disease
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
,	O
hepatomegaly	B-Disease
,	O
encephalopathy	B-Disease
,	O
and	O
hypotonia	B-Disease
.	O
	
biochemical	O
studies	O
indicated	O
vlcad	B-Disease
deficiency	I-Disease
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O
	
clinical	O
recognition	O
of	O
vlcad	B-Disease
deficiency	I-Disease
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B-Disease
in	O
children	O
.	O
	
.	O
	
a	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
dna	O
sequence	O
analysis	O
within	O
the	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
iddm	B-Disease
)	O
locus	O
iddm4	O
on	O
chromosome	O
11q13	O
.	O
	
based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B-Disease
.	O
	
the	O
apc	B-Disease
variants	O
i1307k	O
and	O
e1317q	O
are	O
associated	O
with	O
colorectal	B-Disease
tumors	I-Disease
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O
	
classical	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
carcinoma	I-Disease
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
apc	B-Disease
gene	O
.	O
	
a	O
variant	O
of	O
fap	B-Disease
is	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
apc	B-Disease
gene	O
.	O
	
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
patients	O
have	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
fap	B-Disease
.	O
	
another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B-Disease
has	O
no	O
mutations	O
in	O
the	O
apc	B-Disease
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O
	
recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
apc	B-Disease
(	O
i1307k	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B-Disease
tumors	I-Disease
,	O
including	O
multiple	O
adenomas	B-Disease
,	O
in	O
ashkenazim	O
.	O
	
we	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
carcinoma	I-Disease
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15g	O
)	O
of	O
the	O
apc	B-Disease
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O
	
four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
e1317q	O
missense	O
variant	O
of	O
apc	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B-Disease
polyps	I-Disease
of	I-Disease
the	I-Disease
colorectum	I-Disease
.	O
	
there	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
apc	B-Disease
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
carcinoma	I-Disease
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
fap	B-Disease
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B-Disease
cancer	I-Disease
risk	O
in	O
the	O
general	O
population	O
.	O
	
.	O
	
genomic	O
structure	O
of	O
the	O
human	O
congenital	B-Disease
chloride	I-Disease
diarrhea	I-Disease
(	O
cld	B-Disease
)	O
gene	O
.	O
	
congenital	B-Disease
chloride	I-Disease
diarrhea	I-Disease
(	O
cld	B-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O
	
we	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
cld	B-Disease
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O
	
the	O
genomic	O
structure	O
was	O
determined	O
using	O
dna	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
dna	O
from	O
finnish	O
cld	B-Disease
patients	O
and	O
controls	O
.	O
	
genomic	O
sequencing	O
of	O
a	O
bac	O
clone	O
h	O
_	O
rg364p16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
cld	B-Disease
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
pendred	B-Disease
syndrome	I-Disease
gene	O
(	O
pds	B-Disease
)	O
.	O
	
.	O
	
the	O
apci1307k	O
allele	O
and	O
cancer	B-Disease
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
ashkenazi	O
jews	O
.	O
	
mutations	O
in	O
apc	O
are	O
classically	O
associated	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
multiple	O
intestinal	O
polyps	B-Disease
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B-Disease
cancer	I-Disease
(	O
crc	B-Disease
)	O
.	O
	
apc	B-Disease
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B-Disease
.	O
	
1	O
%	O
of	O
unselected	O
ashkenazi	O
jews	O
and	O
higher	O
proportions	O
of	O
ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
crc	B-Disease
(	O
ref	O
.	O
	
2	O
)	O
.	O
	
to	O
evaluate	O
the	O
role	O
of	O
i1307k	O
in	O
cancer	B-Disease
,	O
we	O
genotyped	O
5	O
,	O
81	O
ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O
	
risk	O
of	O
developing	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
were	O
compared	O
between	O
genotyped	O
i1307k	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O
	
sperm	O
dna	O
analysis	O
in	O
a	O
friedreich	B-Disease
ataxia	I-Disease
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
frda	B-Disease
gene	O
.	O
	
friedreich	B-Disease
ataxia	I-Disease
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
gaa	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
frda	B-Disease
gene	O
.	O
	
the	O
r496h	O
mutation	O
of	O
arylsulfatase	O
a	O
does	O
not	O
cause	O
metachromatic	B-Disease
leukodystrophy	I-Disease
.	O
	
deficiency	B-Disease
of	I-Disease
arylsulfatase	I-Disease
a	I-Disease
(	O
arsa	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
.	O
	
a	O
number	O
of	O
arsa	O
gene	O
mutations	O
responsible	O
for	O
mld	B-Disease
have	O
been	O
identified	O
.	O
	
recently	O
,	O
the	O
r496h	O
mutation	O
of	O
arsa	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
mld	B-Disease
(	O
draghia	O
et	O
al	O
.	O
	
,	O
1997	O
)	O
.	O
	
it	O
is	O
therefore	O
concluded	O
that	O
the	O
r496h	O
mutation	O
of	O
arsa	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
arsa	O
and	O
is	O
not	O
a	O
cause	O
of	O
mld	B-Disease
down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
transgenes	O
.	O
	
to	O
discover	O
genes	O
involved	O
in	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	O
vhl	B-Disease
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
vhl	O
-	O
expressing	O
transgenes	O
.	O
	
reintroduced	O
wild	O
-	O
type	O
vhl	B-Disease
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
ca12	O
gene	O
in	O
the	O
parental	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
cell	O
lines	O
.	O
	
although	O
both	O
domains	O
of	O
the	O
vhl	B-Disease
protein	O
contribute	O
to	O
regulation	O
of	O
ca12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
ca9	O
expression	O
.	O
	
2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B-Disease
.	O
	
additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
ca	O
ix	O
and	O
ca	O
xii	O
enzymes	O
in	O
the	O
regulation	O
of	O
ph	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B-Disease
cell	O
growth	O
.	O
	
a	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B-Disease
mellitus	I-Disease
and	O
optic	B-Disease
atrophy	I-Disease
(	O
wolfram	B-Disease
syndrome	I-Disease
)	O
.	O
	
wolfram	B-Disease
syndrome	I-Disease
(	O
wfs	B-Disease
;	O
omim	O
222300	O
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disorder	I-Disease
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
progressive	O
optic	B-Disease
atrophy	I-Disease
.	O
	
on	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
wfs	B-Disease
gene	O
was	O
localized	O
to	O
a	O
bac	O
/	O
p1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O
	
mutations	O
in	O
a	O
novel	O
gene	O
(	O
wfs1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
wfs	B-Disease
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O
	
stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
brca1	O
and	O
brca2	O
tumor	B-Disease
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O
	
brca1	O
and	O
brca2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hrad51	O
.	O
	
dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
.	O
	
a	O
novel	O
c	O
to	O
a	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
cyp27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
cyp27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
ctx	B-Disease
)	O
.	O
	
our	O
data	O
suggest	O
that	O
the	O
c	O
to	O
a	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
cyp27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
sterol	I-Disease
27	I-Disease
-	I-Disease
hydroxylase	I-Disease
activity	I-Disease
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mrna	O
splicing	O
of	O
the	O
gene	O
.	O
	
atm	O
germline	O
mutations	O
in	O
classical	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
in	O
the	O
dutch	O
population	O
.	O
	
germline	O
mutations	O
in	O
the	O
atm	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
.	O
	
in	O
our	O
study	O
,	O
we	O
have	O
determined	O
the	O
atm	O
mutation	O
spectrum	O
in	O
19	O
classical	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
dutch	O
ethnic	O
origin	O
.	O
	
the	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
turkish	O
a	B-Disease
-	I-Disease
t	I-Disease
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
turkish	O
a	B-Disease
-	I-Disease
t	I-Disease
founder	O
mutation	O
.	O
	
all	O
patients	O
manifested	O
classical	O
a	B-Disease
-	I-Disease
t	I-Disease
and	O
increased	O
cellular	O
radioresistant	O
dna	O
synthesis	O
.	O
	
determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
col4a4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B-Disease
recessive	I-Disease
alport	I-Disease
syndrome	I-Disease
.	O
	
autosomal	B-Disease
recessive	I-Disease
alport	I-Disease
syndrome	I-Disease
is	O
a	O
progressive	O
hematuric	B-Disease
glomerulonephritis	I-Disease
characterized	O
by	O
glomerular	B-Disease
basement	I-Disease
membrane	I-Disease
abnormalities	I-Disease
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
col4a3	O
or	O
the	O
col4a4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
iv	O
collagen	O
chains	O
,	O
respectively	O
.	O
	
we	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
col4a4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B-Disease
recessive	I-Disease
alport	I-Disease
syndrome	I-Disease
.	O
	
founder	O
brca1	O
and	O
brca2	O
mutations	O
in	O
french	O
canadian	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
we	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B-Disease
cancer	I-Disease
-	O
susceptibility	O
genes	O
,	O
brca1	O
and	O
brca2	O
,	O
in	O
french	O
canadian	O
breast	B-Disease
cancer	I-Disease
and	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
from	O
quebec	O
.	O
	
to	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
french	O
canadian	O
cancer	B-Disease
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O
	
7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B-Disease
cancer	I-Disease
were	O
also	O
present	O
in	O
the	O
family	O
.	O
	
3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
in	O
the	O
family	O
.	O
	
interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B-Disease
cancer	I-Disease
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O
	
the	O
identification	O
of	O
common	O
brca1	O
and	O
brca2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
french	O
canadian	O
breast	B-Disease
cancer	I-Disease
and	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
are	O
dp71	O
and	O
dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B-Disease
impairment	I-Disease
in	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
?	O
molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
dmd	B-Disease
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B-Disease
impairment	I-Disease
observed	O
in	O
most	O
dmd	B-Disease
patients	O
.	O
	
complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
dmd	B-Disease
promoters	O
.	O
	
comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B-Disease
impairment	I-Disease
.	O
	
two	O
altered	O
dp71	O
transcripts	O
and	O
two	O
deleted	O
dp140	O
dna	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B-Disease
dysfunction	I-Disease
.	O
	
these	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
dmd	B-Disease
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
dmd	B-Disease
.	O
	
.	O
	
i1307k	O
apc	O
and	O
hmlh1	O
mutations	O
in	O
a	O
non	O
-	O
jewish	O
family	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
we	O
describe	O
a	O
french	O
canadian	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
(	O
hnpcc	B-Disease
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hmlh1	O
.	O
	
interestingly	O
,	O
the	O
i1307k	O
apc	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
,	O
is	O
also	O
present	O
in	O
this	O
family	O
.	O
	
in	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
i1307k	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B-Disease
.	O
	
.	O
	
identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
cpo	O
gene	O
in	O
a	O
japanese	O
hereditary	B-Disease
coproporphyria	I-Disease
family	O
.	O
	
hereditary	B-Disease
coproporphyria	I-Disease
(	O
hcp	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
characterized	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
coproporphyrinogen	I-Disease
oxidase	I-Disease
(	O
cpo	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
cpo	O
gene	O
.	O
	
only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
hcp	B-Disease
patients	O
.	O
	
human	B-Disease
complement	I-Disease
factor	I-Disease
h	I-Disease
deficiency	I-Disease
associated	O
with	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O
	
this	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
human	I-Disease
complement	I-Disease
regulatory	I-Disease
protein	I-Disease
factor	I-Disease
h	I-Disease
(	O
fh	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B-Disease
renal	I-Disease
disease	I-Disease
.	O
	
five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
(	O
hus	B-Disease
)	O
.	O
	
factor	B-Disease
h	I-Disease
deficiency	I-Disease
is	O
the	O
only	O
complement	B-Disease
deficiency	I-Disease
associated	O
with	O
hus	B-Disease
.	O
	
these	O
observations	O
suggest	O
a	O
role	O
for	O
fh	O
and	O
/	O
or	O
fh	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
hus	B-Disease
.	O
	
.	O
	
further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B-Disease
dystrophy	I-Disease
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
japanese	O
population	O
.	O
	
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
mutation	O
is	O
an	O
unstable	O
(	O
ctg	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
dm	B-Disease
chromosomes	O
.	O
	
previous	O
findings	O
in	O
caucasian	O
populations	O
of	O
a	O
dm	B-Disease
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O
	
to	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
dm	B-Disease
mutation	O
exists	O
in	O
the	O
japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
ctg	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O
	
six	O
different	O
haplotypes	O
were	O
found	O
and	O
dm	B-Disease
alleles	O
were	O
always	O
haplotype	O
a	O
.	O
	
to	O
find	O
an	O
origin	O
of	O
the	O
(	O
ctg	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
japanese	O
population	O
we	O
have	O
studied	O
90	O
japanese	O
dm	B-Disease
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O
	
these	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
dm	B-Disease
and	O
friedreichs	B-Disease
ataxia	I-Disease
.	O
	
.	O
	
the	O
molecular	O
basis	O
of	O
c6	B-Disease
deficiency	I-Disease
in	O
the	O
western	O
cape	O
,	O
south	O
africa	O
.	O
	
deficiency	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
c6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
cape	O
,	O
south	O
africa	O
.	O
	
meningococcal	B-Disease
disease	I-Disease
is	O
endemic	O
in	O
the	O
cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
c6	B-Disease
deficiency	I-Disease
(	O
c6q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O
	
we	O
have	O
also	O
observed	O
the	O
879delg	O
defect	O
in	O
two	O
dutch	O
c6	B-Disease
-	I-Disease
deficient	I-Disease
kindreds	O
,	O
but	O
the	O
879delg	O
defect	O
in	O
the	O
cape	O
probably	O
did	O
not	O
come	O
from	O
the	O
netherlands	O
.	O
	
.	O
	
complement	B-Disease
c7	I-Disease
deficiency	I-Disease
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O
	
seven	O
further	O
molecular	O
bases	O
of	O
c7	B-Disease
deficiency	I-Disease
are	O
described	O
.	O
	
the	O
c6	O
/	O
c7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
c7	B-Disease
defects	I-Disease
are	O
tabulated	O
.	O
	
.	O
	
a	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B-Disease
affective	I-Disease
disorder	I-Disease
among	O
the	O
old	O
order	O
amish	O
.	O
	
bipolar	B-Disease
affective	I-Disease
disorder	I-Disease
(	O
bpad	B-Disease
;	O
manic	B-Disease
-	I-Disease
depressive	I-Disease
illness	I-Disease
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B-Disease
and	O
/	O
or	O
hypomania	B-Disease
interspersed	O
with	O
periods	O
of	O
depression	B-Disease
.	O
	
compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
bpad	B-Disease
.	O
	
to	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
bpad	B-Disease
.	O
	
to	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
bpad	B-Disease
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B-Disease
disorders	I-Disease
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B-Disease
disorder	I-Disease
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
old	O
order	O
amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
bpad	B-Disease
.	O
	
these	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
bpad	B-Disease
and	O
perhaps	O
other	O
related	O
affective	B-Disease
disorders	I-Disease
.	O
	
segregation	O
distortion	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O
	
this	O
results	O
in	O
infertility	B-Disease
and	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	I-Disease
(	O
cdm	B-Disease
)	O
with	O
the	O
disappearance	O
of	O
dm	B-Disease
in	O
that	O
pedigree	O
.	O
	
the	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
dm	B-Disease
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
dm	B-Disease
in	O
the	O
population	O
.	O
	
in	O
a	O
survey	O
of	O
dm	B-Disease
in	O
northern	O
ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O
	
sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
dm	B-Disease
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O
	
studies	O
on	O
meiotic	O
drive	O
in	O
dm	B-Disease
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
dm	B-Disease
locus	O
in	O
non	O
-	O
dm	O
heterozygotes	O
for	O
ctgn	O
.	O
	
this	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
dm	B-Disease
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O
	
diagnosis	O
of	O
hemochromatosis	B-Disease
.	O
	
if	O
untreated	O
,	O
hemochromatosis	B-Disease
can	O
cause	O
serious	O
illness	O
and	O
early	B-Disease
death	I-Disease
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O
	
once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B-Disease
overload	I-Disease
.	O
	
liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B-Disease
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O
	
a	O
dna	O
-	O
based	O
test	O
for	O
the	O
hfe	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B-Disease
is	O
still	O
being	O
evaluated	O
.	O
	
currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B-Disease
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O
	
it	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B-Disease
before	O
hepatic	B-Disease
cirrhosis	I-Disease
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O
expectancy	O
.	O
	
.	O
	
prevalence	O
of	O
the	O
i1307k	O
apc	B-Disease
gene	O
variant	O
in	O
israeli	O
jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
background	O
&	O
aims	O
israeli	O
jews	O
of	O
european	O
birth	O
,	O
i	O
.	O
	
e	O
.	O
	
,	O
ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B-Disease
cancer	I-Disease
incidence	O
of	O
any	O
israeli	O
ethnic	O
group	O
.	O
	
the	O
i1307k	O
apc	B-Disease
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O
	
1	O
%	O
of	O
american	O
jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B-Disease
cancer	I-Disease
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
jews	O
.	O
	
we	O
assessed	O
the	O
i1307k	O
prevalence	O
in	O
israeli	O
jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
methods	O
dna	O
samples	O
from	O
500	O
unrelated	O
jews	O
of	O
european	O
or	O
non	O
-	O
european	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B-Disease
,	O
were	O
examined	O
for	O
the	O
i1307k	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
aso	O
)	O
method	O
.	O
	
results	O
in	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
,	O
i1307k	O
was	O
found	O
in	O
5	O
.	O
	
4	O
%	O
of	O
52	O
ashkenazi	O
israelis	O
with	O
familial	O
cancer	B-Disease
(	O
p	O
=	O
0	O
.	O
	
2	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
european	O
jews	O
at	O
increased	O
cancer	B-Disease
risk	O
.	O
	
colorectal	B-Disease
neoplasia	I-Disease
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
ashkenazi	O
i1307k	O
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B-Disease
.	O
	
conclusions	O
the	O
i1307k	O
apc	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B-Disease
,	I-Disease
or	I-Disease
other	I-Disease
,	I-Disease
cancers	I-Disease
in	O
ashkenazi	O
jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B-Disease
cancer	I-Disease
in	O
european	O
israelis	O
.	O
	
systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B-Disease
coproporphyria	I-Disease
and	O
mutation	O
update	O
.	O
	
hereditary	B-Disease
coproporphyria	I-Disease
(	O
hc	B-Disease
)	O
is	O
an	O
acute	O
hepatic	B-Disease
porphyria	I-Disease
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B-Disease
activity	I-Disease
of	I-Disease
coproporphyrinogen	I-Disease
iii	I-Disease
oxidase	I-Disease
(	O
cpo	O
)	O
.	O
	
clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B-Disease
dysfunction	I-Disease
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B-Disease
diseases	I-Disease
.	O
	
the	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
cpo	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
dgge	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
hc	B-Disease
patients	O
from	O
france	O
,	O
holland	O
,	O
and	O
czech	O
republic	O
.	O
	
five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
hc	B-Disease
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
cpo	O
gene	B-Disease
defects	I-Disease
reported	O
so	O
far	O
.	O
	
.	O
	
coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
a	O
alleles	O
and	O
mutation	O
459	O
+	O
1g	O
>	O
a	O
within	O
a	O
family	O
with	O
metachromatic	B-Disease
leukodystrophy	I-Disease
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O
	
in	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
mld	B-Disease
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
a	O
(	O
arsa	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
gs	O
)	O
excretion	O
.	O
	
the	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
arsa	O
and	O
gs	O
values	O
within	O
the	O
range	O
of	O
mld	B-Disease
patients	O
.	O
	
mutation	O
a464v	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
mld	B-Disease
patients	O
and	O
50	O
controls	O
.	O
	
a464v	O
,	O
although	O
clearly	O
modifying	O
arsa	O
and	O
gs	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
mld	B-Disease
,	O
mimicking	O
the	O
frequent	O
arsa	O
pseudodeficiency	O
allele	O
.	O
	
our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
mld	B-Disease
-	O
like	O
arsa	O
and	O
gs	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O
	
human	O
mlh1	O
deficiency	O
predisposes	O
to	O
hematological	B-Disease
malignancy	I-Disease
and	O
neurofibromatosis	B-Disease
type	I-Disease
1	I-Disease
.	O
	
heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
dna	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
we	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
family	O
who	O
developed	O
hematological	B-Disease
malignancy	I-Disease
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B-Disease
type	I-Disease
1	I-Disease
(	O
nf1	B-Disease
)	O
.	O
	
thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
mlh1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B-Disease
and	O
/	O
or	O
lymphoma	B-Disease
associated	O
with	O
neurofibromatosis	B-Disease
type	I-Disease
1	I-Disease
.	O
	
.	O
	
missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
pax6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B-Disease
eye	I-Disease
malformations	I-Disease
.	O
	
mutations	O
of	O
the	O
human	O
pax6	O
gene	O
underlie	O
aniridia	B-Disease
(	O
congenital	B-Disease
absence	I-Disease
of	I-Disease
the	I-Disease
iris	I-Disease
)	O
,	O
a	O
rare	O
dominant	O
malformation	B-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
.	O
	
the	O
spectrum	O
of	O
pax6	O
mutations	O
in	O
aniridia	B-Disease
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O
	
the	O
extraordinary	O
conservation	O
of	O
the	O
pax6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B-Disease
patients	O
.	O
	
this	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
pax6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
pax6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B-Disease
.	O
	
here	O
we	O
present	O
four	O
novel	O
pax6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B-Disease
pupillae	I-Disease
(	O
displaced	B-Disease
pupils	I-Disease
)	O
and	O
congenital	B-Disease
nystagmus	I-Disease
(	O
searching	B-Disease
gaze	I-Disease
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B-Disease
phenotypes	O
.	O
	
our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
pax6	B-Disease
-	I-Disease
related	I-Disease
disease	I-Disease
remains	O
to	O
be	O
uncovered	O
.	O
	
.	O
	
the	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
b	O
,	O
and	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
second	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
.	O
	
the	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
hla	O
to	O
those	O
coding	O
for	O
properdin	O
factor	O
b	O
allotypes	O
and	O
for	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
second	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
c2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O
	
patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
c2	B-Disease
deficiency	I-Disease
.	O
	
12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
c2	B-Disease
deficiency	I-Disease
were	O
found	O
.	O
	
of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
c2	B-Disease
deficiency	I-Disease
gene	O
and	O
the	O
hla	O
-	O
b	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O
	
a	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
c2	B-Disease
deficiency	I-Disease
and	O
hla	O
-	O
b	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O
	
these	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
factor	O
b	O
and	O
c2	B-Disease
deficiency	I-Disease
are	O
located	O
outside	O
those	O
for	O
hla	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
hla	O
-	O
a	O
,	O
-	O
b	O
,	O
-	O
d	O
,	O
factor	O
b	O
allotype	O
,	O
c2	B-Disease
deficiency	I-Disease
,	O
that	O
the	O
genes	O
coding	O
for	O
c2	B-Disease
deficiency	I-Disease
and	O
factor	O
b	O
allotypes	O
are	O
approximately	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
hla	O
-	O
a	O
and	O
hla	O
-	O
b	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
factor	O
b	O
gene	O
and	O
c2	B-Disease
deficiency	I-Disease
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O
	
distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
edmd	B-Disease
)	O
.	O
	
these	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B-Disease
defects	I-Disease
in	O
edmd	B-Disease
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O
	
this	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
a	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
edmd	B-Disease
.	O
	
in	O
edmd	B-Disease
,	O
the	O
additional	O
absence	O
of	O
lamin	O
b1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
	
.	O
	
genetic	O
mapping	O
of	O
the	O
copper	B-Disease
toxicosis	I-Disease
locus	O
in	O
bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O
	
abnormal	O
hepatic	B-Disease
copper	I-Disease
accumulation	I-Disease
is	O
recognized	O
as	O
an	O
inherited	B-Disease
disorder	I-Disease
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O
	
the	O
major	O
cause	O
of	O
hepatic	B-Disease
copper	I-Disease
accumulation	I-Disease
in	O
man	O
is	O
a	O
dysfunctional	O
atp7b	O
gene	O
,	O
causing	O
wilson	B-Disease
disease	I-Disease
(	O
wd	B-Disease
)	O
.	O
	
the	O
atp7b	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B-Disease
overload	I-Disease
disease	O
non	B-Disease
-	I-Disease
indian	I-Disease
childhood	I-Disease
cirrhosis	I-Disease
,	O
indicating	O
genetic	O
heterogeneity	O
.	O
	
by	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B-Disease
toxicosis	I-Disease
(	O
ct	B-Disease
)	O
in	O
bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B-Disease
disease	I-Disease
.	O
	
we	O
examined	O
whether	O
the	O
wd	B-Disease
gene	O
atp7b	O
was	O
also	O
causative	O
for	O
ct	B-Disease
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
atp7b	O
and	O
c04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
fish	O
)	O
.	O
	
c04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
ct	B-Disease
.	O
	
however	O
,	O
bac	O
clones	O
containing	O
atp7b	O
and	O
c04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
cfa22q11	O
and	O
cfa10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	O
wd	B-Disease
cannot	O
be	O
homologous	O
to	O
ct	B-Disease
.	O
	
the	O
copper	O
transport	O
genes	O
ctr1	O
and	O
ctr2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
ct	B-Disease
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
cfa11q22	O
.	O
	
molecular	O
analysis	O
of	O
the	O
apc	B-Disease
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
fap	B-Disease
and	O
evidence	O
for	O
the	O
role	O
of	O
apc	B-Disease
amino	O
acid	O
changes	O
in	O
colorectal	B-Disease
cancer	I-Disease
predisposition	O
.	O
	
background	O
/	O
aims	O
the	O
development	O
of	O
colorectal	B-Disease
cancer	I-Disease
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
mutations	O
.	O
	
in	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
apc	B-Disease
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
apc	B-Disease
mutations	O
in	O
non	O
-	O
fap	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
methods	O
the	O
apc	B-Disease
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
fap	B-Disease
and	O
15	O
non	O
-	O
fap	O
colorectal	B-Disease
cancer	I-Disease
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O
	
results	O
chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
fap	B-Disease
group	O
(	O
105	O
patients	O
)	O
.	O
	
amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
fap	O
group	O
of	O
colorectal	B-Disease
cancer	I-Disease
patients	O
.	O
	
genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
fap	B-Disease
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O
	
this	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
apc	O
associated	O
with	O
both	O
fap	B-Disease
and	O
non	O
-	O
fap	O
colorectal	B-Disease
cancer	I-Disease
patients	O
.	O
	
.	O
	
inherited	B-Disease
colorectal	I-Disease
polyposis	I-Disease
and	O
cancer	B-Disease
risk	O
of	O
the	O
apc	O
i1307k	O
polymorphism	O
.	O
	
germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
apc	B-Disease
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B-Disease
tumor	I-Disease
formation	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
syndrome	I-Disease
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O
	
recently	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
i1307k	O
)	O
of	O
the	O
apc	B-Disease
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
ashkenazi	O
jewish	O
population	O
.	O
	
to	O
assess	O
the	O
risk	O
of	O
this	O
common	O
apc	B-Disease
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
ashkenazi	O
jewish	O
subjects	O
with	O
adenomatous	B-Disease
polyps	I-Disease
and	O
.	O
	
or	O
colorectal	B-Disease
cancer	I-Disease
,	I-Disease
for	O
the	O
apc	O
i1307k	O
polymorphism	O
.	O
	
7	O
for	O
colorectal	B-Disease
neoplasia	I-Disease
(	O
both	O
p	O
=	O
.	O
	
1	O
)	O
.	O
	
furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
apc	O
i1307k	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B-Disease
and	O
colorectal	B-Disease
cancers	I-Disease
per	O
patient	O
(	O
p	O
=	O
.	O
	
3	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O
	
we	O
conclude	O
that	O
the	O
apc	O
i1307k	O
variant	O
leads	O
to	O
increased	O
adenoma	B-Disease
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-	O
4	O
%	O
of	O
all	O
ashkenazi	O
jewish	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
the	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
0	O
americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B-Disease
cancer	I-Disease
prevention	O
in	O
this	O
population	O
.	O
	
localization	O
of	O
human	O
brca1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B-Disease
-	I-Disease
inherited	I-Disease
breast	I-Disease
carcinomas	I-Disease
.	O
	
although	O
the	O
link	O
between	O
the	O
brca1	O
tumour	B-Disease
-	O
suppressor	O
gene	O
and	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
brca1	O
in	O
non	B-Disease
-	I-Disease
familial	I-Disease
cancers	I-Disease
is	O
unclear	O
.	O
	
brca1	O
mutations	O
are	O
rare	O
in	O
sporadic	B-Disease
cancers	I-Disease
,	O
but	O
loss	O
of	O
brca1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	B-Disease
-	I-Disease
familial	I-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
these	O
reagents	O
detect	O
a	O
220	O
-	O
kd	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	B-Disease
malignancies	I-Disease
.	O
	
immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
brca1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B-Disease
lobular	I-Disease
cancers	I-Disease
and	O
low	B-Disease
-	I-Disease
grade	I-Disease
ductal	I-Disease
carcinomas	I-Disease
.	O
	
conversely	O
,	O
brca1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B-Disease
carcinomas	I-Disease
,	O
suggesting	O
that	O
absence	O
of	O
brca1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B-Disease
breast	I-Disease
cancers	I-Disease
.	O
	
germline	O
mutations	O
in	O
brca1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
as	O
a	O
regulated	O
secretory	O
protein	O
,	O
brca1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B-Disease
suppressor	O
gene	O
products	O
.	O
	
.	O
	
ovarian	B-Disease
cancer	I-Disease
risk	O
in	O
brca1	O
carriers	O
is	O
modified	O
by	O
the	O
hras1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
vntr	O
)	O
locus	O
.	O
	
women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
brca1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
by	O
the	O
age	O
of	O
70	O
(	O
ref	O
.	O
	
1	O
)	O
.	O
	
the	O
hras1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
vntr	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
hras1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
	
5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
of	O
cancer	B-Disease
penetrance	O
.	O
	
individuals	O
who	O
have	O
rare	O
alleles	O
of	O
the	O
vntr	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	B-Disease
,	O
including	O
breast	B-Disease
cancer	I-Disease
(	O
2	O
-	O
4	O
)	O
.	O
	
to	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
hras1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
brca1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
pcr	O
-	O
based	O
technique	O
.	O
	
the	O
risk	O
for	O
ovarian	B-Disease
cancer	I-Disease
was	O
2	O
.	O
	
the	O
magnitude	O
of	O
the	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
hras1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B-Disease
ovarian	I-Disease
cancer	I-Disease
(	O
5	O
)	O
.	O
	
susceptibility	O
to	O
breast	B-Disease
cancer	I-Disease
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
hras1	O
alleles	O
.	O
	
this	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B-Disease
cancer	I-Disease
syndrome	I-Disease
a	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
cpg	O
island	O
interrupted	O
by	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
unstable	O
(	O
ctg	O
)	O
n	O
repeat	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
associated	O
with	O
a	O
(	O
ctg	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
dmpk	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O
.	O
	
the	O
dm	B-Disease
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
of	O
chromatin	O
disruption	O
.	O
	
rt	O
-	O
pcr	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
dm	B-Disease
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
dmahp	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
heart	O
and	O
brain	O
.	O
	
germline	O
mutations	O
in	O
the	O
rb1	O
gene	O
in	O
patients	O
with	O
hereditary	B-Disease
retinoblastoma	I-Disease
.	O
	
we	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
rb1	O
gene	O
in	O
familial	B-Disease
or	I-Disease
sporadic	I-Disease
bilateral	I-Disease
retinoblastoma	I-Disease
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
	
type	B-Disease
ii	I-Disease
human	I-Disease
complement	I-Disease
c2	I-Disease
deficiency	I-Disease
.	O
	
type	B-Disease
ii	I-Disease
complement	I-Disease
protein	I-Disease
c2	I-Disease
deficiency	I-Disease
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
c2	O
secretion	O
.	O
	
the	O
type	O
ii	O
c2	O
nan	O
allele	O
(	O
c2q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
mhc	O
)	O
that	O
differ	O
from	O
the	O
mhc	O
of	O
the	O
more	O
common	O
type	B-Disease
i	I-Disease
c2	I-Disease
deficiency	I-Disease
.	O
	
to	O
determine	O
the	O
molecular	O
basis	O
of	O
type	B-Disease
ii	I-Disease
deficiency	I-Disease
the	O
two	O
type	O
ii	O
c2q0	O
genes	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
l	O
-	O
cells	O
.	O
	
subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
c2	O
secretion	O
is	O
impaired	O
in	O
type	B-Disease
ii	I-Disease
c2	I-Disease
deficiency	I-Disease
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
c2q0	O
alleles	O
.	O
	
defective	O
dimerization	O
of	O
von	B-Disease
willebrand	I-Disease
factor	O
subunits	O
due	O
to	O
a	O
cys	O
-	O
>	O
arg	O
mutation	O
in	O
type	B-Disease
iid	I-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
.	O
	
the	O
same	O
heterozygous	O
t	O
-	O
>	O
c	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B-Disease
willebrand	I-Disease
factor	O
(	O
vwf	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B-Disease
iid	I-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
,	O
with	O
no	O
other	O
apparent	O
abnormality	O
.	O
	
we	O
conclude	O
that	O
cys2010	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vwf	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
terminal	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
in	O
type	B-Disease
iid	I-Disease
von	I-Disease
willebrand	I-Disease
disease	I-Disease
.	O
	
.	O
	
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
gtpase	O
cdc42hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O
	
we	O
have	O
identified	O
wasp	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
cdc42hs	O
,	O
but	O
not	O
for	O
the	O
other	O
rho	O
family	O
members	O
,	O
rac	O
and	O
rho	O
.	O
	
thus	O
,	O
wasp	O
provides	O
a	O
novel	O
link	O
between	O
cdc42hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	O
in	O
was	B-Disease
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
addison	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
in	O
young	O
adult	O
male	O
patients	O
.	O
	
x	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ald	B-Disease
)	O
is	O
a	O
genetic	B-Disease
disease	I-Disease
associated	O
with	O
demyelination	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
,	O
adrenal	B-Disease
insufficiency	I-Disease
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
.	O
	
ald	B-Disease
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unknown	O
function	O
.	O
	
the	O
most	O
common	O
phenotype	O
of	O
ald	B-Disease
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
between	O
5	O
-	O
12	O
yr	O
.	O
	
adrenomyeloneuropathy	B-Disease
(	O
amn	B-Disease
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
.	O
	
adrenal	B-Disease
insufficiency	I-Disease
(	O
addisons	B-Disease
disease	I-Disease
)	O
is	O
frequently	O
associated	O
with	O
amn	B-Disease
or	O
cerebral	B-Disease
ald	I-Disease
and	O
may	O
remain	O
the	O
only	O
clinical	O
expression	O
of	O
ald	B-Disease
(	O
8	O
%	O
of	O
cases	O
)	O
.	O
	
the	O
prevalence	O
of	O
ald	B-Disease
among	O
adults	O
with	O
addisons	B-Disease
disease	I-Disease
remains	O
unknown	O
.	O
	
to	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B-Disease
insufficiency	I-Disease
.	O
	
by	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	O
cerebral	B-Disease
ald	I-Disease
,	O
one	O
had	O
adrenomyeloneuropathy	B-Disease
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	O
preclinical	O
amn	B-Disease
.	O
	
our	O
data	O
support	O
the	O
hypothesis	O
that	O
ald	B-Disease
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
addisons	B-Disease
disease	I-Disease
in	O
children	O
and	O
adults	O
.	O
	
.	O
	
tumor	B-Disease
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B-Disease
carcinoma	I-Disease
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O
	
prostate	B-Disease
cancer	I-Disease
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	B-Disease
deaths	O
in	O
the	O
united	O
states	O
.	O
	
prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B-Disease
carcinomas	I-Disease
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B-Disease
carcinomas	I-Disease
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
.	O
	
we	O
report	O
the	O
functional	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B-Disease
adenocarcinoma	I-Disease
cells	O
.	O
	
a	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B-Disease
adenocarcinoma	I-Disease
cell	O
line	O
.	O
	
these	O
data	O
functionally	O
define	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
pac1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
involved	O
in	O
tumor	O
suppression	O
of	O
human	O
prostate	B-Disease
carcinoma	I-Disease
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
be	O
functionally	O
restored	O
in	O
prostatic	B-Disease
adenocarcinoma	I-Disease
.	O
	
.	O
	
low	O
incidence	O
of	O
brca2	O
mutations	O
in	O
breast	B-Disease
carcinoma	I-Disease
and	O
other	O
cancers	B-Disease
.	O
	
inherited	O
mutant	O
alleles	O
of	O
familial	O
tumour	B-Disease
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B-Disease
.	O
	
in	O
addition	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B-Disease
,	O
these	O
tumour	B-Disease
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B-Disease
cancers	I-Disease
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
.	O
	
an	O
exception	O
is	O
brca1	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	O
sporadic	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
this	O
finding	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B-Disease
carcinoma	I-Disease
.	O
	
a	O
second	O
,	O
recently	O
identified	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
gene	O
,	O
brca2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B-Disease
cancer	I-Disease
roughly	O
equal	O
to	O
brca1	O
.	O
	
like	O
brca1	O
,	O
brca2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	B-Disease
suppressor	O
gene	O
.	O
	
individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	O
breast	B-Disease
cancer	I-Disease
,	O
and	O
the	O
tumours	B-Disease
they	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O
	
here	O
we	O
investigate	O
the	O
rate	O
of	O
brca2	O
mutation	O
in	O
sporadic	B-Disease
breast	I-Disease
cancers	I-Disease
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	B-Disease
types	O
.	O
	
surprisingly	O
,	O
mutations	O
in	O
brca2	O
are	O
infrequent	O
in	O
cancers	B-Disease
including	O
breast	B-Disease
carcinoma	I-Disease
.	O
	
however	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B-Disease
tumour	I-Disease
cell	O
line	O
suggests	O
a	O
role	O
for	O
brca2	O
in	O
susceptibility	O
to	O
pancreatic	B-Disease
cancer	I-Disease
.	O
	
.	O
	
founding	O
brca1	O
mutations	O
in	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
southern	O
sweden	O
.	O
	
nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
brca1	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
sweden	O
,	O
by	O
use	O
of	O
sscp	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O
by	O
direct	O
sequencing	O
.	O
	
eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
brca1	O
mutations	O
were	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
,	O
several	O
of	O
them	O
with	O
a	O
predominant	O
ovarian	B-Disease
cancer	I-Disease
phenotype	O
.	O
	
the	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
brca1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
brca1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
tumors	B-Disease
.	O
	
other	O
tumor	B-Disease
types	O
found	O
in	O
brca1	O
mutation	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B-Disease
,	I-Disease
pancreas	I-Disease
,	I-Disease
skin	I-Disease
,	I-Disease
and	I-Disease
lung	I-Disease
cancer	I-Disease
,	O
a	O
malignant	B-Disease
melanoma	I-Disease
,	O
an	O
oligodendroglioma	B-Disease
,	O
and	O
a	O
carcinosarcoma	B-Disease
.	O
	
in	O
all	O
,	O
12	O
of	O
16	O
kindreds	O
manifesting	O
brca1	O
mutation	O
or	O
linkage	O
contained	O
ovarian	B-Disease
cancer	I-Disease
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
p	O
<	O
.	O
	
1	O
)	O
.	O
	
the	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
brca1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
families	O
often	O
characterized	O
by	O
ovarian	B-Disease
cancers	I-Disease
.	O
	
ukcccr	O
familial	O
ovarian	B-Disease
cancer	I-Disease
study	O
group	O
.	O
	
germ	O
-	O
line	O
mutations	O
of	O
the	O
brca1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
cases	O
of	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
we	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
brca1	O
mutations	O
so	O
far	O
reported	O
in	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
	
we	O
have	O
used	O
this	O
technique	O
to	O
analyze	O
brca1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
	
.	O
	
a	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
tp53	O
in	O
a	O
family	O
with	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
.	O
	
we	O
report	O
details	O
of	O
a	O
family	O
with	O
classic	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
in	O
which	O
there	O
is	O
a	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
tumour	B-Disease
suppressor	O
gene	O
tp53	O
.	O
	
this	O
is	O
the	O
first	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B-Disease
tumours	I-Disease
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
.	O
	
the	O
family	O
does	O
not	O
appear	O
to	O
be	O
remarkable	O
in	O
the	O
spectrum	O
of	O
tumours	B-Disease
,	O
and	O
there	O
is	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	B-Disease
from	O
the	O
proband	O
.	O
	
a	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
tumour	B-Disease
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
.	O
	
.	O
	
the	O
spectrum	O
of	O
rb1	O
germ	O
-	O
line	O
mutations	O
in	O
hereditary	B-Disease
retinoblastoma	I-Disease
.	O
	
we	O
have	O
searched	O
for	O
germ	O
-	O
line	O
rb1	O
mutations	O
in	O
119	O
patients	O
with	O
hereditary	B-Disease
retinoblastoma	I-Disease
.	O
	
no	O
correlation	O
between	O
the	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B-Disease
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B-Disease
tumors	I-Disease
was	O
observed	O
.	O
	
.	O
	
phenotypic	O
characterization	O
of	O
individuals	O
with	O
30	O
-	O
40	O
cag	O
repeats	O
in	O
the	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
gene	O
reveals	O
hd	B-Disease
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
.	O
	
abnormal	O
cag	O
expansions	O
in	O
the	O
it	O
-	O
15	O
gene	O
are	O
associated	O
with	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
.	O
	
in	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
cag	O
size	O
ranges	O
on	O
normal	O
and	O
hd	B-Disease
-	O
associated	O
chromosomes	O
.	O
	
seven	O
hd	B-Disease
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
.	O
	
individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
hd	B-Disease
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
.	O
	
the	O
detailed	O
case	O
histories	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	O
of	O
hd	B-Disease
.	O
	
the	O
apparently	O
healthy	O
survival	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
hd	B-Disease
mutation	O
may	O
not	O
always	O
be	O
fully	O
penetrant	O
.	O
	
.	O
	
identification	O
and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
jewish	O
patients	O
with	O
canavan	B-Disease
disease	I-Disease
.	O
	
canavan	B-Disease
disease	I-Disease
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
aspartoacylase	I-Disease
(	O
aspa	O
)	O
.	O
	
the	O
majority	O
of	O
patients	O
with	O
canavan	B-Disease
disease	I-Disease
are	O
from	O
an	O
ashkenazi	O
jewish	O
background	O
.	O
	
the	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
canavan	B-Disease
disease	I-Disease
in	O
25	O
independent	O
patients	O
of	O
non	O
-	O
jewish	O
background	O
.	O
	
the	O
homozygous	O
32	O
deltat	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
african	O
-	O
american	O
origin	O
with	O
canavan	B-Disease
disease	I-Disease
.	O
	
in	O
vitro	O
expression	O
of	O
mutant	O
cdna	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	O
a	O
deficiency	B-Disease
of	I-Disease
aspa	I-Disease
and	O
should	O
therefore	O
result	O
in	O
canavan	B-Disease
disease	I-Disease
.	O
	
.	O
	
identification	O
and	O
chromosomal	O
localization	O
of	O
atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
.	O
	
atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
atm	O
gene	O
defective	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
has	O
been	O
identified	O
.	O
	
the	O
mouse	O
homolog	O
of	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
(	O
wasp	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
x	O
chromosome	O
.	O
	
the	O
mouse	O
wasp	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O
	
the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
wasp	O
sequence	O
.	O
	
this	O
localization	O
makes	O
wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
t	O
cell	O
-	O
mediated	O
fatal	B-Disease
lymphoreticular	I-Disease
disease	I-Disease
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
.	O
	
to	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
(	O
fmf	B-Disease
)	O
.	O
	
the	O
study	O
evaluated	O
4	O
patients	O
with	O
fmf	B-Disease
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
.	O
	
furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
fmf	B-Disease
who	O
continue	O
to	O
take	O
colchicine	O
.	O
	
abnormal	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	B-Disease
in	O
mice	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
commonly	O
associated	O
with	O
ctg	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
dm	O
-	O
protein	O
kinase	O
(	O
dmpk	O
)	O
.	O
	
nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
dmpk	O
transgene	O
expression	O
showed	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
and	O
enhanced	O
neonatal	O
mortality	O
.	O
	
however	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
dm	B-Disease
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B-Disease
,	O
myotonia	B-Disease
,	O
cataract	B-Disease
and	O
male	B-Disease
-	I-Disease
infertility	I-Disease
.	O
	
mice	O
lacking	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
develop	O
a	O
late	O
onset	O
progressive	O
myopathy	B-Disease
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
resulting	O
from	O
the	O
expansion	O
of	O
a	O
ctg	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
dmpk	O
)	O
.	O
	
to	O
elucidate	O
the	O
role	O
of	O
dmpk	O
in	O
dm	B-Disease
pathogenesis	O
we	O
have	O
developed	O
dmpk	B-Disease
deficient	I-Disease
(	O
dmpk	O
-	O
/	O
-	O
)	O
mice	O
.	O
	
dmpk	O
-	O
/	O
-	O
mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B-Disease
skeletal	I-Disease
myopathy	I-Disease
that	O
shares	O
some	O
pathological	O
features	O
with	O
dm	B-Disease
.	O
	
muscles	O
from	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B-Disease
degeneration	I-Disease
and	O
fibrosis	B-Disease
.	O
	
our	O
results	O
indicate	O
that	O
dmpk	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
dmpk	O
levels	O
may	O
contribute	O
to	O
dm	B-Disease
pathology	O
.	O
	
.	O
	
the	O
tumor	B-Disease
suppressor	O
gene	O
brca1	O
is	O
required	O
for	O
embryonic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O
	
mutations	O
of	O
the	O
brca1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
	
we	O
show	O
here	O
that	O
brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B-Disease
by	O
age	O
eleven	O
months	O
.	O
	
increased	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
in	O
japanese	O
-	O
american	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
hdl	O
levels	O
.	O
	
plasma	O
high	O
density	O
lipoprotein	O
(	O
hdl	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
(	O
chd	B-Disease
)	O
.	O
	
however	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
chd	B-Disease
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O
mutations	O
.	O
	
the	O
relative	O
risk	O
(	O
rr	O
)	O
of	O
chd	B-Disease
was	O
1	O
.	O
	
43	O
in	O
men	O
with	O
mutations	O
(	O
p	O
<	O
.	O
	
5	O
)	O
;	O
after	O
adjustment	O
for	O
chd	B-Disease
risk	O
factors	O
,	O
the	O
rr	O
was	O
1	O
.	O
	
increased	O
chd	B-Disease
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
hdl	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
hdl	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
chd	B-Disease
prevalence	O
.	O
	
thus	O
,	O
genetic	O
cetp	B-Disease
deficiency	I-Disease
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
chd	B-Disease
,	O
primarily	O
due	O
to	O
increased	O
chd	B-Disease
prevalence	O
in	O
men	O
with	O
the	O
d442g	O
mutation	O
and	O
hdl	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
dl	O
.	O
	
the	O
rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B-Disease
and	O
is	O
located	O
on	O
human	O
chromosome	O
(	O
chr	O
)	O
13q14	O
.	O
	
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
wasp	O
gene	O
product	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
(	O
wasp	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
was	B-Disease
and	O
in	O
patients	O
showing	O
x	B-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
.	O
	
no	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
was	B-Disease
phenotype	O
.	O
	
influence	O
of	O
pax6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B-Disease
abnormalities	I-Disease
.	O
	
aniridia	B-Disease
in	O
man	O
and	O
small	O
eye	O
in	O
mice	O
are	O
semidominant	B-Disease
developmental	I-Disease
disorders	I-Disease
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
pax6	O
.	O
	
whereas	O
heterozygotes	O
suffer	O
from	O
iris	B-Disease
hypoplasia	I-Disease
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B-Disease
abnormalities	I-Disease
.	O
	
strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	O
specific	O
developmental	B-Disease
abnormalities	I-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O
	
we	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B-Disease
defects	I-Disease
.	O
	
.	O
	
this	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
galt	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B-Disease
metabolic	I-Disease
disorder	I-Disease
galactosemia	B-Disease
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
TRUE	O
molecular	O
homozygotes	O
.	O
	
these	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B-Disease
and	O
galt	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
.	O
	
.	O
	
apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
.	O
	
here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
hd	B-Disease
gene	O
product	O
,	O
huntingtin	O
.	O
	
our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
hd	B-Disease
might	O
be	O
a	O
disorder	B-Disease
of	I-Disease
inappropriate	I-Disease
apoptosis	I-Disease
.	O
	
.	O
	
to	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
the	O
brca1	O
genomic	O
region	O
.	O
	
deletion	O
of	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
snrpn	O
)	O
in	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O
	
the	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
snrpn	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
we	O
describe	O
two	O
sibs	O
with	O
typical	O
pws	B-Disease
presenting	O
deletion	O
of	O
snrpn	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
fish	O
)	O
.	O
	
this	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
pws	B-Disease
critical	O
region	O
.	O
	
fish	O
with	O
a	O
snrpn	O
probe	O
will	O
permit	O
analysis	O
of	O
pws	B-Disease
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O
.	O
	
.	O
	
expression	O
of	O
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
tumour	I-Disease
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
disease	I-Disease
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O
	
germline	O
vhl	B-Disease
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B-Disease
,	I-Disease
cerebellar	I-Disease
and	I-Disease
spinal	I-Disease
haemangioblastomas	I-Disease
,	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
phaeochromocytoma	B-Disease
.	O
	
in	O
addition	O
,	O
somatic	O
inactivation	O
of	O
the	O
vhl	B-Disease
gene	O
is	O
frequent	O
in	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
haemangioblastoma	B-Disease
.	O
	
regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
vhl	B-Disease
gene	O
might	O
modify	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O
	
we	O
therefore	O
investigated	O
the	O
expression	O
of	O
vhl	B-Disease
mrna	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O
	
although	O
vhl	B-Disease
mrna	O
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O
	
within	O
the	O
kidney	O
,	O
vhl	B-Disease
mrna	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
vhl	B-Disease
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O
	
two	O
alternatively	O
spliced	O
vhl	B-Disease
mrnas	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
i	O
)	O
or	O
exclusion	O
(	O
isoform	O
ii	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O
	
to	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
vhl	B-Disease
mrna	O
was	O
reverse	O
transcribed	O
from	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O
	
the	O
quantitative	O
distribution	O
of	O
vhl	B-Disease
mrna	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
two	O
vhl	B-Disease
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O
	
although	O
the	O
genes	O
regulated	O
by	O
the	O
vhl	B-Disease
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
vhl	B-Disease
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
human	O
development	O
.	O
	
.	O
	
genetic	O
heterogeneity	O
in	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
:	O
role	O
of	O
brca1	O
and	O
brca2	O
.	O
	
the	O
common	O
hereditary	O
forms	O
of	O
breast	B-Disease
cancer	I-Disease
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
brca1	O
or	O
brca2	O
genes	O
.	O
	
however	O
,	O
it	O
is	O
not	O
yet	O
clear	O
what	O
proportion	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
is	O
explained	O
by	O
brca1	O
and	O
brca2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O
	
we	O
describe	O
the	O
proportion	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
explained	O
by	O
brca1	O
or	O
brca2	O
in	O
a	O
sample	O
of	O
north	O
american	O
hereditary	B-Disease
breast	I-Disease
cancers	I-Disease
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B-Disease
breast	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
risk	O
.	O
	
twenty	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
breast	B-Disease
cancer	I-Disease
research	O
programs	O
.	O
	
genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
brca1	O
)	O
and	O
13q	O
(	O
brca2	O
)	O
.	O
	
the	O
pattern	O
of	O
hereditary	B-Disease
cancer	I-Disease
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
brca1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O
	
brca1	O
and	O
brca2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
that	O
exists	O
in	O
the	O
north	O
american	O
population	O
.	O
	
however	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
.	O
	
an	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B-Disease
human	I-Disease
disorder	I-Disease
(	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
)	O
.	O
	
three	O
sisters	O
were	O
shown	O
to	O
suffer	O
from	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
(	O
fed	B-Disease
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
lcat	O
)	O
.	O
	
sequencing	O
of	O
the	O
lcat	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
fed	B-Disease
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
ivs4	O
t	O
-	O
22c	O
)	O
.	O
	
in	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
nan	O
allele	O
in	O
a	O
patient	O
with	O
fed	B-Disease
.	O
	
mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
we	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
in	O
which	O
mutation	O
of	O
the	O
atm	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
identified	O
in	O
the	O
united	O
kingdom	O
)	O
.	O
	
the	O
second	O
a	B-Disease
-	I-Disease
t	I-Disease
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O
	
the	O
level	O
of	O
the	O
137	O
-	O
bp	O
pcr	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B-Disease
ataxia	I-Disease
.	O
	
mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
.	O
	
the	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O
	
mutation	O
of	O
the	O
vhl	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
to	O
define	O
the	O
possible	O
role	O
of	O
the	O
vhl	B-Disease
gene	O
in	O
the	O
development	O
of	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
,	O
91	O
different	O
parenchymal	B-Disease
tumours	I-Disease
of	I-Disease
the	I-Disease
kidney	I-Disease
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
vhl	B-Disease
gene	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
sscp	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
hd	O
)	O
techniques	O
.	O
	
chromosome	O
3p	O
deletion	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
in	O
22	O
of	O
the	O
43	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
,	O
abnormally	O
migrating	O
dna	O
bands	O
were	O
detected	O
by	O
sscp	O
and	O
/	O
or	O
hd	O
analysis	O
.	O
	
no	O
mobility	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
in	O
addition	O
,	O
15	O
papillary	B-Disease
renal	I-Disease
cell	I-Disease
tumours	I-Disease
and	O
ten	O
renal	B-Disease
oncocytomas	I-Disease
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
vhl	B-Disease
gene	O
.	O
	
none	O
of	O
these	O
tumours	B-Disease
showed	O
abnormal	O
migration	O
patterns	O
.	O
	
the	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
vhl	B-Disease
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
	
.	O
	
the	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O
	
a	O
muscle	O
biopsy	O
from	O
an	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
emdm	B-Disease
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
edmd	B-Disease
families	O
.	O
	
mutation	O
of	O
msh3	O
in	O
endometrial	B-Disease
cancer	I-Disease
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O
	
many	O
human	O
tumours	B-Disease
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O
	
although	O
this	O
microsatellite	B-Disease
instability	I-Disease
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
dna	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
(	O
hnpcc	B-Disease
)	O
kindreds	O
,	O
many	O
sporadic	B-Disease
tumours	I-Disease
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O
.	O
	
thus	O
,	O
we	O
screened	O
16	O
endometrial	B-Disease
carcinomas	I-Disease
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
fen1	O
(	O
the	O
human	O
homolog	O
of	O
rth	O
)	O
and	O
in	O
msh3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O
	
although	O
we	O
found	O
no	O
fen1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
msh3	O
was	O
observed	O
in	O
an	O
endometrial	B-Disease
carcinoma	I-Disease
and	O
in	O
an	O
endometrial	B-Disease
carcinoma	I-Disease
cell	O
line	O
.	O
	
together	O
the	O
data	O
suggest	O
that	O
the	O
msh3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B-Disease
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
in	O
yeast	O
,	O
msh3	O
and	O
msh6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O
.	O
	
.	O
	
comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
.	O
	
chromosomal	O
locations	O
of	O
the	O
atm	O
(	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
at	B-Disease
)	O
-	O
mutated	O
)	O
and	O
acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
coa	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
were	O
determined	O
by	O
direct	O
r	O
-	O
banding	O
fish	O
.	O
	
fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
at	B-Disease
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O
	
an	O
animal	O
model	O
for	O
norrie	B-Disease
disease	I-Disease
(	O
nd	B-Disease
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
nd	B-Disease
gene	O
.	O
	
in	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
norrie	B-Disease
disease	I-Disease
(	O
nd	B-Disease
)	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
nd	B-Disease
mutant	O
mice	O
.	O
	
the	O
murine	O
homologue	O
of	O
the	O
nd	B-Disease
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O
	
hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
nd	B-Disease
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O
	
these	O
ocular	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
nd	B-Disease
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
neurological	I-Disease
disorder	I-Disease
.	O
	
.	O
	
the	O
hybrid	O
pax3	O
-	O
fkhr	O
fusion	O
protein	O
of	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
transforms	O
fibroblasts	O
in	O
culture	O
.	O
	
pediatric	B-Disease
alveolar	I-Disease
rhabdomyosarcoma	I-Disease
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
pax3	O
and	O
fkhr	O
genes	O
.	O
	
somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B-Disease
deficiency	I-Disease
.	O
	
in	O
most	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O
	
however	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
i	O
)	O
cause	O
more	O
-	O
severe	O
g6pd	B-Disease
deficiency	I-Disease
,	O
and	O
this	O
might	O
provide	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O
	
thus	O
,	O
it	O
appears	O
that	O
severe	O
g6pd	B-Disease
deficiency	I-Disease
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O
	
.	O
	
analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
.	O
	
meiotic	O
drive	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
dm	B-Disease
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O
.	O
	
in	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
dm	B-Disease
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
ctg	O
repeats	O
.	O
	
to	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
pcr	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
allele	O
size	O
at	O
the	O
dm	B-Disease
locus	O
.	O
	
this	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O
	
lpp	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
hmgic	O
in	O
lipomas	B-Disease
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
lim	O
protein	O
gene	O
family	O
.	O
	
a	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B-Disease
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O
	
here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
which	O
we	O
have	O
designated	O
lpp	O
(	O
lipoma	B-Disease
preferred	O
partner	O
gene	O
)	O
.	O
	
using	O
3	O
-	O
race	O
analysis	O
of	O
hmgic	O
fusion	O
transcripts	O
in	O
lipoma	B-Disease
cell	O
line	O
li	O
-	O
501	O
/	O
sv40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
cash	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
and	O
fish	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O
originate	O
from	O
chromosome	O
segment	O
3q27	O
-	O
q28	O
.	O
	
using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B-Disease
cell	O
lines	O
and	O
primary	B-Disease
lipomas	I-Disease
,	O
it	O
appeared	O
that	O
lpp	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
3q27	O
-	O
q28	O
.	O
	
absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
cag	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
huntington	B-Disease
disease	I-Disease
transcript	O
.	O
	
the	O
mutation	O
underlying	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
is	O
cag	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
hd	B-Disease
gene	O
.	O
	
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
cag	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
hd	B-Disease
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
hd	B-Disease
cdna	O
with	O
44	O
cag	O
repeats	O
.	O
	
by	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B-Disease
abnormalities	I-Disease
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O
	
despite	O
high	O
levels	O
of	O
mrna	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
hd	B-Disease
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O
	
in	O
vitro	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
utr	O
in	O
the	O
cdna	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
hd	B-Disease
cdna	O
.	O
	
these	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
hd	B-Disease
is	O
not	O
mediated	O
through	O
dna	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
rna	O
transcript	O
with	O
an	O
expanded	O
cag	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
.	O
	
rather	O
,	O
translation	O
of	O
the	O
cag	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
hd	B-Disease
.	O
	
fish	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B-Disease
aniridia	I-Disease
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
	
2	O
;	O
p13	O
)	O
.	O
	
a	O
2	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B-Disease
sporadic	I-Disease
aniridia	I-Disease
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O
band	O
p13	O
.	O
	
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
fish	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B-Disease
(	O
pax6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
pax6	O
defined	O
by	O
the	O
cosmid	O
fo2121	O
.	O
	
although	O
this	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
pax6	O
,	O
her	O
aniridia	B-Disease
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
pax6	O
.	O
	
this	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	B-Disease
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	O
familial	B-Disease
aniridia	I-Disease
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B-Disease
abnormalities	I-Disease
with	O
11p13	O
breakpoints	O
.	O
	
.	O
	
muscle	O
expression	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
different	O
variants	O
.	O
	
muscle	O
expression	O
of	O
g6pd	B-Disease
deficiency	I-Disease
has	O
been	O
investigated	O
in	O
mediterranean	O
,	O
seattle	O
-	O
like	O
and	O
a	O
-	O
variants	O
.	O
	
gene	O
therapy	O
for	O
phenylketonuria	B-Disease
.	O
	
classical	O
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
pku	B-Disease
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O
	
vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
dna	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
pah	O
cdna	O
into	O
pah	B-Disease
-	I-Disease
deficient	I-Disease
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O
	
in	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
normal	O
hepatic	O
pah	O
activity	O
into	O
pah	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
.	O
	
however	O
,	O
these	O
findings	O
suggest	O
that	O
pku	B-Disease
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
	
.	O
	
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
chrna4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B-Disease
familial	I-Disease
neonatal	I-Disease
convulsions	I-Disease
,	O
autosomal	B-Disease
dominant	I-Disease
nocturnal	I-Disease
frontal	I-Disease
lobe	I-Disease
epilepsy	I-Disease
,	O
and	O
low	O
-	O
voltage	O
eeg	O
.	O
	
recently	O
,	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
chrna4	O
was	O
found	O
to	O
be	O
associated	O
with	O
autosomal	B-Disease
dominant	I-Disease
nocturnal	I-Disease
frontal	I-Disease
lobe	I-Disease
epilepsy	I-Disease
in	O
one	O
extended	O
pedigree	O
.	O
	
the	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
chrna4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B-Disease
epilepsies	I-Disease
.	O
	
.	O
	
brca1	O
and	O
brca2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
in	O
carrier	O
females	O
.	O
	
mutations	O
in	O
brca1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
and	O
90	O
%	O
of	O
inherited	B-Disease
breast	I-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
whereas	O
mutations	O
in	O
brca2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
cases	O
.	O
	
the	O
6174delt	O
mutation	O
in	O
brca2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
ashkenazi	O
jewish	O
women	O
diagnosed	O
with	O
breast	B-Disease
cancer	I-Disease
by	O
age	O
50	O
(	O
ref	O
.	O
	
8	O
)	O
,	O
as	O
well	O
as	O
in	O
three	O
ashkenazi	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
patients	O
.	O
	
we	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
brca1	O
and	O
brca2	O
mutations	O
in	O
ashkenazi	O
jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B-Disease
cancer	I-Disease
.	O
	
this	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
brca1	O
185delag	O
mutation	O
and	O
the	O
brca2	O
6174delt	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
among	O
the	O
ashkenazim	O
,	O
and	O
suggests	O
a	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delt	O
mutation	O
in	O
brca2	O
the	O
gene	O
mutated	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
at	B-Disease
)	O
patients	O
,	O
denoted	O
atm	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O
	
consistent	O
with	O
cellular	O
defects	O
of	O
at	B-Disease
patients	O
,	O
the	O
atm	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
regulation	O
of	O
p53	O
.	O
	
atm	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B-Disease
risk	O
of	O
at	B-Disease
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
	
.	O
	
targeted	O
disruption	O
of	O
atm	O
leads	O
to	O
growth	B-Disease
retardation	I-Disease
,	O
chromosomal	B-Disease
fragmentation	I-Disease
during	I-Disease
meiosis	I-Disease
,	O
immune	B-Disease
defects	I-Disease
,	O
and	O
thymic	B-Disease
lymphoma	I-Disease
.	O
	
atm	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B-Disease
human	I-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
dna	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O
	
initial	O
evaluation	O
of	O
the	O
atm	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
atm	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
the	O
infertility	B-Disease
of	O
atm	O
-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O
	
immune	B-Disease
defects	I-Disease
also	O
are	O
evident	O
in	O
atm	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
b220	O
+	O
cd43	O
-	O
pre	O
-	O
b	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
t	O
cells	O
,	O
as	O
well	O
as	O
functional	O
impairment	O
of	O
t	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O
	
the	O
cerebella	O
of	O
atm	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B-Disease
abnormalities	I-Disease
.	O
	
the	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B-Disease
lymphomas	I-Disease
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O
	
these	O
findings	O
indicate	O
that	O
the	O
atm	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B-Disease
suppression	O
.	O
	
.	O
	
this	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
vlcad	B-Disease
deficiency	I-Disease
.	O
	
northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
pcr	O
amplified	O
vlcad	O
cdna	O
from	O
four	O
unrelated	O
patients	O
with	O
vlcad	B-Disease
deficiency	I-Disease
showed	O
that	O
vlcad	O
mrna	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
vlcad	O
alleles	O
.	O
	
molecular	O
bases	O
of	O
combined	B-Disease
subtotal	I-Disease
deficiencies	I-Disease
of	I-Disease
c6	I-Disease
and	I-Disease
c7	I-Disease
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
c6	B-Disease
and	I-Disease
c7	I-Disease
deficiencies	I-Disease
.	O
	
combined	B-Disease
subtotal	I-Disease
deficiency	I-Disease
of	I-Disease
c6	I-Disease
and	I-Disease
c7	I-Disease
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O
	
the	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
either	O
to	O
c6	B-Disease
or	I-Disease
c7	I-Disease
deficiency	I-Disease
,	O
but	O
with	O
different	O
consequences	O
.	O
	
where	O
it	O
is	O
combined	O
with	O
a	O
c6	B-Disease
-	I-Disease
deficient	I-Disease
gene	O
,	O
the	O
serum	O
c7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
c6	O
generating	O
c56	O
to	O
consume	O
the	O
c7	O
.	O
	
genetic	O
bases	O
of	O
human	O
complement	B-Disease
c7	I-Disease
deficiency	I-Disease
.	O
	
complement	B-Disease
c7	I-Disease
deficiency	I-Disease
(	O
c7d	B-Disease
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B-Disease
infections	I-Disease
,	O
especially	O
meningitis	B-Disease
caused	O
by	O
neisseria	B-Disease
meningitidis	I-Disease
.	O
	
we	O
report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
c7d	B-Disease
in	O
two	O
unrelated	O
japanese	O
males	O
.	O
	
moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
c7d	B-Disease
in	O
case	O
1	O
.	O
	
our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
c7d	B-Disease
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B-Disease
of	I-Disease
complement	I-Disease
components	I-Disease
.	O
	
.	O
	
hprt	B-Disease
-	I-Disease
aprt	I-Disease
-	I-Disease
deficient	I-Disease
mice	O
are	O
not	O
a	O
model	O
for	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
complete	B-Disease
hypoxanthine	I-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyl	I-Disease
-	I-Disease
transferase	I-Disease
(	I-Disease
hprt	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
humans	O
results	O
in	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
.	O
	
hprt	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
aprt	O
)	O
in	O
hprt	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
has	O
produced	O
the	O
suggestion	O
that	O
deficiency	B-Disease
of	I-Disease
aprt	I-Disease
in	O
combination	O
with	O
hprt	B-Disease
-	I-Disease
deficiency	I-Disease
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
mutilation	O
behavior	O
[	O
c	O
.	O
	
l	O
.	O
	
wu	O
and	O
d	O
.	O
	
w	O
.	O
	
melton	O
(	O
1993	O
)	O
nature	O
genet	O
.	O
	
3	O
,	O
235	O
-	O
240	O
]	O
.	O
	
to	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
hprt	B-Disease
-	I-Disease
aprt	I-Disease
-	I-Disease
deficient	I-Disease
mice	O
.	O
	
although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
aprt	B-Disease
deficiency	I-Disease
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
behavior	O
were	O
not	O
detected	O
.	O
	
thus	O
,	O
aprt	B-Disease
-	I-Disease
hprt	I-Disease
-	I-Disease
deficient	I-Disease
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B-Disease
abnormalities	I-Disease
associated	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
as	O
previously	O
suggested	O
somatic	O
alterations	O
of	O
the	O
dpc4	O
gene	O
in	O
human	O
colorectal	B-Disease
cancers	I-Disease
in	O
vivo	O
.	O
	
background	O
&	O
aims	O
the	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B-Disease
cancers	I-Disease
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O
	
the	O
dpc4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B-Disease
cancers	I-Disease
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B-Disease
cancers	I-Disease
.	O
	
methods	O
mutation	O
analyses	O
of	O
the	O
dpc4	O
gene	O
were	O
performed	O
on	O
complementary	O
dna	O
samples	O
from	O
31	O
primary	O
colorectal	B-Disease
cancer	I-Disease
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
dna	O
sequencing	O
.	O
	
results	O
four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
dpc4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B-Disease
(	O
16	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O
	
conclusions	O
the	O
dpc4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B-Disease
cancers	I-Disease
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B-Disease
cancers	I-Disease
,	O
only	O
a	O
minority	O
show	O
dpc4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
	
.	O
	
pleiotropic	O
defects	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
protein	O
-	O
deficient	O
mice	O
.	O
	
we	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
atm	O
protein	O
.	O
	
atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
defects	O
in	O
t	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B-Disease
.	O
	
atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
and	O
in	O
cells	O
derived	O
from	O
them	O
.	O
	
the	O
dcc	O
protein	O
and	O
prognosis	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
background	O
allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B-Disease
ii	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
although	O
the	O
specific	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
dcc	O
(	O
deleted	O
in	O
colorectal	B-Disease
cancer	I-Disease
)	O
gene	O
is	O
a	O
candidate	O
.	O
	
we	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
dcc	O
protein	O
in	O
tumor	B-Disease
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B-Disease
carcinoma	I-Disease
.	O
	
methods	O
the	O
expression	O
of	O
dcc	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B-Disease
ii	I-Disease
and	I-Disease
iii	I-Disease
colorectal	I-Disease
carcinomas	I-Disease
.	O
	
the	O
cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
tumor	B-Disease
site	O
,	O
degree	O
of	O
tumor	B-Disease
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O
	
results	O
the	O
expression	O
of	O
dcc	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B-Disease
ii	I-Disease
and	I-Disease
stage	I-Disease
iii	I-Disease
colorectal	I-Disease
carcinomas	I-Disease
.	O
	
in	O
patients	O
with	O
stage	O
ii	O
disease	O
whose	O
tumors	B-Disease
expressed	O
dcc	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O
	
3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
dcc	B-Disease
-	I-Disease
negative	I-Disease
tumors	I-Disease
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O
	
in	O
patients	O
with	O
stage	B-Disease
iii	I-Disease
disease	I-Disease
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O
	
conclusions	O
dcc	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B-Disease
ii	I-Disease
or	I-Disease
stage	I-Disease
iii	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
in	O
stage	B-Disease
ii	I-Disease
colorectal	I-Disease
carcinomas	I-Disease
,	O
the	O
absence	O
of	O
dcc	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B-Disease
iii	I-Disease
cancers	I-Disease
.	O
	
association	O
of	O
anxiety	B-Disease
-	I-Disease
related	I-Disease
traits	I-Disease
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O
	
transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
ht	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B-Disease
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O
	
association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
htt	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B-Disease
-	I-Disease
related	I-Disease
personality	I-Disease
traits	I-Disease
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
	
.	O
	
phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B-Disease
type	I-Disease
2	I-Disease
and	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O
	
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
transporter	O
gene	O
dtdst	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B-Disease
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B-Disease
dysplasia	I-Disease
(	O
dtd	B-Disease
)	O
,	O
atelosteogenesis	B-Disease
type	I-Disease
2	I-Disease
(	O
ao2	B-Disease
)	O
,	O
and	O
achondrogenesis	B-Disease
type	I-Disease
1b	I-Disease
(	O
acg1b	B-Disease
)	O
.	O
	
to	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
dtdst	B-Disease
chondrodysplasias	I-Disease
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
ao	B-Disease
-	I-Disease
2	I-Disease
,	O
one	O
with	O
dtd	B-Disease
,	O
and	O
one	O
with	O
an	O
intermediate	O
phenotype	O
(	O
ao2	B-Disease
/	O
dtd	B-Disease
)	O
.	O
	
in	O
two	O
patients	O
(	O
dtd	B-Disease
and	O
ao2	B-Disease
/	O
dtd	B-Disease
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cdna	O
showed	O
reduced	O
mrna	O
levels	O
of	O
the	O
wild	O
-	O
type	O
dtdst	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
finnish	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
dna	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
dtdst	O
.	O
	
the	O
third	O
patient	O
(	O
with	O
ao2	B-Disease
)	O
had	O
the	O
r279w	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O
	
the	O
presence	O
of	O
the	O
dtdst	O
r279w	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
ao2	B-Disease
or	O
dtd	B-Disease
emphasizes	O
the	O
overlap	O
between	O
these	O
conditions	O
.	O
	
this	O
mutation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
acg1b	B-Disease
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
.	O
	
.	O
	
identification	O
of	O
wasp	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
,	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
immunodeficiency	I-Disease
disease	I-Disease
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
was	B-Disease
protein	O
(	O
wasp	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
extensive	O
clinical	O
heterogeneity	O
.	O
	
cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
wasp	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	O
was	B-Disease
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O
	
to	O
address	O
this	O
issue	O
we	O
characterized	O
wasp	O
mutations	O
in	O
24	O
unrelated	O
was	B-Disease
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
was	B-Disease
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
wasp	O
mutations	O
with	O
disease	O
severity	O
.	O
	
similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
wasp	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B-Disease
thrombocytopenia	I-Disease
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
was	B-Disease
phenotypes	O
,	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
wasp	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O
.	O
	
these	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
identical	O
wasp	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
was	B-Disease
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
wasp	O
genotypes	O
.	O
	
.	O
	
germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
apc	B-Disease
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O
	
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B-Disease
cancer	I-Disease
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B-Disease
polyps	I-Disease
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O
	
germline	O
mutations	O
in	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
fap	B-Disease
.	O
	
mutations	O
at	O
the	O
5	O
end	O
of	O
apc	B-Disease
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
aapc	B-Disease
)	O
.	O
	
we	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
dutch	O
kindred	O
with	O
aapc	B-Disease
.	O
	
western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
type	O
apc	B-Disease
protein	O
.	O
	
our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
apc	B-Disease
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
aapc	B-Disease
phenotype	O
.	O
	
.	O
	
over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
.	O
	
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B-Disease
from	O
patients	O
with	O
inherited	O
brca1	O
mutations	O
indicates	O
tumor	B-Disease
suppressive	O
function	O
.	O
	
the	O
low	O
incidence	O
of	O
somatic	O
mutations	O
suggests	O
that	O
brca1	O
inactivation	O
in	O
sporadic	O
tumors	B-Disease
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O
	
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
,	O
brca1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
ring	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O
	
the	O
bard1	O
/	O
brca1	O
interaction	O
is	O
disrupted	O
by	O
brca1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B-Disease
cancer	I-Disease
susceptibility	O
,	O
indicating	O
that	O
bard1	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	B-Disease
suppression	O
by	O
brca1	O
.	O
	
.	O
	
45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
brca1	O
.	O
	
autosomal	O
dominant	O
primary	O
hyperparathyroidism	B-Disease
and	I-Disease
jaw	I-Disease
tumor	I-Disease
syndrome	I-Disease
associated	O
with	O
renal	B-Disease
hamartomas	I-Disease
and	O
cystic	B-Disease
kidney	I-Disease
disease	I-Disease
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B-Disease
hamartomas	I-Disease
.	O
	
hereditary	B-Disease
hyperparathyroidism	I-Disease
-	I-Disease
jaw	I-Disease
tumor	I-Disease
syndrome	I-Disease
(	O
hpt	B-Disease
-	I-Disease
jt	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
(	O
omim	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21	O
-	O
q32	O
(	O
hrpt2	O
)	O
.	O
	
here	O
we	O
report	O
two	O
families	O
with	O
hpt	B-Disease
-	I-Disease
jt	I-Disease
syndrome	I-Disease
in	O
which	O
adult	B-Disease
renal	I-Disease
hamartomas	I-Disease
or	O
cystic	B-Disease
kidney	I-Disease
disease	I-Disease
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
hpt	B-Disease
-	I-Disease
jt	I-Disease
syndrome	I-Disease
.	O
	
in	O
the	O
first	O
family	O
,	O
renal	B-Disease
lesions	I-Disease
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
hpt	B-Disease
and	O
jt	B-Disease
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O
	
in	O
the	O
second	O
family	O
,	O
jt	B-Disease
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B-Disease
kidney	I-Disease
disease	I-Disease
.	O
	
a	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B-Disease
hpt	I-Disease
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O
.	O
	
twenty	O
microsatellite	O
markers	O
in	O
the	O
hrpt2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
(	I-Disease
men	I-Disease
)	I-Disease
types	I-Disease
1	I-Disease
and	I-Disease
2	I-Disease
regions	O
at	O
11q13	O
and	O
10q11	O
.	O
	
the	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
	
2	O
-	O
4	O
2	O
-	O
4	O
.	O
	
2	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
men1	B-Disease
and	O
men2	B-Disease
regions	O
was	O
excluded	O
.	O
	
loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
seven	O
renal	B-Disease
hamartomas	I-Disease
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B-Disease
tumor	I-Disease
and	O
a	O
parathyroid	B-Disease
tumor	I-Disease
from	O
the	O
second	O
family	O
.	O
	
all	O
renal	B-Disease
hamartomas	I-Disease
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
region	O
.	O
	
the	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	B-Disease
suppressor	O
gene	O
in	O
this	O
region	O
in	O
a	O
study	O
of	O
g6pd	B-Disease
deficient	I-Disease
patients	O
who	O
presented	O
with	O
clinical	O
favism	B-Disease
in	O
spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
g6pd	O
malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
a	O
-	O
-	O
>	O
t	O
(	O
181	O
asp	O
-	O
-	O
>	O
val	O
)	O
mutation	O
.	O
	
g6pd	O
malaga	O
is	O
associated	O
with	O
enzyme	B-Disease
deficiency	I-Disease
(	O
class	O
iii	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
g6pd	O
malaga	O
and	O
g6pd	O
santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O
	
brca1	O
mutations	O
cause	O
increased	O
risk	O
for	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
frequently	O
of	O
early	O
onset	O
.	O
	
many	O
different	O
mutations	O
occur	O
in	O
brca1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B-Disease
predisposition	O
.	O
	
these	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
brca1	O
lesion	O
.	O
	
we	O
report	O
a	O
novel	O
missense	O
change	O
in	O
brca1	O
,	O
2640	O
c	O
-	O
-	O
>	O
t	O
(	O
r841w	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B-Disease
and	I-Disease
79	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
from	O
orange	O
county	O
,	O
ca	O
.	O
	
in	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B-Disease
,	I-Disease
ovarian	I-Disease
,	I-Disease
or	I-Disease
other	I-Disease
cancers	I-Disease
possibly	O
related	O
to	O
a	O
brca1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B-Disease
incidence	O
with	O
the	O
presence	O
of	O
r841w	O
.	O
	
the	O
age	O
of	O
cancer	B-Disease
onset	O
was	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O
	
testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
r841w	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B-Disease
cancer	I-Disease
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
cancer	B-Disease
in	O
one	O
parent	O
.	O
	
r841w	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
	
7	O
%	O
)	O
of	O
all	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
this	O
population	O
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
:	O
founder	O
effect	O
among	O
north	O
african	O
jews	O
.	O
	
the	O
atm	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
characterized	O
by	O
cerebellar	B-Disease
degeneration	I-Disease
,	O
immunodeficiency	B-Disease
and	O
cancer	B-Disease
predisposition	I-Disease
.	O
	
a	B-Disease
-	I-Disease
t	I-Disease
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B-Disease
-	I-Disease
prone	I-Disease
.	O
	
a	O
wide	O
variety	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O
	
however	O
,	O
a	O
single	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
atm	O
alleles	O
in	O
jewish	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
of	O
north	O
african	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
morocco	O
and	O
tunisia	O
.	O
	
this	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
a	B-Disease
-	I-Disease
t	I-Disease
carriers	O
in	O
a	O
large	O
jewish	O
community	O
.	O
	
.	O
	
mutation	O
analysis	O
of	O
brca1	O
and	O
brca2	O
in	O
a	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
population	O
.	O
	
a	O
population	O
-	O
based	O
series	O
of	O
54	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
cases	O
from	O
southern	O
california	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B-Disease
breast	I-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
genes	O
,	O
brca1	O
and	O
brca2	O
.	O
	
nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
.	O
	
a	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
at	O
least	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O
	
two	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
brca2	O
gene	O
.	O
	
only	O
one	O
of	O
the	O
two	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
patients	O
carrying	O
a	O
brca2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	B-Disease
,	O
with	O
one	O
case	O
of	O
ovarian	B-Disease
cancer	I-Disease
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O
	
the	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
with	O
a	O
family	O
history	O
of	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
brca1	O
gene	O
or	O
the	O
brca2	O
gene	O
.	O
	
.	O
	
molecular	O
basis	O
for	O
duarte	B-Disease
and	I-Disease
los	I-Disease
angeles	I-Disease
variant	I-Disease
galactosemia	I-Disease
.	O
	
human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
duarte	B-Disease
enzyme	I-Disease
variant	I-Disease
of	I-Disease
galactosemia	I-Disease
(	O
d	O
/	O
d	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
enzyme	O
activity	O
.	O
	
we	O
conclude	O
that	O
the	O
codon	O
change	O
n314d	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721c	O
-	O
-	O
>	O
t	O
produces	O
the	O
la	B-Disease
variant	I-Disease
of	I-Disease
galactosemia	I-Disease
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
galt	O
activity	O
by	O
increasing	O
galt	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O
thermal	O
lability	O
.	O
	
the	O
tsg101	O
tumor	B-Disease
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
.	O
	
recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
the	O
ability	O
to	O
produce	O
metastatic	B-Disease
tumors	I-Disease
in	O
nude	O
mice	O
.	O
	
2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B-Disease
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
.	O
	
in	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B-Disease
carcinomas	I-Disease
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
tsg101	O
genomic	O
dna	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
tsg101	O
alleles	O
were	O
identified	O
in	O
four	O
of	O
these	O
cancers	B-Disease
.	O
	
no	O
tsg101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O
	
these	O
findings	O
strongly	O
implicate	O
tsg101	O
mutations	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
ctg	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
utr	O
)	O
of	O
the	O
dm	B-Disease
protein	O
kinase	O
gene	O
(	O
dmpk	O
)	O
.	O
	
moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
dm	B-Disease
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O
	
missense	O
mutations	O
in	O
the	O
fas	O
gene	O
resulting	O
in	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O
	
the	O
fas	O
/	O
apo	O
-	O
1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
mrl	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
alps	B-Disease
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
to	O
mutations	O
in	O
the	O
fas	O
gene	O
.	O
	
we	O
describe	O
a	O
novel	O
family	O
with	O
alps	B-Disease
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
fas	O
-	O
induced	O
apoptosis	O
.	O
	
the	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B-Disease
and	O
lymphadenopathy	B-Disease
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B-Disease
manifestations	I-Disease
.	O
	
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O
	
the	O
product	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
(	O
atm	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O
	
truncated	O
atm	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O
	
mutations	O
in	O
the	O
col3a1	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
type	B-Disease
iv	I-Disease
ehlers	I-Disease
-	I-Disease
danlos	I-Disease
syndrome	I-Disease
,	O
a	O
disease	O
leading	O
to	O
aortic	B-Disease
rupture	I-Disease
in	O
early	O
adult	O
life	O
.	O
	
the	O
major	O
cause	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B-Disease
iv	I-Disease
ehlers	I-Disease
-	I-Disease
danlos	I-Disease
syndrome	I-Disease
.	O
	
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
plp	O
)	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
we	O
report	O
a	O
g	O
-	O
-	O
>	O
a	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
plp	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
.	O
	
the	O
clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
spastic	I-Disease
paraplegia	I-Disease
(	O
spg	B-Disease
)	O
.	O
	
it	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
forms	O
of	O
pmd	B-Disease
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B-Disease
is	O
absent	O
,	O
tremors	B-Disease
are	O
prominent	O
,	O
mental	B-Disease
retardation	I-Disease
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B-Disease
or	O
personality	B-Disease
disorders	I-Disease
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
.	O
	
the	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3b	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
plp	O
but	O
spare	O
dm20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
plp	B-Disease
-	I-Disease
associated	I-Disease
disease	I-Disease
in	O
both	O
humans	O
and	O
mice	O
.	O
	
.	O
	
common	O
brca1	O
variants	O
and	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
the	O
general	O
population	O
.	O
	
most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
brca1	O
and	O
brca2	O
.	O
	
however	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B-Disease
cancer	I-Disease
incidence	O
.	O
	
a	O
much	O
larger	O
fraction	O
of	O
breast	B-Disease
cancer	I-Disease
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O
	
we	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
gln356arg	O
,	O
pro871leu	O
,	O
glu1038gly	O
and	O
ser1613gly	O
in	O
large	O
series	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
and	O
matched	O
controls	O
.	O
	
thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
brca1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
risk	O
.	O
	
however	O
,	O
our	O
data	O
suggest	O
that	O
the	O
arg356	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
from	O
that	O
in	O
controls	O
(	O
arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
p	O
=	O
0	O
.	O
	
1	O
)	O
,	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B-Disease
cancer	I-Disease
.	O
	
kniest	B-Disease
dysplasia	I-Disease
:	O
dr	O
.	O
	
w	O
.	O
	
kniest	B-Disease
dysplasia	I-Disease
is	O
a	O
severe	O
chondrodysplasia	B-Disease
caused	O
by	O
the	O
defective	B-Disease
formation	I-Disease
of	I-Disease
type	I-Disease
ii	I-Disease
collagen	I-Disease
.	O
	
we	O
report	O
about	O
dr	O
.	O
	
kniest	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B-Disease
handicapped	I-Disease
with	O
short	B-Disease
stature	I-Disease
,	O
restricted	B-Disease
joint	I-Disease
mobility	I-Disease
,	O
and	O
blindness	B-Disease
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O
life	O
.	O
	
this	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
kniest	B-Disease
dysplasia	I-Disease
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
col2a1	O
splice	O
site	O
mutations	O
.	O
	
.	O
	
cloning	O
of	O
the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B-Disease
in	O
mouse	O
.	O
	
this	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
alkaptonuria	B-Disease
gene	O
(	O
aku	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O
	
we	O
therefore	O
conclude	O
that	O
the	O
hgo	O
cdna	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	B-Disease
.	O
	
pten	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
and	I-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	O
tumor	B-Disease
suppressor	O
gene	O
,	O
pten	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	B-Disease
.	O
	
in	O
preliminary	O
screens	O
,	O
mutations	O
of	O
pten	O
were	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B-Disease
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B-Disease
cancer	I-Disease
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B-Disease
glioblastomas	I-Disease
.	O
	
these	O
homologies	O
suggest	O
that	O
pten	O
may	O
suppress	O
tumor	B-Disease
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
tumor	B-Disease
cell	O
invasion	O
and	O
metastasis	B-Disease
through	O
interactions	O
at	O
focal	O
adhesions	O
.	O
	
.	O
	
heterogeneity	O
in	O
schwartz	B-Disease
-	I-Disease
jampel	I-Disease
chondrodystrophic	I-Disease
myotonia	I-Disease
.	O
	
the	O
schwartz	B-Disease
-	I-Disease
jampel	I-Disease
syndrome	I-Disease
(	O
sjs	B-Disease
;	O
chondrodystrophic	B-Disease
myotonia	I-Disease
;	O
mck	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B-Disease
inherited	I-Disease
condition	I-Disease
defined	O
by	O
myotonia	B-Disease
,	O
short	B-Disease
stature	I-Disease
,	O
and	O
bone	B-Disease
dysplasia	I-Disease
.	O
	
genetic	O
linkage	O
between	O
sjs	B-Disease
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O
	
in	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
sjs	B-Disease
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O
	
we	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	B-Disease
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B-Disease
dysplasia	I-Disease
with	O
myotonia	B-Disease
.	O
	
we	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
sjs	B-Disease
type	I-Disease
1a	I-Disease
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B-Disease
dysplasia	I-Disease
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
schwartz	O
,	O
jampel	O
and	O
aberfeld	O
;	O
type	O
1b	O
,	O
similar	O
to	O
type	O
1a	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B-Disease
dysplasia	I-Disease
resembling	O
kniest	B-Disease
dysplasia	I-Disease
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B-Disease
dysplasia	I-Disease
resembling	O
pyle	B-Disease
disease	I-Disease
.	O
	
genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
sjs	B-Disease
type	I-Disease
2	I-Disease
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O
	
conclusions	O
sjs	B-Disease
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O
	
the	O
causes	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
sjs	B-Disease
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
sjs	B-Disease
locus	O
.	O
	
mutations	O
in	O
the	O
wt1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B-Disease
cancer	I-Disease
,	O
wilms	B-Disease
tumour	I-Disease
(	O
wt	B-Disease
)	O
.	O
	
while	O
only	O
5	O
%	O
of	O
sporadic	B-Disease
wilms	I-Disease
tumours	I-Disease
have	O
intragenic	O
wt1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
(	O
renal	B-Disease
nephropathy	I-Disease
,	O
gonadal	B-Disease
anomaly	I-Disease
,	O
predisposition	B-Disease
to	I-Disease
wt	I-Disease
)	O
carry	O
constitutional	O
intragenic	O
wt1	O
mutations	O
.	O
	
wt1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B-Disease
granulosa	I-Disease
cell	I-Disease
tumour	I-Disease
,	O
non	B-Disease
-	I-Disease
asbestos	I-Disease
related	I-Disease
mesothelioma	I-Disease
,	O
desmoplastic	B-Disease
small	I-Disease
round	I-Disease
cell	I-Disease
tumour	I-Disease
and	O
,	O
most	O
recently	O
,	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
.	O
	
.	O
	
a	O
mutation	O
in	O
autosomal	B-Disease
dominant	I-Disease
myotonia	I-Disease
congenita	I-Disease
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O
	
autosomal	B-Disease
dominant	I-Disease
myotonia	I-Disease
congenita	I-Disease
is	O
an	O
inherited	B-Disease
disorder	I-Disease
of	I-Disease
skeletal	I-Disease
muscle	I-Disease
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
cl	O
-	O
channel	O
gene	O
(	O
clcn1	O
,	O
7q35	O
)	O
.	O
	
the	O
incidence	O
of	O
pax6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B-Disease
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O
	
twelve	O
aniridia	B-Disease
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B-Disease
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
in	O
the	O
human	O
pax6	O
gene	O
.	O
	
insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
in	O
japanese	O
.	O
	
in	O
the	O
caucasian	O
population	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
ins	O
)	O
region	O
contains	O
the	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
locus	O
(	O
iddm2	O
)	O
.	O
	
in	O
the	O
japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
iddm2	O
to	O
the	O
pathogenesis	O
of	O
iddm	B-Disease
.	O
	
we	O
conducted	O
an	O
association	O
study	O
of	O
iddm	B-Disease
in	O
a	O
large	O
number	O
of	O
japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
ins	O
region	O
.	O
	
we	O
found	O
a	O
significant	O
association	O
of	O
the	O
ins	O
region	O
with	O
iddm	B-Disease
.	O
	
alleles	O
positively	O
associated	O
with	O
iddm	B-Disease
in	O
ins	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
iddm	B-Disease
in	O
caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
	
9	O
)	O
in	O
the	O
japanese	O
general	O
population	O
.	O
	
these	O
data	O
suggest	O
that	O
iddm2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
iddm	B-Disease
in	O
japanese	O
.	O
	
the	O
high	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
iddm2	O
locus	O
is	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
iddm	B-Disease
in	O
japanese	O
.	O
	
deficiency	B-Disease
of	I-Disease
terminal	I-Disease
complement	I-Disease
components	I-Disease
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B-Disease
infections	I-Disease
.	O
	
we	O
studied	O
a	O
previously	O
described	O
swiss	O
family	O
with	O
inherited	B-Disease
c9	I-Disease
deficiency	I-Disease
.	O
	
to	O
identify	O
the	O
genetic	O
basis	O
of	O
c9	B-Disease
deficiency	I-Disease
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
pcr	O
and	O
direct	O
dna	O
sequencing	O
.	O
	
as	O
a	O
cause	O
of	O
c9	B-Disease
deficiency	I-Disease
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
tga	O
stop	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O
	
in	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
c9	B-Disease
deficiency	I-Disease
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O
	
brca1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
background	O
to	O
define	O
the	O
incidence	O
of	O
brca1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
we	O
analyzed	O
dna	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
brca1	O
mutation	O
in	O
individual	O
families	O
.	O
	
methods	O
clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
dna	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
results	O
brca1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B-Disease
cancer	I-Disease
but	O
not	O
ovarian	B-Disease
cancer	I-Disease
had	O
brca1	O
mutations	O
.	O
	
the	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
the	O
presence	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
the	O
presence	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
the	O
same	O
woman	O
,	O
and	O
ashkenazi	O
jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
brca1	O
mutation	O
.	O
	
no	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B-Disease
cancer	I-Disease
or	O
the	O
number	O
of	O
breast	B-Disease
cancers	I-Disease
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
brca1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
the	O
brca1	O
gene	O
and	O
the	O
presence	O
of	O
ovarian	B-Disease
cancer	I-Disease
in	O
a	O
family	O
.	O
	
conclusions	O
among	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
brca1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O
	
mutations	O
in	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
arp	O
)	O
in	O
pancreatic	B-Disease
cancer	I-Disease
.	O
	
at	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B-Disease
tumors	I-Disease
,	O
although	O
not	O
in	O
pancreatic	B-Disease
cancer	I-Disease
.	O
	
we	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
atg50	O
-	O
-	O
>	O
agg	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
arp	O
gene	O
in	O
different	O
tumor	B-Disease
types	I-Disease
(	O
shridhar	O
et	O
al	O
.	O
	
,	O
1996	O
,	O
1996a	O
)	O
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B-Disease
tumors	I-Disease
.	O
	
the	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B-Disease
tumors	I-Disease
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B-Disease
previously	O
examined	O
.	O
	
in	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
pcr	O
subclones	O
in	O
two	O
other	O
pancreatic	B-Disease
tumors	I-Disease
.	O
	
mutations	O
in	O
the	O
arp	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B-Disease
cancer	I-Disease
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B-Disease
.	O
	
difficulties	O
in	O
the	O
ascertainment	O
of	O
c9	B-Disease
deficiency	I-Disease
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
c9	B-Disease
-	I-Disease
deficient	I-Disease
subject	O
.	O
	
the	O
patient	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
dna	O
markers	O
in	O
the	O
c6	O
,	O
c7	O
and	O
c9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
c9	B-Disease
deficiency	I-Disease
genes	O
.	O
	
we	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B-Disease
deficiency	I-Disease
of	I-Disease
c9	I-Disease
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O
c9	O
.	O
	
we	O
also	O
suggest	O
that	O
c9	B-Disease
deficiency	I-Disease
may	O
be	O
more	O
common	O
among	O
caucasians	O
than	O
has	O
been	O
reported	O
.	O
	
.	O
	
screening	O
for	O
esr	O
mutations	O
in	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
patients	O
.	O
	
in	O
the	O
present	O
study	O
,	O
leukocyte	O
dna	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
tumour	B-Disease
dna	O
from	O
96	O
breast	B-Disease
carcinomas	I-Disease
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
gene	O
(	O
esr	O
)	O
.	O
	
three	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	B-Disease
were	O
carrying	O
a	O
gly160cys	O
germline	O
substitution	O
.	O
	
however	O
,	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	B-Disease
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
with	O
breast	B-Disease
cancer	I-Disease
was	O
carrying	O
the	O
variant	O
allele	O
.	O
	
somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B-Disease
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
esr	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B-Disease
receptor	I-Disease
-	I-Disease
positive	I-Disease
breast	I-Disease
carcinomas	I-Disease
.	O
	
.	O
	
molecular	O
bases	O
of	O
c7	B-Disease
deficiency	I-Disease
:	O
three	O
different	O
defects	O
.	O
	
the	O
molecular	O
basis	O
of	O
c7	B-Disease
deficiency	I-Disease
has	O
been	O
investigated	O
in	O
two	O
irish	O
families	O
and	O
a	O
number	O
of	O
israeli	O
families	O
of	O
moroccan	O
sephardic	O
jewish	O
origin	O
.	O
	
the	O
israeli	O
c7	B-Disease
-	I-Disease
deficient	I-Disease
cases	O
all	O
share	O
a	O
c7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
9	O
.	O
	
molecular	O
heterogeneity	O
of	O
classical	B-Disease
and	I-Disease
duarte	I-Disease
galactosemia	I-Disease
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
	
classical	B-Disease
galactosemia	I-Disease
is	O
caused	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
q188r	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
gene	O
.	O
	
to	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B-Disease
and	I-Disease
duarte	I-Disease
galactosemia	I-Disease
,	O
we	O
analyzed	O
the	O
galt	O
mutations	O
in	O
30	O
families	O
with	O
classical	B-Disease
galactosemia	I-Disease
,	O
in	O
10	O
families	O
with	O
the	O
d	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
the	O
d	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
dgge	O
)	O
.	O
	
dgge	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B-Disease
alleles	O
.	O
	
eight	O
novel	O
candidate	O
galactosemia	B-Disease
mutations	O
were	O
found	O
.	O
	
we	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B-Disease
are	O
highly	O
heterogeneous	O
and	O
that	O
k285n	O
is	O
a	O
second	O
common	O
galactosemia	B-Disease
mutation	O
in	O
our	O
population	O
.	O
	
.	O
	
isolation	O
of	O
full	O
-	O
length	O
atm	O
cdna	O
and	O
correction	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
cellular	O
phenotype	O
.	O
	
a	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
atm	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O
	
we	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cdna	O
for	O
atm	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
by	O
transfection	O
with	O
this	O
cdna	O
.	O
	
overexpression	O
of	O
atm	O
cdna	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
dna	O
synthesis	O
,	O
and	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O
	
this	O
correction	O
of	O
the	O
defects	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
atm	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
	
.	O
	
fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
.	O
	
chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B-Disease
and	I-Disease
solid	I-Disease
tumors	I-Disease
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O
	
in	O
the	O
pediatric	O
solid	B-Disease
tumor	I-Disease
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
pax3	O
-	O
fkhr	O
or	O
pax7	O
-	O
fkhr	O
fusion	O
proteins	O
,	O
respectively	O
.	O
	
thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
pax3	O
-	O
fkhr	O
and	O
pax7	O
-	O
fkhr	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O
	
atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B-Disease
radiation	I-Disease
toxicity	I-Disease
.	O
	
mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B-Disease
-	I-Disease
associated	I-Disease
diseases	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
and	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
,	O
respectively	O
.	O
	
atm	O
-	O
nan	O
mice	O
,	O
as	O
well	O
as	O
those	O
nan	O
for	O
p53	O
,	O
develop	O
mainly	O
t	B-Disease
-	I-Disease
cell	I-Disease
lymphomas	I-Disease
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O
	
mice	O
doubly	O
nan	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B-Disease
formation	O
relative	O
to	O
singly	O
nan	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O
	
finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B-Disease
radiation	I-Disease
toxicity	I-Disease
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
dna	O
damage	O
response	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	B-Disease
.	O
	
.	O
	
trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
reduces	O
expression	O
of	O
dmahp	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
,	O
or	O
dystrophia	B-Disease
myotonica	I-Disease
(	O
dm	B-Disease
)	O
,	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
multisystem	I-Disease
disorder	I-Disease
caused	O
by	O
the	O
expansion	O
of	O
a	O
ctg	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
dmpk	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19q13	O
.	O
	
although	O
the	O
dm	B-Disease
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B-Disease
disease	I-Disease
remain	O
elusive	O
.	O
	
analysis	O
of	O
dmahp	O
expression	O
in	O
the	O
cells	O
of	O
dm	B-Disease
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
dmahp	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O
	
together	O
,	O
these	O
results	O
demonstrate	O
that	O
ctg	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
dmahp	O
in	O
dm	B-Disease
pathogenesis	O
.	O
	
constitutively	O
methylated	O
cpg	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
rb1	O
)	O
.	O
	
a	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
rb1	O
)	O
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
tumor	I-Disease
suppressor	O
gene	O
product	O
interacts	O
with	O
sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O
activity	O
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
tumor	I-Disease
suppressor	O
gene	O
(	O
vhl	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B-Disease
-	I-Disease
cell	I-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
rcc	B-Disease
)	O
,	O
as	O
vhl	O
mutations	O
have	O
been	O
found	O
in	O
both	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
-	I-Disease
associated	I-Disease
and	I-Disease
sporadic	I-Disease
rccs	I-Disease
.	O
	
recent	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
vegf	O
)	O
mrna	O
is	O
upregulated	O
in	O
rcc	B-Disease
-	I-Disease
and	I-Disease
von	I-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
-	I-Disease
associated	I-Disease
tumors	I-Disease
.	O
	
vegf	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
vhl	O
(	O
wt	O
-	O
vhl	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
rcc	B-Disease
cell	O
lines	O
.	O
	
furthermore	O
,	O
endogenous	O
vegf	O
mrna	O
levels	O
were	O
suppressed	O
in	O
permanent	O
rcc	B-Disease
cell	O
lines	O
expressing	O
wt	O
-	O
vhl	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
vhl	O
regulation	O
of	O
vegf	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
transcriptional	O
level	O
.	O
	
these	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
vhl	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
sp1	O
and	O
suggest	O
that	O
loss	O
of	O
sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
and	O
rcc	B-Disease
.	O
	
.	O
	
adult	B-Disease
onset	I-Disease
globoid	I-Disease
cell	I-Disease
leukodystrophy	I-Disease
(	O
krabbe	B-Disease
disease	I-Disease
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cdna	O
from	O
four	O
japanese	O
patients	O
.	O
	
we	O
examined	O
galactosylceramidase	O
(	O
galc	O
)	O
cdna	O
in	O
four	O
japanese	O
patients	O
with	O
adult	B-Disease
onset	I-Disease
globoid	I-Disease
cell	I-Disease
leukodystrophy	I-Disease
(	O
krabbe	B-Disease
disease	I-Disease
;	O
ao	B-Disease
-	I-Disease
gld	I-Disease
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
pcr	O
-	O
sscp	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
pcr	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B-Disease
paraplegia	I-Disease
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
all	O
patients	O
had	O
diminished	B-Disease
galc	I-Disease
activity	I-Disease
in	O
their	O
leukocytes	O
.	O
	
three	O
mutations	O
,	O
viz	O
.	O
	
,	O
g270d	O
,	O
l618s	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B-Disease
galc	I-Disease
activity	I-Disease
as	O
expected	O
.	O
	
ao	B-Disease
-	I-Disease
gld	I-Disease
mutations	O
,	O
including	O
those	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
n	O
-	O
terminus	O
(	O
i66m	O
,	O
g270d	O
,	O
535	O
-	O
573del	O
)	O
or	O
c	O
-	O
terminus	O
(	O
l618s	O
)	O
of	O
the	O
galc	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
(	O
if	B-Disease
-	I-Disease
gld	I-Disease
)	O
are	O
in	O
the	O
central	O
domain	O
.	O
	
this	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
gld	B-Disease
.	O